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Thyroid hormone is important for controlling metabolism and many other body 
functions. Changes in thyroid hormone physiology, its regulation and diseases thereof 
have been a concern for the mankind. Understanding of the thyroid hormone(s) has 
been continuously updated and revised. The contributions from different authors 
have been incorporated in this book for this purpose. The original work of these 
contributors will be especially useful in furthering the knowledge on thyroid and help 
in creating new vistas of research.
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Thyroid hormone is important for controlling metabolism and many other body 
functions. Changes in thyroid hormone physiology, its regulation and diseases thereof 
have been a concern for the mankind. 
Understanding of thyroid hormone(s) has been continuously updated and revised. 
The contributions from different authors have been incorporated in this book for this 
purpose. The original work of these contributors will be especially useful in furthering 
the knowledge on thyroid and help in creating new vistas of research. 
The book incorporates physiology of thyroid hormone in maternal-fetal axis, and 
regulation of thyroid hormone synthesis in health and disease. The controversy in the 
cut-off for delineating normal from abnormal thyroid function has also been dealt 
with. Thyroid hormone deficiency and excess states have been highlighted through 
elaborate review to encompass the present understanding and management of such 
problems. A separate section on thyroid hormone changes in special situation has been 
incorporated.  
 
Dr Neeraj Kumar Agrawal 
Associate Professor and Head of Department of Endocrinology and Metabolism 
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1. Introduction 
Thyroid hormones (TH) have major well-known actions on the growth and development of 
the maturing tissues including mammalian brain via activation of specific nuclear receptors 
leading to gene expression and subsequent target protein synthesis. Deficiency of THs has 
serious issues on the development on all types of tissues including brain leading to severe 
thyroid disorders and as a result imposes overall metabolic malfunctioning of all system 
organs. Endemic goiter was probably first described with cretinism by Paracelsus (1493 -1541) 
and by other physicians of the Alps and Central Europe. However, the relationship between 
cretinism and involvement of thyroid gland was lacking over centuries. Thyroid gland was 
literally described by Wharton in 1656. Since then the progress of research on thyroid gland 
gained attention particularly for its most observed pleiotypic action in number of species from 
aquatic animals to humans. Developments of new scientific technologies and the progress in 
the area of molecular biology from time to time are continually changing our concepts of the 
regulation of the functions of THs at the subcellular level [1,2]. 
Immunocytochemical localization studies revealed that TH receptors (TR) in adult 
vertebrates are highly concentrated within choroids plexus, dentate gyrus, hippocampus, 
amygdaloid complex, pyriform cortex, granular layer of cerebellum, mammillary bodies and 
medial geniculate bodies. Although specific nuclear receptors for THs in adult brain have 
been identified, their functions are unclear about target gene expression. 
Imunohistochemical mapping further documented that locus coeruleus norepinephrine 
stimulates active conversion of L-tetraiodothyronine (L-T4) to L-triiodothyronine (L-T3). A 
morphologic linking between central thyronergic and noradrenergic systems has been 
established. This changes in TH ontogeny gradually started drawing attention that possible 
 The Author(s). Licensee InTech. This chapter is distribute  under the terms of th  Creative Commons
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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TH action in mature brain switches its role which may be different from its classical action 
mediated through nuclear receptors. As the brain approaches adulthood, nuclear levels of 
iodothyronines decline gradually reaching a plateau and maintain it, and the TH levels 
increase within nerve terminals of adult vertebrates [1]. In particular, it showed decrease in 
nuclear L-T3 receptor binding in adult brain compared to developing brain. These switching 
differences in TH ontogeny between developing and adult vertebrate brain has gradually 
interested investigators to search for new functional role and mechanism of action of TH. 
Nevertheless, the action of THs remained limitedly judged in mature mammalian central 
nervous system (CNS) [3,4].  
Recent research highlights about the nonconventional nongenomic action of THs and its 
metabolites. Adult mammalian CNS is of specific interest. Clinical observations specifically 
have shown that the adult-onset thyroid disorders lead to several neuropsychological 
diseases including but not limited to anxiety, depression, mood disorders etc. in humans. 
These complications can be improved with appropriate adjustment of circulatory THs [5-8]. 
However, the defined mechanism to explain this is inadequate. The involvement of TH 
nuclear receptors in ameliorating these neuropsychiatric dysfunctions in mature CNS is 
controversial. Current knowledge about the TH-responsive gene expression in adult 
mammalian CNS is largely unavailable except some few discrete reports with differential 
effects in certain brain areas. Indication of new rapid nongenomic effects of THs and its 
metabolites, within seconds to minutes, poses special significance.  
The interest about the action of TH in brain originated because like the classical 
neurotransmitters, catecholamines, THs are also derived from the amino acid, tyrosine. 
Tyrosine is decarboxylased by specific aromatic amino acid decarboxylase to produce 
catecholamines. There are possibilities that THs can also undergo decarboxylation and form 
biogenic amine-like neuroactive compounds, such as thyronamines or iodothyronamines as 
hypothesized. However recent experiment challenges this initial hypothesis since aromatic 
amino acid decarboxylase failed to produce this and thus presence of TH specific 
decarboxylase is speculated [9]. For example, L-T4 and L-T3 can be decarboxylated to 
produce L-T4-amine and L-T3-amine respectively (Figure 1). L-T3-amine can further be 
deiodinated to form L-T2-amine and then further deiodination can generate L-T1-amine. 
Important deaminated metabolites of L-T4 and L-T3 are tetraiodothyroacetic acid (TETRAC) 
and triiodothyroacetic acid (TRIAC) respectively [9,10]. Thyronamines may have 
neurotransmitter-like actions. However, no evidence is present to-date to identify 
physiologic formation of thyronamines that describe their physiologic functions, except one 
new report which identified 3-iodo-thyronamine in adult brain including other tissue 
homogenates in sub-picomolar concentrations [10]. Few pharmacologic actions for these 
synthetically prepared iodothyronamines are known in other tissues. This theory of action 
of thyroid hormones could be like classical neurotransmission led to search for the 
nongenomic mechanism of action of THs.  
Thus, besides the genomic concepts, a parallel idea of nongenomic of TH action was 
emerging with demonstration of direct plasma membrane-TH interaction and expression of 
some hormonal effects in a variety of cells. These studies include activation on Ca2+-ATPase  
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Figure 1. Thyroid hormones and their deaminated and decarboxylated products of interest. 
in red blood cells, acetylcholinesterase in neuronal plasma membrane, inhibition of 
synaptosomal membrane Na+-K+-ATPase (NKA), rapid action of L-T3 on synaptosomal Ca2+-
influx, identification of specific L-T3-binding sites in rat thymocyte membrane, 
synaptosomal membrane, depolarization of actin filaments in cultured astrocytes by TH, 
and changes in second messengers and their corresponding regulatory systems following 
TH treatment [1,11,12].  
Selective uptakes of THs have also been documented within the nerve terminals. 
Intravenous administration of [125I]-L-T4 in rats followed by thaw mount autoradiography 
has described selective distribution of L-T4 in specific adult rat brain areas particularly 
within the nerve terminals. Within the nerve terminal this was concentrated as L-T3 [10]. 
Other reports about the transportation of TH in adult brain also indicated role of 
transthyretin as a major serum binding protein for TH required for its transportation in 
cerebrospinal fluids and ultimately enable crossing of TH of the blood brain barrier 
directing to the brain. A role of monocarboxylate anion transporter protein-8 (MCT-8) also 
has been found to play a major role in TH transportation across the plasma membrane [10]. 
Three important enzymes called monodeiodinase are involved in TH metabolism. These are 
5’-deiodinase type I (D-I), 5’-deiodinase type II (D-II) and 5’-deiodinase type III (D-III). D-I 
and D-II catalyzes conversion of the L-T4 to L-T3. D-I is the major deiodinating enzyme in 
the peripheral tissues. In brain D-II is predominantly localized in glial cells, astrocytes, and 
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in the tanycytes lining the lower part of the third ventricles. D-III catalyzes the conversion of 
L-T3 to L-T2. Concentration of L-T3 within the nervous system has been attributed to the 
brain D-II which has major functions in regulating the overall neuronal homeostasis for TH. 
Expression of D-II in nervous tissue is implicated in the neuronal uptake of the circulatory 
L-T4 and its conversion to L-T3 followed by its supply to the neuronal targets. Expression of 
D-II is an important protective mechanism against hypothyroidism. This prevalence of TH 
homeostasis is a preventive measure and thought to be neuroprotective [1,13-16].  
Interest also materializes to explore further the nongenomic mechanism of action of THs in 
adult mammalian CNS. In this context TH-mediated signal transduction pathways are also 
being investigated. Particularly the regulation of the activation of the second messenger 
systems and subsequent protein phosphorylation are of much awareness. Understanding of 
the mechanism of action of TH in adult mammalian brain has key implications in the higher 
mental functions, learning and memory, and in the regulation of several neuropsychiatric 
disorders developed during adult-onset thyroid dysfunctions in humans.  
2. Aim of the article 
The major goal of this article is to search, discuss and review the nongenomic rapid actions 
of THs in mature mammalian CNS. This article aims to begin with observations describing 
subcellular distribution, and concentrations of THs within the brain and its biochemical and 
physiologic consequences, specific binding of THs onto the neuronal plasma membrane to 
examine for specific plasma membrane receptors of THs and correlate the receptor-binding 
followed by a specific cellular function. Next, the molecular basis of the TH and plasma 
membrane receptor interaction-mediated signals are evaluated via possible activation of G-
protein signaling pathway, second messenger systems, and subsequent target protein 
phosphorylation.  
3. Hypothesis  
Thyroid hormones exercise a nongenomic action on the adult mammalian brain possibly by 
binding to neuronal membrane receptors followed by activation of second messenger 
cascade systems leading to substrate level protein phosphorylation and dephosphorylation 
by protein kinases and protein phosphatases (Figure 2).  
4. Experimental tissue of interest 
Author’s experiments and results reported in this manuscript are obtained from the purified 
synaptosomes prepared from young adult rat brain cerebral cortex. Synaptosomes are 
subcellular nucleus-free preparation purified through density gradient centrifugation [17]. 
The question may arise why synaptosome? Synapses are the ultimate routes of 
communications in neurons where electrical impulses are normally translated to chemical 
signals from one neuron to the other leading to subsequent biochemical and physiologic 
events. This preparation is a fragment of neurons containing the neuronal membrane,   
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Figure 2. Hypothesis: Proposed nongenomic action of thyroid hormones in adult mammalian brain. 
 
Figure 3. (a) A typical neuron. (b) Cartoon of a neuron showing synaptosome. (c) Scanning electron 
microscopic image of synaptosome.  
Synaptic vesicles, and the other intracellular components (Figure 3). Synaptosomes can be 
considered as isolated nerve terminals. Synaptosomes are obtained after homogenization 
and fractionation of nerve tissue. The fractionation step involves several centrifugations 
steps to separate various organelles from the synaptosomes. Synaptosomes are formed from 
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Synaptosomes are frequently used to study synaptic signal transduction pathways because 
they contain almost the entire molecular machinery necessary known for the uptake, 
storage, release of neurotransmitters, receptor properties, and enzyme actions etc. 
5. Subcellular levels of L-triiodothyronine (L-T3) and L-thyroxine (L-T4) 
in adult rat brain cerebral cortex  
As the brain approaches adulthood, nuclear iodothyronine concentrations gradually 
decreases reaching a plateau and maintains it, and the TH levels increase within nerve 
terminals of adult vertebrates [1,18-21]. It also demonstrated decrease in L-T3-binding in 
adult brain compared to developing brain. 
Although, evidence of transportation 125I-L-T3 and 125I-L-T4 within the nerve terminal was 
demonstrated following intravenous injection in adult rat brain [10,18,19,22], its euthyroid 
concentrations and subcellular distribution was never been evaluated until recently [13,23]. 
Intravenous administration of [125I]-L-T4 in rats followed by thaw mount autoradiography 
showed distribution of L-T4 in selective areas of adult brain in a saturable manner. 
Gradually L-T4 was concentrated more within nerve terminals fractions, where L-T4 was 
monodeiodinated to produce L-T3, the active form of TH [10]. L-T4 and L-T3 transportation 
within neurons are shown to occur by two different mechanisms. L-T3 is actively taken up 
in a saturable manner, while L-T4 transportation occurs by diffusion and in a non-saturable 
way. L-T4-transporation within the neuron is dependent upon L-T4-concentration gradient 
between extracellular and intracellular compartments and is maintained by high 
deiodination rate of L-T4 to L-T3 [24]. Role of transthyretin has also been described as a 
major binding protein in cerebrospinal fluid. Transthyretin has been implicated to facilitate 
L-T4 transportation across the blood-brain-barrier and finally into the brain. Recently MCT-
8 has been ascribed to be the most effective TH transporter [25]. These MCT-8 are 12 
transmembrane spanning proteins, and in particular plays a major role for very specific 
transportation of L-T3 within the neurons followed by the active conversion of the 
prohormone L-T4 to L-T3 by the D-II within the CNS [26]. D-II is essentially important for 
the conversion of the prohormone L-T4 into the active L-T3 within the CNS. However, 
understandings of the levels of THs within the neurons are imperative. This information is 
crucial to explore the role of L-T3 in neural signal transmission in mature brain. To help 
meet this requirement the following study was performed to quantify and compare the 
levels of THs in adult rat brain cerebral cortex.   
5.1. Comparison of the levels of L-tetraiodothyronine (L-T4) and L-
triiodothyronine (L-T3) in subcellular fractions 
While serm levels of L-T4 (~ 41 ng/ml) and L-T3 (~ 0.7 ng/ml) were found consistent with the 
normal peripheral results, this assay system could not detect L-T4 in either synaptosomal or 
non-synaptic mitochondrial fractions. However, the L-T3 levels in synaptosomes (0.450.06 
ng/mg synaptosomal protein), and non-synaptic mitochondria (1.440.12 ng/mg 
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mitochondrial protein) were significant. The levels of L-T3 in non-synaptic mitochondria 
were ~3.2-fold higher compared to synaptosomal values in cerebral cortices [13,16]. The 
finding of undetectable levels of synaptosomal L-T4 was consistent with other studies 
[14,27,28]. A higher fractional rate of D-II activity that converts L-T4 to L-T3 is attributed 
[29,30].  
This study quantifies the TH concentrations from adult rat brain synaptosomal and non-
synaptic mitochondria. Although L-T4 levels could not be detected in synaptosomal and non-
synaptic mitochondrial fractions, fair amounts of L-T3 were detected in these fractions purified 
from adult rat brain cerebral cortex [13,16]. Undetectable levels of synaptosomal L-T4 levels 
were also supported within synaptosomal fractions obtained from adult rat brain [27].  
Despite very low levels of TH in hypothyroid condition as determined by serum levels of TH, 
previous report has shown that L-T3 production in brain is pretty high in stress situations like 
hypothyroidism [13]. D-II has also been shown to be activated in other stressful conditions and 
indicated to have a protective role in stressed brain [31]. Stimulated levels of D-II have been 
described during hypothyroidism. This supports the first initial report [13] of elevation of 
brain L-T3 levels during n-propylthiouracil (PTU)-induced hypothyroid conditions [14,15,32]. 
In brain, approximately 80% of the L-T3 is produced locally from L-T4 by D-II. The fractional 
rate of conversion of L-T4 to L-T3 is remarkably high in brain [29]. This might be a possible 
reason for undetectable L-T4 levels due to rapid conversion of L-T4 to L-T3 in these fractions. 
To detect the endogenous TH levels the subcellular fractions were ruptured hypo-osmotically. 
The use of 8-anilinonaphtho-sulfonic acid in the radioimmunoassay medium excluded the 
possibility of the non-detectable protein bound form of the hormone by releasing the 
endogenously bound form of the hormones [13].  
Comparatively higher levels of L-T3 in the mitochondria may have implications on the 
mitochondrial bioenergetics such as, cellular oxygen consumption, oxidative 
phosphorylation and ATP synthesis, mitochondrial gene expression. These are few of the 
major regulatory functions of TH. THs also have been shown to affect mitochondrial 
genome mediated through imported isoforms of nuclear TH receptors and influence various 
mitochondrial transcription factors [3,33]. Concentration and localization of radiolabeled L-
T3 within the nerve terminal was the first landmark research described in adult rat brain. 
This further followed with the immunohistochemical mapping demonstrating locus 
ceruleus norepinephrine stimulating active conversion of L-T4 to L-T3. This established a 
morphologic co-localization of central thyronergic and noradrenergic systems. Overall TH 
levels within different compartment of brain may have discrete, differential and potential 
regulatory function for neurotransmission in adult mammalian brain [10].  
5.1.1. Thyroid hormone levels in hypothyroid rat cerebrocortical synaptosomes 
Synaptosomal levels of L-T3 were also studied in different thyroidal conditions. Serum 
levels of L-T3 and L-T4 confirmed establishment of peripheral hypothyroidism induced by 
14 days of intra-peritoneal (i. p.) injections of PTU (2 mg/g BW). However, surprisingly 
hypothyroid rat brain showed ~9.5-fold higher amount of L-T3 (126 nM) in synaptosomes 
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previous report has shown that L-T3 production in brain is pretty high in stress situations like 
hypothyroidism [13]. D-II has also been shown to be activated in other stressful conditions and 
indicated to have a protective role in stressed brain [31]. Stimulated levels of D-II have been 
described during hypothyroidism. This supports the first initial report [13] of elevation of 
brain L-T3 levels during n-propylthiouracil (PTU)-induced hypothyroid conditions [14,15,32]. 
In brain, approximately 80% of the L-T3 is produced locally from L-T4 by D-II. The fractional 
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possibility of the non-detectable protein bound form of the hormone by releasing the 
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Comparatively higher levels of L-T3 in the mitochondria may have implications on the 
mitochondrial bioenergetics such as, cellular oxygen consumption, oxidative 
phosphorylation and ATP synthesis, mitochondrial gene expression. These are few of the 
major regulatory functions of TH. THs also have been shown to affect mitochondrial 
genome mediated through imported isoforms of nuclear TH receptors and influence various 
mitochondrial transcription factors [3,33]. Concentration and localization of radiolabeled L-
T3 within the nerve terminal was the first landmark research described in adult rat brain. 
This further followed with the immunohistochemical mapping demonstrating locus 
ceruleus norepinephrine stimulating active conversion of L-T4 to L-T3. This established a 
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14 days of intra-peritoneal (i. p.) injections of PTU (2 mg/g BW). However, surprisingly 
hypothyroid rat brain showed ~9.5-fold higher amount of L-T3 (126 nM) in synaptosomes 
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compared to euthyroid control values. A single i. p. injection of L-T3 (2 g/g BW) to the 
hypothyroid rats decreased the synaptosomal levels of L-T3 by ~1.6-fold compared to the 
hypothyroid rats and was still ~6-fold higher than the euthyroid value. An increase in ~2.5-
fold of the L-T3 levels was noticed in euthyroid plus L-T3 (2 g/g BW) group (Figure 4) [13]. 
Although the levels of L-T3 in whole rat brain homogenate was found to be in low 
nanomolar ranges [22], two concurrent reports estimated synaptosomal levels of L-T3 to be 
~14.6 nM [23], and ~13 nM [13] in adult rat brain synaptosomes. Observation of high levels 
of synaptosomal L-T3 were also supportive [15] in hypothyroid rat cerebral cortex by ~1.7-
fold compared to the control values maximally at day 4 of induction of hypothyroidism 
while the serum levels of L-T3 remained at the hypothyroid levels.  
Hypothyroid condition shows an appreciable decline in both serum L-T4 and L-T3 level in 
rats in a usual way as found by other investigators [34]. Although it has been shown earlier 
that in hypothyroid condition, the whole brain, or different regions of the brain, maintain 
similar levels of L-T3 compared to the euthyroid control rats through increased activity of 
D-II, and corresponding high fractional rate of L-T4 to L-T3 conversion [35,36], insufficient 
evidence is available except for a few recent reports  to quantitate the synaptosomal 
concentration of thyroid hormones. Approximately 8-fold higher concentration of L-T3 has 
been found in synaptosome compared to the whole brain in euthyroid rats. Our observation 
of approximately 9.5-fold higher L-T3 content in synaptosome of hypothyroid rats 
compared to the euthyroid controls may be the result of a higher fractional rate of L-T3 
production by increased activity of D-II, and a correspondingly higher selective uptake and 
concentration of L-T3 molecules in the synaptosomes to cope up with the physiological need 
of THs in this tissue at this condition [13,23,37,38].  
 
Figure 4. L-T3 levels in rat cerebrocortical synaptosomes in various thyroid states. (Ref. Sarkar and Ray 
1994, Neuropsychopharmacology 11: 151-155 acknowledged [13]).  
In euthyroid rat brain, selective uptake of 125I-L-T3 and its concentration in synaptosomal 
compartment have been demonstrated [10]. In addition, the use of hypothyroid animals 
only after 14 days of PTU treatment, where some adaptive mechanisms still unknown in 
nature prevail, do not reach the equilibrium as compared to the animals kept in chronic 
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hypothyroid condition for a much longer duration as used by other workers. This may be 
one of the reasons for maintaining a high level of synaptosomal L-T3 in our hypothyroid 
rats. Expression of the data in different forms such as per gram organ (brain) basis, or per 
mg compartmental (synaptosomal) protein basis, as presented in our experiment, also 
becomes an additive factor for discrepancies among different groups of workers regarding 
the quantitative aspects of L-T3 or L-T4 in the brain [23,34,38,39]. The fall in L-T3 
concentration in synaptosomes prepared from L-T3-treated hypothyroid rat cerebral cortex 
may be the result of inhibition of D-II activity after 24 hours of the L-T3 administration, in 
the presence of the considerable amount of exogenous L-T3. An inhibition in the activity of 
D-II has been noticed within 4 hours of L-T3 treatment to the thyroidectomized rats. A rise 
in the synaptosomal L-T3 level in the hypothyroid rats, and a fall in the same in the L-T3-
treated hypothyroid animals after 24 hours of L-T3-treatment, also reflects the tendency for 
a compensatory regulatory mechanism of thyroid hormone metabolism in the adult rat 
brain in altered thyroid conditions, although the nature of the mechanism remains 
unknown. L-T3-treated control rats have shown higher levels of synaptosomal L-T3, 
compared to the control values. This may be a result of the extra L-T3 transport influenced 
by a high dose of exogenously administered L-T3 (2 g/g) [18,19,24].  
Observation of undetected levels of L-T4 within cerebrocortical synaptosomes may reflect a 
state of rapid conversion of L-T4 to L-T3 in the brain by D-II enzyme. Other researchers have 
already shown that after intravenous administration of radiolabeled L-T4 and L-T3, the 
hormone is concentrated as L-T3 in a synaptosomal fraction of the whole rat brain, and L-T4 
to L-T3 conversion occurs very rapidly within the nerve cells. L-T3 formed in the neuronal 
cell body then may be translocated down the axon to the synaptic ends. Saturable and 
nonsaturable uptake of L-T3 and L-T4 in isolated synaptosomes in an in vitro model also 
indicated two-component L-T3-uptake system [18,19,24,37,38].  
The prediction of a role of D-II as suggested [13] is further supported by few other studies 
[15,31]. Increased D-II activity is suggested in hypothyroid brain. This is attributed to the 
maintenance of normal brain concentrations of L-T3 even under low peripheral levels of L-
T4 [31]. The high level of L-T3 as observed by us is supported and suggested for 
maintenance of brain homeostasis. This demonstrated onset of a central homeostasis for THs 
in adult hypothyroid brain between the 1st and 2nd day, its maintenance for about 16-18 days 
and thereafter declined between the 18-20th day [15]. This report also confirms and confers 
higher activity of D-II (~ 1.6-fold higher compared to control) within the cerebrocortical 
synaptosomal fraction during short-term brain-hypothyroidsm. It is described as a 
protective mechanism of brain by raising the brain L-T3 levels. Another study also 
documents an increase in D-II activity within various brain regions and decrease in D-III 
activity, except in cerebrellum and medulla where specific D-III activity remained 
undetected [40]. However, controversially, although these investigation did observe higher 
D-II activity within various areas of adult brain during hypothyroidism, the changes in L-T3 
levels remained lower than normal values as was noticed in case of serum levels of 
hypothyroidism. This investigation could not explain this high D-II activity and lower L-T3 
levels in brain regions. The levels of THs measured in this study also were shown to be 
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hypothyroid condition for a much longer duration as used by other workers. This may be 
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treated hypothyroid animals after 24 hours of L-T3-treatment, also reflects the tendency for 
a compensatory regulatory mechanism of thyroid hormone metabolism in the adult rat 
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unknown. L-T3-treated control rats have shown higher levels of synaptosomal L-T3, 
compared to the control values. This may be a result of the extra L-T3 transport influenced 
by a high dose of exogenously administered L-T3 (2 g/g) [18,19,24].  
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cell body then may be translocated down the axon to the synaptic ends. Saturable and 
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The prediction of a role of D-II as suggested [13] is further supported by few other studies 
[15,31]. Increased D-II activity is suggested in hypothyroid brain. This is attributed to the 
maintenance of normal brain concentrations of L-T3 even under low peripheral levels of L-
T4 [31]. The high level of L-T3 as observed by us is supported and suggested for 
maintenance of brain homeostasis. This demonstrated onset of a central homeostasis for THs 
in adult hypothyroid brain between the 1st and 2nd day, its maintenance for about 16-18 days 
and thereafter declined between the 18-20th day [15]. This report also confirms and confers 
higher activity of D-II (~ 1.6-fold higher compared to control) within the cerebrocortical 
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protective mechanism of brain by raising the brain L-T3 levels. Another study also 
documents an increase in D-II activity within various brain regions and decrease in D-III 
activity, except in cerebrellum and medulla where specific D-III activity remained 
undetected [40]. However, controversially, although these investigation did observe higher 
D-II activity within various areas of adult brain during hypothyroidism, the changes in L-T3 
levels remained lower than normal values as was noticed in case of serum levels of 
hypothyroidism. This investigation could not explain this high D-II activity and lower L-T3 
levels in brain regions. The levels of THs measured in this study also were shown to be 
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lower than found by other investigators. Some assay in brain regions was also performed in 
tissue homogenates instead of particular subcellular fractions. Possibly differences in the 
concentrations of THs could be due to a different method of severe extraction procedure 
employed to extract brain tissue THs resulting in loss of it.  
The data emerged from our study reveal the quantitative aspects of involvement of L-T3 in 
synaptosomes in different thyroid states, and favors its role in neuronal functions as 
formerly described [10,41]. A stimulation of synthesis of synapsin-1 protein (related to 
neurotransmission) by L-T3 in the developing brain has been reported [42]. Although, the 
synaptosomal L-T3 levels varied widely with different treatments, our result illustrates a 
unique, but unknown regulatory mechanism of the TH metabolism in the mature 
mammalian brain. 
5.2. Modulation of neuronal plasma membrane Na+-K+-ATPase specific activity 
as a function of specific binding of L-triiodothyronine in adult rat brain 
cerebrocortical synaptosomes  
Subsequently the idea of concentration, distribution and metabolism of THs within the 
mature brain generated interest to search for potential role of TH and its nongenomic 
interaction, if any, with neuronal plasma membrane. TH is well known for its regulation of 
energy metabolism in developing tissues including brain. However, adult brain has not 
shown this effect on energy metabolism under the influence of TH until recently. 
Maintenance of ionic gradients by plasma membrane Na+-K+-ATPase (NKA) is one of the 
important cellular events by which TH regulate energy metabolism. NKA is an ion pump 
responsible for maintaining Na+ and K+ ion gradients across the cellular plasma membrane 
in eukaryotic cells. The Na+ and K+ ion gradients are important for establishment of resting 
membrane potentials as well as for transport of certain molecules. NKA has special 
significance in maintaining membrane potentials in neurons. Inhibition of NKA has been 
shown to release acetylcholine [43] and norepinephrine [44] from rat cortical synaptosomes, 
presumably as a result of depolarizing effects of lowered K+ gradients. The level of NKA 
activity could therefore have consequence for the regulation of the neurotransmitter release 
and uptake across the synaptic membrane [43].  
5.2.1. In vivo and in vitro actions of L-T3 on synaptosomal Na+-K+-ATPase activity  
A dose-dependent inhibition of synaptosomal NKA activity by L-T3 both in in vivo [45], and 
in in vitro [46] conditions have been shown. This may be related to the differences in L-T3 
status in adult rat cerebrocortical synaptosomes. L-T3 administration in a single i.p. injection 
showed inhibition of synaptosomal NKA specific activity maximally at 24 hours post-
injection by ~ 44% compared to respective control euthyroid values. A range of L-T3 
concentration (0.1 to 4.0 g/g BW, single i. p. injection) administered in vivo showed dose-
dependent inhibition of the synaptosomal NKA activity. In contrast PTU-treated 
hypothyroid animals showed ~ 38% increase in the NKA activity compared to the control 
values. This increase in NKA activity was abolished by injection of a single L-T3 injection 
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(2g/g BW) to almost close to the euthyroid levels. However, this study could not 
distinguish between the genomic and nongenomic effects of L-T3. TH has also been 
reported to inuence K+-evoked release of [3H]-GABA in adult rat cerebrocortical 
synaptosomes. Such evidence indicates a possible role of TH in neurotransmission in adult 
mammalian brain. A functional correlation between L-T3 binding and the corresponding 
inhibition of NKA activity under in vitro conditions in the synaptosomes of adult rat 
cerebral cortex were established [46]. To further test the hypothesis of nongenomic action of 
TH we investigated NKA activity in isolated synaptosomes which is devoid of nucleus to 
avoid the chances of nuclear activation [46]. In fact, in vitro addition of L-T3 (1x10-12 M to 
10x10-8 M) within 10 minutes of incubation indicated a dose-dependent inhibitory response 
to NKA activity. Such immediate action of L-T3 added in in vitro in synaptosomes was 
concluded as rapid nongenomic action of L-T3 on synaptosomal membrane NKA [46]. 
Further inhibition of NKA activity was corroborated with gradual binding of [125I]-L-T3 to 
specific L-T3-binding sites in synaptosomes. Thus a physiologic response tied to the specific 
L-T3-binding in the synaptosomal membrane was demonstrated.  
The presence of high affinity low capacity nuclear TH receptors in adult rat brain has been 
reported. Further evidence shows selective uptake of [125I]-L-T3 and rapid conversion of L-
T4 to L-T3   in synaptosomal fraction of adult rat brain. Specic [125I]-L-T3 binding sites have 
also been demonstrated in the synaptosomes of adult rat brain [47] and chick embryo [48]. 
However, no functional relationship could be established due to the interaction of TH and 
its membrane receptor so far in adult brain.  
Scatchard plot analysis demonstrated two sets of specific L-T3 binding sites: one with high 
affinity (Kd1: 12 pM; Bmax1: 3.73±0.07 fmols/mg protein), and the other with low affinity (Kd2: 
1.4±0.05 nM; Bmax2: 349±7 fmols/mg protein). Kd represents dissociation constant. Bmax 
represents maximum binding capacity. Rationale between gradual L-T3 binding and the 
corresponding dose-dependent L-T3-induced inhibition of synaptosomal NKA was 
established in vitro [46].  
The relative order of potencies of binding afnities for the synaptosomal L-T3 binding sites 
and relative inhibition of NKA activity in the presence of different  L-T3  analogues were as 
follows: L-T3>L-T3-amine>L-T4=L-TRIAC>r-T3>L-T2, and L-T3>L-T3-amine>L-T4>L-
TRIAC>r-T3>L-T2, respectively. The concentrations of TH analogues required to displace 
50% specic binding (ED50 value) of 125I-L-T3 to its synaptosomal binding sites were 10-, 63-, 
63-, 1000- and 6250 nM, respectively. This study showed the nature of inhibition of 
synaptosomal NKA activity as a function of L-T3 occupancy of synaptosomal receptor sites 
in mature rat brain [46].  
This investigation demonstrates a novel action of TH in mature rat brain. This is the rst 
report presenting a relationship between the inhibitions of synaptosomal NKA as a 
functional effect of L-T3 binding to its synaptosomal receptor in the cerebral cortex of adult 
rat. Occupancy of specic high afnity L-T3 binding sites demonstrated a concentration-
dependent inhibition of the NKA activity with a maximum of 59%. At 1x10–10 M L-T3 
concentration the enzyme inhibition was ~35% and the saturation of the L-T3 binding sites 
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lower than found by other investigators. Some assay in brain regions was also performed in 
tissue homogenates instead of particular subcellular fractions. Possibly differences in the 
concentrations of THs could be due to a different method of severe extraction procedure 
employed to extract brain tissue THs resulting in loss of it.  
The data emerged from our study reveal the quantitative aspects of involvement of L-T3 in 
synaptosomes in different thyroid states, and favors its role in neuronal functions as 
formerly described [10,41]. A stimulation of synthesis of synapsin-1 protein (related to 
neurotransmission) by L-T3 in the developing brain has been reported [42]. Although, the 
synaptosomal L-T3 levels varied widely with different treatments, our result illustrates a 
unique, but unknown regulatory mechanism of the TH metabolism in the mature 
mammalian brain. 
5.2. Modulation of neuronal plasma membrane Na+-K+-ATPase specific activity 
as a function of specific binding of L-triiodothyronine in adult rat brain 
cerebrocortical synaptosomes  
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(2g/g BW) to almost close to the euthyroid levels. However, this study could not 
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L-T3-binding in the synaptosomal membrane was demonstrated.  
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represents maximum binding capacity. Rationale between gradual L-T3 binding and the 
corresponding dose-dependent L-T3-induced inhibition of synaptosomal NKA was 
established in vitro [46].  
The relative order of potencies of binding afnities for the synaptosomal L-T3 binding sites 
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63-, 1000- and 6250 nM, respectively. This study showed the nature of inhibition of 
synaptosomal NKA activity as a function of L-T3 occupancy of synaptosomal receptor sites 
in mature rat brain [46].  
This investigation demonstrates a novel action of TH in mature rat brain. This is the rst 
report presenting a relationship between the inhibitions of synaptosomal NKA as a 
functional effect of L-T3 binding to its synaptosomal receptor in the cerebral cortex of adult 
rat. Occupancy of specic high afnity L-T3 binding sites demonstrated a concentration-
dependent inhibition of the NKA activity with a maximum of 59%. At 1x10–10 M L-T3 
concentration the enzyme inhibition was ~35% and the saturation of the L-T3 binding sites 
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was ~74%. This appears to be physiological. Further inhibition of NKA activity as found 
with higher concentrations of L-T3 (5x10–10 – 1x10–7 M), corresponds to the increase in the 
occupancy of the L-T3 binding sites (maximum of ~80%) at the low afnity binding range. 
However, this site was not saturated by 15.4 M L-T3 used for determining non-specic 
binding. Hence, it is possible that this low afnity binding is due to non-specic effects of 
several other proteins located in synaptosomes. The relationship between the binding of L-
T3 to its synaptosomal binding sites and the concentration dependent inhibition of the 
enzyme activity appears to hold good only with the occupancy of high afnity sites up to 5 x 
10–10 M L-T3 [46]. Synaptosomes prepared from chick embryo cortex were also reported to 
have two sets of L-T3 binding sites [48]. Their properties and ontogeny showed a marked 
difference from those of nuclear receptors. Even though NKA activity was suppressed 
beyond the saturating concentration of L-T3 at high afnity binding sites, this may be non-
specic and non-physiological. The relative order of binding afnities for TH analogues to 
the L-T3 binding sites and the inhibitory potencies for NKA activity were also correlated in 
the synaptosomes. L-T3-amine was used to examine its potency to inhibit specic [125I]-L-T3 
binding in synaptosomes with the idea that it may be a decarboxylated product of L-T3 and 
may have actions like L-T3. The ED50 value for L-T3-amine was determined as 10 nM. At this 
dose, L-T3-amine also inhibited the synaptosomal NKA activity by ~51% compared with L-
T3. This result is also in good agreement with earlier studies, in which L-T3-amine was 
shown to be ~71% as effective as L-T3 in stimulating Ca2+-ATPase activity at a dose of 10 nM 
in human RBC [49]. In earlier studies, L-T3-induced increase in NKA activity in the 
developing brain [50] and kidney cortex [51] of rat was reported to be due to an increase in 
the mRNA levels of , + and -subunits of the enzyme, while the NKA in adult was not 
responsive to L-T3. However, a dose-dependent inhibition and regulation of synaptosomal 
NKA activity in different in vivo situations was noticed. The immediate effect of added L-T3 
on the synaptosomes appears to be nongenomic as synaptosomes do not have nuclei. This 
may exclude the possibility of involvement of nuclear receptors as reported earlier by us. 
One possible effect of L-T3 may be mediated through membrane receptors. Recently, 
membrane binding proteins for iodothyronines has been described in plasma membranes of 
most cells [52]. This protein has been designated as an integrin V3. Also a role of MCT-8, 
a membrane spanning protein, has been ascribed as a very active and specific transporter of 
THs and some of its metabolites across the membrane [25,53]. However, its action through 
cytoplasmic L-T3-responsive proteins cannot be ruled out.  
In conclusion this study demonstrates, for the rst time, a correlation between the binding of 
TH to its putative receptors and inhibition of NKA activity in the synaptosomes of adult rat 
brain [46]. This may have implications in the involvement of thyroid hormone on important 
mental functions in adult mammalian brain. 
5.3. In search for possible second messenger mediated events in synaptosomal L-
T3-induced signaling 
The evidence of L-T3-synaptosomal membrane interaction in association with the inhibition 
of the synaptosomal membrane NKA activity led us to search for if the L-T3-induced action 
 
“Quo Vadis?” Deciphering the Code of Nongenomic Action of Thyroid Hormones in Mature Mammalian Brain 15 
is mediated via activation or regulation of the second messenger cascade systems. Besides 
the cyclic nucleotide cyclase systems calcium (Ca2+) also plays an important role in cellular 
signal transmission. Ca2+-influx is a major event in neurotransmission. Keeping such visions 
we further intended to explore the role of Ca2+ in L-T3-induction.  
5.3.1. Effect of L-T3 on synaptosomal Ca2+-influx: A comparison between euthyroid and 
hypothyroid brain 
Metabotropic events are often initiated at the membrane level, mediated and amplified 
through G-protein coupled receptors (GPCR) and/or ion channels followed by activation of 
second messenger system and subsequent substrate protein phosphorylation. Ca2+-influx is 
an important physiological function in brain, following which cascades of membrane events 
occur finally leading to neurosignaling. Disruption in this crucial membrane phenomenon 
may lead to variety of Ca2+-dependent neuropsychological disorders. Although TH-
mediated Ca2+ entry in adult rat brain synaptosomes [54,55], and in hypothyroid mouse 
cerebral cortex [56] have been reported, it’s synaptic functions in adult neurons in 
dysthyroidism is unclear. Keeping in mind the role of Ca2+ ions as a messenger in the 
signaling pathway the effect of L-T3 on intracellular Ca2+-influx, in vitro, was studied.  
 
Figure 5. Effect of L-T3 on intrasynaptosomal Ca2+-concentration in euthyroid and PTU-induced 
hypothyroid rat cerebral cortex in vitro (Ref. Modified from Sarkar and Ray 2003, Hormone and 
Metabolic Research 35: 562-564 acknowledged [57])).  
Our study demonstrates a regulation and homeostatic mechanism of Ca2+ accumulation 
within cerebrocortical synaptosomes of hypothyroid adult rat [57]. Application of brain 
physiologic concentrations of L-T3 (0.001 nM to 10 nM), in vitro, significantly triggered Ca2+-
sequestration both in the euthyroid and hypothyroid rat brain synaptosomes in a dose-
dependent manner (Figure 5). Unexpectedly, PTU-induced hypothyroid synaptosomes 
showed significant levels of increase in Ca2+-influx compared to euthyroid controls between 
0.1 nM and 10 nM doses of L-T3. However, 0.001 nM dose of L-T3 did not show significant 
changes between euthyroid and hypothyroid values.  
Present study validates the role of Ca2+ ions under the influence of L-T3 in the synaptosomes 
from adult rat brain cerebral cortex. L-T3-induced dose-dependent Ca2+-entry both in 
euthyroid and PTU-induced hypothyroid rat brain synaptosomes at low L-T3 doses (0.001 
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was ~74%. This appears to be physiological. Further inhibition of NKA activity as found 
with higher concentrations of L-T3 (5x10–10 – 1x10–7 M), corresponds to the increase in the 
occupancy of the L-T3 binding sites (maximum of ~80%) at the low afnity binding range. 
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T3. This result is also in good agreement with earlier studies, in which L-T3-amine was 
shown to be ~71% as effective as L-T3 in stimulating Ca2+-ATPase activity at a dose of 10 nM 
in human RBC [49]. In earlier studies, L-T3-induced increase in NKA activity in the 
developing brain [50] and kidney cortex [51] of rat was reported to be due to an increase in 
the mRNA levels of , + and -subunits of the enzyme, while the NKA in adult was not 
responsive to L-T3. However, a dose-dependent inhibition and regulation of synaptosomal 
NKA activity in different in vivo situations was noticed. The immediate effect of added L-T3 
on the synaptosomes appears to be nongenomic as synaptosomes do not have nuclei. This 
may exclude the possibility of involvement of nuclear receptors as reported earlier by us. 
One possible effect of L-T3 may be mediated through membrane receptors. Recently, 
membrane binding proteins for iodothyronines has been described in plasma membranes of 
most cells [52]. This protein has been designated as an integrin V3. Also a role of MCT-8, 
a membrane spanning protein, has been ascribed as a very active and specific transporter of 
THs and some of its metabolites across the membrane [25,53]. However, its action through 
cytoplasmic L-T3-responsive proteins cannot be ruled out.  
In conclusion this study demonstrates, for the rst time, a correlation between the binding of 
TH to its putative receptors and inhibition of NKA activity in the synaptosomes of adult rat 
brain [46]. This may have implications in the involvement of thyroid hormone on important 
mental functions in adult mammalian brain. 
5.3. In search for possible second messenger mediated events in synaptosomal L-
T3-induced signaling 
The evidence of L-T3-synaptosomal membrane interaction in association with the inhibition 
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is mediated via activation or regulation of the second messenger cascade systems. Besides 
the cyclic nucleotide cyclase systems calcium (Ca2+) also plays an important role in cellular 
signal transmission. Ca2+-influx is a major event in neurotransmission. Keeping such visions 
we further intended to explore the role of Ca2+ in L-T3-induction.  
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Metabotropic events are often initiated at the membrane level, mediated and amplified 
through G-protein coupled receptors (GPCR) and/or ion channels followed by activation of 
second messenger system and subsequent substrate protein phosphorylation. Ca2+-influx is 
an important physiological function in brain, following which cascades of membrane events 
occur finally leading to neurosignaling. Disruption in this crucial membrane phenomenon 
may lead to variety of Ca2+-dependent neuropsychological disorders. Although TH-
mediated Ca2+ entry in adult rat brain synaptosomes [54,55], and in hypothyroid mouse 
cerebral cortex [56] have been reported, it’s synaptic functions in adult neurons in 
dysthyroidism is unclear. Keeping in mind the role of Ca2+ ions as a messenger in the 
signaling pathway the effect of L-T3 on intracellular Ca2+-influx, in vitro, was studied.  
 
Figure 5. Effect of L-T3 on intrasynaptosomal Ca2+-concentration in euthyroid and PTU-induced 
hypothyroid rat cerebral cortex in vitro (Ref. Modified from Sarkar and Ray 2003, Hormone and 
Metabolic Research 35: 562-564 acknowledged [57])).  
Our study demonstrates a regulation and homeostatic mechanism of Ca2+ accumulation 
within cerebrocortical synaptosomes of hypothyroid adult rat [57]. Application of brain 
physiologic concentrations of L-T3 (0.001 nM to 10 nM), in vitro, significantly triggered Ca2+-
sequestration both in the euthyroid and hypothyroid rat brain synaptosomes in a dose-
dependent manner (Figure 5). Unexpectedly, PTU-induced hypothyroid synaptosomes 
showed significant levels of increase in Ca2+-influx compared to euthyroid controls between 
0.1 nM and 10 nM doses of L-T3. However, 0.001 nM dose of L-T3 did not show significant 
changes between euthyroid and hypothyroid values.  
Present study validates the role of Ca2+ ions under the influence of L-T3 in the synaptosomes 
from adult rat brain cerebral cortex. L-T3-induced dose-dependent Ca2+-entry both in 
euthyroid and PTU-induced hypothyroid rat brain synaptosomes at low L-T3 doses (0.001 
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nM to 10 nM). This evidence indicates role of Ca2+ as a second messenger in synaptic 
functions. L-T3 also has been documented to increase 45Ca uptake and Ca2+-influx in adult 
euthyroid rat synaptosomes, and in hypothyroid mouse cortex. An enhancement of nitric 
oxide synthase (NOS) activity in adult rat cerebrocortical synaptosomes was shown [55]. 
This present study demonstrated a significant increase in Ca2+ accumulation in hypothyroid 
rat brain cerebrocortical synaptosomes compared to euthyroid control at below (0.1 nM) and 
at about brain physiologic concentrations (10 nM) of L-T3. At present clear understanding 
for the L-T3-induced release of intracellular calcium is not known; however possibility for L-
T3-induced action in neuronal cells cannot be left out. Use of sodium azide blocked any 
mitochondrial accumulation of calcium. Our earlier studies have shown that 10 nM and 100 
nM dose of L-T3 could saturate the specific synaptosomal L-T3-binding sites by ~69% and 
~74% respectively. L-T3-mediated physiological increase in synaptosomal Ca2+ accumulation 
could be attributed to receptor-mediated physiological response having its maximal effect at 
10 nM dose of L-T3. The differences in the observation of increased rate of Ca2+ 
accumulation in hypothyroid synaptosomes compared to the euthyroid values reflected an 
adaptive mechanism. This could be credited to homeostatic mechanism to overcome PTU-
induced stress conditions persisted in the adult neuron. High intrasynaptosomal L-T3 level 
(~9.5-fold higher; 2.56 ng/mg synaptosomal protein 126 nM L-T3) could be one of the 
reasons. Although hypothyroid condition showed an appreciable decrease in both serum 
levels of L-T4 and L-T3 as predicted, supportive studies showed maintenance of similar 
levels of brain L-T3 in hypothyroid conditions through increased activity of D-II suggesting 
high fractional rate of L-T4 to L-T3 conversion. In brain approximately ~80% of L-T3 is 
produced locally from L-T4 by D-II. This data supports thyroid hormone-Ca2+-ion 
interaction for normal functioning of adult brain during different neuropsychological 
conditions.  
The important functional role of Ca2+ and several calcium-dependent proteins in neuronal 
signal transduction are well recognized. Ca2+ has been shown to inhibit neuronal NKA 
activity. Ca2+-influx also lead to Ca2+-dependent activation of protein kinase C and/or 
Ca2+/CaM-dependent protein kinases followed by direct or indirect activation of 
phosphorylation of several target proteins. This indicated a rapid nongenomic action of L-
T3.  
5.3.2. Is thyroid hormone-membrane interaction is linked to G-protein coupled receptors 
(GPCR)? 
5.3.2.1. Association of G proteins with membrane receptors 
G proteins are GTP-binding proteins that couple activation of seven-helix receptors by 
neurotransmitters at the cell surface for the activation of the effector enzymes-adenylate 
cyclase (AC) or guanylate cyclase (GC), which synthesize the corresponding cyclic 
nucleotides, cAMP or cGMP respectively and regulate protein kinases., such as protein 
kinase A (PKA), protein kinase C (PKC) etc. Metabotropic events are often initiated at the 
membrane level, mediated and amplified through GPCR followed by activation of second 
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messenger system and subsequent substrate protein phosphorylation. Phospholipase C 
(PLC), another effector enzyme, generates inositol triphosphate (IP3) and diacylglycerol 
(DAG), the latter of which releases intracellular stores of calcium. The cAMP, cGMP, Ca2+, 
DAG and IP3 act as second messengers and activate protein kinases with broad substrate 
specificity. The kinases phosphorylate key intracellular proteins, including ion channels, 
enzymes, and transcription factors which modulate cellular biological processes [58,59]. 
Guanine nucleotides are known to have dual effects on most hormone-sensitive AC systems. 
This modulates activation of AC and binding of hormone to receptor. In neuronal 
membranes guanylate nucleotides has been shown to be required for the stimulation of AC. 
However, no modulation of TH binding at appropriate guanylate nucleotide concentrations 
has been reported. It is well established that cholera toxin enhances the activity of Gs 
(stimulatory G protein -subunit) by ADP-ribosylating Gs subunit and inhibiting GTPase 
activity associated with the protein. This increases cAMP production.  
The activity of NKA is regulated by various catecholamines [45,46,60] as well as by L-T3 
[45,46]. Inhibition of NKA has been demonstrated in intact cell preparations by phorbol 
esters, dibutyryl cAMP, and phospho-DRPP-32 (dopamine- and cAMP-regulated 
phosphoprotein of molecular weight 32 kD), a protein phosphatase inhibitor [61-63].  
Some information focuses to effect of TH or its metabolites on noradrenergic like responses. 
This idea develops since TH has possibility to produce a family of biogenic amine-like 
neurotransmitter compounds catalyzed by aromatic amino acid decarboxylase, such as 
iodothyronamines. Physiologic identification of these family of TH-derived 
iodothyronamines have not yet been discovered until recently in rat brain and in rat and 
human blood. These two compounds are monoiodothyronamine and thyronamine [10]. 
Thinking this could be a possibility before this identification of monoiodothyronamine and 
thyronamine were reported we studied the effect of L-T3 on synaptosomal NKA activity 
using various - and -adrenergic agonists and antagonists known to regulate Gs and Gi 
proteins of the neuronal signal transduction system, in vitro.  
Our studies showed that although both L-T3 and isoproterenol (-adrenergic receptor 
[ADR] agonist and activator of Gs-protein) similarly inhibited synaptosomal NKA activity, 
propranolol (-ADR antagonist) could only block the effect of isoproterenol, but not the 
effect of L-T3. Instead propranolol produced a dose-dependent potentiation of the inhibitory 
influence of L-T3 (Figure 6). The augmentation of L-T3-effect by propranolol appeared to be 
a type of synergistic action and it might be due to some changes in the pre-synaptic 
membrane properties, the mechanism of which is unclear at present. However, clonidine 
(2-ADR agonist, and Gi-protein activator) (Figure 7) and glutamate (acts through 
metabotropic glutamate receptors and activator of Gi protein) (Figure 8) attenuated L-T3-
effect, suggesting its possible coupling with GPCR. Equimolar concentration of clonidine  
(1 nM – 100 nM) counteracted the inhibitory effect of L-T3 on the NKA activity (Figure 7). 
This counteraction by clonidine, 2-ADR agonist, appears to be mediated through the 
inhibition of adenylate cyclase activity with the activation of inhibitory G protein (Gi) 
followed by inhibition of cAMP synthesis and protein phosphorylation cascade mechanism. 
It is known that 2-adrenergic receptor agonist system act through Gi protein activation [64].  
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nM to 10 nM). This evidence indicates role of Ca2+ as a second messenger in synaptic 
functions. L-T3 also has been documented to increase 45Ca uptake and Ca2+-influx in adult 
euthyroid rat synaptosomes, and in hypothyroid mouse cortex. An enhancement of nitric 
oxide synthase (NOS) activity in adult rat cerebrocortical synaptosomes was shown [55]. 
This present study demonstrated a significant increase in Ca2+ accumulation in hypothyroid 
rat brain cerebrocortical synaptosomes compared to euthyroid control at below (0.1 nM) and 
at about brain physiologic concentrations (10 nM) of L-T3. At present clear understanding 
for the L-T3-induced release of intracellular calcium is not known; however possibility for L-
T3-induced action in neuronal cells cannot be left out. Use of sodium azide blocked any 
mitochondrial accumulation of calcium. Our earlier studies have shown that 10 nM and 100 
nM dose of L-T3 could saturate the specific synaptosomal L-T3-binding sites by ~69% and 
~74% respectively. L-T3-mediated physiological increase in synaptosomal Ca2+ accumulation 
could be attributed to receptor-mediated physiological response having its maximal effect at 
10 nM dose of L-T3. The differences in the observation of increased rate of Ca2+ 
accumulation in hypothyroid synaptosomes compared to the euthyroid values reflected an 
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phosphorylation of several target proteins. This indicated a rapid nongenomic action of L-
T3.  
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cyclase (AC) or guanylate cyclase (GC), which synthesize the corresponding cyclic 
nucleotides, cAMP or cGMP respectively and regulate protein kinases., such as protein 
kinase A (PKA), protein kinase C (PKC) etc. Metabotropic events are often initiated at the 
membrane level, mediated and amplified through GPCR followed by activation of second 
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messenger system and subsequent substrate protein phosphorylation. Phospholipase C 
(PLC), another effector enzyme, generates inositol triphosphate (IP3) and diacylglycerol 
(DAG), the latter of which releases intracellular stores of calcium. The cAMP, cGMP, Ca2+, 
DAG and IP3 act as second messengers and activate protein kinases with broad substrate 
specificity. The kinases phosphorylate key intracellular proteins, including ion channels, 
enzymes, and transcription factors which modulate cellular biological processes [58,59]. 
Guanine nucleotides are known to have dual effects on most hormone-sensitive AC systems. 
This modulates activation of AC and binding of hormone to receptor. In neuronal 
membranes guanylate nucleotides has been shown to be required for the stimulation of AC. 
However, no modulation of TH binding at appropriate guanylate nucleotide concentrations 
has been reported. It is well established that cholera toxin enhances the activity of Gs 
(stimulatory G protein -subunit) by ADP-ribosylating Gs subunit and inhibiting GTPase 
activity associated with the protein. This increases cAMP production.  
The activity of NKA is regulated by various catecholamines [45,46,60] as well as by L-T3 
[45,46]. Inhibition of NKA has been demonstrated in intact cell preparations by phorbol 
esters, dibutyryl cAMP, and phospho-DRPP-32 (dopamine- and cAMP-regulated 
phosphoprotein of molecular weight 32 kD), a protein phosphatase inhibitor [61-63].  
Some information focuses to effect of TH or its metabolites on noradrenergic like responses. 
This idea develops since TH has possibility to produce a family of biogenic amine-like 
neurotransmitter compounds catalyzed by aromatic amino acid decarboxylase, such as 
iodothyronamines. Physiologic identification of these family of TH-derived 
iodothyronamines have not yet been discovered until recently in rat brain and in rat and 
human blood. These two compounds are monoiodothyronamine and thyronamine [10]. 
Thinking this could be a possibility before this identification of monoiodothyronamine and 
thyronamine were reported we studied the effect of L-T3 on synaptosomal NKA activity 
using various - and -adrenergic agonists and antagonists known to regulate Gs and Gi 
proteins of the neuronal signal transduction system, in vitro.  
Our studies showed that although both L-T3 and isoproterenol (-adrenergic receptor 
[ADR] agonist and activator of Gs-protein) similarly inhibited synaptosomal NKA activity, 
propranolol (-ADR antagonist) could only block the effect of isoproterenol, but not the 
effect of L-T3. Instead propranolol produced a dose-dependent potentiation of the inhibitory 
influence of L-T3 (Figure 6). The augmentation of L-T3-effect by propranolol appeared to be 
a type of synergistic action and it might be due to some changes in the pre-synaptic 
membrane properties, the mechanism of which is unclear at present. However, clonidine 
(2-ADR agonist, and Gi-protein activator) (Figure 7) and glutamate (acts through 
metabotropic glutamate receptors and activator of Gi protein) (Figure 8) attenuated L-T3-
effect, suggesting its possible coupling with GPCR. Equimolar concentration of clonidine  
(1 nM – 100 nM) counteracted the inhibitory effect of L-T3 on the NKA activity (Figure 7). 
This counteraction by clonidine, 2-ADR agonist, appears to be mediated through the 
inhibition of adenylate cyclase activity with the activation of inhibitory G protein (Gi) 
followed by inhibition of cAMP synthesis and protein phosphorylation cascade mechanism. 
It is known that 2-adrenergic receptor agonist system act through Gi protein activation [64].  
 











































































































































































































Figure 7. In vitro effect of L-T3, clonidine (CLON, and yohimbine (YOH, 2-ADR antagonist) on 
synaptosomal NKA activity.  
Thus it seems that the L-T3 action could be ascribed more to stimulate Gs protein during 
beta-blockade which might be directed to manage this adverse condition. The results also  
suggest that the L-T3-effect on the synaptosomal NKA activity was not mediated via the -
ADR-dependent systems, since it was not blocked by propranolol. Based on these results it 
was also hypothesized that L-T3-effect would alter adenylate cyclase activity. In cultured 
neuroblastoma plasma membrane increased adenylate cyclase activity was noticed followed 
by L-T3-treatment [65]. In fact, later, increased adenylate cyclase activity was noticed in 
brain hypothyroid condition which increases brain L-T3 levels. This observation was 
correlated well with increased D-II activity to the increased brain L-T3 levels in brain 
hypothyroid situations [15]. Guanosine 5'-O-(3-thiotriphosphate) or pertussis toxin also has 
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been reported to inhibit TH-induced mitogen-activated protein kinase (MAPK) 
phosphorylation nongenomically in 293T cells which is consistent with a cell membrane 
mechanism mediated via a G-protein [66]. 3-iodothyronine (T1AM), an endogenous and 
rapid-acting derivative of TH, is associated with Gs-protein coupled-trace amine receptor 
TAR1 in HEK cells. However, no modulation of TH binding at appropriate guanylate 
nucleotide concentrations in adult brain has been reported [67]. Determination of whether 
activation or inactivation of a specific type(s) of G-protein influences TH-effects on protein 


































































Figure 8. Attenuation of L-T3-effect on synaptosomal NKA activity by glutamate, in vitro. 
A diverse nongenomic effect of TH has been observed in non-neural tissues including liver, 
heart, adipocytes, and blood [12,68]. Some possible nongenomic actions of THs include 
modulation of GABA uptake, regulation of NKA activity and increase of presynaptic Ca2+-
influx. In synaptoneurosomes TH inhibits the stimulation of chloride flux by GABA [69]. L-
T4 has been shown to stimulate the MAPK pathway in a variety of cultured cell lines 
including HeLa and CV-1 cells which lack functional nuclear TH receptors [66,70-73], 
consistent with a cell membrane mediated mechanism via G-proteins. L-T4 and L-T3 were 
found to inhibit Go-protein activities in synaptosomes from developing chick brain [48].  
Direct interactions of G protein subunits with Ca2+-channels are not well documented. 
However, increased evidences showed receptor activated G proteins modulate activities of 
ion channels by membrane-confined mechanisms [74]. Isoproterenol induced 
phosphorylation of ventricular Ca2+-channels via PKA has been reported [75]. Gs protein 
also has been shown to regulate Ca2+-channels both in a cAMP-independent membrane-
confined mechanism [74] and in a cAMP-dependent phosphorylation of one of the subunits 
of L-type Ca2+-channel [76]. Synaptosomal NKA has previously been described to be 
inhibited by cAMP in a dose-dependent manner suggesting a role of PKA. The activated 
form of this protein kinase was further phosphorylated a substrate protein which in turn 
depressed the total Na+-dependent phosphorylation of the synaptosomal NKA [77]. Overall, 
 











































































































































































































Figure 7. In vitro effect of L-T3, clonidine (CLON, and yohimbine (YOH, 2-ADR antagonist) on 
synaptosomal NKA activity.  
Thus it seems that the L-T3 action could be ascribed more to stimulate Gs protein during 
beta-blockade which might be directed to manage this adverse condition. The results also  
suggest that the L-T3-effect on the synaptosomal NKA activity was not mediated via the -
ADR-dependent systems, since it was not blocked by propranolol. Based on these results it 
was also hypothesized that L-T3-effect would alter adenylate cyclase activity. In cultured 
neuroblastoma plasma membrane increased adenylate cyclase activity was noticed followed 
by L-T3-treatment [65]. In fact, later, increased adenylate cyclase activity was noticed in 
brain hypothyroid condition which increases brain L-T3 levels. This observation was 
correlated well with increased D-II activity to the increased brain L-T3 levels in brain 
hypothyroid situations [15]. Guanosine 5'-O-(3-thiotriphosphate) or pertussis toxin also has 
 
“Quo Vadis?” Deciphering the Code of Nongenomic Action of Thyroid Hormones in Mature Mammalian Brain 19 
been reported to inhibit TH-induced mitogen-activated protein kinase (MAPK) 
phosphorylation nongenomically in 293T cells which is consistent with a cell membrane 
mechanism mediated via a G-protein [66]. 3-iodothyronine (T1AM), an endogenous and 
rapid-acting derivative of TH, is associated with Gs-protein coupled-trace amine receptor 
TAR1 in HEK cells. However, no modulation of TH binding at appropriate guanylate 
nucleotide concentrations in adult brain has been reported [67]. Determination of whether 
activation or inactivation of a specific type(s) of G-protein influences TH-effects on protein 


































































Figure 8. Attenuation of L-T3-effect on synaptosomal NKA activity by glutamate, in vitro. 
A diverse nongenomic effect of TH has been observed in non-neural tissues including liver, 
heart, adipocytes, and blood [12,68]. Some possible nongenomic actions of THs include 
modulation of GABA uptake, regulation of NKA activity and increase of presynaptic Ca2+-
influx. In synaptoneurosomes TH inhibits the stimulation of chloride flux by GABA [69]. L-
T4 has been shown to stimulate the MAPK pathway in a variety of cultured cell lines 
including HeLa and CV-1 cells which lack functional nuclear TH receptors [66,70-73], 
consistent with a cell membrane mediated mechanism via G-proteins. L-T4 and L-T3 were 
found to inhibit Go-protein activities in synaptosomes from developing chick brain [48].  
Direct interactions of G protein subunits with Ca2+-channels are not well documented. 
However, increased evidences showed receptor activated G proteins modulate activities of 
ion channels by membrane-confined mechanisms [74]. Isoproterenol induced 
phosphorylation of ventricular Ca2+-channels via PKA has been reported [75]. Gs protein 
also has been shown to regulate Ca2+-channels both in a cAMP-independent membrane-
confined mechanism [74] and in a cAMP-dependent phosphorylation of one of the subunits 
of L-type Ca2+-channel [76]. Synaptosomal NKA has previously been described to be 
inhibited by cAMP in a dose-dependent manner suggesting a role of PKA. The activated 
form of this protein kinase was further phosphorylated a substrate protein which in turn 
depressed the total Na+-dependent phosphorylation of the synaptosomal NKA [77]. Overall, 
 
Thyroid Hormone 20 
our data indirectly support the involvement of second messenger system (cAMP and/or 
Ca2+) mediated through G protein activation after specific L-T3-membrane receptor 
interaction. The membrane NKA has been implicated in several aspects of physiologic 
processes including its role in neurotransmitter release [43].  
5.4. First evidence of rapid nongenomic action of thyroid hormone and its 
metabolites on the synaptosomal protein phosphorylation in adult rat brain, in 
vitro 
Protein phosphorylation and dephosphorylation are now recognized to be major regulatory 
mechanisms by which neural activities are controlled by external physiological signals or 
stimuli. Several nongenomic mechanisms are coordinated by rapid post-transcriptional 
modifications, such as protein phosphorylation and dephosphorylation reactions, which act 
like a molecular switch to control intracellular signaling mechanisms. Abnormalities of these 
imperative regulatory signaling processes produce deleterious effects on the CNS. As a 
consequence, variety in unusual protein phosphorylation is the end result of many major 
neuropshychological dysfunctions leading to diseases [78]. Numerous second messenger 
molecules regulate cellular physiology by effects on protein kinases and phosphatases. 
Protein kinases catalyze the transfer of the terminal -phosphate group of ATP or GTP to the 
hydroxyl group of serine, threonine or tyrosine in substrate proteins. Their structure, 
subcellular localization and substrate specificity allow them to control cellular physiology. 
These proteins largely make up the cell signaling pathways that transmit, amplify and 
integrate signals from the extracellular environment. Protein phosphorylation promotes 
enzyme activation or deactivation. Phosphorylated proteins are substrates for protein 
phosphatases and dephosphorylation occur to serve as a molecular switch to fine tune a 
cellular response [79].  
Variety of agents regulating the activity of NKA raises the possibility of the NKA as a 
substrate molecule that is subject to regulation by phosphorylation or dephosphorylation. 
Indeed, inhibition of NKA is associated with the phosphorylation of the enzyme by both 
PKA and PKC. This inhibition of NKA has been attributed to the phosphorylation of 1-
subunit of the NKA molecule at serine residues by PKA and PKC site-specifically. 
Isoproterenol (-adrenergic agonist that activates adenylate cyclase to produce cAMP, an 
activator of PKA), forskolin (adenylate cyclase activator), and okadaic acid (an inhibitor of 
protein phosphatase-1 and -2A) have been reported to increase significantly the level of 
phosphorylation of wild-type 1-subunit of the NKA in COS cells, accompanied by a 
significant inhibition of the enzyme activity [62,63]. Among nine distinct isoforms of 
adenylate cyclase (AC), three isoforms are Ca2+/calmodulin-dependent, including type I-AC, 
III-AC [80,81], and VIII-AC. The Ca2+/calmodulin-dependent AC is an integral membrane 
protein [82]. Hence, one possible role of Ca2+/calmodulin may be to stimulate 
Ca2+/calmodulin-dependent AC followed by cAMP production and phosphorylation of the 
NKA, exactly as -adrenergic receptor agonists do. 
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While a direct effect of TH on protein kinase activity has not been formerly studied in 
tissues from mature brain, hypothyroidism has been linked with reduced levels of 
phosphorylated MAPK in the hippocampus [83]. Based on these observations, possibility of 
a metabotropic pathway for rapid actions of TH on protein phosphorylation in 
synaptosomes from adult rat brain was investigated.  
 
Figure 9. Representative autoradiogram of SDS-PAGE separation of proteins incorporating 32P in the 
presence of L-T3. Lanes were loaded with synaptosomal lysates which had been preincubated at 0°C for 
60 min and 37°C for 5 min with (from left): 1mM Na3VO4 (V), 1, 3, 10, 30, 100, 300, 1000, or 0 (C = 
control) nM L-T3 and then incubated with 20μM of [γ-32P]-ATP (3 μCi) for 1 min at 37°C. Left panel (a): 
Silver-stained gel for visualization of protein bands. Right panel (b): Autoradiogram of same gel 
showing increased incorporation of 32P in four prominent bands (α: 381 kD, β: 531 kD, γ: 631 kD, δ: 
1131 kD). (c) Normalized data showing effect of in vitro addition of graded doses of L-T3 on the levels 
of protein phosphorylation expressed as optical density (OD)/protein (Ref. Sarkar et al. 2006 
Neuroscience 137: 125-132 acknowledged [11]).  
Our observation demonstrated that TH induces rapid changes in synaptosomal protein 
phosphorylation. Incubation with L-T3 or L-T4 specifically showed significant biphasic 
dose-dependent effects on the phosphorylation of 381, 531, 621, and 1131 kD proteins. 
In vitro brain physiologic concentrations of TH (1-30 nM) showed significant increase in the 
levels of protein phosphorylation rapidly within minutes (Figure 9). In contrast, incubations 
with similar doses of reverse-T3 (rT3) were without significant effect, indicating specificity 
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proteins were significantly increased followed by L-T3 and L-T4 treatment as well. Both L-
T3 and L-T4 indicated bi-phasic nature of effect for each of these proteins phosphorylated. 
Maximum levels of phosphorylation were noticed at concentration range from 10-30 nM. 
However, no significant effect on protein phosphorylation was observed as an effect of rT3 
on any of these proteins. This effect of rT3 clearly confirmed very structural and functional 
specificity of L-T3 on protein phosphorylation. Determination of time course of protein 
phosphorylation followed by one single in vitro dose of L-T3 showed it peaked rapidly 
between 180 seconds to 240 seconds and thereafter it decreased. This indicated a rapid 
action of THs and its metabolites [11].  
Our next interest was to see which amino acids present in these phosphoyraled proteins are 
targets. Hence phospho-specifc antibodies for tyrosine and serine were used in western bolt 
analysis. Immunoblot analysis of synaptosomal lysates incubated with L-T3 (1 nM-1 M) 
confirmed phosphorylation at the seryl residues of a ~112 kD protein and phosphorylation 
at tyrosyl residues of a distinct ~ 95 kD protein. These data support that THs have a 
diversity of rapid nongenomic pathways for regulation of protein phosphorylation in 
mature mammalian brain [11]. Especially, the α-subunit of NKA is a ~112 kD membrane 
protein. Indeed, inhibition of NKA is associated with the phosphorylation of its subunits by 
both PKA and PKC. This inhibition of NKA has been attributed to the site-specific 
phosphorylation of the α1-subunit of the NKA at seryl residues by PKA and PKC [61-63]. In 
adult rat alveolar epithelial cell L-T3 induced translocation of NKA to plasma membrane. 
NKA stimulation by L-T3 was assigned to L-T3-induced stimulation of PI3K/PKB pathway 
via the Src family of tyrosine kinases nongenomically [84]. These data suggest possible 
involvement of membrane components in TH-induced protein phosphorylation.  
Examples of nongenomic control of protein phosphorylation by L-T3 also have been 
reported in few other tissues. Nongenomic relationship of MAPK and MAPK-mediated 
protein phosphorylation at the seryl residue of nuclear TH receptor has been described in 
293T cells [68]. This indicated a control of nongenomic mechanism on genomic mechanism. 
In developing brain, inhibition of PKA transcriptionally blocked L-T3-induced actin gene 
expression, whereas PKC and tyrosine kinase did not influence it significantly [85]. 
5.4.1. Thyroid hormones rapidly modulate synaptosomal protein phosphorylation via 
second messenger systems  
In other studies, L-T3 induction has also been shown to nongenomically regulate Ca2+ influx 
and nitric oxide synthase activity within seconds in adult rat brain [57]. Thus, THs are likely 
to have numerous rapid nongenomic effects on signaling mechanisms in neural tissue, 
including alterations in the levels of intracellular second messengers (cAMP and Ca2+) which 
regulate cAMP- and/or Ca2+/calmodulin (CaM)-dependent protein kinases leading to protein 
phosphorylation. Effects of TH on Ca2+-dependent activation of PKC and/or Ca2+/CaM-
dependent protein kinases are also possible, followed by direct or indirect activation of 
phosphorylation of the proteins. Thus further investigation demonstrated for the first time 
the rapid nongenomic second messenger mediated regulation of protein phosphorylation by 
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TH in mature mammalian brain and provided additional support for the contention that TH 
has a unique and complex signaling function in adult brain [12]. 
5.4.1.1. Role of calcium and calmodulin on synaptosomal protein phosphorylation, in vitro 
Many nongenomic mechanisms are modulated by phosphorylation–dephosphorylation of 
substrate proteins. Multiple Ca2+/calmodulin (CaM)-dependent protein kinases (CaM 
kinases) and Ca2+/phospholipid-dependent protein kinases (PKCs) have been identified in 
brain. Among these, CaMPK-II is the most abundant Ca2+/CaM-stimulated protein kinase in 
brain. CaMPK-II is important in several neuronal functions, including neurotransmitter 
release and the modulation of the functional properties of ion channels and receptors. 
CaMPK-II is differentially expressed in different brain regions of cells, exists in both 
cytosolic and membrane-associated forms and is especially concentrated in the postsynaptic 
density and synaptic vesicles. A distinct property of CaMPK-II is that autophosphorylation 
of its threonine residue near the calmodulin binding domain converts it to a Ca2+-
independent state. Further, it has been shown that calmodulin-dependent 
autophosphorylation of CaMPK-II induces a conformational changes in the region of the 
calmodulin binding domain that allows additional stabilizing interactions with calmodulin. 
This autophosphorylation may involve in extending the effects triggered by a transient 
calcium signal. PTU-induced mild hypothyroidism in chick brain during posthatch 
development has been shown to increase the level of Ca2+/CaM-stimulated phosphorylation 
in cytosol, but lower it in the membrane, indicating a role of thyroid hormones in 
distributing CaMPK-II during developmental changes [78,86].  
5.4.1.1.1. Effect of L-T3 on total protein phosphorylation 
The effect of Ca2+ and calmodulin on TH-induced total protein phosphorylation and their 
regulation was explored. L-T3 significantly and dose-dependently (10 nM-1 M) increased 
total 32P- incorporation into synaptosomal proteins, in vitro, over the basal level of 
phosphorylation. Although L-T3 exerted its own independent effect on increase in overall 
total protein phosphorylation, specifically it established its role to be at least dependent on 
Ca2+ and calmodulin. Ca2+ also showed its independent influence on the basal L-T3-induced 
total protein phosphorylation in synaptosomal isolates. The dependency of L-T3-induced 
total synaptosomal protein phosphorylation was evaluated and finally confirmed using 
EGTA (Ca2+-ion chelator) and KN-62 (a specific blocker of CaMK-II). In vitro addition of 10 
nM and 100 nM doses of L-T3 alone did not alter significantly the basal levels of 
phosphorylation. However, the 1 M dose of L-T3 significantly amplified the signal by ~1.3-
fold compared to the basal level (P<0.05). Next, we wanted to determine whether Ca2+ 
augments protein phosphorylation in the presence of L-T3. Ca2+ (0.5 mM) were able to 
significantly increase the basal phosphorylation level. However, no further significant 
changes were noticed with additional 10 nM or 100 nM L-T3. However, 1 μM concentration 
of L-T3 augmented the signal significantly (P<0.05) by ~1.5-fold (0.2167 pmols/min/mg 
protein) as compared to the Ca2+-treated baseline (0.1475 pmols/min/mg protein), and by 
~2.2-fold over the basal phosphorylation (0.097 pmols/min/mg protein). In contrast, the 
effects of low physiological concentrations of L-T3 were dramatically enhanced when 2 M 
CaM was added to the Ca2++ L-T3-treatment group. In the presence of Ca2+ and CaM, L-T3 
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phosphorylation of the proteins. Thus further investigation demonstrated for the first time 
the rapid nongenomic second messenger mediated regulation of protein phosphorylation by 
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TH in mature mammalian brain and provided additional support for the contention that TH 
has a unique and complex signaling function in adult brain [12]. 
5.4.1.1. Role of calcium and calmodulin on synaptosomal protein phosphorylation, in vitro 
Many nongenomic mechanisms are modulated by phosphorylation–dephosphorylation of 
substrate proteins. Multiple Ca2+/calmodulin (CaM)-dependent protein kinases (CaM 
kinases) and Ca2+/phospholipid-dependent protein kinases (PKCs) have been identified in 
brain. Among these, CaMPK-II is the most abundant Ca2+/CaM-stimulated protein kinase in 
brain. CaMPK-II is important in several neuronal functions, including neurotransmitter 
release and the modulation of the functional properties of ion channels and receptors. 
CaMPK-II is differentially expressed in different brain regions of cells, exists in both 
cytosolic and membrane-associated forms and is especially concentrated in the postsynaptic 
density and synaptic vesicles. A distinct property of CaMPK-II is that autophosphorylation 
of its threonine residue near the calmodulin binding domain converts it to a Ca2+-
independent state. Further, it has been shown that calmodulin-dependent 
autophosphorylation of CaMPK-II induces a conformational changes in the region of the 
calmodulin binding domain that allows additional stabilizing interactions with calmodulin. 
This autophosphorylation may involve in extending the effects triggered by a transient 
calcium signal. PTU-induced mild hypothyroidism in chick brain during posthatch 
development has been shown to increase the level of Ca2+/CaM-stimulated phosphorylation 
in cytosol, but lower it in the membrane, indicating a role of thyroid hormones in 
distributing CaMPK-II during developmental changes [78,86].  
5.4.1.1.1. Effect of L-T3 on total protein phosphorylation 
The effect of Ca2+ and calmodulin on TH-induced total protein phosphorylation and their 
regulation was explored. L-T3 significantly and dose-dependently (10 nM-1 M) increased 
total 32P- incorporation into synaptosomal proteins, in vitro, over the basal level of 
phosphorylation. Although L-T3 exerted its own independent effect on increase in overall 
total protein phosphorylation, specifically it established its role to be at least dependent on 
Ca2+ and calmodulin. Ca2+ also showed its independent influence on the basal L-T3-induced 
total protein phosphorylation in synaptosomal isolates. The dependency of L-T3-induced 
total synaptosomal protein phosphorylation was evaluated and finally confirmed using 
EGTA (Ca2+-ion chelator) and KN-62 (a specific blocker of CaMK-II). In vitro addition of 10 
nM and 100 nM doses of L-T3 alone did not alter significantly the basal levels of 
phosphorylation. However, the 1 M dose of L-T3 significantly amplified the signal by ~1.3-
fold compared to the basal level (P<0.05). Next, we wanted to determine whether Ca2+ 
augments protein phosphorylation in the presence of L-T3. Ca2+ (0.5 mM) were able to 
significantly increase the basal phosphorylation level. However, no further significant 
changes were noticed with additional 10 nM or 100 nM L-T3. However, 1 μM concentration 
of L-T3 augmented the signal significantly (P<0.05) by ~1.5-fold (0.2167 pmols/min/mg 
protein) as compared to the Ca2+-treated baseline (0.1475 pmols/min/mg protein), and by 
~2.2-fold over the basal phosphorylation (0.097 pmols/min/mg protein). In contrast, the 
effects of low physiological concentrations of L-T3 were dramatically enhanced when 2 M 
CaM was added to the Ca2++ L-T3-treatment group. In the presence of Ca2+ and CaM, L-T3 
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(10 nM-1 μM) induced a dose-dependent increase in 32P- incorporation into synaptosomal 
protein, by 47±8 , 74±13 and 52±11 % (F = 6.77, P<0.0001) rapidly within 1 min compared 
with the Ca2+/CaM-treated control phosphorylation (0.189 pmols/min/mg protein) [87].  
Physiological concentrations L-T3 in nerve terminals are difficult to measure. Predictable 
levels of L-T3 within the nerve terminals range from ~10 nM to 64 nM. PTU-induced 
peripheral hypothyroidism in adult rats showed endogenous synaptosomal level of L-T3 is 
about ~126 nM. Thus L-T3 (1 μM) is well above this range, and would be considered to have 
a more pharmacological type of action on 32P- incorporation to synaptosomal 
phosphoproteins. Treatment with agents regulating Ca2+ could be a potential strategy for 
enhancing clinical treatment of conditions, such as certain affective disorders, which may be 
responsive to pharmacological doses of TH. In an earlier in vitro study, L-T3 doses (0.1 to 
100 nM), have been shown to induce an increase in intrasynaptosomal Ca2+ levels with an 
optimum at 100 nM of L-T3. Although higher levels of L-T3 (1 μM) produced slight 
depression of intrasynaptosmal Ca2+ levels, picomolar levels of L-T3 were also shown to be 
able to significantly increase intrasynaptosomal Ca2+ levels in vitro. The synergistic effect of 
L-T3 and Ca2+/CaM on protein phosphorylation would likely be further amplified by the 
effect of L-T3 to increase Ca2+ levels intracellularly in the physiological situation. In 
particular, this study demonstrated that of 10 nM dose of L-T3 (brain physiological 
concentration) and a ten times higher dose of L-T3 (as observed to be the brain levels of L-T3 
in PTU-induced hypothyroid young adult rat brain synaptosomes alone or with Ca2+ did 
dramatically increased L-T3-induced total protein phosphorylation. Thus the present study 
demonstrated that Ca2+/CaM-dependent mechanisms synergistically increase the rapid 
nongenomic effect of L-T3 on synaptosomal protein phosphorylation [87]. The Ca2+/CaM-
dependent effects could be due to an activation of an unknown CaM-dependent protein 
kinase(s), deactivation of protein phosphatase(s) or a combination of effects. However, it 
proved to be highly sensitive to L-T3 activation.  
Numerous phosphoproteins are greatly influenced by PKA and PKC in a Ca2+- and/or CaM-
dependent way. Often Ca2+ also functions in combination with CaM or with 
phosphoinositides/diacylglycerol to induce additional signal transduction pathways within 
the synaptic network. Regulation of intracellular Ca2+, CaM and subsequent protein 
phosphorylation are important for brain and cognitive functions affected by various 
psychiatric disorders. Membrane depolarization-induced Ca2+-influx activates 
extracellularly regulated kinases/MAPK in a Ca2+/CaM-dependent way in PC12 cells. THs 
also promote MAPK-mediated serine phosphorylation of the nuclear TH receptor β-1 
isoform nongenomically in 293T cells. Ca2+ and CaM also differentially regulate of TH-
induced neuronal protein phosphorylation [12,87]. 
5.4.1.1.2. L-T3-induced stimulation of phosphorylation of 63- and 53 kD proteins was 
regulated by Ca2+ and calmodulin  
After getting an idea of L-T3-induced total protein phosphorylation within neuronal 
membrane it was an obvious interest to look for specific proteins phosphorylated under the 
influence of L-T3. In vitro addition of L-T3 (10 nM, brain physiologic concentrations of L-T3) 
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demonstrated differential regulation of phosphorylation status of ve different 
synaptosomal proteins (63-, 53-, 38-, 23-, and 16 kD) in both a Ca2+/CaM-dependent and -
independent manner in mature rat brain cortical synaptosomes. L-T3 increased the level of 
phosphorylation of all these ve proteins. Ca2+/CaM further stimulated phosphorylation of 
63- and 53 kD proteins by L-T3, which were inhibited both specifically by EGTA (Ca2+- 
chelator) or KN62 (Ca2+/CaM kinase-II [CaMK-II] inhibitor), suggesting the role of CaMK-II. 
However, presence of Ca2+ significantly decreased L-T3-induced phosphorylation of 63-, 53 
kD proteins (Figure 10). 
       
Figure 10. A. L-T3-stimulated phosphorylation of 63- and 53 kDa proteins are regulated by Ca2+/CaM-
dependent protein kinase II. (a) Representative autoradiogram of the 63- and 53 KD proteins followed 
by various treatment conditions as described. (b) Corresponding protein bands from silver stained gel 
used for normalization of the data and demonstrates comparable equal amounts of sample loading. B. 
The quantification of the L-T3 (10 nM)-induced phosphorylation presented as a graph of ratio of the 
band densities of the phosphorylated proteins in the autoradiogram (a) and the corresponding protein 
in the silver stained gel (b) at different treatment conditions as indicated. * represents the level of 
significance of P<0.05 compared to the corresponding basal level (control). The data presented are 
normalized results (mean ± S.E.M.) for an indicated protein band (Ref. Sarkar 2008 Life Sciences 82: 920-
927 acknowledged [12]).  
5.4.1.1.3. Inert action of Ca2+ and calmodulin on the independent effect of L-T3 on the 
phosphorylation of 38- and 23 kD proteins  
L-T3 also increased the phosphorylation of 23- and 38 kD proteins. The effect was 
independent of EGTA or KN62. L-T3 only slightly enhanced the phosphorylation of the 38 
kD protein (p<0.05, F = 3.74) by ~1.2-fold in the presence of Ca2+/CaM compared to Ca2+/CaM 
control group. Although addition of Ca2+ decreased the level of L-T3-induced 
phosphorylation of 38 kD protein (P = non-significant), it was significantly increased 
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(10 nM-1 μM) induced a dose-dependent increase in 32P- incorporation into synaptosomal 
protein, by 47±8 , 74±13 and 52±11 % (F = 6.77, P<0.0001) rapidly within 1 min compared 
with the Ca2+/CaM-treated control phosphorylation (0.189 pmols/min/mg protein) [87].  
Physiological concentrations L-T3 in nerve terminals are difficult to measure. Predictable 
levels of L-T3 within the nerve terminals range from ~10 nM to 64 nM. PTU-induced 
peripheral hypothyroidism in adult rats showed endogenous synaptosomal level of L-T3 is 
about ~126 nM. Thus L-T3 (1 μM) is well above this range, and would be considered to have 
a more pharmacological type of action on 32P- incorporation to synaptosomal 
phosphoproteins. Treatment with agents regulating Ca2+ could be a potential strategy for 
enhancing clinical treatment of conditions, such as certain affective disorders, which may be 
responsive to pharmacological doses of TH. In an earlier in vitro study, L-T3 doses (0.1 to 
100 nM), have been shown to induce an increase in intrasynaptosomal Ca2+ levels with an 
optimum at 100 nM of L-T3. Although higher levels of L-T3 (1 μM) produced slight 
depression of intrasynaptosmal Ca2+ levels, picomolar levels of L-T3 were also shown to be 
able to significantly increase intrasynaptosomal Ca2+ levels in vitro. The synergistic effect of 
L-T3 and Ca2+/CaM on protein phosphorylation would likely be further amplified by the 
effect of L-T3 to increase Ca2+ levels intracellularly in the physiological situation. In 
particular, this study demonstrated that of 10 nM dose of L-T3 (brain physiological 
concentration) and a ten times higher dose of L-T3 (as observed to be the brain levels of L-T3 
in PTU-induced hypothyroid young adult rat brain synaptosomes alone or with Ca2+ did 
dramatically increased L-T3-induced total protein phosphorylation. Thus the present study 
demonstrated that Ca2+/CaM-dependent mechanisms synergistically increase the rapid 
nongenomic effect of L-T3 on synaptosomal protein phosphorylation [87]. The Ca2+/CaM-
dependent effects could be due to an activation of an unknown CaM-dependent protein 
kinase(s), deactivation of protein phosphatase(s) or a combination of effects. However, it 
proved to be highly sensitive to L-T3 activation.  
Numerous phosphoproteins are greatly influenced by PKA and PKC in a Ca2+- and/or CaM-
dependent way. Often Ca2+ also functions in combination with CaM or with 
phosphoinositides/diacylglycerol to induce additional signal transduction pathways within 
the synaptic network. Regulation of intracellular Ca2+, CaM and subsequent protein 
phosphorylation are important for brain and cognitive functions affected by various 
psychiatric disorders. Membrane depolarization-induced Ca2+-influx activates 
extracellularly regulated kinases/MAPK in a Ca2+/CaM-dependent way in PC12 cells. THs 
also promote MAPK-mediated serine phosphorylation of the nuclear TH receptor β-1 
isoform nongenomically in 293T cells. Ca2+ and CaM also differentially regulate of TH-
induced neuronal protein phosphorylation [12,87]. 
5.4.1.1.2. L-T3-induced stimulation of phosphorylation of 63- and 53 kD proteins was 
regulated by Ca2+ and calmodulin  
After getting an idea of L-T3-induced total protein phosphorylation within neuronal 
membrane it was an obvious interest to look for specific proteins phosphorylated under the 
influence of L-T3. In vitro addition of L-T3 (10 nM, brain physiologic concentrations of L-T3) 
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demonstrated differential regulation of phosphorylation status of ve different 
synaptosomal proteins (63-, 53-, 38-, 23-, and 16 kD) in both a Ca2+/CaM-dependent and -
independent manner in mature rat brain cortical synaptosomes. L-T3 increased the level of 
phosphorylation of all these ve proteins. Ca2+/CaM further stimulated phosphorylation of 
63- and 53 kD proteins by L-T3, which were inhibited both specifically by EGTA (Ca2+- 
chelator) or KN62 (Ca2+/CaM kinase-II [CaMK-II] inhibitor), suggesting the role of CaMK-II. 
However, presence of Ca2+ significantly decreased L-T3-induced phosphorylation of 63-, 53 
kD proteins (Figure 10). 
       
Figure 10. A. L-T3-stimulated phosphorylation of 63- and 53 kDa proteins are regulated by Ca2+/CaM-
dependent protein kinase II. (a) Representative autoradiogram of the 63- and 53 KD proteins followed 
by various treatment conditions as described. (b) Corresponding protein bands from silver stained gel 
used for normalization of the data and demonstrates comparable equal amounts of sample loading. B. 
The quantification of the L-T3 (10 nM)-induced phosphorylation presented as a graph of ratio of the 
band densities of the phosphorylated proteins in the autoradiogram (a) and the corresponding protein 
in the silver stained gel (b) at different treatment conditions as indicated. * represents the level of 
significance of P<0.05 compared to the corresponding basal level (control). The data presented are 
normalized results (mean ± S.E.M.) for an indicated protein band (Ref. Sarkar 2008 Life Sciences 82: 920-
927 acknowledged [12]).  
5.4.1.1.3. Inert action of Ca2+ and calmodulin on the independent effect of L-T3 on the 
phosphorylation of 38- and 23 kD proteins  
L-T3 also increased the phosphorylation of 23- and 38 kD proteins. The effect was 
independent of EGTA or KN62. L-T3 only slightly enhanced the phosphorylation of the 38 
kD protein (p<0.05, F = 3.74) by ~1.2-fold in the presence of Ca2+/CaM compared to Ca2+/CaM 
control group. Although addition of Ca2+ decreased the level of L-T3-induced 
phosphorylation of 38 kD protein (P = non-significant), it was significantly increased 
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(P<0.05) in the presence of CaM compared to Ca2+ + L-T3 treatment and only L-T3 effect. 
However, the presence of Ca2+ or the Ca2+/CaM did not further affect the phosphorylation 
status of the 38 kD protein. This further suggested no involvement of Ca2+/CaM-dependent 
pathways mediated through CaMK-II.  
The study also described the phosphorylation status of a 23 kD protein. Phosphorylation 
level of 23 kD protein was highest among all the proteins. L-T3 significantly increased the 
phosphorylation level of 23 kD by ~2.2-fold compared to the basal level. Especially of 
interest, EGTA or KN62 did not show any more or less influence on the L-T3-induced 
increase in the phosphorylation status of the 23 kD protein suggesting lack of significant 
regulation by CaMK-II (Figure 11).  
 
 
Figure 11. A. Ca2+/CaM do not modulate L-T3-stimulated phosphorylation of 23- and 38 kD proteins. 
(a) A representative autoradiogram of the 23- and 38 kD protein separated by SDS-PAGE showing 
independent stimulatory action of L-T3 upon the phosphorylation of the 23- and 38 kD proteins. B. The 
quantification of the L-T3-induced phosphorylation presented as a graph of ratio of the band densities 
of the phosphorylated proteins in the autoradiogram (a) and the corresponding protein in the silver 
stained gel (b) at different treatment conditions as indicated. The data presented are normalized results 
(mean ± S.E.M.) for an indicated protein band. * Indicates levels of significance P<0.05 (Ref. Sarkar 2008 
Life Sciences 82: 920-927 acknowledged [12]).  
5.4.1.1.4. Calmodulin dephosphorylated 16 kD protein following L-T3-induction 
In vitro addition of L-T3 (10 nM) significantly increased the level of phosphorylation of 16 
kD protein by ~8-fold. The L-T3-induced phosphorylation of 16 kD protein was not further 
activated in the presence of Ca2+. Surprisingly, L-T3-induced phosphorylation of 16 kD 
protein was not augmented further with Ca2+ or Ca2+/CaM; instead, the presence of CaM 
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abolished the L-T3-induced phosphorylation. EGTA or KN62 could not restore the effect of 
CaM-induced dephosphorylation of this protein (Figure 12).   
Immunoblotting experiment with anti-phosphoserine antibodies also showed significant 
enhancement of seryl residue phosphorylation of this protein by Ca2+/CaM (Figure 13). 
Abolition of this effect by EGTA and KN-62 further suggested an important role of CaMK-II. 
This study identied the role of Ca2+/CaM in the regulation of L-T3-induced protein 
phosphorylation and supported a unique nongenomic mechanism of second messenger-
mediated regulation of protein phosphorylation by TH in mature rat brain. 
 
 
Figure 12. A. Phosphorylation of 16 kD protein by L-T3 was conquered by the dephosphorylation 
activity of CaM. (a) A representative autoradiogram of the 16 kD protein separated by SDS-PAGE is 
showing independent stimulatory action of L-T3 upon the phosphorylation of the 16 kD protein. (b). 
Corresponding protein bands of silver stained gel. B. The quantification of the L-T3 (10 nM)-induced 
phosphorylation and its dephosphorylation by CaM are presented as a graph of ratio of the band 
densities of the phosphorylated proteins in the autoradiogram (a) and the corresponding protein in the 
silver stained gel (b) at different treatment conditions as indicated. The data presented are normalized 
results (mean ± S.E.M.) for an indicated protein band. * Indicates levels of significance P<0.05, compared 
to the basal level (control group) (Ref. Sarkar 2008 Life Sciences 82: 920-927 acknowledged [12]). 
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Figure 13. L-T3 induced phosphorylation of the 53 kD protein is regulated by Ca2+/calmodulin protein 
kinase II: Serine residue phosphorylation. (A) Phosphorylation status of the 53 kD protein 
immunoblotted with anti-phosphoserine (PS) antibody. (B) Corresponding protein band of silver 
stained gel. (C) Graphical representation of the levels of phosphorylation of the 53 kD protein at various 
treatment conditions. The data presented are normalized results (mean ± S.E.M.) for an indicated 
protein band. * Indicates levels of significance P<0.05, compared to the basal level (control group).   
5.4.1.2. Role of cAMP on synaptosomal protein phosphorylation, in vitro  
After searching for whether Ca2+ plays a major role as second messenger following L-T3 
induced protein phosphorylation, our next step was to examine for the role of cyclic AMP 
(cAMP) as another second messenger upon L-T3-induction, in vitro, to explore furthermore 
the nongenomic mechanism of TH. To search for any role of cAMP-dependent protein 
kinase (PKA) the effects of cAMP and H7 (a specific blocker of PKA) were studied. In vitro 
addition of H7 significantly diminished the effect of L-T3-induced increase in serine 
phosphorylation of two closely associated proteins with 51- and 53 kD by ~14-fold and ~11-
fold respectively (Figure 14). This suggested prevalence of a PKA-mediated mechanism in 
L-T3-induced synaptosomal protein phosphorylation. To test further whether THs exert 
adrenergic-like actions by binding to or modulating adrenergic receptor activities another 
study was performed to test this hypothesis. The idea of formation of thyronamines and its 
possible binding to the ADR is considered here. Effect of clonidine was studied on the L-T3-
induced protein phosphorylation and on the L-T3-binding to the synaptosomal membrane 
receptors. Scatchard plot analysis revealed clonidine and yohimbine (2-ADR antagonist) 
could not alter specific L-T3 binding at the high affinity L-T3 synaptosomal membrane 
binding sites. L-T3 induced phosphorylation of this 51-/53 kD protein was blocked by H7, a 
PKA inhibitor. Activation of 2-ADR by clonidine normally decreases the levels of cAMP via 
inhibiting adenylate cyclase activity. Possibly in the absence of adequate cAMP levels 
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unchanged. This suggests L-T3-membrane interaction was independent of the activation of 
the 2-ADR system. Overall these data implicate that PKA and CaMK-II both contribute for 
L-T3 regulated protein phosphorylation in adult mammalian brain and reveals a 
nongenomic mechanistic pathway in relation to higher mental functions. 
 
 
Figure 14. L-T3 induced phosphorylation of the 51-/53- kD proteins are abolished by Protein Kinase A 
Inhibitor (H7). (A) One representative phosphorylation status of the 51-/53-kD protein immunoblotted 
with anti-phosphoserine (PS) antibodies. (B) Corresponding protein band of silver stained gel. (C) 
Graphical representation of the levels of phosphorylation of the 51-/53-kD protein at various treatment 
conditions. dbcAMP is dibutyryl cyclic AMP. The data presented are normalized results (mean ± 
S.E.M.) for an indicated protein band. * Indicates levels of significance p<0.05, compared to the basal 
level (control group). 
6. Conclusion  
In conclusion the recent evidence-based information regarding the nongenomic mechanism 
of action of THs are opening new signal transduction clues to be studied and to reveal the 
underlying mechanism in mature mammalian brain. The results of the study conducted will 
advance our knowledge of the fundamental molecular mechanism of TH action in mature 
CNS, likely in future will lead to more rational and effective approach to the development of 
novel therapeutic agents, and thus will shed insights on to the neuropshychological 
manifestations of adult on-set thyroid disorders in humans, particularly in relation to higher 
mental functions.  
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Figure 13. L-T3 induced phosphorylation of the 53 kD protein is regulated by Ca2+/calmodulin protein 
kinase II: Serine residue phosphorylation. (A) Phosphorylation status of the 53 kD protein 
immunoblotted with anti-phosphoserine (PS) antibody. (B) Corresponding protein band of silver 
stained gel. (C) Graphical representation of the levels of phosphorylation of the 53 kD protein at various 
treatment conditions. The data presented are normalized results (mean ± S.E.M.) for an indicated 
protein band. * Indicates levels of significance P<0.05, compared to the basal level (control group).   
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phosphorylation of two closely associated proteins with 51- and 53 kD by ~14-fold and ~11-
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L-T3-induced synaptosomal protein phosphorylation. To test further whether THs exert 
adrenergic-like actions by binding to or modulating adrenergic receptor activities another 
study was performed to test this hypothesis. The idea of formation of thyronamines and its 
possible binding to the ADR is considered here. Effect of clonidine was studied on the L-T3-
induced protein phosphorylation and on the L-T3-binding to the synaptosomal membrane 
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inhibiting adenylate cyclase activity. Possibly in the absence of adequate cAMP levels 
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unchanged. This suggests L-T3-membrane interaction was independent of the activation of 
the 2-ADR system. Overall these data implicate that PKA and CaMK-II both contribute for 
L-T3 regulated protein phosphorylation in adult mammalian brain and reveals a 
nongenomic mechanistic pathway in relation to higher mental functions. 
 
 
Figure 14. L-T3 induced phosphorylation of the 51-/53- kD proteins are abolished by Protein Kinase A 
Inhibitor (H7). (A) One representative phosphorylation status of the 51-/53-kD protein immunoblotted 
with anti-phosphoserine (PS) antibodies. (B) Corresponding protein band of silver stained gel. (C) 
Graphical representation of the levels of phosphorylation of the 51-/53-kD protein at various treatment 
conditions. dbcAMP is dibutyryl cyclic AMP. The data presented are normalized results (mean ± 
S.E.M.) for an indicated protein band. * Indicates levels of significance p<0.05, compared to the basal 
level (control group). 
6. Conclusion  
In conclusion the recent evidence-based information regarding the nongenomic mechanism 
of action of THs are opening new signal transduction clues to be studied and to reveal the 
underlying mechanism in mature mammalian brain. The results of the study conducted will 
advance our knowledge of the fundamental molecular mechanism of TH action in mature 
CNS, likely in future will lead to more rational and effective approach to the development of 
novel therapeutic agents, and thus will shed insights on to the neuropshychological 
manifestations of adult on-set thyroid disorders in humans, particularly in relation to higher 
mental functions.  
 
Thyroid Hormone 30 
7. Future research direction 
Recent information regarding nongenomic mechanism of thyroid hormone action in various 
tissue types including mammalian CNS is interesting. These studies are diligently engaged 
in decoding the molecular consequences of thyroid hormone action from the specific gene 
expression to the nongenomic rapid actions of the hormone. Open-minded investigators are 
desperately searching for the truth and the relationship of thyroid hormone action 
explicated through its classical well-known doctrine which is mediated via activation of 
specific nuclear receptors to the newly emerging idea of rapid nongenomic actions of the 
hormone and an association to enlighten the both. In particular, adult mammalian brain are 
of best curiosity since clinical observations of numerous thyroid dysfunction related 
neuropsychological disorders produced during mature conditions in humans can be 
corrected with the adjustment of the thyroid hormone levels. However the mechanism of 
action is lacking. Nongenomic rapid events mediated by thyroid hormones could have 
connection to the long-term genomic actions. Deciphering the nongenomic molecular 
mechanism of action of thyroid hormones has future prospects to study its importance 
regulating higher mental functions in humans. This fundamental knowledge could be the 
basis to find novel strategies to treat adult-onset thyroid dysfunctions including 
neuropsychological diseases many of which are precisely controlled by demarcated cellular 
fine-tuning of the protein phosphorylation mechanisms related to neuronal signal 
transmission. 
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1. Introduction 
Hormones are important mediators in the responses of a suite of phenotypic traits to 
environmental changes. Therefore, populations inhabiting different environments are 
expected to vary in several hormonal pathways. Such variation results from both plastic 
response to environments and genetic differences. Therefore, information about the genetic 
basis of hormonal variation is crucial to better understand the ecological and evolutionary 
mechanisms of phenotypic diversification in animals. Furthermore, information about the 
racial and geographical variation in hormone physiology is crucial for better diagnosis of 
hormone-related diseases in clinical fields. Thyroid hormones play key roles in regulation of 
many physiological and behavioral traits, such as metabolism, ion homeostasis, basal 
activity, and longevity. Therefore, thyroid hormone can play important roles in 
adaptation to external environments. In the present study, we review interspecies, racial, 
geographical, and interindividual variation in the thyroid hormone pathways in humans 
and other animals. The present review focuses on natural and subclinical variation in 
thyroid hormone physiology and will not cover the genetic basis for congenital 
hypothyroidism [1,2,3,4,5], congenital hyperthyroidism [6,7], autoimmune diseases [8], 
and thyroid cancers [9], for which a number of good review articles are already available. 
We also review what is known about the genetic basis for such variation. We found 
several shared features in the patterns of variation in thyroid hormone physiology in 
humans and other animals. This review demonstrates the importance of undertaking 
further integrative studies of human genetics and animal ecology for a better 
understanding of the ecological and genetic mechanisms of variation in thyroid hormone 
signaling pathways. 
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2. Variation in thyroid hormone physiology in humans 
2.1. Interindividual, geographical, and racial variation 
Geographical variation in the frequency of euthyroid endemic goiter has been extensively 
investigated [10,11,12]. In addition to iodine deficiency, other factors, such as smoking, age, 
sex, goitrogens, and body mass index, can also influence the etiology of euthyroid endemic 
goiter [13]. Although genetic predisposition to euthyroid goiter has been demonstrated 
[12,13,14], the molecular genetic mechanisms underlying the variation in susceptibility to 
goiter are not well understood. Polymorphism at the thyroglobulin (TG) [15,16] and Na+/I− 
symporter (NIS) loci [17] are reportedly associated with euthyroid goiter; however, linkage 
mapping in different families could not connect euthyroid goiter with such genetic variation 
[18,19]. 
Racial variation in the level of thyroid-stimulating hormone (TSH), one of the major 
hormones regulating synthesis and secretion of thyroid hormone, has been also found. 
Multiple studies have revealed that serum TSH levels are higher in whites and Mexican 
Americans than in blacks [20,21,22]. These results suggest that race-specific reference values 
of TSH are necessary for evaluation of thyroid hormone-related diseases. Currently, the 
genetic and ecological basis for the racial variation in TSH levels is not well understood. The 
serum levels of thyroxine-binding globulin (TBG), a major thyroid hormone-binding protein 
in plasma, are lower in Australian Aborigines than in Caucasians in Western Australia [23]. 
Aborigines have a TBG variant that has reduced affinity for thyroid hormone and is more 
susceptible to heat and acid denaturation [24,25,26]. Two amino acids are substituted in this 
variant, one of which is considered responsible for the low binding affinity for thyroid 
hormones [26]. Aborigines usually have lower T4 levels, but have normal TSH levels and 
normal or borderline T3 levels. Because Aborigines do not show any clinical symptoms of 
hypothyroidism, the homeostasis of thyroid hormone physiology in Aborigines differs from 
that in other human populations. 
Although the adaptive significance of the variations remain elusive in the above cases, some 
interpopulation variation may result from adaptive evolution to divergent environments. 
Serum free T4 levels are higher in indigenous Evenki women than in nonindigenous 
Russian women living in the same communities in central Siberia [27]. The variation in free 
T4 levels was correlated with the variation in basal metabolic rate both in Evenki and 
Russian men and women [27]. Similar cases were also found for indigenous Nenets and 
nonindigenous Russians: both showed significant increases in total T4 levels during winter, 
but the magnitude of the increase was significantly greater in the Nenets than in the 
Russians [27]. Because thyroid hormones play important roles in regulating metabolic rate 
and adaptation to cold environments [28,29], human populations inhabiting colder 
environments may acquire genetic basis for more efficient thyroid hormone-induced 
thermogenesis and may therefore be genetically adapted to cold environments [30]. 
Interindividual differences in TSH levels are prevalent, and have been found to be 
associated with variation in life span. In Ashkenazi Jews and Northern Italians, healthy 
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oldest-old people of around 100 years of age had higher TSH levels than elderly controls of 
around 70 years of age [31,32]. In addition, follow-up studies revealed that participants with 
abnormally high TSH levels had a lower mortality rate than those with normal or low TSH 
levels [33]. The offspring of Ashkenazi Jewish centenarians had significantly higher TSH 
levels, suggesting that higher TSH levels and longevity have heritable components [32]; 
however, the molecular mechanisms of this variation are unknown. 
2.2. Genetic basis for variation 
In addition to the case of TGB in Australian Aborigines [34], polymorphisms associated with 
variation in thyroid hormone physiology have been found in other populations [35]. Several 
studies have focused on candidate genes involved in thyroid hormone signaling pathways 
and revealed that single nucleotide polymorphisms (SNPs) of the TSH receptor (TSHR) [36], 
iodothyronine deiodinases (DIO1, DIO2, and DIO3) [36,37], thyroid hormone transporter 
and thyroid hormone receptor genes accounted for variation in serum TSH and thyroid 
hormone levels [38,39]. Genome-wide association studies have also identified several genes 
involved in thyroid hormone signaling. Three SNPs at intron 1 of the phosphodiesterase 8B 
(PDE8B) gene are significantly associated with serum TSH levels [40,41]. PDE8B encodes a 
high-affinity cAMP-specific phosphodiesterase catalyzing the hydrolysis and inactivation of 
cAMP. Because the PDE8B transcript is undetectable in the pituitary, it is thought that 
PDE8B may affect TSH levels through its effect on TSH-dependent thyroid hormone 
synthesis and secretion in the thyroid gland. Interestingly, other cAMP-specific 
phosphodiesterases have also been showed to be associated with variation in TSH levels 
[41]. Since there are only a few studies revealing the mechanisms by which SNPs modify 
thyroid hormone signaling [38], further studies are needed to confirm their actual 
contribution to the natural variation in thyroid hormone physiology. 
If genes involved in thyroid hormone pathways were targets of natural selection, we would 
be able to find some signatures of natural selection in the human genome. When natural 
selection increases the frequency of a new beneficial mutation in a population, the 
neighboring regions will reduce the genetic variation and increase the level of linkage 
disequilibrium [42]. Two genes involved in the thyroid hormone pathway, thyroid hormone 
receptor interactor 4 (TRIP4) and iodotyrosine deiodinase (IYD), showed a signature of 
selection in the genome of African Pygmies [43]. Importantly, a low frequency (9.4%) of 
goiter was reported for an African Pygmy population, although they inhabit an iodine-
deficient region [44]. Because another population in the same region had a much higher 
frequency of goiter (42.9%), López Herráez et al. (2010) concluded that the signatures of 
selection in these genes might reflect genetic adaptations of Pygmies to iodine-deficient 
diets. Another study tried to identify the genes whose allele frequencies were significantly 
correlated with climate. The frequency of an SNP in TRIP6 showed strong correlation with 
latitude [45].  
The high rate of nonsynonymous (amino acid–altering) changes compared with the rate of 
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around 70 years of age [31,32]. In addition, follow-up studies revealed that participants with 
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cAMP. Because the PDE8B transcript is undetectable in the pituitary, it is thought that 
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goiter was reported for an African Pygmy population, although they inhabit an iodine-
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latitude [45].  
The high rate of nonsynonymous (amino acid–altering) changes compared with the rate of 





[42]. By comparing the synonymous and nonsynonymous substitutions in the human and 
chimp genomes, putatively positively selected genes were screened [46]. Genes expressed in 
the thyroid gland have an excess of rapidly evolving genes compared with other tissues, 
except testis, which has more putatively positively selected genes [46]. Changes in thyroid 
hormone physiology may contribute to some of the physiological and morphological 
divergence between humans and apes [47,48]. 
3. Inter-population and geographical variation in thyroid hormone 
physiology in animals 
Anatomical studies conducted in the 1960s and 1970s showed interspecies morphological 
variation for fishes and amphibians [49,50]. Since then, natural variation in thyroid hormone 
physiology has been extensively investigated in diverse taxa of vertebrate (Table 1). Some of the 
variation results from environmental factors. For example, environmental contaminants can 
cause goiter. In salmon populations introduced into the Great Lakes in the late 1960s, the 
frequency of thyroid goiter increased in the mid-1970s [51,52,53]. In addition, herring gulls Larus 
argentatus from the Great Lakes also suffered from goiter in the 1980s [54]. It was demonstrated 
that laboratory rats fed with the salmons caught in the lakes exhibited hypothyroidism and 
goiter, suggesting the presence of goitrogenic substances in the Great Lakes fishes [55]. 
 
Species/Family Phenotypic variation Potential factors and functions Reference 
Intraspecific 
variation 
   
 Coho salmon  Goiter, T4, T3 Goitrogen [51,53,97] 
 Chinook salmon  Goiter Goitrogen [53] 
 Herring gull Goiter Goitrogen [54] 
 American alligator T4 Goitrogen [98] 
 Japanese pond frog Morphology  [49] 
 Bottlenose dolphin  T4 and T3 Temperature [62] 
 Northern cardinal T4 and T3  [61] 
 Alaskan husky  T4 and T3 Temperature [60] 
 Bonnethead shark T4 and T3 in yolk Temperature [70] 
 Brook charr  T4 and T3 Migration [87] 
 Stickleback  Goiter, TSHß, T4,T3 Migration, metabolism [57,58,86] 
Interspecific 
variation 
   
 Poeciliidae Morphology, tumor  [50,99,100] 
 Spadefoot toad T4, T3, sensitivity Dry environment, 
metamorphosis 
[63] 
 Big-eared mouse T4, T3, iodide Low iodide concentration [59] 
 Rodent T4 Life span [101] 
Table 1. Variation in thyroid hormone physiology in natural animal populations 
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Goiters were also observed in hatchery fishes and possibly resulted from iodine deficiency, 
because iodine treatment was able to cure the goiter [56]. In the case of the threespine 
stickleback Gasterosteus aculeatus, interpopulation variation in susceptibility to goiter when 
reared in fresh water was observed [57,58], although whether the goiter in the sticklebacks 
was caused by iodine deficiency is unknown. Interestingly, a mammalian species, 
Auliscomys boliviensis, inhabiting an environment severely depleted of iodine did not show 
goiter [59], suggesting that genetic variation in the susceptibility to endemic goiter exists 
among populations and species. 
Latitudinal variation in plasma concentrations of thyroid hormone has been observed in 
both mammals and birds, and these variations might have evolved as adaptations to 
environments with divergent temperatures. Plasma total T4, free T4, and total T3 levels of 
sled dogs living in Alaska were higher than dogs in New York, especially in winter [60]. In 
addition, plasma T3 increased with increasing latitude in the northern cardinals Cardinalis 
cardinalis, whereas plasma T4 did not show a simple latitudinal cline: both southern and 
northern birds had higher T4 levels than birds living at an intermediate latitude [61]. In 
mammals, bottlenose dolphins Tursiops truncatus show variation in thyroid hormone 
concentrations between populations inhabiting different latitudes [62]: plasma total T3 and 
T4 were higher in dolphins from South Carolina with colder year-round temperatures than 
those from Florida with much warmer water temperatures. Since thyroid hormones play 
key roles in metabolism and heat generation, evolutionary adaptation to habitats with 
different temperatures may account for some of the latitudinal and geographical variation in 
thyroid hormone levels among natural populations. The genetic basis for the latitudinal 
variation is currently unknown. 
Several studies have demonstrated that variation in thyroid hormone physiology correlates 
with other potentially adaptive traits. Interspecies variation in tissue thyroid hormone levels 
and tissue sensitivity to thyroid hormone may be correlated with variation in the duration of 
the larval period in spadefoot toads [63]. For example, the tadpole of the desert-dwelling 
toad Scaphiopus couchii has higher tail and liver levels of thyroid hormone, and the tail tip is 
more sensitive to thyroid hormone in vitro than tail tips of other closely related species [63]. 
Because frog metamorphosis is controlled by thyroid hormone, the higher thyroid hormone 
levels and the higher sensitivity may explain the short larval period in this species. Rapid 
metamorphosis (i.e., the short period of water-dwelling at the tadpole stage) observed in the 
desert toad is likely adaptive for survival in the deserts where water is scarce [64,65]. 
Thyroid hormones also play critical roles as yolk hormones in mammalian [66], bird [67], 
and teleost [68,69] development. In the bonnethead shark Sphyrna tiburo, the concentrations 
of T3 and T4 in the yolk from the Tampa Bay population were consistently higher than those 
in the yolk from the Florida Bay population [70]. The bonnethead shark in Tampa Bay 
develops faster and is larger at birth than that in Florida Bay [71]. Tampa Bay is located in a 
more northern region and is colder than Florida Bay. Because rapid growth is generally 
adaptive in colder environments [72,73], higher york thyroid hormone levels in the Tampa 
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those from Florida with much warmer water temperatures. Since thyroid hormones play 
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the larval period in spadefoot toads [63]. For example, the tadpole of the desert-dwelling 
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Because frog metamorphosis is controlled by thyroid hormone, the higher thyroid hormone 
levels and the higher sensitivity may explain the short larval period in this species. Rapid 
metamorphosis (i.e., the short period of water-dwelling at the tadpole stage) observed in the 
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Thyroid hormone is also implicated in the regulation of longevity in animals [74,75]. Long-
lived species of squirrels, deer mice, bats and mole-rats maintain low levels of thyroid 
hormone [76,77,78,79]. Hypothyroid Wister rats live longer than hyperthyroid rats [80]. 
Furthermore, investigations in the Ames and Snell dwarf mice have demonstrated that 
mutation at the Prop-1 and Pit-1 genes lead to defects in the generation of pituitary cells 
including thyrotrope and the dwarf mice have extended longevity [81,82,83,84,85]. Thus, it 
is possible that changes in the thyroid hormone pathway are involved in variation of life 
span among wild animals, as is observed among human races (see above). Further research 
on the genetic basis for the low thyroid hormone levels observed in the long-lived animals 
should be conducted. 
Divergence in thyroid hormone physiology may also be important for adaptation of 
stickleback fishes to marine and freshwater environments [86]. Stream-resident populations 
of the threespine stickleback have repeatedly evolved from ancestral marine populations. 
First, Kitano et al. (2010) found plasma thyroid hormone levels and metabolic rate were 
lower in stream-resident populations than in ancestral marine populations [86]. Since 
thyroid hormones regulate metabolic rate in sticklebacks [86], it is likely that lower thyroid 
hormone in stream-resident sticklebacks is adaptive for permanent residency in small 
streams where oxygen and food are often scarce. In addition, the expression level of thyroid 
stimulating hormone TSHß2 gene was significantly lower in the pituitary gland of stream-
resident fish than in that of marine fish. Allele-specific expression analysis with F1 hybrids 
revealed that some of the differences in TSHß2 expression levels were caused by cis-
regulatory changes at the TSHß2 locus. Importantly, a signature of natural selection was 
found at TSHß2 locus: several SNPs within the cis-regulatory region exhibited marked 
differences in the allele frequency between marine and stream-resident populations. Thus, 
changes in the thyroid hormone pathways may play important roles in genetic adaptation to 
freshwater environments. In other fishes exhibiting alternate life history style, such as the 
brook charr Salvelinus fontinalis anadromous and resident forms show differences in thyroid 
hormone concentrations, although genetic factors seem to be of little importance in the 
interpopulation variation seen in the brook charr [87]. 
Other than the TSH loci in sticklebacks, there are few studies that have examined whether 
thyroid hormone-related genes are under selective pressure in wild animal populations. 
However, domestication seems to be a strong artificial selection on thyroid hormone-related 
genes. Very strong selective sweeps were found at the TSHR loci in chickens [88] and sheep 
[89]. Because TSH is found to regulate photoperiodic control of reproduction 
[90,91,92,93,94], artificial selection favoring continuous reproduction under domestication 
might act on the TSH locus. 
4. Conclusions and future directions 
We found similar features in the patterns of variation in thyroid hormone physiology in 
humans and other animals. First, genetic variation in the susceptibility to endemic goiter 
exists among populations and species. Second, some of the latitudinal and racial variation in 
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thyroid hormone physiology likely results from adaptation to environments with divergent 
ambient temperatures. Third, variation in thyroid hormone physiology may be associated 
with variation in longevity. Fourth, genomic scan of signatures of selection have revealed 
that some thyroid hormone-related genes experience selective pressure during evolution or 
domestication. 
In humans, it is very difficult to experimentally test the adaptive significance of such 
variation. However, ecological experiments can be conducted using animals. For example, 
reciprocal transplant experiments on divergent populations or species with different thyroid 
hormone physiology can test whether wild animals have higher fitness in native habitats 
than in foreign habitats [95,96]. We can also investigate whether the fitness is correlated with 
the thyroid hormone levels. In addition, hormonal manipulation would be able to directly 
test whether the higher or lower thyroid hormone levels can change the fitness in a variety 
of environments. 
Until recently, it has been difficult to study the genetic basis for physiological differences 
between natural animal populations. However, it is now becoming increasingly easier to 
conduct genomic studies because of the recent progress in genomic technologies. Therefore, 
we can test whether candidate loci involved in thyroid hormone signaling pathways are 
correlated with fitness in natural environments or laboratory conditions. Furthermore, 
ecological and genomic studies of wild animal populations will help answer fundamental 
evolutionary questions, such as whether the same environmental variables are strong agents 
of natural selection on the thyroid hormone pathways and whether genetic variation in the 
same genes caused the adaptive divergence in thyroid hormone physiology across diverse 
taxa, including humans. 
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1. Introduction 
Thyroid hormone secretion by follicular cells is mainly regulated by thyroid-stimulating 
hormone (TSH) from the pituitary gland, which in turn is controlled by thyrotropin 
releasing hormone (TRH) of hypothalamic origin. However, there are a number of 
additional endocrine mediators, such as estrogens and corticosteroids, which are also 
involved in the regulation of the biosynthesis of T3 and T4. Besides this extrathyroidal main 
regulation, thyroid function and growth are under the influence of intrathyroidal peptides. 
Thus, there is evidence of the role played by some local factors released by nerve endings, 
such as vasointestinal peptide (VIP) or neuropeptide Y [1], by follicular cells themselves, 
such as insulin-like growth factors (IGFs) [2], and, specifically, by C cells through a 
paracrine mechanism, acting locally upon neighboring follicular cells [1]. This last 
intrathyroidal mechanism of regulation of follicular-cell activity by C cells is the main 
subject of the present review.  
2. Histological organization of the thyroid gland 
The thyroid gland consists of two lobes connected by a narrow band of thyroid tissue called 
the isthmus, located in the midportion of the neck, immediately in front of the larynx and 
trachea. Each lobe of the thyroid gland consists of numerous follicles, the thyroid follicles, 
which constitute the structural and functional unit of the gland. Each follicle consists of a 
simple layer of cuboidal epithelial cells, the follicular epithelium, enclosing a central lumen 
containing a colloid substance rich in thyroglobulin, an iodinated glycoprotein, yielding a 
periodic-Schiff (PAS)-positive reaction. The shape of the normal follicles varies from round 
to oval and they show a considerable size variation depending on the degree of gland 
activity (Figure 1). 
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The thyroid follicles are composed of two different endocrine cell populations: (1) the 
follicular cells, the most abundant endocrine cells in the gland and responsible for secreting 
T3 and T4, hormones that control the basal metabolism; (2) C cells or parafollicular cells, 
which are very scarce and mainly known for producing calcitonin (CT), a hypocalcemic and 
hypophosphatemic hormone (Figure 1). 
 
Figure 1. Schematic diagram of the histological components of the normal thyroid gland. 
2.1. Embryological development of the thyroid gland and origin of C cells 
The thyroid gland has a dual embryonic origin. Most of the thyroid gland derives from the 
medial anlage, a ventral outpocketing of the foregut endoderm at the level of the first pair of 
pharyngeal pouches. The medial anlage appears as a bilobulate vesicular structure at the 
foramen caecum of the tongue. It then descends as a component of the thyroglosal duct to 
reach its definitive position in the neck. After involution of the thyroglosal duct, the thyroid 
anlage begins to expand laterally to form two lateral lobes and a medial isthmus between 
them. Consequently, the medial anlage gives rise to most, if not all, of the follicular 
epithelium [3]. 
On the other hand, C cells derive from the ultimobranchial bodies (UBB), two outpocketings 
of the forth-fifth pharyngeal pouch complexes that lose their connection and migrate 
centrally to fuse with the medial thyroid anlage. Fusion typically occurs slightly above to the 
middle of the lateral lobes. After incorporation into the larger medial anlage, cells of the 
UBB disperse into the surrounding thyroid tissue and give rise to C cells. UBB may also 
contribute to the formation of a minimal part of thyroid follicular cells [4]. Finally, portions 
of the UBB persist in the postnatal thyroid glands as small cystic structures -the 
“ultimobranchial follicles”- in rodents [5], or as “solid cell nests” in humans [6]. Estimates 
of the relative contributions to thyroid weight from the lateral anlage range from less than 1 
to 30% in humans [7]. In non-mammal vertebrates, the embryonic thyroid and UBB develop 
as separate structures, thus, C cells are confined to the ultimobranchial glands derived from 
the UBB, where they secrete calcitonin [8]. 
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Since Le Douarin and Le Lievre study [9] confirmed, using chick-quail chimeras, that avian 
ultimobranchial C cells originate from the neural crests, it was assumed, without much 
supporting evidence, that mammalian thyroid C cells also originate from the neural crest via 
the UBB. Nevertheless, the neuroectodermical origin of C cells in mammals is currently a 
controversial subject. In fact, Kameda et al. [10] have recently presented evidence that 
murine C cells are derived from the endodermal epithelial cells of the last pharyngeal pouch 
-UBB- and do not originate from neural crest cells. 
2.2. C cells as a member of the Diffuse Neuroendocrine System 
Classically, C cells formed part of the APUD system (term created by Pearse in 1966 [11] 
from the initial letters of Amine Precursor Uptake and Decarboxylation), a collection of cells of 
neuroectodermal origin, characterized by having as their primary function the production of 
endocrine peptides which are stored in secretory granules, and the common possession of a 
number of cytochemical and ultrastructural properties, in whatever situation they occur. 
Subsequently, further evidence indicated that only very few of the original series of APUD 
cells were definitively derived from the neural crests.  
Nevertheless,  according to Pearse [12], whenever APUD cells occur they could properly be 
regarded as “neuroendocrine cells” for synthesizing peptides (neuropeptides) common to 
both the nervous and endocrine systems. Additionally, as not all of these cells accumulate 
amine precursors, the designation APUD was finally replaced by Pearse in 1977 [12] with a 
new concept, the Diffuse Neuroendocrine System (DNES). The DNES includes, besides C cells, 
gastroenteroendocrine cells, pancreatic islet cells, bronchopulmonary and urogenital 
endocrine cells, adenohypophyseal cells, parathyroid cells and chromaffin cells of the 
adrenal medulla, carotid body, and sympathetic ganglia [13]. 
2.3. Normal morphology and distribution of C cells 
C cells represent the neuroendocrine cells that produce calcitonin in the thyroid gland. Since 
their discovering by Baber in 1876, these cells have been given many different terms. 
However, the two most common denominations employed are C cells and parafollicular cells. 
The name “C cell” was coined by Pearse  in 1966  and it is reflective of calcitonin production; 
this term is preferred to that of “parafollicular cell” as these cells are not always related to 
follicles in parafollicular position and may, furthermore, be found outside the thyroid gland, 
unrelated to follicles, as occurs in the ultimobranchial glands in non-mammal vertebrates [11]. 
C cells are difficult to identify in formalin-fixed, paraffin-embedded sections stained with 
H&E. Generally, their nuclei are somewhat larger and paler than those of follicular cells. 
Therefore, the most reliable procedure for the identification of C cells involves the use of 
immunohistochemical procedures with antibodies for calcitonin (Figure 2).  
C cells have variable shapes ranging from polygonal to spindled. The location of C cells 
relative to follicular cells also varies. They may be found between follicular cells or 
completely peripheral to the follicular epithelium. C cells are typically separated from the 
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colloid by the cytoplasm of follicular cells and the basal aspects of C cells are usually in 
contact with follicular basal lamina. Occasionally, C cells emit cytoplasmic processes that 
surround adjacent follicular cells (see Figure 3). At ultrastructural level, many dense 
secretory granules are observed in the cytoplasm of C cells [13, 14]. 
 
Figure 2. Visualization of C cells using an immunohistochemical method for calcitonin. (A) Human 
thyroid gland; (B) Rat thyroid gland. C cells are more abundant in rat in comparison with the  human 
thyroid gland. 200x. 
 
Figure 3. Immunohistochemical demonstration of C cells in the normal rat thyroid gland. (A) 
Immunostaining for calcitonin followed by the PAS method for carbohydrates. (B) Double 
immunostaining for calcitonin (red) and somatostatin (brown). In Fig.A,  the “parafollicular” ubication 
of C cells can be observed. In Fig. B, all C cells are immunostained for calcitonin but only very few of 
them are also immunopositive for somatostatin. This somatostatin-positive C cell  exhibits a 
cytoplasmatic process surrounding neighbouring follicular cells. (x500). 
The distribution of C cells within the thyroid lobes has also been reported to vary among 
species. In most species, C cells are located primarily in the centre of thyroid lobes, 
including humans [15, 16], mice [17], rats [18] and rabbits [17]. The area where C cells 
predominate has been termed as ‘C-cell region’ [19], which is also the place where the most-
active follicles of the gland predominate [20]. In general, portions of the thyroid containing 
the highest concentration of C cells correspond to the typical fusion sites of between the UBB 
and the medial thyroid anlage. As another reminder of their embryonic origin, C cells could 
also be located within the parathyroid gland and thymus in some species, such as rabbits 
and cats [17]. 
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The ratio of C cells to follicular cells in the thyroid gland differs markedly among species. In 
humans, C cells comprise less than 1% of the total endocrine-cell population [21], while the 
proportion of C cells to follicular cells is at least 5% in rats [18]. Furthermore, C cell 
concentration may vary according to age. In humans, however, data are very contradictory: 
Wolfe et al. in 1974  found that the number of C cells per unit area appeared to decrease 
with age [15], while Gibson et al. in 1982 found an age-dependant increase in C cells [16]. In 
contrast, thyroid glands of adult rodents have clearly more numerous C cells than those of 
neonates [14, 18].  
2.4. Substances synthesized by C cells 
The C cells share with other neuroendocrine cells the expression of different characteristic 
neuroendocrine markers, such as chromogranin, synaptophysin and NSE, with 
chromogranin A as the most reliable marker generally used to characterize cells of DNES 
(see Figure 4). Most of those neuroendocrine markers are shared with different populations 
of nervous cells (Table 1). 
 
Neuroendocrine markers Species Authors
NSE (Neuron-Specific Enolase) Human Lloyd et al. 1983 [22] 
PGP 9.5 (Protein Gene Product 9.5) Human Thompson et al., 1983 [23] 
Chromogranins (A, B) Human  
O’Connor et al., 1983 [24, 25]); 
Weiler at al., 1989 [24, 25] 
7B2 protein Human, rat, pig Marcinkiewicz et al., 1988 [26] 
Synaptophysin Human Weiler at al., 1989 [25] 
Secretogranin-II/chromogranin C Human Weiler at al., 1989 [25] 
Secretoneurin Human Schmid et al., 1995 [27] 
MMP-2 and MMP-9 Human Tomita, 1997 [28] 
SV2 (Synaptic Vesicle Protein 2) Human Weiler at al., 1989 [25] 
PC1 and PC2 (Prohormone Convertases) Mouse Kurabuchi et al., 2002 [29] 
Table 1. Characteristic substances identified in different neuroendocrine cells, including C cells, 
according to a chronological order. 
In addition to calcitonin, C cells may also contain many other regulatory peptides (Table 2), 
such as calcitonin gene-related peptide (CGRP) [30], katacalcin [31] or GRP [32]. 
Somatostatin has also been identified within C cells of most species. In the adult rabbits, bats 
and guinea pigs, most calcitonin-positive cells also contain somatostatin; however, in adult 
human and rat thyroid glands, only a small proportion of the calcitonin-positive cells are 
also somatostatin positive [33]. Similarly, peptides including neuromedin U [34] and 
helodermin-like peptide [35], have been demonstrated to colocalize with CT in normal C 
cells. Lately, a new generation of regulatory peptides, similar to those characteristically 
found in some hypothalamic nuclei, such as TRH [36], CART [37] or ghrelin [38], has 
increased the long list of substances synthesized by C cells. 
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2.4. Substances synthesized by C cells 
The C cells share with other neuroendocrine cells the expression of different characteristic 
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chromogranin A as the most reliable marker generally used to characterize cells of DNES 
(see Figure 4). Most of those neuroendocrine markers are shared with different populations 
of nervous cells (Table 1). 
 
Neuroendocrine markers Species Authors
NSE (Neuron-Specific Enolase) Human Lloyd et al. 1983 [22] 
PGP 9.5 (Protein Gene Product 9.5) Human Thompson et al., 1983 [23] 
Chromogranins (A, B) Human  
O’Connor et al., 1983 [24, 25]); 
Weiler at al., 1989 [24, 25] 
7B2 protein Human, rat, pig Marcinkiewicz et al., 1988 [26] 
Synaptophysin Human Weiler at al., 1989 [25] 
Secretogranin-II/chromogranin C Human Weiler at al., 1989 [25] 
Secretoneurin Human Schmid et al., 1995 [27] 
MMP-2 and MMP-9 Human Tomita, 1997 [28] 
SV2 (Synaptic Vesicle Protein 2) Human Weiler at al., 1989 [25] 
PC1 and PC2 (Prohormone Convertases) Mouse Kurabuchi et al., 2002 [29] 
Table 1. Characteristic substances identified in different neuroendocrine cells, including C cells, 
according to a chronological order. 
In addition to calcitonin, C cells may also contain many other regulatory peptides (Table 2), 
such as calcitonin gene-related peptide (CGRP) [30], katacalcin [31] or GRP [32]. 
Somatostatin has also been identified within C cells of most species. In the adult rabbits, bats 
and guinea pigs, most calcitonin-positive cells also contain somatostatin; however, in adult 
human and rat thyroid glands, only a small proportion of the calcitonin-positive cells are 
also somatostatin positive [33]. Similarly, peptides including neuromedin U [34] and 
helodermin-like peptide [35], have been demonstrated to colocalize with CT in normal C 
cells. Lately, a new generation of regulatory peptides, similar to those characteristically 
found in some hypothalamic nuclei, such as TRH [36], CART [37] or ghrelin [38], has 
increased the long list of substances synthesized by C cells. 
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Figure 4. Immunohistochemical demonstration of chromogranin A (A), calcitonin (B) and CGRP (C) in 
consecutive sections of the rat thyroid gland. All C cells express the different markers, being slightly 
less intense CGRP-positive C cells. (x400). 
 
Regulatory factors Species Authors
Calcitonin (CT) Pig, dog Bussolati and Pearse, 1967 
[39]  
Somatostatin Mammals Kameda et al., 1982 ([33] 
Katacalcin-I/CCP-I/PDN-21 Human Ali-Rachedi et al., 1983 [31] 
CGRP (Calcitonin Gene-Related 
Peptide) Mammals 
Sabate et al., 1985 [30, 40]; 
Kameda, 1987 [30, 40] 
Serotonin Sheep Barasch et al., 1987 [41] 
GRP (Gastrin-Releasing Peptide) Human Sunday et al., 1988 [32] 
Helodermin-like peptide Human, rat, pig, dog, etc. Grunditz et al., 1989 [35] 
CCK/ C-terminal gastrin Rat Arias et al., 1989 [42] 
TRH (Thyroid Releasing Hormone) Rat Gkonos et al., 1989 [36] 
Neuromedin U Rat Domin et al., 1990 [34]  
CCP-II (CT Carboxyl terminal 
Peptide) Human Cohen et al., 1992 [43]  
PTHrP (Parathyroid Hormone-
related Protein)  Sheep Okada et al., 1995 [44] 
Melatonin Rat Kvetnoy, 1999 [45] 
Neuropéptide Y Human Scopsi et al., 1990 [46] 
Ghrelin Rat, human Raghay et al., 2006 [38] 
Pneumadin Rat Kosowicz et al., 2003 [47] 
CART (Cocaine- and Amphetamine-
Regulated Transcript) Pig Wierup et al., 2004 [37] 
Motilin Human Xu et al., 2008 [48]  
NERP (NeuroEndocrine Regulatory 
Peptide) Human Matsuo et al., 2010 [49] 
Table 2. Regulatory factors identified in the cytoplasm of C cells, according to a chronological order. 
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In addition to the regulatory peptide products, C cells also contain a variety of biologically 
active amines including serotonin [41] and melatonin [45] (see Table 2). Additionally, C cells 
are also implicated in the synthesis of many other different substances, such as tetranectin 
[50] or CEA [51] (see Table 3). 
 
Other substances Species Authors
CEA (Carcinoembryonic Antigen) Human Kodama et al., 1980 [51]  
Tetranectin Human Christensen et al., 1987 [50]  
PAM (Peptidylglycine Alpha-amidating 
Monooxygenase) 
Rat Braas et al., 1992 [52] 
E-cadherin Rat Nishiyama et al., 1996 [10, 53]; 
Kameda et al., 2007  [10, 53] 
NCAM (Neural Cell Adhesion Molecule) Rat Nishiyama et al., 1996 [53] 
RESP18 (Regulated Endocrine-Specific 
Protein 18) 
Rat Darlington et al., 1997 [54] 
c-erbB-2-like product Human, 
guinea pig 
Martín-Lacave and Utrilla, 
2000 [55] 
Table 3. Other substances synthesized by C cells, according to a chronological order. 
2.5. Paracrine role played by C cells 
Apart from their role in calcium homeostasis, C cells are also probably involved in the 
intrathyroidal regulation of follicular cells. This hypothesis is supported by different 
features, such as their characteristic ‘parafollicular’ position, their predominance in the 
central region of the thyroid lobe – the so-called “C-cell region” [19]–  where the most-active 
follicles of the gland predominate [20], and their implication in the secretion of many 
different regulatory factors [1, 46, 56]. Some of these regulatory peptides display an 
inhibiting action on thyroid hormone secretion, such as calcitonin, calcitonin gene-related 
peptide (CGRP) and somatostatin [1], whereas others act as local stimulators of thyroid 
hormone synthesis, such as gastrin-releasing peptide (GRP), helodermin, and serotonin [35, 
57, 58]. For any of those peptides, a requirement to exert an effective paracrine regulation of 
follicular cells is the presence of their specific receptors in this endocrine cell population. At 
this point, the existence of some of those receptors on follicular cells, such as somatostatin or 
serotonin receptors, has already been described [58, 59]. Furthermore, we have recently 
demonstrated the expression of TRH-receptor on follicular cells [60].  
There is additional evidence that C cells and follicular cells somehow interact functionally. 
Thus, C cells, in the normal-appearing thyroid tissue adjacent to follicular tumours, have 
been reported to display reactive changes. These changes may include the development of a 
C cell hyperplasia [61] or the presence of an increased percentage of immunopositive C cells 
for GRP [32] or somatostatin [62], being the latter a potent inhibitor of TSH-enhanced mitotic 
activity and T3 and T4 synthesis by follicular cells. Moreover, we have found hyperplastic 
changes in the C-cell population of rat thyroid glands in a model of non-hypercalcemic 
hypothyroidism induced by propylthiouracil administration [63]. As we have recently 
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demonstrated the presence of TSH receptors on C cells [64], we can infer that those 
hyperplastic changes may be due to the corresponding increased TSH-serum levels. 
Nevertheless, the influence of local secretion of growth factors by follicular cells themselves, 
or by the surrounding tissue could not be discarded. 
The main secretagogue of C cells is calcium, which is concordant with the classical role of 
calcitonin as a plasma calcium- and bone metabolism-related hormone. Nevertheless, C-cell 
activity appears to be subjected to a more complex regulation, for which different regulatory 
peptides, either with inhibitory (somatostatin) or stimulatory effect (glucagon, pentagastrin), 
have being reported [65]. Furthermore, Suzuki et al. in 1998 [66] reported that C cells 
expressed the thyroid transcription factor 1 (TTF-1), which is typically expressed by 
follicular cells and known for its critical role in thyroid-specific gene expression. According 
to these authors, TTF-1 is calcium-modulated and coordinately regulates genes involved in 
calcium homeostasis in C cells. All these data constitute new evidence of interdependence 
between the two endocrine cell populations of the thyroid gland.  
3. Description of the different regulatory factors synthesized by C cells 
and their potential effects on thyroid hormone synthesis 
The most important objective of the current review is to present new evidence of the 
paracrine regulation exerted by C cells upon follicular cells, through the secretion of 
numerous factors synthesized by C cells in the immediate vecinity of the follicular 
epithelium, which could act in a synergistic or antagonist manner. To accomplish that 
objective, we will expose the functional role played by the most studied C-cell secreted 
factors on the activity of follicular cells mediated through their specific receptors. 
3.1. Calcitonin and calcitonin family of peptides 
In 1961, Copp et al. were the first in postulating the existence of a hypocalcemic hormone 
secreted by the thyro-parathyroid complex which was named calcitonin (CT) [67]. 
Subsequently, in 1963, Kumar et al. [68] confirmed the secretion of this hypocalcemic 
hormone by the thyroid gland. The evidence that parafollicular cells contained calcitonin 
was provided by immunofluorescent techniques in dog and pig thyroids [39], and these 
findings led to the name of ‘C’ cells for parafollicular cells. In more recent years, however, 
accumulating evidence supports the existence of nonthyroidal calcitonin or CT-like peptides 
in brain, prostate and uterus, although their biological role is unknown [69]. 
Calcitonin is expressed in many species including fish, amphibians, reptiles, birds and 
mammals, and it is normally a 32 amino acid peptide with a carboxy terminal proline amide 
and a disulfide bridge between cysteine residues at positions 1 and 7 [70, 71]. The CT amino 
acid sequence in the amino terminal loop region is highly conserved within species, but 
displays less homologies in the rest of the sequence [69].  
The hypocalcemic action of calcitonin is due to inhibition of bone resorption and to effects 
on other tissues indirectly related to bone remodeling such as kidneys. Additional cellular 
actions of calcitonin include its effect on the growth of breast cancer cells [72].  
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Calcitonin is synthesized as a 136 amino acid precursor which is processed by proteolytic 
cleavage and by amidation of the carboxy terminal proline residue before being secreted. 
The gene transcript encoding CT also encodes calcitonin gene related peptide (CGRP), 
another peptide in the CT family of peptides. The CT/CGRP gene was one of the first 
described examples of tissue-specific alternative RNA processing, it has six exons, of which 
the first four are spliced together to generate calcitonin mRNA in C cells, which encodes 
calcitonin and katacalcin (CCP), while the transcripts from CT/CGRP gene in neurons are 
processed into CGRP mRNA containing exons 1-3, 5 and 6 [30, 73] (see figure 5). In thyroid 
C cells 95% of the transcripts encode calcitonin, while more than 98% of the transcripts 
encode CGRP in the nervous system [69]. 
 
Figure 5. Schematic representation of alternative RNA processing of CT/CGRP gene. Transcription of 
the CT/CGRP gene produces a pre-mRNA, which has two polyadenylation sites. From the primary 
transcript two different mRNAs are produced, one coding for the calcitonin (CT)/katacalcin (CCP) 
precursor and the other coding for the CGRP precursor. The blue boxes indicate sequences 
complementary to exons, the lines between them are the sequences complementary to introns and the 
black boxes indicate the noncoding sequences of RNA. 
The alternative product of the CT/CGRP gene, a neuropeptide referred to as CGRP, is a 37 
amino acid peptide widely expressed in nerves in both the central and peripheral nervous 
systems and in several neuroendocrine tissues [74]. CT and CGRP have some homologies in 
the amino terminal region, but are almost entirely different in the rest of the molecule [74]. 
CGRP is a potent vasodilator, relaxant of mesangial cells and has functional roles in 
response to painful stimuli [75]. 
CT interacts with a member of seven-transmembrane-domain G-protein-coupled receptor 
superfamily cloned in 1991 [76]. High-affinity CT receptors (CTRs) were characterized on 
isolated osteoclasts, the physiological CT target cells.  Moreover, calcitonin receptors have 
been identified in a variety of tissues, such as brain, testis, spermatozoa, kidney, skeletal 
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muscle, breast cancer cell lines and human primary breast cancer cells [77]. Numerous 
studies have demonstrated that multiple CTR mRNA isoforms are present in a number of 
species. In humans, two isoforms (h-CTR1 and h-CTR2) differing by a 16 amino-acid insert 
in the first intracellular loop have been reported [78]. Finally, studies have revealed h-CTR2 
expression in normal thyroid glands, in medullary thyroid carcinoma (MTC), and in a 
model of human MTC cell line (TT), suggesting an autocrine regulation of CTR in C cells 
[79]. Nevertheless, there is still no evidence of the CTR expression in follicular cells. 
A family of receptors for CGRP and CT has been demonstrated throughout the nervous 
systems of both man and rat. CGRP-specific binding sites have been found in the 
cerebellum, spinal cord and other brain regions including vessels and pia mater. In contrast 
to calcitonin receptors found in bone, these receptors are not linked to adenylate cyclase, 
however, CGRP stimulates adenylate cyclase activity by acting at the calcitonin receptor in 
more than one tissue. Furthermore, specific cAMP linked CGRP receptors have been 
identified both in the intima and media of vessels as well as the atria and ventricles of the 
heart [80]. Seifert et al. [81] demonstrated the presence of a novel specific receptor for CGRP 
in the acinar cells of the pancreas. Finally, specific CGRP binding has also been 
demonstrated on cloned lung and bone cancer cells [82]. 
CGRP has a double location in the thyroid, one in nerve fibers around blood vessels and 
follicles and the other in C cells. This may suggest a functional role on the follicular cells; 
however, it seems not to affect basal or TSH-stimulated thyroid hormone secretion [83]. In 
contrast, CT, CGRP and katacalcin, which have been demonstrated to have no effect on 
basal and TSH-stimulated thyroid hormone secretion when separately administered alone, 
inhibited TSH-stimulated thyroid hormone secretion when the three peptides were applied 
together [83]. Despite this, further studies about the CTRs or calcitonin like receptors (CLRs) 
expression in follicular cells are necessary to dilucidate the role of CT/CGRP family peptides 
in the thyroid gland function. 
3.2. Somatostatin  
Somatostatin (SS) was first identified in 1973 in ovine hypothalamus as a tetradecapeptide 
(SS-14) with a disulfure bond between 3 and 14 cysteines. Its main function was to inhibit 
the release of growth hormone [84]. Subsequently, a big family of functional and structural 
peptides related to somatostatin was discovered. Over the years several forms of 
somatostatin depending on the tissue and species have been described.  
SS-like immunoreactivity has been found in all vertebrates as well as in some invertebrate 
species and in the plant kingdom. SS-producing cells occur at high densities throughout the 
central and peripheral nervous systems, such as the hypothalamus, pituitary, cerebellum, 
limbic lobe, retina, sympathetic ganglia and the vagus and sciatic nerves. SS-producing cells 
have also been reported in the endocrine pancreas, the gut and in small numbers in the 
thyroid, adrenals, submandibular glands, kidneys, prostate, and placenta [85-87].  
SS has many physiological actions, it functions as a neurotransmitter in the brain with 
effects on cognitive, locomotor, sensory, and autonomic functions [88]. Moreover, it has 
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inhibitory effects on the endocrine system, gut exocrine secretion, adrenal glands, kidneys, and 
on proliferation of lymphocytes, cartilage and bone precursor cells [86, 87, 89, 90]. Other effects 
consist on the inhibition of the release of growth factors (IGF1, EGF, PDGF) and cytokines (IL6, 
IFN-g) [91]. All of these diverse effects of SS can be explained by the inhibitory actions of the 
peptide on two key cellular processes: secretion and cell proliferation. 
The above-listed functions of SS are mediated by a family of receptors that recognizes these 
ligands with different affinities [92]. Originally, five different somatostatin receptor types 
(SSR1-5) were identified, cloned and found able to bind not only native SS forms (SS-14 and 
SS-28), but also their synthetic analogues [93].  SS receptors belong to the family of G 
protein-coupled receptors, typically consisting of extracellular domains forming the ligand 
binding site, a single polypeptide chain with seven transmembrane domains and 
intracellular domains mediating signal transduction. Each SS receptor subtype mediates 
different biological actions of SS, via the activation of different intracellular systems such as 
inhibition of adenylate cyclase (with decrease of intracellular cyclic AMP levels), reduction 
of intracellular calcium levels, and stimulation of phosphotyrosine phosphatase or MAP 
kinase activity [94]. 
Within the thyroid, SS coexists with CT in a subpopulation of C cells, with a variable 
extension. Thus, while the frequency for somatostatin-immunoreactive (SS-IR) CC varies in 
rats throughout their lives, as they are scarce in the foetus, abundant at the time of birth and 
scarce again in adults (see Figure 6) [33, 95-97], the majority of calcitonin immunoreactive 
(CT-IR) CC in guinea pigs and rabbits are also SS-IR, besides positivity is seen in the 
parathyroid gland [33]. On the contrary, SS-IR CC are observed very occasionally in normal 
pig and human thyroid glands [98]. 
 
Figure 6. Immunohistochemical demonstration of calcitonin (A), somatostatin (B) and serotonin (C) in 
consecutive sections of the rat thyroid gland. Only a subpopulation of calcitonin-positive C cells is also 
immunopositive for somatostatin. Serotonin is exclusively located in mast cells, being C cells negative in 
the rat. (x400). 
The effects of SS on the thyroid include the inhibition of the TSH-stimulated release of T4 
and T3 [99], as well as the inhibition of TSH-stimulated radioiodine turnover accumulation 
in thyroid glands of euthyroid volunteers [100]. SS inhibition of basal as well as TSH-
stimulated adenyl cyclase activity has been demonstrated in normal and neoplastic human 
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muscle, breast cancer cell lines and human primary breast cancer cells [77]. Numerous 
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inhibitory effects on the endocrine system, gut exocrine secretion, adrenal glands, kidneys, and 
on proliferation of lymphocytes, cartilage and bone precursor cells [86, 87, 89, 90]. Other effects 
consist on the inhibition of the release of growth factors (IGF1, EGF, PDGF) and cytokines (IL6, 
IFN-g) [91]. All of these diverse effects of SS can be explained by the inhibitory actions of the 
peptide on two key cellular processes: secretion and cell proliferation. 
The above-listed functions of SS are mediated by a family of receptors that recognizes these 
ligands with different affinities [92]. Originally, five different somatostatin receptor types 
(SSR1-5) were identified, cloned and found able to bind not only native SS forms (SS-14 and 
SS-28), but also their synthetic analogues [93].  SS receptors belong to the family of G 
protein-coupled receptors, typically consisting of extracellular domains forming the ligand 
binding site, a single polypeptide chain with seven transmembrane domains and 
intracellular domains mediating signal transduction. Each SS receptor subtype mediates 
different biological actions of SS, via the activation of different intracellular systems such as 
inhibition of adenylate cyclase (with decrease of intracellular cyclic AMP levels), reduction 
of intracellular calcium levels, and stimulation of phosphotyrosine phosphatase or MAP 
kinase activity [94]. 
Within the thyroid, SS coexists with CT in a subpopulation of C cells, with a variable 
extension. Thus, while the frequency for somatostatin-immunoreactive (SS-IR) CC varies in 
rats throughout their lives, as they are scarce in the foetus, abundant at the time of birth and 
scarce again in adults (see Figure 6) [33, 95-97], the majority of calcitonin immunoreactive 
(CT-IR) CC in guinea pigs and rabbits are also SS-IR, besides positivity is seen in the 
parathyroid gland [33]. On the contrary, SS-IR CC are observed very occasionally in normal 
pig and human thyroid glands [98]. 
 
Figure 6. Immunohistochemical demonstration of calcitonin (A), somatostatin (B) and serotonin (C) in 
consecutive sections of the rat thyroid gland. Only a subpopulation of calcitonin-positive C cells is also 
immunopositive for somatostatin. Serotonin is exclusively located in mast cells, being C cells negative in 
the rat. (x400). 
The effects of SS on the thyroid include the inhibition of the TSH-stimulated release of T4 
and T3 [99], as well as the inhibition of TSH-stimulated radioiodine turnover accumulation 
in thyroid glands of euthyroid volunteers [100]. SS inhibition of basal as well as TSH-
stimulated adenyl cyclase activity has been demonstrated in normal and neoplastic human 
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thyroid tissues [101] as well as in cultures of human thyrocites [102]. Besides its effects on 
thyroid function, suppression of thyroid follicular cell growth has been demonstrated by the 
inhibition of both TSH and IGF-1 proliferative stimulation [103].  
These evidences of the expression of SS in thyroid, more precisely limited to the C cells, and 
the actions in the follicular cells have led us to the speculation that this peptide could elicit 
local effects on thyroid hormone release acting locally in a paracrine fashion. 
3.3. TRH 
Thyrotropin-releasing hormone (TRH) is a tripeptide (pGlu-His-ProNH2) that was 
originally described to be synthesized in the mammalian hypothalamus, released into the 
hypothalamic–pituitary portal system and has the capability of inducing the release of 
thyroid-stimulating hormone (TSH) from the anterior pituitary [104, 105]. TRH binds to 
specific seven transmembrane domain, Gq/11-protein-coupled receptors of which, two 
subtypes have been cloned and characterized so far: TRHR1 and TRH-R2 [106, 107]. The two 
receptor subtypes exhibit similar affinities to TRH but different tissue distribution [108] and 
basal activities [109].  
Besides stimulation of TSH secretion at the pituitary, main role of TRH as key factor in the 
hypothalamic-pituitary-thyroid axis, numerous morphological and pharmacological studies 
have described TRH as neurotransmitter or neuromodulator in the CNS affecting behaviour, 
temperature regulation, food intake, and nociception [110, 111]. Furthermore, as suggested 
by the wide tissue-distribution of TRH and TRH receptors, TRH is implicated in many 
physiological and pathological processes of prostate, pancreas, testis, adrenal gland, heart, 
skin and thyroid tissues [112-119]. 
In the case of thyroid, it has been well established that C cells express TRH at both mRNA 
and protein levels (see Figure 7) [36]. Furthermore, our research group have described that 
C-cell cultures express TRH-R1 and TRH-R2, whereas only TRH-R2 subtype is expressed by 
PC-Cl3 rat thyrocytes [60]. It has also been reported that TRH inhibits the TSH-induced 
increase of cAMP and subsequent release of thyroid hormones by the dog thyroid gland 
[120, 121], suggesting that TRH could participate in the regulation of thyroid hormone 
secretion as an antagonist to TSH [122]. 
In accordance to this point, Rausell et al. in 1999 [122] found that the levels of TRH and 
TRH-like peptides in the thyroid were strongly influenced by thyroid status. Furthermore, 
Rausell et al. demonstrated that TRH exerted a direct effect on thyroid hormone release in 
vitro [123] and administration of TRH to hyperthyroid patients with very low levels of TSH 
resulted in decreased levels of circulating thyroid hormones [124].  
Although the effects of TRH on thyroid hormone secretion could, at least in part, be due to 
hypothalamic TRH, the results so far published in the literature and reviewed above would 
open the possibility of a paracrine regulation of follicular cell activity through C-cell 
released TRH as a putative additional mechanism for thyroid function. 
 
Paracrine Regulation of Thyroid-Hormone Synthesis by C Cells 63 
 
Figure 7. Immunofluorescent staining for calcitonin (A) and TRH (B) in rat thyroid tissue. All 
calcitonin-immunopositive C cells are also immunopositive for TRH. (x400). 
3.4. Ghrelin 
Ghrelin, is a 28 amino-acid acylated-peptide with powerful GH-releasing, orexigenic and 
adipogenic functions that, at hypothalamic level, regulates appetite, food-intake and energy 
metabolism in mammals [125, 126]. Since its initial description in 1999 [125], a variety of new 
functions for ghrelin have been characterized in the literature. Thus, apart from its GH-
releasing and orexigenic effects, ghrelin has been reported to influence sleep and behaviour 
[127, 128], and the pituitary-gonadal axis at both peripheral [129] and central levels [130, 131]. 
The enteroendocrine cells of the stomach mucosa are the main source of circulating ghrelin 
[132]. Ghrelin synthesis and plasma levels rise and fall in relation to food intake, increasing with 
fasting and decreasing after eating [133, 134].Besides its gastric secretion, ghrelin is also 
expressed in many other tissues and organs [38, 135, 136] and despite the fact that molecular 
mechanisms have not yet been characterized, recent investigations have implicated ghrelin in 
many pathological conditions of heart, bone, liver, kidney and, specifically thyroid tissues [137].  
The first observation regarding the presence of ghrelin in thyroid tissue was that by 
Kanamoto et al. in 2001 [138], describing the production of ghrelin in human medullary 
thyroid carcinoma tissue. Also, Gnanapavan et al. in 2002 [139] showed a very low 
expression of ghrelin at mRNA level and suggested to be carried-out by a very minor 
thyroid cell-population in normal human thyroid tissue. Those findings were concordant to 
those from Volante et al. [140] who failed to detect ghrelin-immunopositive cells in normal 
human adult thyroid gland. This last fact, being probably due to the very scarce presence of 
C cells in the human adult thyroid gland as compared to rats, where their percentage, in 
relation to follicular cells, ranges from 4.5 to 10.4% [18]. These observations were supported 
by the study by Raghay et al. in 2006 [38] in which ghrelin was described in the thyroid 
gland to be synthesized only by C cells.  
Moreover, the ghrelin functional receptor has been demonstrated to be expressed in the 
neighbouring follicular cells [141],  supporting, one more time the idea, increasingly found 
in the literature, that C cells would modulate thyroid function [38, 60, 63, 64], in this case, in 
a paracrine fashion, via ghrelin. Addressing this last point, up to date there are evidences 
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thyroid tissues [101] as well as in cultures of human thyrocites [102]. Besides its effects on 
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In accordance to this point, Rausell et al. in 1999 [122] found that the levels of TRH and 
TRH-like peptides in the thyroid were strongly influenced by thyroid status. Furthermore, 
Rausell et al. demonstrated that TRH exerted a direct effect on thyroid hormone release in 
vitro [123] and administration of TRH to hyperthyroid patients with very low levels of TSH 
resulted in decreased levels of circulating thyroid hormones [124].  
Although the effects of TRH on thyroid hormone secretion could, at least in part, be due to 
hypothalamic TRH, the results so far published in the literature and reviewed above would 
open the possibility of a paracrine regulation of follicular cell activity through C-cell 
released TRH as a putative additional mechanism for thyroid function. 
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calcitonin-immunopositive C cells are also immunopositive for TRH. (x400). 
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metabolism in mammals [125, 126]. Since its initial description in 1999 [125], a variety of new 
functions for ghrelin have been characterized in the literature. Thus, apart from its GH-
releasing and orexigenic effects, ghrelin has been reported to influence sleep and behaviour 
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[132]. Ghrelin synthesis and plasma levels rise and fall in relation to food intake, increasing with 
fasting and decreasing after eating [133, 134].Besides its gastric secretion, ghrelin is also 
expressed in many other tissues and organs [38, 135, 136] and despite the fact that molecular 
mechanisms have not yet been characterized, recent investigations have implicated ghrelin in 
many pathological conditions of heart, bone, liver, kidney and, specifically thyroid tissues [137].  
The first observation regarding the presence of ghrelin in thyroid tissue was that by 
Kanamoto et al. in 2001 [138], describing the production of ghrelin in human medullary 
thyroid carcinoma tissue. Also, Gnanapavan et al. in 2002 [139] showed a very low 
expression of ghrelin at mRNA level and suggested to be carried-out by a very minor 
thyroid cell-population in normal human thyroid tissue. Those findings were concordant to 
those from Volante et al. [140] who failed to detect ghrelin-immunopositive cells in normal 
human adult thyroid gland. This last fact, being probably due to the very scarce presence of 
C cells in the human adult thyroid gland as compared to rats, where their percentage, in 
relation to follicular cells, ranges from 4.5 to 10.4% [18]. These observations were supported 
by the study by Raghay et al. in 2006 [38] in which ghrelin was described in the thyroid 
gland to be synthesized only by C cells.  
Moreover, the ghrelin functional receptor has been demonstrated to be expressed in the 
neighbouring follicular cells [141],  supporting, one more time the idea, increasingly found 
in the literature, that C cells would modulate thyroid function [38, 60, 63, 64], in this case, in 
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that would help to elucidate some aspects of this putative new mechanism. Thus, Volante et 
al. showed differences in ghrelin content in foetal and pathologic thyroid as compared to 
normal adult glands, [140]. Moreover, Park et al. [141] demonstrated that ghrelin, via GHS-
receptor and calcium signalling, enhanced the TSH-induced proliferation of FRLT5 rat 
follicular cells, suggesting the thyroid function as a target for ghrelin, via GHS-receptor and 
protein kinase C, one of the key signal-pathways for thyroid follicular-cell function and 
thyroid hormone synthesis [142].  
In regard to the implication of ghrelin in thyroid hormone synthesis, after the demonstration 
of the ghrelin receptor in human thyroid tissue [143], Kluge et al. [144] described a ghrelin-
mediated decrease in TSH levels and an increase of serum T4, probably due to a ghrelin 
direct stimulatory action on the thyroid gland. These results has been supported by a study 
from our research group which have demonstrated that, effectively, ghrelin has a direct 
effect on the three tissue-specific genes involved in thyroid hormone synthesis: 
thryroperoxidase (TPO), Na+/I- symporter (NIS) and thyroglobulin [144, 145]. This direct 
effect on follicular-cell activity could be responsible for the effects observed at the 
hypothalamus-pituitary-thyroid axis [144, 145].  
3.5. CART 
Cocaine and amphetamine related transcript (CART) is an abundantly expressed and 
widely distributed neuropeptide that has been implicated in a number of physiologic 
processes.  The existence of a CART peptide fragment was first reported by Spiess et al. in 
1981 in extracts of ovine hypothalamus as a somatostatine-like polypeptide [146], but its 
functional significance was not explored further. Almost fifteen years later, Douglass et al. 
found the first evidence of the existence of mRNA encoding neuropeptide CART in the rat 
brain after psychostimulant drugs were administered [147]. 
CART gene is composed of 3 exons and 2 introns, with rats and mice having alternatively 
spliced variants resulting in the production of two peptides, the longest of which has 129 
amino acids (lCART) while the shortest is composed by 116 amino acids (sCART) [148]. The 
C-terminal end of CART, consisting of 48 amino acid residues and three disulfide bonds, it 
is thought to constitute the biologically active part of the molecule, and several fragments, 
notably, rlCART 55-102 and rlCART 62-102, have been shown to be active in vivo. In 
humans, only the short form is expressed (116 amino acids).  
Distribution of CART mRNA and peptides has been demonstrated by several techniques 
showing a wide distribution throughout the nervous system, including sensory processing 
areas, central autonomic control areas, pathways involved in drug reward and 
reinforcement (nucleus accumbeus, lateral hypothalamus and projections to dopaminergic 
ventral tegmental area neurons), areas controlling feeding and body weight (hypothalamic 
nuclei), and stress related brain regions [149-152]. Furthermore, CART expressing cells have 
been found in the anterior pituitary, adrenal gland, islets of Langerhans, myenteric plexus of 
small intestine and in the ovary [153, 154].  Wierup et al. [155] reported for the first time the 
existence of CART IR in C cells in the porcine thyroid, in addition to porcine pancreas, 
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gastrointestinal tract and adrenal gland, thus suggesting that the widespread expression of 
CART reveals a role for CART as modulator of neurohormonal functions. 
Besides as nervous system neurotransmitters , CART peptides have been implicated in the 
regulation of feeding and body weight, drug reward and reinforcement and other processes 
[156]. They also have neuroprotective properties and promote the survival and 
differentiation of neurons in vitro [157].  Moreover, there is some evidence of its role as a 
modulator of anxiety and stress response [158]. 
While the importance of CART peptides is clear, little is known about the cellular mechanisms 
by which CART exert their effects. No receptor for CART peptides has yet been identified, but 
some cellular effects have been observed, such as the induction of c-Fos activity in brain areas 
that are related to feeding and energy expenditure [159] or the induction of phosphorylation of 
ERK in AtT20 cells [160] which  activates the MAP kinase pathways. 
Due to important CART roles in the regulation of food intake and energy balance, where the 
thyroid plays a relevant function, several studies have been focused in the effects of CART 
in the regulation of Hypothalamus-Pituitary-Thyroid axis (HPT) and whether the thyroid 
status could regulate the expression of CART in the hypothalamus. CART-IR neurons in the 
paraventricular hypothalamic nucleus are reported to co-express thyrotropin releasing 
hormone (TRH) in rats, this neuronal populations co-containing TRH and CART project 
their axons to the median eminence, suggesting that CART peptides may have an important 
role in the regulation of thyroid-stimulating hormone (TSH) in the anterior pituitary [161]. 
In 2002, López et al. [162] demonstrated the existence of functional interrelations of the HPT 
axis with CART peptides. In other studies, the importance of the CART signaling system in 
the regulation of the HPT axis is suggested by the potent stimulatory effect of CART on the 
TRH gene expression of hypophysiotropic neurons [163]. Intracerebroventricular 
administration of CART increases TRH mRNA in hypophysiotropic neurons of fasting 
animals, and CART increases TRH content and release of hypothalamic cells in vitro [163]. 
These results together with those from Wierup et al. [155] described above provide the basis 
for future studies of the role played by C-cell secreted CART on thyroid function.  
3.6. Serotonin 
Serotonin or 5-hydroxytryptamine (5-HT) is a biogenic amine synthesized by serotonergic 
neurons of the CNS, pineal gland and enterochromaffin cells of the gastrointestinal tract of 
humans and other mammals. Serotonin was isolated for the first time by Rapport et al. in 
1948 [164] as a vasoconstrictor plasma agent. In fact, platelet serotonin is released to blood 
clots contributing to the haemostasis regulation. Serotonin synthesized by enterochromaffin 
cells is mainly involved in intestinal motility, whereas that synthesized in CNS acts as a 
neurotransmitter implicated in the regulation of mood, appetite, sleep, memory and 
learning. Besides, serotonin has antidepressant actions and regulates behaviour, 
cardiovascular function, muscle contraction, endocrine activity and body temperature [165]. 
Serotonin is derived from the essential amino acid L-tryptophan. The biosynthetic pathway 
of serotonin has two enzymatic steps: the first is catalyzed by the enzyme tryptophan-
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that would help to elucidate some aspects of this putative new mechanism. Thus, Volante et 
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gastrointestinal tract and adrenal gland, thus suggesting that the widespread expression of 
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[156]. They also have neuroprotective properties and promote the survival and 
differentiation of neurons in vitro [157].  Moreover, there is some evidence of its role as a 
modulator of anxiety and stress response [158]. 
While the importance of CART peptides is clear, little is known about the cellular mechanisms 
by which CART exert their effects. No receptor for CART peptides has yet been identified, but 
some cellular effects have been observed, such as the induction of c-Fos activity in brain areas 
that are related to feeding and energy expenditure [159] or the induction of phosphorylation of 
ERK in AtT20 cells [160] which  activates the MAP kinase pathways. 
Due to important CART roles in the regulation of food intake and energy balance, where the 
thyroid plays a relevant function, several studies have been focused in the effects of CART 
in the regulation of Hypothalamus-Pituitary-Thyroid axis (HPT) and whether the thyroid 
status could regulate the expression of CART in the hypothalamus. CART-IR neurons in the 
paraventricular hypothalamic nucleus are reported to co-express thyrotropin releasing 
hormone (TRH) in rats, this neuronal populations co-containing TRH and CART project 
their axons to the median eminence, suggesting that CART peptides may have an important 
role in the regulation of thyroid-stimulating hormone (TSH) in the anterior pituitary [161]. 
In 2002, López et al. [162] demonstrated the existence of functional interrelations of the HPT 
axis with CART peptides. In other studies, the importance of the CART signaling system in 
the regulation of the HPT axis is suggested by the potent stimulatory effect of CART on the 
TRH gene expression of hypophysiotropic neurons [163]. Intracerebroventricular 
administration of CART increases TRH mRNA in hypophysiotropic neurons of fasting 
animals, and CART increases TRH content and release of hypothalamic cells in vitro [163]. 
These results together with those from Wierup et al. [155] described above provide the basis 
for future studies of the role played by C-cell secreted CART on thyroid function.  
3.6. Serotonin 
Serotonin or 5-hydroxytryptamine (5-HT) is a biogenic amine synthesized by serotonergic 
neurons of the CNS, pineal gland and enterochromaffin cells of the gastrointestinal tract of 
humans and other mammals. Serotonin was isolated for the first time by Rapport et al. in 
1948 [164] as a vasoconstrictor plasma agent. In fact, platelet serotonin is released to blood 
clots contributing to the haemostasis regulation. Serotonin synthesized by enterochromaffin 
cells is mainly involved in intestinal motility, whereas that synthesized in CNS acts as a 
neurotransmitter implicated in the regulation of mood, appetite, sleep, memory and 
learning. Besides, serotonin has antidepressant actions and regulates behaviour, 
cardiovascular function, muscle contraction, endocrine activity and body temperature [165]. 
Serotonin is derived from the essential amino acid L-tryptophan. The biosynthetic pathway 
of serotonin has two enzymatic steps: the first is catalyzed by the enzyme tryptophan-
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hydroxylase (TPH), which converts the tryptophan in 5-hydroxytryptophan (5-HTP), while 
the second is catalyzed by an amino-acid decarboxylase which removes a carboxyl group 
from 5-hydroxytryptophan, forming 5-hydroxytryptamine or serotonin. TPH has been 
shown to exist in two forms: TPH1, found in several tissues, and TPH2, which is a brain-
specific isoform [58].                                                                                             
In 1960, Giarman and Freedman confirmed that the pineal gland was the richest site of 
serotonin in the brain [166]. This discovery suggested the pineal gland as an important site 
of serotonergic activity. In the pineal gland, much of this serotonin is acetylated and then 
methylated to yield melatonin during the night. In fact, there are day-night variations in 
pineal serotonin-content which is low at night, as opposite to plasmatic melatonin, which is 
low during the day and increases to a peak during the night [167].  
Many regulatory factors that control thyroid activity at hypothalamic level have been 
described. Specifically, serotonin stimulates hypothalamic TRH production, leading to an 
increase in TSH production from the pituitary. Adequate serotonin production is necessary 
to maintain thyroid hormone levels. In fact, in depressed patients with low levels of 
serotonin, treatment with thyroid hormones has increasing effects on selective serotonin re-
uptake inhibitors (SSRI) [168].  
In normal mouse and rat thyroid glands, serotonin is stored as a component of mast-cell 
granules (see Figure 6C) [169, 170]. Variations on mast-cell exocytosis and serotonin-content 
seem to be chronobiologically-linked to circadian variations of thyroid activity [169]. In rats, 
thyrotropin induces a gradual amine release from mast cells within the thyroid gland, where 
5-HT stimulates thyroid blood flow and/or vascular permeability [170, 171]. In addition, a 5-
HT-inactivating transporter (SERT), identical to that of serotonergic neurons has been found 
in follicular cells of several mammals [172]. Furthermore, follicular cells express specific 5-
HT2 receptors through which serotonin modulates TSH response and stimulates thyroid 
hormone synthesis [58].  
Besides mast-cell synthesis, serotonin is also expressed by thyroid C cells of different 
mammal species, however, as far as we know only sheep, goats, cows, bats and marmosets 
apparently convert endogenous 5-HTP into 5-HT [173-175]. Mice and rats belong to these 
many species in which endogenous 5-HT has not yet been found in adult C cells, unless the 
thyroid gland is pretreated with 5-HTP. C cells store serotonin in the same secretory 
granules as calcitonin [41, 176], where 5-HT is linked to a specific protein called serotonin-
binding-protein (SBP) [41, 177-179]. Furthermore, C cells have been proposed as a 
serotonergic neuron study model since they exhibit some properties of serotonergic 
neurons, including biosynthesis and storing of serotonin and regulated release and 
expression of both the 5-HT autoreceptor and the 5-HT transporter [180]. Finally, C cells 
have been demonstrated to be stimulated by both: extracellular calcium and, in the same 
way to that described for mast cells, by TSH; these results support the putative regulatory 
role of the C-cell secreted serotonin [181]. 
The effects observed on thyroid function could be partly due to extrathyroidal serotonin 
and, on the other hand, serotonin-synthesis is not a general feature of C cells of every animal 
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model. Nevertheless, in accordance to the literature published so far, C-cell secreted 
serotonin could be, at least for some animal models, considered as a local factor involved in 
the control of the follicular-cell activity through the hypothalamic-pituitary-thyroid axis. 
3.7. Melatonin 
Melatonin, chemically known as N-acetyl-5-methoxytryptamine, is an indoleamine 
rhythmically secreted by the pineal gland and involved in the regulation of circadian and, 
sometimes, seasonal rhythms [182]. Although it was originally discovered as a skin-lightening 
molecule acting on frog and fish melanocytes [183], melatonin is present in all vertebrates and 
is also produced by bacteria, protozoa, plants, fungi and invertebrates [184, 185]. 
Pineal melatonin biosynthesis, that takes place during the night, it is activated by 
norepinephrine through its specific receptor located in the membranes of pinealocytes and 
consists of four enzymatic reactions. The first two are common to the synthesis of serotonin. 
Then, serotonin is converted to N-acetylserotonin (NAS) by the enzyme arylalkylamine N-
acetyltransferase (AANAT) [186]. NAS is subsequently methylated by hydroxyindole-O-
methyltransferase (HIOMT) to form melatonin [187] (see Figure 8).  
Melatonin has a wide spectrum of biological activities and it is considered as a pleiotropic 
compound with important chronobiotic properties. This indoleamine has the capacity to 
resynchronize circadian rhythms [188-190] and regulate sleep-wake-cycles [191]. Besides 
playing an important role as a transmitter of photoperiodic information, melatonin has well-
characterized antioxidant capacities, either, directly as a free-radical neutralizer or, 
indirectly by enhancing the activity or the expression of antioxidant enzymes [192, 193]. In 
certain aspects, related to these last activities, there is evidence in the literature that 
describes potential anti-aging and anticarcinogenic effects for melatonin [194]. 
Action mechanisms of melatonin are very varied. In this respect, this hormone can bind to 
specific G-protein coupled membrane receptors, of which there are two subtypes in 
mammals: melatonin-receptor 1a (MT1) and melatonin-receptor 1b (MT2) [195]. MT1 and 
MT2 possess high-affinity binding sites for melatonin and are widely distributed in CNS and 
in a wide-spectrum of peripheral tissues [196, 197]. Furthermore, and in addition to its 
abilities as a free-radical scavenger described above, melatonin has been described to 
interact with nuclear receptors [198, 199] as well as cytoplasmic proteins such as calmodulin 
and protein kinase C.  
Since its discovery, melatonin had been considered an exclusive hormone of the pineal 
gland. However, numerous published studies have changed this view, describing many 
extrapineal tissues, such as retina [200], Harderian gland [201], gut [202], ovary [203, 204], 
immune system [205, 206], skin [207], and testes [208], as melatonin synthesizers. 
Moreover, melatonin has also been found in the rat thyroid-gland, specifically, 
immunopositive C cells for melatonin have been detected [45]. Furthermore, our research 
group has recently demonstrated endogenous melatonin biosynthesis by rat thyroid C cells 
through the expression of the two key melatonin biosynthetic enzymes, AANAT and 
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HIOMT and, moreover, melatonin membrane receptors have also been found in the rat 
thyroid gland, specifically, on follicular-cell and C-cell membranes [209] (see Figure 8).  
 
Figure 8. Immunolocalization of AANAT in a rat C-cell line (CA77) (A), and melatonin receptor (MT1) 
in a follicular-cell line (PC-Cl3) (B) by immunofluorescence. 
Many effects of melatonin on the thyroid gland have been described so far in the literature. 
In rodents, high doses of melatonin inhibit basal and TSH-stimulated mitotic activity of 
thyroid follicular cells in vivo and in primary culture [210]. Besides, melatonin has a direct 
inhibitory effect on T4 secretion and, also, depresses the response of the thyroid to TSH [211]. 
Furthermore, melatonin plays a protective role against oxidative stress in the rat thyroid 
gland [212-214].   
As regard to the latter, reactive oxygen species (ROS) are deeply involved in cellular 
processes of the thyroid gland. Follicular cells are subjected to high oxidative stress since 
they require hydrogen peroxide (H2O2) for thyroid hormones biosynthesis and moreover, a 
large number of diseases associated with H2O2 accumulation in the thyroid gland have been 
described. For example, H2O2 participates in the Wolff-Chaikoff’s effect and in 
hypothyroidism caused by iodine excess in the thyroid [213]. Melatonin has been suggested 
to be able to directly scavenge H2O2 [215]; in accordance to this last point melatonin 
synthesized by C cells might play a role in thyroid antioxidant defense against oxidative 
stress. Endogenous synthesized intrathyroidal melatonin could, thus, be a kind of local 
regulator that could regulate redox homeostasis and modulate thyroid function [216].  
3.8. Other C-cell secreted peptides 
The data presented here describe, according to our criteria, the most significant regulatory 
factors produced by C cells and their effects and pathways involved on follicular-cell 
activity according to the literature. Nevertheless, as illustrated in the present review, the list 
of C-cell secreted peptides and their putative paracrine functions on follicular cells is 
constantly being enlarged.  
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In addition to those described along the present chapter, and despite the fact that there is 
still limited evidence in the literature, there is a small group of regulatory factors such as 
bombesin/GRP, CCK (cholecystokinin) and helodermin, that should be observed as 
potential new candidates for thyroid local-modulators.  
Bombesin/GRP (gastrin-releasing peptide) was first described as being expressed by 
neoplastic C cells from MTCs by the group of Kameya et al. In 1983 [217]. Moreover, Ahren 
in 1989 [57] confirmed that GRP had the capacity to stimulate both basal and TSH-
stimulated thyroid hormone secretion in mice. Furthermore, differences in GRP synthesis 
among developing thyroid C cells, normal adult C cells, and neoplastic C cells led Sunday et 
al [32] to hypothesize that C-cell GRP gene-expression might play a role in both normal and 
neoplastic growth processes.  
In the case of CCK, its expression in C cells was described by Arias et al. in rat thyroid gland 
[42]. Recently, its receptor CCK2R, which is shared with gastrin, has been described to be 
expressed at different intensities in normal and malignant C cells by Blakër et al. [218]. No 
additional data has been published with regard to the putative functional role of CCK 
signalling in thyroid, however, there are initial encouraging therapeutic results with the use 
of CCK/Gastrin R2-binding peptides in patients with MTC [219, 220].  
The last factor from this “other” group is the amidated peptide helodermin. Originally 
isolated from Heloderma suspectum [221, 222], helodermin was described to be expressed by 
rat C cells by Grunditz et al. in 1999 [35]. Furthermore, these authors reported dose and time 
course experiments which showed a consistent stimulatory effect of helodermin on thyroid 
hormone synthesis. 
Although some of these data seemed to have well-characterized new pathways for C-cell and 
thyrocytes interrelationships, surprisingly no further studies that illustrated new insights for 
this evidence have been reported so far. Therefore, to our knowledge, future studies are still 
necessary to finally clarify their involvement in thyroid function and homeostasis. 
 
Figure 9. Schematic diagram of the different mechanisms of regulation of  the synthesis of thyroid 
hormones by follicular cells. 
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4. Conclusion 
In conclusion, according to the data published so far in the literature and revised through 
this chapter, a number of regulatory factors are produced at thyroid level by C cells and 
have direct effects on follicular-cell activity at both proliferative and thyroid hormone 
synthesis levels (Figure 9). These new paracrine regulatory mechanisms would justify, from 
a phylogenetic point of view, the parafollicular localization of C cells in mammals and might 
open new molecular approaches for the treatment of human thyroid disease.  
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1. Introduction 
Although thyroid hormone effects on the brain are most prominent in development, also in 
adult-acquired hypothyroidism symptoms such as sensory impairments, disagreeable 
smells and taste, slowness of thought and action, changes of speech, irritability, headaches, 
sleep disturbances, confusion up to delusions and hallucinations, impairments of memory, 
of vision as well as of hearing frequently occur. This involvement of the nervous system was 
already discussed in the first reports on myxoedema (1–3) and a systematic description 
included in the first extensive investigation by the Committee of the Clinical Society of 
London (4). Many of these symptoms have since been studied in considerable detail. The 
conspicuous slowing of movements of hypothyroid subjects has been shown to correlate 
with peripheral sensory and motor nerve dysfunctions and abnormal neuromuscular 
transmission (5–10). The slowing of thoughts and mental function occurs concomitant with a 
decrease in the frequency of the alpha rhythm of the EEG (11–15). In addition to the slowing 
of the alpha-rhythm increased latencies of visual, auditory and somatosensory evoked 
potentials in adult-onset hypothyroidism indicate a slowed conduction of information in the 
central nervous system (16–24). In addition to a slowing of neuronal conduction velocity, 
changes in the threshold of hearing (25–29) and of the sensation of smell have been reported 
(30, 31). Cognitive and memory tests revealed impaired performances, which could at least 
partially be reversed by hormone substitution (24, 32–34). The extent of the reversibility of 
these symptoms is still a matter of debate (35).  
Since many of the neurological symptoms observed in hypothyroidism point to a 
conspicuous mental slowing as leading symptom of hypothyroidism, we here were 
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interested to test in a small sample of 6 patients, whether already a transient hypothyroid 
state, induced by 4 weeks of total thyroid hormone withdrawal, would result in detectable 
changes in the speed of sensory perception and cognitive functions. For this aim we 
combined different psychophysical tests shown to be sensitive in previous studies of 
hypothyroidism with some new examinations. While cognitive tests, such as the trail 
making test as well a calculation task showed a non-significant tendency toward slowing, a 
more complex visual- spatial performance test revealed a significant slowing of mental 
function after four weeks of hypothyroidism. The speed of speech was significantly reduced 
and a fast Fourier analysis showed a shift to lower frequencies in the hypothyroid test 
persons. A significant decrease in red-green colour fusion frequency was found, indicating 
an impaired temporal resolution of visual stimuli. Smelling of two odorants tested, odorant 
discrimination (Sniffin`sticks) and the hearing thresholds were slightly, but insignificantly 
impaired in the hypothyroid test persons. The results of these tests indicate that the most 
prominent and first significant clinical symptom to develop in hypothyroidism is a slowing 
of speech and of visual perception. 
Slowing of conduction velocity can be explained by a reduced myelination. A second 
mechanisms is a decrease in voltage-gated sodium current density, leading to a slowed 
charging of the membrane capacitor thus resulting in a decreased slope of the action 
potential upstroke velocity which in turn decreases conduction velocity. Although several 
investigations support the concept that thyroid hormone affects myelination, recently 
evidence has accumulated, that thyroid hormone also increases sodium current density in 
neurons from several species. We will thus discuss reports on the regulation of voltage 
gated ion currents in neurons and muscle cells later in the chapter, which could offer an 
explanation for the observed slowing of thoughts and movements at the cellular and 
molecular level. 
Furthermore, it has been known for a long time, that thyroid hormone regulates energy 
expenditure (see also Yehuda-Shnaidman et al. in this issue). Pumping of Na+ out of the cells 
has been accounted for the expense of 40% of energy consumed at rest (36, 37). Thus an 
increased influx of Na+ due to enhanced voltage-gated Na+-influx will most likely also 
stimulate Na+/K+-ATPase activity, and could also account at least to some extent for the 
stimulation of an enhanced expression of Na+/K+-ATPase subunits in the membranes. We 
thus conclude the chapter by reviewing data on the regulation of Na+/K+-ATPase by thyroid 
hormone in the brain and its potential link to Na+ current regulation. 
2. Clinical symptoms during transient severe hypothyroidism quantified 
by psychophysical investigations in adult human test persons 
To illustrate some conspicuous effects of thyroid hormone on brain function we studied 6 
patients after total thyroidectomy for thyroid carcinoma who had discontinued taking 
thyroid hormone prior to routine diagnostic 131I- scanning and who thus showed a 
reproducible degree and duration of hypothyroidism. Symptoms described to occur a few 
weeks after discontinuation of thyroid hormone therapy are changes in peripheral 
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conduction velocity and in the EEG (15). Furthermore, subjective impairments of the quality 
of life (38–40) as well as changes in mood (41, 42) and decreases in working memory (43) 
have been reported. 
3. Methods 
Test persons. A test battery was developed to allow a relatively fast examination of several 
aspects of sensory and cognitive function. To integrate the investigation into the normal 
clinical examination procedures the whole testing protocol was designed to be completed 
within 1.5 hours. All tests were carried out on 6 patients after thyroid hormone withdrawal 
for 26 to 28 days and on 6 healthy volunteers which were age (maximal difference: 3 years) 
and sex matched (with the exception of one female control person for a male patient). 
Patients were retested after at least 6 weeks of hormone substitution, after obtaining low TSH 
values. To elaborate the optimal test parameters some of the tests had been performed in more 
detail on an additional hypothyroid test person, the data of which are included in the 
appropriate results sections. In the 7 test persons (age 42-64, 4 female, 3 male) TSH-suppressive 
thyroid hormone substitution after total thyroidectomy and radioiodine therapy for thyroid 
carcinoma had been discontinued for 26-28 days for routine diagnostic application of 131I. 
Thyroid hormone levels measured in hypothyroidism were FT3: < 2.0 pmol/l, FT4: <2.6 pmol/l 
in 6 patients and FT3: 2.6 pmol/l, FT4: 4.8 pmol/l in the remaining patient, TSH was > 80 mU/l 
in three patients and 48.7 ± 10.4 mU/l (mean ± SE) in the remaining four patients. After 6 - 10 
weeks of hormone substitution these values were: FT3: 6.2 ± 0.5 pmol/l, FT4: 26.0 ± 3.0 pmol/l 
and TSH: 0.09 ± 0.04 mU/l, n=7 (normal ranges: FT3: 3.4 - 7.6 pmol/l (SPART, Amerlex MAB, 
Johnson & Johnson); FT4: 11 - 23 pmol/l (SPART, Amerlex MAB, Johnson & Johnson), TSH: 0.3 
- 4.0 mU/l (IRMA, Dynotest, Brahms). Results are given as means ± standard error. Statistical 
analysis was performed using paired Student`s t-test. Informed consent was obtained from all 
individuals before performing the tests. 
Speed of speech. To investigate possible changes in the speed of speech we asked the test 
persons to repeat four times the same word as fast as possible (in this case the word 
„Apfelmus“). They were asked the repeat the series of four words four times and were 
encouraged to accelerate their speech as much as possible. The four series of words were 
stored on magnetic tape with a SONY WTC-D6C stereo cassette recorder and analysed off-
line using a Digidata 1200A analog-digital converter with “Axoscope” software (Axon 
Instruments). The time needed to pronounce the four words was then read from a digital 
storage oscilloscope. In addition a fast Fourier analysis was performed on the record of the 
second syllable (“mus”) selected from the two fastest traces obtained from each test person 
in the hypothyroid and the euthyroid condition. The section of the record to be analysed 
was selected with “Axoscope” and then analysed with “Origin 5” software. 
Tests of cognitive performance:  
a. Calculation and Correlation. To test more complex mental performances patients were 
first handed a sheet of paper and asked to complete a set of 24 simple calculation tasks 
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of third grade difficulty (like: 23+11=?). Each result of a calculus task was assigned one 
of five colours (yellow, red, green, dark and light blue). After completing the calculation 
task the test persons were asked to fill a second form, consisting of an outline drawing 
containing 54 numbered areas, where each number equalled one of the results of the 
preceding calculus task (some numbers were used several times). The patients were 
handed coloured pencils and asked to assign the appropriate colour from the result of 
the calculus task to each of the numbers given in the drawing. This procedure finally 
resulted in the appearance of a meaningful picture (in this case a boat). The time taken 
by the patients to complete the calculus task and to assign the colours to the figures in 
the drawing was monitored.  
b. Trail making. The test consisted of a piece of DIN A4 paper, containing randomly dis-
tributed numbers (24 pt size, black, surrounded by a black circle). The paper was placed 
on a table in front of the test persons who were asked to connect the numbers from one 
to 25 (version A). In version B numbers from 1 to 13 and letters from A to L were 
distributed randomly and the test persons asked to connect them alternating between 
the numbers and the succession of the alphabet, e.g., 1-A 2-B- 3-C etc. The time needed 
for completion of the test was recorded (44).  
Tests to determine time resolution of visual perception and colour contrast perception: 
a. Flicker fusion frequency. Light flashes delivered with a sufficiently high frequency fuse to 
give the impression of a continuous light source. The lowest frequency at which an in-
termittent light source is perceived as a continuous one is termed the „flicker fusion fre-
quency“. A light source containing red (660nm), green (565 nm) or blue (470nm) diodes 
of 1 cm2 diameter with an intensity of 14 Cd m2 (determined with a Minolta luminance 
meter) was displayed to the test persons at a distance of 52 cm (to excite a 1° area of the 
visual field). The screen was positioned at the back of a 50 x 50 cm wide and 52 cm deep 
box with black walls. The flicker frequency was generated with a square wave pulse 
generator with a 50% duty cycle. The frequency could be changed with a dial. Test 
persons were asked to focus on the light with both eyes while the frequency was 
increased and to give a sign when they perceived the flashes to fuse to a continuous 
light source. Since it turned out to be too time-consuming to test the right or the left 
eyes, foveal and peripheral illumination separately and to use lights of different colours 
and since preliminary experiments showed no qualitative differences in the results, 
most patients were only retested with the red colour fixed by two eyes. The average 
value of three determinations of flicker fusion frequency always starting from low 
frequencies was determined. 
b. Red-Green fusion. Changes in the perception of chromatic flicker were tested in addition 
to the critical flicker fusion frequency of luminance flicker. In this test a rotating disk of 
12 cm diameter was shown to the test persons. The disk was diagonally partitioned into 
four sections which were painted alternatively in light red (Plaka Nr. 82) and light 
green (Plaka No. 90; 16 – 20 Cd/m2, determined with a Minolta LS 100 luminance 
meter). The speed of rotation was increased continuously and the number of rotations 
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per minute was electronically counted. Increasing the speed of rotation first gave the 
impression of a luminance flicker. A further increase in the speed of rotation resulted in 
the impression of a homogenous dark yellow colour. The patients were asked to give a 
sign at the frequency were they saw the first signs of a luminance flicker and as soon as 
they perceived the impression of a homogenous yellow colour. Each test was repeated 
three times starting with low frequencies and the average value of the three 
determinations was noted. 
Sense of Smell. Two tests were used to detect possible changes in the sense of smell: First a 
test for the recognition and discrimination of 16 different odorants, including familial smells 
like cinnamon and rather unusual flavours, like leather, was used. Then the threshold of 
perception was tested using two different odours, one that tests the excitation of the 
olfactory nerve (phenylethyl alcohol (Phe)), smelling like rose, and one, exciting both, 
trigeminal and olfactory nerves (eugenol (Eu)), Sniffing´sticks, (45)). In brief, for the odorant 
tests, caps were removed from plastic sticks containing odorants of different concentrations 
filled into the sticks ending in felt tips extruding about 5 mm from the tip of the stick. A 
stick was gently moved at a distance of about 1 cm below the nostril of the test person. 
Sticks containing the test solution in ascending concentration (descending numbers on the 
stick) were presented to the test person in series of three sticks, two of which contained 
distilled water. The threshold was defined as the concentration at which the patient 
correctly recognised the odour in two out of three presentations.  
Hearing threshold. Hearing thresholds were determined for 8 different frequencies using an 
Ascom Audiosys Maico ST20 audiometer. Changes in threshold for sinusoidal tones of 1 
and 8 kHz were evaluated. 
3.1. Experimental results 
Speed of speech. Figures 1A and B show digitized traces of speech records of a female test 
person in hypothyroidism (upper trace, a) and after hormone substitution (lower trace, b). 
After hormone substitution this test person pronounced the four words faster. As shown in 
Fig. 1C, on average the test persons needed a significantly longer time to pronounce the 
same words in the hypothyroid condition as compared to the euthyroid control persons or 
after thyroid hormone substitution. Figure 1D gives a more elaborate example of the 
development of the slowing of speech during hormone withdrawal and resubstitution. Here 
an additional test person was asked to repeat a short poem in regular intervals at maximal 
speed and the time taken to complete this poem was recorded. During hormone withdrawal 
the time needed to finish the poem became increasing longer. During resubstitution with 
thyroid hormone the time to finish the poem gradually decreased during the following 
month. To find out whether the increase in speed of speech during hormone resubstitution 
was accompanied by an increase in pitch a fast Fourier analysis was performed on the 
syllable “mus” (encircled by the rectangles in Fig. 1A). The analysis of the pronounciation of 
this syllable, consisting with predominant amplitude of the noun “u” showed several clear 
frequency peaks (Fig. 1B). The records from four of the five male subjects included in the 
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of third grade difficulty (like: 23+11=?). Each result of a calculus task was assigned one 
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per minute was electronically counted. Increasing the speed of rotation first gave the 
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this syllable, consisting with predominant amplitude of the noun “u” showed several clear 
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study showed a peak between 100 and 200 Hz which was not seen in the records from any 
of the female test persons. Since the most prominent peak in all test persons was found 
between 200 and 300 Hz this peak was evaluated in hypothyroidism and after hormone 
substitution. As shown in Table 2 and illustrated in Fig. 1B the peak frequency was shifted 
by an average of about 30 Hz to higher frequencies by the hormone substitution. This shift 
was found in all subjects with the exception of one test person, aged 61, who suffered from 
paresis of the n. recurrens.  
 
Figure 1. Changes of speech during thyroid hormone withdrawal. Original voltage traces of a record from a 
female test person (A) repeating four times the word “Apfelmus” as fast as possible after four weeks of 
thyroxine withdrawal (a) and after 10 weeks of hormone resubstitution (b). The darker yellow shadow 
indicates the time needed to pronounce the first word in the hypothyroid condition. B: Fast Fourier 
analysis of sections of the speech record shown within the squares in A. Inset: 100 ms long sections from 
the analysed traces. C: average time needed to pronounce the four words after hormone withdrawal 
(Hypo), resubstitution (Eu) and by control subjects (mean ± SE, n=6) asterisk: p<0.05, 2 asterisks: p<0.01. 
D: time needed to complete a short poem of an additional test person recorded daily during last 20 days 
of thyroxine withdrawal and during the following 60 days of resubstitution. Note the gradual decline in 
speed of speech with increasing time of thyroid hormone withdrawal. 
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Speed of visual perception. In hypothyroidism, the frequency, at which patients first 
reported to perceive a flickering light source as a continuous one was slightly but 
insignificantly smaller than the frequency determined in the control group. The 
hypothyroid group showed no significant improvement after 6 weeks of hormone therapy 
(Figure 2Ab). In a single test person, where the flicker fusion frequency was recorded 
daily for blue, green and red light and both eyes tested separately, however, a significant 
decrease in flicker fusion frequency was shown in the third week after the arrest of 
hormone substitution. After six weeks of hormone resubstitution the flicker fusion 
frequency had significantly recovered with respect to the last week without the hormone 
(Table 1 and Figure 2 Aa).  
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thyroid hormone
withdrawal 
Days 17-22 of 
hormone 
withdrawal 
P (1st week 
versus 3rd 
week) 
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versus 3 weeks 
after hormone 
withdrawal) 












12 35.3 0.6 12 29.9 0.5 0.0000004 12 37.2 0.3 <0.0000000001 
Table 1. Critical flicker fusion frequency for three different colours (12 measurements on 2 eyes 
determined on 6 successive days were pooled from one test person, SEM: standard error of the mean, 
unpaired t-test), the original data for red light are displayed in Figure 2Aa. 
The critical colour fusion frequency (CCFF), determined with a rotating wheel of alternating 
green and red sectors was significantly reduced in the hypothyroid test persons compared 
with the control subjects. The frequencies at which the rotating, red-green disk was 
perceived as starting to show a luminance flicker (Fig. 2 Ba) as well as the frequency at 
which a uniform yellow colour was reported (Fig. 2Bb) were both significantly smaller in the 
hypothyroid test persons as compared to the control group.  
Cognitive performance. Since several cognitive tests have been shown to be sensitive for 
thyroid hormone we here tested whether hypothyroidism for 4 weeks has an effect on 
calculation and visual-spatial orientation. A slight but insignificant slowing of the speed 
with which the hypothyroid persons completed the calculation task compared with the 
euthyroid control group was observed (Table 2, Figure 3A). A stronger effect was seen, 
 
Thyroid Hormone 90 
study showed a peak between 100 and 200 Hz which was not seen in the records from any 
of the female test persons. Since the most prominent peak in all test persons was found 
between 200 and 300 Hz this peak was evaluated in hypothyroidism and after hormone 
substitution. As shown in Table 2 and illustrated in Fig. 1B the peak frequency was shifted 
by an average of about 30 Hz to higher frequencies by the hormone substitution. This shift 
was found in all subjects with the exception of one test person, aged 61, who suffered from 
paresis of the n. recurrens.  
 
Figure 1. Changes of speech during thyroid hormone withdrawal. Original voltage traces of a record from a 
female test person (A) repeating four times the word “Apfelmus” as fast as possible after four weeks of 
thyroxine withdrawal (a) and after 10 weeks of hormone resubstitution (b). The darker yellow shadow 
indicates the time needed to pronounce the first word in the hypothyroid condition. B: Fast Fourier 
analysis of sections of the speech record shown within the squares in A. Inset: 100 ms long sections from 
the analysed traces. C: average time needed to pronounce the four words after hormone withdrawal 
(Hypo), resubstitution (Eu) and by control subjects (mean ± SE, n=6) asterisk: p<0.05, 2 asterisks: p<0.01. 
D: time needed to complete a short poem of an additional test person recorded daily during last 20 days 
of thyroxine withdrawal and during the following 60 days of resubstitution. Note the gradual decline in 
speed of speech with increasing time of thyroid hormone withdrawal. 
Thyroid Hormone Effects on Sensory Perception,  
Mental Speed, Neuronal Excitability and Ion Channel Regulation 91 
Speed of visual perception. In hypothyroidism, the frequency, at which patients first 
reported to perceive a flickering light source as a continuous one was slightly but 
insignificantly smaller than the frequency determined in the control group. The 
hypothyroid group showed no significant improvement after 6 weeks of hormone therapy 
(Figure 2Ab). In a single test person, where the flicker fusion frequency was recorded 
daily for blue, green and red light and both eyes tested separately, however, a significant 
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green and red sectors was significantly reduced in the hypothyroid test persons compared 
with the control subjects. The frequencies at which the rotating, red-green disk was 
perceived as starting to show a luminance flicker (Fig. 2 Ba) as well as the frequency at 
which a uniform yellow colour was reported (Fig. 2Bb) were both significantly smaller in the 
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Cognitive performance. Since several cognitive tests have been shown to be sensitive for 
thyroid hormone we here tested whether hypothyroidism for 4 weeks has an effect on 
calculation and visual-spatial orientation. A slight but insignificant slowing of the speed 
with which the hypothyroid persons completed the calculation task compared with the 
euthyroid control group was observed (Table 2, Figure 3A). A stronger effect was seen, 
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however, if a more complex performance task, like the correlation of numbers with colours 
and finding and colouring the appropriate numbered area, had to be accomplished (visual-
spatial orientation). Here the hypothyroid patients performed somewhat slower than the 
control subjects. After 6 weeks of hormone substitution the formerly hypothyroid persons 
showed a significantly improved performance (Figure 3B). Hypothyroid persons completed 
the trail making test insignificantly slower than the euthyroid controls or after hormone 
substitution, (Figure 3C, D). 
 
Figure 2. Speed of visual perception. Aa: critical flicker fusion frequency for a luminance flicker of red 
light, 100 Cd/m2 measured once daily at the same time in the morning in a test person during the last 20 
days of thyroxine withdrawal and during resubstitution. Note the gradual continuous decrease in CFF 
with increased time of thyroxine withdrawal and the gradual increase after hormone resubstitution. 
Dark red symbols: right eye, light red symbols: left eye. Ab: average critical flicker fusion frequency 
determined in six separate test persons after four weeks of hormone withdrawal (green bars), 
resubstitution (violet bars) and in control subjects (pink bars). B: critical colour fusion frequency in same 
test persons for luminance flicker of red and green sectors of a rotating disk (a) and fusion of the red-
green sectors to homogenous yellow (b) (mean ± SE, n=6) asterisk: p<0.05. 
Hearing threshold. Since thyroid hormone has been reported to also affect the auditory 
system here we tested whether thyroid hormone withdrawal for several weeks has a 
measurable effect on hearing thresholds. No changes in hearing threshold were obvious for 
frequencies below 8 kHz. Hence only the measurements at 1 kHz and 8 kHz were evaluated 
(Table 2). If data from both ears were pooled, the improvement of 8 dB seen after hormone 
substitution at the test frequency of 8 kHz just reached significance. 
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Figure 3. Performance in cognitive tests. A: Average time needed by test persons after four weeks of 
hormone withdrawal (light bars), thyroid hormone resubstitution for at least nine weeks (grey bars) and 
by control subjects (black bars) to complete a set of simple calculations. B: Average time needed by the 
same subjects to combine numbers in an outline drawing with corresponding colours. C: Average time 
needed by the same subjects to complete the Trail A test and D: the Trail B test (mean ± SE, n=6). 
Asterisk: p<0.05 
Sense of smell. Finally, thyroid hormone might also affect the sense of smell. Of the six test 
persons tested one had been anosmic since childhood and a second subject did not want to 
repeat the smelling threshold test. Hence only 4 persons could be retested in the euthyroid 
state (Table 2). Using the odorant discrimination task, the hypothyroid test persons rated 
66% of the presented flavours correctly. After hormone substitution they showed a slightly 
increased performance rating 72% of the presented flavours correctly, while the controls 
gave 70% correct answers. After four weeks of hypothyroidism, small but insignificant 
decreases in the threshold of odorant detection were found for both odorants which were 
still below the thresholds determined for the control subjects (Table 2). 
Age-dependence of thyroid hormone effects 
Although hypothyroid subjects performed on average slower in several tests it could have 
been possible that some test persons showed only a slowing of speech while others 
showed a slower resolution of visual signals. To find out whether some subjects were on 
average, slower or faster than others for each of seven tests, the speed of speech, 
calculation time, picture filling, Trail A, Trail B, critical flicker fusion frequency for red 
luminance flicker and fusion frequency for chromatic flicker, all twelve test persons were 
assigned numbers of 1 to 12 for each test, were the fasted was scored with 1 and the 
slowest with 12. If two persons showed the same speed of performance they were 
assigned an equal score, such that the highest value was less than 12 for several tests. For 
each test person the average score in the seven tests was calculated (Fig. 4). If differences 
in performance in the different tests were random, then the scores would scatter around a 
value of somewhere below 6.5 (assuming that in some tests several test persons showed 
the same speed). As Fig. 4 shows, this was not the case. As expected, the hypothyroid test 
persons were on average slower than the control subjects (Fig. 4A). As also somewhat 
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however, if a more complex performance task, like the correlation of numbers with colours 
and finding and colouring the appropriate numbered area, had to be accomplished (visual-
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Hearing threshold. Since thyroid hormone has been reported to also affect the auditory 
system here we tested whether thyroid hormone withdrawal for several weeks has a 
measurable effect on hearing thresholds. No changes in hearing threshold were obvious for 
frequencies below 8 kHz. Hence only the measurements at 1 kHz and 8 kHz were evaluated 
(Table 2). If data from both ears were pooled, the improvement of 8 dB seen after hormone 
substitution at the test frequency of 8 kHz just reached significance. 
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Thyroid Hormone 94 
expected the speed of performance showed a tendency to decline with age, such that the 
older test persons, displayed at the right side of the series of columns in Fig 4A, scored on 
average higher than the younger subjects. In comparison of the performance of the test 
persons during hormone substitution with the control subjects an increase in overall 
speed of performance of the formerly hypothyroid subjects was seen, such that the 
average speed of the substituted test persons became indistinguishable from that of the 
controls (Fig. C). Interestingly, the relative increase in speed seemed to be larger in the 










Controls P (HypoTP 
versus 
Controls) 
 n mean SEM n mean SEM  n mean SEM  
Speed of speech / s 12 2.09 0.05 12 1.91 0.04 0.03 12 1.88 0.05 0.003 
Pitch of „u“ /Hz 12 236 13 12 263 10 0.008 12 264 10 0.16 NS 
CFF /Hz 6 28.3 1.0 6 28.2 1.1 0.90 NS 6 30.3 1.6 0.38 NS 
CCFF I /Hz 6 22.0 1.2 6 23.0 2.1 0.73 NS 6 27.3 2.4 0.03 
CCFF II /Hz 6 26.2 1.8 6 30.8 1.8 0.21 NS 6 31.8 2.3 0.02 
Calculation time /s 6 146 42 6 142 40 0.75 NS 6 118 19 0.51 NS 
Visual-spatial 
orientation/s 
6 576 56 6 478 71 0.02 6 504 74 0.44 NS 
Trail A /s 6 122 25 6 105 26 0.16 NS 6  96 16 0.40 NS 
Trail B /s 6 203 40 6 163 44 0.13 NS 6 189 36 0.79 NS 
Odour recognition 
(%) 
5 66 6 5 72 6 0.32 NS 5 70 6 0.48 NS 
Smell threshold 
(eugenol) 
5 6.7 0.6 4 6.9 1.2 0.91 NS 5 7.8 0.5 0.19 NS 
Smell threshold 
(Phe) 
5 5.9 1.1 4 6.7 0.5 0.54 NS 5 7.8 0.5 0.23 NS 
Smell threshold 
(Pyr) 
5 5.1 0.5 4 5.4 0.8 0.37 NS 5 5.9 1.1 0.50 NS 
Hearing threshold 
for 8 kHz /-dB 
12 32 5 12 24 6 0.05 12 25 4 0.24 NS 
Hearing threshold 
for 1 kHz /-dB 
12 22 3 12 21 4 0.43 NS 12 23 2 0.83 NS 
Speed and pitch of speech: the two fastest measurements of each test and control persons were included. CFF: critical 
flicker fusion frequency, CCFF: critical colour fusion frequency, Smell thresholds: a lower threshold of smell 
corresponds to a higher test score: Phe: Phenylethylalcohole, Eu: Eugenol: Pyr: pyridine, hearing thresholds: data from 
right and left ears were pooled, SEM: standard error of the mean, paired t-Test 
Table 2. Summary of the effects of hypothyroidism on performance in the different psychophysical 
tests in hypothyroid test persons, hormone substituted hypothyroid test persons and euthyroid control 
subjects. 
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Figure 4. Effects of age and thyroid status on speed of performance of individual test persons. Mean scores 
obtained by the 12 test and control subjects in 7 tests. A: Comparison of speed of performance in the 
sum of 7 tests in hypothyroid subjects with control subjects. Smallest score: fastest person, largest score: 
slowest person. B: Comparison of former hypothyroid subjects after at least 6 weeks of hormone 
substitution (a) with controls (b). C: Mean values of scores of all six persons after thyroid hormone 
withdrawal compared with control subjects (a) and of test persons after hormone replacement with 
controls (b). Light bars: test persons after hormone withdrawal, grey bars: test persons after hormone 
resubstitution, black bars: control subjects.**: p<0.01.D: Overall improvement in speed of performance 
after hormone substitution. For each of the 6 test persons the number of tests in which performance was 
speeded minus the number of tests in which performance was slowed was determined (maximal value 
of improvement: 8, maximal value of slowing: -8). While 5 persons considerably increased their speed of 
performance (e.g. an increase in speed in 6 tests and a decrease in performance in 1 test) only 1 test 
person showed no average increase in speed.  
To investigate whether only the younger test persons responded with an increase in the 
speed of neuronal information processing to thyroid hormone we evaluated the individual 
change in performance of each test person. For each of the 6 test persons and eight tests (the 
speed of speech, pitch of speech, calculation time, picture filling, Trail A, Trail B, critical 
flicker fusion frequency for red luminance flicker and fusion frequency for chromatic flicker) 
we rated an increase in the speed of performance in a test assigning a 1 to an increase in 
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expected the speed of performance showed a tendency to decline with age, such that the 
older test persons, displayed at the right side of the series of columns in Fig 4A, scored on 
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subjects. 
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Figure 4. Effects of age and thyroid status on speed of performance of individual test persons. Mean scores 
obtained by the 12 test and control subjects in 7 tests. A: Comparison of speed of performance in the 
sum of 7 tests in hypothyroid subjects with control subjects. Smallest score: fastest person, largest score: 
slowest person. B: Comparison of former hypothyroid subjects after at least 6 weeks of hormone 
substitution (a) with controls (b). C: Mean values of scores of all six persons after thyroid hormone 
withdrawal compared with control subjects (a) and of test persons after hormone replacement with 
controls (b). Light bars: test persons after hormone withdrawal, grey bars: test persons after hormone 
resubstitution, black bars: control subjects.**: p<0.01.D: Overall improvement in speed of performance 
after hormone substitution. For each of the 6 test persons the number of tests in which performance was 
speeded minus the number of tests in which performance was slowed was determined (maximal value 
of improvement: 8, maximal value of slowing: -8). While 5 persons considerably increased their speed of 
performance (e.g. an increase in speed in 6 tests and a decrease in performance in 1 test) only 1 test 
person showed no average increase in speed.  
To investigate whether only the younger test persons responded with an increase in the 
speed of neuronal information processing to thyroid hormone we evaluated the individual 
change in performance of each test person. For each of the 6 test persons and eight tests (the 
speed of speech, pitch of speech, calculation time, picture filling, Trail A, Trail B, critical 
flicker fusion frequency for red luminance flicker and fusion frequency for chromatic flicker) 
we rated an increase in the speed of performance in a test assigning a 1 to an increase in 
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speed, a 0 for an unchanged performance and a –1 for a slowing of performance at retesting 
during hormone resubstitution. If a person showed no overall change in speed of 
performance, a score scattering around 0 should result, if the subject slowed considerably 
the score should be in the negative range and if a subject speeded in all tasks, the maximal 
score would reach 8. As depicted in Fig. 4D out of the 6 persons tested with all 8 identical 
tests 5 showed a considerable speeding which corresponded to an increased performance in 
at least 6 out of 8 tests. Only one of the test persons, aged 57, showed an increased 
performance in only 4 tests and a decreased performance in 4 tests. This person was the only 
one who showed no increase in the speed of speech with thyroid hormone substitution. 
Nevertheless Fourier- analysis revealed an increase in pitch by 11% after prolonged 
hormone resubstitution in this test person.  
Our findings, that younger persons are more impaired than older subjects after thyroid 
hormone withdrawal is in accordance with recent findings by Heinzel et al., who reported a 
stronger subjective impairment in younger patients after thyroid hormone withdrawal than 
in older patients (46). This is in accordance with observations of age-dependent effects on 
heart action potential parameters observed to parallel age-related thyroid states (47, 48). 
This observation might relate to a down-regulation of thyroid hormone receptors with aging 
(49). 
4. Evaluation of the experimental data in the context of previous 
observations of the action of thyroid hormone on mental speed 
Taken together, this short survey of measurable changes in sensory perception and reaction 
after a period of a few weeks of severe hypothyroidism indicates that the first effects of 
hypothyroidism to become significantly evident concern changes in the speed of speech and 
visual perception. 
Speed of speech 
Although slowing of speech and thinking had already been noticed in the first description of 
myxedema (2) and by the Committee of the Clinical Society in 1888 (4) to be one of the most 
prominent symptoms of hypothyroidism we are aware of only one published attempt to 
quantify changes in speech due to different thyroid states. This study reported a negative 
correlation between the basal frequency of speech and the duration of the achilles tendon 
reflex (50). These authors performed investigations before and after treatment of hypo- and 
hyperthyroidism with reported time intervals from 7 days to 17 weeks, but did not further 
comment on the severity of thyroid dysfunction and the time course of development of 
recovery of the changes in pitch. A further study observed a decrease of the fundamental 
frequency of speaking 4 days after thyroid ablation (51). Although the cause for the slowing 
of speech is difficult to interpret, increased intervals between the different words (see Fig. 
1A) suggest, that in addition to a possible slowing of muscle contraction and a potential 
decrease in tension of the vocal cords a central slowing of neuronal information processing 
is likely to occur. 
Thyroid Hormone Effects on Sensory Perception,  
Mental Speed, Neuronal Excitability and Ion Channel Regulation 97 
Speed of processing of visual signals 
The second most prominent effect of hypothyroidism revealed by our tests is a slowing of 
the speed of perception of visual information. These results confirm several previous 
studies, one of which reported critical flicker fusion frequencies (CFF) up to 41 - 48 Hz in 23 
hyperthyroid patients and a decrease in flicker fusion frequency to the normal value of 37 
Hz within one month after treatment of the hyperthyroidism (52). Decreased values of the 
critical flicker fusion frequency as well as of the maximal speed of finger movements were 
shown in hypothyroid patients (53). A third study revealed an increase in CFF in 
hypothyroid subjects with a delay of 2-3 weeks after an increase in dose of thyroid hormone 
substitution (54). We could find no previous reports on influences of thyroid hormone on 
the critical colour-fusion frequency (CCFF) which tests the speed of processing of chromatic 
pathways in addition to the CFF, which tests the speed of luminance processing. CCFF 
occurs at a lower frequency as CFF (55). The lower frequency of colour processing compared 
to luminance flicker already starts to arise at the level of the retina (56). 
Since thyroid hormone affects the renewal rate of the photoreceptor outer segments in the 
rat (57, 58) one locus of action of thyroid hormone could be the retina. This is confirmed by 
the finding of increased amplitudes of chiefly the b-waves of the electroretinogram in 
hyperthyroidism and a decrease in hypothyroidism (59, 60), suggesting that thyroid 
hormone influences retinal sensitivity to light. Since there is evidence that thyroid releasing 
hormone (TRH) in the circulation decreases the critical flicker fusion frequency (61) the 
effect could also be due to the enhanced TRH level in the investigated test persons. Since, 
however, no effects of hypothyroidism on peripheral circulating TRH values have been 
found (62) it seems presently more likely that the decrease in flicker fusion frequency is due 
to a direct effect of thyroid hormone.  
Increased voltages of EEG records and a decreased duration of arousal responses to photic 
stimulation after administration of thyroid hormone (63) could be explained by an increased 
light-sensitivity of the retina, but additionally also by an increased transmission of sensory 
signals to the visual cortex. Substantial experimental evidence has been obtained to show 
that the upper frequency limit with which signals are transmitted in the visual pathways 
decreases with the number of synaptic stations traversed (for review see (64)). Hence a 
modulation of synaptic transmission at the thalamic level seems to be responsible for the 
increase of CFF by psychotropic stimulants and the decrease by sedatives (for reviews see 
(65, 66)). Furthermore, investigations of the relation between CFF and intelligence revealed 
only non-significant relations between different scores for intelligence and CFF (67, 68), 
however a decrease of 4 Hz of was found in mentally retarded persons (69) suggesting that a 
larger decline of cognitive function may be accompanied by decreases in CFF. In addition a 
correlation was found between the decline of CFF and the decline in performance on 
cognitive tests in old age (70). 
Complementary to a reduction in CFF, flash evoked potentials showed increased latencies 
and reduced amplitudes in hypothyroid patients 6 weeks after thyroidectomy which were 
reversed after 8 weeks of treatment (16). Consistently, visual evoked potentials using 
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This observation might relate to a down-regulation of thyroid hormone receptors with aging 
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after a period of a few weeks of severe hypothyroidism indicates that the first effects of 
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Although slowing of speech and thinking had already been noticed in the first description of 
myxedema (2) and by the Committee of the Clinical Society in 1888 (4) to be one of the most 
prominent symptoms of hypothyroidism we are aware of only one published attempt to 
quantify changes in speech due to different thyroid states. This study reported a negative 
correlation between the basal frequency of speech and the duration of the achilles tendon 
reflex (50). These authors performed investigations before and after treatment of hypo- and 
hyperthyroidism with reported time intervals from 7 days to 17 weeks, but did not further 
comment on the severity of thyroid dysfunction and the time course of development of 
recovery of the changes in pitch. A further study observed a decrease of the fundamental 
frequency of speaking 4 days after thyroid ablation (51). Although the cause for the slowing 
of speech is difficult to interpret, increased intervals between the different words (see Fig. 
1A) suggest, that in addition to a possible slowing of muscle contraction and a potential 
decrease in tension of the vocal cords a central slowing of neuronal information processing 
is likely to occur. 
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Speed of processing of visual signals 
The second most prominent effect of hypothyroidism revealed by our tests is a slowing of 
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studies, one of which reported critical flicker fusion frequencies (CFF) up to 41 - 48 Hz in 23 
hyperthyroid patients and a decrease in flicker fusion frequency to the normal value of 37 
Hz within one month after treatment of the hyperthyroidism (52). Decreased values of the 
critical flicker fusion frequency as well as of the maximal speed of finger movements were 
shown in hypothyroid patients (53). A third study revealed an increase in CFF in 
hypothyroid subjects with a delay of 2-3 weeks after an increase in dose of thyroid hormone 
substitution (54). We could find no previous reports on influences of thyroid hormone on 
the critical colour-fusion frequency (CCFF) which tests the speed of processing of chromatic 
pathways in addition to the CFF, which tests the speed of luminance processing. CCFF 
occurs at a lower frequency as CFF (55). The lower frequency of colour processing compared 
to luminance flicker already starts to arise at the level of the retina (56). 
Since thyroid hormone affects the renewal rate of the photoreceptor outer segments in the 
rat (57, 58) one locus of action of thyroid hormone could be the retina. This is confirmed by 
the finding of increased amplitudes of chiefly the b-waves of the electroretinogram in 
hyperthyroidism and a decrease in hypothyroidism (59, 60), suggesting that thyroid 
hormone influences retinal sensitivity to light. Since there is evidence that thyroid releasing 
hormone (TRH) in the circulation decreases the critical flicker fusion frequency (61) the 
effect could also be due to the enhanced TRH level in the investigated test persons. Since, 
however, no effects of hypothyroidism on peripheral circulating TRH values have been 
found (62) it seems presently more likely that the decrease in flicker fusion frequency is due 
to a direct effect of thyroid hormone.  
Increased voltages of EEG records and a decreased duration of arousal responses to photic 
stimulation after administration of thyroid hormone (63) could be explained by an increased 
light-sensitivity of the retina, but additionally also by an increased transmission of sensory 
signals to the visual cortex. Substantial experimental evidence has been obtained to show 
that the upper frequency limit with which signals are transmitted in the visual pathways 
decreases with the number of synaptic stations traversed (for review see (64)). Hence a 
modulation of synaptic transmission at the thalamic level seems to be responsible for the 
increase of CFF by psychotropic stimulants and the decrease by sedatives (for reviews see 
(65, 66)). Furthermore, investigations of the relation between CFF and intelligence revealed 
only non-significant relations between different scores for intelligence and CFF (67, 68), 
however a decrease of 4 Hz of was found in mentally retarded persons (69) suggesting that a 
larger decline of cognitive function may be accompanied by decreases in CFF. In addition a 
correlation was found between the decline of CFF and the decline in performance on 
cognitive tests in old age (70). 
Complementary to a reduction in CFF, flash evoked potentials showed increased latencies 
and reduced amplitudes in hypothyroid patients 6 weeks after thyroidectomy which were 
reversed after 8 weeks of treatment (16). Consistently, visual evoked potentials using 
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chequerboard reversal patterns showed reversible increases in latencies and reductions in 
amplitudes in hypothyroidism (17, 19–21, 23, 24, 71–73). However, this increase in latency is 
not consistently observed in all cases of hypothyroidism and thus it is still controversial 
after which duration and or severity of hypothyroidism significant increases in latency can 
be observed (74). Nevertheless, blink reflex prolongation could be consistently observed in 
hypothyroid patients confirming a slowing in visual pathways in adult onset 
hypothyroidism (75). From the available studies no definitive conclusion concerning the 
targets for thyroid hormone action in the visual pathways can be drawn. Thyroid hormone 
could already effect photoreceptor sensitivity as well as increase the speed of impulse 
propagation and synaptic transmission in any of the following relay stations. 
Cognitive performance 
Several reports have described mental changes in hypothyroidism, ranging from difficulties 
to perform simple calculations to memory impairments and finally to hallucinations (76–79). 
Although these impairments are probably the most troublesome symptoms for the patients, 
it has been difficult to quantify cognitive problems in adult-onset hypothyroidism. Daytime 
sleepiness as well as mental and physical fatigue are complaints in 70 - 80% of the 
hypothyroids (80, 81). Disturbances of sleep during thyroid dysfunction might account for 
some of the problems delineated above, as the different sleep stages are necessary for 
memory consolidation (82, 83). Sleep fragmentation in hypothyroids is not necessarily 
caused by nocturnal breathing disorders (sleep apnea) (84, 85).  
The trail making test, which tests skills including vigilance, concentration, visual scanning 
and visuomotor tracking speed was shown by Reitan (44, 86) to respond to different types of 
organic brain damage. Later on slowed performance on the trail making test (part B) was 
shown in hypothyroid patients (78, 87). Subsequently Osterweil et al. (24) observed that the 
performance for Trail A was significantly slowed in old and very old hypothyroid patients 
as compared to age-matched controls and Wahlin et al. (88) reported that TSH was 
predictive for Trail-B in very old persons. Our finding of a non-significant slowing in the 
trail making tests confirms the observation of Osterweil et al., that carcinoma patients off 
thyroid hormone replacement show no statistically significant differences in test 
performance compared to euthyroid controls. However, 5 of the six persons tested showed 
an increase in performance when retested after hormone replacement, which escaped 
statistical significance because of the large scatter between the different individuals. This 
suggests that thyroid hormone withdrawal of longer duration is necessary before changes in 
this test become statistically significant. 
Apart from this relatively simple test effects of thyroid hormone on more complex cognitive 
tasks have been investigated. The first measurement of an increase in the intelligence level 
by a mean of 20 I. Q. points of three adult myxedematous patients after three months of 
treatment with thyroid hormone has been reported by Crown (32). Especially in older 
hypothyroid persons, reversible decreases in the Folstein mini mental state score were found 
(24, 89, 90). In a double-blind study on adult persons with subclinical hypothyroidism out of 
17 patients 4 showed improved performance on at least two and 7 test persons improved in 
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one of a reaction time, an object memory and a figure identification test after a six month 
period of thyroxine supplementation (33). Likewise, in subclinically hypothyroid adults the 
Wechsler Memory Scale indicated a significant decrease in logical memory (91, 92) as well as 
verbal and visual memory (93) (for a recent review see (94)) and severe hypothyroidism for 
a short time decreased working memory (43). Using fMRI changes in hypothyroid subjects 
during working memory tasks could be visualized (95). Finally also changes in the 
estimation of time spans have been observed in hypothyroid subjects (96). All these 
experiments were performed after a longer period of hypothyroidism or latent thyroid 
dysfunction. To be able to complete our test battery in a reasonably short time we designed 
a short tests for calculation and visual-spatial performance. Our present results indicate that 
a severe hypothyroidism of a short duration already causes significantly slowed 
performance in a visuo-spatial orientation task. This is in line with findings of increased 
latencies of event-related evoked potentials in hypothyroidism (97, 98). 
Perception of smells 
Although perversions of taste and smell during myxoedema have already been noticed in 
the first descriptions of this disease (99, 100) there have only been a few investigations on 
this subject, which provided no clear answers concerning the prevalence of olfactory 
disorders during hypothyroidism. Reversible increases in the threshold of smell and taste 
have previously been found in hypothyroid subjects (30, 31, 101). In addition to the reduced 
threshold, hypothyroid persons rated bitter and salty tastes as more agreeable than 
euthyroid control persons in the latter study. Interestingly, a more general study concerned 
with smell and taste disorders reported a more than average complaint of patients taking 
levothyroxine about a loss of the sense of taste. The investigation of these patients revealed, 
in contrast to their subjective impressions, higher scores on a taste-identification test. 
Additionally, the patients taking thyroxine perceived a test concentration of coffeine as 
having a greater intensity as the other patients, without showing significantly different taste 
thresholds (102). The discrepancy between subjective impression and test results could have 
resulted from increases in thresholds of taste preceding hormone substitution resulting in an 
increased awareness of the sense of smell. A study of taste thresholds, measured in 11 
hypothyroid subjects after total thyroid ablation, which had stopped taking replacement for 
4-8 weeks prior to a 131I scan showed no increases in recognition thresholds to NaCl and urea 
(103). These patients showed, however, a decrease in intensity rating for the two tastants and 
less dislike to both substances at higher concentrations as compared to control subjects. 
Although the authors conclude that hypothyroidism probably has to persist for a longer time 
in order to develop more pronounced changes in taste, the preference and intensity rating 
tests could indicate the beginning of changes in taste after this period. Our present findings of 
an insignificant tendency towards a higher threshold of smell for both odours in the 
hypothyroid compared with the euthyroid subjects are in line with the assumption of a 
beginning loss of taste and smell after 4 weeks of hypothyroidism. In contrast, however, a 
study by Lewitt et al. (104) found no significant changes in the thresholds for taste and smell 
even in longer standing hypothyroidism. Since this study, in addition, reported no increase in 
the latencies of visual evoked potentials, in contrast to seven other available reports, it could 
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chequerboard reversal patterns showed reversible increases in latencies and reductions in 
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it has been difficult to quantify cognitive problems in adult-onset hypothyroidism. Daytime 
sleepiness as well as mental and physical fatigue are complaints in 70 - 80% of the 
hypothyroids (80, 81). Disturbances of sleep during thyroid dysfunction might account for 
some of the problems delineated above, as the different sleep stages are necessary for 
memory consolidation (82, 83). Sleep fragmentation in hypothyroids is not necessarily 
caused by nocturnal breathing disorders (sleep apnea) (84, 85).  
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trail making tests confirms the observation of Osterweil et al., that carcinoma patients off 
thyroid hormone replacement show no statistically significant differences in test 
performance compared to euthyroid controls. However, 5 of the six persons tested showed 
an increase in performance when retested after hormone replacement, which escaped 
statistical significance because of the large scatter between the different individuals. This 
suggests that thyroid hormone withdrawal of longer duration is necessary before changes in 
this test become statistically significant. 
Apart from this relatively simple test effects of thyroid hormone on more complex cognitive 
tasks have been investigated. The first measurement of an increase in the intelligence level 
by a mean of 20 I. Q. points of three adult myxedematous patients after three months of 
treatment with thyroid hormone has been reported by Crown (32). Especially in older 
hypothyroid persons, reversible decreases in the Folstein mini mental state score were found 
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be possible, that the discordant findings of this report were due to the high median age of the 
investigated subjects (61 ± 16 years) which could already have displayed age-dependent 
declines in sensory function. In addition, the possibility exists, that only a fraction of the 
hypothyroid subjects shows changes in taste thresholds (105).  
Possible causes of a loss in smell during hypothyroidism have also been investigated in rats. 
Here prolonged hypothyroidism has been shown to result in deficits in migration of 
olfactory receptor neurones while the mitotic rates of basal cells remained unaltered in 
postnatal (106) as well as in adult rats (107). The effects of propylthiouracil (PTU) – induced 
hypothyroidism were reversed by thyroxine therapy. Further experiments could, however, 
not confirm increases in the threshold to olfactory and taste stimuli in adult rats rendered 
hypothyroid with PTU for 5 weeks (108, 109) in which only changes in taste preferences for 
sour, bitter and salty, not of detection threshold were found. Additional confusion arose 
from several case reports describing thyreostatic drugs to also induce decreases in the sense 
of taste and smell in patients (methylthiouracil, - (110); methimazole - (111); thiamazol and 
carbimazol, (112–114). Sometimes, only the sensation of taste, sometimes also olfaction was 
impaired. Some patients could have actually become hypothyroid, but in some patients no 
other symptoms of hypothyroidism were noted and the symptoms did not reappear during 
thyroidectomy-induced hypothyroidism (110). A histological examination showing 
destruction of the olfactory epithelium, sparing the basal cells already after 32 hours of 
methimazol administration to rats further substantiates the possibility of toxic effects of 
antithyroid medication (115), which lead to apoptosis of rat olfactory receptor neurons (116). 
However, in studies of methimazol toxicology effects of hypothyroidism should be carefully 
excluded. Likewise, we cannot presently exclude, that changes in taste, which have been 
reported to occur frequently in patients as side effects of a high dose 131I therapy (117) could 
also have resulted to some extent from the accompanying hypothyroidism, which also has 
been reported as a potential cause of a “bourning mouth symptom” (118). 
Hearing 
Impairments of hearing have long been reported to occur in hypothyroidism (for reviews 
see (27, 119)). The incidence of decreases in hearing threshold observed in hypothyroid 
patients varies from study to study, ranging from 85% (28), 80% (29), 62% (120), 55% (121) 
43% (122), 31% (80) to as low as 12% [98]. 
The only study showing no evidence of reversible hearing losses in hypothyroid patients 
(123) was performed on old patients between 61-92 years, in which the effects of 
presbyacusis may have a stronger effect on hearing threshold than those of thyroid 
hormone. The most dramatic hearing impairments arise if the thyroid hormone supply is 
insufficient during development, where irreversible structural impairments in the cochlea, 
presumably a disruption of the smooth fit of the tectorial membrane to the hair cells occurs 
(see e.g. (124–126). While a thyroid-hormone induced selective expression of neurotrophin-
receptors could underly the morphogenetic changes shaping the inner ear (127) the 
acceleration of the expression of a fast potassium conductance (128) and the development of 
rapidly activating Ca2+- and voltage-activated K+ (BK) conductances in inner hair cells (129) 
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could be necessary for the proper development of cochlear sensory transduction. 
Furthermore, hypothyroidism causes delays in the development of synaptic inhibition in the 
auditory brainstem (130). In line with a larger susceptibility of the immature auditory 
system to thyroid hormone deficiency Heinemann (131) reported no case of hearing 
impairment in 23 patients with primary hypothyroidism if treated in time but in 4 out of 7 
cases if hormone substitution had been delayed. Besides the irreversible effects of thyroid 
hormone on the development of inner ear function, reversible changes of hearing acuity 
have already been described in early reports on the symptoms of adult-onset 
hypothyroidism (132, 133). Improvements of hearing threshold with treatment in some pa-
tients with hypothyroidism have since been shown with pure tone audiometric testing (25, 
28, 29, 134, 135). Especially noteworthy in this context is the finding, that in 7- 11 year old, 
normal, but latently hypothyroid schoolchildren living in endemic areas of severe iodine 
deficiency iodine prophylaxis led to an average improvement of hearing (30 children tested 
in each village) by 15 db over the course of three years (136). Smaller changes in hearing 
threshold were reported after a total thyroid hormone withdrawal for a few weeks: 6 - 12 
weeks after hormone withdrawal Post (137) reported 26 normal audiograms, decreased 
hearing thresholds which did not reverse after 3- 12 months of treatment in 5 patients and 
small, partially subjective improvements with hormone substitution in 4 patients from a 
total of 35 patients. No acute changes in hearing were also found by Mra and Wax (138) in 
10 patients 2-6 weeks after total thyroidectomy. In contrast, Rubenstein et al. (120) described 
a case of a reversible hearing loss of 20 dB in a 5 year old child, that had been induced by 
stopping thyroid hormone therapy for four weeks. Another case report, where audiometric 
investigations were available 2 months before thyroidectomy a high frequency hearing loss 
started on the 40th day of hormone withdrawal, which was partially reversible after 
hormone substitution (139). These inconsistent findings correspond to our results of 
borderline significant increases in hearing thresholds of about 8 dB for high frequencies after 
4 weeks of thyroid hormone withdrawal. 
Animal experiments showed that in guinea pigs thyroid ablation caused decreased 
amplitudes of cochlear microphonic potentials (140) and cochlear action potentials of 
decreased amplitudes and increased delay when recorded four to eight months after 
administration of an ablative dose of radioactive iodine (124). Likewise, increased hearing 
thresholds have been observed in adult guinea pigs (125) at high frequencies of 8kHz (141) 
after 120 days of hypothyroidism. In contrast, Ritter (26) measured only deafness in five out 
of 166 experimental rats rendered hypothyroid on the 21st day of life. Interestingly, changes 
in the number of spines/per shaft of pyramidal neurones (indicating synaptic densities) could 
be shown in the auditory cortex of adult rats thyroidectomized at 120 days of age and 
investigated 120 days later (142). The authors note that in auditory pyramidal cells these 
changes develop much more slowly than in pyramidal cells of the visual cortex, which could 
indicate that the adult auditory system may respond to hypothyroidism on a slower time 
scale than the visual system. Perhaps these considerations could also explain why, in contrast 
to visual evoked potentials which consistently show slowing in hypothyroidism, some 
authors found no changes in auditory evoked potentials (24, 143) while other studies (18, 21, 
22) found reversible increases in latencies of auditory evoked potentials in hypothyroidism.  
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be possible, that the discordant findings of this report were due to the high median age of the 
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Taken together, the auditory system may lose its sensitivity to thyroid hormone with in-
creasing age and this may also depend on an individual susceptibility. In addition, effects 
on hearing may develop only after a thyroid hormone withdrawal for more than five weeks 
in the adult. 
Effects of thyroid hormone on sensory perception and brain function  
The present tests performed on a small number of patients indicate that the most prominent 
symptom after 4 weeks of thyroid hormone withdrawal is a beginning decline in the speed of 
central neuronal information processing, which was reflected in decreases in the speed of 
visual perception, speed of speech as well as of visual-spatial orientation. Hearing and 
smelling thresholds were only slightly changed, and in the context with the publications 
discussed above this indicates that auditory and olfactory perception may change only with 
thyroid dysfunctions of longer duration or are more sensitive to thyroid hormone in 
development. The experiments illustrated here complement previous findings, that 
hypothyroidism slows peripheral conduction velocity (144), reduces EEG frequencies and 
increases latencies of evoked potentials (73). The conception that thyroid hormone deficiency 
causes a general decrease in neuronal excitability was recently supported by the observation 
of a decreased cortical excitability and increased motor thresholds using transcranial 
magnetic stimulation in adult patients (145). Accordingly, in a small percentage of epileptic 
seizures in humans (146) thyrotoxicosis was identified as sole cause of the seizures and the 
seizures were found to fully subside after restoration of euthyroidism, again indicating an 
effect of thyroid hormone on cortical excitability. An increased susceptibility to seizures was 
also noticed in hyperthyroid animals such as cats (147) and mice (148). 
5. Explanations of thyroid hormone effects on the brain at the molecular 
and cellular level  
Owing to the complex actions of thyroid hormone there is currently no concluding explanation 
concerning the molecular mechanisms underlying the effects of thyroid hormone on cortical 
excitability. At the morphological level, in the mature brain thyroid hormone excess (149) as 
well as deficiency (150) have been reported to decrease the number of dendritic spines, 
assumed to represent postsynaptic endings, already after 5 days in adult rats. Even more 
dramatically, hypothyroidism leads to a reduction of the neuropile in CA1 and CA3 
hippocampal areas and in addition to a loss of pyramidal cells in the CA1 area (151). Thus it 
seems possible that adult-onset hypothyroidism may actually cause neuronal degeneration, as 
already occasionally observed in autopsies of early cases of patients who had died with 
myxedema (152, 153). A reversible shrinkage of neuropile could also explain the findings of 
reversibly widened ventricular spaces in the brains of hypothyroid subjects (154, 155).  
The development of cholinergic terminals in rat forebrain, hippocampus and amygdala is 
regulated to a considerable extent by thyroid hormone (see e.g. (156)). Although smaller and 
more localized effects are reported in adults, several lines of evidence suggest that 
acetylcholine -release may be enhanced by thyroid hormone and decreased in hypothyroidism 
in the adult nervous system as well (157, 158). A decrease of cholinergic activity could perhaps 
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also explain the occurrence of slow EEG waves (159) as well as the cognitive impairments 
frequently seen in hypothyroid subjects. A regulation of cholinergic function also fits to the 
observation of a regulation of nerve growth factor which has been suggested to be involved in 
maintaining the function of cholinergic hippocampal projections by thyroid hormone in adult 
rat brain (160). Thyroid hormone, however, does not seem to interfere exclusively with 
cholinergic forebrain neurons but to regulate the balance of a variety of other 
neurotransmitters in a region-specific manner. Hence dopamine levels were found to be 
increased in the midbrain of hyperthyroid rats (161) and decreased in hypothyroid rats (162). 
Also the dopaminergic input into striatal neurons could be upregulated by thyroid hormone 
(163). Furthermore, a differential regulation of serotonin levels (162, 164) as well as 5-HT2 
receptors have been found (165). Regulations of various adrenoceptors as well as GABA- 
receptors have been described see e.g. (166–168). In addition T3 could act as a cotransmitter to 
modulate noradrenergic action (169) or as a modulator of endogenous benzodiazepine action 
(170). While it is believed that thyroid hormone exerts its effects predominantly via nuclear 
receptors possible direct effects on membrane receptors further complicate the picture (157, 171, 
172). In addition to a membrane action via αVβ3intergins, high doses of 20 µM T3 or T4 have 
been shown to directly act on GABA receptors to down-regulate GABAergic postsynaptic 
currents in cultured hippocampal neurons (173, 174), which could explain acute increases in 
neuronal excitability induced by iontophoretecally injected T4 and T3 (171). Although the 
regulatory influences exerted by thyroid hormone are complex it seems that T3 regulates to 
some extent the release of neurotransmitters such as acetylcholine, dopamine, 5-HT and 
noradrenalin in specific pathways as well as the density of the corresponding receptors (166).  
A stimulating effect of thyroid hormone on transmitter synthetic enzymes or precursor-
uptake systems as well as the protein synthesis of the receptors could in principle explain 
the decrease in cerebral responsiveness in hypothyroid subjects. Furthermore, a down-
regulation of postsynaptic inhibitory currents in hyperthyroidism, as suggested by Puia and 
Losi (174), could account for the increased irritability seen in hyperthyroid subjects. A 
diminished postsynaptic current density due to a decrease in transmitter release or receptor 
density or activation could also explain some of the increased latencies since a smaller 
current density would lead to a delay in the charging of the membrane capacitance. 
However, investigations using transcranial magnetic stimulation provided evidence that in 
hypothyroid patients the cortical excitability as such is decreased (145). Furthermore, 
experiments on peripheral nerves of hyperthyroid rats indicated enhanced afferent spikes 
and a drop in the chronaxia for direct activation of action potentials in rat peripheral nerves 
(175). Hence thyroid hormone could also influence neuronal excitability directly, which 
could secondarily result in a decrease in transmitter release. 
Changes in conduction velocity, action potential waveform and the regulation of voltage-gated ion 
currents by thyroid hormone 
Changes in Achilles tendon reflexes and the slowing of peripheral conduction velocity in 
hypothyroidism have so far mostly been explained by a reduction in myelination, and the 
gene for myelin basic protein is, in fact, regarded as one of the few genes known to be 
directly regulated by thyroid hormone (for review see (176)). However, a decrease in 
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sodium current density could as well explain the decreases in peripheral conduction 
velocities and increases in latencies of evoked potentials found in hypothyroidism (16–24) 
and reversely the increased amplitudes in hyperthyroidism (177, 178). Since there seems to 
be an optimal density of sodium channels that ensures maximal neuronal conduction 
velocity (179), beyond which no further increase or even a slowing of conduction velocity 
occurs, an upregulation of sodium currents by thyroid hormone could also explain the 
inconsistent findings concerning latencies of evoked visual potentials in hyperthyroidism, 
where some authors found decreases in latencies (180) or even increases with increases in 
thyroid hormone (21, 71, 177, 178). Because of the temperature sensitivity of the activation of 
sodium and calcium currents the fall in core temperature during hypothyroidism and its 
increase in hyperthyroidism could further exacerbate the symptoms (19). 
Influences of thyroid hormone on action potentials and underlying ion currents in the heart 
Evidence that thyroid hormone could indeed change action potential waveforms became 
available from electrical recordings performed in ventricular cells from guinea pig hearts, that 
showed decreases in action potential length in the course of hours after application of thyroxine, 
which then gradually recovered over the course of days (181). In line with these observations, 
prolongations of action potential durations were observed in hypothyroid rat heart cells (182) 
and guinea pig ventricular myocytes (183). That thyroid hormone directly effects the electrical 
properties of heart cells, and not just alters sympathetic receptors was shown by Valcavi et al. 
(184), who demonstated an increase in the intrinsic activity of the sinus node in hyperthyroid 
patients that persisted after chemical blockage of autonomous innervation. Patch clamp 
recordings revealed that in heart cells from neonatal rats (185, 186) and in cat atrial myocytes 
(187), acute applications of 5-20 nM T3 increased voltage activated sodium currents. Single 
channel recordings revealed that the application of 5-50 nM T3 induced bursting of Na+-
channels in rabbit ventricular myocytes (188). Later studies showed, that T3 increases the 
sodium channel open probability by binding directly inside the membrane and that the 
interaction with a pertussis toxin sensitive G-protein greatly enhances this effect (189). More 
recent experiments by Schmidt et al. (190), confirmed rapid effects of T3 on human hearts, 
however, suggesting a contribution of the sympathetic nervous system. After a period of 
prolonged hyperthyroidism in rats, in contrast to acute effects, no changes in Na+current density 
as well as of inward potassium currents were found. At that time increased rates of rise of the 
action potentials could be rather explained by an increase in Ca2+-currents and a shortened 
action potential duration by an increase in a delayed rectifier current (191). Although it is 
presently not completely understood, which channel regulations exactly determine short and 
long term effects of thyroid hormone, it is safe to conclude, that an upregulation of voltage 
activated Na+-, Ca2+ and K+-currents plays a pivotal role in decreases in action potential duration, 
the acceleration of the heart beat and modulation of contraction amplitude by thyroid hormone. 
Influences of thyroid hormone on action potentials and underlying ion currents in the central 
nervous system 
The influence of thyroid hormone on the electrical properties of neurons has been studied in 
less detail. The first experiments using whole cell patch clamp recordings were carried out 
on cultured postnatal rat hippocampal neurons and showed an upregulation of voltage-
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gated Na+-currents (INav) by T3 (192). An upregulation of the density of voltage-gated Na+ 
currents was also found in acutely isolated neurons from the occipital cortex of 
hyperthyroid rats and a down regulation observed in cells from hypothyroid rats. The 
changes in Na+current density led to increased action potential upstroke velocities as well as 
to enhanced discharge rates in thyroid hormone treated cells in response to identical 
stimulus strengths (193). Similarly, increases in voltage-gated Na+ currents were observed in 
human neuroepithelial cells as well as mesenchymal stem cells after incubation with 1 nM 
T3 for 72h to 6 days in culture. Neuroepithelial cells additionally responded with increases 
in Ca2+ currents to prolonged T3-treatment (194). In the in vivo situation thyroid hormone 
effects seem to be more complex: Thus in CA1 neurons of the rat hippocampus changes in 
the bursting pattern have been observed, which could be explained by an upregulation of a 
low-threshold Ca2+ current (195). Furthermore, consistent with Hoffmann and Dietzel, 2004, 
decreases in action potential depolarization rate and decreases in discharge rate were 
observed by thyroid hormone withdrawal. In contrast to the action of thyroid hormone in 
the heart these authors additionally observed a shortening of action potental duration upon 
thyroid hormone withdrawal, that could be explained by the upregulation of an A-type 
potassium current (196). Finally in a somewhat distant animal, in Rohon-Beard neurons 
from the embryonic zebrafish rapid increases of voltage-gated Na+currents by thyroxine 
were found (197). This Na+current regulation was shown to be essential for the further 
development of the embryo and depended on αVβ3 integrin activation and the MAPK (p38) 
pathway (198). An increase in voltage-gated Na+current density by thyroid hormone would 
cause a general speeding of mental functions as illustrated in figure 5: 
 
Figure 5. Simulation of action potential spread in a hippocampal model neuron, for action potential 
with high (A-red) and low (A-blue) Na+-current density. A an increase in Na+current density increases 
action potential depolarization (Aa), amplitude and discharge frequency (Ab). B. Simulation of action 
potential spread in a ramified neuron 1 ms after application of a stimulus at t=1ms. 
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thyroid hormone withdrawal, that could be explained by the upregulation of an A-type 
potassium current (196). Finally in a somewhat distant animal, in Rohon-Beard neurons 
from the embryonic zebrafish rapid increases of voltage-gated Na+currents by thyroxine 
were found (197). This Na+current regulation was shown to be essential for the further 
development of the embryo and depended on αVβ3 integrin activation and the MAPK (p38) 
pathway (198). An increase in voltage-gated Na+current density by thyroid hormone would 
cause a general speeding of mental functions as illustrated in figure 5: 
 
Figure 5. Simulation of action potential spread in a hippocampal model neuron, for action potential 
with high (A-red) and low (A-blue) Na+-current density. A an increase in Na+current density increases 
action potential depolarization (Aa), amplitude and discharge frequency (Ab). B. Simulation of action 
potential spread in a ramified neuron 1 ms after application of a stimulus at t=1ms. 
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B shows the spread for the neuron with high current density and B for the neuron with 
low current density. The magnified inserts (Ba and Cb) clearly show, that the overshoot 
of the action potential (light colours) reaches the synapses much earlier in the cell with 
high current density than in the cell with lower current density (Cb). Simulations 
performed using the Hodgkin-Huxley equations and the program Neuron version 3.2.3 
(199). 
Hypothyreosis also affects a prominent EEG pattern, namely the alpha rhythm (11–15). This 
may be also related to altered Na+ channel function, since TTX-insensitive Na+ currents of 
cortical bursting neurones have been implicated in the generation of the alpha rhythm (200). 
Subsequently, the presence of SCN5A mRNA, encoding the TTX-resistant Na+ channel had 
been demonstrated in the mammalian brain (201, 202). 
It is noteworthy that the mental symptoms observed with the psychophysical tests used in 
the present study developed gradually, as most prominently demonstrated in the 
continuous observations on a single person and only recovered with a similar slow time 
course in the first weeks of hormone resubstitution (see Fig. 1D and 2A). Prolonged recovery 
phases for the reversal of several of the symptoms accompanying hypothyroidism have 
been described (20, 84, 203–205) and subjective improvements of well-being, quantified with 
a “Quality of life-Thyroid scale” were found only after four weeks compared to one week of 
thyroid hormone replacement (38). 
This corresponds to the observation of a lack of acute effects of T3 in hippocampal slices 
(206) and the observation of a slow upregulation of Na+current density in hippocampal 
cultures (207). In the later study the Na+current regulation was shown to depend on the 
presence of glial cells in the culture medium. Thyroid hormone has been shown to induce 
protein secretion from glial cells (208), including basic fibroblast growth factor (FGF-2) (209) 
and epidermal growth factor (210). Furthermore, thyroid hormone has been shown to 
elevate nerve growth factor, neurotrophin-3 and brain derived neurotrophic factor (BDNF) in the 
brain (see e.g.(211)). A first indication that intermediate steps, including growth factors 
could be involved in the regulation of Na+currents by thyroid hormone were experiments, 
that showed, that the effect of T3 on Na+ currents could be reduced by a simultaneous 
incubation of cultures with antibodies against FGF-2, leading to the hypothesis depicted 
in Figure 6. 
Concerning the action of thyroid hormone on neuronal excitability there seems to be a 
common finding that the density of voltage-gated Na+currents is up-regulated by thyroid 
hormone rendering the cells more excitable. This mechanism would explain many of the 
symptoms observed in thyroid disease, such as slowed peripheral conduction velocity and 
decreased excitability of the hypothyroid brain. In other tissues, such as various epithelial 
cells, thyroid hormone could, likewise, play an essential role in the regulation of the 
expression of amiloride sensitive, epithelial Na+channels (see e.g. (212)). The molecular 
mechanisms, leading to Na+current upregulation, may however, differ in different species 
and tissues and warrant further elucidation. 
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Figure 6. Illustration of a potential mechanism leading to Na+-current regulation in the hippocampus of 
rats: T3 stimulates glial cells (stained red by antibodies against GFAP) to secrete growth factors (such as 
FGF-2) which in turn up-regulate Na+currents in neurons. (stained green by antibodies against βIII 
tubulin). Thus in addition to regulating the neuronal environment and stimulating synapse formation 
glial cells could also be involved in modulating neuronal excitability.  
Regulation of Na+/K+-ATPase expression by thyroid hormone 
Since thyroid hormone has long been known to increase energy expenditure, and about 40% 
of energy at rest is consumed by activity of the Na+/K+-ATPase (36, 37, 213) many 
researchers focused on studying effects of thyroid hormone on Na+/K+-ATPase activity and 
expression. The Na+/K+-ATPase is a heterodimeric membrane spanning protein complex 
composed of three catalytic alpha subunits (α1, α2 and α3) with molecular weights of ~97-
116kDa and two glycosylated β subunits (β1 and β2 of ~35-55kDa). While the α subunits 
contain the Na+, K+ and the intracellular ATP binding site, the β subunits are required to 
insert the catalytic α subunits into the appropriate locations of the cell membrane (214). An 
intracellular Na+ load of the cell leads to binding of three Na-ions to their intracellular 
binding sites, thus triggering phosphorylation of the α subunit and inducing a 
conformational change of the pump to expose the Na-ions to the extracellular surface at the 
expense of ATP (see e.g. (37)). Thus an increased intracellular Na+-load, as induced by a 
larger or longer Na+ influx will increase energy consumption by stimulating the demand for 
ATP. Interestingly, the Na+/K+-ATPase shows a 10-12 fold increase in expression during 
postnatal development of the brain (215) which parallels the postnatal increase in Na+ 
current density (216).  
The different isoforms of the Na+/K+-ATPase were reported to be distributed in a cell and 
tissue dependent manner. Thus in brain tissue the α3 isoform transcript is expressed 
abundantly in comparison with the mRNA for the α1 and α 2 subunits. The α3 expression 
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increases 10 fold within the first 7 days after birth and remains at this elevated level until the 
55th day of age in the rat. In contrast, the mRNA for the α1, α2 and β isoforms reach their 
maximal expression levels only after the rats are at 25 days old (215).  
In general, thyroid hormone was found to up-regulate Na+/K+-ATPase activity and 
expression in many tissues: For instance, in rat cardiomyocytes, T3 was observed to increase 
the mRNA pattern of Na+/K+-ATPase α1 and β1 subunits 4fold after 48hrs and the α2 mRNA 
expression even 7fold after 72hrs of treatment (217). A similar effect of T3 was found in a rat 
liver cell line. Here, a non transformed continuous cell line derived from adult rat liver 
treated with T3 showed a 1.3 fold increased activity of Na+/K+-ATPase. More specifically, the 
mRNA expression of the α1 and β1 isoforms of the Na+/K+-ATPase increased 1.5 and 2.9 fold 
respectively compared with controls maintained in T3 free (hypothyroid) media (218). 
In rat brains thyroid hormone has been shown to up-regulate Na+/K+-ATPase activity and 
protein expression in synaptosomes only in the first two postnatal weeks (219). In addition 
Schmitt et al., in 1988 showed that the hypothyroid condition reduces the expression of the 
mRNA for Na+/K+-ATPase α isoforms in rat brain (220). However, observing thyroid 
hormone effects in identified brain regions in the adult rat indicated, that hypothyroidism 
could down-regulate Na+/K+-ATPase activity in specific brain regions, such as the adult 
hippocampus (221, 222). Further experiments showed that the predominant brain cell 
specific α3 isoform of the Na+/K+-ATPase decreased in hypothyroid rat brain as well and 
that the relative sensitivity of the different Na+/K+-ATPase α subunits in brain cells for 
thyroid hormone is α3>α1>α2 (223). The expression of all Na+/K+-ATPase isoforms and their 
regulation by T3 was also observed in primary neuronal cell cultures of rat brain at the 
mRNA and protein level using northern and western blot techniques (224). In contrast to 
neurons, glia cells express α1, α 2 and β1, 2 not α3. The mRNAs as well as the proteins of the 
four subunits expressed in glia cells showed an upregulation when the cells were grown 
with the supplement of T3 for 5 and 10 days respectively (225).  
Although a T3-responsive element has been found in the promotor region of the α3 subunit 
(226) two reports on muscle cells indicate, that the regulation of the Na+/K+-ATPase by 
thyroid hormone might be at least to some extent secondary to an enhanced sodium influx. 
Thus Brodie and Sampsom (227) observed that a blockage of Na+-influx by tetrodotoxin to 
block the voltage-gated Na+currents or by amiloride to block further Na+transport routes 
both reduced the T3-induced increase of 3[H]-ouabain binding sites, which represent 
membrane inserted Na+/K+-ATPase in cultured myotubes. These results were confirmed by 
Harrison and Clausen (228) in skeletal muscle, who showed that an increase in saxitoxin 
binding (reflecting Na+channel density) preceded an increase in 3[H]-ouabain binding 
(reflecting membrane inserted Na+/K+-ATPases). These experiments indicate a link between 
Na+ current regulation and the regulation of the Na+/K+-ATPase by thyroid hormone. This is 
in agreement with other experiments in chick skeletal muscle that suggested that the 
activation of voltage-gated Na+channels by veratridine leads to an increased biosynthesis of 
Na+/K+-ATPase in chick myogenic cultures (229). Whether these findings also apply to 
neurons, or whether some subunits are regulated directly by thyroid hormone receptors and 
others are regulated by the sodium load of the cells remains, however, to be clarified. 
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6. Conclusions 
Thyroid hormone deficiency leads to a general slowing of many body functions, including a 
slowing of heart rate, a slowing of intestinal movements as well as of thoughts and 
movements. As demonstrated here in an exemplary fashion on a small sample of patients 
the most conspicuous symptom to develop during a short period of severe hypothyroidism 
is a gradual, quantifiable slowing of speech and of critical flicker fusion frequency. 
Although several explanations at the cellular and molecular level are feasible an intriguing 
hypothesis is, that a central aspect of the origin of many of these symptoms might be a 
regulation of the sodium current density that is a key player of neuronal and cellular 
excitability. In fact, some effects of thyroid hormone can to some extent be blocked by the 
sodium channel blocker TTX: Thus the upregulation of the membrane Na+/K+ATPase 
expression in myotubes (227) and skeletal muscle (228) as well as of soma growth in L-
GABAergic neurons (230) by thyroid hormone were all to some extent blockable by TTX, 
suggesting that some effects of thyroid hormone occur downstream of sodium channel 
regulation. In future it will be exciting to elucidate the full signal cascade involved in the 
regulation of the different sodium channel subunits as well as to conclusively sort out the 
primary and the secondary targets of thyroid hormone action. It will be interesting to study 
whether some of these thyroid hormone actions decline in the aging brain. 
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1. Introduction 
Life is getting complicated in the world of local thyroid hormones (THs) regulation. On 
account of TH action can be controlled in individual cells through selective TH uptake and 
intracellular TH metabolism, the placenta is an important link in the maternal-fetal 
communication network for THs which are essential for the normal development and 
differentiation of the fetus [1-3]. Generally, intracellular activation or inactivation of L-
thyroxine (T4) and 3,5,3'-triiodothyronine (T3) in turn is determined by three types of 
iodothyronine deiodinases (Ds), namely DI, DII, and DIII [4-7]. The placenta transports and 
metabolizes maternal THs, and mainly expresses DIII, which inactivates T4 and other 
iodothyronines and thus limits the transfer of maternal active THs to the fetus in the late 
pregnancy [8]. DII is also active in the placenta and locally provides active T3 from the 
maternal prohormone T4 for placental metabolic functions [1,2]. The placental expression of 
DI, which also activates T4 to T3, is still controversial. Because of the lipophilic nature of 
THs, it was thought that they traversed the plasma membrane by simple diffusion [9,10]. 
The transport of T4 and T3 in and out of cells is controlled by several classes of 
transmembrane TH-transporters (THTs) [11], including members of the organic anion 
transporter family (OATP), L-type amino acid transporters (LATs), Na+/Taurocholate 
cotransporting polypeptide (NTCP), and monocarboxylate transporters (MCTs) [10,12]. 
Particularly, monocarboxylate transporter 8 (MCT8) has recently been identified as an active 
and specific TH transporter. Also, placental membranes are also involved in 4'-OH-sulfation 
reactions of iodothyronines [8]. Sulfation (S) plays a role in TH metabolism by interacting 
between the deiodination and sulfation pathways of TH [13]. Interestingly, placental cells 
express high affinity, stereo-specific, energy-dependent uptake systems for T4 and T3. On 
the other hand, the cellular activity of THs is usually classified as genomic (nuclear) and 
non-genomic (initiated either at cytoplasm or at membrane TH receptors) [14-21]. Binding of 
T3 to its nuclear thyroid receptors (TRs) directly affects transcription of many genes that are 
important in development [22].  
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In general, pregnancy is accompanied by profound alterations in the thyroidal economy 
(hypo- or hyper-thyroidism), resulting from a complex combination of factors specific to the 
pregnant state, which together concur to stimulate the maternal thyroid machinery [1,23]. 
Also, clinical studies showed that maternal TH deficiency during the first trimester of 
pregnancy can affect the outcome of human neurodevelopment [24,25]. Experiments in rats 
showed that early maternal TH deficiency affects neuronal migration in the cortex [26], 
while maternal hyperthyroidism too can disturb fetal brain development [27]. Experimental 
data on the mechanisms regulating intracellular TH availability and action prior to the onset 
of fetal TH secretion, however, remain scarce. Thus, in this chapter will be aware about the 
significant roles of THs, their metabolism by Ds and sulfotransferases, their transport by 
THTs and their binding to TRs from the mother via the placenta to the fetal compartment 
especially during the gestation period in both human and animals. 
2. Placental transport of thyroid hormones 
2.1. By thyroid hormone-deiodinases (Table 1 and Figure 1) 
The synthesis of THs is regulated through the hypothalamus–pituitary–thyroid (HPT) axis 
[28] and the follicular cells of the thyroid gland synthesize and secrete T4 and T3 [1,2,21]. 
This process is under the control of the circulating TH levels through negative feedback 
loops of this axis [28]. The availability of the active ligand T3 within tissues is locally 
determined by the action of the iodothyronine deiodinases (Ds) [29]. There are three 
selenocysteine monodeiodinase subtypes (DI, DII and DIII) [30]. Whilst T3 is generated by 
the activity of DI and DII, via 5'- reductive or outer ring deiodination (ORD) of the T4 [31], 
DIII activity (and to a lesser extent that of DI) convert T4 to 3,3',5'-tri-iodothyronine (reverse 
T3; rT3) and T3 into 3,3'-T2 via inner ring deiodination (IRD), in effect acting as a 
deactivating enzyme for THs [13,32].  
Activities of all three iodothyronine deiodinase subtypes have been demonstrated in most 
rat placenta [33]. However, in contrast to man, rodent total serum T3 and T4 increase with 
gestation [34] and the predominant subtype expressed appears to be DIII [35], although 
DII is also present with significant activity [36]. Placental DIII activity is much greater 
(approx. 200 times) than DII activity; however, the activity and expression of both DII and 
DIII fall as gestation progresses [37-40]. Placental DII provides T3 for ‘housekeeping’ 
processes, and as indicated above, its activity is much less than that of D3 [40]. DII has 
been localized to the villous cytotrophoblasts in the first trimester and 
syncytiotrophoblasts in the third trimester, whereas DIII has been localized to the villous 
syncytiotrophoblasts in both the first and third trimesters of pregnancy [39]. Both DIII 
mRNA and activity are present at the implantation site in rodents, as early as gestational 
day 9 (GD 9), being expressed in mesometrial and antimesometrial decidual tissue [41]. 
Also, in rabbit [42] and pig [43], the placenta appears to express DIII activity 
predominantly. The positioning of the deiodinases, particularly DIII, suggests that they 
might regulate the amount of maternal TH reaching fetal circulation [40]. Interestingly, 
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however, fetuses with total thyroid agenesis but with evidence of circulating maternal TH 
have normal placental DIII activity, suggesting that there might be other factors 
modulating T4 access to the deiodinases, such as intracellular protection of TH by TH-
binding protein (THBP) [40,44]. Collectively, express placental Ds (II, III) may play a 
critical role in delivery of TH to the fetus as summarized in figure1 [2,45-47] and table 1 
[1,2,31,48].  
 
Figure 1. Summary about the interactions of maternal, placental and fetal thyroid metabolism. I, II 
and III denote deiodinases type 1 (DI), type two (DII) and type three (DIII). SO4 is a sulfation 
pathway and –SO4 is a desulfation pathway. CNS is central nervous system, TRH is thyroid releasing 
hormone, M-TRH is maternal thyroid releasing hormone, TSH is thyrotrophin, T2 is 
diiodothyronine, T3 is triiodothyronine, rT3 is reverse triiodothyronine, T4 is thyroxine, T2S is 
diiodothyronine sulfate, T3S is triiodothyronine sulfate, T4S is thyroxine sulfate, rT3S is reverse 
triiodothyronine sulfate, MCT8 is monocarboxylate transporter 8, OATP4A1 is organic anion 
transporter 4A1, TBG is thyroxin binding globulin, TTR is transthyretin, ACTH is 
adrenocorticotrophin and hCG is human chorionic gonadotrophin. 
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Characteristic DI DII DIII 
Reaction kinetics Ping-pong Sequential
Reaction catalyzed
(Deiodination) 
5 or 5' (ORD+IRD) 5' (ORD) 5 (IRD) 
Main form T4-T3, rT3- T2 - T4- rT3, T3- T2 - T4- rT3- T2 
Substrate preference 5: T4S>T3S>>T3, T4
5': rT3, rT3S>T2S>>T4 
T4>rT3 T3>T4
Sulfation of substrates Stimulation Inhibition
Substrate limiting KM 0.5 mM 1–2 nM 5–20 mM 
In vitro cofactor limiting
KM 
1–10 Mm DTT >10 mM DTT =70 mM DTT 
 
Molecular mass (kDa) 29 30 32
Selenocysteine present
Homodimer Yes




hearta and skeletal 
musclea. 
- Brain, skin, uterus, 
placenta, fetus and 
in other sites of the 
maternal- fetal 
interface, such as 
the umbilical 
arteries and veins. 
Subcellular location - Liver: endoplasmic 




Functions - Production serum
T3 and the clearance 
of serum rT3. 
- Catalyzes the
outer ring 
deiodination of T4 
to T3 and is thus  
important for the 
local production  
of T3. 
- Catalyzes the 
inner ring 
deiodination of T4 




- Decrease in liver
and kidney. 
- increase in thyroid. 
- Increase in all
tissues. 
- Decrease in brain. 
Activity in 
hyperthyroidism 
- Unknown in liver
and kidney. 
- Increase in thyroid. 
- Decrease in most
tissues. 
- Increase in 
thyroida. 
- Increase in brain. 
Low-T3 syndrome - Decrease - No change
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Active site residues - Selenocysteine
histidine and 
phenylalanine.
- (Seleno-)cysteine? - Selenocysteine 
Human gene structure
and location 
- 1p32-p33, 17.5 kb 
and 4 exons.




















a Humans only. T2 is diiodothyronine, T3 is triiodothyronine, rT3 is reverse triiodothyronine, T4 is thyroxine, T2S is 
diiodothyronine sulfate, T3S is triiodothyronine sulfate, T4S is thyroxine sulfate, rT3S is reverse triiodothyronine 
sulfate, ORD is outer ring deiodination, IRD is inner ring deiodination, TRE is T3-responsive element, RXR is retinoid 
X receptors and DDT is dithiols. 
Table 1. General characteristics of the iodothyronine deiodinases. 
2.2. By thyroid hormone-transporters (THTs) (Tables 2 & 3 and Figure 1) 
Membrane transporters mediate cellular uptake and efflux of TH [12,40,49]. The ability to 
transport TH has been described in members of different transporter groups including the 
monocarboxylate transporters (MCT), L-type amino acid transporters (LAT), Na+/Taurocholate 
cotransporting polypeptide (NTCP), and organic anion transporting polypeptides (OATP) 
[50]. With the exception of MCT8, these transporters do not exclusively transport TH and they 
all have slightly different affinities for specific forms of TH. To date six different THTs are 
known to be present in the placenta: MCT8, MCT10, LAT1, LAT2, OATP1A2 and OATP4A1 
but their relative contributions to placental TH transport are unknown [50-55]. Also, their 
anatomical localization, ontogeny in the human placenta and relative affinity for the TH and 
thyronines are very complex. MCT8, MCT10, OATP1A2, OATP4A1 and LAT1 are expressed 
in villous syncytiotrophoblasts, and MCT8, MCT10 and OATP1A2 in cytotrophoblasts [50]. 
Although transporters in the apical syncytiotrophoblast membrane are well placed to 
maximize maternal cellular TH uptake early in gestation, the large numbers and variety of 
THTs are intriguing [51,53,55]. Moreover, the expression of MCT8 mRNA increased with 
advancing gestation [55] but there is limited information regarding the ontogeny of the other 
THTs. In addition, it is likely that the lower expression of MCT8, MCT10, OATP1A2 and LAT1 
before 14 week compared to term, as well as the nadir in OATP4A1 expression in the late 1st 
and early 2nd trimester, may play a role in the necessary limitation of maternal-fetal TH 
transfer, particularly around the time of onset of endogenous fetal TH production in the early 
2nd trimester [56]. Increased expression of THTs in late gestation is consistent with the proposal 
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that there is continued/ increased maternal to fetal supply of TH in the 3rd trimester despite 
increasing fetal TH production [57]. It is also likely that increased expression of these 
transporters with gestation may also fulfil the increased need for other biological substances 
for fetal growth and development, such as amino acids. The most factors regulating the 
placental expression of these transporters are unknown until now. There are suggestions in 
rodents that the activity of system-L and the expression of MCT8 in non-placental tissues are 
influenced by thyroid status [58] suggesting that TH may be a regulator of its own transporters 
[50]. During the passage of THs from the maternal circulation to the fetal circulation, each THT 
is likely to have a specific role in each different plasma membrane layer, which might include 
cellular influx, efflux, or both [59]. To sum, THTs of the various placental cell types serve as 
channels that help to maintain the differences in the composition of THs and their metabolites 
between maternal and fetal circulations (figure1 [2,45-47] and tables 2 & 3 [51,52,55,59,60,61]). 
The relative contributions of these THTs to the transplacental transport of thyroid hormones 
are still a subject for research.  
Transportera Iodothyronine derivates Specificityb 
MCT8  T3, T4, rT3, T2 +++ 
MCT10  T3, T4 ++ 
OATP1A1  T3, T4, rT3, T2, T4S, T3S, rT3S, T2S + 
OATP1A2  T4, T3, rT3
OATP1A3  T4, T3
OATP1A4 
OATP1A5 
OATP1B1  T4, T3, T3S, T4S, rT3S
OATP1B2  T3, T4
OATP1B3  rT3, T4S, T3S, rT3S
OATP1C1  T4, rT3, T3, T4S ++ 
OATP2B1  T4 + 
OATP3A1 (V1/V2) ++ 
OATP4A1  T3, T4, rT3 + 
OATP4C1  T3, T4
OATP6B1 
OATP6C1 
LAT1  T3, T4, rT3, T2
LAT2 
NTCP  T4, T3, T4S, T3S ++ 
a The human protein symbol is presented, if TH transport has been demonstrated in different species including 
humans. b If a transporter only transports iodothyronine derivatives, specificity is high (+++). If fewer than five other 
ligands are known, specificity is moderate (++). If more than five ligands are known, the transporter is denoted as 
multispecific (+). 
Table 2. Types of thyroid hormone transporters and their iodothyronine derivates. 
 













MCT8 MCT10 LAT1 LAT2 OATP1A2 OATP4A1 



















ST N/A STap N/A STap 
Km T4 (μM) 4.7c >Km T3d 7.9 8.0 >Km T3 
Km T3 (μM) 4.0c ≤4.0d 0.8 6.5 0.9 
Km rT3 (μM) 2.2c N/A 12.5 N/A 
Km T2 (μM) N/A 7.9 N/A 
aOnly MCT8 has been localized in the placenta in all three trimesters of pregnancy. bLAT1 and OATP4A1 have been 
localized only at term. c These Km values were determined for the rat MCT8 protein expressed in Xenopus laevis 
oocytes. The other Km values shown are mainly from studies using the human gene expressed in X. laevis oocytes. 
dHuman MCT8 or MCT10 transporters expressed in COS1 cells both showed a greater preference for T3 than T4 
uptake. Whereas MCT10 showed a greater capacity than MCT8 to transport T3, MCT8 was found to be a more active 
transporter of T4. 
Abbreviations: CT is cytotrophoblast cells, EVT is extravillous trophoblast cells, N/A is no data available, rT3 is reverse 
T3, ST is syncytiotrophoblast layer and STap is predominantly at apical surface of the ST. 
Table 3. Expression of the thyroid hormone transporters in human placenta. 
2.3. By thyroid hormone-sulfotransferases (Figure 1) 
Sulfation (S) appears to be an important pathway for the reversible inactivation of THs 
during fetal development [2,13,45-47]. Monique Kester and the group from Erasmus 
University have used a rat model to study the regulation of fetal TH status and have also 
extended their studies to human pregnancy [62]. The sulfotransferases catalyze the sulfation 
of the hydroxyl group of compounds, using 3'-phosphoadenosine-5'-phosphsulfate (PAPS) 
as the universal sulfate donor [63]. This co-factor PAPS is synthesized from two ATP 
molecules and inorganic sulfate. Neither the DII or DIII iodothyronines catalyze the 
deiodination of sulfated iodothyronines nor sulfation strongly facilitates the inner ring 
deiodination of T4 and T3 by DI, but blocks the outer ring deiodination of T4 (activation) 
[13,64]. The outer ring deiodination of rT3 by DI is not affected by sulfation [64]. Sulfation 
thus induces the irreversible degradation of TH. Thus, rapid inner ring deiodinations of T4S, 
T3S and out ring deiodination of rT3S lead to high concentrations of these sulfates in plasma 
of adult humans [13,65]. 
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High concentrations of the different iodothyronine sulfates, T4S (thyroxine sulfate), T3S 
(triiodothyronine sulfate), rT3S (reverse triiodothyronine sulfate) and T2S (diiodothyronine 
sulfate), have been documented in human fetal and neonatal plasma as well as in amniotic 
fluid [65,66], and similar findings have been reported for sheep [67]. This has classically 
been explained by the low hepatic DI expression in the human fetus until the postnatal 
period [68] and lack of hepatic DI expression until birth in rats [69]. Also, in the rat placenta, 
where there are insignificant sulfotransferases activities but high DIII activity, irreversible 
inactivation of DIII appears to be the predominant pathway of iodothyronine metabolism 
[13]. In the rat fetal liver, sulfotransferase activity is present from the end of the third 
trimester (GD 17), a time when DI activity is relatively absent [69]. The TH-sulfates may 
accumulate under such circumstances to form a ‘reservoir’ of inactive TH from which active 
hormone may be liberated, in a tissue specific and gestational dependent manner by the 
action of arylsulfases [13]. To date, six members of this family (ARSAeARSF) have been 
identified in humans [13,70]. It is interesting that DIII is abundantly expressed in the human 
placenta [39] and deiodinates T4 and T3 to 3,3'-T2 and rT3, respectively, thus providing 
substrates for these actions. In the human fetal circulation, T4S and in particular T3S, may 
represent a reservoir of inactive TH, from which active hormone may be liberated as 
required (vide supra) [13]. The iodothyronine sulfates in human fetal circulation and 
amniotic fluid may be derived, at least in part, from sulfation of THs by thermostabile 
phenol sulfotransferases in the uterus and placenta [13,45]. This may provide a route for the 
supply of maternal TH to the fetus in addition to placental transfer. Alternatively, 
iodothyronine sulfates may accumulate in the fetal circulation because of the absence of 
hepatic transporters which mediate their removal from plasma. It has been demonstrated 
recently that hepatic uptake of the different iodothyronine sulfates in rats is mediated at 
least in part through the NTCP and OATP families [71]. Thus, the TH-sulfation mechanism 
might be useful for non-invasive prenatal diagnostics of fetal thyroid function which is 
autonomously regulated. The overviews presented here are consistent with the evolving 
view that sulfation is a major chemical defense system in the maternal-fetal thyroid axis and 
will hopefully provide a basis for understanding more about these enzymes. 
2.4. By thyroid hormone-genomic and non-genomic actions (Tables 4 & 5 and 
Figure 2) 
Although the thyroid gland predominantly secretes T4, T3 is the most active TH, since it has 
a higher affinity by the nuclear thyroid hormone receptors (TRs; α, β) (Figure 2A) [75], 
which mediate most actions of these hormones [72,73]. THs are released by the thyroid 
gland to the circulation where they are carried bound to proteins such as thyroxin binding 
globulin (TBG), transthyretin (TTR) or serum albumin (Table 4) [74]. The level of albumin, 
which has the lowest T4 affinity and enables a fast release of T4 [76], gradually decreases 
during pregnancy [77]. TBG is an active carrier and has a possibility to switch between the 
high-affinity and the low-affinity form [78]. TBG levels are the highest in the second and 
third trimester of pregnancy [79,80] and the same holds true for TH-binding ratio [81] and 
thyroid-binding capacity [82], which decreases as soon as 3-4 days after delivery.  
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Abbreviations: T3 is triiodothyronine, T4 is thyroxine, TR is thyroid hormone receptor, RXR is retinoid X receptors, 
TRE is T3-responsive element, nTRE is none T3-responsive element, Ds is deiodonases, S is sulfotransferases, MCT is 
monocarboxylate transporter, OATP is organic anion transporter, MAPK/ERK1/2 is mitogen-activated protein kinase, 
P is phosphorylation and PI-3K is phosphatidylinositol 3-kinase. 
Figure 2. (A) Schematic representation of major thyroid hormone receptors (TRα, β) domains and 
functional sub-regions. (B) General model for genomic and non-genomic actions of TH in both adult 
and fetus; Schematic representation of thyroid hormones (THs; T4 and T3) genomic actions, initiated at 
the nuclear receptors (TRβ), and non-genomic actions, initiated at cytoplasmatic receptors (TRβ, TRα) 
and at the plasma membrane on the membrane receptors, particularly integrin αvβ3 receptor. T4 
binding (but not T3) to cytoplasmic TRα may cause a change of state of actin. T3 binding (but not T4) to 
cytoplasmic TRβ activates the phosphatidylinositol 3-kinase (PI-3K) pathway leading to alteration in 
membrane ion pumps and to transcription of specific genes. TH binding to the integrin receptor results 
in activation of mitogen-activated protein kinase (MAPK/ERK1/2). Phosphorylated MAPK (pMAPK) 
translocates to the nucleus where it phosphorylates transcription factors including thyroid receptors 
(TRβ), estrogen receptor (ER) and signal transducer activators of transcription (STAT). Generally, 
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TH-binding protein Cellular location 




Myosin light chain kinase Cytoplasmic 
Pyruvate kinase, subtype M1 
Pyruvate kinase, subtype M2 
Prolyl 4-hydroxylase, b-subunit 
Aldehyde dehydrogenase 
Table 4. Types of thyroid hormone-binding proteins. 
2.4.1. General genomic action (Table 5 and Figure 2) 
T4 and T3 enter the cell through transporter proteins such as MCT8 and 10 or OATPs. Inside 
the cells, deiodinases (DI, II) convert T4, the major form of thyroid hormone in the blood, to 
the more active form T3. DIII produces rT3 and T2 from T4 and T3, respectively [1,73,83]. T3 
binds to nuclear TRs, TRα and TRβ, that activate transcription by binding, generally as 
heterodimers with the retinoid X receptor (RXR) (Table 5) [87], to thyroid hormone response 
elements (TREs) located in regulatory regions of target genes [84]. Activity is regulated by 
an exchange of corepressor (CoR) and coactivator (CoA) complexes. Negative TREs (nTRE) 
can mediate ligand-dependent transcriptional repression, although in this case the role of 
coactivators and corepressors is not well defined [73,85]. TRs can also regulate the activity of 
genes that do not contain a TRE through “cross-talk” with other transcription factors (TF) 
that stimulate target gene expression [28,86]. Both receptors and coregulators are targets for 
phosphorylation (P) by signal transduction pathways stimulated by hormones and growth 
factors [84,85]. Thus, the nuclear actions of T3 are sensitive to inhibitors of transcription and 
translation and have a latency of hours to days [9,73]. Thus, the genomic action will play a 
critical role in the cellular proliferations and differentiations.  
2.4.2. General non-genomic action (Table 5 and Figure 2) 
Although T3 is known to exert many of its actions through the classical genomic regulation 
of gene transcription, a number of T3 effects occur rapidly and are unaffected by inhibitors 
of transcription and protein synthesis [88,89]. However, the levels of circulating THs are 
tightly regulated and stable and thus rapidly mediated responses must involve regulation of 
pre-receptor ligand metabolism, ligand membrane transport or receptor availability leading 
to local cell type specific variation in thyroid hormone signaling [87]. Non-genomic actions 
of THs have been described at the plasma membrane, in the cytoplasm and in cellular 
organelles [15,21,83,90,91]. They have included the modulation of Na+, K+, Ca2+ and glucose 
transport, activation of protein kinase C (PKC), protein kinase A (PKA) and mitogen-
activated protein kinase (ERK/MAPK) and regulation of phospholipid metabolism by 
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activation of phospholipase C (PLC) and D (PLD) [92-94]. Generally, binding of T3 to a 
subpopulation of receptors located outside the nuclei can also cause rapid “non-genomic” 
effects through interaction with adaptor proteins, leading to stimulation of signaling 
pathways. T4 can also bind to putative membrane receptors such as integrin receptor (αVβ3) 
inducing MAPK activity [18,73,95,96]. Thus, several observations suggest that the rapid 
nongenomic effects of TH are widespread and may be involved in multiple physiological 
processes in many different cell types [87]. However, no specific membrane associated TR 
isoform or thyroid hormone binding G protein-coupled receptors (GPCR) have been 
identified or cloned and thus the area remains controversial. 
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Abbreviations: T4 is Thyroxine, T3 is triiodothyronine, T2 is diiodothyronine, RXR is retinoid X receptor, TR is thyroid 
hormone receptor, GPCR is G protein coupled receptor, mtRXR is mitochondrial retinoid X receptor α isoform, 
mtPPAR is mitochondrial peroxisome proliferator activator receptor γ2 isoform, NCoR is nuclear receptor co-
repressor, SMRT is silencing mediator of RAR and TR, SRC is steroid receptor cooactivator, TRAPs is thyroid receptor 
associated protein, Raf1 is Raf serine/threonine kinase, MEK is mitogen activated protein kinase kinase, MAPK is 
mitogen activated protein kinase, STAT is signal transducers and activators of transcription, ANT is adenine 
nucleotide translocase and UCP is uncoupling protein. 
Table 5. General thyroid hormone actions. 
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There also are reports of nongenomic effects on cell structure proteins by THs. Actin 
depolymerization blocks DII inactivation by T4 in cAMP-stimulated glial cells, suggesting that 
an intact actin cytoskeleton is important for this downregulation of deiodinase activity [9,97]. 
Interestingly, T4, but not T3, can promote actin polymerization in astrocytes [98] and thus may 
influence the downregulation of DII activity by a secondary mechanism, perhaps by targeting 
to lysosomes [9,99]. Moreover, the regulation of actin polymerization and F-actin contents also 
could contribute to the effects of TH on arborization, axonal transport, and cell-cell contacts 
during brain development, where the regulation of these factors is fundamental for the 
organization of guidance molecules such as laminin on the astrocyte plasma membrane and 
modulates integrin–laminin interactions [3]. T4 was required for integrin clustering and 
attachment to laminin by integrin in astrocytes [100]. These data suggest that the non-genomic 
action may play an important role in promoting the normal development. 
3. Maternal-fetal thyroid in normal state 
THs are essential for normal neonatal development in both humans and rodents [3,23,101-104] 
and the experimental work indicated that THs are transported from the mother to the fetus, 
albeit in limited amounts, and that the fetal brain is exposed to THs before initiation of fetal 
TH synthesis [1]. In addition, the maternal TH regulates early fetal brain development in 
human and animal models [2]. The TH of maternal origin can cross the placenta and reach the 
fetus [2,105,106] and that TRs are expressed in the fetal rat brain before the onset of fetal 
thyroid function [107]. Thus, the THs are essential for brain maturation from early embryonic 
stages onward [103,104,108]. However, TH-dependent stages of fetal brain development 
remain to be characterized. Notably, the maternal thyroid is the only source of T4 and T3 for 
the brain of the fetus because its thyroid gland does not start contributing to fetal requirements 
until midgestation in man, and days 17.5–18 in rats [109]. Therefore, the amount of maternal 
T4 that the fetus receives early in pregnancy will determine TH action in its brain because it 
depends on maternal T4 for its intracellular supply of the active form of the hormone, T3. 
However, fetal brain total T3 levels are low (ca. 100 pM) at this time [1], but receptor 
occupancy approximates 25% since free T3 concentrations are high in the nucleus relative to 
the cytosol [110]. In general, materno-fetal transfer of THs has been demonstrated in early fetal 
stages [111] and continues, at least in the case of fetal inability, to produce sufficient TH until 
term [44]. Actually, brain cells can protect themselves against higher fetal T4 and T3 values by 
decreasing DII and increasing DIII activity [2]. Taken together, thyroid activity undergoes 
many changes during normal pregnancy including [1,112-115]: (a) a significant increase in 
serum thyroxine-binding globulin, thyroglobulin, total T4, and total T3; (b) an increase in renal 
iodide clearance; and (c) stimulation of the thyroid by human chorionic gonadotropin (hCG). 
These changes can make diagnosis of thyroid dysfunction during pregnancy difficult.  
4. Maternal-fetal thyroid in hypothyroid state 
THs are important for growth and differentiation of a variety of organs, including the brain. 
In developing brain, THs stimulate and coordinate processes such as neuronal proliferation, 
migration, growth of axons and dendrites, synapse formation and myelination [1,2]. 
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Disturbance of these processes leads to abnormalities in the neuronal network and may 
result in mental retardation and other neurological defects, including impaired motor skills 
and visual processing [115]. If TH deficiency occurs at the perinatal stage, such as in 
congenital hypothyroidism, timely treatment may rescue most of the symptoms. A shortage 
of THs starting at the early stages of pregnancy, such as in cretinism, results in neurological 
deficits that cannot be rescued by exogenous TH addition at later stages [25]. 
The role of THs in brain development has been studied most extensively in the cerebellum 
[23,116]. The cellular proliferation and migration processes are disturbed by TH deficiency 
as investigated predominantly in rodents, where most of cerebellar maturation occurs in the 
early postnatal period [2]. In the hypothyroid cerebellum, the number and length of 
Purkinje cell dendrites is severely reduced [1]. At the same time the granule cell parallel 
fiber growth is reduced, leading to a reduction in axodendritic connections between the 
Purkinje cells and the granule neurons [117]. Additionally, other cell types such as 
astrocytes, Golgi epithelial cells, basket cells, and oligodendrocytes show abnormalities 
under hypothyroid conditions [116]. Several TH target genes have been identified over the 
years, including genes coding for myelin proteins, cytoskeletal proteins, neurotrophins and 
their receptors, transcription factors, and intracellular signaling proteins [118] and recent 
transcriptome analyses continue to increase their number [119-121]. Some of these genes 
only respond to thyroid status for a short and specific period during development, a feature 
that is typical for many TH target genes in brain [122]. Interestingly, a reduction or absence 
of TH during brain maturation yields molecular, morphological and functional alterations in 
the cerebral cortex, hippocampus and cerebellum [123-132]. 
5. Maternal-fetal thyroid in hyperthyroid state (Figure 3) 
Neonatal hyperthyroidism was described as a critical disease marked mainly by cardiac 
symptoms, poor weight gain and severe neurological manifestations [1,133-137]. Fetal 
thyrotoxicosis is the result of thyroid-stimulating antibody transfer to the fetus in the setting 
of maternal Grave’s disease [2,138]. It may present with a variety of clinical features, which 
include persistent sinus tachycardia, fetal hydrops, intrauterine growth restriction, goiter 
and fetal demise [1,139]. The vast majority of cases of excessive serum TH concentration 
seen in pregnancy are due to the overproduction of THs (Graves’ disease, toxic nodular 
goiter); in the postpartum period, thyrotoxicosis may be due to exacerbation of Graves’ 
hyperthyroidism or to the release of thyroid hormone due to an acute autoimmune injury to 
the thyroid tissue (postpartum thyroiditis-PPT) [2,140].  
The management of hyperthyroidism in pregnancy, which most often is caused by Graves’ 
disease, has been reviewed recently [141,142]. Hyperthyroidism occurs in about 0.2–0.4% of all 
pregnancies. Hyperthyroidism should be distinguished from gestational transient 
thyrotoxicosis, which is due to the TSH-receptor stimulating effects of hCG [143,144]. This hCG-
induced hyperthyroidism is mostly mild and need not be treated. Only rare cases with 
extremely high hCG (i.e. due to a hydatidiform mole) might induce severe thyrotoxicosis [145]. 
The signs and symptoms of hyperthyroidism due to Graves’ disease may aggravate in the first 
trimester and thereafter may become mild. Untreated hyperthyroidism is associated with severe 
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effects on maternal and neonatal outcome. The risk for premature fetal loss, preeclampsia, 
preterm delivery, intrauterine growth retardation and low birth weight is significantly 
increased [144]. It has to be considered that the transfer of stimulating receptor antibodies 
(TSAbs) are transferred from the mother to the child, and therefore the fetus is at risk to develop 
Graves’ disease. Close monitoring of the fetus is, therefore, strictly recommended, even in 
mothers treated by thyroidectomy before pregnancy but have still elevated TSAbs [142]. 
 
Figure 3. Different cases of hyperthyroidism. 
Taken together, there are two known causes of central hyperthyroidism [1,146]; (1) TSH-
producing pituitary tumors (TSHomas) and (2) the syndrome of pituitary resistance to 
thyroid hormone (PRTH). In general, thyrotoxicosis is the syndrome resulting from an 
excess of circulating free T4 and/or free T3 [147,148]. Babies likely to become hyperthyroid 
have the highest TSH receptor antibody titer whereas if TSH receptor antibodies are not 
detectable, the baby is most unlikely to become hyperthyroid (Figure 3) [1,2,149]. In the 
latter case, it can be anticipated that the baby will be euthyroid, have transient 
hypothalamic-pituitary suppression or have a transiently elevated TSH, depending on the 
relative contribution of maternal hyperthyroidism versus the effects of maternal antithyroid 
medication, respectively [150].  
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6. Summary  
about the developmental thyroid hormone mechanisms (deiodinases, transporters, 
sulfotransferases and receptors) in human [1,2,50,52,127,130,151-154], rat [1,2,41,60,135,154-
156] and chicken [7,157-170]. Note that the chicken is born early compared to the rat and 
human, as well as the rat is born early compared to the human (Table 6). 
Human Rodent (rat) Chicken 
Week post conception Day post conception Incubation day 
1 W - DIII is detected
in uterine wall. 
1 GD DII and DIII are 
observed in 
uterine wall. 
5 h  
(blastula 
stage) 
- TRα mRNA is noticed and 
the levels markedly increased 
during neurulation. 




- Time of 
implantation 
process.  






- mRNA levels of DI, DII and 
DIII are detected in whole 
embryos. 
4-6 W  - TBG is observed 
in thyroid follicle 
cells at GD 29. 
- TRH is detected 
in fetal whole-
brain at 4.5 weeks 
of gestation. 
- T4 is transferred 
via the placenta 
and has been 
found in the 
gestational fluid 
sac from 4 to 6 W. 
9 GD - Thyroid gland 
is first visible as 
an endodermal 
thickening in the 
primitive buccal 
cavity. 










transfer of THs has 
been detected in 
embryonic 
coelomic fluid and 
amniotic fluid. 
- All the mRNAs 
encoding THTs 
are expressed in 
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mothers treated by thyroidectomy before pregnancy but have still elevated TSAbs [142]. 
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relative contribution of maternal hyperthyroidism versus the effects of maternal antithyroid 
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- All the mRNAs 
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8 W - T4, T3 and rT3 
are detected in 
coelomic/amniotic 
fluids. 
- TRs, DII and DIII 
are noticed in  
fetal brain. 
10 GD - T4, T3 and TRβ 
are detected in 
embryo/trophobl
ast unit. 
E2-E4 - T3, THTs, Ds and TRs are 
expressed in whole embryos. 
10 W - TSH is first 
detected in the 
fetal pituitary. 
E4 - OATP1c1 expression is 
more than 10-fold higher in 
the telencephalon and 
diencephalon compared to 
the mesencephalon and 
rhombencephalon.  
- DII mRNA levels are 
highest in the diencephalon. 
8-10 
W 
- The fetus is able 
to produce THs 
during this 
period, but prior 
to that time, is 
totally dependent 
on maternal THs. 
E5 - TRα mRNA is widely 
distributed in fore-, mid- and 
hind-brain. 
11 W - TBG levels are 








- TRH is detected 
in fetal 
hypothalamus. 
E7 - DII activity is observed in 
the brain before the onset of 
thyroid function and 
increases significantly. 
12 W - T4 and T3 are 
observed in serum 
and brain. 
- Total serum T4 
and T3 are low, 
free T4 is 
relatively high.  
- rT3 is noticed in 
serum relatively 
high. 
- TH synthesis 
begins in fetal 
thyroid. 
13 GD - Placental 
circulation 
established. 
- TRs and TH are 
observed in fetal 
brain. 




E8 - DII mRNA is noticed in cell 
clusters throughout the 
brain, particularly in 
rhombencephalon.  
- OATP1c1 levels are 
declined substantially in all 
brain regions. 
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- Decreased 
mRNA expression 
of OATP1A2 but 
no change for 
OATP4A1 at 9–12 
W compared to 
term. 






lower prior to 14 
W compared to 
term 
 
14 GD - TRH mRNA is 
detected in 
neurons of the 
fetal 
hypothalamus. 
E4-E8 - DIII mRNA levels are 
markedly different in the 
telencephalon and 
diencephalon but remain 
stable, while the levels in 
mesencephalon and 
rhombencephalon show a 
sharp decrease and increase, 
respectively, during these 
days. 




- TRH mRNA is 
detected in the 
developing 
paraventricular 
nuclei of the 
hypothalamus. 
E9-10 - Several elements of the TH 
action cascade are present in 
the brain of embryos long 
before their own thyroid 
gland starts hormone 
secretion. 
16 W - DIII is observed 
in placenta and 
fetal epithelial 
cells. 
- DIII and TRs are 
detected in fetal 
liver. 
- DI is noticed in 
heart and lung. 





- TRs are 
observed in liver, 
heart and lung. 
- DI and DII are 
noticed in fetal 
tissues. 
- TRH is 











- Duplication of 
TBG 
concentrations. 
17 GD - TH synthesis 
begins in fetal 
thyroid  
E13 - Brain DII is elevated at the 
peak of neuroblast 
proliferation. 
 
Thyroid Hormone 140 
8 W - T4, T3 and rT3 
are detected in 
coelomic/amniotic 
fluids. 
- TRs, DII and DIII 
are noticed in  
fetal brain. 
10 GD - T4, T3 and TRβ 
are detected in 
embryo/trophobl
ast unit. 
E2-E4 - T3, THTs, Ds and TRs are 
expressed in whole embryos. 
10 W - TSH is first 
detected in the 
fetal pituitary. 
E4 - OATP1c1 expression is 
more than 10-fold higher in 
the telencephalon and 
diencephalon compared to 
the mesencephalon and 
rhombencephalon.  
- DII mRNA levels are 
highest in the diencephalon. 
8-10 
W 
- The fetus is able 
to produce THs 
during this 
period, but prior 
to that time, is 
totally dependent 
on maternal THs. 
E5 - TRα mRNA is widely 
distributed in fore-, mid- and 
hind-brain. 
11 W - TBG levels are 








- TRH is detected 
in fetal 
hypothalamus. 
E7 - DII activity is observed in 
the brain before the onset of 
thyroid function and 
increases significantly. 
12 W - T4 and T3 are 
observed in serum 
and brain. 
- Total serum T4 
and T3 are low, 
free T4 is 
relatively high.  
- rT3 is noticed in 
serum relatively 
high. 
- TH synthesis 
begins in fetal 
thyroid. 
13 GD - Placental 
circulation 
established. 
- TRs and TH are 
observed in fetal 
brain. 




E8 - DII mRNA is noticed in cell 
clusters throughout the 
brain, particularly in 
rhombencephalon.  
- OATP1c1 levels are 
declined substantially in all 
brain regions. 
 
Maternal-Fetal Thyroid Interactions 141 
- Decreased 
mRNA expression 
of OATP1A2 but 
no change for 
OATP4A1 at 9–12 
W compared to 
term. 






lower prior to 14 
W compared to 
term 
 
14 GD - TRH mRNA is 
detected in 
neurons of the 
fetal 
hypothalamus. 
E4-E8 - DIII mRNA levels are 
markedly different in the 
telencephalon and 
diencephalon but remain 
stable, while the levels in 
mesencephalon and 
rhombencephalon show a 
sharp decrease and increase, 
respectively, during these 
days. 




- TRH mRNA is 
detected in the 
developing 
paraventricular 
nuclei of the 
hypothalamus. 
E9-10 - Several elements of the TH 
action cascade are present in 
the brain of embryos long 
before their own thyroid 
gland starts hormone 
secretion. 
16 W - DIII is observed 
in placenta and 
fetal epithelial 
cells. 
- DIII and TRs are 
detected in fetal 
liver. 
- DI is noticed in 
heart and lung. 





- TRs are 
observed in liver, 
heart and lung. 
- DI and DII are 
noticed in fetal 
tissues. 
- TRH is 











- Duplication of 
TBG 
concentrations. 
17 GD - TH synthesis 
begins in fetal 
thyroid  
E13 - Brain DII is elevated at the 
peak of neuroblast 
proliferation. 
 
Thyroid Hormone 142 






- The total T4 and 
T3 concentrations 
in fetuses are 
increased drama-
tically because of 
maturation of 
hormone 






and Ds is 
regulated both 
transplacental 
TH passage from 
mother to fetus 
and the 
development of 




E14 - The strong increase in 
intracellular T3 has been 
observed. 
20 W - A steady 
increase in serum 
TH levels begins 
and continues to 
term. 
19 GD - Significant fetal 
TH secretion 
begins. 
- Marked rise in 
serum TH but 
levels at birth 
still below those 
in adult. 
E15 - Plasma T4 levels start rising 
markedly around this day. 
22-32 
W 
- Serum total and 
free T4 and T3 
near and below 
adult levels, 
respectively. 
- The HPT axis 
begins to mature 
during the second 
half of gestation. 
22 GD  - Birth state. 
- Thyroid system 
is less 
developed.  
- As much as 
17.5% of THs 
found in the 
newborn are of 
maternal origin.  
E16 - The decrease in DI activity 
in gonads is combined with 
the relatively high DIII 
activity. 
- A significant increase in T3 
production and in DII-activity 
and -mRNA expression are 
combined with a decreased in 
DIII activity. 
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- LAT1 and 
OATP4A1 have 
been localized 
only during the 
third trimester. 




- MCT8 has been 
localized in the 
placenta in all 






sulfates, T4S, T3S, 
rT3S and T2S, 
have been 
documented in 
human fetal and 
neonatal plasma 













- Brain DII activity is 
moderately elevated, 
whereas DIII activity and 
mRNA expression are 
highest between these days, 




- Serum TH 
levels continue 





E18 - DI and DIII are expressed in 
the granule cells, whereas DII 
is found mostly in the 
molecular layer and the 
Purkinje cells at that time. 
14-50 
PND 




from PND 14–16 
until reaching 
adult levels at 
PND 40. 
- TRH levels 
increase to adult 
levels by PNDI7–




levels are once 
again reached at 
PND 50. 




present at PND 
22. 
E19 - The increase in brain T3 
production correlates with 
the appearance of TRβ 
expression in the cerebellum, 








- The brain is quite well 
developed at the time of 
hatching. 
- The gradual increases in 
plasma T4 and hepatic DI are 
detected. 
- DIII levels are decreased in 
spleen and increased in skin 
and the lungs towards 
hatching. 
- T3 production seems to be 
elevated markedly in liver. 
- The rise of T4 is much more 
pronounced than in plasma. 
- Diminished T4 sulfation is 
detected. 
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- The T3 breakdown capacity 
by DIII is high in liver but 
low in kidney. 
E15/16-
E20 
- T4 levels in plasma increase 
gradually during these days.  
- In contrast to TRα 
expression which increases 
gradually towards hatching, 
expression of TRβ shows an 
abrupt elevation in late 
development, especially in 
the cerebellum.  
- The majority of tissues 
express DIII together with 
either DI or DII. 
E17-E20 - The levels of DIII activity 
present in liver are rapidly 
drop by more than 90%.  
- DI levels in testis and ovary 
strongly decrease around 
hatching.  
E18–E20 - Brain DII activity is 
moderately decreased, 
whereas DIII activity is low. 
E19-E20 - The low T3/T4 ratio is 
associated with high T3 
breakdown in liver and with 
high T4 inactivation or T3 
secretion in kidney. 
E20-C0 - DI activity gradually 
increases, reaching a 
maximum around these 
period, and decreases slowly 





- The expression of DI is 
limited to the mature granule 
cells and that of DIII to the 
Purkinje cells exclusively, 
whereas DII remains clearly 
present in the molecular 
layer. 
 
Maternal-Fetal Thyroid Interactions 145 
C2 - Highest DI-activities and -
mRNA expressions are 
detected in the liver, kidney, 
and intestine. 
C1-C7 - The circulating T3/T4 ratio 
started to increase gradually 
during the first week after 
hatching. 
Abbreviations: W is week, GD is gestation day, E is incubation day, PND is postnatal day, C is posthatch day, THs is 
thyroid hormones, TRH is thyroid releasing hormone, TSH is thyroid stimulating hormone, THTs is thyroid hormone 
transporters, MCT is monocarboxylate transporter, OATP is organic anion transporter, Ds is deiodinases (DI, II, III), 
TRs is thyroid hormone receptors (TRα, β), T4 is Thyroxine, T3 is triiodothyronine, rT3 is reverse triiodothyronine, T2S 
is diiodothyronine sulfate, T3S is triiodothyronine sulfate, T4S is thyroxine sulfate, rT3S is reverse triiodothyronine 
sulfate, HPT is hypothalamic-pituitary-thyroid axis and TBG is thyroxin binding globulin. 
Table 6. Summary about the developmental thyroid hormone mechanisms (deiodinases, transporters, 
sulfotransferases and receptors) in human, rat and chicken. 
7. Conclusion 
The actions of THs are highly pleiotropic, affecting many tissues at different developmental 
stages. As a consequence, their effects on proliferation and differentiation are highly 
heterogeneous depending on the cell type, the cellular context, and the developmental or 
transformation status. 
Maternal THs are important in promoting normal fetal development especially the placental 
and CNS development. Clinical epidemiological and basic findings clearly show that 
maintaining normal TH regulation from the beginning of pregnancy is important to reduce 
the risk of obstetric complications and to ensure optimal neurodevelopment of the offspring.  
In normal pregnancy, transplacental TH passage is modulated by plasma membrane THTs, 
Ds, sulfotransferases, TRs and several different proteins within placental cells.  
In pathological/abnormal pregnancies with either maternal or fetal THs disturbances (hypo- 
or hyper-thyroidism), the placenta lacks the full compensatory mechanisms necessary to 
optimize the maternal–fetal transfer of THs to achieve the normality of TH levels in the 
fetus. 
8. Future challenges 
Further studies are still needed to improve our understanding of the mechanisms mediating 
the transplacental transport of THs in both human and animals, particularly the role of the 
different THTs, and the mechanisms that ensure that sufficient amounts of THs are 
protected from D3 inactivation during their transit across the placenta. Such knowledge 
would facilitate the development of interventions to increase TH passage in pathological 
situations, in order to ensure normal fetal development. A better understanding of these 
mechanisms would also permit us to refine the timing and dosage of the increase in 
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levothyroxine therapy in hypothyroid pregnant women and to establish whether thyroxine 
on its own is indeed the best form of TH replacement in pregnancy.  
Elucidation of tissue-, cell-, and sex-specific expression of individual Ds and THTs during 
the development of both human and animals, in the adult, during aging and when sick. 
I hope that new insights into the complex actions by which the THs and their receptors 
control cell proliferation and differentiation will be provided in the near future. 
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1. Introduction 
Thyroid hormone excess due to any cause is state of thyrotoxicosis, whereas 
hyperthyroidism is a state of thyroid hormone excess due to hyperfunctioning of thyroid 
gland. The major causes of thyrotoxicosis include Graves’ disease, solitary toxic adenoma, 
and toxic multinodular goiter. In thyrotoxicosis, free hormone levels are invariably 
increased. The reverse is not true in that increased free thyroid hormone levels do not 
always point to thyrotoxicosis. In illness or resistance to thyroid hormones increased free 
hormone levels are present while the patients are clinically euthyroid or even sometimes 
hypothyroid. Subclinical thyrotoxicosis is defined as a state in which free thyroid homones 
(FT4 & FT3) are within normal limit, but serum TSH level is low. The most common cause of 
subclinical thyrotoxicosis is exogenous administration of thyroid hormone rather than 
Graves’ disease. Patients of subclinical thyrotoxicosis either have no symptoms or have mild 
non specific symptoms. 
The various causes of thyrotoxicosis are listed below in table 1 
1.1. Clinical features 
Clinical manifestations of the thyrotoxicosis are similar for various causes of thyrotoxicosis. 
However certain features provide some clues about specific cause of throtoxicosis. These 
features include the duration and mode of onset of thyrotoxicosis, size and shape of the 
thyroid gland, presence or absence of the extra-thyroidal manifestations like Graves’ eye 
sign, pre-tibial myxoedema, acropachy. Patient presenting with toxic features can be 
because of thyroiditis or Graves’ disease, but the symptoms are of few weeks duration in 
former while in later condition, it is for several months, most of the time. The common 
clinical features of thyrotoxicosis are listed below in table 2. 
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A. Thyroid hormone excess with hyperthyroidism 
a. Primary Hyperthyroidism 
i. Graves’ Disease 
ii. Toxic Thyroid adenoma 
iii. Toxic Multinodular Goiter 
iv. Metastases from Thyroid carcinoma 
v. Mutations of TSH receptor, Gsα (Mc Cune Albright Syndrome) 
vi. Struma Ovarii 
vii. Iodine ingestion (jod-Basedow phenomenon) 
b. Secondary hyperthyroidism 
i. TSH secreting pituitary tumours 
ii. Pituitary Thyroid hormone resistance 
B. Thyroid hormone excess without hyperthyroidism 
a. Throiditis: subacute, silent 
b. Ingestion of thyroid tissue, thyroid hormone  
c. Thyroid gland destruction by amiodarone, radiotherapy, infarction in 
thyroid adenoma 
Table 1. Causes of thyroid hormone excess 
Symptoms Signs
Irritability, Hyperactivity, Dysphoria Tachycardia, Lone Atrial Fibrillation  
Heat Intolerance Fine tremor 
Palpitation, Nervousness Warm moist skin, Goiter 
Fatigue, lethargy Proximal Myopathy 
Dyspnoea Hyperreflexia 
Weight loss despite polyphagia Lid lag, Lid tremors 
Hyperdefecation, Polyuria Gynaecomastia 
Oligomenorrhoea Loss of libido 
Table 2. Common clinical features 
2. Graves’ disease  
Diffuse toxic goitre is commonly known as Graves’ disease. Classically it is characterized by 
hyperthyroidism and diffuse goiter. Graves’ disease may be associated with an infiltrative 
orbitopathy and ophthalmopathy and less commonly with an infiltrative dermopathy. 
Infiltrative orbitopathy is an unique manifestation of Graves’ disease.  
2.1. Historical perspective 
Robert James Graves, an Irish physician, first described 3 females with this disease in 18351 
and for his contribution, this disease is known as Graves’ disease in most part of the world. 
Although a similar syndrome was described by Caleb Hiller Parry, a physician from Bath, 
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England, in 1825.2 Carl A. Von Basedow from Germany first described the triad of 
exophthalmos, goiter and palpitation.3 In most non English speaking European countries the 
disease is still known as Basedow’s disease.  
2.2. Epidemiology 
Graves’ disease is the most common cause of thyrotoxicosis and it accounts for 60-80% cases 
of thyrotoxicosis. Prevalence of Graves’ disease varies with the degree of iodine sufficiency, 
and it is the most common cause of thyrotoxicosis in iodine sufficient countries.4 High 
dietary iodine intake is associated with an increased prevalence of Graves’ disease. 
Prevalence of Graves’ disease is about 0.4% in USA,5 0.6% in Italy,6 and 1.1% in UK.7 A 
recent meta-analysis of various studies showed that prevalence of the Graves’ disease is 
about 1% in general population.7 Prevalence of Graves’ disease is 1-2% in women, and it is 
about 10 fold more prevalent in women than men. Peak age of onset of Graves’ disease is in 
fourth to sixth decade of life,8 but it can occur in children and elderly.  
2.3. Risk Factors for Graves’ disease 
Graves’ disease is a multifactorial disease in which genetic ,environmental, and hormonal 
factors play their role.  
2.3.1. Genetic factors for Graves’ disease 
High prevalence of Graves’ disease in family members and relatives of Graves’ disease and 
Hashimoto’s thyroiditis support that genetic factors are involved in causation of Graves’ 
disease. There is also evidence that occurrence rate of Graves’ disease is higher in 
monozygotic twins than dizygotic twins. The concordance rate in monozygotic twins is only 
17-35% which indicate low penentrance of genes.  
Graves’ disease is a polygenic disease. Polymorphism in HLA-DR, CTLA-4 and PTPN-22 
genes are associated with increased risk of Graves’ disease. HLA-DR3 (HLA-DRB1*03), 
HLA-DQA1*0501 and HLA-B8 gives a risk ratio of three fold to fourfold in white 
population. HLA-DQ3 is involved in patients with African descent whereas HLA-BW46 is 
involved in patients with Asian descent. The other genes involved in pathogenesis of 
Graves’ disease are CD40 gene, thyroglobulin gene, TSHR gene, immunoglobulin genes, 
GD-1 gene (on chromosome 14q13), GD-2 gene (on chromosome 20) and GD-3 gene (on 
chromosome Xq21-22). 
2.3.2. Environmental Factors for Graves’ disease 
Infection 
From very early it has been suggested that Graves’ disease is associated with infectious 
agents, but this hypothesis has not been confirmed. Incidence of recent viral infections are 
high in patients with Graves’ disease. The association of Graves’ disease with infectious 
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agents can be explained by molecular mimicry. Molecular mimicry implies structural 
similarity between infectious agent with a self antigen. Circulating antibody against Yersinia 
enterocolitica has been found in high percentage of patients with Graves’ disease. 
Furthermore, serum from some patients recovering from Yersinia infections block the 
binding of TSH to its receptor. Low affinity binding sites for TSH have also been found with 
Leishmania and Mycoplasma species. However, no studies proved that infections agents 
have causative role in Graves’ disease.  
Stress 
In different studies, it has been found that stressful life events precedes the onset of Graves’ 
disease. Severe emotional and physical stress, like separation from the loved one or 
following road traffic accident, cause release of cortisol ad corticotrophin releasing hormone. 
So, stress is a relatively immune suppression state. Immune system overcompensates once 
stress is over which can precipitate disease similar to postpartum period. In conclusion there 
is limited but significant evidence that stressful life events can precipitate the onset of 
Graves’ disease in genetically susceptible individuals. 
Gender 
Typically Graves’ disease is more prevalent in females than males. It is about 5-10 times 
more common in females at any age. 6,7 In children this difference is smaller. The exact cause 
for female preponderance is not known, but it is similar to other autoimmune disorders. In 
experimental animal models of autoimmune thyroiditis it has been seen that androgens 
appear to down regulate the immune system.8,9 Other possible explanation for female 
preponderance is female sex steroids. But Graves’ disease also occurs in men and 
postmenopausal women. These observations have suggested that it is the X-chromosome, 
not the sex steroids, which is responsible. But most of the x-linked disorders are only 
present in man, it has been thought that a gene with dose dependent effect on  
X-chromosome is responsible. 
Pregnancy 
Postpartum period is an important risk factor for both the onset and relapse of Graves’ 
disease. Postpartum period is associated with a fourfold to eightfold increased risk for the 
onset of Graves’ disease. Rebound immunity is the likely explanation for this increased risk. 
Graves’ disease is associated with low pregnancy rate because thyrotoxicosis decreases the 
fertility rate. However in women with Graves’ disease who became pregnant, successful 
pregnancy outcome is low because Graves’ disease causes increased pregnancy loss and its 
complications. Graves’ disease exacerbates during the first trimester of pregnancy and 
postpartum period, while it improves during the second and third trimester of pregnancy. 
Smoking 
Smoking is a minor risk factor for Graves’ disease; however it is a major risk factor for 
Graves’ ophthalmopathy. There are number of studies showing relationship between 
Graves’ disease, Graves’ ophthalmopathy and smoking. 11,12 
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Other risk factors: 
Direct trauma to the thyroid gland, ethanol injection for the treatment of autonomously 
functioning thyroid nodules, or thyroid injury following radio-iodine treatment for toxic 
adenoma or toxic multinodular goiter are associated with an increased risk of Graves’ 
disease. Radio-iodine treatment may also cause onset or worsening of ophthalmopathy. 
Possible explanation is that thyroid injury by any means cause massive release of thyroid 
antigens, which in turn stimulate an autoimmune reaction to TSHR in susceptible 
individuals. 
Graves’ disease onset and recurrence is also associated with iodine and iodine containing 
drugs like amiodarone and radio-contrast media especially in iodine deficient population. 
3. Pathogenesis 
Graves’ disease is an example of organ specific autoimmune disorder in which both 
humoral and cell mediated immunity directed against different thyroid antigens are 
involved. TSHR is the primary autoantigen of Graves’ disease, while other autoantigens like 
thyroglobulin and thyroid peroxidase are secondarily involved.  
3.1. Humoral immunity 
TSHR is a member of GPCR super family and involves cAMP and phosphoinositol 
pathways for signal transduction. TSHR has large intracellular domain (subgroup B). It is a 
glycoprotein consisting of 744 amino acids and having molecular weight of 84 kd. Gene for 
TSHR is located on chromosome 14q31 and is formed by 10 exons. Circulating autoantibody 
directed against the TSHR is the primary factor responsible for Graves’ disease. TSHR 
antibodies (TSHR-Ab) are of three types- namely stimulating antibody, blocking antibody 
and neutral antibody. Stimulating antibodies are those who after binding to TSHR activate 
adenylate cyclase and cause increased thyroid growth and vascularity, and increases the 
production of thyroid hormones. Blocking antibodies are those who after binding to TSHR 
act as an antagonist, whereas neutral antibodies does not have any functional activity. 
Almost 50 years ago(in 1956) long acting thyroid stimulators (LATS) was discovered by 
Adams and Purves during a search for thyroid stimulating activity in patients with Graves' 
disease. 13 Later on it was found that LATS are nothing but immunoglobulin of IgG1 
subclass. 
Transplacental transfer of TSHR stimulating antibodies (TSAb) from TSAb positive 
pregnant mother to fetus causes transient neonatal thyrotoxicasis that improves 
spontaneously after the disappearance of TSAb. 14 This provides the definite role of TSAb in 
the causation of Graves' disease. TSAb are oligoclonal.  
TSAb are produced mainly by the lymphocytes infiltrating the thyroid gland and 
lymphocytes present in the draining lymph nodes, and partly by the circulating blood 
lymphocytes.15,16 There is a positive correlation exists between the TSAb level and serum 
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triiodothyronine level, serum thyroglobulin level and goiter size. TSAb are found in 90-
100% of untreated Graves' disease patients.17, 18 Level of TSAb decreases after treatment with 
anti- thyroid drugs and radio-iodine.19, 20 
3.2. Assays for TSHR-Ab 
Two types of assays are used for TSHR-Ab-Radioreceptor assays and invitro bioassays. 
3.2.1. Radioreceptor assay 
Radioreceptor assay is most readily available and most widely used in clinical practice. Basic 
principle of radioreceptor assay is displacement of labeled TSH from solubilized TSHR from 
patient's serum. This TSH- binding inhibitory immunoglobulins (TBII) assay does not provide 
information regarding the functionality of TSHR-Ab. TBII assays are cheaper and having good 
precision. The first generation TBII assays have sensitivity of 75-95% in untreated Graves' 
disease patients. Most recently a monoclonal human antibody to TSHR is used. This second 
generation radio-receptor assay has sensitivity of 99% and very high specificity. 21 
3.2.2. In vitro bioassays 
In vitro bioassays are based on the ability of patients serum to stimulate adenylate cyclase 
and produce cAMP from cultured hamster ovary cells transfected with human TSHR (CHO-
R),23 or rat thyroid cell strain (FRTL-5)24 or human thyroid follicular cells 25 are used as a 
source for functional TSHR. CHO-R system is slightly more sensitive, and requires an easier 
culture condition than other systems. Advantages of bioassays are that it gives information 
about the functional property of TSHR-Ab, but bioassays are more expensive, not widely 
available, having poor precision and sensitivity of more than 90%. These problems have 
been solved in newer bioassays. 
3.2.3. Cellular immunity 
The thyroid gland in Graves' disease is characterized by non-homogenous lymphocytic 
infiltration. Majority of the intrathyroidal lymphocytes are T lymphocytes. B-lymphocytes 
are much less common than Hashimoto's thyroiditis. Cytokine profile produced by 
intrathyroidal T lymphocytes suggested that both TH1 & TH2 cells are present in thyroid. 
Majority of the T-lymphocytes are of TH1 subtype.26,27 
TH1 cells are mainly involved in delayed type of hypersensitivity reactions, and it produces 
the cytokines like TNF-B, IFN-Y, IL-2, IL-10 and IL-17. TH1 cells are implicated in the 
pathogenesis of organ specific autoimmune diseases that is mediated mainly by TNF-β 
subtype, which uniquely produces IL-17. TH 2 cells are mainly responsible for humoral 
immune responses and they produce cytokines like IL-4, IL-5, IL-6 and IL-13.TH1 cells may 
also induce antibody formation through secretion of IL-10 28. IgG1 subclass of antibody are 
selectively induced by TH1 cells. Most of the intrathyroidal T cells are of memory (CD4+, 
CD29+) subtype. Concentration of cytotoxic T cells (CD8+) are much less in Graves' disease 
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patients than patients of Hashimoto's thyroiditis. So the functional role of T cells in Graves' 
disease is primarily a helper than a suppressor or cytotoxic role. 
4. Pathogenic mechanisms 
4.1. Molecular mimicry or specificity crossover 
Structural or conformational similarity between different antigens like infectious agent with 
a self antigen can lead to crossover of specificity or molecular mimicry. Molecular mimicry 
has been reported between Reoviral antigen and a tissue antigen expressed in multiple 
endocrine tissues, Yersinia enterocolitica and TSHR, Retroviral sequences and TSHR & 
Borrelia and TSHR. 
4.2. Bystander effect 
There is evidence that bystander activation of local resident antigen specific and nonspecific 
T- cells by a local viral infection would induce an inflammatory reaction and stimulates the 
production of cytokines induce autoimmunity. This bystander activation can also occur in 
any infections and antigens unrelated to the thyroid gland.  
4.3. Aberrant expression of class II HLA Antigens 
MHC class II molecules (HLA-DP, DQ, and DR) are not expressed on the normal thyroid 
epithelial cells but they are expressed on thyroid epithelial cells in patients of autoimmune 
thyroid disease. This aberrant expression of class II HLA antigens on thyroid epithelia cells 
can be induced by local thyroid insult which causes production of interferon γ and other 
cytokines. Interferon γ is able to over express HLA class I molecule and induce the 
expression of class II molecule on thyroid epithelial cells. 
4.4. Cryptic antigens 
Autoimmunity results from the loss of tolerance or the ability to differentiate between self and 
non self. Tolerance induction is a staged process that initiates in the thymus during T-cell 
maturation. This process depends in part on the presence of peripheral antigens in the thymus. 
Peripheral antigens are antigens normally expressed in tissues outside of the immune system 
which are expressed at low levels in thymus. T cells that react strongly to these peripheral 
molecules in the context of MHC are deleted in thymus. T cells that react with peripheral 
antigens that are not expressed in the thymus have a greater opportunity to escape tolerance.  
4.5. Hygiene hypothesis 
Hygiene hypothesis implies that infection may protect form autoimmune diseases rather 
than precipitating it. Decreased exposure to antigens due to improved living standards can 
lead to increased risk of autoimmune disorder. 
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patients than patients of Hashimoto's thyroiditis. So the functional role of T cells in Graves' 
disease is primarily a helper than a suppressor or cytotoxic role. 
4. Pathogenic mechanisms 
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Structural or conformational similarity between different antigens like infectious agent with 
a self antigen can lead to crossover of specificity or molecular mimicry. Molecular mimicry 
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endocrine tissues, Yersinia enterocolitica and TSHR, Retroviral sequences and TSHR & 
Borrelia and TSHR. 
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can be induced by local thyroid insult which causes production of interferon γ and other 
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which are expressed at low levels in thymus. T cells that react strongly to these peripheral 
molecules in the context of MHC are deleted in thymus. T cells that react with peripheral 
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than precipitating it. Decreased exposure to antigens due to improved living standards can 
lead to increased risk of autoimmune disorder. 
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4.6. Super antigens 
Super antigens are endogenous or exogenous proteins such as microbial proteins, capable of 
stimulating a strong immune response through molecular interactions with non-variant 
parts of the T- cell repertoire and the HLA class II proteins. 
5. Pathology 
Grossly the thyroid gland is diffusely enlarged with smooth and hyperemic surface. Rarely 
the gland is grossly nodular. Consistency of the gland varies from soft to firm. Pyramidal 
lobe is often prominent. 
Microscopically both hypertrophy and hyperplasia are seen. Follicles are small with scanty 
colloid, and lined by hyperplasic columnar epithelium which can give a pseudopapillary 
appearance. Vascularity of the gland is increased. There is varying degree of infiltration by 
lymphocytes and plasma cells. T cells predominate in the interstitium, whereas B cells and 
plasma cells predominate in lymphoid follicles. 
On electron microscopy there is increased golgi reticulum and mitochondria, and it is also 
characterized by presence of prominent microvilli. 
After treatment with antithyroid drugs and radioiodine, the vascularity of the gland 
decreases, follicles enlarges and filled with colloid, and papillary projection regresses. 
6. Clinical features 
Graves' disease is the most common cause of thyrotoxicosis. Most common age of onset is 
third to fourth decade of life but it can occur in children and elderly. The hallmark of 
Graves' disease is signs and symptoms of thyrotoxicosis along with diffuse goiter and 
typical Graves' orbitopathy. Most of the signs and symptoms are similar to other causes of 
thyrotoxicosis, but some of the signs and symptoms like orbitopathy, dermopathy or 
pretibial myxedema and thyroid acropachy are unique to Graves' disease. 
Onset of Graves' disease is usually gradual. Signs and symptoms are presents months before 
the diagnosis, and usually patients do not remember the exact date of onset of symptoms. 
Onset can be abrupt in some cases. The signs and symptoms are usually more severe than 
other causes of thyrotoxicosis. 
6.1. Thyroid gland 
Thyroid gland is diffusely enlarged in Graves' disease, but it can be nodular especially in 
areas of iodine deficiency where nodular goiter preexists before the onset of Graves' disease. 
Goiter size is variable. It can range from normal size thyroid gland to massively enlarged 
thyroid. Usually size of goiter is two to three times that of normal. Normal size thyroid 
gland can the seen in as many as 20% of patients and most of them are elderly. The 
consistency of the goiter varies from soft to firm but softer than the goiter of Hashimoto's 
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thyroiditis. Thrill and bruit can be present over goiter in severe cases and it is due to 
increased vascularity of the gland. Thrill and bruit are present usually on upper or lower 
pole and continuos in nature, but sometimes can present only in systole. Large goiter with 
intrathoracic extension can be associated with facial swelling and flushing, and neck vein 
distension upon raising the arm above the head. This is known as Pemberton sign. 
6.2. Graves’ ophthalmopathy 
Graves' ophthalmopathy is one of the distinctive manifestations of Graves’ disease. Overall 
clinical ophthalmopathy is present in about 50% of Graves’ disease patients,29 however CT 
or MRI reveals extraocular muscle enlargement in about 70% of patients without overt 
clinical ophthamopathy.30,31 Bimodal age distribution was noted for ophthalmopathy in both 
men and women. Peak age is 40 to 44 years and 60 to 64 years in women, whereas in men it 
is 45 to 49 years and 65 to 69 years. 
6.2.1. Risk factors for Graves' ophthalmopathy 
There is no specific genetic predisposition for graves' ophthalmopathy. Environmental 
factors are more important for ophthalmopathy. 
Smoking 
Smoking is a major risk factor for ophthalmopathy. Smoking also increases the risk for 
worsening of ophthalmopathy after radioiodine treatment. Possible contributors are orbital 
hypoxia and free radical present is smoke. 32,33 
Gender 
Graves’ disease is predominantly a disease of females (F: M= 8-10:1). In comparison to 
Graves’ disease, ophthalmopathy is relatively more common in males (F: M= 1:1.8-2.8) than 
females. 34,35 
Radioiodine 
Graves' disease patients treated with radioiodine are at increased risk for onset and 
worsening of eye disease, as compared to antithyroid drugs alone. 36,37 This risk can be 
decreased by concurrent use of corticosterodis.38,39 
6.2.2. Pathogenesis 
Current evidence support an autoimmune pathogenesis with important environmental 
influences, particularly smoking. Orbital muscles, connective tissues, and adipose tissues are 
infiltrated by lymphocytes and macrophages. TH1 mediated immune response 
predominates in early stage of disease while TH2 response predominates in late stage. 40 In 
response to cytokines secreted by the infiltrating immune cells, orbital fibroblasts start 
synthesizing and secreting hydrophilic glycosaminoglycans, resulting in edema of orbital 
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tissues. Additionally adipocytes present in orbit become active and results in expansion of 
orbital adipose tissues. Both these factors are responsible for expansion of orbital tissues.  
6.2.3. Natural history 
Onset of eye disease usually coincides with that of thyrotoxicosis in 40% of cases, follow it in 
40%, and precedes it in 20%.41,42 Even when the onset of the two disorders does not coincide, 
each occurs within 18 months from the onset of the first manifestation. Eye disease usually 
shows a progressive deterioration lasting for several months followed by a phase of 
spontaneous improvement lasting upto a year and longer and quiescent stage when 
inflammatory signs disappear and clinical features stabilizes. 
6.2.4. Sings and symptoms 
The earliest manifestations of ophthalmopathy are usually a sensation of grittiness, eye 
discomfort, and excess tearing. Other common symptoms are spontaneous retroorbital pain, 
pain on ocular movement and diplopia. Diplopia is most common in upgaze or in extremes 
of lateral gaze, because of the involvement of inferior or lateral rectus muscle. About one 
third of patients have proptosis which can best be detected by visualization of the sclera 
between the lower border of iris and the lower eyelid when the eyes are kept in primary 
position. 
In severe cases proptosis can cause exposure keratitis and corneal ulcerations. Proptosis is 
frequently assymetrical. Retraction of the upper eyelid and less commonly of lower eyelid 
results in lid lag, globe lag, and lagophthalmos. Movements of the lids are jerky, and also 
there is tremor of lightly closed eyes. These are the non specific manifestations of 
thyrotoxicosis. Other signs and symptoms are photophobia, swelling of the eyelids, blurring 
of vision, conjunctival injection and chemosis, periorbital edema. 
Decreased visual acuity and color vision, corneal ulceration, and subluxation of globe are 
present in most severe cases. Blindness may result from corneal ulceration and compression 
of the optic nerve at the orbital apex due to increased orbital pressure and venous 
congestion. 
Graves' ophthalmopathy can occur in absence of Graves' disease in 10% cases, that’s why it 
is also known as thyroid associated ophthalmopathy, or euthyroid Graves’ opthalmopathy. 
Graves' ophthalmopathy is usually bilateral but it can be unilateral in upto 10% cases.  
6.2.5. Staging severity of ophthalmopathy 
The acronym NO SPECS was given by American Thyroid Association for severity of 
ophthalmopathy, where no indicates absence or mild ophthalmopathy, and SPECS indicates 
more severe degree of involvement, but NO SPECS scheme is inadequate and patients do 
not necessarily progress from one class to other. 
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Classes  Ocular symptoms and signs
0 No signs and symptoms  
1 Only signs (lid retraction, lid lag, proptosis upto 22 mm) 
2 Soft tissue involvement (periorbital edema) 
3 Proptosis (>22 mm) 
4 Extraocular muscle involvement (diplopia) 
5 Corneal involvement  
6 Sight loss (optic nerve involvement)  
Table 3.  
6.2.6. Clinical activity of ophthalmopathy 
To know the clinical activity of ophthalmopathy is important, because active disease is more 
likely to respond to immunosuppressive therapy. Clinical Activity Score (CAS) is used to 
know the clinical activity. Seven parameters are used in the clinical activity scoring which 
include spontaneous retrobulbar pain, pain on eye movement, eyelid erythema, conjuctival 
injection, swelling of the eyelids, inflammation of the caruncle and conjunctival edema or 
chemosis. Each parameter is assigned 1 point. CAS of more than or equal to 3/7 indicates 
active ophthalmopathy.  
6.3. Thyroid dermopathy 
Thyroid dermopathy presents in less than 5% of patients with Graves’ disease. It is almost 
always accompanied by moderate to severe ophthalmopathy. Most commonly it is present 
over anterior and lateral aspects of leg, hence it is also known as pretibial myxoedema. Less 
commonly it can present over dorsa of the feet, dorsa of the hands, forearm, face and 
elbows, particularly after trauma. The typical lesion is a noninflamed, indurated plaque 
with a deep pink or purple color and an orange skin appearance. Nodular form is the 
intermediate while elephantiasis is the most severe form of thyroid dermopathy. Thyroid 
dermopathy occurs due to accumulation of glycosaminoglycans in the dermis and 
subcutaneous tissues.  
6.4. Thyroid acropachy 
Thyroid acropachy is the least common manifestation of Graves' disease. It is a form of 
clubbing, and presents in less than 1 percent of patients of Graves' disease. It is almost 
always associated with the severe and long standing ophthalmopathy and dermopathy. 
An alternate diagnosis should be considered in the absence of ophthalmopathy and 
dermopathy. Deposition of glycosaminoglycans in skin is responsible for thyroid 
acropachy.  
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7. Laboratory diagnosis 
Diagnosis of Graves' disease can be confirmed by measurement of serum TSH and total 
thyroxine (TT4) and triiodothyronine (TT3). Serum TSH level is suppressed or undetectable 
with increased TT4 and TT3 level in patients of Graves' disease. Serum TSH level is the most 
sensitive test. The free T4 (FT4) and free T3 (FT3) levels are increased more than that of TT4 
and TT3. Measurement of FT4 and FT3 are expensive, and there is more chance of laboratory 
errors. FT4 and FT3 can be measured in conditions associated with high serum TBG level like 
pregnancy, oral contraceptive use and chronic liver disease. In patients of Graves' disease 
serum T3 level is proportionately more elevated than the serum T4 level. In upto 12% of 
patients, especially in the iodine deficient areas, only TT3 or FT3 is elevated with a normal 
TT4 or FT4 level, a condition known as T3 toxicosis. Conversely in some patients (iodine 
induced hyperthyroidism, drugs like amiodarone and propronolol which block the 
conversion of T4 to T3), only TT4 or FT4 is elevated with normal TT3 and FT3 (T4 toxicosis). 
Serum thyroglobulin level is high in all cases of thyrotoxicosis except factitious 
thyrotoxicosis.  
Anti TPO antibody can be detected in upto 90%43,44 of patients with Graves' disease 
whereas anti-thyroglobulin antibody is present in 50-80% cases.45,46 They are useful in 
confirming the presence of thyroid autoimmunity but they are of limited diagnostic value. 
TSHR-Ab assay is very sensitive and specific (upto 98%) for the diagnosis of Graves' 
disease. But TSHR-Ab assay is quite expensive and not widely available. TSHR-Ab assay 
is indicated only when clinical and laboratory diagnosis are not clear. Indications for 
TSHR-Ab assay are:  
 Euthyroid Graves' disease, especially when it is unilateral  
 Pregnant women with Graves' disease to predict the likelihood of neonatal 
thyrotoxicosis  
 Nodular variant of Graves' disease 
TSHR-Ab assay is also a useful indicator of the degree of disease activity. It can also predict 
the prognosis of Graves' disease. There is more chance of relapse in patients with 
persistently high TSHR-Ab level after cessation of antithyroid drug.47  
Associated hematological abnormalities include increased RBC mass, leucopenia with 
relative lymphocytosis, monocytosis and eosinophilia, increased factor VIII level. Other 
associated abnormalities include elevated liver enzymes, bilirubin and ferritin.  
7.1. Radioactive iodine uptake (RAIU) 
RAIU is not required in each and every case of Graves' disease, but it is useful in excluding 
thyrotoxicosis caused by thyroiditis, factitious thyrotoxicosis, and type II amiodarone 
induces thyrotoxicosis. RAIU is absolutely contraindicated in pregnancy. In Graves' disease 
RAIU is diffusely increased.  
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7.2. Thyroid ultrasound 
In Graves' disease thyroid tissue typically become hypoechoic because of reduction in 
colloid content, increase in thyroid vascularity and lymhocytic infiltration. In colour flow 
doppler there is a distinct pattern characterized by markedly increased signals, inferior 
thyroid artery and itrathyroidal artery velocities more than 40 cm/s. This pattern, in 
conjunction with a hypoechoic pattern allows distinction from Hashimoto's thyroiditis.  
7.3. Differential diagnosis 
If a patient presented with diffuse goiter with clinical and biochemical thyrotoxicosis, 
ophthalmopathy and positive autoimmune markers like anti TPO antibody or TSHR-Ab, 
diagnosis of Graves' disease is straight forward. In absence of these classical features 
radionuclide scan (I123, I131, Tc99m) in the most reliable distinguishing test. In case of Graves' 
disease there is diffuse and high uptake, whereas in patients with toxic adenoma or toxic 
multinodular goiter there is patchy uptake. In patients with thyroiditis and factitious 
thyrotoxicosis there is decreased uptake. In patients with TSH producing adenoma, there is 
also a diffuse goiter, but TSH is inappropriately normal or increased instead of suppress 
TSH of graves' disease. Panic attacks, mania, pheochromocytoma and malignancy can be 
easily ruled out by thyroid function test.  
8. Treatment 
There is no ideal treatment option present targeting the basic pathogenic mechanisms of 
Graves' disease. Available treatment options target the increased synthesis of thyroid 
hormones by antithyroid drugs, or ablation of thyroid tissue by surgery or radioiodine. 
Antithyroid drugs are the predominant therapy in Europe and Japan whereas radioiodine is 
first line of treatment in USA. No single treatment is optimal and patients often require 
multiple treatment.  
8.1. Antithyroid drugs 
Thionamides are the main antithyroid drugs which includes propylthiouracil, carbimazole 
and methimazole. Thionamides act by inhibiting the enzyme thyroid peroxidase, reducing 
the oxidation and organification of iodide and coupling of iodotyrosines. Carbimazole is not 
an active drug, and in body it is converted to active metabolite methimazole. 
Proylthiouracil, in addition to inhibit thyroid hormone synthesis, also inhibits the peripheral 
conversion of T4 to T3. Methimazole is ten times more potent than prophylthiouracil. Half 
life of methimazole is about 6 hours while that of prophylthiouracil is about 90 minutes. 
Duration of action of methimazole is more than 24 hours while that of propylthiouracil is 12-
24 hours. Transplacental transfer of prophylthiouracil is lowest. Antithyroid drugs do not 
block the release of preformed hormones, so euthyroidism is not obtained until 
intrathyroidal hormone store is depleted. These drugs also reduce thyroid antibody level. 
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 Pregnant women with Graves' disease to predict the likelihood of neonatal 
thyrotoxicosis  
 Nodular variant of Graves' disease 
TSHR-Ab assay is also a useful indicator of the degree of disease activity. It can also predict 
the prognosis of Graves' disease. There is more chance of relapse in patients with 
persistently high TSHR-Ab level after cessation of antithyroid drug.47  
Associated hematological abnormalities include increased RBC mass, leucopenia with 
relative lymphocytosis, monocytosis and eosinophilia, increased factor VIII level. Other 
associated abnormalities include elevated liver enzymes, bilirubin and ferritin.  
7.1. Radioactive iodine uptake (RAIU) 
RAIU is not required in each and every case of Graves' disease, but it is useful in excluding 
thyrotoxicosis caused by thyroiditis, factitious thyrotoxicosis, and type II amiodarone 
induces thyrotoxicosis. RAIU is absolutely contraindicated in pregnancy. In Graves' disease 
RAIU is diffusely increased.  
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7.2. Thyroid ultrasound 
In Graves' disease thyroid tissue typically become hypoechoic because of reduction in 
colloid content, increase in thyroid vascularity and lymhocytic infiltration. In colour flow 
doppler there is a distinct pattern characterized by markedly increased signals, inferior 
thyroid artery and itrathyroidal artery velocities more than 40 cm/s. This pattern, in 
conjunction with a hypoechoic pattern allows distinction from Hashimoto's thyroiditis.  
7.3. Differential diagnosis 
If a patient presented with diffuse goiter with clinical and biochemical thyrotoxicosis, 
ophthalmopathy and positive autoimmune markers like anti TPO antibody or TSHR-Ab, 
diagnosis of Graves' disease is straight forward. In absence of these classical features 
radionuclide scan (I123, I131, Tc99m) in the most reliable distinguishing test. In case of Graves' 
disease there is diffuse and high uptake, whereas in patients with toxic adenoma or toxic 
multinodular goiter there is patchy uptake. In patients with thyroiditis and factitious 
thyrotoxicosis there is decreased uptake. In patients with TSH producing adenoma, there is 
also a diffuse goiter, but TSH is inappropriately normal or increased instead of suppress 
TSH of graves' disease. Panic attacks, mania, pheochromocytoma and malignancy can be 
easily ruled out by thyroid function test.  
8. Treatment 
There is no ideal treatment option present targeting the basic pathogenic mechanisms of 
Graves' disease. Available treatment options target the increased synthesis of thyroid 
hormones by antithyroid drugs, or ablation of thyroid tissue by surgery or radioiodine. 
Antithyroid drugs are the predominant therapy in Europe and Japan whereas radioiodine is 
first line of treatment in USA. No single treatment is optimal and patients often require 
multiple treatment.  
8.1. Antithyroid drugs 
Thionamides are the main antithyroid drugs which includes propylthiouracil, carbimazole 
and methimazole. Thionamides act by inhibiting the enzyme thyroid peroxidase, reducing 
the oxidation and organification of iodide and coupling of iodotyrosines. Carbimazole is not 
an active drug, and in body it is converted to active metabolite methimazole. 
Proylthiouracil, in addition to inhibit thyroid hormone synthesis, also inhibits the peripheral 
conversion of T4 to T3. Methimazole is ten times more potent than prophylthiouracil. Half 
life of methimazole is about 6 hours while that of prophylthiouracil is about 90 minutes. 
Duration of action of methimazole is more than 24 hours while that of propylthiouracil is 12-
24 hours. Transplacental transfer of prophylthiouracil is lowest. Antithyroid drugs do not 
block the release of preformed hormones, so euthyroidism is not obtained until 
intrathyroidal hormone store is depleted. These drugs also reduce thyroid antibody level. 
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Antithyroid drugs can be used as a primary treatment or as a preparatory treatment before 
radioiodine or surgery. The antithyroid drugs are usually started in higher doses. The 
starting dose of methiomazole or carbimazole is 10-20 mg every 8-12 hours and that of 
propylthiouracil is 100-200 mg every 6-8 hours. Once euthyroidism is achieved which 
usually takes 4-5 weeks, methimazole can be given in single daily dose while 
propylthiouracil is given in multiple daily doses throughout the treatment. There are two 
treatment strategies for using antithyroid drugs. In titration regimen, antithyroid drugs are 
started in high doses and dose can be gradually decreased to maintain euthyroid state. In 
Block and Replace regimen, the antithyroid drugs are maintained in high doses and 
subsequently levothyroxine is added to maintain the euthyroid status. At present there is no 
proven advantage of block and replace regimen over titration regimen.  
Patient should be reviewed clinically and biochemically after every 3-4 weeks. Dose of 
antithyroid drugs is adjusted based on the TT4 or FT4 level, as TSH level often remain 
suppressed for several months. The usual daily maintenance dose of carbimazole or 
methimazole is 2.5 – 10 mg and that of propylthiouracil is 50-100 mg. When TSH level 
become normal, it can also be used to monitor therapy. Size of the goiter decreases in about 
30-50% of patients during treatment. In remaining patients it may remain unchanged or 
even enlarge. Increase in goiter size is one of the earliest manifestations of iatrogenic 
hypothyroidism. The other features are weight gain, lethargy, fatigue and other signs of 
mild hypothyroidism.  
Maximum remission rate with antithyroid drugs is 30-50%, which can be achieved by 
continuation of the drug for 6-18 months or even longer. Most of the relapses occur within 
first 3-6 months after discontinuation of drug. Suppressed TSH level below the normal limit 
is the first signal of relapse even in the presence of a normal serum T4 level. In most of the 
studies, the relapse rate is 50-80%.48,49 Most important predictor of relapse is goiter size.50 
Other factors influencing recurrence of Graves' disease include high TSHR-Ab 
concentration, large iodine intake, marked residual goiter, short duration of antithyroid 
drug treatment and previous recurrence. Factors which favor long term remission after 
therapy include the initial presence of T3 toxicosis, a small goiter, decrease in the size of 
goiter, and return of TSH to normal during treatment, the return of serum thyroglobulin to 
normal, and low iodine diet.  
Most common side effects of thionamides are pruritus, skin rash, urticaria, fever and 
arthralgia. These may resolve spontaneously or after substituting another drug. Rare but major 
side effects are hepatitis, cholestasis, SLE like syndrome, ANCA positive vasculitis and most 
importantly agranulocytosis. Major side effects occur in less than 1% of patients.Antithyroid 
drugs should be stopped and not restarted if patient develop major side effects.  
8.2. Iodine and iodine containing components 
Inorganic iodine acts in many ways in thyrotoxicosis. Iodine blocks its own transport in 
thyroid, inhibits iodine organification and inhibits the release of hormone. Inhibition of 
iodine organification by inorganic iodide is known as Wolf-Chaikoff effect. Major action of 
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iodine is inhibition of hormone release. Iodine also decreases the vascularity of thyroid 
gland. All of these effects of iodine are transient and lasts only for a few days or weeks. Now 
a days iodine is used only for preoperative preparation for Graves’ disease and in the 
management of thyrotoxic crisis. The usual dose of Lugol's solution is 3-5 drops three times 
per day and that of SSKI is 2-3 drops twice daily. Iodine decreases the effect of subsequently 
administad thionamides and radioiodine for severe weeks. 
Iodinated radio contrast agents like iopanoic acid, and sodium ipodate acts by blocking the 
peripheral conversion of T4 to T3 and inhibition of hormone release. They are ideally used 
in emergency situations when rapid control of thyrotoxicosis is needed or in preoperative 
preparation or while awaiting the response of radioiodine. 
8.3. Thiocyanate and perchlorate 
They act by intititing the transport of iodine to thyroid gland. 
8.4. Lithium 
Lithium also acts as a thyroid constipating agent (block the release of thyroid hormones). 
Lithium also potentiates the beneficial effect of radioiodine. The usual dose of lithium is 450-
900 mg per day in divided doses. Serum lithium concentration should be maintained at 
1meEq/L. No adverse effects are reported with this dose of lithium. 
8.5. Glucocorticoids 
Dexamethasone in high doses (8mg/day) decreases the T4 secretion by the thyroid gland, 
inhibit the peripheral conversion of T4 to T3, and has immunosuppressive effect. Effect on 
peripheral conversion of T4 to T3 is additive to propylthiouracil. Glucocorticaids are 
indicated for the treatment of ophthalmopathy, dermopathy and in thyrotoxic crisis.  
8.6. β- blockers 
β- blockers do not affect the synthesis or secretion of thyroid hormones. Many of the 
symptoms & signs of thyrotoxicosis are due to hypersensitivity of the sympathetic nervous 
system to thyroid hormones. Thus use of β- blockers in thyrotoxicosis, improve the signs 
and symptoms mediated by the sympathetic nervous system. Tachycardia, palpitation, 
tremor, anxiety, excess sweating, lid retraction improves with β- blockers. Propranolol has 
additional advantage over other β- blockers. It inhibits the peripheral conversion of T4 to T3. 
β- blockers reduce cardiac output without altering oxygen consumption, can have adverse 
effect in liver, where the arteriovenous oxygen difference is already elevated in the 
hyperthyroid state. Propranolol is most commonly used agent but other β- blockers can also 
be used. It is used in a dose of 20-60 mg every 6-8 hours. Short acting agents like esmolol is 
used for intravenous purpose. Long acting agents like atenolol or metoprolol are used for 
prolonged treatment. β- blockers should be rapidly tapered and discontinued once stable 
euthyroidism it achieved.  
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is the first signal of relapse even in the presence of a normal serum T4 level. In most of the 
studies, the relapse rate is 50-80%.48,49 Most important predictor of relapse is goiter size.50 
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concentration, large iodine intake, marked residual goiter, short duration of antithyroid 
drug treatment and previous recurrence. Factors which favor long term remission after 
therapy include the initial presence of T3 toxicosis, a small goiter, decrease in the size of 
goiter, and return of TSH to normal during treatment, the return of serum thyroglobulin to 
normal, and low iodine diet.  
Most common side effects of thionamides are pruritus, skin rash, urticaria, fever and 
arthralgia. These may resolve spontaneously or after substituting another drug. Rare but major 
side effects are hepatitis, cholestasis, SLE like syndrome, ANCA positive vasculitis and most 
importantly agranulocytosis. Major side effects occur in less than 1% of patients.Antithyroid 
drugs should be stopped and not restarted if patient develop major side effects.  
8.2. Iodine and iodine containing components 
Inorganic iodine acts in many ways in thyrotoxicosis. Iodine blocks its own transport in 
thyroid, inhibits iodine organification and inhibits the release of hormone. Inhibition of 
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iodine is inhibition of hormone release. Iodine also decreases the vascularity of thyroid 
gland. All of these effects of iodine are transient and lasts only for a few days or weeks. Now 
a days iodine is used only for preoperative preparation for Graves’ disease and in the 
management of thyrotoxic crisis. The usual dose of Lugol's solution is 3-5 drops three times 
per day and that of SSKI is 2-3 drops twice daily. Iodine decreases the effect of subsequently 
administad thionamides and radioiodine for severe weeks. 
Iodinated radio contrast agents like iopanoic acid, and sodium ipodate acts by blocking the 
peripheral conversion of T4 to T3 and inhibition of hormone release. They are ideally used 
in emergency situations when rapid control of thyrotoxicosis is needed or in preoperative 
preparation or while awaiting the response of radioiodine. 
8.3. Thiocyanate and perchlorate 
They act by intititing the transport of iodine to thyroid gland. 
8.4. Lithium 
Lithium also acts as a thyroid constipating agent (block the release of thyroid hormones). 
Lithium also potentiates the beneficial effect of radioiodine. The usual dose of lithium is 450-
900 mg per day in divided doses. Serum lithium concentration should be maintained at 
1meEq/L. No adverse effects are reported with this dose of lithium. 
8.5. Glucocorticoids 
Dexamethasone in high doses (8mg/day) decreases the T4 secretion by the thyroid gland, 
inhibit the peripheral conversion of T4 to T3, and has immunosuppressive effect. Effect on 
peripheral conversion of T4 to T3 is additive to propylthiouracil. Glucocorticaids are 
indicated for the treatment of ophthalmopathy, dermopathy and in thyrotoxic crisis.  
8.6. β- blockers 
β- blockers do not affect the synthesis or secretion of thyroid hormones. Many of the 
symptoms & signs of thyrotoxicosis are due to hypersensitivity of the sympathetic nervous 
system to thyroid hormones. Thus use of β- blockers in thyrotoxicosis, improve the signs 
and symptoms mediated by the sympathetic nervous system. Tachycardia, palpitation, 
tremor, anxiety, excess sweating, lid retraction improves with β- blockers. Propranolol has 
additional advantage over other β- blockers. It inhibits the peripheral conversion of T4 to T3. 
β- blockers reduce cardiac output without altering oxygen consumption, can have adverse 
effect in liver, where the arteriovenous oxygen difference is already elevated in the 
hyperthyroid state. Propranolol is most commonly used agent but other β- blockers can also 
be used. It is used in a dose of 20-60 mg every 6-8 hours. Short acting agents like esmolol is 
used for intravenous purpose. Long acting agents like atenolol or metoprolol are used for 
prolonged treatment. β- blockers should be rapidly tapered and discontinued once stable 
euthyroidism it achieved.  
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8.7. Radioiodine 
Radioiodine is one of the first line therapy for the Graves' disease. Among different isotopes 
of radioiodine, I131 is the agent of choice. I131 is a β-emitter isotope. After oral administration, 
I131is completely absorbed and rapidly concentrated in thyroid follicular cells. β- particles, 
which are emitted by I131, destroy the thyroid follicular cells that results in reduced thyroid 
hormone synthesis. Initially destruction of thyroid follicular cells results in release of 
preformed hormones that can precipitate the thyortoxic crisis. Weeks to months are required 
for control of thyrotoxicosis. Long term effects of radioiodine include atrophy and fibrosis, 
and a chromic inflammatory response resembling Hashimoto's thyroiditis.  
Radioiodine is given as single oral dose. Three outcomes of radioiodine treatment are 
possible- patients become euthyroid or remain thyrotoxic or become permanently 
hypothyroid. Dose of radioiodine depends on the size of gland, the uptake of I131 and its 
subsequent rate of release. Dose of radioiodine ranges from 80-200 Ci/gm of thyroid 
tissues. A total dose of 20 mCi achieves thyroid ablation in almost all patients and results in 
permanent hypothyroidisms in 75-90% of patients. 51 The incidence of post radioiodine 
hypothyroidism in first year is 25% and steadily increases thereafter at a rate of 5% per year. 
When required, the second dose of radioiodine should be given at least 6 months after the 
first dose. Failure of radioiodine treatment is more common in patients with large goiter, 
rapid iodine turnover and adjunctive antithyroid drugs too soon after radioiodine. Prior use 
of antithyorid drugs decreases the risk of thyrotoxic crisis. Chance of worsening 
ophthalmopathy can also be reduced by antithyroid drugs. Antithyroid drugs should be 
stopped 3 to 8 days prior to radioiodine treatment and should be restarted after 7 days when 
required. Propylthiouracil may cause radio-resistance, but it not a major concern. Short term 
side effects of radioiodine include transient exacerbation of thyrotoxicosis in the first few 
months, transient worsening of ophthalompathy, acute radiation thyroids in the first week. 
Radiation thyroidits may lead to transient worsening of thyrotoxicosis and ophthalmopathy. 
Presence of mild to moderate ophthalmopathy is not a contraindication for radioiodine 
treatment. Concomitant use of oral glucocorticoids, decreases the risk of worsening 
ophthalmopathy. Long term side effect of radioiodine is permanent hypothyroidism. Initially 
there was a concern regarding possible carcinogenic effect and risk of genetic damage after 
radioiodine treatment. But now it is proven that there is no association between radioiodine 
treatment and thyroid carcinoma, leukemia, solid tumors and genetic damage.52 Thyroid 
cancer is associated with low dose of I131 rather than higher dose of I131 in children. 53 Some 
centers uses radioiodine even in children of 10 years of age or younger, but still there is no 
consensus regarding use of radioiodine for persons younger than 16 to 18 years. 
8.8. Surgery 
Surgery is a form of ablative therapy. Enough thyroid tissue is removed by surgery to reduce 
the synthesis of thyroid hormones and prevent recurrence. Two type of thyoid surgery are 
used for Graves' disease. In subtotal thyroidectomy, bulk of the thyroid gland is removed and 
only about 2 gm (0.5%) of thyroid tissue is left in both lobes. In near total thyroidectomy, most 
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of the thyroid gland is removed, with only subcentimeter fragment are left around recurrent 
laryngeal nerve and parathyroid glands. Subtotal thyroidectomy was the procedure of choice 
in past, but it is associated with higher recurrence rate. Now-a-days near total thyroidectomy 
is used most often. Near total thyroidectomy is associated with more chance of permanent 
hypothyroidism but less chance of recurrence than subtotal thyroidectomy. 
Complications of thyroid surgery depends on the skill and experience of operating surgeon. 
In specialized hands, complication rate is as low as 2%, whereas complication rate increases 
up to 10-15% in non specialized centers. Post Operative bleeding is the most serious 
complication. It can be fatal by producing asphyxia, if it is not evacuated immediately. Other 
complications like thyroid storm, injury to recurrent laryngeal nerve and 
hypoparathyroidism are specific to thyroid surgery. Thyroid storm is rare now-a-days. 
Injury to recurrent laryngeal nerve causes dysphonia, that usually improves with time, but 
that may leave the patient slightly hoarse. Hypoparathyroidism can be transient or 
permanent. Transient hypoparathyroidism is due to removal of the some parathyroid and 
impairment of blood supply to parathyroid glands, whereas permanent 
hypoparathyroidism is due to inadvertent removal of all 4 glands. Transient 
hypoparathyroidism usually occur on day 1-7 postoperatively. Severe symptomatic 
hypoparathyroidism should be treated by intravenous calcium gluconate. Oral calcium 
(upto 3 gm/day) is sufficient for milder cases. Immediate postoperative hypocalcemia is due 
to hungry bone syndrome. Recurrence of hyperthyroidism and permanent hypothyroidism 
are inversely related and depends on the amount of thyroid tissue left. In case of recurrence, 
radioiodine should be used as treatment, as second surgery is technically difficult.  
Preoperative preparation 
Preoperative use of thionamides is associated with lesser morbidity and mortality. 
Preoperative thionamides are recommended to achieve euthyroidism and to deplete. The 
hormone store. Preoperative use of inorganic iodine decreases the gland size and 
vcascularity. In case of emergency surgery oral cholecystographic agents are the fastest way 
to obtain euthyroidism. The goal of preoperative management is to maintain euthyroid 
states by thionamides and then to induce involution of the gland by the inorganic iodine. β 
blockers can be used in preoperative preparation. 
Choice of therapy 
Choice of therapy depends on the patient preference, personal experience of the treating 
doctor and availability of the treatment options. All the three treatment options (antithyroid 
drugs, radioiodine, surgery) can be used as first line therapy. In most of the Europe, 
antithyroid drugs are the preferred treatment whereas in USA, radioiodine is the preferred 
treatment. Primary choice of treatment in children and young adults upto 18 years of age is 
antithyroid drugs, although radioiodine is not associated with any adverse events. 
Pregnancy should be delayed for 6-12 months after radioiodine treatment. Presence of 
severe ophthalmopathy is a contraindication for radioiodine treatment. Surgery is the 
preferred treatment for patients with large goiter, especially if compressive symptoms are 
present, endemic goiter with multiple cold nodules, and suspected malignancy.  
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of the thyroid gland is removed, with only subcentimeter fragment are left around recurrent 
laryngeal nerve and parathyroid glands. Subtotal thyroidectomy was the procedure of choice 
in past, but it is associated with higher recurrence rate. Now-a-days near total thyroidectomy 
is used most often. Near total thyroidectomy is associated with more chance of permanent 
hypothyroidism but less chance of recurrence than subtotal thyroidectomy. 
Complications of thyroid surgery depends on the skill and experience of operating surgeon. 
In specialized hands, complication rate is as low as 2%, whereas complication rate increases 
up to 10-15% in non specialized centers. Post Operative bleeding is the most serious 
complication. It can be fatal by producing asphyxia, if it is not evacuated immediately. Other 
complications like thyroid storm, injury to recurrent laryngeal nerve and 
hypoparathyroidism are specific to thyroid surgery. Thyroid storm is rare now-a-days. 
Injury to recurrent laryngeal nerve causes dysphonia, that usually improves with time, but 
that may leave the patient slightly hoarse. Hypoparathyroidism can be transient or 
permanent. Transient hypoparathyroidism is due to removal of the some parathyroid and 
impairment of blood supply to parathyroid glands, whereas permanent 
hypoparathyroidism is due to inadvertent removal of all 4 glands. Transient 
hypoparathyroidism usually occur on day 1-7 postoperatively. Severe symptomatic 
hypoparathyroidism should be treated by intravenous calcium gluconate. Oral calcium 
(upto 3 gm/day) is sufficient for milder cases. Immediate postoperative hypocalcemia is due 
to hungry bone syndrome. Recurrence of hyperthyroidism and permanent hypothyroidism 
are inversely related and depends on the amount of thyroid tissue left. In case of recurrence, 
radioiodine should be used as treatment, as second surgery is technically difficult.  
Preoperative preparation 
Preoperative use of thionamides is associated with lesser morbidity and mortality. 
Preoperative thionamides are recommended to achieve euthyroidism and to deplete. The 
hormone store. Preoperative use of inorganic iodine decreases the gland size and 
vcascularity. In case of emergency surgery oral cholecystographic agents are the fastest way 
to obtain euthyroidism. The goal of preoperative management is to maintain euthyroid 
states by thionamides and then to induce involution of the gland by the inorganic iodine. β 
blockers can be used in preoperative preparation. 
Choice of therapy 
Choice of therapy depends on the patient preference, personal experience of the treating 
doctor and availability of the treatment options. All the three treatment options (antithyroid 
drugs, radioiodine, surgery) can be used as first line therapy. In most of the Europe, 
antithyroid drugs are the preferred treatment whereas in USA, radioiodine is the preferred 
treatment. Primary choice of treatment in children and young adults upto 18 years of age is 
antithyroid drugs, although radioiodine is not associated with any adverse events. 
Pregnancy should be delayed for 6-12 months after radioiodine treatment. Presence of 
severe ophthalmopathy is a contraindication for radioiodine treatment. Surgery is the 
preferred treatment for patients with large goiter, especially if compressive symptoms are 
present, endemic goiter with multiple cold nodules, and suspected malignancy.  
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Thyroid ophthalmopathy 
Mild to moderate ophthalmopathy does not require any specific treatment. General 
measures include control of thyrotoxicosis, smoking cessation, dark glasses with side frame 
for photophobia and sensitivity to air, artificial tear (1% methyl cellulose) or eye ointment 
for eye discomfort and dry eye, eye patches or taping during sleep for lagophthalmos, 
elevation of the head end for periorbital edema, prism for correction of mild diplopia.  
Other patients with more severe signs and symptoms affecting daily lives to a significant 
extent may benefit from immunosuppressive therapy in active disease or surgical 
decompression in case of inactive disease. Severe ophthalmopathy with optic neuropathy 
and corneal ulcer is an emergency. 
Glucocorticoids 
Oral glucocorticoids is initiated at a relatively high dose, such as 40-80 mg of prednisolone 
per day. After 2-4 weeks, the daily dose is tapered by 2.5-10 mg every 2-4 weeks. 
Improvement in soft tissue inflammation begins within 1-2 days. Intravenous 
methylprednisolone pulse therapy is more effective and better tolerated than oral 
prednisolone.54 500 mg of methylprednisolone per week for 6 weeks followed by 250 mg of 
methylprednisolone per week for 6 weeks is most commonly used regimen. Cyclosporine 
can also be used either as a single therapy or in combination with oral prednisolone. 
Combination therapy of cyclosporine with prednisolone is more effective than either drug 
alone.55 
Orbital Radiotherapy 
Orbital radiotherapy is well tolerated and provide benefit in approximately two third of 
patients. This treatment is steroid sparing rather than steroid replacing therapy.  
Other immunomodulatory therapy 
Rituximab, azathioprine, cyclophosphamide, ciamexon, pentoxifylline and intravenous 
immunoglobulins have some benefit and are currently under trial. 
Orbital decompression 
Indications for orbital decompression include optic neuropathy, severe proptosis, vision 
threatening ocular exposure, debilitating retrobulbar and periorbital pain and intolerable 
corticosteroid side effects. Transantral orbital decompression with removal of a portion of 
medial wall and the orbital floor is most commonly used procedure. Upto 5 mm reduction 
in proptosis can be achieved by orbital decompression. Orbital decompression can cause 
onset or worsening of diplopia.  
Thyroid storm 
Thyroid storm or thyrotoxic crisis is a life threatening exacerbation of hyperthyroidism. 
Most of the cases of thyroid storm are associated with Graves' disease, but it can also occur 
with toxic multinodular goitre. Precipitating factor for thyroid storm include infection, 
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trauma, thyroid surgery, radioiodine, diabetic ketoacidosis, stroke etc. It can present with 
fever, tachycardia, arrhythmias, profuse sweating, diarrhea and vomiting, confusion, 
delirium, seizures, jaundice, coma, congestive heart failure, hypotension. Thyroid storm is 
associated with very high mortality rate (upto 30%, even with treatment).  
Treatment of thyroid storm requires strict monitoring and proper care. Precipitating factors 
should be identified and treated. Supportive treatment include cooling blankets and drugs 
like acetaminophen, chlorpromazine or meperidine for hyperthermia, oxygen inhalation, 
intravenous fluids. Antithyroid drug of choice is prophylthiouracil but carbimazole can also 
be used. Prophylthiouracil 600 mg is given as loading dose by mouth or nasogastric tube or 
per rectum followed by 200-300 mg every 6-8 hourly. One hour after the first dose of 
propylthiouracil, stable iodide is given in the form of SSKI (3 drops twice daily) or Lugol's 
iodine (10 drops twice daily). Propranolol should also be given in a dose of 40-80 mg orally 
every 6 hours or 2 mg intravenously every 4 hours. If β blockers are contraindicated, 
calcium channel blockers like diltiazem can be used to control tachycardia. Large dose of 
dexamethasone (8 mg) by oral or intravenous route should be given to block the release of 
hormone from gland and peripheral conversion of T4 to T3.  
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1. Introduction 
Subclinical hypothyroidism (sHT) is defined as serum thyrotropin-stimulating hormone 
(TSH) concentration above the statistically defined upper limit of the reference range in the 
face of serum free T4 (FT4) and free T3 (FT3) concentrations within the normal range (Ross, 
2004). sHT is a frequent condition among the general population, especially middle-aged 
and elderly women (Canaris et al., 2000). Depending on the degree of TSH elevation, sHT 
has been associated with hyperlipidemia, intermediary metabolism alterations, arterial 
hypertension and cardiovascular disease (CVD) as well as neuropsychiatric features, 
including cognitive impairment (Ashizawa et al., 2010; Biondi & Cooper., 2008; Cappola et 
al., 2006; Ceresini et al., 2010; Mitrou et al., 2011; Monzani et al., 2006; Rodondi et al., 2010; 
Tan et al., 2008; Tappy, 1987). Interestingly, the analysis of variation in thyroid function tests 
in healthy volunteers has shown that the physiological individual reference ranges for test 
results are narrow compared with laboratory references (Andersen et al., 2002). This finding 
suggests that a test result within laboratory reference limits is not necessarily normal for an 
individual. Giving that serum TSH responds with logarithmically amplified degree to minor 
changes in serum T4 and T3, abnormal serum TSH may indicate that T4 and T3 are not normal 
for an individual although still within the laboratory references. These data point out that 
the distinction between subclinical and overt thyroid failure (elevated serum TSH and low 
T4 and/or T3) is somewhat arbitrary. Indeed, for the same degree of thyroid function 
abnormality, the diagnosis depends to a considerable extent on the position of the patient’s 
normal set point for T4 and T3 within the laboratory reference range.  
Because sHT is mainly detected as a biochemical TSH abnormality, the definition of the TSH 
reference range represents a critical point, especially in the elderly (Baloch et al., 2003; Olsen, 
1978; Dayan et al., 2001). In the past, the upper normal limit of TSH was considered about 10 
mIU/L with the first-generation TSH RIA assay while, the current normal reference range of 
serum TSH concentration is around 0.45 to 4.5 mIU/L (Biondi & Cooper, 2008; Surks et al., 
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2004).  Considering that serum TSH concentrations in a healthy population have a skewed 
distribution with a "tail" toward higher TSH values, the use of age specific reference limits 
for TSH has been suggested (Surks et al., 2004). This is especially proper in the elderly, in 
whom normal TSH is often shifted to a higher level (Mariotti, 1995) and the clinical 
presentation may differ from that in their younger counterparts (Mohandas, 2003). These 
considerations outline how making a correct diagnosis of sHT is challenging in the elderly 
but crucial to avoid significant misclassification of patients with abnormal TSH, who may or 
may not have thyroid dysfunction and may receive unnecessary or even harmful therapy 
(Laurberg, 2011). Indeed, the clinical significance of sHT in the elderly should be ascertained 
also in relation to the physiological changes of thyroid function with ageing (Biondi & 
Cooper, 2008; Carlè, 2007; Ceresini, 2010; Helfand, 2004; Surks et al., 2004). Therefore, the 
fundamental clinical question regarding these patients is on the clinical significance of sHT 
and the actual need of hormone replacement therapy (Villar, 2007). 
2. Epidemiology  
Several population-based studies have reported that sHT is common in the general 
population, with a prevalence that increases with increasing age (Gharib et al., 2005a,b; 
Hollowell et al., 2002; Samuels, 1998; Tunbridge et al., 1977). In interpreting epidemiologic 
data, it should be taken into account that the ability to identify people with sHT varies by 
TSH assay and cut-off value, which ranged from >3 to >7 mIU/L (Kanaya et al., 2002; Rivolta 
et al., 1999). In this setting, it is noteworthy that some investigators suggest that the upper 
limit of normal for serum TSH level should be 2.5 mIU/L (Spencer et al., 1993). In support of 
this position is a higher prevalence of anti-thyroid antibodies in subjects with serum TSH 
levels >2.5 mIU/L (Vanderpump  et al., 1995). Reasoning about these considerations, it is not 
astonishing that the reported prevalence of sHT in the general population ranges widely 
from 1.3% to 21%, depending on age, gender, and iodine intake (Kanaya et al., 2002; Rivolta 
et al., 1999; Samuels, 1998; Sawin et al., 1985; Tunbridge et al., 1977; Wang et al., 1997).  
In the Wickham survey, the prevalence of sHT (TSH > 6 mIU/L) was 7.5% in women and 
2.8% in men (Wickham study). An age dependent increase in serum TSH concentrations was 
found only when women with high serum anti-thyroid antibody values were included in 
the analysis; with 17.4% prevalence of sHT in women older than 75 years (Wickham study). 
Accordingly, in a Dutch study the prevalence of sHT in a group of middle-aged women 
(mean age 55 years) was 4%, the rate rising to 7.3% 10 years later (Geul et al., 1993). The 
higher prevalence of sHT in older people was confirmed by data from the Framingham 
Study, which reported a prevalence of sHT of 8.2% in men and 16.9% in women, older than 
60 years and, the Colorado study (16% in men and 21% in women older than 74 yrs) (Sawin 
et al., 1979, Canaris et al., 2000). Overall these findings demonstrate that ageing is associated 
with an increased prevalence of positive anti-thyroid antibody titers and mild 
hypothyroidism (Mariotti et al., 1995). The prevalence of sHT varies also according to iodine 
intake; being higher in areas with elevated intake with respect to areas with low-normal or 
deficient intake (Biondi & Cooper, 2012). In this setting,  the occurrence of sHT among 
nursing home elderly residents was 4.2% in an iodine-deficient area (urinary iodine 72 
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micrograms/g creatinine), 10.4% in region of obligatory iodinated salt prophylaxis (urinary 
iodine 100 micrograms/g creatinine) and 23.9% in an abundant iodine intake area (urinary 
iodine 513 micrograms/g creatinine) (Szabolcs et al., 1997).  
Overall, these data show that sHT is a very frequent condition and raise the question of the 
opportunity for general population screening programs, although a consensus is still lacking 
on this topic (Biondi & Cooper, 2012). The above notwithstanding, screening older people 
for thyroid disorders is still suggested by some authorities, aiming at the discovery of 
previously undiagnosed cases of overt hypothyroidism and the monitoring of cases with 
subclinical dysfunction (Ladenson et al., 2000; Surks et al., 2004).  
3. Subclinical hypothyrodism: Clinical features and etiology 
Hypothyroidism is a graded phenomenon that encompasses a wide variety of clinical 
conditions from full blown myxedema to sHT, which is characterized by elevated serum 
TSH concentrations in the face of normal free thyroid hormone levels (Cooper, 2001). 
Currently, the most widely accepted interpretation of these biochemical findings is that 
increased TSH is an indication of slightly reduced peripheral thyroid hormone effect, 
leading to mild hypothyroidism instead of a new steady state of euthyroidism (Karmisholt 
et al., 2011, Ross, 2004). In a consensus statement of the American Association of Clinical 
Endocrinologists, sHT was classified in two categories according to TSH level: mildly 
increased serum TSH levels (4.5–10 mIU/liter), and more severely increased serum TSH 
value (>10 mIU/liter) (Gharib et al., 2005a,b). However, this classification was not adopted in 
all clinical investigations, thus making the comparison of different trials quite difficult.  
There is scientific consensus that sHT is caused by the same etiology of overt 
hypothyroidism (Biondi & Cooper, 2008), the most frequent one being Hashimoto’s 
thyroiditis. This is an autoimmune, inflammatory disorder of the thyroid gland, whose 
prevalence increases with increasing age, being higher in women (Canaris et al., 2000; Surks 
et al., 1996). Other causes of primary hypothyroidism may result from therapies that destroy 
the thyroid tissue such as radioactive iodine treatment, external radiation therapy or partial 
thyroidectomy (Cooper, 2001). Chemotherapy also was associated to hypothyroidism in 
patients with cancer or lymphoma (Hancock et al., 2001; Kumar et al., 2004). Moreover, both 
subclinical and overt hypothyroidism could be induced by many drugs such as amiodarone, 
lithium carbonate, type I interferons, sulfonamides and several other toxic molecules 
(Basaria & Cooper, 2004; Caraccio et al., 2005). 
Patients with sHT have a different rate of progression to clinically overt hypothyroidism in 
the presence or not of autoimmunity: 2.6% each year if thyroperoxidase (TPO) antibodies are 
absent and 4.3% if they are present (Vanderpump et al., 1995). However, a significant number 
of sHT subjects do not show progression and some experiences normalization. One of the most 
predictive markers of progression to overt hypothyroidism is serum TSH level higher than 10 
mIU/L, by contrast a level less than 6 mIU/L depicts a lower likelihood of progression 
(Fatourechi, 2009).  Accordingly, a clinical study, enrolling men and women older than 55 
years with mean follow-up of 32 months, indicated that serum TSH levels normalized in 52% 
of those with serum TSH value less than 10 mIU/L (Díez & Iglesias, 2004).  
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The most common symptoms reported by sHT patients are the same although less evident 
than those observed in overt hypothyroidism: dry skin, poor memory, slow thinking, 
muscle weakness, fatigue, muscle cramp, cold intolerance, puffy eyes, constipation, and 
hoarseness (Canaris et al., 2000; Canaris et al., 1997). It is conceivable that clinical symptoms 
of hypothyroidism are related to the degree of thyroid failure, disease duration, and 
individual sensitivity to thyroid hormone deficiency (Biondi & Cooper, 2008). However, the 
presence of typical symptoms in patients with sHT remains controversial considering that 
many of them are non-specific and shared with many clinical conditions, especially in the 
elderly. Therefore, it is difficult to distinguish euthyroid subjects from sHT patients only by 
using clinical symptoms (Biondi & Cooper, 2008). Baseline data from a randomized clinical 
study confirmed a significant prevalence of hypothyroid symptoms among individuals 
with sHT (Cooper et al., 1984). Moreover, Canaris et al., (2000) reported fewer symptoms 
related to hypothyroidism in subclinical than in overt hypothyroid patients, but more 
frequently than in euthyroid controls. However, this study did not distinguish between 
treated or untreated subclinical and overt hypothyroid patients. By contrast, other cross-
sectional and case-control studies did not confirm these observations, but they were 
conducted among selected or referred populations often involving old hospitalized patients 
(Bemben et al., 1994; Zulewski et al., 1997). Age represents a confounding factor that may 
hinder the identification of symptoms of mild hypothyroidism: the typical findings of 
hypothyroidism are less common in the elderly and, if present, often either resemble or are 
attributed to chronic illnesses, drugs, depression or ageing per se (Billewitc et al., 1969; 
Samuels, 1998). Therefore, clinical signs and symptoms are poor predictors of sHT especially 
in the elderly; this fact may explain why the diagnosis of sHT, and sometime overt disease yet, 
may be delayed in older people (Biondi & Cooper, 2008).  
4. Thyroid function and ageing  
The relationship between thyroid function and ageing has been hypothesized more than one 
decade ago (Mariotti et al., 1995). Human ageing is associated with an increased prevalence 
of serum anti-thyroid antibodies and overt or mild thyroid dysfunction (Hollowell et al., 
2002; Gharib et al., 2005a,b; Samuels, 1998; Tunbridge et al., 1977). Several clinical studies 
confirmed an age-dependent decrease of thyroid function including iodine uptake and 
thyroid hormone production (Hollowell et al., 2002; Gharib et al., 2005a,b; Samuels, 1998; 
Sawin et al., 2009; Tunbridge et al., 1977). Although there is a consensus on the detrimental 
effects of overt hypothyroidism in older patients, the clinical relevance of mild to moderate 
thyroid failure remains an uncertain area (Surks et al., 2004) and, animal models indicated 
that low thyroid hormones are associated to increased life span (Ooka et al., 1983). The 
relative small number of epidemiological studies with inappropriate statistical power, and 
the lack of large prospective randomized trials directed to evaluate the therapeutic effect 
and impact on survival of hormonal therapy in mild thyroid impairment, does not allow to 
conclude whether mild thyroid impairment is a favorable phenotype or a negative clinical 
condition, especially in older people. An age-dependent thyroid dysfunction (particularly 
hypothyroidism) has been well documented in the elderly, including the oldest-old 
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population (>85 yr) (Helfand et al., 2004; Mariotti et al., 1993). An interesting study focused 
on thyroid function during physiological ageing was carried out by Mariotti et al. (1993). In 
this study thyroid status was assessed in 41 healthy centenarians and 33 healthy elderly 
subjects as compared to two control groups: 98 healthy normal adult subjects and 52 
patients with miscellaneous non-thyroidal illness. Healthy centenarians showed a lower 
prevalence of positive anti-thyroid autoantibody titer than elderly controls with a relatively 
low (7%) prevalence of sHT although the median serum FT3 level was lower than in each 
other group. Interestingly, median serum TSH level of centenarians was lower than in 
healthy elderly subjects, in whom however, was significantly lower than in young controls 
(Mariotti et al., 1993). This study did not resolve the question whether the decreased FT3 and 
TSH value observed in healthy centenarians, represents an adaptive mechanism to reduced 
metabolic homeostasis or a protective condition in ageing. At partial odds with these data, a 
population based survey and one large cross-sectional study (Atzmon et al., 2009; Surks et 
al., 2007) showed a progressive shift of the normal serum TSH range towards higher values 
from healthy young individuals up to centenarians. Overall these data seem to suggest that 
ageing is associated with a certain degree of down regulation of the hypothalamus-
pituitary-thyroid-peripheral axis, although the clinical significance of such condition is far to 
be elucidated. To this regard, Rozing et al. (2010) reported that the offspring of 
nonagenarian siblings presented a lower thyroidal sensitivity to TSH and a paradoxical 
beneficial cardiometabolic profile as compared to their partners. The authors concluded that 
the favorable role of low thyroid hormone metabolism on health and longevity, already 
observed in animal models, might be applicable to humans as well. However, the study by 
Rozing et al. (2010) enrolled a specific population in order to identify familial determinants 
of healthy longevity in nonagenarian siblings.  The results might, therefore, be affected by 
some bias and cannot be extended to the general population. On the other hand, a cross-
sectional study by Corsonello et al. (2010) carried out in 604 home-dwelling subjects born in 
Calabria (southern Italy), with ancestry in the region ascertained up to the grandparents, 
confirms a declining of serum thyroid hormone levels with ageing. Moreover, lower levels 
of FT3, FT4 and TSH were found in centenarians’ children and nieces/nephews with respect 
to age-matched controls. Indeed, the authors conclude that an age-related subtle decline of 
thyroid function (either due to a familial component or due to a reset of the thyroid function 
occurring between the sixth and the eighth decade of life) seems to be related to longevity. 
Two other studies support the hypothesis that mild hypothyroidism in elderly might be 
associated to a better survival and performance status.  In the first, Gussekloo et al. (2006) 
found lower all-cause and cardiovascular mortality in hypothyroid subjects aged more than 
85 years followed for 4 years, when compared with euthyroid individuals. In the second, 
van den Beld et al. (2005) showed that low-serum T3 (with normal rT3) concentrations were 
associated with a better survival and physical performance, while subjects with low-serum 
T3 and high rT3 concentrations (“low T3 syndrome”) did not show any survival advantage 
and had lower baseline physical activity. The authors suggested that higher serum rT3 
concentrations may result from a decreased peripheral metabolism of thyroid hormones due 
to the ageing process itself and/or disease and may reflect a catabolic state although, a 
certain degree of lower activity of the thyroid hormone axis might be beneficial during the 
aging process.  
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population based survey and one large cross-sectional study (Atzmon et al., 2009; Surks et 
al., 2007) showed a progressive shift of the normal serum TSH range towards higher values 
from healthy young individuals up to centenarians. Overall these data seem to suggest that 
ageing is associated with a certain degree of down regulation of the hypothalamus-
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All together, these findings might support the idea that mild physiologically decline of 
thyroid activity at the tissue level might have favorable effects in the oldest-old subjects. 
However, the interpretation of the predictive value of thyroid failure in old subjects has to 
be considered with caution, carefully defining the context and the criteria of analyzed 
populations. In this setting, the comparison of observational trials is not so easy and the 
different population analyzed should be taken into account. Indeed, there is not a unique 
definition of TSH limits for patient classification in the clinical studies or statistical analysis, 
and the population of published trials is very heterogeneous differing for the age of enrolled 
patients, life styles, comorbidities, treatments, ethnics etc. Although in some selected elderly 
subjects (specific ethnic population or very old subjects) (subtle) thyroid failure might be a 
beneficial factor or a longevity associated character, one of the most debated issues 
regarding the health consequences of (subclinical) hypothyroidism in the elderly is 
represented by the potential increase of ischemic heart disease (IHD) or other CVDs as well 
as cognitive impairment (Mariotti et al., 2005).  
5. Subclinical hypothyroidism and cardiovascular diseases  
5.1. Pathophysiology  
The most characteristic and common symptoms and signs, experienced by patients with 
thyroid disease, are those related to the cardiovascular (CV) system (Klein & Ojamaa, 2001). 
Both hyperthyroidism and hypothyroidism produce changes in cardiac contractility, 
myocardial oxygen consumption, cardiac output, blood pressure, and systemic vascular 
resistances (SVR) (Dillmann, 2002). Indeed, either hyper or hypothyroidism can produce 
heart arrhythmias, although it is less well recognized that hypothyroidism may predispose 
to specific dysrhythmias (Klein & Danzi., 2007). Cardiovascular signs and symptoms of 
hypothyroidism include bradycardia, mild (diastolic) hypertension, narrowed pulse 
pressure, cold intolerance, and fatigue (Klein & Ojamaa, 2001).  
Subclinical hypothyroidism might be interpreted as an intermediate alteration between 
overt dysfunction and euthyroidism, consequently, the modifications of CV system 
observed in sHT qualitatively resemble those produced by overt hypothyroidism even if 
less evident. Accordingly, several evidences indicated that there is a direct association 
between serum TSH value and CV alterations as well as blood pressure, cholesterol level 
etc. (Biondi & Cooper, 2008; Asvold et al., 2007). There are many evidences that, in major 
part of the cases of thyroid patients, cardiovascular changes are reversible when the 
underlying thyroid disorder is recognized and treated (Kahaly et al., 2005). Moreover, there 
is substantial evidence that overt hypothyroidism and also sHT, although to a lesser extent, 
may alter several of the traditional risk factors for ischemic CVD.  
The effects of thyroid hormone deficiency on the cardiovascular system have been evaluated 
from many points of view as heart diastolic and systolic dysfunction, endothelial 
dysfunction, hypertension, metabolic alterations and impaired exercise performance (Biondi 
& Cooper, 2008). To understand well the impact of sHT on CV system and the consequent 
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increased risk of cardiovascular  events, it is necessary to review the molecular effects of T3 
and T4, and the modifications that they exert in myocytes, endothelium, vascular muscle 
cells, intermediate metabolism etc. The decrease of cardiac output associated with 
hypothyroidism results, in part, from changes in cardiac gene expression, specifically 
reduced expression of the sarcoplasmic reticulum Ca2-ATPase, and increased expression of 
its inhibitor, phospholamban (Belke et al., 2007). In addition, these molecular changes 
explain the prolonged isovolumic relaxation phase of the hypothyroid myocardium and 
early reversible diastolic impairment (Klein & Danzi, 2007). Interestingly, this mechanism 
functionally resembles the progressive age related myocardium modification, in which 
increased fibrosis, myocyte hypertrophy and myocyte loss result in increased myocardial 
stiffness leading to diastolic heart failure (Biondi & Cooper, 2008). 
Triiodothyronine produces a decrease in systemic vascular resistance enhancing arteriole 
dilatation of the peripheral circulation (Klein & Ojamaa, 2001). The endothelium and smooth 
muscle cells are biological targets of action of T3 with a vasodilatation effect, also in coronary 
arteries (Ojamaa et al., 1996). As stated by Klein & Ojamaa (2001), T3 induces in vitro 
relaxation of smooth muscle cells with a non-genomic effect and independently of nitric 
oxide production (Klein & Ojamaa, 2001). Indeed, Ojamaa et al. (1996) found that the 
exposure of primary cultures vascular smooth muscle cells to T3 resulted in cellular 
relaxation within 10 min while, the exposure of primary cultures of vascular endothelial 
cells to the same hormone did not induce nitric oxide production, suggesting a direct effect 
of T3 on vascular smooth muscle cells. By contrast, Colantuoni et al. (2005) showed that in 
vivo thyroid hormone induced vasodilatation is delayed and mainly dependent to nitric 
oxide. The aim of their study was to assess the effects of topically applied T3 and T4 on the 
arterioles of hamster cheek pouch microcirculation in vivo by visualizing microvessels 
through a fluorescent microscopy technique. Topical application of both T3 and T4 
consistently induced a dose-dependent dilation of arterioles within few minutes. However, 
T3-induced dilation was countered by the inhibition of nitric oxide synthase with specific 
iNos inhibitors. These discrepancies between in vitro and in vivo findings might be related to 
differences in experimental procedures and to the fact that in vivo conditions are more 
complex than in vitro insolated cell cultures (Galli et al., 2010). The vascular action of T3 and 
T4 has been also reported to be associated with the modulation of gene expression related to 
endothelial homeostasis like angiotensin receptors (Fukuyama et al., 2003), reinforcing the 
hypothesis that thyroid hormones mainly target the vasculature. Accordingly, a cross-sectional 
study on 30728 patients without previous known thyroid diseases revealed a linear positive 
association between TSH level and systolic and diastolic blood pressure (Asvold et al., 2007). 
In this setting, Fommei et al. (2002) reported the physiological relationships between blood 
pressure and neuro-humoral modifications induced by acute hypothyroidism [levothyroxine 
(LT4) withdrawal] in normotensive subjects. During the hypothyroid state daytime arterial 
blood pressure (mainly diastolic) significantly increased along with noradrenaline and 
adrenaline levels. By contrast, plasma renin activity remained unchanged. These data, besides 
confirming the role of thyroid hormones in systemic arterial blood pressure homeostasis, 
suggest that sympathetic and adrenal reversible activation may contribute to the development 
of arterial hypertension in human hypothyroidism (Fommei et al., 2002).  
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increased risk of cardiovascular  events, it is necessary to review the molecular effects of T3 
and T4, and the modifications that they exert in myocytes, endothelium, vascular muscle 
cells, intermediate metabolism etc. The decrease of cardiac output associated with 
hypothyroidism results, in part, from changes in cardiac gene expression, specifically 
reduced expression of the sarcoplasmic reticulum Ca2-ATPase, and increased expression of 
its inhibitor, phospholamban (Belke et al., 2007). In addition, these molecular changes 
explain the prolonged isovolumic relaxation phase of the hypothyroid myocardium and 
early reversible diastolic impairment (Klein & Danzi, 2007). Interestingly, this mechanism 
functionally resembles the progressive age related myocardium modification, in which 
increased fibrosis, myocyte hypertrophy and myocyte loss result in increased myocardial 
stiffness leading to diastolic heart failure (Biondi & Cooper, 2008). 
Triiodothyronine produces a decrease in systemic vascular resistance enhancing arteriole 
dilatation of the peripheral circulation (Klein & Ojamaa, 2001). The endothelium and smooth 
muscle cells are biological targets of action of T3 with a vasodilatation effect, also in coronary 
arteries (Ojamaa et al., 1996). As stated by Klein & Ojamaa (2001), T3 induces in vitro 
relaxation of smooth muscle cells with a non-genomic effect and independently of nitric 
oxide production (Klein & Ojamaa, 2001). Indeed, Ojamaa et al. (1996) found that the 
exposure of primary cultures vascular smooth muscle cells to T3 resulted in cellular 
relaxation within 10 min while, the exposure of primary cultures of vascular endothelial 
cells to the same hormone did not induce nitric oxide production, suggesting a direct effect 
of T3 on vascular smooth muscle cells. By contrast, Colantuoni et al. (2005) showed that in 
vivo thyroid hormone induced vasodilatation is delayed and mainly dependent to nitric 
oxide. The aim of their study was to assess the effects of topically applied T3 and T4 on the 
arterioles of hamster cheek pouch microcirculation in vivo by visualizing microvessels 
through a fluorescent microscopy technique. Topical application of both T3 and T4 
consistently induced a dose-dependent dilation of arterioles within few minutes. However, 
T3-induced dilation was countered by the inhibition of nitric oxide synthase with specific 
iNos inhibitors. These discrepancies between in vitro and in vivo findings might be related to 
differences in experimental procedures and to the fact that in vivo conditions are more 
complex than in vitro insolated cell cultures (Galli et al., 2010). The vascular action of T3 and 
T4 has been also reported to be associated with the modulation of gene expression related to 
endothelial homeostasis like angiotensin receptors (Fukuyama et al., 2003), reinforcing the 
hypothesis that thyroid hormones mainly target the vasculature. Accordingly, a cross-sectional 
study on 30728 patients without previous known thyroid diseases revealed a linear positive 
association between TSH level and systolic and diastolic blood pressure (Asvold et al., 2007). 
In this setting, Fommei et al. (2002) reported the physiological relationships between blood 
pressure and neuro-humoral modifications induced by acute hypothyroidism [levothyroxine 
(LT4) withdrawal] in normotensive subjects. During the hypothyroid state daytime arterial 
blood pressure (mainly diastolic) significantly increased along with noradrenaline and 
adrenaline levels. By contrast, plasma renin activity remained unchanged. These data, besides 
confirming the role of thyroid hormones in systemic arterial blood pressure homeostasis, 
suggest that sympathetic and adrenal reversible activation may contribute to the development 
of arterial hypertension in human hypothyroidism (Fommei et al., 2002).  
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Arterial hypertension related to thyroid hormone deficiency may result in aortic stiffness 
and early atherosclerosis. In this setting, aortic stiffness was studied in 30 patients who 
never received treatment for hypertension or hypothyroidism, 15 patients with normal 
blood pressure and hypothyroidism, and 15 patients with hypertension and normal thyroid 
function. Aortic diameter, evaluated by M-mode echocardiography and blood pressure 
measured by sphygmomanometer, were assessed to calculate the aortic stiffness index. 
Patients with hypertension and hypothyroidism have increased aortic stiffness, which was 
decreased in all patients by hormone replacement therapy, although hypertension resulted 
completely reversible in 50% of the patients (Dernellis et al., 2002).  In addition, it has been 
hypothesized that thyroid hormone deficiency might be related to endothelial dysfunction. 
In this area, Lekakis et al. (1997) enrolled 35 subjects with various serum TSH levels to assess 
endothelial and smooth muscle responses of the brachial artery by high-resolution 
ultrasound imaging. Results of this study showed that flow-mediated, endothelium-
dependent (FMD) vasodilatation progressively impaired with increasing serum TSH value; 
the phenomenon appearing still in patients with TSH value within the normal reference 
range (2.01-4.00 microIU/mL) (Lekakis et al., 1997). Furthermore, in order to assess vascular 
reactivity and NO availability in patients with sHT and its relation to the serum lipid 
profile, Taddei et al. (2003) evaluated, by strain-gauge plethysmography, the forearm blood 
flow response to intrabrachial acetylcoline, an endothelium-dependent vasodilator, at 
baseline and during infusion of the eNO synthase inhibitor Ng-monomethyl-L-arginine (L-
NMMA). Results from sHT patients were compared with two groups of euthyroid control 
subjects, one with normal lipid profile and one with mildly elevated serum TC levels, 
comparable to those of sHT patients. They found that vasodilation in response to 
acetylcholine of patients affected by sHT was reduced as compared to that of both groups of 
euthyroid control subjects. Similarly, L-NMMA blunted the vasodilation in response to 
acetylcholine either in normolipemic or in mildly hypercholesterolemic controls, whereas it 
was ineffective in sHT patients, thus suggesting a reduced NO availability due to impaired 
NO synthase induced by sHT per se. Interestingly, six months of euthyroidism induced by 
LT4 replacement increased acetylcholine vasodilation and restored L-NMMA inhibition. 
Subsequently, the same group (Taddei et al. 2006) demonstrated that endothelial 
dysfunction of a cohort of sHT patients with autoimmune thyroiditis was, at least partially, 
related to oxidative stress and low-grade systemic inflammation. Indeed, sHT patients had 
higher plasma C-reactive protein (CRP) levels as compared to euthyroid controls, and 
endothelium dysfunction was significantly improved after either local infusion of vitamin C 
or systemic administration of indomethacin, a non-selective cyclo-oxygenase (COX) 
inhibitor. Comparable results were obtained after administration of celecoxib, a selective 
COX-2 inhibitor, thus suggesting that an association between thyroid function and low-
grade systemic inflammation could be postulated. Accordingly, several studies (Kvetny et 
al., 2004; Luboshitzky et al., 2004; Christ-crain et al., 2003; Lee et al., 2004) investigated the 
possible relationship between TH deficiency and serum CRP level, that was mostly found 
higher in hypothyroid patients, although unaffected by LT4 therapy (Christ-crain, 2003).    
Another concurring factor for developing early atherosclerosis in hypothyroidism is 
represented by the metabolic alterations induced by hormone deficiency. Hypothyroidism is 
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characterized by hypercholesterolaemia with elevation of low-density lipoprotein 
cholesterol (LDLc) levels because of decreased fractional clearance of LDLc by a reduced 
number of the receptors in the liver (Duntas et al., 2002; Staub et al., 1992). Early studies in 
hypothyroid humans, using isotopically labeled LDLc, demonstrated a prolonged half-life 
of LDLc due to a decreased catabolism; this effect was reversible with LT4 therapy (Walton 
et al., 1965). Accordingly, the addition of T3 to human fibroblast cultures induced a higher 
LDLc degradation, through an increase in LDLc receptor number, without any receptor 
affinity change (Chait et al., 1979). Molecular mapping has revealed functional thyroid 
response elements in the promoter region of the LDLc receptor. Indeed, specific stimulation by 
T3 of a chimeric gene resulting from the LDLc receptor promoter linked to a reporter gene, 
cotransfected with the isoform of the thyroid hormone receptor into a hepatic cell line, has 
been reported (Bakker et al., 2001). Moreover, the deletion of the upstream thyroid response 
elements in the LDLc receptor promoter inhibited T3-mediated reporter gene activity (Cappola 
et al., 2003). Although the relationship between thyroid function and altered lipid profile is 
well documented in overt hypothyroidism it is still controversial in sHT (Biondi & Cooper, 
2012). The conflicting results about lipid profile and sHT might reflect differences in study 
design as well as in age, gender, and ethnicity of the study cohorts (Palmieri et al., 2002).  
Various changes in the coagulation-fibrinolytic system have been described in patients with 
thyroid dysfunction although, data regarding the association between thyroid failure and 
modifications of the coagulation-fibrinolytic system are still controversial (Chadarevian et 
al., 2001; Canturk et al., 2003; Muller et al., 2001). The influence of thyroid hormone on the 
coagulation fibrinolytic system is mainly mediated by the interaction between the hormone 
and its receptors (Shih et al., 2004). Various abnormalities have been described, ranging 
from subclinical laboratory abnormalities to major hemorrhages or fatal thromboembolic 
events (Squizzato et al. 2007). The relationship between thyroid hormones and the 
coagulation system is, however, often ignored. One of the reasons could be that, although 
several in vivo abnormalities have been reported in patients with hypothyroidism and 
hyperthyroidism, most published studies focus on laboratory measurements, and good 
studies on the relationship between thyroid dysfunction and clinically manifest bleeding or 
thrombosis are lacking. However, most studies confirm that both overt hyper- and 
hypothyroidism modify the coagulation-fibrinolytic balance. Thyroid hormone excess or 
deficit is the probable main pathophysiological mechanism and, patients with overt hypo- 
and hyperthyroidism appear to have an increased risk of bleeding and of thrombosis, 
respectively (Squizzato et al. 2007). 
Overall, these findings support a biologically plausible role for hypothyroidism in 
increasing the risk of atherosclerotic CV disease, via the increase in circulating levels of 
LDLc, systemic (diastolic) hypertension, diastolic dysfunction and heart failure as well as an 
imbalance of the coagulation system and direct effects on vascular smooth muscle (Cappola 
et al., 2003). However, the actual relationship between sHT and increased cardiovascular 
risk is still unresolved and represents one of the most common topics in endocrinology, 
leading to several controversies concerning the clinical management of sHT patients 
(Turemen et al., 2011). 
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Various changes in the coagulation-fibrinolytic system have been described in patients with 
thyroid dysfunction although, data regarding the association between thyroid failure and 
modifications of the coagulation-fibrinolytic system are still controversial (Chadarevian et 
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increasing the risk of atherosclerotic CV disease, via the increase in circulating levels of 
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5.2. Clinical evidences   
As above described, thyroid hormone deficiency is associated to several cardiovascular and 
metabolic abnormalities (Biondi & Cooper, 2008; Caraccio et al., 2003; Dardano & Monzani, 
2008). Indeed, thyroid failure may favour the onset of several CV risks like diastolic 
hypertension, hyperlipidemia, vascular stiffness, heart failure etc. However, although the 
relationship between overt hypothyroidism and coronary heart disease (CHD) as well as 
increased CHD mortality is widely recognized (Klein, 2004), the clinical significance of sHT 
is still controversial and conflicting opinions remain on the association between sHT and 
CVD or mortality, especially in older people (Biondi & Cooper, 2008; Monzani et al., 2006). 
Indeed, data regarding the association between sHT and CHD or total mortality are 
contradictory among various population based, observational studies (Aho et al., 1984; 
Cappola et al., 2004; Hak et al., 2000; Walsh et al., 2005).  
One of the first large study (Whickham Survey) that evaluated vascular events over 20 years 
in community-dwelling subjects stratified by thyroid function and thyroid autoantibody 
status did not show any association between CHD and sHT (Vanderpump et al., 1995). This 
result appeared at odds with the findings of other subsequent cohort studies (Hak et al., 
2000; Imaizumi et al., 2004; Walsh et al., 2005). However, while reanalyzing incident CHD 
events and mortality in Whickham participants including LT4 replacement during follow-up 
as covariate, a significant increment of incident CHD events and mortality was found in 
individuals with baseline sHT (Razvi et al., 2010). Based on the results of this analysis, it 
would appear that treatment of sHT might be associated with reduced mortality as well as 
CHD events. However, besides the small total number of events in each group of sHT 
participants, there is a potential for bias in this retrospective observational analysis (i.e. sHT 
patients who were treated may have been more health conscious leading to a healthy user 
bias). Therefore, these results need to be interpreted with caution until a large prospective, 
randomized controlled trial will be available. The inconsistency in results among several 
studies (Aho et al., 1984; Hak et al., 2000; Cappola et al., 2004; Razvi et al., 2010; Walsh et al., 
2005) may be due to differences in the enrolled populations as well as the duration either of 
tissues exposure to sHT or of follow-up of the various studies. Nonetheless, meta-analyses 
of CHD events and sHT have shown that such an association probably exists (Razvi et al., 
2008; Rodondi et al., 2006), especially in younger cohorts. In this regard, to assess the risks of 
CHD and total mortality for adults with sHT, Rodondi et al. (2010) carried out a large meta-
analysis on 11 prospective cohorts, enrolling a total of 55,287 participants. The risk of CHD 
events was examined in 25,977 participants from 7 cohorts with available data. Among 
55,287 adults, 3450 had sHT (6.2%) and 51,837 were euthyroid. The Authors found that the 
risk of CHD events and mortality increased with higher TSH concentrations. Results were 
similar after adjustment for traditional cardiovascular risk factors. Moreover, this pooled 
analysis showed a higher rate of CHD events in sHT patients with higher TSH levels (>10 
mIU/L). These data are consistent with most previous meta-analysis and several naturalistic 
studies, showing an increased risk of CHD events associated with sHT (Hak et al., 2000; 
Singh et al., 2007; Walsh et al., 2005).  
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These studies, however, did not accurately explore potential differences related to 
participant characteristics like age, even if older people represented large a share of the 
population. In this setting, the pooled analysis of large cohort of patients may be affected by 
hypothetical bias and may not investigate specific classes of patients like very old people 
versus moderate elderly patients or other specific conditions affecting the clinical outcome. 
Ochs et al. (2008) analysed in a meta-analysis the effect of ageing on sHT associated CV 
events and total mortality. Similar to previous meta-analysis, they found a pattern of 
modestly increased risk for CHD and mortality associated with sHT. A weak evidence for 
statistical heterogeneity among individual study findings was found, and age explained part 
of the heterogeneity for the association between sHT and CHD, with an increased risk for 
CHD only in cohorts with a younger mean age. Accordingly, Cappola et al. (2006), in a large 
population-based, longitudinal study of coronary heart disease and stroke in adults aged 65 
years and older, concluded that the results did not support the hypothesis of an association 
between unrecognized sHT and increased CV events or mortality. On the other hand, one 
cross-sectional study with subgroup analyses by age found that increased risk for CHD was 
present in younger sHT participants only (<50 years old) (Kvetny et al. 2004). In this regard, 
a prospective, observational, population-based follow-up study carried out on 599 
participants followed up from age 85 years through age 89 years showed no association 
between serum TSH and FT4 levels and disability in daily life, depressive symptoms, and 
cognitive impairment at baseline or during follow-up. Moreover, increasing serum TSH 
levels were associated with a lower mortality rate that remained after adjustments for 
baseline disability and health status (Gusseklo et al. 2004). Overall, these data support the 
hypothesis that in the oldest old population, individuals with abnormally high levels of TSH 
do not experience adverse effects and may have a prolonged life span. The study focused on a 
specific class of patients (very older people), for this reason, the results should be rigorously 
interpreted, also considering the weakness of observational studies. However, these data 
together with the results obtained by Rozing et al., (2010) that demonstrated a possible genetic 
predisposition of nonagenarians to a decrease function of hypothalamus-pituitary-thyroid 
axis, suggest that the oldest old may represent a different population respect to moderate old 
people or young adults. Potential explanations for these age differences might be competing 
mortality among older adults (for example, due to cancer) or more competing risk factors for 
CHD among older adults (for example, age or sex). However, the above reported substantial 
age differences should be interpreted with caution, given the possibility of ecological fallacy 
without individual patient data and, should be confirmed by stratified analyses in future 
prospective cohort studies with a wide age range (Egger et al., 2001).  
There are few clinical studies evaluating the effects of hormone replacement in sHT subjects 
and none aimed to determine the impact of therapy on total mortality especially in older 
people. Previous research in this area has shown contradictory results, with some 
randomized, controlled trials (number of patients ranging from 45 to 63) showing an 
improvement in the atherogenic lipid profile as well as surrogate endpoints of 
atherosclerosis (Meier et al., 2001; Caraccio et al., 2002; Monzani et al., 2004) but others 
(number of patients ranging from 17 to 35) showing no difference (Cooper et al., 1984; 
Jaeschke et al., 1996; Kong et al., 2002; Nystrom et al., 1988). Recently, Razvi et al. (2007) 
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5.2. Clinical evidences   
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studies, showing an increased risk of CHD events associated with sHT (Hak et al., 2000; 
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without individual patient data and, should be confirmed by stratified analyses in future 
prospective cohort studies with a wide age range (Egger et al., 2001).  
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and none aimed to determine the impact of therapy on total mortality especially in older 
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conducted a randomized, double-blind, crossover study to determine the short-term (12 
weeks) effect of LT4 replacement therapy in 100 sHT patients (age range 18-80 yrs, mean 
53.8) with serum TSH level>4.0 mIU/L. Primary end points included: serum cholesterol level 
variations along with improvement in flow-mediated dilation (FMD) as a marker of 
vascular endothelial function. LT4 treatment significantly reduced either TC or LDLc 
concentrations, and improved FMD, as compared to placebo group. Moreover, multivariate 
analysis showed that increased serum FT4 level was the most significant variable predicting 
reduction in TC or FMD improvement. The Authors hypothesized that if the reduction of 
LDLc level would be long term sustained, this would result in a relative reduction in 10-yr CV 
mortality of about 10%, thus supporting the use of LT4 replacement therapy also in patients 
with slightly elevated TSH value. Long-term studies are nonetheless required to confirm 
whether these apparent short-term benefits will translate into reduction in CV mortality and 
morbidity. Moreover, notwithstanding the wide age range of the studied patients, these results 
cannot directly transfer to the elderly, especially the oldest old population. 
In summary, conflicting results among large prospective cohort studies regarding the 
relationship between sHT and cardiovascular disease might reflect differences in 
participants such as age, gender, TSH value, or pre-existing cardiovascular disease. 
However, as demonstrated by some meta-analyses, the negative effect of sHT on 
cardiovascular risk is well established in younger people while in moderately old 
population (>65 and <85 years) it appears no longer evident.  Moreover, in the oldest old 
people (>85 years) one study suggested that high levels of TSH not only do not exert adverse 
effects but also may favor a prolonged life span (Fig. 1). In this regard, elderly population 
can be interpreted as a heterogeneous group, nonagenarians representing a genetically 
selected cluster. Indeed, these subjects may have a genetic background that protects from 
CVD and/or thyroid hormone deficiency, thus suggesting an intriguing link between gene, 
thyroid status and longevity. 
6. Thyroid function and cognitive impairment   
Thyroid hormones are crucial for brain development and function: thyroid failure at any age 
causes cognition to deteriorate because thyroid hormones are essential for adequately 
sustaining the energy (glucose)-consuming processes needed for neurotransmission, 
memory, and other higher brain functions (Herholz, 2010; Patel et al., 2011). Low brain 
uptake of glucose is commonly associated with deteriorating cognition and Alzheimer’s 
disease and can be present decades before clinical evidence of Alzheimer’s disease occurs 
(Herholz, 2010). Brain hypometabolism therefore appears to be a precursor lesion increasing 
the risk of at least some forms of cognitive decline. Elevated TSH levels in the range found 
in patients with overt hypothyroidism have been described to be associated with impaired 
function in many cognitive domains, but the association between sHT and cognition is less 
clear (Graham et al., 1997; Gardner, 2004; Chavanne et al., 2011). On the other hand, several 
cross-sectional studies have observed that high or low TSH levels, still within the normal 
range (clinically euthyroid), are each related to poor cognitive performance, although some 
other investigations failed to demonstrate these findings (Prinz et al., 1999; Volpato et al., 
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2002). It should be underlined, however, that different cognitive deficits possibly related to 
thyroid failure do not necessarily follow a consistent pattern, and LT4 treatment may not 
always completely restore normal functioning in patients with hypothyroidism. Giving 
these premises, we summarize here the growing, conflicting literature on the relationship 
between cognitive performance and thyroid function from an ageing perspective.  
 
Figure 1. Hypothetical relationship between risk of total mortality and age in patients with subclinical 
hypothyroidism (sHT) (Modified from Mariotti, 2005). 
Subclinical hypothyroidism and cognitive function have been investigated in several 
preclinical experiments and clinical trials. To date, the actual relationship between mild 
thyroid hormone deficiency and cognitive impairment in the elderly is not well understood. 
In fact, there are several contrasting data resulting from cross-sectional and clinical 
experiments (Gussekloo et al., 2004; Roberts et al., 2006; Tan et al., 2008; Ceresini et al., 2009). 
Moreover, the available published data, in many cases, are not easily comparable 
considering the differences in inclusion criteria of each clinical study. Several small 
observational and interventional studies have reported an association, although not 
homogeneously, between cognitive impairment and sHT and, in some cases, it was 
described a cognitive performance improvement after LT4 replacement (Etgen et al., 2011; 
Monzani et al., 1993; Osterweil et al., 1992; St. John et al., 2009; Volpato et al., 2002). 
Moreover, Hogervost et al. (2008) studied the association between TSH and FT4 levels and 
cognition at baseline and after 2 years of follow-up in 1047 participants over 64 years of age, 
without physical frailty or severe cognitive impairment. The study showed that elevated 
TSH levels were associated with lower MMSE performance at baseline, independently of 
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FT4 value, age, sex, education and mood. Interestingly, epidemiological surveys using the 
revised Wechsler Adult Intelligence Scale (WAIS-R) and the Mini-Mental State Examination 
(MMSE) showed a relationship between plasma thyroid hormone levels and cognitive status 
in subjects with thyroid function still within the upper limit of the normal range (Prinz et al., 
1999; Volpato et al., 2002). Accordingly, altered plasma thyroid hormone concentrations 
have been recognized as a risk factor for cognitive impairment or dementia (Bulens, 1981; 
Kalmijn et al., 2000; Tan et al., 2008). More specifically, with the increasing sensitivity of 
neuropsychological tools, it has become evident that thyroid hormone deficiency might 
produce measurable deficits in very specific neuropsychological functions (Zoeller & Rovet 
2004). In this regard, in a recent prospective, open-labeled interventional study, cognitive 
impairment associated with (mild) thyroid failure appeared predominantly mnemonic in 
nature, suggesting that the etiology is not indicative of general cognitive slowing (Correia et 
al., 2009). 
Conflicting data were obtained by large, population-based studies, leading to uncertain 
conclusions regarding the association between (mild) thyroid failure and cognition 
(Gussekloo et al., 2004; Roberts et al., 2006; Tan et al., 2008; Ceresini et al., 2009). In this 
setting, one critical point that could affect the results of these studies is the diverse age 
groups of the enrolled patients (moderate or very old) as well as the presence of 
comorbidity. Cognitive impairment observed in older sHT individuals might be also an 
epiphenomenon of the increased risk for atherosclerosis or the effect of thyroid hormone on 
vasculature. Indeed, arterial stiffness is a potential mechanism of advancing cognitive 
decline in sHT (Yamamoto et al., 2012) and elevated TSH values might negatively affect 
vascular function through systemic low-grade inflammation (Taddei et al., 2006). Moreover, 
whereas in moderate older people sHT might produce a detrimental effect on cognitive 
performance, in very old individuals (mild) thyroid failure might be not associated to a 
negative outcome (Gussekloo et al., 2004; Tan et al., 2008). To determine whether subclinical 
thyroid dysfunction should be treated in old age and the long-term impact of thyroid 
dysfunction on performance and survival in the elderly, a prospective, observational, 
population-based survey was carried out within the Leiden 85-Plus Study. A total of 599 
participants were followed up from age 85 years through age 89 years. Plasma levels of TSH 
and FT4 were not associated with disability in daily life, depressive symptoms, and cognitive 
impairment at baseline or during follow-up. Conversely, increasing levels of TSH were 
associated with a lower mortality rate that remained after adjustments were made for 
baseline disability and health status (Gussekloo et al., 2004). It is noteworthy, however, that 
similarly to CHD risk, these results should be confirmed by stratified analyses in future 
prospective large cohort studies with a wide age range.  
Another important aspect is the possible relationship between sHT and the risk to develop 
Alzheimer disease (AD). On this basis, many studies investigated a possible association 
between AD and thyroid dysfunction. Increasing evidence supports an extensive 
interrelationship between thyroid hormones and the cholinergic system, which is selectively 
and early affected in AD. Thyroid hormones negatively regulate expression of the amyloid-
beta protein precursor, which plays a key role in the development of AD (Belakavadi et al., 
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2011). In a study aimed to examine the feasibility of using thyroid hormone as a therapeutic 
agent for AD, mice were injected intra-hippocampally with aggregated amyloid beta-
peptide (Abeta) to produce AD animal model. Intraperitoneal administration of LT4 into 
Abeta-induced AD model mice prevented their cognitive impairment and improved their 
memory function. The authors suggested that the mechanisms of LT4 treating AD might be 
associated with regulating cholinergic function, protecting the brains of AD model mice 
against damage and rescuing hippocampal neurons from apoptosis. The results of this study 
seem indicate that the use of thyroid hormone may have some therapeutic potential in AD 
(Fu et al., 2010).  Accordingly, in a post mortem study it was evaluated the brain thyroid 
hormone levels in AD measured with radioimmunoassay (RIA) samples of prefrontal cortex 
of patients with pathologically confirmed AD and controls without any primary 
neurological disease. Thyroxine levels did not differ between groups while T3 levels were 
significantly lower in Alzheimer’s brains respect to controls. These results suggest that the 
conversion of T4 to T3 may be altered in advanced AD, perhaps due to modifications in 
deiodinase activity, and the reduced hormone conversion might be associated with both AD 
pathology and the clinical presentation of dementia (Davis et al., 2008). Moreover, Tan et al. 
(2008) related serum TSH concentrations to the risk of Alzheimer disease in 1864 cognitively 
intact, euthyroid participants of the Framingham original cohort (mean age 71 years). 
During a mean follow-up of 12.7 years, 209 participants (142 women) developed AD. 
Women in the lowest (<1.0 mIU/L) and highest (>2.1 mIU/L) tertiles of serum TSH 
concentration were at increased risk for AD compared with those in the middle tertile while, 
TSH levels were not related to AD risk in men. On the other hand, at odds with these 
findings, the InChianti study showed an association between subclinical hyperthyroidism 
and cognitive impairment without any correlation with mild thyroid failure in a large cohort 
of older people (Ceresini et al., 2009).  
In conclusion, a certain degree of cognitive (mnemonic) impairment is generally recognized 
in case of overt hypothyroidism while, the relationship between cognition and sHT is still a 
disputed field, and it remains unclear whether to treat or not this kind of patients. In 
particular, there is little or no consensus in the literature whether thyroid failure is 
associated with impaired cognitive performance in the elderly, especially in the oldest old 
population. While interpreting the above reported conflicting results it should be outlined, 
however, that thyroid hormone concentrations change with age and cognitive decline is 
often concomitant with ageing; therefore, a reciprocal relationship could exist between 
changes of thyroid function and cognitive decline during normal ageing. 
7. Conclusions 
Levothyroxine replacement therapy for reducing sHT associated CV risk factors is still 
controversial, especially in the elderly. The lack of specific randomized trials, enrolling 
either old or very old subjects, aimed to evaluate the efficacy of hormonal replacement on 
overall survival and cardiovascular risk reduction as well as the possible negative effects of 
LT4 supplementation, makes the decision to treat elderly people very difficult. Generally, 
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participants were followed up from age 85 years through age 89 years. Plasma levels of TSH 
and FT4 were not associated with disability in daily life, depressive symptoms, and cognitive 
impairment at baseline or during follow-up. Conversely, increasing levels of TSH were 
associated with a lower mortality rate that remained after adjustments were made for 
baseline disability and health status (Gussekloo et al., 2004). It is noteworthy, however, that 
similarly to CHD risk, these results should be confirmed by stratified analyses in future 
prospective large cohort studies with a wide age range.  
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2011). In a study aimed to examine the feasibility of using thyroid hormone as a therapeutic 
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In conclusion, a certain degree of cognitive (mnemonic) impairment is generally recognized 
in case of overt hypothyroidism while, the relationship between cognition and sHT is still a 
disputed field, and it remains unclear whether to treat or not this kind of patients. In 
particular, there is little or no consensus in the literature whether thyroid failure is 
associated with impaired cognitive performance in the elderly, especially in the oldest old 
population. While interpreting the above reported conflicting results it should be outlined, 
however, that thyroid hormone concentrations change with age and cognitive decline is 
often concomitant with ageing; therefore, a reciprocal relationship could exist between 
changes of thyroid function and cognitive decline during normal ageing. 
7. Conclusions 
Levothyroxine replacement therapy for reducing sHT associated CV risk factors is still 
controversial, especially in the elderly. The lack of specific randomized trials, enrolling 
either old or very old subjects, aimed to evaluate the efficacy of hormonal replacement on 
overall survival and cardiovascular risk reduction as well as the possible negative effects of 
LT4 supplementation, makes the decision to treat elderly people very difficult. Generally, 
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LT4 replacement therapy should be considered for three main reasons: i) to prevent 
progression of sHT to overt hypothyroidism which, however, is much more important in 
young patients; ii) to reduce the symptoms associated with mild thyroid failure, which are 
especially scarce in the elderly; iii) to improve the lipid profile and other risk factors that 
may contribute to atherosclerosis progression and CV events.  
Subclinical thyroid failure causes changes in cardiac function similar to, but less marked 
than, those occurring in patients with overt hypothyroidism. Diastolic dysfunction both at 
rest and upon effort is the most consistent cardiac abnormality in patients with sHT, even in 
those with slightly elevated TSH levels (>6 mIU/L) (Arem et al., 1996; Biondi & Cooper, 
2012;). Mild thyroid failure may also increase diastolic blood pressure as a result of 
increased systemic vascular resistances (Faber et al., 2002; Kahaly, 2000; Luboshitzky et al., 
2002). Interestingly, restoration of euthyroidism by LT4 replacement is able to reduce 
systemic hypertension as well as improve left ventricular myocardial function (Brenta et al., 
2003). Moreover, sHT has been claimed to be a risk factor for atherosclerosis and ischemic 
CVD, therefore, it is appropriate to consider whether treatment confers some protection 
from such a risk. Although a consensus is still lacking, the strongest evidence for a beneficial 
effect of levothyroxine replacement therapy is the substantial demonstration that restoration 
of euthyroidism can lower TC and LDLc levels in most patients with sHT. Besides 
hypercholesterolemia several emerging risk factors for CHD have been claimed to be 
associated with sHT. Among them, altered coagulation parameters, endothelial dysfunction, 
and elevated CRP levels are consistently regarded to combine with the raised LDLc levels of 
untreated patients with sHT to enhance the cardiovascular risk.  
As a whole, these findings suggest that the decision to treat patients with sHT should 
depend on the presence of risk factors, rather than on a TSH threshold. International 
organizations and guidelines suggest starting replacement therapy in patients who have 
TSH concentrations greater than 10 mIU/liter and in those with evidence of autoimmunity, 
and in symptomatic patients with TSH levels between 4.5 and 10 mIU/L (Gharib et al., 
2005a,b; Surks et al., 2004). However, the treatment of sHT patients, especially the elderly, 
must be individualized once any underlying coexisting morbidity or pharmacologic 
interference has been excluded. Generally LT4 replacement results effective and safe in 
young patients, providing that excessive dosing is avoided by monitoring serum TSH level. 
Indeed, LT4 replacement therapy can always be discontinued if there is no apparent benefit. 
It is noteworthy that, once a stable, elevated TSH value is detected, the costs of annual 
follow-up with clinical assessment and laboratory testing are relatively similar whether or 
not a patient is treated with LT4 (Cooper et al., 2001). On the other hand, the possibility that 
restoring euthyroidism may be harmful in the older population has been raised, and should 
be taken into account in making the decision of treating such patients, especially those older 
than 85 years. In this setting, hormonal replacement might be considered in old patients on 
the base of a specific evaluation of the possible thyroid dysfunction causes, pre-existent 
cardiovascular risk including cholesterol level, hearth failure as well as the presence of 
comorbidities or frailty and the level of TSH. However, until adequate data are 
accumulated, clinicians should consider each patient a unique situation, and best clinical 
practice continues to be a combination of clinical judgment and the patient’s preference. 
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1. Introduction 
The primary function of adipose tissue is storing energy in triacylglycerol (TG) form, 
neutralizing the excess of circulating lipids and saving non-adipose tissues of a fat 
overload. Under normal conditions, in the postprandial state, there is lipogenic endocrine 
system stimulation, allowing that positive energy balance can be stored as TG in adipose 
tissue, a process called lipogenesis. In contrast, the mobilization of fat in adipocytes 
occurs through the hydrolysis of TG by hormone sensitive lipase (HSL), a phenomenon 
called lipolysis. At the center of this interface - lipolysis and lipogenesis - is the insulin 
hormone, which exerts a potent inhibitory role on the HSL, allowing lower rates of 
lipolysis and hence, highest fat mass [1]. However, adipose tissue is not only a passive 
stock organ of triacylglycerol, being currently recognized as an endocrine organ with 
multiple functions [1, 2]. Produces several biologically active substances called 
adipokines, among them tumor necrosis factor- (TNF-), monocyte chemoattractant 
protein 1 (MCP-1), interleukin-6 (IL-6), leptin, resistin and adiponectin. These substances 
actively participate in, among others, body energy regulation, mainly, by endocrine, 
paracrine and autocrine signals, which allow the adipocyte play a metabolic role in other 
tissues [3-5].  
However, in obesity there is an imbalance in adipokines production, a fact which, together 
with the inability to store fat in the adipocytes, results in a process of adipose tissue 
dysfunction [6], a known risk factor for developing obesity-associated metabolic disorders 
[1, 2, 6]. This fact occurs because the adipocytes (hypertrophic and hyperactive) initiates the 
production of adipokines and chemotactic factors (such as MCP-1), which attract 
macrophages into the adipose tissue [7]. Consequently there is a synergistic interaction on 
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proinflammatory adipokines production - mainly TNF-α - and antagonistic on adiponectin. 
These substances lead to insulin resistance, reducing the lipogenic action of insulin in 
adipocytes, which results in higher rates of lipolysis in the adipose tissue [8, 9]. On the other 
hand, calorie restriction affects the regulation of adipose tissue gene expression, normalizing 
the adipokines changes observed in obesity [10]. 
 
Figure 1. Adapted from van Kruijsdijk et al, 2009 [6]. In obesity the hypertrophic and hyperactive 
adipocytes initiate the production of MCP-1, which attract macrophages into the adipose tissue, 
increasing proinflammatory adipokines production (mainly TNF-α) and decreasing adiponectin 
production, leading to insulin resistance and inflammation. The weight loss process revert this 
alterations, improving insulin resistance and inflammation. FFA: fatty free acids; PAI1: Plasminogen 
activator inhibitor 1; TNFα: tumor necrosis factor-α; MCP1: monocyte chemoattractant protein 1; IL6: 
interleukin 6. 
In this chapter will be revised about the influence of thyroid hormones on adipokines in 
obesity and weight loss. Also will be discussed the physiological role of adipokines as well 
as the effect of obesity and weight loss on the adipokines. 
2. Adipokines physiological role  
The adipose tissue is considered an endocrine organ and shows great dynamism. Since 1940 
there is a hypothesis that adipose tissue has signals to communicate with other tissues [11], 
but only later was shown that this tissue is able to synthesize and secrete a large number of 
protein factors (which also act as cytokines) collectively called adipokines. These 
adipokines, in most part, are related, directly or indirectly, in processes involving 
atherosclerosis, hypertension, insulin resistance (IR) and type 2 diabetes (DM2), 
dyslipidemia, ie, represent the link between adiposity, metabolic syndrome and 
cardiovascular diseases [12-15]. Among these is Leptin, Resistin, Adiponectin, and others 
such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), plasminogen activator 
inhibitor-1 (PAI-1), acylation stimulating protein (ASP) and factors involved in the renin-
angiotensin system (RAS). 
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2.1. Leptin 
With its gene identified in 1994 [16] leptin is the adipokine most studied and thenceforth it 
has been identified more than 30 biochemical products secreted by adipocytes. Leptin is a 
peptidic hormone with 167 amino acids and 16kDa of molecular weight and synthesized 
from the “ob” gene in adipocytes, being more common in subcutaneous adipose tissue than 
in visceral fat [17]. Besides to be considered an important lipostate, or energy balance 
regulator according to body fat mass in long-term [18, 19] has been implicated in the 
regulation of immune, respiratory and reproductive systems [20]. The term Leptin comes 
from Greek "leptos" which means "thin" due to the fact that this protein lead to increased 
energy expenditure and act on satiety signals in hypothalamus, reducing caloric intake [21]. 
The expression and circulating leptin levels are controlled by a number of factors that may 
increase its secretion (insulin, glucocorticoids, TNF-α, estrogens, thyroid hormone and 
CCAAT/enhancer-binding protein-alpha) or decrease (Beta3-adrenergic activity, androgens , 
free fatty acids, GH, and peroxisome proliferator-activated receptor-gamma agonists) 
depending on the physiological assembly expressed by the body, especially on satiety and 
energy intake [22]. 
When circulating this adipokine reaches various body tissues as pancreas, increasing insulin 
secretion; liver, causing a satiety sensation by the increase in glucose production and 
increasing energy expenditure; hypothalamus, increasing stimulation of hypothalamic-
pituitary-adrenal axis, and decreasing the stimulus of hypothalamic-pituitary-thyroid and 
hypothalamic-pituitary-gonadal axis; muscle tissue, increasing glucose uptake and 
metabolism [23]. 
Many of the effects of leptin result from their actions on the central nervous system, 
particularly in the hypothalamus, which acts in satiety and appetite regulation. Reaching 
these tissues after crossing the blood-brain barrier, leptin acts in the arcuate nucleus where 
there is a large concentration of leptin receptors, when binding to reduce the action of 
neurons that use neuropeptide Y (NPY) signaling and agouti-related protein (ARGP). NPY 
is a peptide of 36 amino acids, synthesized mainly in the arcuate nucleus, which projects to 
the paraventricular nucleus, ventromedial, perifornical and lateral, also involved in energy 
balance regulation. It is the most potent orexigenic. The ARGP also synthesized in the 
arcuate nucleus, also is projected to paratentricular nucleus, ventromedial and lateral, acting 
as a melanocortin system analogue on receptors MC-3 and MC-4, stimulating food intake. 
Leptin acts by decreasing the activity of these orexigenics signals, inhibiting food intake and 
increasing energy expenditure by activating the sympathetic nervous system [24, 25]. Also 
in the hypothalamus, leptin activates neurons pro-opiomelanocortin (POMC) producing 
alpha-melanocyte stimulating hormone (alpha-MHS). All substances expressed in this 
system are anorexigenics, ie, act on reducing food intake [14]. This product acts on 
malanocortin-4 receptors and also on neurons that express cocaine and amphetamine-
regulated transcript (CART). POMC/CART neurones also have projections to the lateral 
hypothalamus and paraventricular nucleus, with a reciprocal innervation of these nuclei to 
the arcuate nucleus. Both alpha-MSH and CART are potent anorexigenic agents. The 
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nucleus tractus solitarius (NTS) participates in the satiety control, involved in the end of 
food intake process. Afferent inputs related satiety signals include neurological vagus nerve 
and sympathetic system associated with chemical signals such as endocrine factors of gut 
cholecystokinin. There are many interconnections between hypothalamic nuclei including 
the paraventricular nucleus and the NTS (Figure 2). 
 
Figure 2. Food intake regulation by leptin at arcuate nucleus level. NPY: Neuropeptide Y; AGRP: 
Agouti-related protein; POMC: Pro-opiomelanocortin; CART: Cocaine and amphetamine-regulated 
transcript. 
Among the actions taken by other hypothalamic nuclei in relation to energy homeostasis, 
can be highlight the ventromedial nucleus as a satiety center, lateral hypothalamus as the 
center of hunger and paraventricular nucleus on increased energy expenditure effects, as 
production of corticotropin releasing hormone and thyrotropin releasing hormone, 
activators the sympathetic nervous system. In perifornical nucleus, there is production of 
peptides termed orexins A and B, which act in the ventromedial nucleus and inhibits satiety 
and increase food intake. These areas receive nucleus axons of neurons in the arcuate 
nucleus, POMC/CART and NPY/ARGP, being considered as secondary action areas of 
leptin (downstream) [14, 26]. The leptin role in the CNS as a regulator is thus triggering 
mechanism (cascading effect), in order to stimulate or inhibit substances that act directly or 
indirectly in the hypothalamic areas involved in energy balance control. 
In addition to their central effects, leptin also interacts with numerous peripheral tissues. 
Essentially, there are two major isoforms of leptin receptor, a long isoform which is required 
for full stimulation of the janus kinase-signal transducers and activators of transcription 
(JAK-STAT) pathway, and the short isoforms which result in the activation of JAK2 but not 
STAT. In skeletal muscle, for example, there are the two isoforms but the expression of short 
isoform is greater than the long one, making the leptin signalization in skeletal muscle 
activate various kinases including PI3-kinase, Akt (or PKB), PKC, MAP kinase kinase and 
Jun ERK [27, 28]. 
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In the immune system the leptin receptor are expressed in hematopoietic cells, where leptin 
produced by adipocytes stimulates the normal growth of myeloid and erythroid [14]. In 
addition, leptin synergistically acts with other cytokines by increasing the proliferation of 
leukocytes, specifically T4 cells. 
Leptin effects on reproduction are varied and the target organs range of hypothalamus, 
ovary and endometrial. In the hypothalamic-pituitary axis there is a stimulatory effect [29]. 
Its levels have a circadian and ultradian cycle, and these variations are associated with 
varying levels of luteinizing hormone (LH) and estradiol, informing to the brain about the 
critical fat stores necessary for secretion of luteinizing releasing hormone and activation of 
hypothalamic-pituitary-gonadal axis [30]. The amount of leptin released in the brain is 
greater in women than in men, suggesting that women may be more resistant to the leptin 
action and require higher levels to achieve an appropriate response [31]. It is known that 
leptin, in ovaries, may affect the menstrual cycle by a direct inhibitory effect on the follicles 
development [29]. Leptin may still have an important role in the early stages of cleavage and 
embryonic development [32], in the fetal growth regulation and development, 
hematopoiesis and angiogenesis, as leptin receptors were found in syncytiotrophoblast, 
suggesting that leptin may play an important role in fetal endocrine function of feto-
placental unit [33]. In addition, leptin may play a central role in other target organs for 
reproduction, such as endometrial and mammary gland, influencing important functions 
including lactation and prevention of misbirth [34]. 
In the respiratory system leptin acts as a growth factor in the lung and as a modulator in the 
mechanisms of breathing central control. Leptin levels are elevated in patients with sleep 
apnea, independent of body fat, being associated with leptin resistance [14]. 
For hypothalamic-pituitary-thyroid axis leptin acts on the expression of thyrotropin-
releasing hormone (TRH). Mice in vitro and in vivo study has demonstrated that leptin 
stimulates neurons directly in the paraventricular nucleus, which express TRH, increasing 
proTRH expression [35]. During fasting, the prohormone convertases 1 and 2 (PC1 and PC2) 
are decreased and leptin showed to restore PC1 and PC2 to pre-fasting levels [36]. Studies in 
rodents have shown that calorie restriction rapidly suppresses TRH expression in the 
paraventricular nucleus, leading to decreased thyroxine (T4) and triiodothyronine (T3) levels 
[37], and leptin can reverse these changes [38]. 
Both partial and complete deficiency of leptin is associated with hypothyroidism. Ob/ob 
mice exhibit hypothyroidism at birth [39] and normal mice have decreased T4 levels during 
fasting [38]. Individuals with congenital leptin deficiency have a disorganized TSH 
secretion, suggesting that leptin may regulate the pulsatile characteristics of TSH and the 
circadian cycle [40]. In women with hypothalamic amenorrhea leptin treatment significantly 
increased free T3 and free T4, however did not affect TSH levels [41]. The lack of significant 
changes in TSH levels in many studies may be due to pulsatile nature of this hormone, but 
leptin can directly stimulate the T4 release from the thyroid gland and/or increase TSH 
bioactivity [42, 43]. 
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2.2. Resistin 
Resistin is a polypeptide at approximately 12kDa and belongs to proteins family with 
cysteine-rich C-terminal domain call resistin-like molecules, which are identical to those 
found in inflammatory zone family, giving to resistin the alias FIZZ3 [44]. Its expression is 
15 fold higher in visceral adipose tissue when compared to subcutaneous adipose tissue, in 
rodents [44], but it is also expressed in human macrophages [45]. Its name is due to the 
resistin presents a significant role in obesity-associated insulin resistance [46] and its 
molecular structure is very similar to adiponectin. Resistin production increases with food 
intake and obesity, and decreases in the presence of PPAR-gamma ligands [47]. 
Resistin promotes insulin resistance by increasing hepatic gluconeogenesis, and presenting 
rapid effect on this tissue [47]. Other in vivo study also found effects of administration and 
neutralization of resistin on glucose tolerance in skeletal muscle and adipose tissue, 
indicating resistin action also in these tissues by negative modulation of insulin signaling on 
glucose uptake [46]. 
Regarding the specific body fat deposits, resistin expressions 2-3 fold higher is found in 
visceral adipose tissue, followed by subcutaneous, abdominal and gluteal-femoral 
subcutaneous. Its expression is 3 fold higher in preadipocytes compared with mature 
adipocytes, also functioning as a potential regulator of adipogenesis [48]. 
Resistin deficient mice have weight and fat mass similar to wild-type mice, even when 
high-fat fed. However, resistin deficient mice significantly improved fasting glucose levels 
in control diet and improved glucose tolerance in high-fat diet. Insulin sensitivity is 
unaffected. The improvement in glucose homeostasis in resistin deficient mice is 
associated with decreased hepatic gluconeogenesis. Whereas these data support a resistin 
role in glucose homeostasis during fasting in rodents, a similar role in humans remains to 
be determined [3]. 
2.3. Adiponectin 
Adiponectin, also known as ACRP 30 (adipocyte complement related protein of 30kDa), 
apM1 (adipose most abundant gene transcript 1), AdipQ or GBP28 (gelatin binding protein 
of 28 kDa) [49-52], is a protein exclusively expressed in differentiated adipocytes and 
circulates in high levels in the blood [53], presenting greater expression in subcutaneous 
adipose tissue than in visceral adipose tissue [54]. Unlike other factors secreted by adipose 
tissue, adiponectin acts as a protective factor for cardiovascular disease and increases insulin 
sensitivity. It is an approximately 30 kDa polypeptide that shows high homology with 
collagen VIII and X, and complement component C1q. A proteolytic cleavage product 
containing the globular domain of adiponectin circulate in physiologically significant levels 
and has biological activity [53]. 
Except for cases of severe malnutrition [55] and in neonates [56], there is a strong negative 
correlation between plasma adiponectin and fat mass [52]. 
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Were identified two adiponectin receptors isoforms (Adipo-R1 and -R2) [57]. This receptors 
present seven transmembrane domains but are functionally different of receptors coupled to 
G protein. AdipoR1 is expressed mainly in muscle tissue and has high affinity for globular 
adiponectin, and low affinity for full-length adiponectin. AdipoR2 has high expression in 
liver and has intermediate affinity for both isoforms of circulating adiponectin. Thus, it is 
noted that the biological effects of adiponectin depends not only on circulating levels or the 
properties of each isoform but also receptor subtype and its expression in each tissue [3]. 
Adiponectin anti-inflammatory and anti-atherogenic actions occurs through decreased 
expression of adhesion molecule-1 (via reduced expression of TNF-alpha activity and 
resistin); decreased macrophage chemotaxis to fat cells formation; and inhibition of 
inflammatory signaling in endothelial tissue [58]. It increases insulin sensitivity via 
increased fatty acid oxidation and glucose uptake and utilization in skeletal muscle and 
adipose tissue; reduction of hepatic glucose release, leading to better control of glucose 
serum levels, free fatty acids and triglycerides [59]. In rat adipocytes, in vitro, the 60% 
reduction in adiponectin expression increased significantly insulin resistance. The presence 
of nucleotide polymorphisms in adiponectin caused by genetic or environmental factors 
(diet rich in fat, for example), can be a determining factor in reducing their insulin 
sensitizing action [60]. 
In the liver, adiponectin increases insulin sensitivity by reducing nonesterified fatty acids 
uptake, increasing fatty acid oxidation and decreasing glucose output. In muscle, 
adiponectin stimulates glucose metabolism and fatty acid oxidation. In the endothelium, it 
inhibits monocyte adherence by reducing adhesion molecules; inhibits macrophages 
transformation and reduces migrating smooth muscle cells proliferation in response to 
growth factors. Adiponectin also increases nitric oxide production by endothelial cells and 
stimulates angiogenesis. Taken together, these effects suggest that adiponectin is the only 
adipokine that present antidiabetic, anti-inflammatory and anti-atherogenic effects [3]. 
2.4. Others adipokines 
Tumor Necrose Factor - alpha (TNF-α) – TNF-α is a cytokine expressed by adipocytes and 
stromovascular cells, with higher expression in subcutaneous adipose tissue compared to 
visceral adipose tissue, acting directly on adipocytes, promoting apoptosis induction, 
lipogenesis inhibition, by inhibiting lipoprotein lipase (LLP), GLUT-4 and the acetyl CoA 
synthetase expressions, as well as increased lipolysis, therefore exerting an important 
regulatory role in fat accumulation in adipose tissue [61, 62]. TNF-α is a transmembrane 
protein of 26 kDa, which, after being cleaved generates a portion of 17-kDa, which is 
biologically active and exerts its effects through TNF- receptor type I and II. It is a cytokine 
initially described as an endotoxin-induced factor causing necrosis in tumors. The ability of 
TNF to induce cachexia in vivo led to an extensive evaluation of its role in energy 
homeostasis [3]. TNF-α alters gene expression of metabolically important tissues such as 
adipose tissue and liver [63] and impairs the insulin signaling by activation of serine kinases 
that increase the insulin receptor substrate-1 and -2 phosphorylation, increasing its 
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synthetase expressions, as well as increased lipolysis, therefore exerting an important 
regulatory role in fat accumulation in adipose tissue [61, 62]. TNF-α is a transmembrane 
protein of 26 kDa, which, after being cleaved generates a portion of 17-kDa, which is 
biologically active and exerts its effects through TNF- receptor type I and II. It is a cytokine 
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degradation [64]. Both TNF-α and triiodothyronine are involved in the tissue homeostasis 
maintenance of the anterior pituitary gland, however, triiodothyronine inhibit the signaling 
cascade that TNF-α promotes on this tissue in signaling pathways affecting MAPK p38 and 
nuclear factor kappaB [65]. 
Interleukin-6 (IL-6) – IL-6 is also a cytokine with pro-inflammatory effect in acute responses 
and action on carbohydrates and lipids metabolism [66, 67]. IL-6 circulates in glycosylated 
form ranging from 22 to 27 kDa. Its receptor (IL-6R) is homologous to the leptin receptor 
and exists in two isoforms, a membrane-bound and soluble. The infusion of IL-6 near 
physiological doses, in healthy humans, increase lipolysis independently of catecholamines, 
glucagon and insulin modulation [68], indicating IL-6 as an important factor in lipid 
metabolism. As TNF-α, it inhibits the LLP and increases free fatty acids and glycerol release. 
Furthermore, the increased expression may be related to leptin suppression and stimulation 
of C-reactive protein production, as well as in reducing IRS-1 and GLUT-4 expression in the 
liver and muscle [66]. IL-6 is secreted by adipocytes and macrophages, which are 
responsible for 30% of its secretion [67]. Catecholamines can stimulate IL-6 expression via 
β2-and β3-adrenoceptors in adipose tissue, when in high concentrations [69]. The IL-6 
central administration increases energy expenditure and decreases body fat in rodents. Also, 
transgenic mice with IL-6 overexpressed showed generalized growth deficiency and 
reduced body mass, however, IL-6 deficient mice develop obesity and metabolic 
abnormalities, suggesting that IL-6 may prevent, rather than cause these conditions [70]. 
Monocyte chemotactic protein-1 (MCP-1) – MCP-1 is a chemokine and a member of the small 
inducible cytokine family, which plays a role in the recruitment of monocytes and T 
lymphocytes to sites of injury and infection. Its main receptor is the chemokine CC motif 
receptor (CCR) 2 that is expressed in various cell types including adipocytes, skeletal muscle 
cells and macrophages. MCP-1 was first described as a secretory product of monocytes and 
endothelial cells with a role in atherosclerosis. MCP-1, acting through its receptor CCR2, is 
now thought to play a central role in the recruitment of monocytes to atherosclerotic lesions 
and in the development of intimal hyperplasia after arterial injury. Owing to their crucial 
roles in monocyte recruitment in vascular and nonvascular diseases, MCP-1 and CCR2 have 
become important therapeutic targets in cardiovascular research. Furthermore, MCP-1 plays 
a role in inflammation in insulin-responsive tissues. As for skeletal muscle, MCP-1 is 
increased during myopathies and can be induced by interferon-gamma. Recently, MCP-1 
has been attributed an additional role in the pathophysiology of obesity [71]. 
Plasminogen activator inhibitor (PAI)-1 – Adipocytes can secrete many proteins in hemostasis 
and fibrinolytic system as PAI-1 [72]. PAI-1 is a member of the serine protease inhibitor 
family and is the primary inhibitor of fibrinolysis by inactivating urokinase-type and tissue-
type plasminogen activator. PAI-1 has also been implicated in a variety of other biological 
processes including angiogenesis and atherogenesis. PAI-1 is expressed by many cell types 
within adipose tissue including adipocytes [3]. PAI-1 expression and secretion are greater in 
visceral adipose tissue relative to subcutaneous adipose tissue [54]. PAI-1 promotes thrombi 
formation and unstable atherogenic plaque rupture, and change the fibrinolytic balance by 
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inhibition of plasmin production, contributing to vascular architecture remodeling and 
atherosclerotic process [66, 73].  
Adipsin and acylation stimulating protein (ASP) – Also secreted by adipose tissue it has an 
important effect on lipogenesis [59]. APS inhibits the lipolysis by inhibition of hormone 
sensitive lipase (HSL), and stimulating lipogenesis by increasing GLUT4 translocation from 
cytosol to membrane; increases glycerol-3-phosphate production and increases 
diacylglycerol acyltransferase activity, an catalyst enzyme in triglycerides synthesis [74]. 
Thus affects both the glucose and the lipid metabolism.  
Proteins of the renin angiotensin system (RAS) – Pathogenic models have been proposed to 
explain the association between adiposity and the renin angiotensin system [75]. This seems 
to be related to fat accumulation in adipose tissue, as well as its involvement in 
inflammatory and atherogenic process. Adipose tissue secretes many proteins related to the 
RAS as renin, angiotensinogen (AGT), angiotensin I, angiotensin II, angiotensin type I 
receptors (AT1) and type 2 (AT2) angiotensin-converting enzyme (ACE), and other 
proteases capable of producing angiotensin II (chymase, cathepsins D and G) [76, 77]. The 
angiotensin I receptor is secretion inductor of series 2 prostaglandins which participates in 
preadipocytes cell differentiation, and the angiotensin II stimulates adipocytes 
differentiation and lipogenesis in time of angiotensin I to II conversion, indicating their 
involvement in the accumulation of fat mass process [78].  
3. Adipokines and thyroid hormones 
The thyroid gland mainly produces the thyroid hormones T3 and T4. However, also 
produces small amounts of other iodothyronines as reverse T3 and 3,5-diiodo-L-thyronine. 
This gland is part of hypothalamic-pituitary-thyroid axis. Thyroid hormones secretion is 
regulated by the classical mechanism of negative feedback; briefly, thyroid releasing 
hormone (TRH), produced predominantly by neurons of the paraventricular nucleus in 
the hypothalamus, stimulates the release of thyroid stimulating hormone (TSH) in 
pituitary and this in turn, stimulates the synthesis and release of thyroid hormones. The 
increase in thyroid hormones serum concentrations inhibit the production of both TRH 
and TSH, leading to decreased thyroid function. The subsequent decrease in thyroid 
hormones serum levels, in turn, stimulates TRH and TSH, again increasing the 
concentration of hormones [79]. Thyroid hormones act in the body through the coupling 
to its receptor  (TR) and  (TR). The thyroid hormone receptors (TRs), members of the 
superfamily of nuclear receptors interact with a specific DNA sequence, called responsive 
element in the promoter region of target gene and regulates gene transcription [80]. 
Generally, TRs are repressors in the absence of binding T3 and transcriptional activators in 
its presence [81]. 
Although the thyroid hormones are essential for the survival [37], thyroid function disorder 
leads to changes in metabolic parameters, for example, thyroid hormone excess is associated 
with weight loss and reduced muscle and fat mass [82] , showing that thyroid hormones 
play a central role in regulating the adipose tissue metabolism [83]. Furthermore, Viguerie et 
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degradation [64]. Both TNF-α and triiodothyronine are involved in the tissue homeostasis 
maintenance of the anterior pituitary gland, however, triiodothyronine inhibit the signaling 
cascade that TNF-α promotes on this tissue in signaling pathways affecting MAPK p38 and 
nuclear factor kappaB [65]. 
Interleukin-6 (IL-6) – IL-6 is also a cytokine with pro-inflammatory effect in acute responses 
and action on carbohydrates and lipids metabolism [66, 67]. IL-6 circulates in glycosylated 
form ranging from 22 to 27 kDa. Its receptor (IL-6R) is homologous to the leptin receptor 
and exists in two isoforms, a membrane-bound and soluble. The infusion of IL-6 near 
physiological doses, in healthy humans, increase lipolysis independently of catecholamines, 
glucagon and insulin modulation [68], indicating IL-6 as an important factor in lipid 
metabolism. As TNF-α, it inhibits the LLP and increases free fatty acids and glycerol release. 
Furthermore, the increased expression may be related to leptin suppression and stimulation 
of C-reactive protein production, as well as in reducing IRS-1 and GLUT-4 expression in the 
liver and muscle [66]. IL-6 is secreted by adipocytes and macrophages, which are 
responsible for 30% of its secretion [67]. Catecholamines can stimulate IL-6 expression via 
β2-and β3-adrenoceptors in adipose tissue, when in high concentrations [69]. The IL-6 
central administration increases energy expenditure and decreases body fat in rodents. Also, 
transgenic mice with IL-6 overexpressed showed generalized growth deficiency and 
reduced body mass, however, IL-6 deficient mice develop obesity and metabolic 
abnormalities, suggesting that IL-6 may prevent, rather than cause these conditions [70]. 
Monocyte chemotactic protein-1 (MCP-1) – MCP-1 is a chemokine and a member of the small 
inducible cytokine family, which plays a role in the recruitment of monocytes and T 
lymphocytes to sites of injury and infection. Its main receptor is the chemokine CC motif 
receptor (CCR) 2 that is expressed in various cell types including adipocytes, skeletal muscle 
cells and macrophages. MCP-1 was first described as a secretory product of monocytes and 
endothelial cells with a role in atherosclerosis. MCP-1, acting through its receptor CCR2, is 
now thought to play a central role in the recruitment of monocytes to atherosclerotic lesions 
and in the development of intimal hyperplasia after arterial injury. Owing to their crucial 
roles in monocyte recruitment in vascular and nonvascular diseases, MCP-1 and CCR2 have 
become important therapeutic targets in cardiovascular research. Furthermore, MCP-1 plays 
a role in inflammation in insulin-responsive tissues. As for skeletal muscle, MCP-1 is 
increased during myopathies and can be induced by interferon-gamma. Recently, MCP-1 
has been attributed an additional role in the pathophysiology of obesity [71]. 
Plasminogen activator inhibitor (PAI)-1 – Adipocytes can secrete many proteins in hemostasis 
and fibrinolytic system as PAI-1 [72]. PAI-1 is a member of the serine protease inhibitor 
family and is the primary inhibitor of fibrinolysis by inactivating urokinase-type and tissue-
type plasminogen activator. PAI-1 has also been implicated in a variety of other biological 
processes including angiogenesis and atherogenesis. PAI-1 is expressed by many cell types 
within adipose tissue including adipocytes [3]. PAI-1 expression and secretion are greater in 
visceral adipose tissue relative to subcutaneous adipose tissue [54]. PAI-1 promotes thrombi 
formation and unstable atherogenic plaque rupture, and change the fibrinolytic balance by 
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inhibition of plasmin production, contributing to vascular architecture remodeling and 
atherosclerotic process [66, 73].  
Adipsin and acylation stimulating protein (ASP) – Also secreted by adipose tissue it has an 
important effect on lipogenesis [59]. APS inhibits the lipolysis by inhibition of hormone 
sensitive lipase (HSL), and stimulating lipogenesis by increasing GLUT4 translocation from 
cytosol to membrane; increases glycerol-3-phosphate production and increases 
diacylglycerol acyltransferase activity, an catalyst enzyme in triglycerides synthesis [74]. 
Thus affects both the glucose and the lipid metabolism.  
Proteins of the renin angiotensin system (RAS) – Pathogenic models have been proposed to 
explain the association between adiposity and the renin angiotensin system [75]. This seems 
to be related to fat accumulation in adipose tissue, as well as its involvement in 
inflammatory and atherogenic process. Adipose tissue secretes many proteins related to the 
RAS as renin, angiotensinogen (AGT), angiotensin I, angiotensin II, angiotensin type I 
receptors (AT1) and type 2 (AT2) angiotensin-converting enzyme (ACE), and other 
proteases capable of producing angiotensin II (chymase, cathepsins D and G) [76, 77]. The 
angiotensin I receptor is secretion inductor of series 2 prostaglandins which participates in 
preadipocytes cell differentiation, and the angiotensin II stimulates adipocytes 
differentiation and lipogenesis in time of angiotensin I to II conversion, indicating their 
involvement in the accumulation of fat mass process [78].  
3. Adipokines and thyroid hormones 
The thyroid gland mainly produces the thyroid hormones T3 and T4. However, also 
produces small amounts of other iodothyronines as reverse T3 and 3,5-diiodo-L-thyronine. 
This gland is part of hypothalamic-pituitary-thyroid axis. Thyroid hormones secretion is 
regulated by the classical mechanism of negative feedback; briefly, thyroid releasing 
hormone (TRH), produced predominantly by neurons of the paraventricular nucleus in 
the hypothalamus, stimulates the release of thyroid stimulating hormone (TSH) in 
pituitary and this in turn, stimulates the synthesis and release of thyroid hormones. The 
increase in thyroid hormones serum concentrations inhibit the production of both TRH 
and TSH, leading to decreased thyroid function. The subsequent decrease in thyroid 
hormones serum levels, in turn, stimulates TRH and TSH, again increasing the 
concentration of hormones [79]. Thyroid hormones act in the body through the coupling 
to its receptor  (TR) and  (TR). The thyroid hormone receptors (TRs), members of the 
superfamily of nuclear receptors interact with a specific DNA sequence, called responsive 
element in the promoter region of target gene and regulates gene transcription [80]. 
Generally, TRs are repressors in the absence of binding T3 and transcriptional activators in 
its presence [81]. 
Although the thyroid hormones are essential for the survival [37], thyroid function disorder 
leads to changes in metabolic parameters, for example, thyroid hormone excess is associated 
with weight loss and reduced muscle and fat mass [82] , showing that thyroid hormones 
play a central role in regulating the adipose tissue metabolism [83]. Furthermore, Viguerie et 
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al. [84] showed by microarray that 19 genes of human white adipose tissue are regulated by 
thyroid hormone. These modulated genes give rise to proteins involved in transduction 
signal, lipid metabolism, apoptosis and inflammatory responses. The thyroid hormones 
inhibit proliferation and stimulate differentiation of adipocytes [85], regulate lipid 
metabolism by upregulation lipolytic enzymes expression, increase oxygen consumption 
and modulate tissue sensitivity to other hormones [84]. 
Since thyroid hormones affect adipose tissue metabolism, it is interesting to evaluate the 
relationship between thyroid hormones and adipokines in obese and weight loss, the focus 
of discussion in next sections. 
4. Thyroid hormone effect on adipokines in obesity 
4.1. Leptin 
A potential interaction between leptin and thyroid hormones has been suggested since both 
hormones are associated with body weight and energy expenditure regulation. 
Leptin deficiency leads to severe obesity, however, in humans it’s usually find high levels of 
leptin associated with leptin-resistance state [86-91]. Although thyroid function is usually 
normal in obese subjects, many studies have demonstrated that TSH levels are slightly 
increased in obese subjects [92-94]. Several studies have suggested that leptin influences 
TSH release, suggesting a regulatory role by leptin on thyroid axis at least in some 
conditions [35, 40, 95-101]. Thyroid hormones regulate the expression of several genes in 
human adipocyte [84], however, the role of thyroid hormones in leptin modulation remains 
controversial (Figure 3).   
 
Figure 3. Adapted from Feldt-Rasmussem, 2007. Leptin can act on TRH or can directly influence T4 – 
T3 conversion, showing a regulatory role on thyroid axis. Despite contradictory data, thyroid 
hormone also regulates leptin levels increasing or decreasing depending on condition. TRH: thyroid 
release hormone; TSH: thyroid stimulating hormone; UCP3: uncoupling protein 3; T4: thyroxine; T3: 
triiodothyronine. 
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Studies with rodents indicate that thyroid hormones exert a negative influence on serum 
leptin concentrations [102-105]. Syed et al. [106] also found similar results, but report that 
thyroid hormones influence leptin levels indirectly through the regulation of fat mass. Wang 
et al. [107] reported that although leptin and thyroid hormones might affect the same 
pathways to regulate energy metabolism, the leptin effects on metabolism are not 
dependent upon the presence of thyroid hormones. In agreement, Luvizotto et al. [108] 
reported that T3 administration in obese rats promotes weight loss and diminishes serum 
levels and gene expression of leptin and other adipokines. Contrary to these results, Yoshida 
et al. [109] founds increased leptin mRNA levels in 3T3-L1 cell cultures treated with T3 at 
physiological and supraphysiological doses.  
Obese human subjects have high serum leptin levels as leptin concentrations are directly 
proportional to body fat mass, more specifically to adipocyte volume [110, 111]. Regarding 
to thyroid hormones, there is indications that human obesity is usually associated with 
increased TSH and T3 levels [92, 112]. As in rats, studies with humans reached to 
controversial results about the effect of thyroid hormones over leptin concentrations. In fact, 
human studies present more difficulties in terms of controlling variables as patient 
characteristics, treatments and method for measuring leptin levels and body composition. In 
hypothyroid subjects serum leptin was found to be increased [83, 113], decreased [114, 115] 
or unchanged [116, 117] when compared with euthyroid subjects. The same controversial 
results are found in studies with hyperthyroid subjects [83, 113, 115-118]. 
These conflicting results might be explained by the existence of many factors influencing 
leptin levels and thyroid hormones, and more studies are needed to fully understand the 
relationship between leptin and thyroid hormones. 
4.2. Resistin 
Resistin is strongly related to insulin resistance, showing increased resistin concentrations in 
obese and diabetic animals [46], and additionally it has been associated with inflammatory 
condition [119]. There is evidence that the hyperlipidic diet-induced obesity as well as leptin 
gene mutations are associated with high resistin circulating levels [120]. Resistin 
administered intraperitoneally increases plasma glucose and induces a hepatic insulin 
resistance. Other studies involving administration of resistin-recombinant promoted insulin 
resistance and reduced glucose transport stimulated by insulin, whereas administration of 
anti-resistin antibodies produced the opposite effect in rats [46]. Moreover, anti-resistin 
antibodies decrease blood glucose levels and improve the insulin sensitivity in obese rats 
[121, 122]. In mice with diet-induced obesity, immunoneutralization of resistin resulted in a 
20% drop in blood glucose and improved insulin sensitivity as measured by insulin 
tolerance testing [46]. 
Resistin in humans is primarily produced in peripheral blood monocytes and its levels 
correlate with IL-6 concentrations [120], the question of its inflammatory role has been 
raised  [123, 124], however the physiological role of resistin is far from clear and its role in 
obesity and insulin resistance and/or diabetes is controversial. Janke et al. [121] describes in 
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al. [84] showed by microarray that 19 genes of human white adipose tissue are regulated by 
thyroid hormone. These modulated genes give rise to proteins involved in transduction 
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inhibit proliferation and stimulate differentiation of adipocytes [85], regulate lipid 
metabolism by upregulation lipolytic enzymes expression, increase oxygen consumption 
and modulate tissue sensitivity to other hormones [84]. 
Since thyroid hormones affect adipose tissue metabolism, it is interesting to evaluate the 
relationship between thyroid hormones and adipokines in obese and weight loss, the focus 
of discussion in next sections. 
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A potential interaction between leptin and thyroid hormones has been suggested since both 
hormones are associated with body weight and energy expenditure regulation. 
Leptin deficiency leads to severe obesity, however, in humans it’s usually find high levels of 
leptin associated with leptin-resistance state [86-91]. Although thyroid function is usually 
normal in obese subjects, many studies have demonstrated that TSH levels are slightly 
increased in obese subjects [92-94]. Several studies have suggested that leptin influences 
TSH release, suggesting a regulatory role by leptin on thyroid axis at least in some 
conditions [35, 40, 95-101]. Thyroid hormones regulate the expression of several genes in 
human adipocyte [84], however, the role of thyroid hormones in leptin modulation remains 
controversial (Figure 3).   
 
Figure 3. Adapted from Feldt-Rasmussem, 2007. Leptin can act on TRH or can directly influence T4 – 
T3 conversion, showing a regulatory role on thyroid axis. Despite contradictory data, thyroid 
hormone also regulates leptin levels increasing or decreasing depending on condition. TRH: thyroid 
release hormone; TSH: thyroid stimulating hormone; UCP3: uncoupling protein 3; T4: thyroxine; T3: 
triiodothyronine. 
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Studies with rodents indicate that thyroid hormones exert a negative influence on serum 
leptin concentrations [102-105]. Syed et al. [106] also found similar results, but report that 
thyroid hormones influence leptin levels indirectly through the regulation of fat mass. Wang 
et al. [107] reported that although leptin and thyroid hormones might affect the same 
pathways to regulate energy metabolism, the leptin effects on metabolism are not 
dependent upon the presence of thyroid hormones. In agreement, Luvizotto et al. [108] 
reported that T3 administration in obese rats promotes weight loss and diminishes serum 
levels and gene expression of leptin and other adipokines. Contrary to these results, Yoshida 
et al. [109] founds increased leptin mRNA levels in 3T3-L1 cell cultures treated with T3 at 
physiological and supraphysiological doses.  
Obese human subjects have high serum leptin levels as leptin concentrations are directly 
proportional to body fat mass, more specifically to adipocyte volume [110, 111]. Regarding 
to thyroid hormones, there is indications that human obesity is usually associated with 
increased TSH and T3 levels [92, 112]. As in rats, studies with humans reached to 
controversial results about the effect of thyroid hormones over leptin concentrations. In fact, 
human studies present more difficulties in terms of controlling variables as patient 
characteristics, treatments and method for measuring leptin levels and body composition. In 
hypothyroid subjects serum leptin was found to be increased [83, 113], decreased [114, 115] 
or unchanged [116, 117] when compared with euthyroid subjects. The same controversial 
results are found in studies with hyperthyroid subjects [83, 113, 115-118]. 
These conflicting results might be explained by the existence of many factors influencing 
leptin levels and thyroid hormones, and more studies are needed to fully understand the 
relationship between leptin and thyroid hormones. 
4.2. Resistin 
Resistin is strongly related to insulin resistance, showing increased resistin concentrations in 
obese and diabetic animals [46], and additionally it has been associated with inflammatory 
condition [119]. There is evidence that the hyperlipidic diet-induced obesity as well as leptin 
gene mutations are associated with high resistin circulating levels [120]. Resistin 
administered intraperitoneally increases plasma glucose and induces a hepatic insulin 
resistance. Other studies involving administration of resistin-recombinant promoted insulin 
resistance and reduced glucose transport stimulated by insulin, whereas administration of 
anti-resistin antibodies produced the opposite effect in rats [46]. Moreover, anti-resistin 
antibodies decrease blood glucose levels and improve the insulin sensitivity in obese rats 
[121, 122]. In mice with diet-induced obesity, immunoneutralization of resistin resulted in a 
20% drop in blood glucose and improved insulin sensitivity as measured by insulin 
tolerance testing [46]. 
Resistin in humans is primarily produced in peripheral blood monocytes and its levels 
correlate with IL-6 concentrations [120], the question of its inflammatory role has been 
raised  [123, 124], however the physiological role of resistin is far from clear and its role in 
obesity and insulin resistance and/or diabetes is controversial. Janke et al. [121] describes in 
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adipose tissue of obese individuals, although this adipokine has been identified, there was 
no correlation between resistin gene expression and their body weight, adiposity and 
insulin resistance. In contrast, high resistin levels are related to obesity and insulin 
resistance [46], and since body mass index has a possible association with thyroid hormones 
during periods of weight gain [125], could be establish a relationship between thyroid 
hormones and resistin in obesity.  
Thyroid hormones appear to regulate resistin, at least in rats, however, in humans, studies 
on resistin levels and thyroid status have produced conflicting results. Some studies report 
that patients with hyperthyroidism have elevated resistin concentrations when compared 
with euthyroid control subjects [126]. Normalization of circulating thyroid hormones was 
accompanied by a significant decrease in resistin concentrations [126]. Others showed that 
hyperthyroid patients exhibit a significant decrease in resistin levels compared with 
euthyroid individuals. Normalization of circulating thyroid hormones levels was not 
accompanied by any significant change in resistin levels [127]. After adjusting the weight by 
the body mass index, the resistin levels of hyperthyroid patients were similar to euthyroid 
individuals [128]. 
Azza et al. [129] in their study with hypothyroid rats found an increase in body mass index 
without changes in resistin levels. On the other hand, Nogueiras et al. [130], found that 
adipose tissue resistin mRNA levels were increased in hypothyroid rats and decreased, to 
almost undetectable levels, in hyperthyroid rats. These data may help to explain previous 
findings showing a marked improvement in insulin resistance observed in obese rats after 
treatment with exogenous thyroid hormones [106]. Luvizotto et al. [108] reported that 
administration of T3 supraphysiological doses decreased resistin serum levels and ressitin 
mRNA gene expression in adipose tissue in obese rats. 
Data on the effect of thyroid hormones on resistin are scarce and controversial, so more 
studies are needed to elucidate the exact mechanism by which thyroid hormones may 
influence resistin levels. 
4.3. Adiponectin 
The main target tissue and the precise mechanism of adiponectin action are not fully 
understood. The adiponectin activity is probably regulated at several levels, including gene 
expression, post-transcriptional modifications, oligomeric complexes formation, and 
proteolytic cleavage into smaller and perhaps more active fragments [131]. Some 
experimental models suggest that reduced adiponectin expression is associated with obesity 
and insulin resistance. Adiponectin expression may be activated during adipogenesis, but 
the feedback inhibition on its production may be involved in obesity development. It has 
been shown that adipogenic genes expression was suppressed during obesity and diabetes 
development in mice [132]. A negative correlation between obesity and circulating 
adiponectin has been well accepted. 
Studies of a possible relationship between adiponectin and lipid metabolism changes 
associated with thyroid dysfunction are scarce. Hyperthyroid patients showed an increase 
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in body weight, body mass index and cholesterol serum levels after controlling for 
thyrotoxicosis. The lack of correlation between these parameters and serum adiponectin 
suggests that changes in body composition and lipid profile observed in hyperthyroidism 
are independent of adiponectin. In contrast, patients with hypothyroidism showed 
elevated cholesterol and triglycerides levels when compared to normal subjects. Thyroid 
function control was followed by a significant decrease in serum cholesterol and 
triglyceride concentrations. However no relationship between adiponectin and lipid 
profile before and after therapy was evidenced. Furthermore, after adjusting adiponectin 
levels for body mass index, no significant change was observed in patients with hyper- 
and hypothyroidism, suggesting that thyroid hormones play a small role in adiponectin 
levels modulation [128]. 
An experimental study of rats with hyperthyroidism showed an important rise in serum 
adiponectin [133]. However, in contrast, Cabanelas et al. [134] show reduced adiponectin 
gene expression in inguinal explants of normal rats. Confirming this data Luvizotto et. al. 
[108] demonstrate that obese animals had decreased adiponectin serum levels when 
compared to control animals; and the administration of T3, interestingly, even diminishing 
the body fat mass, presented lower levels of adiponectin; showing that supraphysiological 
T3 doses alter adiponectin expression in obesity, suggesting that T3 may cause undesirable 
effects on adipose tissue. 
4.4. Others adipokines 
TNF-α - Fruhbeck et al. [135] in their investigations revealed a narrow molecular link 
between TNF-α and obesity, verifying that TNF-α expression is increased in obesity, which 
in turn decreased insulin sensitivity, the same way of resistin. High-fat fed rodents showed 
significantly increased TNF-α expression and alteration in insulin signaling pathway in 
vivo [136]. Anti-TNF-α antibodies improves insulin sensitivity in obese rats, whereas TNF-
α deficient animals, even when subjected to high-fat diet, present themselves "protected" 
from obesity development and insulin resistance. TNF-α is a cytokine that may be 
involved in autoimmune thyroid disease development [137, 138]. Jiskra & Telicka [138] 
examined the relationship between thyroid function and cytokines, using patients with 
Graves' disease (characterized by hyperthyroidism), and patients with Hashimoto 
thyroiditis (disease characterized by hypothyroidism). The cytokine profile was assessed 
and patients with Hashimoto's thyroiditis present body mass index above the ideal level 
and TNF-α serum levels smaller than in patients with Graves' disease, who had body 
mass index within normal limits. Díez et al. [139] show that patients with 
hyperthyroidism before treatment present TNF-α serum levels higher than in control 
group, but hyperthyroidism treatment was accompanied by normalization of TNF-α 
levels. However TNF-α reduction was not observed in patients with hypothyroidism who 
have had the thyroid function normalized, despite a positive correlation between the 
TNF-α post-treatment levels and weight loss.  
IL-6 - IL-6 levels are increased in obesity [140], and is also a marker of insulin resistance [141, 
142]. According Nonogaki et al [143], metabolic impact produced by increased expression of 
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adipose tissue of obese individuals, although this adipokine has been identified, there was 
no correlation between resistin gene expression and their body weight, adiposity and 
insulin resistance. In contrast, high resistin levels are related to obesity and insulin 
resistance [46], and since body mass index has a possible association with thyroid hormones 
during periods of weight gain [125], could be establish a relationship between thyroid 
hormones and resistin in obesity.  
Thyroid hormones appear to regulate resistin, at least in rats, however, in humans, studies 
on resistin levels and thyroid status have produced conflicting results. Some studies report 
that patients with hyperthyroidism have elevated resistin concentrations when compared 
with euthyroid control subjects [126]. Normalization of circulating thyroid hormones was 
accompanied by a significant decrease in resistin concentrations [126]. Others showed that 
hyperthyroid patients exhibit a significant decrease in resistin levels compared with 
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accompanied by any significant change in resistin levels [127]. After adjusting the weight by 
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individuals [128]. 
Azza et al. [129] in their study with hypothyroid rats found an increase in body mass index 
without changes in resistin levels. On the other hand, Nogueiras et al. [130], found that 
adipose tissue resistin mRNA levels were increased in hypothyroid rats and decreased, to 
almost undetectable levels, in hyperthyroid rats. These data may help to explain previous 
findings showing a marked improvement in insulin resistance observed in obese rats after 
treatment with exogenous thyroid hormones [106]. Luvizotto et al. [108] reported that 
administration of T3 supraphysiological doses decreased resistin serum levels and ressitin 
mRNA gene expression in adipose tissue in obese rats. 
Data on the effect of thyroid hormones on resistin are scarce and controversial, so more 
studies are needed to elucidate the exact mechanism by which thyroid hormones may 
influence resistin levels. 
4.3. Adiponectin 
The main target tissue and the precise mechanism of adiponectin action are not fully 
understood. The adiponectin activity is probably regulated at several levels, including gene 
expression, post-transcriptional modifications, oligomeric complexes formation, and 
proteolytic cleavage into smaller and perhaps more active fragments [131]. Some 
experimental models suggest that reduced adiponectin expression is associated with obesity 
and insulin resistance. Adiponectin expression may be activated during adipogenesis, but 
the feedback inhibition on its production may be involved in obesity development. It has 
been shown that adipogenic genes expression was suppressed during obesity and diabetes 
development in mice [132]. A negative correlation between obesity and circulating 
adiponectin has been well accepted. 
Studies of a possible relationship between adiponectin and lipid metabolism changes 
associated with thyroid dysfunction are scarce. Hyperthyroid patients showed an increase 
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in body weight, body mass index and cholesterol serum levels after controlling for 
thyrotoxicosis. The lack of correlation between these parameters and serum adiponectin 
suggests that changes in body composition and lipid profile observed in hyperthyroidism 
are independent of adiponectin. In contrast, patients with hypothyroidism showed 
elevated cholesterol and triglycerides levels when compared to normal subjects. Thyroid 
function control was followed by a significant decrease in serum cholesterol and 
triglyceride concentrations. However no relationship between adiponectin and lipid 
profile before and after therapy was evidenced. Furthermore, after adjusting adiponectin 
levels for body mass index, no significant change was observed in patients with hyper- 
and hypothyroidism, suggesting that thyroid hormones play a small role in adiponectin 
levels modulation [128]. 
An experimental study of rats with hyperthyroidism showed an important rise in serum 
adiponectin [133]. However, in contrast, Cabanelas et al. [134] show reduced adiponectin 
gene expression in inguinal explants of normal rats. Confirming this data Luvizotto et. al. 
[108] demonstrate that obese animals had decreased adiponectin serum levels when 
compared to control animals; and the administration of T3, interestingly, even diminishing 
the body fat mass, presented lower levels of adiponectin; showing that supraphysiological 
T3 doses alter adiponectin expression in obesity, suggesting that T3 may cause undesirable 
effects on adipose tissue. 
4.4. Others adipokines 
TNF-α - Fruhbeck et al. [135] in their investigations revealed a narrow molecular link 
between TNF-α and obesity, verifying that TNF-α expression is increased in obesity, which 
in turn decreased insulin sensitivity, the same way of resistin. High-fat fed rodents showed 
significantly increased TNF-α expression and alteration in insulin signaling pathway in 
vivo [136]. Anti-TNF-α antibodies improves insulin sensitivity in obese rats, whereas TNF-
α deficient animals, even when subjected to high-fat diet, present themselves "protected" 
from obesity development and insulin resistance. TNF-α is a cytokine that may be 
involved in autoimmune thyroid disease development [137, 138]. Jiskra & Telicka [138] 
examined the relationship between thyroid function and cytokines, using patients with 
Graves' disease (characterized by hyperthyroidism), and patients with Hashimoto 
thyroiditis (disease characterized by hypothyroidism). The cytokine profile was assessed 
and patients with Hashimoto's thyroiditis present body mass index above the ideal level 
and TNF-α serum levels smaller than in patients with Graves' disease, who had body 
mass index within normal limits. Díez et al. [139] show that patients with 
hyperthyroidism before treatment present TNF-α serum levels higher than in control 
group, but hyperthyroidism treatment was accompanied by normalization of TNF-α 
levels. However TNF-α reduction was not observed in patients with hypothyroidism who 
have had the thyroid function normalized, despite a positive correlation between the 
TNF-α post-treatment levels and weight loss.  
IL-6 - IL-6 levels are increased in obesity [140], and is also a marker of insulin resistance [141, 
142]. According Nonogaki et al [143], metabolic impact produced by increased expression of 
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IL-6 in the body fat deposits can be very importante in the obesity pathogenesis. The 
increase in IL-6 plasmatic could stimulate the hepatic synthesis of triacylglycerol, 
contributing to hypertriglyceridemia associated with visceral obesity. Data on relationship 
of thyroid hormones and IL-6 in obesity are scarce, but the association between reduction of 
T3 circulating levels and increasing pro-inflammatory cytokines, particularly IL-6, is 
described in the literature in both animals’ models and human studies - septic patients 
and in patients with systemic inflammatory response [144, 145]. The acute subcutaneous 
administration of IL-6 (5 mg) in rats was associated with decrease in T4,T3 and TSH serum 
concentrations, while the T4/T3 ratio decreased, suggesting that T4 deiodination was not 
affected [144]. Changes in serum thyroid hormone concentrations could effectively be 
ascribed to IL-6, since they could be prevented by IL-6 preincubation with its neutralizing 
antibody [144]. The continuous IL-6 intraperitoneal infusion (15 mg/day for 7 consecutive 
days) in rats was associated with a transient decrease in serum T4 and TSH, although less 
than that caused by IL-1 [145]. In latter study, pro-TRH mRNA hypothalamic and 
pituitary TSH-b mRNA were unaffected by IL-6, suggesting that the effects of IL-6 on TSH 
might not necessarily be associated with a decreased synthesis of thyrotropin [145]. On 
the other hand, the observation that the intracerebroventricular IL-6 administration to rats 
was followed by a decrease in serum TSH and an increase in serum adrenocorticotropin 
(ACTH) concentrations, while these changes could be reproduced in hemipituitaries only 
for ACTH, but not for TSH, suggested that the action of IL-6 on TSH might be exerted 
predominantly at the hypothalamic levels [146]. Increased concentrations of cytokines, 
especially IL-6, are often found in nonthyroidal illness patients and correlate with changes 
in thyroid hormone concentrations [144]. 
MCP-1 - Expression in adipose tissue and plasma MCP-1 levels have been found to 
correlate positively with the degree of obesity [7, 147-149]. Elevated circulating levels of 
MCP-1 as well as MCP-1 mRNA have been reported in obese mice [149, 150]. The 
possibility that MCP-1 formation in adipose tissue is due to macrophage infiltration must 
be considered since obesity is associated with various degrees of macrophage 
accumulation in adipose tissue [7, 147]. No data on this adipokines and thyroid hormone 
have been published. 
PAI-1 - Adipose tissue PAI-1 gene expression and serum concentration have been reported 
in several pathological conditions, such as obesity, hyperinsulinemia, and hyperglycemia 
[151, 152]. The thyroid hormones T4 and T3 also have cardiovascular effects, probably 
through the regulation of circulating clotting proteins and fibrinolytic activity [153]; 
however, the mechanisms leading to cardiovascular and thromboembolytic diseases in 
thyroid dysfunction are controversial. Some reports have described an increase in serum 
PAI-1 concentration in hyperthyroidism, whereas others did not detect any differences [154, 
155]. Biz, et al. [158] determined the effects of in vivo treatment of rats with the thyroid 
hormone T4 on gene expression and the serum concentration of PAI-1. Additionally, the 
effects of T3 and T4 on PAI-1 gene expression in 3T3-L1 adipocytes were also evaluated. The 
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results demonstrated that adipocytes present different responses to thyroid hormones when 
considering in vivo and in vitro experiments. Other investigations have also demonstrated 
different in vivo and in vitro responses. The diverse in vivo and in vitro effects of thyroid 
hormones on PAI-1 gene expression regulation are not related to the inhibitory effect of T4 
on thyroid-stimulating hormone (TSH) secretion, since the literature has not shown any 
relationship between TSH and PAI-1 serum concentration [157]. However, it could be 
suggested that the lower amount of thyroid hormone receptors and deiodinase present in 
white adipose tissue than in brain, liver, brown adipose tissue, and kidney may be involved 
in this process. In addition, the low blood flow in white adipose tissue in comparison to 
other tissue types [158] could contribute to hormone distribution in vivo, suggesting that 
lower amounts of T4 and T3 were achieved in adipocytes in vivo in comparison to the in vitro 
study. Thyroid hormones have different effects in relation to PAI-1 gene expression in 
adipocytes in the intact rat (in vivo study) and in cultured adipocytes (in vitro study). Further 
studies are required to better elucidate the diverse in vivo and in vitro effects of thyroid 
hormone on adipocytes PAI-1 gene expression [156]. 
ASP - In a number of studies, ASP has been demonstrated to be increased in obesity, 
diabetes and cardiovascular disease [159-161]. Plasma ASP levels correlate positively with 
body mass index, as well as with plasma lipids. Study using culture of human adipocytes 
revealed increased secretion of chylomicrons induced by ASP [162]. There is evidence that 
circulating lipids also stimulate the expression of ASP after drinking large quantities of these 
nutrients [163]. There is no data available regarding the effect of thyroid hormones on ASP 
levels in obesity. 
RAS- Adipose tissue synthesizes and secretes the major components of RAS [164]. There is 
evidence for overactivation of adipose tissue RAS in obesity in rodents [165], and for a 
positive correlation between adipose tissue angiotensinogen levels and BMI in humans 
[166]. Also Ang II secretion from adipose tissue is increased in obese, but not lean, 
individuals [167]. Increased production of angiotensinogen with excess gain in white 
adipose tissue contributes to glucose intolerance development, insulin resistance, 
cardiovascular and renal diseases [76, 168, 169]. In addition, increased RAS activity 
contributes to inflammation in fat tissue [170]. The interaction of RAS with other adipokines 
also contributes to the development of metabolic syndrome. Ang II appears to stimulate 
leptin production by adipocytes [76]; which in turn, hyperleptinemia may further 
hyperactivity of RAS by stimulating renin release by the kidney. Ang II may also regulate 
negatively adipocyte production of adiponectin in both rodents and humans [171, 172]. 
Thyroid hormones are important regulators of cardiac and renal functions while RAS 
components act systemically and locally in individual organs also to control cardiovascular 
and renal functions. Several studies have implicated the systemic and local RAS in the 
mediation of functional and structural changes in cardiovascular and renal tissues due to 
abnormal thyroid hormone levels [173, 174]. Thyroid hormones also appear to stimulate 
expression and synthesis of RAS components [175-177]. 
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IL-6 in the body fat deposits can be very importante in the obesity pathogenesis. The 
increase in IL-6 plasmatic could stimulate the hepatic synthesis of triacylglycerol, 
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concentrations, while the T4/T3 ratio decreased, suggesting that T4 deiodination was not 
affected [144]. Changes in serum thyroid hormone concentrations could effectively be 
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was followed by a decrease in serum TSH and an increase in serum adrenocorticotropin 
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MCP-1 as well as MCP-1 mRNA have been reported in obese mice [149, 150]. The 
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PAI-1 - Adipose tissue PAI-1 gene expression and serum concentration have been reported 
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results demonstrated that adipocytes present different responses to thyroid hormones when 
considering in vivo and in vitro experiments. Other investigations have also demonstrated 
different in vivo and in vitro responses. The diverse in vivo and in vitro effects of thyroid 
hormones on PAI-1 gene expression regulation are not related to the inhibitory effect of T4 
on thyroid-stimulating hormone (TSH) secretion, since the literature has not shown any 
relationship between TSH and PAI-1 serum concentration [157]. However, it could be 
suggested that the lower amount of thyroid hormone receptors and deiodinase present in 
white adipose tissue than in brain, liver, brown adipose tissue, and kidney may be involved 
in this process. In addition, the low blood flow in white adipose tissue in comparison to 
other tissue types [158] could contribute to hormone distribution in vivo, suggesting that 
lower amounts of T4 and T3 were achieved in adipocytes in vivo in comparison to the in vitro 
study. Thyroid hormones have different effects in relation to PAI-1 gene expression in 
adipocytes in the intact rat (in vivo study) and in cultured adipocytes (in vitro study). Further 
studies are required to better elucidate the diverse in vivo and in vitro effects of thyroid 
hormone on adipocytes PAI-1 gene expression [156]. 
ASP - In a number of studies, ASP has been demonstrated to be increased in obesity, 
diabetes and cardiovascular disease [159-161]. Plasma ASP levels correlate positively with 
body mass index, as well as with plasma lipids. Study using culture of human adipocytes 
revealed increased secretion of chylomicrons induced by ASP [162]. There is evidence that 
circulating lipids also stimulate the expression of ASP after drinking large quantities of these 
nutrients [163]. There is no data available regarding the effect of thyroid hormones on ASP 
levels in obesity. 
RAS- Adipose tissue synthesizes and secretes the major components of RAS [164]. There is 
evidence for overactivation of adipose tissue RAS in obesity in rodents [165], and for a 
positive correlation between adipose tissue angiotensinogen levels and BMI in humans 
[166]. Also Ang II secretion from adipose tissue is increased in obese, but not lean, 
individuals [167]. Increased production of angiotensinogen with excess gain in white 
adipose tissue contributes to glucose intolerance development, insulin resistance, 
cardiovascular and renal diseases [76, 168, 169]. In addition, increased RAS activity 
contributes to inflammation in fat tissue [170]. The interaction of RAS with other adipokines 
also contributes to the development of metabolic syndrome. Ang II appears to stimulate 
leptin production by adipocytes [76]; which in turn, hyperleptinemia may further 
hyperactivity of RAS by stimulating renin release by the kidney. Ang II may also regulate 
negatively adipocyte production of adiponectin in both rodents and humans [171, 172]. 
Thyroid hormones are important regulators of cardiac and renal functions while RAS 
components act systemically and locally in individual organs also to control cardiovascular 
and renal functions. Several studies have implicated the systemic and local RAS in the 
mediation of functional and structural changes in cardiovascular and renal tissues due to 
abnormal thyroid hormone levels [173, 174]. Thyroid hormones also appear to stimulate 
expression and synthesis of RAS components [175-177]. 
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5. Thyroid hormone effects on adipokines in weight loss 
5.1. Leptin 
After weight loss, leptin levels decrease [178-180], as well TSH and T3 reduces to normal 
levels [92, 93, 112]. In starvation conditions, serum leptin levels decrease and thyroid 
hormones levels are quickly supressed, leading to a consequent reduction in energy 
expenditure [83].  
Varady et al. [181] studying severely obese women have suggested that a minimum weigh 
loss of 5% is required to improve adipokines profile, including the reduction of leptin levels. 
Not only a minimal weight loss is required but a maximal weigh loss beyond which further 
improvements in circulating adipokine levels are no longer observed has been suggested 
[179, 182]. The method or diet content by which weigh loss is achieved seems to be less 
important than the overall weight loss [179, 183]. 
As mentioned before, studies investigating the correlation between thyroid hormones and 
leptin levels present conflicting results. Luvizotto et al. showed that administration of 
physiologic levels of T3 increases leptin mRNA expression with no influence on body weight 
in calorie-restricted obese rats [108], while administration of supraphysiological T3 dose 
promotes weight loss and diminishes serum levels and gene expression of leptin [108] 
(Figure 3). Again, as Syed et al. [106] reported, the effects of thyroid hormones in leptin 
concentrations might be indirect trough the regulation of fat mass (Figure 4). The decline of 
TSH release and T3 concentrations associated with decrease in leptin levels after weight loss 
may contribute to the compensatory reductions of energy expenditure and catabolism that 
typically accompany weight loss [184]. 
As both thyroid hormones and leptin have major roles in energy balance and regulation of 
body weight, an interaction between these hormones could not be discarded to achieve or 
maintain weight loss but further studies are necessary to elucidate the relationship between 
leptin and thyroid hormones. 
5.2. Resistin 
Since obesity is considered a global epidemic and one of majors public health problem, 
affecting developed and developing countries [185, 186], and obese subjects may presente 
increased resistin levels [46], which can worse insulin resistance and inflammation [119], one 
of the most used strategies is the weight loss by reduction of caloric intake [187]. Caloric 
restriction affects the regulation of adipose tissue gene expression, normalizing the 
adipokines changes caused by obesity [10], while thyroid hormones play a central role in 
regulating adipose tissue metabolism [83], being related to body weight changes, thyroid 
hormones may therefore play a key role in the normalization of resistin in weight loss. 
Nogueiras et al. [130] show a decrease in resistin mRNA expression in epididymal adipose 
tissue of pregnant and nonpregnant rats that were subjected to food restriction. Kim et al. [188] 
showed that resistin mRNA levels were decreased during fasting, but increased considerably 
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when the animals were refed or after insulin infusion. T3 had no effect on resistin mRNA levels 
in adipose tissue of obese animals submitted to calorie restriction [189]. 
Normalization of circulating thyroid hormones was accompanied by a significant decrease 
in resistin concentrations [126]. Others showed that hyperthyroid patients exhibit a 
significant decrease in resistin levels compared with euthyroid individuals, and the 
normalization of circulating thyroid hormones was not accompanied by any significant 
change in resistin levels [127]. After adjusting the weight by the body mass index, the 
resistin levels in hyperthyroid patients were similar to euthyroid subjects [128] (Figure 4). 
The association between thyroid hormone and resistin in weight loss present conflicting 
data, requiring further studies to evaluate this relation. 
5.3. Adiponectin 
Negative correlation between obesity and circulanting adiponectin has been well accept, 
and adiponectin concentration increases concomitantly to weight loss [190].  
Experimental study on caloric restriction showed increased levels of circulating adiponectin 
[191]. Accordingly, Zhu et al. [194] showed that calorically restricted animals exhibited a 
significant increase in plasma adiponectin levels accompanied by significant decline in 
triglyceride levels, showing that adiponectin levels are inversely proportional to the degree 
of adiposity [192, 193].  
Thyroid hormones perform a central role in adipose tissue metabolism regulation [83], 
which produces the biologically active substances adipocytokines, or adipokines, that 
include adiponectin [127, 194], indeed thyroid hormones share some physiological actions 
with adiponectin, such as reduction of body fat by increased thermogenesis and lipid 
oxidation [194].  
The interaction between thyroid hormones and adiponectin concentration remains unclear. 
In humans, hyperthyroidism has been associated with both similar [128, 195] and elevated 
adiponectin concentrations [196], while experimental study with hyperthyroid rats found an 
increase in adiponectin serum concentration [133]. In agreement, some data shown that 
therapy to normalize hyperthyroidism significantly reduced circulating adiponectin levels 
[197]. In contrast Luvizotto et al. [189] show that thyroid hormone, at the doses of 5 and 25 
μg T3 / 100 g BW, diminishes adiponectin gene expression, suggesting that thyroid hormone 
modulates negatively adiponectin expression in calorie-restricted obese rats (Figure 4). 
5.4. Others adipokines 
TNF-α - The first information about the TNF-α biological effects indicated an involvement in 
insulin resistance, weight loss and anorexia. The increase in lipolysis result from TNF-α 
stimulus in hormone-sensitive lipase expression, leading to decreased activity of lipoprotein 
lipase. However, more recent investigations have revealed a molecular mechanism of 
weight loss on TNF-α levels, showing TNF-α expression is increased in obesity and 
 
Thyroid Hormone 228 
5. Thyroid hormone effects on adipokines in weight loss 
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when the animals were refed or after insulin infusion. T3 had no effect on resistin mRNA levels 
in adipose tissue of obese animals submitted to calorie restriction [189]. 
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change in resistin levels [127]. After adjusting the weight by the body mass index, the 
resistin levels in hyperthyroid patients were similar to euthyroid subjects [128] (Figure 4). 
The association between thyroid hormone and resistin in weight loss present conflicting 
data, requiring further studies to evaluate this relation. 
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and adiponectin concentration increases concomitantly to weight loss [190].  
Experimental study on caloric restriction showed increased levels of circulating adiponectin 
[191]. Accordingly, Zhu et al. [194] showed that calorically restricted animals exhibited a 
significant increase in plasma adiponectin levels accompanied by significant decline in 
triglyceride levels, showing that adiponectin levels are inversely proportional to the degree 
of adiposity [192, 193].  
Thyroid hormones perform a central role in adipose tissue metabolism regulation [83], 
which produces the biologically active substances adipocytokines, or adipokines, that 
include adiponectin [127, 194], indeed thyroid hormones share some physiological actions 
with adiponectin, such as reduction of body fat by increased thermogenesis and lipid 
oxidation [194].  
The interaction between thyroid hormones and adiponectin concentration remains unclear. 
In humans, hyperthyroidism has been associated with both similar [128, 195] and elevated 
adiponectin concentrations [196], while experimental study with hyperthyroid rats found an 
increase in adiponectin serum concentration [133]. In agreement, some data shown that 
therapy to normalize hyperthyroidism significantly reduced circulating adiponectin levels 
[197]. In contrast Luvizotto et al. [189] show that thyroid hormone, at the doses of 5 and 25 
μg T3 / 100 g BW, diminishes adiponectin gene expression, suggesting that thyroid hormone 
modulates negatively adiponectin expression in calorie-restricted obese rats (Figure 4). 
5.4. Others adipokines 
TNF-α - The first information about the TNF-α biological effects indicated an involvement in 
insulin resistance, weight loss and anorexia. The increase in lipolysis result from TNF-α 
stimulus in hormone-sensitive lipase expression, leading to decreased activity of lipoprotein 
lipase. However, more recent investigations have revealed a molecular mechanism of 
weight loss on TNF-α levels, showing TNF-α expression is increased in obesity and 
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decreases with weight loss, thereby improving insulin sensitivity [135, 198]. After weight 
loss there is a decrease of macrophages number in adipose tissue [199], this can lead to 
decreased TNF-α levels, since both adipose tissue and macrophages produce this cytokine. 
There are few studies correlating the thyroid status with TNF-α levels in weight loss. 
Patients with HIV tend to lose weight and in some cases it is observed a decrease in T3 levels 
accompanied by increased TNF-α levels, when these individuals are compared to patients 
with HIV with normal T3 levels. These results corroborate to other study linking the sick 
euthyroid syndrome to high TNF-α levels in cachectic patients with HIV [200].  
 
Figure 4. Thyroid hormone may modulate adipokines concentration by regulating adipose tissue 
metabolism by, i.e., increasing lipid oxidation leading to body fat decreased. The exact influence of 
thyroid hormone on adipokines remains unclear.  
IL-6 - IL-6 levels decrease with weight loss [140-142]. The intracerebroventricular 
administration of this cytokine can decrease body fat [201]. Association studies between 
thyroid hormones and IL-6 in weight loss are scarce, but studies in critically patients 
demonstrated a direct association between decreased T3 levels and high IL-6 plasma levels, 
demonstrating that approximately 28% of T3 fall could be directly related to increased IL-6 
[202]. In another study, of 270 patients admitted to intensive care unit, serum T3, T4 and IL-6 
were measured and again was observed a negative correlation between T3 and T4 levels and 
IL-6 levels, demonstrating that this cytokine could be an important factor associated with 
decreased circulating thyroid hormones levels [203].  
MCP-1 - Chronic inflammation associated with obesity exists in dogs, and it is evident that 
weight loss decreases this inflammation as observed by decreasing MCP-1 after weight loss 
[204]. In agreement, Kanda et al. [205] demonstrated that MCP-1 deficient mice have 
reduced adipose tissue macrophage infiltration. Few studies correlate weight loss and MCP-
1 levels, and no data was found regarding weight loss, MCP-1 and thyroid association. 
PAI-1 - Weight loss secondary to calorie restriction is associated with reduced PAI-1 activity 
in adults [206, 207]. However, in children no significant change in PAI-1 levels was observed 
in 43 obese children after a physical training program [208]. This may be explain by the 
increase in fibrinolytic activity due to a decrease in PAI-1 antigen levels in obese children 
after weight loss, and a significant positive correlation was observed between variations in 
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body mass index and variations in PAI-1 levels. Moreover, the largest decrease in PAI-1 
levels was observed in the obese children with the highest previous PAI-1 levels [209]. 
Weight loss induced by a low calorie diet causes a decrease in plasma PAI-1 levels especially 
among obese individuals [210, 211], and these increase once again if weight is regained 
[212]. Surgically removing fat confers the same beneficial effect [212]. Antidiabetic drugs 
such as thiazolidinediones, metformin, and AT1-receptor antagonists reduce adipose PAI-1 
expression [211].  Interestingly, waist-to-hip ratio, a reflection of central fat accumulation, 
has been found in women to be the only independent predictor of circulating PAI-1 activity 
[213]. In individuals subjected to a calorie restricted diet, PAI-1 levels were more closely 
related to changes in the central fat deposit than in the subcutaneous fat deposit [214]. Thus, 
the visceral fat deposit may be importante for the occurrence of increased plasma PAI-1 
levels. There is few data available regarding the thyroid hormones and PAI-1. Studies have 
been focused on serum measurements, in severe hypothyroidism was found decreased PAI-
1 levels [215], while in hyperthyroidism some studies show increased [113, 216, 217], other 
decreased [83, 218] as well as unaffected PAI-1 levels [219, 220].  
RAS - Studies with RAS manipulation (deletion) showed that function loss in any single 
component of RAS tested so far, provides protection from diet-induced obesity and insulin 
resistance [221-224]. Therefore, RAS seems to play a role in obesity development; however 
systemic RAS overactivation via gene overexpression or chronic Ang II infusion also induces 
insulin resistance, but not necessarily obesity [225]. Weight loss in humans results in decreases 
in circulating components of the RAS [226]. In fact, Engeli et al. [226] suggest that a 5% 
reduction in body fat mass can reduce meaningfully the RAS in plasma and adipose tissue, 
which may contribute to reduce blood pressure. Genetic polymorphisms of RAS may also play 
a role in response to weight loss in obese individuals [227]. Decrease of RAS leads to 
improvement in insulin sensitivity, blood pressure, and renal function. As RAS interacts with 
others adipokines, reduction in RAS concentrations followed weight loss may also contributes 
to improvement of other adipokines levels and, consequently, improve other metabolic 
disorders [226, 228]. As mentioned, thyroid hormones appear to stimulate expression and 
synthesis of RAS components [175-177]. However, precise interaction between thyroid 
hormones and RAS components in weight loss process are scarce in the literature. 
Literature on newer adipokines and thyroid disorders is scarce. No data on ASP and weight 
loss is available and no data on these adipokines and thyroid hormone have been published 
so far. Future research studying these associations is awaited. 
6. The use of TRβ analogues 
Thyroid hormone analogues, termed thyromimetics, are molecules with activate signaling 
pathway property similar to thyroid hormones, sometimes with tissue specificity or by 
activating a singular pathway stimulated by thyroid hormones, other with less effect, but 
even with a way close to thyroid hormones. The thyromimetics have a great pharmaceutical 
potential since they present certain specificity as intracellular signaling that stimulate and 
thus may have a tissue specific action. However, only the past 20 years, with increasing 
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decreases with weight loss, thereby improving insulin sensitivity [135, 198]. After weight 
loss there is a decrease of macrophages number in adipose tissue [199], this can lead to 
decreased TNF-α levels, since both adipose tissue and macrophages produce this cytokine. 
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IL-6 levels, demonstrating that this cytokine could be an important factor associated with 
decreased circulating thyroid hormones levels [203].  
MCP-1 - Chronic inflammation associated with obesity exists in dogs, and it is evident that 
weight loss decreases this inflammation as observed by decreasing MCP-1 after weight loss 
[204]. In agreement, Kanda et al. [205] demonstrated that MCP-1 deficient mice have 
reduced adipose tissue macrophage infiltration. Few studies correlate weight loss and MCP-
1 levels, and no data was found regarding weight loss, MCP-1 and thyroid association. 
PAI-1 - Weight loss secondary to calorie restriction is associated with reduced PAI-1 activity 
in adults [206, 207]. However, in children no significant change in PAI-1 levels was observed 
in 43 obese children after a physical training program [208]. This may be explain by the 
increase in fibrinolytic activity due to a decrease in PAI-1 antigen levels in obese children 
after weight loss, and a significant positive correlation was observed between variations in 
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body mass index and variations in PAI-1 levels. Moreover, the largest decrease in PAI-1 
levels was observed in the obese children with the highest previous PAI-1 levels [209]. 
Weight loss induced by a low calorie diet causes a decrease in plasma PAI-1 levels especially 
among obese individuals [210, 211], and these increase once again if weight is regained 
[212]. Surgically removing fat confers the same beneficial effect [212]. Antidiabetic drugs 
such as thiazolidinediones, metformin, and AT1-receptor antagonists reduce adipose PAI-1 
expression [211].  Interestingly, waist-to-hip ratio, a reflection of central fat accumulation, 
has been found in women to be the only independent predictor of circulating PAI-1 activity 
[213]. In individuals subjected to a calorie restricted diet, PAI-1 levels were more closely 
related to changes in the central fat deposit than in the subcutaneous fat deposit [214]. Thus, 
the visceral fat deposit may be importante for the occurrence of increased plasma PAI-1 
levels. There is few data available regarding the thyroid hormones and PAI-1. Studies have 
been focused on serum measurements, in severe hypothyroidism was found decreased PAI-
1 levels [215], while in hyperthyroidism some studies show increased [113, 216, 217], other 
decreased [83, 218] as well as unaffected PAI-1 levels [219, 220].  
RAS - Studies with RAS manipulation (deletion) showed that function loss in any single 
component of RAS tested so far, provides protection from diet-induced obesity and insulin 
resistance [221-224]. Therefore, RAS seems to play a role in obesity development; however 
systemic RAS overactivation via gene overexpression or chronic Ang II infusion also induces 
insulin resistance, but not necessarily obesity [225]. Weight loss in humans results in decreases 
in circulating components of the RAS [226]. In fact, Engeli et al. [226] suggest that a 5% 
reduction in body fat mass can reduce meaningfully the RAS in plasma and adipose tissue, 
which may contribute to reduce blood pressure. Genetic polymorphisms of RAS may also play 
a role in response to weight loss in obese individuals [227]. Decrease of RAS leads to 
improvement in insulin sensitivity, blood pressure, and renal function. As RAS interacts with 
others adipokines, reduction in RAS concentrations followed weight loss may also contributes 
to improvement of other adipokines levels and, consequently, improve other metabolic 
disorders [226, 228]. As mentioned, thyroid hormones appear to stimulate expression and 
synthesis of RAS components [175-177]. However, precise interaction between thyroid 
hormones and RAS components in weight loss process are scarce in the literature. 
Literature on newer adipokines and thyroid disorders is scarce. No data on ASP and weight 
loss is available and no data on these adipokines and thyroid hormone have been published 
so far. Future research studying these associations is awaited. 
6. The use of TRβ analogues 
Thyroid hormone analogues, termed thyromimetics, are molecules with activate signaling 
pathway property similar to thyroid hormones, sometimes with tissue specificity or by 
activating a singular pathway stimulated by thyroid hormones, other with less effect, but 
even with a way close to thyroid hormones. The thyromimetics have a great pharmaceutical 
potential since they present certain specificity as intracellular signaling that stimulate and 
thus may have a tissue specific action. However, only the past 20 years, with increasing 
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resolution of three-dimensional models, docking experiments and crystallography models 
the specificity of thyromimetics has been revealed. 
Thyroid hormone is one of the most responsible for metabolism controlling and cell oxygen 
consumption, affecting growth, cell differentiation and homeostasis control [229]. The 
thyroid hormone also has specific functions depending on tissue: in liver, controlling lipid 
metabolism [230-232]; in heart, regulating the calcium handling and the heart rate [233]. As 
for lipid deposits, the thyroid hormone acts in brown adipose tissue by controlling heating 
and adaptive thermogenesis during rest [234]. Under high hormone levels conditions in the 
organism, such as hyperthyroidism, there is an increase in metabolic rate with consequent 
weight loss and decrease cholesterol serum levels, desirable conditions for metabolic 
diseases treatment such as obesity [235] and hyperlipidemia [230-232]. In this context, the 
possible specificity through thyroid homone analogues may lead to desirable effects on 
adipokines release control and obesity, without the undesirable symptoms on heart or on 
TSH release. 
Thyromimetics can be seen as thyroid hormone derivative or its metabolites derivative. 
Studies on the direct influence of these analogues on adipokines levels are scarce, but the 
tissue selectivity shown may be interesting in the study of non thyroid diseases, mainly 
involving the lipid rate control in adipose tissue and decreased cholesterol by the liver. This 
selectivity in many cases is related to action pathway stimulate by thyromimetics. Some of 
them may have actions in liver and adipose tissue through its selective binding to TR-β1, 
while not lead to effects such as tachycardia since there is no selectivity for the TR-α1 (most 
expressed isoform in the heart). Thus we can highlight some known thyromimetics and 
some details of their actions. 
The first developed analogue, in the mid-1980s, was 3,5-dibromo-3-pyridazinone-L-
thyronine (L-94901) present 50% of binding T3 to TRs in liver, and only 1.3% effective for 
cardiac TRs [236, 237]. L-94901 showed an increase of oxygen overall consumption and a 
reduction in cholesterol serum levels in animal models submitted to low dose, sufficient to 
prevent cardiotoxic effects, however, also led to lower TSH, T4 and T3 plasma levels [236]. 
An analogue selectivity-related to TR-β1 is 3,5-Dichloro-4-[(4-hydroxy-3-isopropylphenoxy)-
phenyl] acetic acid (KB-141), with 10-fold greater ability to reduce the cholesterol rate than 
increase heart rate [238, 239], stimulating metabolic rate and oxygen consumption [240]. 
Eprotirome (KB2115) is a thyroid hormone analogue that has a low uptake by non-hepatic 
tissues. It has preferential selectivity for the TRβ, leading to decreased total cholesterol, LDL 
and apolipoprotein B levels without apparent side-effects. It showed good results in 
hypercholesterolemia treatment and associated with statin was effective in reducing 
atherogenic lipoproteins levels without extra-hepatics effects of thyroid hormone [241]. 
One of the most widely studied thyroid hormone analogues is 3,5-dimethyl-4-[(4'-hydroxy-
3'-isopropylbenzyl)-phenoxy] acetic acid (CG-1), with selectivity for TRβ 10-fold greater 
than for TR-α. Hypercholesterolemic rats models treated with GC-1 showed decrease in 
cholesterol, LDL and triglyceride serum levels, without significantly altering heart function 
or regulated-thyroid hormone gene expression as MHC-HT and α, β-MHC and SERCA2 
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[242]. The same results were observed with KB-141 use, but with a subtle increase in heart 
rate. Contributing to cholesterol serum levels reduction by GC-1 is the increased SR-BI 
expression, a receptor that promotes cholesterol uptake in the liver, stimulating the bile 
acids production [243]. Deleterious effects absence of GC-1 on cardiac structure and function 
[244], skeletal muscle and bone mass [245] suggests that GC-1 has potential therapeutic use 
for metabolic disorders such as obesity and hyperlipidemia [246]. 
Started studies during the mid-1990s, N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-
phenyl] oxamic acid (CGS-23425) was a potent ability to decrease cholesterol in rats and 
dogs at dose 25 times higher than the minimum for producing lipid lowering effects [247]. 
In hypercholesterolemic rats, CGS-23425 had the desired effects of decreasing serum LDL 
and increased apoA1, with a corresponding increase in apoA1 gene transcription by TR-β1 
selectively [248]. 
A thyroid hormone analogue currently in phase II clinical trial is the 3.5-
diiodothyropropionic acid (DITPA), with affinity equivalent between TR-α1 and β1 but with 
100 times less affinity than T3 [249]. In hypothyroid rats, DITPA improved cardiac 
performance with half the chronotropic effect and less metabolic stimulation than 
levothyroxine [250]. In normal volunteers, DITPA does not affect the heart rate or blood 
pressure, while the serum cholesterol and triglycerides were significantly decreased [251]. 
Observations have shown that DIPTA exerts its action by stimulating nongenomic pathways 
stimulated by T3 as the αVβ3 integrin receptor, activating the MAPK cascade and causing 
similar effects to those seen with GC-1, leading to angiogenesis, indicating that some cardiac 
effects may be caused by nongenomic pathway activation [252]. 
Although there are few studies on thyromimetics and adipokines, studies on obesity and 
lipid lowering show interesting results. Other compounds have been studied as thyroid 
hormone natural metabolic intermediates: 3-iodothyronamine (T1AM) showed effects on 
cardiac output, heart hate and decreased body temperature with neuroprotective action; 
Diiodothyronine-3.5 (T2) with effects such as increased lipid peroxidation and fatty acids 
oxidation, among others; 3,3 ', 5'-triiodothyronine (rT3) able to initiate actin polymerization; 
triiodothyroacetic acid (Triac) that increases the metabolic rate and thermogenesis, and one 
of the few identified analogues able to increase leptin secretion [246]. Like thyromimetics, 
these natural metabolites, collectively, show body weight and fat mass reduction, while 
thyromimetics are more specific to reduce cholesterol serum levels, but both have effects 
saving cardiac activity. However, before they are used in large scale, attention should be 
paid to non-selectivity presented by natural metabolites, and for TSH suppression showed 
by thyromimetics, which may lead to undesirable tissue hypothyroidism. Thus, the tissue 
specificity and selectivity for TR brings a good perspective for thyromimetics, however there 
is still a long way from its use as therapeutic agent. 
7. Final considerations 
Adipose tissue produces a wide range of biological active substances, named adipokines, 
involved in glucose metabolism, lipid metabolism, inflammation, coagulation, blood 
pressure, and feeding behavior, thus affecting metabolism and function of many organs and 
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resolution of three-dimensional models, docking experiments and crystallography models 
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thyronine (L-94901) present 50% of binding T3 to TRs in liver, and only 1.3% effective for 
cardiac TRs [236, 237]. L-94901 showed an increase of oxygen overall consumption and a 
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prevent cardiotoxic effects, however, also led to lower TSH, T4 and T3 plasma levels [236]. 
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[242]. The same results were observed with KB-141 use, but with a subtle increase in heart 
rate. Contributing to cholesterol serum levels reduction by GC-1 is the increased SR-BI 
expression, a receptor that promotes cholesterol uptake in the liver, stimulating the bile 
acids production [243]. Deleterious effects absence of GC-1 on cardiac structure and function 
[244], skeletal muscle and bone mass [245] suggests that GC-1 has potential therapeutic use 
for metabolic disorders such as obesity and hyperlipidemia [246]. 
Started studies during the mid-1990s, N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-
phenyl] oxamic acid (CGS-23425) was a potent ability to decrease cholesterol in rats and 
dogs at dose 25 times higher than the minimum for producing lipid lowering effects [247]. 
In hypercholesterolemic rats, CGS-23425 had the desired effects of decreasing serum LDL 
and increased apoA1, with a corresponding increase in apoA1 gene transcription by TR-β1 
selectively [248]. 
A thyroid hormone analogue currently in phase II clinical trial is the 3.5-
diiodothyropropionic acid (DITPA), with affinity equivalent between TR-α1 and β1 but with 
100 times less affinity than T3 [249]. In hypothyroid rats, DITPA improved cardiac 
performance with half the chronotropic effect and less metabolic stimulation than 
levothyroxine [250]. In normal volunteers, DITPA does not affect the heart rate or blood 
pressure, while the serum cholesterol and triglycerides were significantly decreased [251]. 
Observations have shown that DIPTA exerts its action by stimulating nongenomic pathways 
stimulated by T3 as the αVβ3 integrin receptor, activating the MAPK cascade and causing 
similar effects to those seen with GC-1, leading to angiogenesis, indicating that some cardiac 
effects may be caused by nongenomic pathway activation [252]. 
Although there are few studies on thyromimetics and adipokines, studies on obesity and 
lipid lowering show interesting results. Other compounds have been studied as thyroid 
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of the few identified analogues able to increase leptin secretion [246]. Like thyromimetics, 
these natural metabolites, collectively, show body weight and fat mass reduction, while 
thyromimetics are more specific to reduce cholesterol serum levels, but both have effects 
saving cardiac activity. However, before they are used in large scale, attention should be 
paid to non-selectivity presented by natural metabolites, and for TSH suppression showed 
by thyromimetics, which may lead to undesirable tissue hypothyroidism. Thus, the tissue 
specificity and selectivity for TR brings a good perspective for thyromimetics, however there 
is still a long way from its use as therapeutic agent. 
7. Final considerations 
Adipose tissue produces a wide range of biological active substances, named adipokines, 
involved in glucose metabolism, lipid metabolism, inflammation, coagulation, blood 
pressure, and feeding behavior, thus affecting metabolism and function of many organs and 
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tissues including muscle, liver, vasculature, and brain. Obesity cause imbalance in the 
adipokines production, while the weight loss are able to normalize these changes. In obese, 
the stabilization of weight loss even in calorie restricted diet has been attributed to the 
decrease in serum T3 concentrations, leading to a reduction in metabolic rate. Because of 
this, and despite not being accepted as an obesity treatment, the administration of thyroid 
hormones, in isolation or in association with hypocaloric diets, is sometimes used illicitly. 
The thyroid hormones regulate the energetic balance and act on the adipokines, regulating 
several genes in adipose tissue. However, the available data on the effects of thyroid 
hormone on adipokines in obesity or weight loss are conflicting. A clear association has not 
yet been established between in obesity and calorie restriction in obesity and the effect of 
thyroid hormone on adipokines, requiring further studies. Despite studies of TRβ analogs 
show good results, the direct influence of these analogues on adipokines levels are scarce. 
More research is needed to fully elucidate the exact mechanism of thyroid hormone and its 
analogues on adipokines in obesity and weight loss. 
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The thyroid hormones regulate the energetic balance and act on the adipokines, regulating 
several genes in adipose tissue. However, the available data on the effects of thyroid 
hormone on adipokines in obesity or weight loss are conflicting. A clear association has not 
yet been established between in obesity and calorie restriction in obesity and the effect of 
thyroid hormone on adipokines, requiring further studies. Despite studies of TRβ analogs 
show good results, the direct influence of these analogues on adipokines levels are scarce. 
More research is needed to fully elucidate the exact mechanism of thyroid hormone and its 
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1. Introduction 
Thyroid hormones play a crucial role in the skeletal growth, peak bone mass acquisition and 
maintenance of bone mass. Abnormalities in hypothalamic–pituitary–thyroid axis in infancy 
and childhood have been shown to interfere with a normal linear growth and skeletal 
maturation. Hypothyroidism compromises normal bone formation and results in slowing of 
linear growth. Thyrotoxicosis leads to growth acceleration, diminution of bone mass and 
advance in bone age. Studies in animal models have demonstrated the importance of 
thyroid hormone signaling in the maintenance of bone mass in adulthood. Increased risk of 
fracture has been demonstrated in both hypothyroidism and hyperthyroidism. The thyroid 
hormone, 3,5,3’-triiodothyronine (T3), has long been considered to play a primordial role in 
the skeletal homeostasis. However, recent studies have shown that TSH acts as a direct 
regulator of bone remodeling, highlighting the importance of integrity of the hypothalamo-
pituitary-thyroid axis. 
This chapter will review our current understanding regarding the action of thyroid 
hormones on the bone development and maintenance of bone mass, under normal 
conditions and as a result of thyroid gland dysfunction. Mechanism of thyroid hormone 
action will be illustrated in relation to bone with the focus on the genetic regulation and the 
molecular interactions between thyroid hormones and skeletal cells. Clinical consequences 
of thyroid dysfunction on the growth and skeletal maturation will be detailed. We will 
review the published literature regarding BMD in hyperthyroid and hypothyroid patients 
including patients on medical therapy, as well as the influence of sex and menopause on the 
maintenance of bone mass. The impact of treatments for thyroid dysfunction on the bone 
mineral metabolism will be discussed.  
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2. Role of thyroid hormones in bone growth and metabolism 
Thyroid hormones are critical for the skeletal development and the bone maintenance. The 
thyroid hormone, 3,5,3’-triiodothyronine (T3), is responsible for major actions of thyroid 
hormones. T3 binds to nuclear receptors that regulate gene transcription via interaction with 
thyroid hormone response elements of specific genes (Sap et al., 1986; Weinberger et al., 
1986; Thompson et al., 1987). Recently, non-genomic actions of T3 and T4 have been 
described (Cheng et al., 2010). Local tissue availability of T3 seems to be regulated by type 2 
and 3 deiodinase (St Germain et al, 2009). The nuclear thyroid hormone receptors (TRs) are 
derived from the THRA and THRB genes coding for the TRα1 and β1-2 T3-binding 
isoforms, truncated isoforms ∆α1, ∆α2 and ∆β3, and a TRa2 non-T3-binding isoform of 
unknown function (Lazar et Chin et al, 1990; Lazar, 1993; Chassande et al, 1997; Williams, 
2000; Cheng et al, 2010). Expression of TRα1 and TRβ1 was described in growth plate 
chondrocytes, osteoblasts, and stromal cells of bone marrow (Williams et al, 1994; Abu et al, 
1997; Ballock et al, 1999; Bradley et al, 1992; Bassett et Williams, 2003; Siddiqi et al, 2002). 
Expression of TRα in the skeleton is higher than that of TRβ (Bookout et al, 2006; O’Shea et 
al, 2003). 
2.1. Thyroid hormone and bone development 
Studies on animal models have brought valuable insights into role of TRs in bone 
development and growth. Mice lacking TRβ or TRα1 did not display abnormalities in 
skeletal development (Forrest et al, 1996; Wikstrom et al, 1998). On the other hand, genetic 
disruption of both receptors (TRα1 and TRβ) led to delayed ossification and disorders in 
development of epiphyseal growth plates (EGPs; Gothe et al, 1999). Pax-8−/− mice, expressing 
all TR isoforms, but lacking the follicular cells producing T4 and T3 in the thyroid gland, 
displayed more severe abnormalities in bone development than mice KO for all TRs (TRα0/0, 
TRβ−/−) (Flamant et al, 2002). The authors concluded that the unliganded TRs (aporeceptors) 
on thyroid hormone responsive genes have repressor effects during bone development. In 
support of this, Pax-8−/−TRα0/0, but not Pax-8−/−TRβ−/−, compound mutants presented a partial 
rescue of the bone phenotype (O’Shea et Williams, 2002; Flamant et al, 2002). Another study 
was realized employing mice invalidated for TRα. These animals were euthyroid, but 
displayed a growth delay with abnormal bone development and ossification (Bassett et al 
2007a, 2007b; Gauthier et al, 1999, 2001; O’Shea 2003, 2005). Mice lacking all TRα isoforms 
presented a less severe impairment of bone development than TRα-/- mice, pointing to the 
role of non-T3 binding TRα isoforms (∆α1 and ∆α2) (Gauthier et al, 2001). On the other 
hand, mice with nonfunctional TRβ displayed augmentation in circulating thyroid hormone 
levels associated with dysregulation of hypothalamo-pituitary-thyroid axis. These animals 
had skeletal signs of hyperthyroidism, increased bone mineral deposition and acceleration 
of growth-plate maturation, resulting in a short adult body size (Bassett et al, 2007a; O’Shea 
et al, 2003). These findings suggested an increased skeletal response to T3 via TRα, which 
was consistent with the hypothesis that elevated circulating thyroid hormone levels in TRβ 
mutant mice result in an increased skeletal response to T3 via TRα (O’Shea et al, 2006). 
Recently, GC-1, thyroid hormone analogue targeting preferentially TRβ1 over TRα1, has 
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partially reverted skeletal development and maturation defects in hypothyroid rats (Freitas 
et al, 2005). This finding is suggestive of TRβ1 involvement in bone growth.  
Thyroid hormones regulate bone development also indirectly through the growth hormone 
(GH) and insulin-like growth factor-I (IGF-I) axis. Previously, it was demonstrated that T4 
enhanced the growth promoting effect of GH/IGF-I (Thorngren et Hansson, 1974) and could 
stimulate longitudinal bone growth in hypophysectomized rats (Thorngren et Hansson, 
1973; Ray et al, 1954). T3 was shown to interact with the thyroid hormone receptor - thyroid 
hormone responsive element complex (TR-TRE) in the GH promoter to regulate GH gene 
transcription (Glass et al, 1987; Koenig et al, 1987). However, GH without T3 did not 
promote the maturation (Ballock et Reddi, 1994) and organization (Lewinson et al, 1989) of 
growth plate chondrocytes and GH replacement could not rescue the impaired ossification 
in TRα and TRβ-null mice (Kindblom et al, 2001). In TRα1−/−β−/− mice, GH substitution 
reversed the growth phenotype, but not the defective ossification (Kindblom et al, 2001).  On 
the other hand, inactivation of GH or IGF-I receptors in mice was associated with delayed 
ossification (Liu et al, 1993; Sjogren et al, 2000). 
Overall, the literature data indicate importance of both TRs and GH-IGF-I axis in skeletal 
development. Other factors, such as the Indian Hedgehog (Ihh), parathyroid hormone-
related peptide (PTHrP), fibroblast growth factor receptor and Wnt--catenin signaling 
pathways, are implicated in this process (Barnard et al, 2005; O’Shea et al, 2005; Stevens et 
al, 2000, 2003; Wang et al, 2007). Further studies are warranted to clarify the exact 
mechanisms underlying the physiological regulation of bone development. 
2.2. Thyroid hormone and bone remodeling 
Literature evidence points to the critical importance of thyroid hormones in bone 
remodeling and maintenance. Adult euthyroid mice invalidated for TRα have reduced 
osteoclastic bone resorption and increased trabecular bone volume and mineralization 
(Bassett et al, 2007a, 2007b), indicating a critical role of TRα in T3 action in bone cells. On the 
other hand, increased osteoclastic bone resorption and severe osteoporosis were 
demonstrated in adult TRβ mutant mice, suggestive of thyroid hormone excess in TRα-
expressing skeletal cells (Bassett et al, 2007a, 2007b; Gauthier et al, 2001; O’Shea et al, 2006). 
The bone architecture and strength are maintained by a balanced process of remodeling, 
which involves recruitment of osteoclast and osteoblasts. T3 can induce differentiation and 
inhibits proliferation of osteoblastic cells. T3 was shown to promote production of IL-6, IL-8, 
IGF-I and its binding proteins IGFBP2-4 in bone marrow stromal cells and osteoblasts (Milne 
et al, 2001; Siddiqi et al, 1998), and to increase the expression of several bone-related genes, 
including osteocalcin, collagen type I, gelatinase B and collagenase 3 (Gouveia et al 2001; Milne 
et al 1998; Pereira 1999; Varga et al 1997; Williams et al 1994). T3 is implicated in 
chondrogenesis, angiogenesis, bone matrix formation and mineralization (Himeno et al, 2002; 
Makihira et al, 2003; Pereira et al, 1999). In primary cultures of growth plate chondrocytes, T3 
inhibits chondrocyte clonal expansion and cell proliferation, induces hypertrophic 
chondrocyte differentiation and promotes cartilage matrix mineralization (Robson et al, 2000).  
 
Thyroid Hormone 252 
2. Role of thyroid hormones in bone growth and metabolism 
Thyroid hormones are critical for the skeletal development and the bone maintenance. The 
thyroid hormone, 3,5,3’-triiodothyronine (T3), is responsible for major actions of thyroid 
hormones. T3 binds to nuclear receptors that regulate gene transcription via interaction with 
thyroid hormone response elements of specific genes (Sap et al., 1986; Weinberger et al., 
1986; Thompson et al., 1987). Recently, non-genomic actions of T3 and T4 have been 
described (Cheng et al., 2010). Local tissue availability of T3 seems to be regulated by type 2 
and 3 deiodinase (St Germain et al, 2009). The nuclear thyroid hormone receptors (TRs) are 
derived from the THRA and THRB genes coding for the TRα1 and β1-2 T3-binding 
isoforms, truncated isoforms ∆α1, ∆α2 and ∆β3, and a TRa2 non-T3-binding isoform of 
unknown function (Lazar et Chin et al, 1990; Lazar, 1993; Chassande et al, 1997; Williams, 
2000; Cheng et al, 2010). Expression of TRα1 and TRβ1 was described in growth plate 
chondrocytes, osteoblasts, and stromal cells of bone marrow (Williams et al, 1994; Abu et al, 
1997; Ballock et al, 1999; Bradley et al, 1992; Bassett et Williams, 2003; Siddiqi et al, 2002). 
Expression of TRα in the skeleton is higher than that of TRβ (Bookout et al, 2006; O’Shea et 
al, 2003). 
2.1. Thyroid hormone and bone development 
Studies on animal models have brought valuable insights into role of TRs in bone 
development and growth. Mice lacking TRβ or TRα1 did not display abnormalities in 
skeletal development (Forrest et al, 1996; Wikstrom et al, 1998). On the other hand, genetic 
disruption of both receptors (TRα1 and TRβ) led to delayed ossification and disorders in 
development of epiphyseal growth plates (EGPs; Gothe et al, 1999). Pax-8−/− mice, expressing 
all TR isoforms, but lacking the follicular cells producing T4 and T3 in the thyroid gland, 
displayed more severe abnormalities in bone development than mice KO for all TRs (TRα0/0, 
TRβ−/−) (Flamant et al, 2002). The authors concluded that the unliganded TRs (aporeceptors) 
on thyroid hormone responsive genes have repressor effects during bone development. In 
support of this, Pax-8−/−TRα0/0, but not Pax-8−/−TRβ−/−, compound mutants presented a partial 
rescue of the bone phenotype (O’Shea et Williams, 2002; Flamant et al, 2002). Another study 
was realized employing mice invalidated for TRα. These animals were euthyroid, but 
displayed a growth delay with abnormal bone development and ossification (Bassett et al 
2007a, 2007b; Gauthier et al, 1999, 2001; O’Shea 2003, 2005). Mice lacking all TRα isoforms 
presented a less severe impairment of bone development than TRα-/- mice, pointing to the 
role of non-T3 binding TRα isoforms (∆α1 and ∆α2) (Gauthier et al, 2001). On the other 
hand, mice with nonfunctional TRβ displayed augmentation in circulating thyroid hormone 
levels associated with dysregulation of hypothalamo-pituitary-thyroid axis. These animals 
had skeletal signs of hyperthyroidism, increased bone mineral deposition and acceleration 
of growth-plate maturation, resulting in a short adult body size (Bassett et al, 2007a; O’Shea 
et al, 2003). These findings suggested an increased skeletal response to T3 via TRα, which 
was consistent with the hypothesis that elevated circulating thyroid hormone levels in TRβ 
mutant mice result in an increased skeletal response to T3 via TRα (O’Shea et al, 2006). 
Recently, GC-1, thyroid hormone analogue targeting preferentially TRβ1 over TRα1, has 
 
Thyroid Disorders and Bone Mineral Homeostasis 253 
partially reverted skeletal development and maturation defects in hypothyroid rats (Freitas 
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inhibits chondrocyte clonal expansion and cell proliferation, induces hypertrophic 
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Furthermore, T3 is involved in local signaling pathways by stimulating osteoblast responses 
to IGF1-I, PTH and fibroblast growth factors. T3 is a critical regulator of the Ihh - bone 
morphogenetic protein (BMP) – PTHrP feedback loop (Stevens et al, 2000). Hypothyroidism 
is marked by increased PTHrP expression and impaired hypertrophic chondrocyte 
differentiation (Stevens et al, 2000). In hyperthyroidism, reduced expression of PTHrP 
associated with augmentation of BMP enhances hypertrophic chondrocyte differentiation 
(Lassova et al, 2009; Stevens et al, 2000). It has also been shown that T3 regulates terminal 
differentiation of growth plate chondrocytes in part through controlling cell cycle 
progression at the G1/S restriction point (Ballock et al, 2000). T3 mediates osteoclastic bone 
resorption through activation of osteoblasts, which then release receptor activator for NF-κB 
ligand (RANKL), a member of the TNF cytokine family. RANKL is a ligand for 
osteoprotegerin, a cytokine that regulates osteoclastic differentiation, and functions as a key 
factor for osteoclast differentiation and activation by inhibiting osteoclasts apoptosis (Allain 
et al, 1992; Britto et al, 1994).  
Overall, T3 seems to enhance activity of osteoblasts by various mechanisms and signaling 
loops. Although the effects of thyrotoxicosis in adult bone are characterized by increased 
bone resorption, it is not known whether T3 acts directly in osteoclasts or whether effects on 
osteoclasts are secondary to the actions of T3 in osteoblasts. 
2.3. Role of TSH on bone 
Thyroid stimulating hormone (TSH) is a ligand hormone between hypothalamic-pituitary 
axis and the thyroid gland. TSH has long been recognized to act on the thyroid gland to 
control follicle development and thyroid hormone production and secretion. Beyond 
thyroid, TSH has also been shown to have additional effects on other tissues. TSH can exert 
a direct effect on bone metabolism independently of the peripheral thyroid hormone 
(thyroxine, T4, and triiodothyronine, T3) levels. This effect is mediated through the receptor 
for binding the thyroid-stimulating hormone (TSH-R), which is a pituitary G protein-
coupled transmembrane receptor. Its expression has been demonstrated on osteoblast and 
osteoclast precursors. The TSH-R haploinsufficient mice display osteoporosis and focal 
osteosclerosis and thyroid hormone replacement did not restore bone mass but corrected 
growth deficiency in these animals (Abe et al, 2003). It has been suggested that the effects of 
TSH on the skeleton are independent of thyroid hormone levels.  
In vitro and in vivo studies have provided evidence that TSH has negative effects on both 
osteoclasts and osteoblasts (Abe et al, 2003; Hase et al, 2006; Sun et al, 2006; Ma et al, 2011). 
TSH inhibits osteoclastogenesis by attenuating Janus N-terminal kinase (JNK) and NF-KB 
signaling. The osteoclast-inhibitory actions of TSH are partially mediated also through 
effects on tumor necrosis factor (TNF)-alpha production as it has been demonstrated in 
murine models (Abe et al, 2003). Mice lacking the TSHR present osteoporosis, early in 
embryogenesis, due to increased osteoclast formation (Abe et al, 2003; Hase et al 2006; Ma et 
al, 2009). These observations have not been confirmed in double-null mice of TSHR and 
TNF-alpha supporting thus the role of TNF-alpha in increased osteoclastogenesis (Abe et al, 
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2003; Hase et al 2006; Ma et al, 2009). Yamoah et al (2008) have recently described RANKL-
responsive elements on the TNF alpha gene providing new insights into regulation of TNF 
transcription in osteoclast formation. The role of TSH on RANKL remains controversial 
since the administration of the exogenous recombinant TSH in animal models and humans 
has been shown to increase and in other series to decrease RANKL serum levels (Martini et 
al, 2008; Sampath et al, 2007; Abe et al, 2003). Role of TSH in osteoblastogenesis seems to be 
mediated through attenuation of Wnt and VEGF signaling (Abe et al, 2003). Enhanced 
osteoblastogenesis in TSHR deficiency was found to be associated with increased expression 
of low-density lipoprotein receptor–like protein-5 and Flk-1 proteins (Abe et al, 2003). 
Expression of these receptors, but not that of osteoblastic transcription factors, was inhibited 
by rhTSH. Altogether, these observations suggest that TSH negatively modulates bone 
turnover, however, further research is warranted to explain in detail the regulatory 
pathways.  
3. Thyroid hormones and skeletal growth in infancy and adolescence 
In prepubertal children, the linear growth is controlled mainly by GH-IGF-I axis, with 
influence from glucocorticoids and thyroid hormones. Thyroid hormones were shown to 
play an essential role for normal onset of the childhood component of growth (Heyerdahl, 
1997). Role of the GH/IGF-I axis in the regulation of thyroid gland growth has recently been 
demonstrated (Boas et al, 2009). During pubertal period, sex steroids are important co-
regulators of skeletal growth. Age related consequences of thyroid dysfunction on bone 
development have largely been described. Nevertheless, the exact role of thyroid hormone 
in the peak bone mass acquisition during childhood and early adulthood is not well 
understood. The same is for the gender specific action of T3 in the developing skeleton 
(Gauthier et al, 1999). 
Euthyroid status is essential for normal skeletal development and linear growth. 
Generalized retardation in endochondral and intramembranous ossification associated with 
alterations in the EGPs, such as reduced thickness, disorganized columns of chondrocytes, 
and impaired differentiation of hypertrophic chondrocytes, have been reported in 
hypothyroid status during development (Lewinson et al, 1989; Stevens et al, 2000). The 
clinical consequences are reduced growth and skeletal abnormalities (Allain & McGregor, 
1993). Theodore Kocher was awarded the Nobel Prize in Medicine in 1909 for his 
description of consequences of thyroidectomy. He showed the impact of hypothyroidism on 
the child growth (Kocher, 1883). Hypothyroid children present with the growth retardation 
and disproportionately short limbs in relation to the trunk. Radiographic skeletal 
examination may reveal, depending on the age and onset of hypothyroidism, a delayed 
closure of the fontanelles, enlargement of pituitary fossa and epiphyseal dysgenesis. Reilly 
& Smyth have described in 1937 stippled appearance of epiphyses on X-ray films in 
hypothyroid children. The pathognomonic nature of these changes was later confirmed by 
Wilkis (Wilkis, 1941). Epiphyseal dysgenesis has been demonstrated in the ossification 
centers that normally ossify after the onset of the hypothyroid status. Delayed appearance of 
ossification centers and delayed bone age are also noted in hypothyroid children. BMD 
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Furthermore, T3 is involved in local signaling pathways by stimulating osteoblast responses 
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2003; Hase et al 2006; Ma et al, 2009). Yamoah et al (2008) have recently described RANKL-
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seems to be also affected by a hypothyroid status during childhood. In one cross-sectional 
study, BMD was reported to be lower in prepubertal children with congenital 
hypothyroidism than in controls (Demartini et al, 2007). 
Treatment with thyroxine results in a period of rapid catch-up growth, although predicted 
final height based on midparental height calculations may not be achieved, particularly 
when hypothyroidism is prolonged (Rivkees et al, 1988). The LT4 replacement for 8 years in 
children with congenital hypothyroidism did not have a negative effect on BMD for the 
lumbar spine and the femoral site and on biochemical markers of bone turnover (Leger et al, 
1997). The results showed normal serum levels of calcium, phosphate, alkaline phosphatase, 
parathyroid hormone and 25-hydroxyvitamin D and did not demonstrate any relationship 
between BMD and L-T4 dosage or biochemical markers of bone formation. These findings 
were confirmed by other studies reporting no alterations of bone mass in adolescents and 
young adults with congenital hypothyroidism, treated from the neonatal period (Salerno et 
al, 2004, Demeester-Mirkine et al, 1990). 
On the other hand, thyroid hormone excess results in accelerated skeletal maturation, 
premature closure of the EGPs and subsequent decrease in longitudinal bone growth with a 
compromised final adult height (Allain & McGregor, 1993; O’Shea et al, 1993; Harvey et al, 
2002). In severe cases, hyperthyroidism during early childhood may also cause 
craniosynostosis due to premature fusion of the sutures of the skull (Segni et al 1999). Low 
bone density values and high bone resorption rates were demonstrated at diagnosis of 
hyperthyroidism in children and adolescents (Mora et al, 1999). Successful treatment of 
hyperthyroidism was shown to increase BMD in children and improve the conditions for 
the best obtainable peak bone mass (Mora et al, 1999). 
Consequences of syndrome of resistance to thyroid hormone (RTH) on the skeletal 
development have been described in literature. RTH results from dominant negative 
mutations in the carboxyl terminus of the thyroid hormone receptor β gene. The mutant 
receptors are transcriptionally impaired and inhibit thyroid hormone receptor action. RTH 
is characterized by phenotypic variability including skeletal manifestations (Weiss et 
Refetoff, 2000). Our current understanding is based mainly on the published case reports. 
Involvement of the skeleton can cause a short stature, advanced or delayed bone age, 
increased bone turnover, osteoporosis, fractures, craniofacial abnormalities and 
craniosynostosis. The clinical variability might be secondary to functional properties of 
mutant proteins and heterogeneity of cofactors mediating action of TR (Kvistad et al, 2004).  
4. Effects of thyroid dysfunction on bone turnover in adult bone 
4.1. Hypothyroidism 
Reduced bone turnover in hypothyroidism impairs bone formation and mineralization 
(Eriksen et al, 1986). Results of population studies indicate an increased fracture risk in 
hypothyroid individuals (Ahmed et al, 2006; Vestegaard et al 2002, 2005). The association 
between subclinical hypothyroidism and decreased BMD with increased fracture risk has 
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also been reported, but has not been confirmed by others (Lee et al, 2006, 2010; Bertoli et al, 
2002). Overall, the literature data have so far presented conflicting results. We will review 
the current literature and discuss changes in the bone metabolism, BMD and fracture risk in 
adult men and women with overt and subclinical hypothyroidism. 
4.1.1. Mineral metabolism in hypothyroidism 
Slight perturbations in some parameters of bone and mineral metabolism have been 
reported in hypothyroid patients. Minor abnormalities of calcium metabolism may exist 
with slightly elevated serum calcium, PTH and 1,25(OH)2 vitamin D, decreased level of 
alkaline phosphatase, decreased urinary calcium excretion and glomerular filtration rate. 
The exchangeable pool of calcium and its rate of turnover may be reduced, reflecting 
decreased bone formation and resorption. However, these changes seem not to be different, 
even during the treatment, in hypothyroid patients compared to euthyroid controls 
(Sabuncu et al, 2001). 
4.1.2. Overt hypothyroidism and skeletal changes 
Large population based studies identified an increased fracture risk in individuals with 
hypothyroidism (Vestegaard et al 2000; 2002). The first of these studies (Vestegaard et al, 
2000) analyzed 408 patients with primary hypothyroidism and found a temporary increase 
in fracture risk within the first 2 years after diagnosis, mainly in the age group >50 years, 
and was limited to the forearms. In the following study (Vestegaard, 2002), 4473 patients 
with autoimmune hypothyroidism (mean age, 66.1 +/- 17.3) were shown to present a 
significantly increased fracture risk up to 8 years prior to diagnosis with a peak around the 
time of diagnosis. The fracture risk was found to return to normal more than 5 years after its 
diagnosis. 
An increased fracture risk in hypothyroid patients is not probably due to modifications of 
bone density. There are no convincing literature data as to changes in bone architecture 
during hypothyroidism. Neuromuscular symptoms and impaired muscle energy 
metabolism could be responsible for bone changes in this population. Hypothyroid patients 
have been shown to display impaired neuromuscular response to exercise persisting even 
after restoration of euthyroid status (Caraccio et al, 2005). 
4.1.3. Subclinical hypothyroidism and skeletal changes 
Subclinical hypothyroidism is a relatively frequent clinical condition, particularly among 
aged population, characterized by a low-normal free T4 level and a slightly elevated TSH 
level. The prevalence of subclinical hypothyroidism has been reported between 3.9 and 6.5% 
(Hollowell et al, 2002; Huber et al, 2002) 
In Trosmo study, Grimnes et al. (2008) have demonstrated that, after multivariate 
adjustment, 25 out of 950 postmenopausal women with serum TSH above the 97.5 percentile 
had significantly higher BMD at the femoral neck than women with serum TSH in the 
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bone density values and high bone resorption rates were demonstrated at diagnosis of 
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hyperthyroidism was shown to increase BMD in children and improve the conditions for 
the best obtainable peak bone mass (Mora et al, 1999). 
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development have been described in literature. RTH results from dominant negative 
mutations in the carboxyl terminus of the thyroid hormone receptor β gene. The mutant 
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is characterized by phenotypic variability including skeletal manifestations (Weiss et 
Refetoff, 2000). Our current understanding is based mainly on the published case reports. 
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increased bone turnover, osteoporosis, fractures, craniofacial abnormalities and 
craniosynostosis. The clinical variability might be secondary to functional properties of 
mutant proteins and heterogeneity of cofactors mediating action of TR (Kvistad et al, 2004).  
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Reduced bone turnover in hypothyroidism impairs bone formation and mineralization 
(Eriksen et al, 1986). Results of population studies indicate an increased fracture risk in 
hypothyroid individuals (Ahmed et al, 2006; Vestegaard et al 2002, 2005). The association 
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also been reported, but has not been confirmed by others (Lee et al, 2006, 2010; Bertoli et al, 
2002). Overall, the literature data have so far presented conflicting results. We will review 
the current literature and discuss changes in the bone metabolism, BMD and fracture risk in 
adult men and women with overt and subclinical hypothyroidism. 
4.1.1. Mineral metabolism in hypothyroidism 
Slight perturbations in some parameters of bone and mineral metabolism have been 
reported in hypothyroid patients. Minor abnormalities of calcium metabolism may exist 
with slightly elevated serum calcium, PTH and 1,25(OH)2 vitamin D, decreased level of 
alkaline phosphatase, decreased urinary calcium excretion and glomerular filtration rate. 
The exchangeable pool of calcium and its rate of turnover may be reduced, reflecting 
decreased bone formation and resorption. However, these changes seem not to be different, 
even during the treatment, in hypothyroid patients compared to euthyroid controls 
(Sabuncu et al, 2001). 
4.1.2. Overt hypothyroidism and skeletal changes 
Large population based studies identified an increased fracture risk in individuals with 
hypothyroidism (Vestegaard et al 2000; 2002). The first of these studies (Vestegaard et al, 
2000) analyzed 408 patients with primary hypothyroidism and found a temporary increase 
in fracture risk within the first 2 years after diagnosis, mainly in the age group >50 years, 
and was limited to the forearms. In the following study (Vestegaard, 2002), 4473 patients 
with autoimmune hypothyroidism (mean age, 66.1 +/- 17.3) were shown to present a 
significantly increased fracture risk up to 8 years prior to diagnosis with a peak around the 
time of diagnosis. The fracture risk was found to return to normal more than 5 years after its 
diagnosis. 
An increased fracture risk in hypothyroid patients is not probably due to modifications of 
bone density. There are no convincing literature data as to changes in bone architecture 
during hypothyroidism. Neuromuscular symptoms and impaired muscle energy 
metabolism could be responsible for bone changes in this population. Hypothyroid patients 
have been shown to display impaired neuromuscular response to exercise persisting even 
after restoration of euthyroid status (Caraccio et al, 2005). 
4.1.3. Subclinical hypothyroidism and skeletal changes 
Subclinical hypothyroidism is a relatively frequent clinical condition, particularly among 
aged population, characterized by a low-normal free T4 level and a slightly elevated TSH 
level. The prevalence of subclinical hypothyroidism has been reported between 3.9 and 6.5% 
(Hollowell et al, 2002; Huber et al, 2002) 
In Trosmo study, Grimnes et al. (2008) have demonstrated that, after multivariate 
adjustment, 25 out of 950 postmenopausal women with serum TSH above the 97.5 percentile 
had significantly higher BMD at the femoral neck than women with serum TSH in the 
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normal range. However, there was no association between TSH and BMD, and serum TSH 
as a continuous variable had no effect on BMD. 
Bone quality was studied by Nagata et al. using quantitative ultrasound in postmenopausal 
women with subclinical hypothyroidism. The results demonstrated that calcaneo osteo sono 
assessment indices of right feet measured by ultrasound bone densitometer decreased 
according to the increase in TSH concentration. The authors have suggested that 
hypothyroidism affects bone structure (Nagata et al, 2007). 
4.2. Hyperthyroidism 
Hyperthyroid patients present with an increased bone turnover and a risk for osteoporosis. 
The activity of osteoblasts and osteoclasts are increased, the latter predominates favoring 
resorption, negative balance of calcium, and bone loss (Melsen & Mosekilde, 1977; 
Mosekilde et al, 1990). Thyrotoxicosis in adults is a recognized cause of high-bone-turnover 
osteoporosis. Reduced bone mineral density was noted in hyperthyroid patients with an 
increased susceptibility to fragility fracture (Mosekilde et al, 1990; Vestergaard et al, 2002, 
2005). 
In both, clinical and subclinical hyperthyroidism, elevation of markers of bone turnover and 
decreased BMD have been reported (Kumeda et al, 2000; Heemstra et al, 2006; Lee et al, 
2006). Previous studies that investigated impact of thyroid dysfunction on BMD and 
fracture risk did not provide conclusive results. Recently published population studies 
indicate association of endogenous subclinical hyperthyroidism with an increased fracture 
risk (Bauer et al, 2001; Jamal et al, 2005; Vadiveloo et al, 2011). Consequences of the 
hyperthyroid status (overt and subclinical) on bone turnover, BMD and fracture risk will be 
discussed and compared with the data in healthy population. 
4.2.1. Mineral metabolism in hyperthyroidism 
Hyperthyroidism is associated with impaired mineral metabolism. Increased serum calcium 
levels have been reported in up to 27% of hyperthyroid patients (Begic-Karup et al, 2001), 
but severe and symptomatic hypercalcemia is rare. Concentrations of serum alkaline 
phosphatase and osteocalcin are also frequently elevated. These findings are reminiscent of 
those in primary hyperparathyroidism, however, serum parathyroid hormone is mostly 
low-normal (Iqbal et al, 2003). True primary hyperparathyroidism and thyrotoxicosis may 
coexist (Beus & Stack, 2004; Wagner et al, 1999). Decreased plasma 25-
hydroxycholecalciferol levels observed in hyperthyroidism could participate to the lower 
intestinal absorption of calcium and osteopenia in these patients (Mohan et al, 2004). Bone 
resorption markers, urinary pyridinoline and deoxypyridinoline, are increased 7-8 times 
more than in age and sex matched controls (Kraenzlin et al, 2008). Furthermore, 
hyperthyroid patients display a greater increase in urinary pyridinoline cross-links than that 
in serum markers of bone formation (osteocalcin, bone-specific alkaline phosphatase) 
(Akalin et al, 2002; Kisakol et al, 2003). Altogether, an increased bone turnover in these 
patients is in favor of osteoclastic bone resorption. 
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After initiation of anti-thyroid treatment, biochemical markers of bone resorption, such as 
urinary hydroxyproline, serum pyridinoline, serum deoxypiridinoline cross-links, have 
been found to fall, with a subsequent rise of the bone formation markers (Mosekilde et al 
1990; Siddiqi et al, 1997; Garnero et al, 1994). Elevation of serum PTH has been reported in 
some patients with severe thyrotoxicosis under anti-thyroid treatment (Pantazi et al, 2000). 
This rise in PTH was suggested to play a role in inducing some temporal changes in mineral 
metabolism and participate to the reversal of the catabolic bone status of hyperthyroidism to 
anabolic. Furthermore, another study found that in hyperthyroidism, despite normal or high 
IGF-I levels, IGF-I bioactivity is reduced, probably because of high levels of IGF-binding 
protein-1 (Miell et al, 1993). Treatment of thyrotoxicosis reverses this abnormality. The rise 
in IGF-I bioactivity may therefore have a positive effect on the bone metabolism. 
4.2.2. Overt hyperthyroidism and skeletal changes 
Pathological skeletal changes, including osteopenia and osteoporosis, with higher 
incidence of fracture rates have been reported in hyperthyroid patients. Accordingly, 
hyperthyroidism was found 2.5-fold more often in postmenopausal women presenting 
with hip fracture than in controls. Among postmenopausal women, risk of hip fracture 
was significantly higher in patients with overt untreated hyperthyroidism and a history of 
past hyperthyroidism (Wejda et al, 1995). These findings were confirmed by a prospective 
follow-up study realized in 9516 Caucasian women, 65 years of age or older (Cummings 
et al, 1995). The authors demonstrated a higher risk of hip fracture among women who 
had previous hyperthyroidism. Another study reported that the prevalence of all types of 
fractures in patients with a history of thyroid disease was not different from that of 
control subjects.  
However, women with a history of hyperthyroidism or thyroid cancer appeared to have 
their first fracture earlier than women without thyroid disease (Solomon et al, 1993). Median 
lumbar BMD in patients with thyrotoxicosis was shown to be 12.6% lower than that of 
normal individuals before the initiation of treatment (Krolner et al, 1983). Decreased BMD in 
hyperthyroid patients was demonstrated particularly in areas consisting of cortical bone. 
The risk of hip fracture increased significantly with age at diagnosis of hyperthyroidism 
(Campos-Pastor et al, 1993; Udayakmar et al, 2006; Vestergaard et al, 2002, 2005). The 
etiology of hyperthyroidism is not believed to play a role in the severity of hyperthyroid 
bone disease (Jodar et al, 1997). 
A recent meta-analysis (Vestergaard et al, 2005) evaluated data regarding BMD and fracture 
risk in 20 (962 patients) and 5 publications, respectively (62 830 patients and controls). The 
results showed that patients with hyperthyroidism have a significantly decreased BMD. 
These values were lower in untreated patients compared to those under treatment, 
particularly for the lumbar spine (-0.83 vs. -0.27 Z-score) and the femoral site (-0.75 vs. -0.15 
Z-score). The risk of hip fracture at the moment of diagnosis of hyperthyroidism was 1.6 
(95% CI 0.7 to 3.4), and the value of BMD alone was associated with a risk of hip fracture 
corresponding to 1.2 (95% CI 0.9-1.5).  
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normal range. However, there was no association between TSH and BMD, and serum TSH 
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Hyperthyroidism is associated with impaired mineral metabolism. Increased serum calcium 
levels have been reported in up to 27% of hyperthyroid patients (Begic-Karup et al, 2001), 
but severe and symptomatic hypercalcemia is rare. Concentrations of serum alkaline 
phosphatase and osteocalcin are also frequently elevated. These findings are reminiscent of 
those in primary hyperparathyroidism, however, serum parathyroid hormone is mostly 
low-normal (Iqbal et al, 2003). True primary hyperparathyroidism and thyrotoxicosis may 
coexist (Beus & Stack, 2004; Wagner et al, 1999). Decreased plasma 25-
hydroxycholecalciferol levels observed in hyperthyroidism could participate to the lower 
intestinal absorption of calcium and osteopenia in these patients (Mohan et al, 2004). Bone 
resorption markers, urinary pyridinoline and deoxypyridinoline, are increased 7-8 times 
more than in age and sex matched controls (Kraenzlin et al, 2008). Furthermore, 
hyperthyroid patients display a greater increase in urinary pyridinoline cross-links than that 
in serum markers of bone formation (osteocalcin, bone-specific alkaline phosphatase) 
(Akalin et al, 2002; Kisakol et al, 2003). Altogether, an increased bone turnover in these 
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metabolism and participate to the reversal of the catabolic bone status of hyperthyroidism to 
anabolic. Furthermore, another study found that in hyperthyroidism, despite normal or high 
IGF-I levels, IGF-I bioactivity is reduced, probably because of high levels of IGF-binding 
protein-1 (Miell et al, 1993). Treatment of thyrotoxicosis reverses this abnormality. The rise 
in IGF-I bioactivity may therefore have a positive effect on the bone metabolism. 
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incidence of fracture rates have been reported in hyperthyroid patients. Accordingly, 
hyperthyroidism was found 2.5-fold more often in postmenopausal women presenting 
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was significantly higher in patients with overt untreated hyperthyroidism and a history of 
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follow-up study realized in 9516 Caucasian women, 65 years of age or older (Cummings 
et al, 1995). The authors demonstrated a higher risk of hip fracture among women who 
had previous hyperthyroidism. Another study reported that the prevalence of all types of 
fractures in patients with a history of thyroid disease was not different from that of 
control subjects.  
However, women with a history of hyperthyroidism or thyroid cancer appeared to have 
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lumbar BMD in patients with thyrotoxicosis was shown to be 12.6% lower than that of 
normal individuals before the initiation of treatment (Krolner et al, 1983). Decreased BMD in 
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The risk of hip fracture increased significantly with age at diagnosis of hyperthyroidism 
(Campos-Pastor et al, 1993; Udayakmar et al, 2006; Vestergaard et al, 2002, 2005). The 
etiology of hyperthyroidism is not believed to play a role in the severity of hyperthyroid 
bone disease (Jodar et al, 1997). 
A recent meta-analysis (Vestergaard et al, 2005) evaluated data regarding BMD and fracture 
risk in 20 (962 patients) and 5 publications, respectively (62 830 patients and controls). The 
results showed that patients with hyperthyroidism have a significantly decreased BMD. 
These values were lower in untreated patients compared to those under treatment, 
particularly for the lumbar spine (-0.83 vs. -0.27 Z-score) and the femoral site (-0.75 vs. -0.15 
Z-score). The risk of hip fracture at the moment of diagnosis of hyperthyroidism was 1.6 
(95% CI 0.7 to 3.4), and the value of BMD alone was associated with a risk of hip fracture 
corresponding to 1.2 (95% CI 0.9-1.5).  
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Decreased bone density in hyperthyroid patients tended to normalize under treatment 
(Wejda et al, 1995, Jodar et al, 1997). The improvement of BMD was noted even though no 
other specific anti-osteoporotic measures were introduced. The type of treatment of 
hyperthyroidism, iodine 131 or anti-thyroid drugs was not shown to alter the fracture risk 
(Vestergaard et al, 2005). 
4.2.3. Subclinical hyperthyroidism and skeletal changes 
Subclinical hyperthyroidism is defined as subnormal serum TSH with normal serum free 
thyroid hormones without signs or symptoms of thyrotoxicosis. Its prevalence in the U.S. 
population has been reported 0.7% (Hollowell et al, 2002). By definition, such patients 
should not have any clinical abnormalities associated with thyrotoxicosis (Biondi et al, 
2005). However, a reduced bone mass was reported among postmenopausal patients (Bauer 
et al 2001). These observations could thus have a broader impact on the healthcare systems, 
as the subclinical hyperthyroidism is more frequent than overt thyrotoxicosis (Hollowell et 
al, 2002). Improvement of bone mineral density was shown in postmenopausal women with 
subclinical hyperthyroidism after normalization of their thyroid function (Faber et al, 1998). 
These data would justify indications of treatment in the older population. However, the 
risk/benefit ratio needs to be demonstrated by long-term, randomized studies. 
On the other hand, the bone mineral density of the lumbar spine, femoral neck and the 
midshaft of the radius were not significantly decreased in premenopausal women (Foldes et 
al, 1993). The impact of subclinical hyperthyroidism in men is less known. A recent work 
suggests that a serum TSH concentration at the lower end of the reference range may be 
associated with low BMD in men (Kim et al, 2010). 
5. Impact of thyroid hormone treatment on bone metabolism 
Effects of thyroid replacement therapy or thyroid suppressive therapy on bone mineral 
density (BMD) are controversial. Results of previous studies are confounded by differences 
in study design, insufficient prospective data and small numbers of subjects. In the 
population study by Vestergaard et al (2005), the use of anti-thyroid drugs was associated 
with a significantly reduced fracture risk, no effect of levothyroxine on fracture risk was 
observed. No influence of L-thyroxine therapy on BMD was reported in young adults with 
congenital hypothyroidism (Salerno et al, 2004). Recently published population based case-
control study has demonstrated a significantly increased fracture risk in adults over 70 years 
treated by levothyroxine (Turner et al, 2011). Publications on the association between the 
thyroid replacement and suppressive treatments and the bone mineral metabolism will be 
discussed. 
5.1. Thyroid hormone replacement therapy 
The objective of thyroid hormone replacement therapy is to normalize TSH levels. Some 
authors have suggested that treatment with levothyroxine may cause long-term 
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osteoporosis, but there is no evidence to support this theory, and studies have shown no 
difference in bone density or fracture risk in patients undergoing treatment.  
Previously, the effects of thyroid hormone treatment upon lumbar spine BMD were studied 
in a consecutive series of patients with myxedema. Patients with myxoedema did not differ 
from normal individuals as regards initial lumbar BMD, but levothyroxine-treatment caused 
a significant reduction in this variable. The median decrease in lumbar BMC after 1 year was 
8.9% (95% confidence limits 1.5-15.4%, P less than 0.05). This loss of bone might be 
attributed to an inappropriate increase in bone turnover in the euthyroid status (Krolner et 
al, 1983). Accelerated bone turnover was shown to occur in women with subclinical 
hypothyroidism during replacement L-T4 treatment and normal TSH levels (Meier et al, 
2004; Tarraga Lopez et al, 2011). In these women, bone loss was attributed to an adaptive 
mechanism on decreased bone turnover in pre-existent hypothyroidism. Finally, a long-term 
L-T4 treatment in children and adolescents with congenital hypothyroidism, diffuse goiter 
or with chronic lymphocytic thyroiditis did not affect BMD nor had a negative effect on the 
attainment of peak bone mass (Kooh et al, 1996; Saggese et al, 1996; Tumer et al, 1999). These 
results suggest that careful regulation of thyroid replacement is critical. Significant effects of 
prolonged L-T4-replacement therapy on bone tissue in patients with congenital 
hypothyroidism can be avoided by careful monitoring of serum TSH and adjustment of 
doses of L-T4 (Salerno et al, 2004). 
5.2. Thyroid hormone suppressive therapy 
Treatment with thyroid hormones with the objective to suppress TSH levels is used for 
example after surgery and radioiodine in differentiated thyroid carcinomas. The patients are 
maintained in subclinical hyperthyroidism, a condition associated with increased bone 
turnover.  
Previous studies indicated that adults receiving high doses of L-T4-replacement therapy 
may be at risk of excessive bone loss. Reduction in BMD was observed after exogenous 
administration of high L-T4 doses used to fully suppress TSH in cases of thyroid cancer, 
goiters or nodules. Further, a review of cross-sectional and prospective studies examining 
the effect of thyroid hormone suppression on skeletal integrity in adults showed neither 
significant negative effect nor a decrease in BMD (Greenspan et al, 1990). Conflicting results 
were reported also in children. A significant reduction in peripheral BMD was found in 
children and adolescents receiving suppressive doses of L-T4 treatment for endemic goiter, 
Hashimoto’s thyroiditis or thyroid cancer (Radetti et al, 1993). 
More recently, suppression of TSH in hyperthyroidism or after thyroid hormone treatment 
has been shown to result in decrease in BMD and increase in fracture risk in 
postmenopausal women (Vestergaard et al, 2000; Bauer et al, 2001; Jamal et al, 2005; Kim et 
al, 2006). Similar results have been demonstrated in premenopausal women and men by 
Karner et al (2005).  Recently realized systematic reviews analyzing effects of subclinical 
hyperthyroidism showed that postmenopausal women with subclinical hyperthyroidism 
may present an increased risk, whereas no increased risk has been demonstrated in men and 
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Decreased bone density in hyperthyroid patients tended to normalize under treatment 
(Wejda et al, 1995, Jodar et al, 1997). The improvement of BMD was noted even though no 
other specific anti-osteoporotic measures were introduced. The type of treatment of 
hyperthyroidism, iodine 131 or anti-thyroid drugs was not shown to alter the fracture risk 
(Vestergaard et al, 2005). 
4.2.3. Subclinical hyperthyroidism and skeletal changes 
Subclinical hyperthyroidism is defined as subnormal serum TSH with normal serum free 
thyroid hormones without signs or symptoms of thyrotoxicosis. Its prevalence in the U.S. 
population has been reported 0.7% (Hollowell et al, 2002). By definition, such patients 
should not have any clinical abnormalities associated with thyrotoxicosis (Biondi et al, 
2005). However, a reduced bone mass was reported among postmenopausal patients (Bauer 
et al 2001). These observations could thus have a broader impact on the healthcare systems, 
as the subclinical hyperthyroidism is more frequent than overt thyrotoxicosis (Hollowell et 
al, 2002). Improvement of bone mineral density was shown in postmenopausal women with 
subclinical hyperthyroidism after normalization of their thyroid function (Faber et al, 1998). 
These data would justify indications of treatment in the older population. However, the 
risk/benefit ratio needs to be demonstrated by long-term, randomized studies. 
On the other hand, the bone mineral density of the lumbar spine, femoral neck and the 
midshaft of the radius were not significantly decreased in premenopausal women (Foldes et 
al, 1993). The impact of subclinical hyperthyroidism in men is less known. A recent work 
suggests that a serum TSH concentration at the lower end of the reference range may be 
associated with low BMD in men (Kim et al, 2010). 
5. Impact of thyroid hormone treatment on bone metabolism 
Effects of thyroid replacement therapy or thyroid suppressive therapy on bone mineral 
density (BMD) are controversial. Results of previous studies are confounded by differences 
in study design, insufficient prospective data and small numbers of subjects. In the 
population study by Vestergaard et al (2005), the use of anti-thyroid drugs was associated 
with a significantly reduced fracture risk, no effect of levothyroxine on fracture risk was 
observed. No influence of L-thyroxine therapy on BMD was reported in young adults with 
congenital hypothyroidism (Salerno et al, 2004). Recently published population based case-
control study has demonstrated a significantly increased fracture risk in adults over 70 years 
treated by levothyroxine (Turner et al, 2011). Publications on the association between the 
thyroid replacement and suppressive treatments and the bone mineral metabolism will be 
discussed. 
5.1. Thyroid hormone replacement therapy 
The objective of thyroid hormone replacement therapy is to normalize TSH levels. Some 
authors have suggested that treatment with levothyroxine may cause long-term 
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osteoporosis, but there is no evidence to support this theory, and studies have shown no 
difference in bone density or fracture risk in patients undergoing treatment.  
Previously, the effects of thyroid hormone treatment upon lumbar spine BMD were studied 
in a consecutive series of patients with myxedema. Patients with myxoedema did not differ 
from normal individuals as regards initial lumbar BMD, but levothyroxine-treatment caused 
a significant reduction in this variable. The median decrease in lumbar BMC after 1 year was 
8.9% (95% confidence limits 1.5-15.4%, P less than 0.05). This loss of bone might be 
attributed to an inappropriate increase in bone turnover in the euthyroid status (Krolner et 
al, 1983). Accelerated bone turnover was shown to occur in women with subclinical 
hypothyroidism during replacement L-T4 treatment and normal TSH levels (Meier et al, 
2004; Tarraga Lopez et al, 2011). In these women, bone loss was attributed to an adaptive 
mechanism on decreased bone turnover in pre-existent hypothyroidism. Finally, a long-term 
L-T4 treatment in children and adolescents with congenital hypothyroidism, diffuse goiter 
or with chronic lymphocytic thyroiditis did not affect BMD nor had a negative effect on the 
attainment of peak bone mass (Kooh et al, 1996; Saggese et al, 1996; Tumer et al, 1999). These 
results suggest that careful regulation of thyroid replacement is critical. Significant effects of 
prolonged L-T4-replacement therapy on bone tissue in patients with congenital 
hypothyroidism can be avoided by careful monitoring of serum TSH and adjustment of 
doses of L-T4 (Salerno et al, 2004). 
5.2. Thyroid hormone suppressive therapy 
Treatment with thyroid hormones with the objective to suppress TSH levels is used for 
example after surgery and radioiodine in differentiated thyroid carcinomas. The patients are 
maintained in subclinical hyperthyroidism, a condition associated with increased bone 
turnover.  
Previous studies indicated that adults receiving high doses of L-T4-replacement therapy 
may be at risk of excessive bone loss. Reduction in BMD was observed after exogenous 
administration of high L-T4 doses used to fully suppress TSH in cases of thyroid cancer, 
goiters or nodules. Further, a review of cross-sectional and prospective studies examining 
the effect of thyroid hormone suppression on skeletal integrity in adults showed neither 
significant negative effect nor a decrease in BMD (Greenspan et al, 1990). Conflicting results 
were reported also in children. A significant reduction in peripheral BMD was found in 
children and adolescents receiving suppressive doses of L-T4 treatment for endemic goiter, 
Hashimoto’s thyroiditis or thyroid cancer (Radetti et al, 1993). 
More recently, suppression of TSH in hyperthyroidism or after thyroid hormone treatment 
has been shown to result in decrease in BMD and increase in fracture risk in 
postmenopausal women (Vestergaard et al, 2000; Bauer et al, 2001; Jamal et al, 2005; Kim et 
al, 2006). Similar results have been demonstrated in premenopausal women and men by 
Karner et al (2005).  Recently realized systematic reviews analyzing effects of subclinical 
hyperthyroidism showed that postmenopausal women with subclinical hyperthyroidism 
may present an increased risk, whereas no increased risk has been demonstrated in men and 
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premenopausal women (Quan et al, 2002; Heemstra et al, 2006). However, both reviews 
found methodological differences between different studies, making a structured meta-
analysis impossible. Lately, a randomized prospective controlled trial has shown significant 
adverse effects of TSH suppressive therapy on BMD in women ≥ 50 years of age (Sugitani et 
Fujimoto, 2011). However, the results have not been adjusted for confounding factors, such 
as menopause status, dietary calcium, vitamin D intake, and smoking.  
Overall, literature data enhance the hypothesis that low TSH levels may have a deleterious 
effect on bone homeostasis. Nevertheless, the exact relationship between subclinical 
hyperthyroidism and osteoporosis remains to be explained. 
6. TSH as a metabolic regulator 
We previously discussed (see paragraph 1.2) the role of TSH in the control of bone 
remodeling in animal models (Abe E, Marians RC et al, 2003). Systemic administration of 
TSH to ovariectomised rats has been shown to prevent bone loss and restore bone mass 
(Sampath et al, 2007; Sun et al, 2008) have demonstrated that intermittent administration of 
exogenous TSH in ovariectomised rats and mice have anti-resorptive effects. Recent findings 
indicate that TSH might play a crucial role in bone turnover in humans. Bone loss has been 
shown in women with polymorphism in the TSHR gene (Onigata et al, 2005). 
There is a growing body of evidence that variations of TSH even in its reference range may 
influence BMD. A higher BMD has been reported in postmenopausal women with TSH 
within the physiological range comparing to these with the low level of TSH (Baqi et al, 
2010). Clinical observations show that patients with subclinical hyperthyroidism and normal 
circulating thyroid hormone levels display osteoporotic changes (De Menis et al, 1992; 
Kisakol et al, 2003). Strong correlation between serum TSH and bone status has been 
demonstrated in postmenopausal women (Bauer et al, 2001; Morris et al, 2007). Based on 
these findings it has been suggested that it is the suppressed TSH rather than the elevated 
thyroid hormones that exert a deleterious effect on bone density. In a recent observational 
study, low-normal TSH values were shown to be associated with high prevalence of 
vertebral fractures in women with post-menopausal osteoporosis or osteopenia, even after 
correction for age, BMD, BMI and serum free-thyroxine values (Mazziotti et al, 2010). Svare 
et al, 2009, in a cross-sectional, population-based study, analyzed 5778 women without and 
944 with self-reported thyroid disease aged >40 years. Women with the TSH level <0.50 
mU/l had lower forearm BMD than the reference group and the prevalence of osteoporosis 
was higher in women who reported hyperthyroidism than in women without self-reported 
thyroid disease. Finally, Kim et al, 2010 investigated the association between serum 
thyrotropin (TSH) concentration and bone mineral density (BMD) in 1478 healthy euthyroid 
men in a cross-sectional community based survey. Lumbar spine BMD and femoral neck 
BMD were shown to increase with TSH level after adjustment for age, weight and height. 
The odds of lower BMD were significantly increased in subjects with low-normal TSH, 
when compared to high-normal TSH after adjustment for confounding factors. These results 
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suggested that a serum TSH concentration at the lower end of the reference range may be 
associated with low BMD in men.  
The role of TSH on bone metabolism has also been analyzed through markers of bone 
metabolism after administration of recombinant TSH (rhTSH). TSH has been demonstrated 
to activate directly osteoblasts according to the increased levels of N-terminal propeptide of 
type I procollagen (PINP) (Martini et al, 2008). Others showed that TSH promotes the 
production and activity of alkaline phosphatase and of osteocalcin (Sampath et al, 2007; Abe 
et al, 2003), while some studies found inhibition of osteoblast differentiation induced by the 
administration of TSH (Abe et al, 2003). These finding suggested that TSH may enhance the 
differentiation of osteoblasts precursors.   
Clinically, it has been found that the administration of exogenous TSH may have 
antiresorptive effects of TSH on bone turnover.  In women monitored for thyroid carcinoma, 
a short-term stimulation with rhTSH had inhibitory effect on bone resorption. Acute 
administration of rhTSH in thyroidectomised postmenopausal women with suppressed 
endogenous serum TSH resulted in diminution in serum C-telopeptides of type-1 collagen 
and increase in bone alkaline phosphatase (Mazziotti et al., 2005). A transient inhibition of 
bone resorption and increase in osteoblastic activity, measured by markers of bone 
metabolism, after acute TSH administration was demonstrated also by other studies (Karga 
et al, 2010; Iakovou et al, 2010; Martini et al, 2008).  
Overall, these data constitute the evidence for relationship between TSH and a change in 
bone mass in humans. 
7. Bone effects of thyroid hormone analogues 
Synthetic analogues of thyroid hormones display tissue-specific actions (Baxter and Webb 
2009). They have been developed for their lipid lowering activity by preferential activation 
of the TRβ1 isoform in the liver while sparing the TRα1 mediated cardiac effects (Angelin & 
Rudling, 2010; Pramfalk et al., 2010; Webb, 2010). Previous animal and human studies have 
demonstrated that thyromimetics can influence bone metabolism. Skeletal effects of thyroid 
hormone analogues recently reported in literature on cell lines, animal models and humans 
are summarized in Table 1. 
Previously studied selective thyromimetic, tiratricol (3,5,3’-triiodothyroacetic acid; Triac) 
was shown to enhance skeletal metabolic activity (Sherman, et al 1997) and to produce 
adverse effects on bone metabolism (Alvarez et al 2004; Brenta et al 2003; Kawaguchi et al 
1994a, 1994b). DITPA, 3,5-diiodothyropropionic acid, has a higher affinity for the TRβ 
compared to the TRα. Administration of DITPA to humans for 24 weeks was associated 
with a significant rise in serum osteocalcin, N-telopeptide, and deoxypyridinoline levels, 
indicating an increased bone turnover (Ladenson el al 2010b). GC-1, [3,5-dimethyl-4-(4′-
hydroxy-3′isopropylbenzyl)-phenoxy acetic acid],  binds TRβ1 with the same affinity as T3, 
but TRα1 with a 10-fold lower affinity (Scanlan, 2010). Bone sparing effects in adult female 
rats have been observed after treatment by GC-1 for 64 days (Freitas et al, 2003). In another     
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premenopausal women (Quan et al, 2002; Heemstra et al, 2006). However, both reviews 
found methodological differences between different studies, making a structured meta-
analysis impossible. Lately, a randomized prospective controlled trial has shown significant 
adverse effects of TSH suppressive therapy on BMD in women ≥ 50 years of age (Sugitani et 
Fujimoto, 2011). However, the results have not been adjusted for confounding factors, such 
as menopause status, dietary calcium, vitamin D intake, and smoking.  
Overall, literature data enhance the hypothesis that low TSH levels may have a deleterious 
effect on bone homeostasis. Nevertheless, the exact relationship between subclinical 
hyperthyroidism and osteoporosis remains to be explained. 
6. TSH as a metabolic regulator 
We previously discussed (see paragraph 1.2) the role of TSH in the control of bone 
remodeling in animal models (Abe E, Marians RC et al, 2003). Systemic administration of 
TSH to ovariectomised rats has been shown to prevent bone loss and restore bone mass 
(Sampath et al, 2007; Sun et al, 2008) have demonstrated that intermittent administration of 
exogenous TSH in ovariectomised rats and mice have anti-resorptive effects. Recent findings 
indicate that TSH might play a crucial role in bone turnover in humans. Bone loss has been 
shown in women with polymorphism in the TSHR gene (Onigata et al, 2005). 
There is a growing body of evidence that variations of TSH even in its reference range may 
influence BMD. A higher BMD has been reported in postmenopausal women with TSH 
within the physiological range comparing to these with the low level of TSH (Baqi et al, 
2010). Clinical observations show that patients with subclinical hyperthyroidism and normal 
circulating thyroid hormone levels display osteoporotic changes (De Menis et al, 1992; 
Kisakol et al, 2003). Strong correlation between serum TSH and bone status has been 
demonstrated in postmenopausal women (Bauer et al, 2001; Morris et al, 2007). Based on 
these findings it has been suggested that it is the suppressed TSH rather than the elevated 
thyroid hormones that exert a deleterious effect on bone density. In a recent observational 
study, low-normal TSH values were shown to be associated with high prevalence of 
vertebral fractures in women with post-menopausal osteoporosis or osteopenia, even after 
correction for age, BMD, BMI and serum free-thyroxine values (Mazziotti et al, 2010). Svare 
et al, 2009, in a cross-sectional, population-based study, analyzed 5778 women without and 
944 with self-reported thyroid disease aged >40 years. Women with the TSH level <0.50 
mU/l had lower forearm BMD than the reference group and the prevalence of osteoporosis 
was higher in women who reported hyperthyroidism than in women without self-reported 
thyroid disease. Finally, Kim et al, 2010 investigated the association between serum 
thyrotropin (TSH) concentration and bone mineral density (BMD) in 1478 healthy euthyroid 
men in a cross-sectional community based survey. Lumbar spine BMD and femoral neck 
BMD were shown to increase with TSH level after adjustment for age, weight and height. 
The odds of lower BMD were significantly increased in subjects with low-normal TSH, 
when compared to high-normal TSH after adjustment for confounding factors. These results 
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suggested that a serum TSH concentration at the lower end of the reference range may be 
associated with low BMD in men.  
The role of TSH on bone metabolism has also been analyzed through markers of bone 
metabolism after administration of recombinant TSH (rhTSH). TSH has been demonstrated 
to activate directly osteoblasts according to the increased levels of N-terminal propeptide of 
type I procollagen (PINP) (Martini et al, 2008). Others showed that TSH promotes the 
production and activity of alkaline phosphatase and of osteocalcin (Sampath et al, 2007; Abe 
et al, 2003), while some studies found inhibition of osteoblast differentiation induced by the 
administration of TSH (Abe et al, 2003). These finding suggested that TSH may enhance the 
differentiation of osteoblasts precursors.   
Clinically, it has been found that the administration of exogenous TSH may have 
antiresorptive effects of TSH on bone turnover.  In women monitored for thyroid carcinoma, 
a short-term stimulation with rhTSH had inhibitory effect on bone resorption. Acute 
administration of rhTSH in thyroidectomised postmenopausal women with suppressed 
endogenous serum TSH resulted in diminution in serum C-telopeptides of type-1 collagen 
and increase in bone alkaline phosphatase (Mazziotti et al., 2005). A transient inhibition of 
bone resorption and increase in osteoblastic activity, measured by markers of bone 
metabolism, after acute TSH administration was demonstrated also by other studies (Karga 
et al, 2010; Iakovou et al, 2010; Martini et al, 2008).  
Overall, these data constitute the evidence for relationship between TSH and a change in 
bone mass in humans. 
7. Bone effects of thyroid hormone analogues 
Synthetic analogues of thyroid hormones display tissue-specific actions (Baxter and Webb 
2009). They have been developed for their lipid lowering activity by preferential activation 
of the TRβ1 isoform in the liver while sparing the TRα1 mediated cardiac effects (Angelin & 
Rudling, 2010; Pramfalk et al., 2010; Webb, 2010). Previous animal and human studies have 
demonstrated that thyromimetics can influence bone metabolism. Skeletal effects of thyroid 
hormone analogues recently reported in literature on cell lines, animal models and humans 
are summarized in Table 1. 
Previously studied selective thyromimetic, tiratricol (3,5,3’-triiodothyroacetic acid; Triac) 
was shown to enhance skeletal metabolic activity (Sherman, et al 1997) and to produce 
adverse effects on bone metabolism (Alvarez et al 2004; Brenta et al 2003; Kawaguchi et al 
1994a, 1994b). DITPA, 3,5-diiodothyropropionic acid, has a higher affinity for the TRβ 
compared to the TRα. Administration of DITPA to humans for 24 weeks was associated 
with a significant rise in serum osteocalcin, N-telopeptide, and deoxypyridinoline levels, 
indicating an increased bone turnover (Ladenson el al 2010b). GC-1, [3,5-dimethyl-4-(4′-
hydroxy-3′isopropylbenzyl)-phenoxy acetic acid],  binds TRβ1 with the same affinity as T3, 
but TRα1 with a 10-fold lower affinity (Scanlan, 2010). Bone sparing effects in adult female 
rats have been observed after treatment by GC-1 for 64 days (Freitas et al, 2003). In another     
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mouse calvariae: Triac 
vs. T3 
More potent stimulation of  
resorption and less potent 






Cultured fetal rat long 
bones and neonatal 
mouse calvariae; Triac 
vs. T3 
Equal or greater stimulation of 






Rats; Triac vs. T3 Greater increase in beta-CTX 
levels, no alteration of BMD 





trial (2 months); 
athyreotic patients: 
Triac vs. L-T4  
Increased serum osteocalcin 
and urinary excretion of 
calcium and pyridinium cross-
links 





trial (11 months); 
euthyroid goitrous 
women: 
Triac vs. L-T4  
Significant increase in serum 
deoxypyridinoline and 
significant decrease in hip 
bone density, but ns compared 
to L-T4;  






trial (24 weeks):                 
DITPA vs. placebo 
Increase in serum osteocalcin,  
N-telopeptide and 
deoxypyridinoline 




Rat and mouse               
osteoblast-like cells  
Induction of differentiation 
and activity of osteoblasts 





Female adult Wistar 
rats;  study groups (64 
days):                 
GC-1; T3 ; control 
No effects on BMD in L2-L5, 
femur, and tibia; no changes in 
histomorphometric 
parameters of the femur 





21-day old female 
hypothyroid rats, 
treatment for 5 weeks: 
GC-1 vs. placebo  
Induction of ossification,             
HC differentiation, expression 
of collagen II and X mRNA, 
increase in EGP thickness 







week clinical trial:             
Eprotirome vs. placebo  
No changes in b-ALP and type 
I collagen breakdown product;   
ns increase in PINP  
Ladenson      
2010a 
Table 1. Skeletal effects of thyroid hormone analogues: b-ALP – bone alcalic phosphatase; BMD - 
bone mineral density; EGP - epiphyseal growth plate; HC – hypertrophic chondrocytes; ns – non 
significant; PINP - procollagen type I N-terminal propeptide 
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study, partial reversion of the skeletal development and maturation defects has been shown 
in hypothyroid rats after 5 week therapy by GC-1 (Freitas et al 2005). Eprotirome, (KB2115), 
3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic 
acid, displays a higher affinity for TRβ1 isoform with hepatic uptake (Berkenstam 2008). 
Administration of eprotirome to humans for 12 weeks has not been associated with 
unfavorable bone effects (Ladenson et al 2010a). 
Altogether the data are consistent with potentially adverse skeletal effects of thyroid 
hormone analogues. However, no conclusive evidence can be drawn and further 
investigations would be justified to establish an accurate benefice/risk ratio before their 
clinical use. 
8. Conclusion 
The last decades have seen an increasing interest in the action of thyroid hormones in bone 
mineral homeostasis. In vivo and in vitro studies in cell lines as well as animal models have 
demonstrated a critical role of thyroid hormones, TSH and their receptors in the skeletal 
growth and its maintenance. However, many of the molecular mechanisms of thyroid 
hormone action remain still poorly defined.  
Clinical studies, consistently with animal data, indicate a close association between thyroid 
status and bone metabolism. Thyrotoxicosis results in an increased bone turnover, 
osteoporosis and a risk of fragility fracture. Thyroid hormone deficiency decreases bone 
turnover with a subsequent risk of bone fragility. Exogenous administration of suppressive 
doses of thyroxine was shown to negatively influences BMD and bone turnover. In future, 
prospective studies a prolonged time of observation will be necessary, as well as to increase 
the number of studied patients, in order to better assess the relative risk of osteoporosis in 
patients undergoing TSH-suppressive treatment. Another question that remains to be 
answered is if there is a benefit from treatment of subclinical thyroid disease on skeletal 
health.  
Finally, thyroid hormone analogues represent a promising therapeutic option for their lipid 
lowering activity. Nevertheless, literature data suggest their potentially adverse skeletal 
effects. No conclusive evidence can be drawn and further investigations would be justified 
to establish an accurate benefice/risk ratio before their clinical use. 
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Female adult Wistar 
rats;  study groups (64 
days):                 
GC-1; T3 ; control 
No effects on BMD in L2-L5, 
femur, and tibia; no changes in 
histomorphometric 
parameters of the femur 





21-day old female 
hypothyroid rats, 
treatment for 5 weeks: 
GC-1 vs. placebo  
Induction of ossification,             
HC differentiation, expression 
of collagen II and X mRNA, 
increase in EGP thickness 







week clinical trial:             
Eprotirome vs. placebo  
No changes in b-ALP and type 
I collagen breakdown product;   
ns increase in PINP  
Ladenson      
2010a 
Table 1. Skeletal effects of thyroid hormone analogues: b-ALP – bone alcalic phosphatase; BMD - 
bone mineral density; EGP - epiphyseal growth plate; HC – hypertrophic chondrocytes; ns – non 
significant; PINP - procollagen type I N-terminal propeptide 
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study, partial reversion of the skeletal development and maturation defects has been shown 
in hypothyroid rats after 5 week therapy by GC-1 (Freitas et al 2005). Eprotirome, (KB2115), 
3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic 
acid, displays a higher affinity for TRβ1 isoform with hepatic uptake (Berkenstam 2008). 
Administration of eprotirome to humans for 12 weeks has not been associated with 
unfavorable bone effects (Ladenson et al 2010a). 
Altogether the data are consistent with potentially adverse skeletal effects of thyroid 
hormone analogues. However, no conclusive evidence can be drawn and further 
investigations would be justified to establish an accurate benefice/risk ratio before their 
clinical use. 
8. Conclusion 
The last decades have seen an increasing interest in the action of thyroid hormones in bone 
mineral homeostasis. In vivo and in vitro studies in cell lines as well as animal models have 
demonstrated a critical role of thyroid hormones, TSH and their receptors in the skeletal 
growth and its maintenance. However, many of the molecular mechanisms of thyroid 
hormone action remain still poorly defined.  
Clinical studies, consistently with animal data, indicate a close association between thyroid 
status and bone metabolism. Thyrotoxicosis results in an increased bone turnover, 
osteoporosis and a risk of fragility fracture. Thyroid hormone deficiency decreases bone 
turnover with a subsequent risk of bone fragility. Exogenous administration of suppressive 
doses of thyroxine was shown to negatively influences BMD and bone turnover. In future, 
prospective studies a prolonged time of observation will be necessary, as well as to increase 
the number of studied patients, in order to better assess the relative risk of osteoporosis in 
patients undergoing TSH-suppressive treatment. Another question that remains to be 
answered is if there is a benefit from treatment of subclinical thyroid disease on skeletal 
health.  
Finally, thyroid hormone analogues represent a promising therapeutic option for their lipid 
lowering activity. Nevertheless, literature data suggest their potentially adverse skeletal 
effects. No conclusive evidence can be drawn and further investigations would be justified 
to establish an accurate benefice/risk ratio before their clinical use. 
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1. Introduction 
One of the most pronounced effects of Thyroid Hormone (TH, Triiodothyronine (T3), 
Tetraiodothyronine (T4)) is modulation of metabolic efficiency, energy expenditure and 
calorigenesis. Thus, hypothyroidism results in decreased energy expenditure and basal 
metabolic rate  accompanied by weight gain and cold intolerance, while hyperthyroidism 
results in hypermetabolism,    weight loss despite increased energy intake, intolerance to 
heat, loss of lean mass,  bone resorption and tachycardia. TH role in modulating metabolic 
efficiency has been realized for over a century but its cellular mode-of-action remained to be 
resolved.  
2. Mode-of-action of TH in modulating metabolic efficiency 
The first description of TH-induced calorigenesis dates to 1895 (1). That initial report has 
been followed by exhaustive data focusing on the phenomenology of TH action as reflected 
by hyper- and hypothyroidsm. Thus, high levels of TH in mammals increase oxygen 
consumption and heat production, resulting in pronounced body weight loss, while low 
levels of TH are associated with a decrease in  metabolic rate and the oxidation of energy 
substrates (glucose, fatty acids and amino acids), resulting in pronounced increase in body 
weight  (2-6). Although it was widely accepted that TH stimulates calorigenesis by affecting 
respiration, its cellular mode-of-action remained to be resolved. Hence, exhaustive attempts 
were made by the scientific community throughout the twentieth century to verify the 
mechanism(s) involved in modulating metabolic efficiency by TH. Studies by Lardy and 
Feldott (7) and Hess and Martius (8) have pointed out during the 1950s, that the respiratory 
control ratio of  isolated mitochondria was robustly decreased in the presence of added T4. 
TH was thus claimed to have direct action at the mitochondrial level by inducing 
‘mitochondrial uncoupling’, namely, dissociating mitochondrial phosphorylation from its 
substrate oxidation driver.  However, the high T4 doses used in those studies implied 
possible non-physiological activity rather than authentic TH-induced calorigenesis.  Later 
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evidence in support of ‘mitochondrial uncoupling’ has however  indicated  increase in 
oxygen consumption and mitochondrial proton permeability of isolated liver mitochondria 
derived from hyperthyroid rats,  with concomitant  decrease in   mitochondrial phosphate 
potential and inner mitochondrial membrane (IMM) potential (9, 10).  These observations 
were further corroborated by increase in liver oxidizing capacity of hyperthyroid rats  
accompanied by decrease in  phosphate and  cytosolic redox potential (11), while opposite 
effects were reported in livers of hypothyroid rats (12).  Similarly, hepatocytes isolated from 
T3-treated rats show higher oxygen consumption and lower IMM potential as compared 
with non-treated control (13-16).  Also, a decrease in IMM potential has been reported in 
TH-treated human lymphocytes or those derived from hyperthyroid patients (17).   Overall, 
these findings suggested that TH indeed induces mitochondrial uncoupling, and that 
mitochondrial uncoupling may account for the cellular mode-of-action of TH in modulating 
metabolic efficiency in vivo. 
Concomitantly with the proposed mitochondrial paradigm of TH, others have proposed 
non-mitochondrial activity of TH in modulating metabolic efficiency. Thus, TH was claimed 
to induce “futile substrate cycles”, namely, opposing energy-requiring metabolic pathways 
that proceed simultaneously without generating net products, e.g. glycolysis accompanied 
by gluconeogenesis, lipolysis with lipogenesis (18, 19),  Na+/K+ ATPase with concomitant 
Na+/K+ leakage (13),  or  glycerol-3- phosphate/NADH mitochondrial shuttling (20).  
However, these proposed mechanisms could account for only a small fraction (about 15%) 
of the total increase in oxygen consumption induced by TH (13, 21), resulting in a 
mitochondrial paradigm consensus for TH-induced calorigenesis. Yet, the concerned 
mitochondrial targets still remained enigmatic. 
3. Nuclear / mitochondrial targets of TH 
TH effects in the mitochondrial context may consist of long-term effects that are dependent 
upon gene expression, and short-term effects that are refractory to inhibitors of protein 
synthesis.  An important finding reported by Tata et al (2), indicated that the calorigenic 
activity of TH was abrogated by actinomycin D, implying that TH-induced mitochondrial 
uncoupling is mediated by modulating nuclear gene expression of respective mitochondrial 
and/or extra-mitochondrial proteins. These results were followed by extensive studies ((22, 
23) and others) that resulted in discovering the nuclear TH receptors (THR) of the 
superfamily of nuclear receptors, acting as target for TH in modulating nuclear gene 
expression. THR are encoded by two distinct tissue-dependent genes coding for splice 
variants of the THRbrain, bone, heart) and THRliver, brain, heart) isoforms. THR 
homodimers or heterodimers with other members of the superfamily of nuclear receptors 
(e.g., retinoic X receptor (RXR)) may interact with TH-response elements (TRE) in the 
promoters of TH-responsive genes, resulting in transcriptional activation or suppression as 
function of transcriptional co-activators or co-suppressors recruited by TH/THR to the 
transcriptional complex of respective promoters.  Indeed, TH binding to nuclear THR results 
in direct transcriptional activation of the expression of genes coding for components of 
mitochondrial oxidative phosphorylation (i.e. βF1-adenosine triphosphatase, adenine 
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nucleotide translocase (ANT), cytochrome c1) (24, 25), or genes coding for intermediate 
factors that are indirectly involved in promoting the nuclear expression of mitochondrial 
components (i.e. nuclear respiratory factors 1 and -2, peroxisome proliferator-activated 
receptor-γ coactivator-1) (26), or in stimulating mitochondrial DNA replication (27). Hence, 
TH-induced mitochondrial uncoupling was believed to be accounted for by TH-induced 
gene expression of respective protein targets that modulate mitochondrial oxidative 
phosphorylation. In pursuing putative proteins involved in TH-induced mitochondrial 
uncoupling, a number of candidates have been suggested. These included the adenine 
nucleotide translocase, proteins that are involved in phosphatidylglycerol and cardiolipin 
synthesis (28), and in particular the mitochondrial uncoupling proteins (UCPs). 
4. Mitochondrial uncoupling proteins (UCPs) 
With the discovery of UCPs, extensive efforts were invested in verifying their putative role in 
mediating the calorigenic effect of TH. In fact, the UCP-coding genes have TREs in their 
promoters and their expression level is increased by TH treatment, implying their putative role 
in mediating TH-induced calorigenesis (40). UCP1 (29) mediates proton leak in brown adipose 
tissue IMM (30), resulting in uncoupling fuel oxidation  from ATP synthesis  and in dissipating 
IMM potential as heat. The adaptive thermogenic response of UCP1 is driven by the 
sympathetic nervous system in response to cold temperature or high-energy cafeteria diet, and 
could apparently serve as target for TH in modulating total body energy expenditure. Indeed, 
recent findings by Lopez et al (31) have indicated that TH treatment results in suppressing 
hypothalamic AMP-activated protein kinase (AMPK) activity, resulting in SNS-induced 
thermogenic response of brown adipose fat. However, UCP1 is specifically expressed in 
brown adipose tissue, which is sparse in adult humans. While recent findings point to some 
brown adipose islets in adult humans (32-37), their putative impact on total body energy 
expenditure still remains to be resolved.  Hence, other proteins that share sequence homology 
with UCP1(38), including the ubiquitously expressed UCP2,  and in particular the UCP3 that is 
expressed in skeletal muscle, were pursued for their role in mediating TH-induced 
calorigenesis (39). However, the following observations may indicate that  UCP2 and UCP3 
may not account for TH-induced mitochondrial uncoupling (41).  Thus, findings suggest that 
UCP2/3  do not contribute to adaptive thermogenesis (42), but may have a role in ROS 
signaling (43) and/or in exporting fatty acid anions from the mitochondrial matrix (44). Also, 
the expression of liver UCP2/3 proteins is restricted to Kupffer cells, implying that the 
uncoupling effect of TH in liver parenchymal cells is not due to UCPs. Most importantly, 
UCP3 knock-out mice are lean and show normal response to TH (45), leaving unresolved the 
specific proteins that may mediate TH metabolic effects in the mitochondrial context.  
5. Mitochondrial permeability transition pore (PTP)  
In analogy to UCPs, mitochondria consist of Permeability Transition Pores (PTP) (46-50) 
located at the contact sites of the inner (IMM) and outer (OMM) mitochondrial membranes. 
The molecular composition and structure of mitochondrial PTP still remains to be resolved. 
The current model of PTP consists of the integral proteins ANT (in the IMM), the voltage-
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evidence in support of ‘mitochondrial uncoupling’ has however  indicated  increase in 
oxygen consumption and mitochondrial proton permeability of isolated liver mitochondria 
derived from hyperthyroid rats,  with concomitant  decrease in   mitochondrial phosphate 
potential and inner mitochondrial membrane (IMM) potential (9, 10).  These observations 
were further corroborated by increase in liver oxidizing capacity of hyperthyroid rats  
accompanied by decrease in  phosphate and  cytosolic redox potential (11), while opposite 
effects were reported in livers of hypothyroid rats (12).  Similarly, hepatocytes isolated from 
T3-treated rats show higher oxygen consumption and lower IMM potential as compared 
with non-treated control (13-16).  Also, a decrease in IMM potential has been reported in 
TH-treated human lymphocytes or those derived from hyperthyroid patients (17).   Overall, 
these findings suggested that TH indeed induces mitochondrial uncoupling, and that 
mitochondrial uncoupling may account for the cellular mode-of-action of TH in modulating 
metabolic efficiency in vivo. 
Concomitantly with the proposed mitochondrial paradigm of TH, others have proposed 
non-mitochondrial activity of TH in modulating metabolic efficiency. Thus, TH was claimed 
to induce “futile substrate cycles”, namely, opposing energy-requiring metabolic pathways 
that proceed simultaneously without generating net products, e.g. glycolysis accompanied 
by gluconeogenesis, lipolysis with lipogenesis (18, 19),  Na+/K+ ATPase with concomitant 
Na+/K+ leakage (13),  or  glycerol-3- phosphate/NADH mitochondrial shuttling (20).  
However, these proposed mechanisms could account for only a small fraction (about 15%) 
of the total increase in oxygen consumption induced by TH (13, 21), resulting in a 
mitochondrial paradigm consensus for TH-induced calorigenesis. Yet, the concerned 
mitochondrial targets still remained enigmatic. 
3. Nuclear / mitochondrial targets of TH 
TH effects in the mitochondrial context may consist of long-term effects that are dependent 
upon gene expression, and short-term effects that are refractory to inhibitors of protein 
synthesis.  An important finding reported by Tata et al (2), indicated that the calorigenic 
activity of TH was abrogated by actinomycin D, implying that TH-induced mitochondrial 
uncoupling is mediated by modulating nuclear gene expression of respective mitochondrial 
and/or extra-mitochondrial proteins. These results were followed by extensive studies ((22, 
23) and others) that resulted in discovering the nuclear TH receptors (THR) of the 
superfamily of nuclear receptors, acting as target for TH in modulating nuclear gene 
expression. THR are encoded by two distinct tissue-dependent genes coding for splice 
variants of the THRbrain, bone, heart) and THRliver, brain, heart) isoforms. THR 
homodimers or heterodimers with other members of the superfamily of nuclear receptors 
(e.g., retinoic X receptor (RXR)) may interact with TH-response elements (TRE) in the 
promoters of TH-responsive genes, resulting in transcriptional activation or suppression as 
function of transcriptional co-activators or co-suppressors recruited by TH/THR to the 
transcriptional complex of respective promoters.  Indeed, TH binding to nuclear THR results 
in direct transcriptional activation of the expression of genes coding for components of 
mitochondrial oxidative phosphorylation (i.e. βF1-adenosine triphosphatase, adenine 
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nucleotide translocase (ANT), cytochrome c1) (24, 25), or genes coding for intermediate 
factors that are indirectly involved in promoting the nuclear expression of mitochondrial 
components (i.e. nuclear respiratory factors 1 and -2, peroxisome proliferator-activated 
receptor-γ coactivator-1) (26), or in stimulating mitochondrial DNA replication (27). Hence, 
TH-induced mitochondrial uncoupling was believed to be accounted for by TH-induced 
gene expression of respective protein targets that modulate mitochondrial oxidative 
phosphorylation. In pursuing putative proteins involved in TH-induced mitochondrial 
uncoupling, a number of candidates have been suggested. These included the adenine 
nucleotide translocase, proteins that are involved in phosphatidylglycerol and cardiolipin 
synthesis (28), and in particular the mitochondrial uncoupling proteins (UCPs). 
4. Mitochondrial uncoupling proteins (UCPs) 
With the discovery of UCPs, extensive efforts were invested in verifying their putative role in 
mediating the calorigenic effect of TH. In fact, the UCP-coding genes have TREs in their 
promoters and their expression level is increased by TH treatment, implying their putative role 
in mediating TH-induced calorigenesis (40). UCP1 (29) mediates proton leak in brown adipose 
tissue IMM (30), resulting in uncoupling fuel oxidation  from ATP synthesis  and in dissipating 
IMM potential as heat. The adaptive thermogenic response of UCP1 is driven by the 
sympathetic nervous system in response to cold temperature or high-energy cafeteria diet, and 
could apparently serve as target for TH in modulating total body energy expenditure. Indeed, 
recent findings by Lopez et al (31) have indicated that TH treatment results in suppressing 
hypothalamic AMP-activated protein kinase (AMPK) activity, resulting in SNS-induced 
thermogenic response of brown adipose fat. However, UCP1 is specifically expressed in 
brown adipose tissue, which is sparse in adult humans. While recent findings point to some 
brown adipose islets in adult humans (32-37), their putative impact on total body energy 
expenditure still remains to be resolved.  Hence, other proteins that share sequence homology 
with UCP1(38), including the ubiquitously expressed UCP2,  and in particular the UCP3 that is 
expressed in skeletal muscle, were pursued for their role in mediating TH-induced 
calorigenesis (39). However, the following observations may indicate that  UCP2 and UCP3 
may not account for TH-induced mitochondrial uncoupling (41).  Thus, findings suggest that 
UCP2/3  do not contribute to adaptive thermogenesis (42), but may have a role in ROS 
signaling (43) and/or in exporting fatty acid anions from the mitochondrial matrix (44). Also, 
the expression of liver UCP2/3 proteins is restricted to Kupffer cells, implying that the 
uncoupling effect of TH in liver parenchymal cells is not due to UCPs. Most importantly, 
UCP3 knock-out mice are lean and show normal response to TH (45), leaving unresolved the 
specific proteins that may mediate TH metabolic effects in the mitochondrial context.  
5. Mitochondrial permeability transition pore (PTP)  
In analogy to UCPs, mitochondria consist of Permeability Transition Pores (PTP) (46-50) 
located at the contact sites of the inner (IMM) and outer (OMM) mitochondrial membranes. 
The molecular composition and structure of mitochondrial PTP still remains to be resolved. 
The current model of PTP consists of the integral proteins ANT (in the IMM), the voltage-
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dependent anion channel (VDAC, in the OMM), cyclophylin D (CypD, in the mitochondrial 
matrix) and the Bcl2 family of proteins (in the OMM). PTP gating may present itself in 
definitive or transient modes, differing in reversibility and synchronization (51, 52). 
Definitive synchronized PTP gating is induced by intramitochondrial Ca+2 load (53),  and is 
enhanced by oxidative stress, depletion of adenine nucleotides, increased inorganic 
phosphate, increased matrix pH, and depolarization of the IMM (54-56). This 
opening/gating mode results in high-conductance PTP (HC-PTP), extensive depolarization 
of the IMM (~70% decrease in IMM potential), rapid passage of ions and solutes of less than 
1500 Da across the IMM, and mitochondrial swelling. These may lead to rupture of the 
OMM, release of mitochondrial proapoptotic proteins (such as cytochrome c, apoptotic 
intrinsic factor), followed by programmed cell death/apoptosis (57).  Alternatively, 
spontaneous, non-synchronized, transient/flickering  PTP gating due to cyclic opening and 
closure of individual PTP channels may result in reversible and limited depolarization of the 
IMM (~30% decrease in IMM potential), moderate decrease in proton motive force, and 
passage of solutes of less than 300 Da, accompanied by mitochondrial contraction rather 
than swelling (58-63). Most importantly, in contrast to the irreversible proapoptotic 
depolarization inflicted by definitive PTP gating, transient low conductance PTP (LC-PTP) 
gating is innocuous and reversible, leading to mild mitochondrial uncoupling. These 
findings may indicate that LC-PTP may serve as mitochondrial target of TH in inducing 
physiological mitochondrial uncoupling and calorigenesis.   
6. Mitochondrial PTP gating by TH 
In testing the role played by PTP gating in TH action, a straightforward approach would be to 
examine whether TH-induced uncoupling is inhibited by the PTP specific inhibitor, 
cyclosporin A (CSA).  CSA acts as a potent inhibitor of PTP gating due to its binding to CypD, 
resulting in interfering with CypD interaction with PTP-ANT (64, 65). Indeed, TH-induced 
lowering of mitochondrial membrane potential and proton gradient followed by 
mitochondrial swelling are all eliminated by added CSA, pointing to PTP involvement in TH 
mitochondrial activity (66, 67). In addition, liver mitochondria of hypothyroid rats show  
decrease  in mitochondrial Ca+2  efflux, swelling and protein release, being restored by TH 
treatment (68-70). Furthermore, TH treatment of Jurkat cells induces induce LC-PTP gating 
(71), implying that mitochondrial PTP may serve as target for TH in inducing mitochondrial 
uncoupling. However, as described below, TH activity in gating PTP is not accounted for by 
modulating gene expression of structural components of mitochondrial PTP.  
Adenine Nucleotide Translocase (ANT): ANT is a central player in oxidative 
phosphorylation due to its primary function in translocating adenine-nucleotides via the IMM. 
ANT function in the PTP context  has been verified by its direct association with CypD and 
VDAC (72), as well as by PTP gating being activated and inhibited by the ANT ligands 
Atractylate and Bongrekic acid, respectively (73). Moreover, ANT/CypD/VDAC- reconstituted 
liposomes show PTP characteristics in terms of sensitivity to Ca+2,  CSA and ANT ligands ((74, 
75) but see also (76)).  Also, over-expression of ANT isoforms (ANT1, ANT3) promotes 
apoptosis, being inhibited by CSA (77, 78). Moreover, ANT expression levels affect 
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mitochondrial IMM potential, with high ANT levels resulting in IMM depolarization and 
mitochondrial proton leak (71, 77, 79). Hence, in light of ANT structural and  regulatory 
functions in the PTP context, and  since  the expression level of ANT2, the only ANT isoform 
expressed in liver, is increased in hyperthyroidism  and decreased  by hypothyroidism (80), 
TH-induced ANT expression could apparently account for liver TH-induced LC-PTP gating. 
However, over-expression of ANT2 in HeLa cell line or in rat primary hepatocytes resulted in 
extensive mitochondrial depolarization that was not inhibited by CSA (71), implying  the 
formation of PTP-nonrelated ANT channels (81), or of CSA-insensitive PTP (82).  Lack of an 
obligatory linkage between PTP and ANT conforms to other findings pointing to PTP gating 
by proapoptotic ligands in liver cells or isolated mitochondria that lack ANT (76).  
Cyclophilin D (CypD): CypD is a member of the family of peptidyl-prolyl cis-trans 
isomerases (PPIase) (83). The CypD protein contains a mitochondrial-targeting sequence 
that directs it specifically to the mitochondrial matrix. The link between CypD and PTP has 
been verified by CypD direct association with ANT (72) as well as by CSA inhibition of PTP 
gating due to its interaction and inhibition of  CypD activity (64, 65, 84). Moreover, PTP 
opening by Ca+2  and oxidative stress was enhanced in isolated mitochondria of neurons 
over-expressing CypD (85), while CSA-sensitive PTP opening was abrogated in isolated 
mitochondria of CypD knock-out mice (86). These CypD characteristics may indicate that 
CypD could apparently serve as protein target of TH in inducing PTP opening and 
mitochondrial uncoupling. Indeed, liver mitochondria of hyperthyroid rats show increased 
expression of CypD as well as its PPIase enzymatic activity (71), while opposite effects 
prevailed in liver mitochondria isolated from hypothyroid rats.  However, over-expression 
of CypD in HeLa cell line, or in rat primary hepatocytes, resulted in mitochondrial 
hyperpolarization rather than PTP opening (71, 87). Moreover, over-expressed CypD was 
found to desensitize cells to apoptotic stimuli or to protect cells from mitochondrial 
depolarization and apoptosis induced by over-expression of ANT1 (77, 78). Hence, TH-
induced CypD expression may not account for TH-induced PTP gating and calorigenesis.  
CypD  induction by TH may reflect TH activity in inducing peptidyl-prolyl cis-trans 
isomerase activity and protein folding rather than PTP opening (88). 
Voltage Dependent Anion Channel (VDAC): VDAC is a highly abundant protein of the 
OMM. Its primary function consists of  exchanging anions between the cytosol and the inter-
membrane mitochondrial space (89). Previous findings have indicated its putative role in 
gating mitochondrial PTP (90-94). However, its expression level  is  not changed by in vivo 
TH treatment (71), excluding VDAC from being a molecular target of TH in inducing 
mitochondrial uncoupling. 
7. Modulation of Bcl2-family proteins by TH 
The family of Bcl2 proteins consists of more than 20 proteins that were extensively studied 
in terms of their role in cell death (95). The Bcl2 family is grouped into two main 
subfamilies: proapoptotic proteins (e.g. Bax, Bak, and others) and anti-apoptotic proteins 
(e.g. Bcl2), which promote or inhibit PTP gating, respectively (95-97). Bcl2-family proteins 
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dependent anion channel (VDAC, in the OMM), cyclophylin D (CypD, in the mitochondrial 
matrix) and the Bcl2 family of proteins (in the OMM). PTP gating may present itself in 
definitive or transient modes, differing in reversibility and synchronization (51, 52). 
Definitive synchronized PTP gating is induced by intramitochondrial Ca+2 load (53),  and is 
enhanced by oxidative stress, depletion of adenine nucleotides, increased inorganic 
phosphate, increased matrix pH, and depolarization of the IMM (54-56). This 
opening/gating mode results in high-conductance PTP (HC-PTP), extensive depolarization 
of the IMM (~70% decrease in IMM potential), rapid passage of ions and solutes of less than 
1500 Da across the IMM, and mitochondrial swelling. These may lead to rupture of the 
OMM, release of mitochondrial proapoptotic proteins (such as cytochrome c, apoptotic 
intrinsic factor), followed by programmed cell death/apoptosis (57).  Alternatively, 
spontaneous, non-synchronized, transient/flickering  PTP gating due to cyclic opening and 
closure of individual PTP channels may result in reversible and limited depolarization of the 
IMM (~30% decrease in IMM potential), moderate decrease in proton motive force, and 
passage of solutes of less than 300 Da, accompanied by mitochondrial contraction rather 
than swelling (58-63). Most importantly, in contrast to the irreversible proapoptotic 
depolarization inflicted by definitive PTP gating, transient low conductance PTP (LC-PTP) 
gating is innocuous and reversible, leading to mild mitochondrial uncoupling. These 
findings may indicate that LC-PTP may serve as mitochondrial target of TH in inducing 
physiological mitochondrial uncoupling and calorigenesis.   
6. Mitochondrial PTP gating by TH 
In testing the role played by PTP gating in TH action, a straightforward approach would be to 
examine whether TH-induced uncoupling is inhibited by the PTP specific inhibitor, 
cyclosporin A (CSA).  CSA acts as a potent inhibitor of PTP gating due to its binding to CypD, 
resulting in interfering with CypD interaction with PTP-ANT (64, 65). Indeed, TH-induced 
lowering of mitochondrial membrane potential and proton gradient followed by 
mitochondrial swelling are all eliminated by added CSA, pointing to PTP involvement in TH 
mitochondrial activity (66, 67). In addition, liver mitochondria of hypothyroid rats show  
decrease  in mitochondrial Ca+2  efflux, swelling and protein release, being restored by TH 
treatment (68-70). Furthermore, TH treatment of Jurkat cells induces induce LC-PTP gating 
(71), implying that mitochondrial PTP may serve as target for TH in inducing mitochondrial 
uncoupling. However, as described below, TH activity in gating PTP is not accounted for by 
modulating gene expression of structural components of mitochondrial PTP.  
Adenine Nucleotide Translocase (ANT): ANT is a central player in oxidative 
phosphorylation due to its primary function in translocating adenine-nucleotides via the IMM. 
ANT function in the PTP context  has been verified by its direct association with CypD and 
VDAC (72), as well as by PTP gating being activated and inhibited by the ANT ligands 
Atractylate and Bongrekic acid, respectively (73). Moreover, ANT/CypD/VDAC- reconstituted 
liposomes show PTP characteristics in terms of sensitivity to Ca+2,  CSA and ANT ligands ((74, 
75) but see also (76)).  Also, over-expression of ANT isoforms (ANT1, ANT3) promotes 
apoptosis, being inhibited by CSA (77, 78). Moreover, ANT expression levels affect 
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mitochondrial IMM potential, with high ANT levels resulting in IMM depolarization and 
mitochondrial proton leak (71, 77, 79). Hence, in light of ANT structural and  regulatory 
functions in the PTP context, and  since  the expression level of ANT2, the only ANT isoform 
expressed in liver, is increased in hyperthyroidism  and decreased  by hypothyroidism (80), 
TH-induced ANT expression could apparently account for liver TH-induced LC-PTP gating. 
However, over-expression of ANT2 in HeLa cell line or in rat primary hepatocytes resulted in 
extensive mitochondrial depolarization that was not inhibited by CSA (71), implying  the 
formation of PTP-nonrelated ANT channels (81), or of CSA-insensitive PTP (82).  Lack of an 
obligatory linkage between PTP and ANT conforms to other findings pointing to PTP gating 
by proapoptotic ligands in liver cells or isolated mitochondria that lack ANT (76).  
Cyclophilin D (CypD): CypD is a member of the family of peptidyl-prolyl cis-trans 
isomerases (PPIase) (83). The CypD protein contains a mitochondrial-targeting sequence 
that directs it specifically to the mitochondrial matrix. The link between CypD and PTP has 
been verified by CypD direct association with ANT (72) as well as by CSA inhibition of PTP 
gating due to its interaction and inhibition of  CypD activity (64, 65, 84). Moreover, PTP 
opening by Ca+2  and oxidative stress was enhanced in isolated mitochondria of neurons 
over-expressing CypD (85), while CSA-sensitive PTP opening was abrogated in isolated 
mitochondria of CypD knock-out mice (86). These CypD characteristics may indicate that 
CypD could apparently serve as protein target of TH in inducing PTP opening and 
mitochondrial uncoupling. Indeed, liver mitochondria of hyperthyroid rats show increased 
expression of CypD as well as its PPIase enzymatic activity (71), while opposite effects 
prevailed in liver mitochondria isolated from hypothyroid rats.  However, over-expression 
of CypD in HeLa cell line, or in rat primary hepatocytes, resulted in mitochondrial 
hyperpolarization rather than PTP opening (71, 87). Moreover, over-expressed CypD was 
found to desensitize cells to apoptotic stimuli or to protect cells from mitochondrial 
depolarization and apoptosis induced by over-expression of ANT1 (77, 78). Hence, TH-
induced CypD expression may not account for TH-induced PTP gating and calorigenesis.  
CypD  induction by TH may reflect TH activity in inducing peptidyl-prolyl cis-trans 
isomerase activity and protein folding rather than PTP opening (88). 
Voltage Dependent Anion Channel (VDAC): VDAC is a highly abundant protein of the 
OMM. Its primary function consists of  exchanging anions between the cytosol and the inter-
membrane mitochondrial space (89). Previous findings have indicated its putative role in 
gating mitochondrial PTP (90-94). However, its expression level  is  not changed by in vivo 
TH treatment (71), excluding VDAC from being a molecular target of TH in inducing 
mitochondrial uncoupling. 
7. Modulation of Bcl2-family proteins by TH 
The family of Bcl2 proteins consists of more than 20 proteins that were extensively studied 
in terms of their role in cell death (95). The Bcl2 family is grouped into two main 
subfamilies: proapoptotic proteins (e.g. Bax, Bak, and others) and anti-apoptotic proteins 
(e.g. Bcl2), which promote or inhibit PTP gating, respectively (95-97). Bcl2-family proteins 
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may directly interact with PTP components such as ANT (98-100) or VDAC (101), and when 
over-expressed or added to isolated mitochondria  may specifically induce (e.g. Bax and 
Bak) (102-104) or antagonize (e.g. Bcl2) (105) PTP gating. Similarly, depletion of 
proapoptotic Bax or Bak results in failure of PTP gating (98, 105, 106), whereas Bcl2 
inactivation results in definitive PTP gating triggered by oxidative stress (107). Thus, 
mitochondrial Bcl2-family proteins and their respective heterodimers (e.g., Bax/Bcl2, 
Bad/Bcl2) may apparently serve as candidate targets of TH in inducing mitochondrial 
uncoupling (108-110). Indeed, TH-induced PTP gating is accompanied by increase in 
mitochondrial Bax and Bak, together with decrease in mitochondrial Bcl2 content, whereas 
hypothyroidism results in opposite effects that are reversed by TH (71). Modulation of the 
mitochondrial content of Bcl2 proteins by TH is due to their specific translocation in/out of 
mitochondria, rather than reflecting modulation of their expression and total cellular 
content.  Amplifying the ratio of mitochondrial pro- vs. anti-apoptotic proteins, results in 
robust decrease in mitochondrial Bax/Bcl2 heterodimer with concomitant increase in free 
Bax, leading to PTP gating by free mitochondrial Bax (111). Indeed, over-expression of Bcl2 
protects against TH-induced mitochondrial PTP gating (71), implying that depletion of 
mitochondrial Bcl2 by TH may account for TH-induced mitochondrial uncoupling.  
8. Extra-mitochondrial upstream signals that induce TH-induced  
PTP gating mediated by Bcl2-family proteins 
Since Bcl2-Bax hetrodimerization may depend on Bcl2(S70) phosphorylation state (112), 
mitochondrial Bcl2 depletion by T3 was further verified in terms of Bcl2(S70) 
phosphorylation profile. Indeed, concomitantly with decrease in mitochondrial Bcl2, T3 
treatment results in decreased phosphorylation of monomeric mitochondrial Bcl2(S70) as 
well as of Bcl2(S70)-Bax heterodimer (113), indicating that mitochondrial Bcl2 depletion may 
reflect Bcl2(S70) dephosphorylation by TH. In pursuing kinases (e.g. PKA, PKC) or 
phosphatases (e.g. PP2A, PP2B/Calcineurin) reported to be involved in Bcl2(S70) 
phosphorylation (112, 114), neither PKA, PKC nor PP2A were found to mediate 
phosphorylation/dephosphorylation of Bcl2(S70) by TH (113). In contrast, 
dephosphorylation of Bcl2(S70) and the depletion of mitochondrial Bcl2 protein by T3 are 
both reversed by the FK506 inhibitor of PP2B, indicating that the TH effect may  be 
mediated by activation of PP2B (113). Furthermore, added FK506 blocksT3-induced opening 
of PTP, indicating that dephosphorylation of Bcl2(S70) and its mitochondrial depletion by 
T3-activated PP2B may account for mitochondrial PTP opening by TH.  Since TH-induced 
PP2B activation was not accompanied by increase in PP2B expression, PP2B activation  was 
further pursued by searching for TH-induced increase in cytosolic Ca+2 (113).  Indeed, Ca+2 -
activated PP2B has previously been reported to bind and dephosphorylate Bcl2(S70)  (115, 
116). Most importantly, T3 treatment resulted in pronounced increase in Ca+2, while Ca+2  
chelation by BAPTA resulted in abrogating LC-PTP gating by TH, indicating that TH-
induced PP2B activity  involved mobilization of intracellular Ca+2 (113). Indeed, T3-induced 
mobilization of intracellular Ca+2  has recently been reported to mediate a variety of non-
genomic effects of TH (117, 118).      
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The dynamic equilibrium between cytosolic Ca+2 ([Ca+2]c) and endoplasmic reticulum (ER) 
Ca+2 ([Ca+2]ER) is maintained by an interplay between the inositol 1,4,5-trisphosphate 
receptor (IP3R1) and the sarcoplasmic Ca+2 ATPase (SERCA) that catalyzes  ER Ca+2 efflux 
and influx, respectively (119).  IP3R1 is activated by binding of the IP3 ligand and may 
further be modulated by its phosphorylation by PKA, PKC or CaMKII, its 
dephosphorylation by PP2B, or by its association with one or more of about 50 proteins, 
including FKBP12 or Bcl2 (120, 121). The putative role played by IP3R1 in TH-induced PTP 
gating was evaluated by verifying the effect of TH in cells lacking IP3R1 (113). Thus, PTP 
opening, dephosphorylation of mitochondrial Bcl2(S70) and depletion of mitochondrial Bcl2 
are all abrogated in cells lacking IP3R1, indicating that IP3R1 is indeed required for TH-
induced mitochondrial uncoupling.  Similarly, T3 is ineffective in increasing [Ca+2]c upon 
inhibition of IP3R1 by 2APB, indicating a specific requirement for IP3R1 activity in 
modulating [Ca+2]c by TH. Furthermore, T3-induced gating of IP3R1 is accounted for by 
both, increase in IP3R1 expression and protein levels, complemented by IP3R1 truncation 
into channel-only isoforms.  Truncated IP3R1 isoforms have been reported to serve as  
channel-only peptides capable of carrying out [Ca+2]ER efflux in the absence of  added IP3 
(122-126). IP3R1 truncation by TH may reflect TH activation of IP3R1 proteases that remain 
to be further verified. The  IP3R1 / PP2B crosstalk in mediating TH-induced PTP gating is 
supported by  constitutive PP2B-induced PTP gating  under conditions of suppressing 
IP3R1 expression by siRNA (127). Hence, PP2B is acting downstream to TH-induced IP3R1, 
and is obligatory as well as sufficient in mediating PTP by [Ca+2]c.   
Over all,  TH-induced expression of the IP3R1 channel accompanied by its truncation is 
proposed to result in [Ca+2]ER efflux, increase in [Ca+2]c and  [Ca+2]c-activated PP2B, 
followed by dephosphorylation of mitochondrial Bcl2(S70) with concomitant decrease in 
mitochondrial Bcl2 protein levels and increase in mitochondrial free Bax (Scheme 1). The 
decrease in mitochondrial Bcl2 and/or the respective increase in mitochondrial free Bax 
may initiate and promote variable PTP gating, resulting in physiological LC-PTP–
induced calorigenesis. LC-PTP gating may drift to HC-PTP–induced apoptosis as 
function of additional prevailing conditions that may affect mitochondrial permeability 
transition.    
9. Thyromimetic agents and energy expenditure     
Increase in energy expenditure by TH has long been considered for treating obesity.  Indeed, 
treating obesity by thyroid extracts was quite popular throughout the 20th century and well 
into the 1970s, being later abandoned due to severe side effects consisting of cardiac 
dysrhythmias, bone resorption / osteoporosis, electrolyte disturbances, and loss of lean body 
mass (128). Thus, a final ruling warning against the use of thyroid preparations for the 
treatment of obesity of euthyroid subjects has been issued by the FDA on 1978.  Similarly to 
TH, treating obesity by uncoupling of mitochondrial oxidative phosphorylation by 2,4-
dinitrophenol (DNP) has been introduced on 1933, but  abandoned on 1938 due to fatal 
hyperthermia (129). 
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may directly interact with PTP components such as ANT (98-100) or VDAC (101), and when 
over-expressed or added to isolated mitochondria  may specifically induce (e.g. Bax and 
Bak) (102-104) or antagonize (e.g. Bcl2) (105) PTP gating. Similarly, depletion of 
proapoptotic Bax or Bak results in failure of PTP gating (98, 105, 106), whereas Bcl2 
inactivation results in definitive PTP gating triggered by oxidative stress (107). Thus, 
mitochondrial Bcl2-family proteins and their respective heterodimers (e.g., Bax/Bcl2, 
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PTP gating mediated by Bcl2-family proteins 
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reflect Bcl2(S70) dephosphorylation by TH. In pursuing kinases (e.g. PKA, PKC) or 
phosphatases (e.g. PP2A, PP2B/Calcineurin) reported to be involved in Bcl2(S70) 
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activated PP2B has previously been reported to bind and dephosphorylate Bcl2(S70)  (115, 
116). Most importantly, T3 treatment resulted in pronounced increase in Ca+2, while Ca+2  
chelation by BAPTA resulted in abrogating LC-PTP gating by TH, indicating that TH-
induced PP2B activity  involved mobilization of intracellular Ca+2 (113). Indeed, T3-induced 
mobilization of intracellular Ca+2  has recently been reported to mediate a variety of non-
genomic effects of TH (117, 118).      
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The dynamic equilibrium between cytosolic Ca+2 ([Ca+2]c) and endoplasmic reticulum (ER) 
Ca+2 ([Ca+2]ER) is maintained by an interplay between the inositol 1,4,5-trisphosphate 
receptor (IP3R1) and the sarcoplasmic Ca+2 ATPase (SERCA) that catalyzes  ER Ca+2 efflux 
and influx, respectively (119).  IP3R1 is activated by binding of the IP3 ligand and may 
further be modulated by its phosphorylation by PKA, PKC or CaMKII, its 
dephosphorylation by PP2B, or by its association with one or more of about 50 proteins, 
including FKBP12 or Bcl2 (120, 121). The putative role played by IP3R1 in TH-induced PTP 
gating was evaluated by verifying the effect of TH in cells lacking IP3R1 (113). Thus, PTP 
opening, dephosphorylation of mitochondrial Bcl2(S70) and depletion of mitochondrial Bcl2 
are all abrogated in cells lacking IP3R1, indicating that IP3R1 is indeed required for TH-
induced mitochondrial uncoupling.  Similarly, T3 is ineffective in increasing [Ca+2]c upon 
inhibition of IP3R1 by 2APB, indicating a specific requirement for IP3R1 activity in 
modulating [Ca+2]c by TH. Furthermore, T3-induced gating of IP3R1 is accounted for by 
both, increase in IP3R1 expression and protein levels, complemented by IP3R1 truncation 
into channel-only isoforms.  Truncated IP3R1 isoforms have been reported to serve as  
channel-only peptides capable of carrying out [Ca+2]ER efflux in the absence of  added IP3 
(122-126). IP3R1 truncation by TH may reflect TH activation of IP3R1 proteases that remain 
to be further verified. The  IP3R1 / PP2B crosstalk in mediating TH-induced PTP gating is 
supported by  constitutive PP2B-induced PTP gating  under conditions of suppressing 
IP3R1 expression by siRNA (127). Hence, PP2B is acting downstream to TH-induced IP3R1, 
and is obligatory as well as sufficient in mediating PTP by [Ca+2]c.   
Over all,  TH-induced expression of the IP3R1 channel accompanied by its truncation is 
proposed to result in [Ca+2]ER efflux, increase in [Ca+2]c and  [Ca+2]c-activated PP2B, 
followed by dephosphorylation of mitochondrial Bcl2(S70) with concomitant decrease in 
mitochondrial Bcl2 protein levels and increase in mitochondrial free Bax (Scheme 1). The 
decrease in mitochondrial Bcl2 and/or the respective increase in mitochondrial free Bax 
may initiate and promote variable PTP gating, resulting in physiological LC-PTP–
induced calorigenesis. LC-PTP gating may drift to HC-PTP–induced apoptosis as 
function of additional prevailing conditions that may affect mitochondrial permeability 
transition.    
9. Thyromimetic agents and energy expenditure     
Increase in energy expenditure by TH has long been considered for treating obesity.  Indeed, 
treating obesity by thyroid extracts was quite popular throughout the 20th century and well 
into the 1970s, being later abandoned due to severe side effects consisting of cardiac 
dysrhythmias, bone resorption / osteoporosis, electrolyte disturbances, and loss of lean body 
mass (128). Thus, a final ruling warning against the use of thyroid preparations for the 
treatment of obesity of euthyroid subjects has been issued by the FDA on 1978.  Similarly to 
TH, treating obesity by uncoupling of mitochondrial oxidative phosphorylation by 2,4-
dinitrophenol (DNP) has been introduced on 1933, but  abandoned on 1938 due to fatal 
hyperthermia (129). 
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Scheme 1. PTP-induced calorigenesis by Thyroid Hormone and MEDICA Analogs 
These early attempts were followed by rational drug design of  synthetic structural analogs 
of TH that may  avoid  the  lethal chronotropic cardiac effects of TH, while maintaining the 
beneficial effects of TH in the context of diseases of the Metabolic Syndrome (130, 131). Most 
efforts in that direction were invested in designing thyromimetics that selectively target the 
liver TH-receptor isoforms (THR) while avoiding the heart isoforms (THR). Tissue 
selectivity has been further pursued by designing thyromimetics that undergo selective 
hepatic uptake. These efforts have mainly resulted in thyromimetics effective in treating 
dyslipidemia, due to increased expression of hepatic LDL-receptors together with CYP7A1 / 
7-alpha-cholesterol hydroxylase, resulting in enhancing hepatic uptake of LDL-cholesterol 
and its conversion into bile. Liver-specific thyromimetics were further found to induce the 
expression of the hepatic scavenger receptor SR-B1 that mediates reverse cholesterol 
transport.  However, in contrast to the advances made in designing hypolipidemic 
thyromimetics, the efficacy of thyromimetics in treating obesity and obesity-induced 
diabetes type 2 still remains to be verified. Moreover,  the use of thyromimetics for treating 
diseases of the Metabolic Syndrome involves potential harmful risks due to:   a. The partial 
selectivity of  thyromimetics for hepatic THR, resulting in positive chronotropic effects as 
well as enhanced bone and muscle catabolism induced by high-dose. Hence, the safety of 
hypolipidemic thyromimetics still remains to be verified in subjects suffering from 
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of hypothalamic TSH, thyromimetics may suppress the production of endogenous TH, 
resulting in combined hypo- and hyperthyroidsm. These limitations, combined with our 
present view of the mode-of-action of TH in the mitochondrial context, may however point 
to an alternative strategy, namely synthesizing thyromimetics that may directly target 
mitochondrial PTP while avoiding the TH/THR transduction pathway altogether.  
Long chain fatty acids (LCFA) have long been shown to induce mitochondrial uncoupling 
due to   their protonophoric activity (81, 132) and/or PTP gating ((51, 133), and ref therein), 
implying a potential mitochondrial thyromimetic activity. However, the uncoupling activity 
of LCFA is confounded by their dual role as putative uncouplers of oxidative 
phosphorylation and as substrates for oxidation or esterification. MEDICA analogs consist 
of long chain dioic acids (HOOC-C(α′)-C(β′)-(CH2)n-C(β)-C(α)-COOH (n=10-14)) that are 
substituted in the αα′ or ββ′ carbons (134). MEDICA analogs may be thioesterified 
endogenously into their respective mono acyl-CoA thioesters (135), however, they are not 
esterified into lipids nor β-oxidized, thus dissociating between the substrate role and the 
putative uncoupling activity of natural LCFA. 
Similarly to TH, MEDICA analogs induce calorigenesis in animal models in vivo. Thus, 
treatment of   rats with MEDICA analogs results in an increase in oxygen consumption 
accompanied by a decrease in liver mitochondrial phosphate potential and cytosolic redox 
potential, reflecting mitochondrial uncoupling in vivo (136). Furthermore, treatment of obese 
leptin receptor-deficient rats (e.g. Zucker, cp/cp) with MEDICA analogs results in increased 
oxygen consumption and food consumption together with weight loss, implying increased 
total body energy expenditure (137, 138). Also, the non-protonophoric mitochondrial 
activity of MEDICA analogs is similar to that of TH (71), in terms of promoting CSA-
sensitive decrease in phosphate and redox potentials with concomitant increase in oxygen 
consumption in cultured cells as well as in vivo (11, 16, 67, 139, 140), indicating that both 
MEDICA analogs and TH do converge onto LC/HC-PTP gating  (11, 71).  Indeed, similarly 
to TH, PTP gating by MEDICA analogs is mediated by modulating the profile of 
mitochondrial Bcl2-family proteins, resulting in decrease in mitochondrial Bcl2-Bax 
heterodimer with concomitant  increase in mitochondrial free Bax (71, 113). However, 
different transduction pathways are involved in modulating the mitochondrial content of 
free Bax by TH or MEDICA analogs.  Thus, dissociation of the Bcl2-Bax heterodimer by TH 
is driven by dephosphorylation of Bcl2(Ser-70) by T3-activated PP2B (113), whereas 
dissociation of the Bcl2/Bax heterodimer by MEDICA analogs is driven by 
dephosphorylation of Bad(Ser-112, Ser-155) (141). The decrease in phosphorylated Bad(Ser-
112, Ser-155) results in its decreased binding to14-3-3 followed by its increased binding to 
mitochondrial Bcl2, resulting in Bax displacement and PTP gating (142, 143). Decrease in 
phosphorylated Bad by MEDICA analogs is due  to  suppression of the Raf1/MAPK/RSK1 
and the adenylate cyclase/PKA transduction pathways, and their respective downstream 
targets Bad(Ser-112) and Bad(Ser-155) (141). Hence, the TH and MEDICA transduction 
pathways converge at their downstream Bax target but diverge upstream of the Bcl2/Bax 
heterodimer (Scheme 1).  LC-PTP gating by MEDICA analogs may account for their 
thyromimetic calorigenic activity in vivo. 
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of hypothalamic TSH, thyromimetics may suppress the production of endogenous TH, 
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total body energy expenditure (137, 138). Also, the non-protonophoric mitochondrial 
activity of MEDICA analogs is similar to that of TH (71), in terms of promoting CSA-
sensitive decrease in phosphate and redox potentials with concomitant increase in oxygen 
consumption in cultured cells as well as in vivo (11, 16, 67, 139, 140), indicating that both 
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10. Conclusion 
Energy expenditure by TH has long been realized to be accounted for by uncoupling of 
mitochondrial oxidative phosphorylation. However, the mode-of-action of TH in promoting 
mitochondrial uncoupling remained elusive. Mitochondrial uncoupling by TH is transduced 
by TH-induced gating of mitochondrial PTP due to modulating its Bcl2-family proteins.  
This mode-of-action underscores the physiological aspects of mitochondrial PTP in 
modulating metabolic rate, in contrast to most previous studies that analyzed mitochondrial 
PTP in its apoptotic context. TH-induced gating of mitochondrial PTP may offer a whole 
new dimension of developing novel anti-obesity drugs that promote weight loss by 
targeting mitochondrial PTP. 
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1. Introduction 
Thyroid disorders are known to involve all the organ systems of the body and the skin is no 
exception. Some dermatological skin findings and diseases may be the first symptoms of 
thyroid disease [1]. Available data suggest that thyroid hormone plays a pivotal role in 
embryonic development of mammalian skin as well as in maintenance of normal cutaneous 
function an adult skin. Thyroid hormone stimulates epidermal oxygen consumption, protein 
synthesis, mitosis, and determination of epidermal thickness [2]. Thyroid hormone is an 
important regulator of epidermal homeostasis. In tissue culture studies using surrogates for 
DNA expression, T 3 has been shown to stimulate growth of both epidermal keratinocytes 
and dermal fibroblastes [3, 4]. In addition, thyroid hormone appears to be necessary for both 
the initiation and maintenance of hair growth and normal secretion of sebum.  
Both hypothyroidism and hyperthyroidism are known to cause skin change. 
Hypothyroidism may result from either inadequate circulating levels of thyroid hormone or 
target cell resistance to hormonal action. Primary hypothyroidism is as a result of glandular 
failure is the most common cause and most frequently result from autoimmune disease [5]. 
In hypothyroidism, the skin is cold, xerotic and pale. The coldness is due to reduced core 
temperature and cutaneous vasoconstriction. The decreased skin perfusion has been 
documented with nail fold capillaroscopy [6]. It has been suggested that the diminished skin 
perfusion is reflex vasoconstriction compensatory to diminished core temperature. The 
diminished core temperature itself may be secondary to reduced thermogenesis [7]. 
Occasionally, purpura may be noted in hypothyroid patients as a result of diminished levels 
of clothing factors and the loss of vascular support secondary to the dermal mucin [8]. The 
dryness of hypothyroid skin results from decreased eccrine gland secretion. The mechanism 
for decreased sweating is not clear although the hypothyroid glands are atrophic on 
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documented with nail fold capillaroscopy [6]. It has been suggested that the diminished skin 
perfusion is reflex vasoconstriction compensatory to diminished core temperature. The 
diminished core temperature itself may be secondary to reduced thermogenesis [7]. 
Occasionally, purpura may be noted in hypothyroid patients as a result of diminished levels 
of clothing factors and the loss of vascular support secondary to the dermal mucin [8]. The 
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sterol biosynthesis, may lead to acquired palmoplantar keratoderma. Xerosis is due to a 
change in skin texture and poor hydratation of the stratum corneum. The skin is rough and 
covered with fine scales. Palms and soles may be quite dry. The epidermis is thin and 
hyperkeratotic, and there is follicular plugging. Because the changes are generalized, they 
can be differentiated from similar alterations in the skin of atopic individuals and keratosis 
pilaris, where the findings are more prominent on the extremities [10]. Hypothyroidism also 
may affect the development of the lamellar granules (Odland bodies), which are vital in the 
establishment of a normal stratum corneum [11]. In hypothyroidism, the skin tends to be 
pale both because of the dermal mucopolysaccharides and dermal water content which alter 
the refraction of light. The name myxedema refers to the associated skin condition caused by 
increased glycosaminoglycan deposition in the skin. Generalized myxedema is still the 
classic cutaneous sign of hypothyroidism. The mucopolysaccharides that accumulate in the 
dermis are hyaluronic acid and chondriotin sulfate. They appear first in the papillary dermis 
and are most prominent around hair follicles and vassels. They separate the collagen 
bundles and there may be some secondary degeneration of collagen [10]. Generally, 
myxedema is diffuse, but focal mucinous papules have been describes. Skin may appear 
swollen, dry, pale, waxy, and firm to the touch. In addition, increased dermal carotene may 
appear as a prominent yellowish discoloration on the palms, soles and nasolabial folds. 
Hypothyroid patients may sometimes suffer Candida folliculitis. It has been theorized that 
because the sebaceous glands of hypothyroid patients secrete decreased sebum relative to 
those of euthyroid persons, the hair follicles may develop a flora with lipophilic organisms, 
which are replaced by Candida albicans (12). The hypothyroid skin heals slowly, and this 
tendency is proportional to the degree of hormone deficiency. In hypothyroidism, hair can 
be dry, coarse, brittle and slow growing. There is both patchy and diffuse loss of scalp hair, 
a very characteristic loss of the outer third of the eyebrow (madarosis), and diminished body 
hair. Pubic and axillary hair may be sparse. The alopecia connected to hypothyroidism may 
be mediated by hormone effects on the initiation as well as the duration of hair growth. 
Massive telogen effluvium may occur when there is abrupt onset of hypothyroidism, and 
the percentage of scalp hairs in telogen is generally increased in hypothyroid states [10]. 
Using DNA flow cytometry, Schell et al. observed that cell proliferation indices were 
reduced in hair bulbs of hypothyroid subjects and increased in hyperthyroidism compared 
with normal values [13]. Hypothyroid patients, especially children, frequently develop long, 
lanugo-type hair on the back, shoulders, and extremities [10]. Diminished sebum secretion 
contributes to the coarse appearance of the hair. Sometimes, hair loss is the only apparent 
symptom of hypothyroidism and the dermatologist is the first to diagnose and treat the 
condition. Nails grow slowly and tend to be thickened, striated and brittle. Onycholysis is 
also associated with hypothyroidism [1]. 
The specific pathophysiology linking hyperthyroidism to classic cutaneous findings remains 
to be well explained (5). In hyperthyroidism, the skin is warm, soft, moist and smooth. The 
epidermis is thin but not atrophic, and the stratum corneum is well hydrated. While the 
smooth skin is an epidermal finding, the warmth is caused by increased cutaneous blood 
flow and the moisture is a reflection of the underlying metabolic state [10]. The warmth is 
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often accompanied by a persistent flush of the face, redness of the elbows, and palmar 
erythema. Hyperhydrosis, especially on palms and soles may be observed. Scalp hair may be 
fine and soft, and may be accompanied by a diffuse nonscarring alopecia. In vitro studies 
suggest increased hair growth rate in thyrotoxicosis. L-Triiodothyronine was shown to 
stimulate proliferation of outer root sheath keratinocytes and dermal papilla cells [14]. 
Hypertrichosis is can be observed in cases of thyroid dermatopathy and may be related to 
alterations in the proteoglycans associated with dermal papilla [15]. Sometimes an early 
symptom of hyperthyroidism is loss of pigment and early gray hair development. Nail 
changes may also occur, characterized by a concave contour accompanied by distal 
onycholysis (Plummer's nails). Hyperpigmentation has been described in thyrotoxic patients 
in both localized and generalized distribution. There is speculation that the hyperpigmentation 
is due to increased release of pituitary adrenocorticotropic hormone compensating for 
accelerated cortisol degradation [16].  Hyperthyroidism may also induce pruritus with or 
without urticaria [17]. Patients with autoimmune mediated thyrotoxicosis may also have 
distinct cutaneous manifestations such as pretibial myxedema and acropachy. Pretibial 
myxedema is the localized thickening of the pretibial skin due to accumulation of acid 
mukopolysaccharides. It usually present with firm nodules and plaques varying in colour 
from pink to purple-brown, and sometimes accompanied by woody induration on extensor 
surfaces. A diffuse brawny edema may be present without nodules. Localized hyperhydrosis 
has been reported in cases of pretibial myxedema. Less common is an elephantiasis nostras 
variant in which the extremity becomes enlarged and covered with verrucous nodules [10]. 
Thickening of the skin of the extensor surface of the forearm (preradial myxedema) has been 
reported [18]. Excessive amounts of hyaluronic acid and chondriotin are present in lesions as 
well as in clinically normal skin [19]. The precise pathogenesis of pretibial myxedema remains 
to be defined. One leading theory is that pretibial fibroblasts are the target for antithyroid 
antibodies. After stimulation by thyroid autoantibodies, fibroblasts may produce excess 
glukosaminglycans [5]. Other theories have implicated T cells as the primary effector of 
dermopathy. T-cells may interact with an autoantigen that is either identical or cross-reactive 
with a thyroid autoantigen in the dermis. In turn, this may induce secretion of cytokines such 
as glycosaminoglycan-stimulatory lymphokine, interleukin1, tumor necrosis factor, and 
gamma interferon, which activate fibroblasts to secrete hyaluronic acid and chondriotin sulfate 
[20]. Thyroid acropachy consist of the triad of digital clubbing, soft-tissue swelling of the 
hands and feet, and characteristic periostal reactions. The vast majority of cases are associated 
with Graves' disease, although it has been reported to occur in Hashimoto's thyroiditis. 
Scleromyxedema has been reported in the setting of hyperthyroidism. This rare entity is 
comprised of numerous firm, white, yellow, or pink papules scattered on the face, trunk, and 
extremitates. Cutaneous lesions are the result of accumulation of acid mucopolysaccharides, 
mostly hyaluronic acid, in the dermis, accompanied by large fibrocytes [5]. 
Skin manifestations of thyroid dysfunction may be divided into two main categories: (I) 
direct action of thyroid hormone on skin tissues, and (II) autoimmune skin disease 
associated with thyroid dysfunction of autoimmune etiology. Direct thyroid hormone action 
on skin is mediated through thyroid hormone receptor (TR). All three widely recognized 
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with normal values [13]. Hypothyroid patients, especially children, frequently develop long, 
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The specific pathophysiology linking hyperthyroidism to classic cutaneous findings remains 
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epidermis is thin but not atrophic, and the stratum corneum is well hydrated. While the 
smooth skin is an epidermal finding, the warmth is caused by increased cutaneous blood 
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often accompanied by a persistent flush of the face, redness of the elbows, and palmar 
erythema. Hyperhydrosis, especially on palms and soles may be observed. Scalp hair may be 
fine and soft, and may be accompanied by a diffuse nonscarring alopecia. In vitro studies 
suggest increased hair growth rate in thyrotoxicosis. L-Triiodothyronine was shown to 
stimulate proliferation of outer root sheath keratinocytes and dermal papilla cells [14]. 
Hypertrichosis is can be observed in cases of thyroid dermatopathy and may be related to 
alterations in the proteoglycans associated with dermal papilla [15]. Sometimes an early 
symptom of hyperthyroidism is loss of pigment and early gray hair development. Nail 
changes may also occur, characterized by a concave contour accompanied by distal 
onycholysis (Plummer's nails). Hyperpigmentation has been described in thyrotoxic patients 
in both localized and generalized distribution. There is speculation that the hyperpigmentation 
is due to increased release of pituitary adrenocorticotropic hormone compensating for 
accelerated cortisol degradation [16].  Hyperthyroidism may also induce pruritus with or 
without urticaria [17]. Patients with autoimmune mediated thyrotoxicosis may also have 
distinct cutaneous manifestations such as pretibial myxedema and acropachy. Pretibial 
myxedema is the localized thickening of the pretibial skin due to accumulation of acid 
mukopolysaccharides. It usually present with firm nodules and plaques varying in colour 
from pink to purple-brown, and sometimes accompanied by woody induration on extensor 
surfaces. A diffuse brawny edema may be present without nodules. Localized hyperhydrosis 
has been reported in cases of pretibial myxedema. Less common is an elephantiasis nostras 
variant in which the extremity becomes enlarged and covered with verrucous nodules [10]. 
Thickening of the skin of the extensor surface of the forearm (preradial myxedema) has been 
reported [18]. Excessive amounts of hyaluronic acid and chondriotin are present in lesions as 
well as in clinically normal skin [19]. The precise pathogenesis of pretibial myxedema remains 
to be defined. One leading theory is that pretibial fibroblasts are the target for antithyroid 
antibodies. After stimulation by thyroid autoantibodies, fibroblasts may produce excess 
glukosaminglycans [5]. Other theories have implicated T cells as the primary effector of 
dermopathy. T-cells may interact with an autoantigen that is either identical or cross-reactive 
with a thyroid autoantigen in the dermis. In turn, this may induce secretion of cytokines such 
as glycosaminoglycan-stimulatory lymphokine, interleukin1, tumor necrosis factor, and 
gamma interferon, which activate fibroblasts to secrete hyaluronic acid and chondriotin sulfate 
[20]. Thyroid acropachy consist of the triad of digital clubbing, soft-tissue swelling of the 
hands and feet, and characteristic periostal reactions. The vast majority of cases are associated 
with Graves' disease, although it has been reported to occur in Hashimoto's thyroiditis. 
Scleromyxedema has been reported in the setting of hyperthyroidism. This rare entity is 
comprised of numerous firm, white, yellow, or pink papules scattered on the face, trunk, and 
extremitates. Cutaneous lesions are the result of accumulation of acid mucopolysaccharides, 
mostly hyaluronic acid, in the dermis, accompanied by large fibrocytes [5]. 
Skin manifestations of thyroid dysfunction may be divided into two main categories: (I) 
direct action of thyroid hormone on skin tissues, and (II) autoimmune skin disease 
associated with thyroid dysfunction of autoimmune etiology. Direct thyroid hormone action 
on skin is mediated through thyroid hormone receptor (TR). All three widely recognized 
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thyroid hormone binding isoforms of TR have been identified in skin tissues [14, 21]. TRs 
have been detected in epidermal keratinocytes, skin fibroblasts, hair arrector pili muscle 
cells, sebaceous gland cells, vascular endothelial cells, and a number of cells types that make 
up the hair follicle [9]. The demonstration of TR expression in hair follicle cells indicates that 
thyroid hormone can affect hair growth directly, rather than through an intermediate 
mechanism such as a general metabolic status [22]. In addition, several thyroid hormone 
responsive genes have been identified in skin.  
When thyroid disease is of autoimmune etiology, additional skin findings may be evident 
which reflect associated autoimmune disease [9]. Patients with autoimmune thyroid disease 
are at increased risk for other autoimmune diseases, both tissue-specific and generalized. In 
autoimmune disease such as Graves' disease and Hashimoto's thyroiditis the skin 
manifestations may be related to either thyroid hormone levels themselves or to associated 
T and/or B cell abnormalities [23]. A list of autoimmune conditions apparent when 
examining the skin includes alopecia areata, vitiligo, chronic urticaria, bullous disorders, 
connective tissue diseases and palmoplantar pustulosis. 
There is convincing evidence of a significant association between thyroid autoimmunity and 
skin disorders. Most commonly reported cutaneous disorder related with thyroid diseases is 
alopecia areata, which have especially autoimmune etiology. 
2. Thyroid autoimmunity in patients with alopecia areata 
2.1. Introduction 
Alopecia areata (AA) is a clinical condition characterized by well circumscribed, round, or oval 
patches of hair loss on the scalp or other parts of the body. Sometimes, alopecia totalis (AT), 
loss of all scalp hair, or alopacia universalis (AU), loss of all body hair, may develop. This 
disorder affects both sexes equally and occurs at all ages, although children and young adults 
are affected most often. The etiopathogenesis of AA is still unclear, but there is evidence that 
autoimmunity and endocrine dysfunction may be involved [24-26]. The autoimmune etiology 
has been proposed on the basis of its association with various autoimmune diseases, the 
presence of autoantibodies and various underlying immune abnormalities in the affected sites 
of these patients [27, 28]. One of the main associations is with thyroid abnormalities. This 
association was further supported by an increased incidence of abnormal thyroid structure, 
function tests and/or presence of thyroid autoantibodies found in many studies [29-32]. 
The aim of this study was to determine the prevalence of thyroid autoimmunity in patients 
with AA. 
2.2. Patients and methods 
The study included 70 patients with AA (40 female and 30 male). A detailed history and 
examination were taken in all study subjects, including patients age, age at onset, duration 
of disease, associated diseases, history of thyroid disorders and the extent and severity of 
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disease. The diagnosis of AA was made on clinical grounds. Skin biopsy was performed in 
selected cases. No patient was diagnosed before this study as having any type of thyroid 
dysfunction. The control group consisted of 70 volunteers (40 female and 30 male) who had 
skin diseases other then AA or autoimmune disorders. Blood samples were taken and a 
physical examination and thyroid sonography was performed. All subjects gave their 
informed consent in accordance with the requirements of the institutional Ethichs 
Committee. Thyroid autoantibodies (thyroglobulin antibody, anti-Tg, and thyroid 
peroxidase antibody, anti-TPO) and thyroid hormones (thyroxine (T4), triiodthyronine (T3) 
and thyroid stimulating hormone (TSH) were measured in all subjects. Total T4 (normal 
range: 70-180 nmol/L) and total T3 (normal range: 1.3-3.3 nmol/L) were measured by use of 
radioimmunoassay (RIA); TSH (normal range: 0.3-4.2 mlU/L) was determined by use of 
immunoradiometric assay (IRMA) (BRAHMS Aktiengesellshaft, Hennigsdorf, Germany). 
Serum levels of anti-Tg (threshold value: 115 IU/mL) and anti-TPO (borderline value: 34 
IU/mL) were measured by use of electrochemiluminiscence immunoassay (ECLIA) 
according to standard protocols (COBAS, Roche Diagnostics GmbH, Mannheim, Germany). 
Baseline clinical characteristics for the two groups were compared with the use of Student’s 
t-test for continuous variables, the chi-square test or Fisher’s exact test (two-sided) for 
categorical variables, as appropriate. Data were considered statistically significant at P <0.05. 
Statistical analyses were performed using MedCale for Windows, version 11.4.1.0 (MedCale 
Software, Mariakerke, Belgium). 
2.3. Results 
We performed a cross-sectional study in 70 consecutive patients with alopecia areata and 70 
age- and sex-matched controls. Demographic data of patients and controls are shown in 
Table 1. The mean (SD) age of the patient and control groups was 40.39 (±14.39) and 40.71 
(±15.30), respectively (P = 0.896). The onset of AA occurred in 14 (20%) of the patients before 
16 years of age, 3 (4.28%) patients had AA more than 10 years. The duration of alopecia 
areata ranged from 1 to 150 months. A family history of the same disease was present in 7 
(10%) patients. According to the clinical type of AA, 13 patients had unilocular lesion, 37 
patients had multilocular lesions, 12 alopecia totalis and 8 alopecia universalis (Table 2).  
Thyroid functional abnormalities were found in 8 (11,43%) patients. In the control group 
only one patient had abnormalities in hormonal status. 
Hypoechogenic thyroid tissue was seen in 7 (10%) patients who all had elevated levels of 
thyroid autoatibodies. The thyroid gland was enlarged in 5 (7.14%) patients. Goitre was 
diagnosed in 4 (5.71%) cases. The ultrasound examination of the thyroid gland in control 
group was interpreted as normal in 64 (91.42%), and 6 (5.45%) volunteers had small simple 
goiter. Thyroid volume did not differ significantly between the study patients and the 
controls (p>0.05). 
In patients with alopecia areata anti-Tg titers were ranging from 11.10 to 915.30 IU/mL and 
anti-TPO antibody titers from 5.10 to 714.40 IU/mL. In control group anti-Tg titers were 
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disease. The diagnosis of AA was made on clinical grounds. Skin biopsy was performed in 
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Software, Mariakerke, Belgium). 
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We performed a cross-sectional study in 70 consecutive patients with alopecia areata and 70 
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Table 1. The mean (SD) age of the patient and control groups was 40.39 (±14.39) and 40.71 
(±15.30), respectively (P = 0.896). The onset of AA occurred in 14 (20%) of the patients before 
16 years of age, 3 (4.28%) patients had AA more than 10 years. The duration of alopecia 
areata ranged from 1 to 150 months. A family history of the same disease was present in 7 
(10%) patients. According to the clinical type of AA, 13 patients had unilocular lesion, 37 
patients had multilocular lesions, 12 alopecia totalis and 8 alopecia universalis (Table 2).  
Thyroid functional abnormalities were found in 8 (11,43%) patients. In the control group 
only one patient had abnormalities in hormonal status. 
Hypoechogenic thyroid tissue was seen in 7 (10%) patients who all had elevated levels of 
thyroid autoatibodies. The thyroid gland was enlarged in 5 (7.14%) patients. Goitre was 
diagnosed in 4 (5.71%) cases. The ultrasound examination of the thyroid gland in control 
group was interpreted as normal in 64 (91.42%), and 6 (5.45%) volunteers had small simple 
goiter. Thyroid volume did not differ significantly between the study patients and the 
controls (p>0.05). 
In patients with alopecia areata anti-Tg titers were ranging from 11.10 to 915.30 IU/mL and 
anti-TPO antibody titers from 5.10 to 714.40 IU/mL. In control group anti-Tg titers were 
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ranging from 10.00 to 153.00 IU/mL, and anti-TPO antibody titers from 4.40 to 129.00 IU/mL. 
Anti-Tg antibody in 16 (23%) patients, anti-TPO antibody in 21 (30%) and both anti-Tg and 
anti-TPO antibodies in 13 (19%) were higher than the normal antibody titres. In the control 
group, one subject (1%) had positive anti-Tg and one volunteer (1%) had positive anti-TPO. 
The frequency of thyroid autoantibodies was significantly higher in alopecia areata patients 
than in control group (Table 3). 
A Chi-square test for independence (with Yates Continuity Correction) indicated significant 
association between higher values of anti-Tg (values more than 115 IU/ml) and alopecia 
areata, χ2 (1, n=140)= 13.123, P=0.0003. 
A Chi-square test for independence (with Yates Continuity Correction) indicated significant 
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Table 1. Demographic data of patients (Alopecia areata group) and volunteers (Control group) 
Mean age of onset (SD) (year) 38.14 (14.61) 
Age of onset range (year) 14-65 
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 anti-Tg 
(threshold value115 IU/ml) Types of alopecia areata (P) 
Type of 
alopecia areata Negative n Positive n Total Multiloculares Totalis Universalis 
Unilocularis 12 1 13 0.662246 0.160248 0.047472* 
Multiloculares  30 7 37 N/A 0.426673 0.085080 
Totalis 8 4 12 N/A N/A 0.647916 
Universalis 4 4 8 N/A N/A N/A 
Total 54 16 70    
Table 4. The frequencies of positive detectable thyroid autoantibody (anti-Tg) and differences between 
types of alopecia areata 
A Fisher’s exact indicated significant association between higher values of anti-Tg (values 
more than 115 IU/ml) and some types of alopecia areata, Universalis vs Unilocularis 
(P=0.047472) (Table 4.) 
 
Scheme 3. Types of alopecia areata and frequencies positive/negative values of anti-Tg (threshold 
value115 IU/ml) 
A Fisher’s exact indicated significant association between higher values of anti-TPO (values 
more than 34 IU/ml) and some types of alopecia areata: Unilocularis vs Totalis (P=0.005217), 
Unilocularis vs Universalis (P=0.000069) and Multiloculares vs Universalis (P=0.000925) 
(Table 5). 
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 anti-TPO 
(threshold value 34 IU/ml) Types of alopecia areata (P) 
Type of 
alopecia areata Negative n Positive n Total Multiloculares Totalis Universalis 
Unilocularis 13 0 13 0.092788 0.005217* 0.000069* 
Multiloculares  29 8 37 N/A 0.075803 0.000925* 
Totalis 6 6 12 N/A N/A 0.157688 
Universalis 1 7 8 N/A N/A N/A 
Total 49 21 70    
Table 5. The frequencies of positive detectable thyroid autoantibody (anti-TPO) and differences 
between types of alopecia areata 
 
Scheme 4. Types of alopecia areata and frequencies positive/negative values of anti-TPO (threshold 
value 34 IU/ml) 
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Alopecia areata is an ancient disease that was known to Egyptians even in the pre-Christian 
time [33]. Despite its long history, our knowledge is actually limited. Today, AA is 
hypothezed to be an autoimmune, organ specific T-cell mediated reaction directed against 
an unknown autoantigen of the hair follicle. T lymphocytes that have been shown to be 
oligoclonal and autoreactive are predominantly present in the peribulbous inflammatory 
infiltrate [34]. Although the skin is the primary location of the clinical phenotype, the 
determination of disease expression involves a complex interplay between different 
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inflammatory cell subsets in the skin, skin draining lymphonodes, and spleen of the affected 
individuals [35]. 
Clinical association with AA has known for many years. AA frequently occurs in association 
with other autoimmune disorders such as vitiligo, lupus erythematosus, pernicious anemia 
and others [34, 36-38]. Among endocrine disorders, thyroid diseases are the commonest that 
has been described as associated with AA, but the issued values were different. In the 
greatest study reported till now, Muller and Winkelmann have found the evidences of 
different types of thyroid disease in 8% of 736 patients in compare to less than 2% of the 
control population in North America [39]. Broniarczyk-Dyla et al. observed abnormalities of 
thyroid structure and function in even 78% of AA patients [40]. Conversely, Puavilai et al. 
estimated that the prevalence of thyroid disease is relatively low (7.2%) and was not 
statistically different from the control group [41]. 
In accordance to previous studies, current study reported a high frequency of thyroid 
diseases in AA patients. We detected elevated anti-Tg in 16 (23%) and elevated anti-TPO in 
21 (30%) of patients with AA. Compared with the control group, the frequency of the both 
anti-Tg and anti-TPO antibodies was significantly higher in those with AA. Statistically 
significant difference was also found in values of anti-Tg and anti-TPO between patients 
with different clinical type of the disease. The highest anti-Tg concentrations were observed 
in patients with alopecia universalis. Patients with thyroid diseases were on an average 
older and reported longer duration, but the results were not statistically significant. These 
results are consistent with a clinical study performed by Seyrafi et al. [32]. They analyzed 
serum TgAb level in 123 Iranian patients with AA and found it to be elevated in 29.3% of 
study patients. Grandolfo et al. observed the presence of thyroid autoantibodies in even 44% 
of AA patients [42]. Goh et al. also confirmed the frequent coexistence of AA and thyroid 
abnormalities [43]. They found 19% of probands with thyroid disease including simple 
goitre, Grave´s disease and Hashomoto´s thyroiditis. Our findings showed that the 
frequency of anti-TPO was more significant than anti-Tg. This antibody, historically referred 
to as the antimicrosomal antibody, is established as a sensitive tool for the detection of early 
subclinical autoimmune thyroid diseases and identification of at-risk cases for autoimmune 
thyroid diseases [44]. Nordyke et al. reported that anti-TPO antibody tends to have more 
correlation than does the anti-Tg antibody [45]. 
Alopecia areata offers many benefits as a model for the study of autoimmunity, in that it can 
be used to identify the contributing roles of immunogenetics and neuroendocrine factors in 
the initiation and propagation of autoimmune disease [24]. 
The study revealed a significant association between AA and thyroid disease and showed 
the tests used to detected thyroid autoantibodies to be relevant in patients with AA. Further 
exploration of this relationship in clinical setting and at a molecular level may help in the 
understanding of the pathogenesis of both diseases. 
3. Conclusions 
Thyroid autoimmunity is the most prevalent autoimmune condition in the general 
population, and is also associated with various skin diseases. The evidence is strong for the 
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association with alopecia areata. Although their etiology is still unclear, the autoimmune 
hypothesis is most commonly accepted. 
The nature of the relationship between anti-thyroid autoimmunity and the pathogenesis of 
autoimmune diseases is presently unknown. Some authors have shown that anti-Tg 
antibodies can form immune complexes [46], and anti-microsomal antibodies not only bind 
to thyroid peroxidase but also modulate natural killer cell activity in autoimmune 
thyroiditis [47]. Possible explanations for the relationship of these autoimmune diseases 
include: (1) immunomodulatory effects of antithyroid antibodies, (2) molecular mimicry 
between thyroid and disease-specific epitopes, and (3) genetic link between anti-thyroid 
autoimmunity and the susceptibility to autoimmune disease [48]. It is a multidisciplinary 
problem requiring cooperation of specialists in different fields of medicine. Both 
dermatologists and endocrinologists have to inquire their patients about the family history 
of autoimmune diseases and to look for associated autoimmune disorders. 
This chapter is an attempt to update the current knowledge about the relationship between 
the thyroid and the skin diseases. Although cutaneous manifestations of autoimmune 
thyroid diseases are well described and thyroid hormone is known to regulate the 
development and function of skin, a better understanding of these processes is needed. 
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1. Introduction 
Advances in systemic chemotherapy and radiotherapy have had a profound effect on the 
prognosis of patients affected by many cancer histotypes. Nonetheless, one of the main 
challenges for modern oncology is in improving the tolerability of these treatments. The 
frequency and pathophysiology of the most common side effects induced by cytotoxic 
agents are well known. They may be immediate or delayed in onset and prevalently involve 
bone marrow, gastrointestinal system, liver, and cutaneous annexes. 
Abnormalities in thyroid function and thyroid disease are variably associated with cancer or 
cancer therapy [1]. These disorders encompass a broad variety of pathophysiological 
mechanisms, may be subtle in presentation, sometimes difficult to be identified, and even 
more difficult to relate to a particular chemotherapeutic regimen due to the lack of specific 
wide clinical trials [2]. The alteration of thyroid hormone metabolism, more commonly 
known as “euthyroid sick syndrome”, may occur in patients with advanced cancers. 
Thyroid dysfunction, such as the altered synthesis or clearance of thyroid hormone-binding 
proteins are observed in certain malignancies, or may be caused by treatments that modify 
total but not free concentration of thyroid hormones. However, the clinical influence of this 
abnormalities is marginal, if any. 
Endocrine disorders are among the most commonly reported long-term complications of 
cancer treatment by adult survivors of childhood cancers [3]. In adults, cytotoxic drugs are 
infrequently associated to overt endocrine toxicity. However, excluding gonadotoxic 
consequence [4], only few studies thoroughly evaluated the endocrine dysfunction induced 
by cytotoxic anticancer therapy in this population [2]. Similarly, hormonal therapies, widely 
used as effective treatment of patients affected by endocrine responsive breast cancer and 
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prostate cancer, have shown only marginally influence on thyroid function and thyroid 
toxicities attributed to these drugs are anecdotic. 
In contrast to cytotoxics and hormonal therapies, several novel antineoplastic agents, 
including targeted therapies and immunotherapies, are unexpectedly associated with 
thyroid dysfunction and thyroid disease, despite their high selectivity of action [5]. 
Even diagnostic procedures using iodinated contrast agents can be associated with acute 
effects on the thyroid, including hyperthyroidism (i.e. in patients with thyroid autonomous 
nodules or mild Graves disease), or transient hypothyroidism (i.e. in patients with 
Hashimoto thyroiditis) [6,7]. Radiation therapy can be responsible for hypothyroidism from 
direct damage on the thyroid or secondary to hypopituitarism from brain irradiation. 
Irradiation received during childhood has been associated with thyroid nodules and thyroid 
cancer [8]. 
In this chapter, available data on thyroid abnormalities induced by anticancer drugs only 
are discussed. 
2. Cytotoxic agents 
Cytotoxic chemotherapy seems to alter endocrine functions in a relatively small proportion 
of patients and is infrequently associated with thyroid abnormalities in the absence of 
irradiation. Cytotoxics may sensitize the thyroid gland to the effects of concomitant 
radiation therapy, increasing the risk of radiation-induced primary hypothyroidism [9]. 
In a small published series, some agents such as 5-fluorouracil, glucocorticoids, estrogens, 
tamoxifen, podophyllin and L-asparaginase alter levels of thyroid hormone–binding 
proteins without any clinical consequence [10-15]. L-asparaginase can also be responsible for 
transient hypothalamic or pituitary hypothyroidism [16]. Other agents such as lomustine, 
vincristine, and cisplatin have in vitro effects on thyroid cells, but clinically relevant 
consequences have not been reported [17]. Mitotane is the only active agent against 
advanced adrenocortical cancer (ACC) and is under evaluation in patients who underwent 
radical resection of this rare disease. Mitotane showed a complex interference on the 
endocrine system that may require multiple hormone replacement therapy. In a prospective 
trial [18] on 17 patients who underwent radical resection for ACC, a marked reduction in 
free-T4 (FT4) levels was found, without any significant changes in serum thyroid 
stimulating hormone (TSH) and free-T3 (FT3) concentration. FT4 reduction was inversely 
correlated with mitotane concentrations and dropped in the hypothyroid range in most 
evaluable patients. These findings mimic central hypothyroidism and are consistent with 
data from clinical experiments which showed that mitotane directly reduces both secretory 
activity and cell viability on pituitary TSH-secreting mouse cells [19]. Alternatively, it has 
been suggested that mitotane may affect deiodase activity, thus changing the FT4 to FT3 
ratio. However, despite limited information on free thyroid hormone concentrations during 
mitotane treatment has been reported, for some patients thyroxine replacement may be 
necessary [20]. 
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An increased incidence of primary hypothyroidism has been documented in patients treated 
with multiple drug regimens, with or without radiotherapy [2]. In patients with testicular 
cancer who received combinations of cisplatin, bleomycin, vinblastine, etoposide, and 
dactinomycin, 4 out of 27 individuals (15%) developed primary hypothyroidism. In 
particular, the cumulative doses of cisplatin and vincristine seem to exacerbate these 
symptoms [21]. In another trial evaluating the combination of mechlorethamine, vinblastine, 
procarbazine and prednisolone (MOPP regimen) as treatment of Hodgkin’s disease, 44% of 
patients developed elevated serum TSH concentrations, even though a causative role of 
iodine load during lymphangiograpy cannot be excluded [22]. Children with brain tumors 
(not involving the hypothalamic-pituitary axis) who receive vincristine, carmustine or 
lomustine, and procarbazine in combination and brain irradiation have a 35% incidence of 
hypothyroidism, compared with a 10% incidence in the group with brain irradiation alone 
[23]. Young age and use of chemotherapy have been associated with a higher incidence of 
hypothyroidism in patients receiving radiotherapy for medulloblastoma [24]. Again, the 
highest incidence occurred when the thyroid gland was included in the radiation field. 
Finally, there is no evidence that cytotoxic agents by itself may represent a risk factor for 
developing thyroid tumors, compared to radiotherapy [2]. 
3. Immunoregulatory agents 
3.1. Cytokines 
3.1.1. Interferon- 
Interferon- is a human recombinant cytokine that increases the expression of major 
histocompatibility complex (MHC) class I and tumor-specific antigens on the tumor cell 
surface, stimulating immune-mediated destruction of these cells, as well as possibly exerting 
direct antitumor effects [25]. Interferon- demonstrated variable efficacy in patients affected 
by melanoma, renal cell carcinoma (RCC), AIDS-related Kaposi's sarcoma, follicular 
lymphoma, hairy cell leukemia, and chronic myelogenous leukemia [25]. Reduction in viral 
load is another relevant activity of interferons. In combination with ribavidin, interferon- 
prolongs survival in patients with hepatitis C [26,27]. Flu-like syndrome, malaise, 
neuropsychiatric disorders, hematologic and liver toxicity are the most common dose-
limiting side-effects. 
Thyroid diseases secondary to treatment with Interferon- are common and may become 
clinically evident as destructive thyroiditis, autoimmune hypothyroidism or Graves-like 
hyperthyroidism. Patients receiving the drug for hepatitis appear more prone to present 
thyroid dysfunction than patients with malignant disease [28]. However, the infection from 
the hepatitis C virus itself has been demonstrated to increase the risk of thyroid damage 
[28]. The pegylated form of interferon- is more effective than interferon- in triggering 
antiviral response, but showed a similar rate of thyroid dysfunction [29]. 
Destructive or autoimmune thyroiditis is the most common thyroid abnormality following 
treatment with interferon-. This condition may lead to hypothyroidism after a brief 
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thyrotoxic phase and usually occurs in the first few weeks of interferon treatment and is in 
close temporal relationship with the appearance of thyroid autoantibodies, especially anti-
thyroglobulin (anti-TG) antibodies. Another form of autoimmune thyroid toxicity associated 
to interferon- is characterized by the development of thyroid antibodies without 
hypothyroidism. In the setting of interferon therapy, the risk of hypothyroidism is 2.4%–
10% [30-35], with a risk of thyroid autoimmunity onset (including development of thyroid 
autoantibodies) approaching 20% [36,37]. Hypothyroidism is persistent in the majority of 
patients [33,38], even though although transient hypothyroidism has also been described 
[39]. The presence of anti-thyroperoxidase (anti-TPO) antibodies before treatment 
considerably increases the risk of hypothyroidism [40-42]. Thyroid abnormalities can occur 
as early as 4 weeks and as late as 23 months after initiating treatment, with a median of 4 
months [30,34].  
Interferon- has also been associated with classical Graves disease and sometimes Graves’ 
ophthalmopathy also develops, however the latter is less common [30]. This condition does 
not generally remit on withdrawal of the drug [35]. 
Several evidence supports the hypothesis that thyroid toxicity may likely be related to an 
autoimmune response to interferon-. Overexpression of MHC class I antigens are 
associated with activation of cytotoxic T-cells resulting in cellular destruction [43]. It has 
been reported that interferon- increases MHC class I expression on thyroid tissue from 
Graves patients, provided that lymphocytes are present in the thyroid tissue [44]. Hence, 
interferon- might worsen local immune response in subjects who have preexisting 
subclinical thyroiditis with intrathyroidal lymphocytes [44]. In addition, interferon- can 
shift the immune response to a Th1-mediated immune response, with increased 
production of the proinflammatory cytokines interferon-γ and interleukin-2, which may 
in turn amplify an autoimmune response. Interferon- has been demonstrated to elicit a 
direct damage on thyroid cells, which may be responsible for the onset of destructive 
thyroiditis [28,35,42,45]. However, despite accumulating evidence, the precise 
mechanisms underlying thyroid toxicity associated to interferon, especially in cancer 
patients, remain to be elucidated. 
Levothyroxine (LT4) therapy is indicated as treatment of interferon-induced 
hypothyroidism and withdrawal of interferon is not generally needed. When destructive 
thyroiditis is present, treatment with corticosteroids is needed and β-blockers are often 
useful to control the signs and symptoms of thyrotoxicosis. When interferon causes 
hyperthyroidism, antithyroid agents such as methimazole or propylthiouracil may be 
administered, if clinically indicated. In patients with relapsing flares of thyroiditis during 
prolonged courses of interferon-, ablation with 131I during remission may be offered to 
prevent further episodes of the condition [46]. 
Despite specific recommendations for patients treated with interferon- for oncological 
diseases are lacking, it appears rational to apply the recommendations available for patients 
with hepatitis C [47]. In particular, the same serological screening is suggested, including 
pretreatment TSH and anti-TPO antibodies evaluation, followed by TSH serum 
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measurement every 2 months and then every six months in the case of negative anti-thyroid 
peroxidase (anti-TPO) antibodies [1]. 
3.1.2. Interleukin-2 
Interleukin-2 is a cytokine involved in several mechanisms of immune response, including 
activation of natural killer cells and antigen-specific T-cells. These properties are used to 
stimulate tumor cell killing, also in combination with interferon or lymphokine-activated 
killer cells. Interleukin-2 is approved for the treatment of metastatic melanoma and RCC, 
although its use has been recently reduced in concomitance with the availability of more 
effective and better tolerated agents. 
Several autoimmune side-effects have been associated to interleukin-2 therapy, including 
thyroid disease with an incidence of 10%–50% [48-54]. Hypothyroidism usually occurs 4–17 
weeks after initiation of treatment [48,49]. It may be reversible following discontinuation of 
the drug [49,55]. Most patients who developed hypothyroidism showed positive anti-TG or 
anti-TPO antibodies. In addition to hypothyroidism, thyroiditis and thyrotoxicosis have also 
been reported at a lesser frequency [55,56]. An early phase of presumably destructive 
thyrotoxicosis is common, with variable degrees of hyperthyroidism [57]. 
Evidence suggests that thyroid disease associated to interleukin-2 may be induced by 
stimulating autoreactive lymphocytes, leading to autoimmune thyroiditis. Patients under 
treatment with interleukin-2 showed high levels of interferon-γ and tumor necrosis 
factor-, which may trigger autoimmunity by enhancing the presentation of human 
leukocyte antigen class II and associated autoantigens by thyrocytes. Also, interleukin-2 
may have direct effects on thyrocyte functioning [58,59]. Increase in serum thyroid 
autoantibodies levels [48,53] and lymphocyte infiltration of the thyroid gland [57] were 
found in patients treated with interleukin-2, suggesting a cell-mediated autoimmune 
mechanism. Similarly to interferon, preexisting positivity of thyroid autoantibodies 
seems to predict an increased risk of developing hypothyroidism during interleukin-2 
treatment [49]. 
Occurrence of hypothyroidism was associated with a favorable response to treatment 
[48,60], but other studies did not confirm these results [61]. It has been suggested that 
thyroid dysfunction may develop more often in the responders because they receive longer 
courses of the treatment [46,62]. Patients with interleukin-2-induced hypothyroidism may be 
treated with LT4, while thyrotoxicosis only requires symptom control with β-blockers and 
corticosteroids. Measuring TSH before treatment and then every 2–3 months during 
treatment with interleukin-2 is advisable [1]. 
3.2. Thalidomide and lenalidomide 
Thalidomide and lenalidomide are immunomodulatory drugs with antineoplastic activity 
[63,64]. These agents enhance T-cell stimulation and proliferation, induce endogenous 
cytokine release, and increase number and function of natural killer cells, thus enhancing 
 
Thyroid Hormone 314 
thyrotoxic phase and usually occurs in the first few weeks of interferon treatment and is in 
close temporal relationship with the appearance of thyroid autoantibodies, especially anti-
thyroglobulin (anti-TG) antibodies. Another form of autoimmune thyroid toxicity associated 
to interferon- is characterized by the development of thyroid antibodies without 
hypothyroidism. In the setting of interferon therapy, the risk of hypothyroidism is 2.4%–
10% [30-35], with a risk of thyroid autoimmunity onset (including development of thyroid 
autoantibodies) approaching 20% [36,37]. Hypothyroidism is persistent in the majority of 
patients [33,38], even though although transient hypothyroidism has also been described 
[39]. The presence of anti-thyroperoxidase (anti-TPO) antibodies before treatment 
considerably increases the risk of hypothyroidism [40-42]. Thyroid abnormalities can occur 
as early as 4 weeks and as late as 23 months after initiating treatment, with a median of 4 
months [30,34].  
Interferon- has also been associated with classical Graves disease and sometimes Graves’ 
ophthalmopathy also develops, however the latter is less common [30]. This condition does 
not generally remit on withdrawal of the drug [35]. 
Several evidence supports the hypothesis that thyroid toxicity may likely be related to an 
autoimmune response to interferon-. Overexpression of MHC class I antigens are 
associated with activation of cytotoxic T-cells resulting in cellular destruction [43]. It has 
been reported that interferon- increases MHC class I expression on thyroid tissue from 
Graves patients, provided that lymphocytes are present in the thyroid tissue [44]. Hence, 
interferon- might worsen local immune response in subjects who have preexisting 
subclinical thyroiditis with intrathyroidal lymphocytes [44]. In addition, interferon- can 
shift the immune response to a Th1-mediated immune response, with increased 
production of the proinflammatory cytokines interferon-γ and interleukin-2, which may 
in turn amplify an autoimmune response. Interferon- has been demonstrated to elicit a 
direct damage on thyroid cells, which may be responsible for the onset of destructive 
thyroiditis [28,35,42,45]. However, despite accumulating evidence, the precise 
mechanisms underlying thyroid toxicity associated to interferon, especially in cancer 
patients, remain to be elucidated. 
Levothyroxine (LT4) therapy is indicated as treatment of interferon-induced 
hypothyroidism and withdrawal of interferon is not generally needed. When destructive 
thyroiditis is present, treatment with corticosteroids is needed and β-blockers are often 
useful to control the signs and symptoms of thyrotoxicosis. When interferon causes 
hyperthyroidism, antithyroid agents such as methimazole or propylthiouracil may be 
administered, if clinically indicated. In patients with relapsing flares of thyroiditis during 
prolonged courses of interferon-, ablation with 131I during remission may be offered to 
prevent further episodes of the condition [46]. 
Despite specific recommendations for patients treated with interferon- for oncological 
diseases are lacking, it appears rational to apply the recommendations available for patients 
with hepatitis C [47]. In particular, the same serological screening is suggested, including 
pretreatment TSH and anti-TPO antibodies evaluation, followed by TSH serum 
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measurement every 2 months and then every six months in the case of negative anti-thyroid 
peroxidase (anti-TPO) antibodies [1]. 
3.1.2. Interleukin-2 
Interleukin-2 is a cytokine involved in several mechanisms of immune response, including 
activation of natural killer cells and antigen-specific T-cells. These properties are used to 
stimulate tumor cell killing, also in combination with interferon or lymphokine-activated 
killer cells. Interleukin-2 is approved for the treatment of metastatic melanoma and RCC, 
although its use has been recently reduced in concomitance with the availability of more 
effective and better tolerated agents. 
Several autoimmune side-effects have been associated to interleukin-2 therapy, including 
thyroid disease with an incidence of 10%–50% [48-54]. Hypothyroidism usually occurs 4–17 
weeks after initiation of treatment [48,49]. It may be reversible following discontinuation of 
the drug [49,55]. Most patients who developed hypothyroidism showed positive anti-TG or 
anti-TPO antibodies. In addition to hypothyroidism, thyroiditis and thyrotoxicosis have also 
been reported at a lesser frequency [55,56]. An early phase of presumably destructive 
thyrotoxicosis is common, with variable degrees of hyperthyroidism [57]. 
Evidence suggests that thyroid disease associated to interleukin-2 may be induced by 
stimulating autoreactive lymphocytes, leading to autoimmune thyroiditis. Patients under 
treatment with interleukin-2 showed high levels of interferon-γ and tumor necrosis 
factor-, which may trigger autoimmunity by enhancing the presentation of human 
leukocyte antigen class II and associated autoantigens by thyrocytes. Also, interleukin-2 
may have direct effects on thyrocyte functioning [58,59]. Increase in serum thyroid 
autoantibodies levels [48,53] and lymphocyte infiltration of the thyroid gland [57] were 
found in patients treated with interleukin-2, suggesting a cell-mediated autoimmune 
mechanism. Similarly to interferon, preexisting positivity of thyroid autoantibodies 
seems to predict an increased risk of developing hypothyroidism during interleukin-2 
treatment [49]. 
Occurrence of hypothyroidism was associated with a favorable response to treatment 
[48,60], but other studies did not confirm these results [61]. It has been suggested that 
thyroid dysfunction may develop more often in the responders because they receive longer 
courses of the treatment [46,62]. Patients with interleukin-2-induced hypothyroidism may be 
treated with LT4, while thyrotoxicosis only requires symptom control with β-blockers and 
corticosteroids. Measuring TSH before treatment and then every 2–3 months during 
treatment with interleukin-2 is advisable [1]. 
3.2. Thalidomide and lenalidomide 
Thalidomide and lenalidomide are immunomodulatory drugs with antineoplastic activity 
[63,64]. These agents enhance T-cell stimulation and proliferation, induce endogenous 
cytokine release, and increase number and function of natural killer cells, thus enhancing 
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immune-mediated destruction of tumor cells. They also inhibit proliferation and induce 
apoptosis of tumor cells and exert antiangiogenic activity [63,64].  
Thalidomide and lenalidomide are approved for the treatment of multiple myeloma. 
Lenalidomide has also been approved for 5q myelodysplastic syndrome. Both agents are 
under evaluation for the treatment of several solid tumors, including thyroid cancer [65-67] 
and for a range of autoimmune diseases [68]. 
Hypothyroidism has been associated to treatment with these drugs with varying grades and 
frequency [68-71]. In a recent study on patients affected by multiple myeloma and treated 
with thalidomide [69], subclinical hypothyroidism was reported in 20% of participants, and 
7% showed overt hypothyroidism, mostly occurring 1–6 months after initiating treatment 
[69]. 
Lenalidomide is more potent and showed a more favorable toxicity profile compared to 
thalidomide [72,73]. Hypothyroidism due to lenalidomide has been reported in 5%–10% of 
patients [74,75]. Thyroid abnormalities were found in 10 out of 170 patients who received 
lenalidomide for various hematological cancers. After a median of 5 months of therapy the 
patients reported both hypothyroidism and thyrotoxicosis. However, many of them had 
been exposed to prior radiation or thalidomide [76]. 
Many mechanisms have been suggested for the hypothyroidism induced by these drugs 
[69], including inhibition of thyroid hormone secretion [77] or a reduction of iodine uptake 
into follicular cells [78]. Most probably, since thalidomide and lenalidomide exert an 
antiangiogenic activity, compromise the blood flow to the thyroid may explain thyroid 
toxicity [69]. In some patients, TSH suppression has been documented before the 
development of hypothyroidism, suggesting ischemic thyroiditis [69]. Alternatively, a 
thyrotoxicosis triggered by an immune-mediated destructive thyroiditis may be 
hypothesized. This condition may be induced by deregulation of cytokine levels or through 
direct effects on T-lymphocytes [69]. A direct toxic effect on thyroid cells is also possible, but 
this has not been evaluated. TSH measurement before treatment and then every 2–3 months 
during treatment is recommended [1,79]. 
3.3. Anti-CTLA4 monoclonal antibodies 
Ipilimumab and tremelimumab are monoclonal antibodies directed against cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) (anti–CTLA-4 mAbs), a receptor expressed on T-
cells that exerts a suppressive effect on the immune response after T-cell/antigen-presenting 
cell interaction [80]. Blocking the receptor, an increased T-cell activation and antitumor 
effects are obtained. Ipilimumab is approved for the treatment of unresectable or metastatic 
melanoma. 
These agents have been associated with several immune-related adverse events (IRAEs), 
most frequently enterocolitis, hepatitis, cutaneous reactions [81-83]. The spectrum of 
autoimmune endocrine adverse events experienced by patients treated with anti–CTLA-4 
mAbs includes hypopituitarism, primary thyroid disease, and sporadically primary adrenal 
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insufficiency [84]. The prevalence of autoimmune hypophysitis varies among different 
studies (0%–17%) [85], being 3-5% in larger studies. Similarly to classical autoimmune 
hypophysitis, secondary hypothyroidism has been reported in patients who develop 
hypophysitis induced by anti-CTLA-4 monoclonal antibodies. 
Direct damage to the thyroid induced by these agents presents two clinical common forms: 
hyperthyroidism in Graves’ disease and thyroid destruction with hypothyroidism in 
Hashimoto’s thyroiditis. Since these conditions are classically included in autoimmune thyroid 
diseases phenotype and previous studies suggested that CTLA-4 is a candidate gene conferring 
susceptibility to thyroid autoimmunity [86], an autoimmune pathogenesis has also been 
suggested for thyropathies induced by anti-CTLA4-mAbs (anti-CTLA4-IT). The incidence of 
these conditions varies from 0 to 4% among the different trials. In two studies [87,88], 
tremelimumab (15 mg/Kg body weight) was associated with thyreopathy (hyper-
/hypothyroidism, autoimmune-thyroiditis, or Graves’ disease) in 4% of cases. In studies on 
ipilimumab, the reported incidence of anti-CTLA4-IT was apparently lower, namely 0-2%, 
being mild hypothyroidism the most frequent thyroid side-effect. Recently, Hodi et al. in a large 
phase III trial, reported for the first time an improvement in overall survival obtained by 
ipilimumab in pretreated patients affected by metastatic melanoma [89]. The treatment was 
associated with thyroid disorders or abnormal thyroid function tests in approximately 2% of 
patients. In a randomized phase II study on a cohort of 115 patients affected by metastatic 
melanoma, evaluating the potential protective effect of budesonide on IRAEs induced by 
ipilimumab, hypothyroidism was diagnosed in 5.3% of patients who received ipilimumab with 
placebo (3 out of 57 patients; with severe hypothyroidism in one of them, 1.8%), compared with 
no cases in the group of patients treated with budesonide as well. These data suggest a potential 
protective effect of budesonide in terms of reduced incidence of ipilimimab-related thyroiditis, 
but this hypothesis needs to be confirmed in specifically designed clinical trials [90]. 
In a phase I study [91] evaluating the combination of ipilimumab (10 mg/Kg every 3 weeks 
for 4 cycles, than every 3 months) with bevacizumab (7.5 mg/kg - Cohort 1; 15 mg/kg - 
cohort 2 every 3 weeks) in a group of 21 patients affected by unresectable stage III or stage 
IV melanoma, thyroiditis was diagnosed in 4 (19%) patients. No cases of endocrine-IRAEs 
were reported in a trial on 36 patients who received both ipilimumab (0.1-3 mg/kg; 24 
patients received the higher dose) and interleukin-2 (720,000 IU/kg every 8 hours) which is 
not infrequently associated with autoimmune thyroiditis [92].  
The onset of anti-CTLA4-IT appears rather earlier than other IRAEs, occurring after 2-4 
infusions. In most cases the anti-CTLA4-ITs have a subclinical course or may be transient. 
Alternatively, this condition may be characterized either by hypothyroidism with increased 
serum TSH concentrations, normal free-T4, and presence of anti-TPO antibodies, less 
frequently anti-TG antibodies or evolve in permanent hypothyroidism, requiring thyroid 
hormone supplementation [93]. 
Sporadic cases of Graves’ ophthalmopathy associated with ipilimumab therapy in euthyroid 
patients have been reported [82,94]. In these cases the effective treatment was to administer 
a high dose of glucocorticoids in the acute phase, rapidly tapered down and continue with 
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immune-mediated destruction of tumor cells. They also inhibit proliferation and induce 
apoptosis of tumor cells and exert antiangiogenic activity [63,64].  
Thalidomide and lenalidomide are approved for the treatment of multiple myeloma. 
Lenalidomide has also been approved for 5q myelodysplastic syndrome. Both agents are 
under evaluation for the treatment of several solid tumors, including thyroid cancer [65-67] 
and for a range of autoimmune diseases [68]. 
Hypothyroidism has been associated to treatment with these drugs with varying grades and 
frequency [68-71]. In a recent study on patients affected by multiple myeloma and treated 
with thalidomide [69], subclinical hypothyroidism was reported in 20% of participants, and 
7% showed overt hypothyroidism, mostly occurring 1–6 months after initiating treatment 
[69]. 
Lenalidomide is more potent and showed a more favorable toxicity profile compared to 
thalidomide [72,73]. Hypothyroidism due to lenalidomide has been reported in 5%–10% of 
patients [74,75]. Thyroid abnormalities were found in 10 out of 170 patients who received 
lenalidomide for various hematological cancers. After a median of 5 months of therapy the 
patients reported both hypothyroidism and thyrotoxicosis. However, many of them had 
been exposed to prior radiation or thalidomide [76]. 
Many mechanisms have been suggested for the hypothyroidism induced by these drugs 
[69], including inhibition of thyroid hormone secretion [77] or a reduction of iodine uptake 
into follicular cells [78]. Most probably, since thalidomide and lenalidomide exert an 
antiangiogenic activity, compromise the blood flow to the thyroid may explain thyroid 
toxicity [69]. In some patients, TSH suppression has been documented before the 
development of hypothyroidism, suggesting ischemic thyroiditis [69]. Alternatively, a 
thyrotoxicosis triggered by an immune-mediated destructive thyroiditis may be 
hypothesized. This condition may be induced by deregulation of cytokine levels or through 
direct effects on T-lymphocytes [69]. A direct toxic effect on thyroid cells is also possible, but 
this has not been evaluated. TSH measurement before treatment and then every 2–3 months 
during treatment is recommended [1,79]. 
3.3. Anti-CTLA4 monoclonal antibodies 
Ipilimumab and tremelimumab are monoclonal antibodies directed against cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) (anti–CTLA-4 mAbs), a receptor expressed on T-
cells that exerts a suppressive effect on the immune response after T-cell/antigen-presenting 
cell interaction [80]. Blocking the receptor, an increased T-cell activation and antitumor 
effects are obtained. Ipilimumab is approved for the treatment of unresectable or metastatic 
melanoma. 
These agents have been associated with several immune-related adverse events (IRAEs), 
most frequently enterocolitis, hepatitis, cutaneous reactions [81-83]. The spectrum of 
autoimmune endocrine adverse events experienced by patients treated with anti–CTLA-4 
mAbs includes hypopituitarism, primary thyroid disease, and sporadically primary adrenal 
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insufficiency [84]. The prevalence of autoimmune hypophysitis varies among different 
studies (0%–17%) [85], being 3-5% in larger studies. Similarly to classical autoimmune 
hypophysitis, secondary hypothyroidism has been reported in patients who develop 
hypophysitis induced by anti-CTLA-4 monoclonal antibodies. 
Direct damage to the thyroid induced by these agents presents two clinical common forms: 
hyperthyroidism in Graves’ disease and thyroid destruction with hypothyroidism in 
Hashimoto’s thyroiditis. Since these conditions are classically included in autoimmune thyroid 
diseases phenotype and previous studies suggested that CTLA-4 is a candidate gene conferring 
susceptibility to thyroid autoimmunity [86], an autoimmune pathogenesis has also been 
suggested for thyropathies induced by anti-CTLA4-mAbs (anti-CTLA4-IT). The incidence of 
these conditions varies from 0 to 4% among the different trials. In two studies [87,88], 
tremelimumab (15 mg/Kg body weight) was associated with thyreopathy (hyper-
/hypothyroidism, autoimmune-thyroiditis, or Graves’ disease) in 4% of cases. In studies on 
ipilimumab, the reported incidence of anti-CTLA4-IT was apparently lower, namely 0-2%, 
being mild hypothyroidism the most frequent thyroid side-effect. Recently, Hodi et al. in a large 
phase III trial, reported for the first time an improvement in overall survival obtained by 
ipilimumab in pretreated patients affected by metastatic melanoma [89]. The treatment was 
associated with thyroid disorders or abnormal thyroid function tests in approximately 2% of 
patients. In a randomized phase II study on a cohort of 115 patients affected by metastatic 
melanoma, evaluating the potential protective effect of budesonide on IRAEs induced by 
ipilimumab, hypothyroidism was diagnosed in 5.3% of patients who received ipilimumab with 
placebo (3 out of 57 patients; with severe hypothyroidism in one of them, 1.8%), compared with 
no cases in the group of patients treated with budesonide as well. These data suggest a potential 
protective effect of budesonide in terms of reduced incidence of ipilimimab-related thyroiditis, 
but this hypothesis needs to be confirmed in specifically designed clinical trials [90]. 
In a phase I study [91] evaluating the combination of ipilimumab (10 mg/Kg every 3 weeks 
for 4 cycles, than every 3 months) with bevacizumab (7.5 mg/kg - Cohort 1; 15 mg/kg - 
cohort 2 every 3 weeks) in a group of 21 patients affected by unresectable stage III or stage 
IV melanoma, thyroiditis was diagnosed in 4 (19%) patients. No cases of endocrine-IRAEs 
were reported in a trial on 36 patients who received both ipilimumab (0.1-3 mg/kg; 24 
patients received the higher dose) and interleukin-2 (720,000 IU/kg every 8 hours) which is 
not infrequently associated with autoimmune thyroiditis [92].  
The onset of anti-CTLA4-IT appears rather earlier than other IRAEs, occurring after 2-4 
infusions. In most cases the anti-CTLA4-ITs have a subclinical course or may be transient. 
Alternatively, this condition may be characterized either by hypothyroidism with increased 
serum TSH concentrations, normal free-T4, and presence of anti-TPO antibodies, less 
frequently anti-TG antibodies or evolve in permanent hypothyroidism, requiring thyroid 
hormone supplementation [93]. 
Sporadic cases of Graves’ ophthalmopathy associated with ipilimumab therapy in euthyroid 
patients have been reported [82,94]. In these cases the effective treatment was to administer 
a high dose of glucocorticoids in the acute phase, rapidly tapered down and continue with 
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hydrocortisone, if required. None of the patients affected by anti-CTLA4-IT showed 
concomitant hypophysitis or other IRAEs. 
Patients who need to receive anti–CTLA-4 mAbs should be carefully informed on the 
importance of observing and early reporting signs or symptoms potentially related to 
IRAEs, and that these symptoms may occur weeks to months after starting treatment. In 
these patients, TSH, free-T4, serum electrolytes, serum glucose, and blood cell counts should 
be assessed before initiating treatment and before each cycle. 
3.4. Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors (TKIs) have emerged as a new class of molecular targeted anti-
cancer agents with proven efficacy in several types of carcinoma and in some hematologic 
cancers. At the moment, about 150 kinase-targeted drugs are in clinical development and 
many more are in various stages of preclinical development [95]. 
The registered kinase inhibitors are small molecules, that, with sporadic exceptions, exert 
their pharmacological action at the ATP-site of a wide variety of tyrosine kinases critical for 
tumor cell survival and proliferation and angiogenesis. TKIs compete with ATP for binding 
to the catalytic domain that act by preventing ATP binding to these targets with different 
selectivity, potency and pharmacokinetic properties. However, despite their inherent 
selectivity, the available TKIs showed a variable grade of affinity for the different tyrosine 
kinases, but none specific for a single kinase. In addition, interference is frequently extended 
to off-target intracellular processes of normal cells. As a direct consequence, TKIs may cause 
a number of infrequent or even new toxicities. TKI-induced endocrine side effects mainly 
include thyroid dysfunction and disease, but also may be responsible for gonadal and 
adrenal dyfunction, bone and glucose altered metabolism, impairment in linear growth and 
fetal development [96]. 
Two types of thyroid dysfunctions have been observed with TKIs [97]. The first is 
worsening of hypothyroidism in patients under satisfactory treatment with thyroid 
hormone replacement. This effect was initially noted in patients under treatment with 
imatinib, but also other TKIs were found responsible for increase in LT4 supplementation in 
hypothyroid patients [98-102]. The second type of thyroid disturbance is primary 
hypothyroidism in patients with previously normal thyroid function. Almost all TKIs are 
responsible, at a variable extent, of primary hypothyroidism, with the exception of gefitinb 
and erlotinib. 
The mechanisms of TKI-induced thyroid dysfunction are unclear. An increase in the 
requirement of replacement therapy with LT4 during certain TKIs has been suggested to be 
dependent on possible interference of the drug at nondeiodination clearance of LT4 [98]. 
Several drugs (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, and nicardipine) 
can increase thyroid hormone clearance through the induction of hepatic microsomal 
enzymes, including mixed function oxygenases and uridine diphosphate–
glucuronosyltransferases [103]. These drugs can cause hypothyroidism in patients who 
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undergo LT4 [11,104-106]. For example, imatinib is a potent competitive inhibitor of several 
mixed function oxygenases (CYP2C9, CYP2D6, and CYP3A4/5), and the induction of uridine 
diphosphate–glucuronosyl transferases has been hypothesized to be a possible mechanism 
of interference of imatinib on levothyroxine metabolism [98]. Alternatively, an interference 
of sunitinib with thyroid hormone action at the pituitary level has been suggested [122]. 
TKI-induced hypothyroidism (de novo primary hypothyroidism) may have several 
explanations. In some cases thyrotoxicosis may precede the development of 
hypothyroidism, suggesting a thyroiditis-induced thyrotoxicosis [107,108,123]. Other 
possible mechanisms include direct toxic effects on thyrocytes, namely the reduced 
synthesis of thyroid hormones related to inhibition of thyroid peroxidase activity [109], 
impaired iodine uptake [110], the drug induced regression of the gland vascular bed with 
significant capillary alteration and reduction in density [111]. However, a role for iodine 
uptake in TKI-hypothyroidism was not confirmed by in vitro studies [112] and anti-
peroxidase effect seems unable to provide an explanation for cases with initial destructive 
thyrotoxicosis, or with thyroid atrophy. 
Induction of Hashimoto thyroiditis has also been proposed [113], although Hashimoto 
thyroiditis is unlikely to be the main mechanism because of the low prevalence of anti-TPO 
antibodies. 
The most likely explanation is that the thyroid dysfunction may be related to the effects of 
these agents on tyrosine kinase receptors involved in vascular function, such as vascular 
endothelial growth factor (VEGF) receptor (VEGFR). This could cause a reduction in thyroid 
blood flow to this extremely vascular gland. If the blood flow decreases rapidly, an ischemic 
thyroiditis could result, leading to a transient period of thyrotoxicosis. If the decreased 
blood flow develops more slowly, gradual thyroid destruction may occur with resulting 
hypothyroidism [114]. Supporting evidence for this theory include findings that thyroid 
cells express VEGF and VEGFR mRNA, and preclinical studies in mouse models have 
shown glandular capillary regression with TKI exposure [115]. In humans, case reports 
demonstrated reduced thyroid volume and reduced vascularity by Doppler ultrasound 
[116,117], with rapid increase in the size of the thyroid with cessation of sunitinib. This 
reduced thyroid volume secondary to reduced blood flow, may also explain the impaired 
radioactive iodine uptake in vivo, but not in vitro [118]. However, the role of VEGF in thyroid 
signaling is uncertain. Unlike treatment with antiangiogenic TKIs, bevacizumab is not 
associated with altered thyroid homeostasis [119]. In addition, in vitro experiments showed 
that VEGF reduces TSH induced iodine uptake by thyroid cells, and inhibition of VEGF 
restores iodine uptake [120]. Other factors, such as platelet derived growth factor α and c-
KIT, contribute to maintaining thyroid homeostasis, but so far no data on their role in this 
toxicity have been published. 
3.4.1. Imatinib  
Imatinib inhibits the kinase activity of the tyrosine kinases of breakpoint cluster region 
proto-oncogene ABL1 (BCR-ABL fusion protein), c-Kit and platelet derived growth factor 
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hydrocortisone, if required. None of the patients affected by anti-CTLA4-IT showed 
concomitant hypophysitis or other IRAEs. 
Patients who need to receive anti–CTLA-4 mAbs should be carefully informed on the 
importance of observing and early reporting signs or symptoms potentially related to 
IRAEs, and that these symptoms may occur weeks to months after starting treatment. In 
these patients, TSH, free-T4, serum electrolytes, serum glucose, and blood cell counts should 
be assessed before initiating treatment and before each cycle. 
3.4. Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors (TKIs) have emerged as a new class of molecular targeted anti-
cancer agents with proven efficacy in several types of carcinoma and in some hematologic 
cancers. At the moment, about 150 kinase-targeted drugs are in clinical development and 
many more are in various stages of preclinical development [95]. 
The registered kinase inhibitors are small molecules, that, with sporadic exceptions, exert 
their pharmacological action at the ATP-site of a wide variety of tyrosine kinases critical for 
tumor cell survival and proliferation and angiogenesis. TKIs compete with ATP for binding 
to the catalytic domain that act by preventing ATP binding to these targets with different 
selectivity, potency and pharmacokinetic properties. However, despite their inherent 
selectivity, the available TKIs showed a variable grade of affinity for the different tyrosine 
kinases, but none specific for a single kinase. In addition, interference is frequently extended 
to off-target intracellular processes of normal cells. As a direct consequence, TKIs may cause 
a number of infrequent or even new toxicities. TKI-induced endocrine side effects mainly 
include thyroid dysfunction and disease, but also may be responsible for gonadal and 
adrenal dyfunction, bone and glucose altered metabolism, impairment in linear growth and 
fetal development [96]. 
Two types of thyroid dysfunctions have been observed with TKIs [97]. The first is 
worsening of hypothyroidism in patients under satisfactory treatment with thyroid 
hormone replacement. This effect was initially noted in patients under treatment with 
imatinib, but also other TKIs were found responsible for increase in LT4 supplementation in 
hypothyroid patients [98-102]. The second type of thyroid disturbance is primary 
hypothyroidism in patients with previously normal thyroid function. Almost all TKIs are 
responsible, at a variable extent, of primary hypothyroidism, with the exception of gefitinb 
and erlotinib. 
The mechanisms of TKI-induced thyroid dysfunction are unclear. An increase in the 
requirement of replacement therapy with LT4 during certain TKIs has been suggested to be 
dependent on possible interference of the drug at nondeiodination clearance of LT4 [98]. 
Several drugs (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, and nicardipine) 
can increase thyroid hormone clearance through the induction of hepatic microsomal 
enzymes, including mixed function oxygenases and uridine diphosphate–
glucuronosyltransferases [103]. These drugs can cause hypothyroidism in patients who 
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undergo LT4 [11,104-106]. For example, imatinib is a potent competitive inhibitor of several 
mixed function oxygenases (CYP2C9, CYP2D6, and CYP3A4/5), and the induction of uridine 
diphosphate–glucuronosyl transferases has been hypothesized to be a possible mechanism 
of interference of imatinib on levothyroxine metabolism [98]. Alternatively, an interference 
of sunitinib with thyroid hormone action at the pituitary level has been suggested [122]. 
TKI-induced hypothyroidism (de novo primary hypothyroidism) may have several 
explanations. In some cases thyrotoxicosis may precede the development of 
hypothyroidism, suggesting a thyroiditis-induced thyrotoxicosis [107,108,123]. Other 
possible mechanisms include direct toxic effects on thyrocytes, namely the reduced 
synthesis of thyroid hormones related to inhibition of thyroid peroxidase activity [109], 
impaired iodine uptake [110], the drug induced regression of the gland vascular bed with 
significant capillary alteration and reduction in density [111]. However, a role for iodine 
uptake in TKI-hypothyroidism was not confirmed by in vitro studies [112] and anti-
peroxidase effect seems unable to provide an explanation for cases with initial destructive 
thyrotoxicosis, or with thyroid atrophy. 
Induction of Hashimoto thyroiditis has also been proposed [113], although Hashimoto 
thyroiditis is unlikely to be the main mechanism because of the low prevalence of anti-TPO 
antibodies. 
The most likely explanation is that the thyroid dysfunction may be related to the effects of 
these agents on tyrosine kinase receptors involved in vascular function, such as vascular 
endothelial growth factor (VEGF) receptor (VEGFR). This could cause a reduction in thyroid 
blood flow to this extremely vascular gland. If the blood flow decreases rapidly, an ischemic 
thyroiditis could result, leading to a transient period of thyrotoxicosis. If the decreased 
blood flow develops more slowly, gradual thyroid destruction may occur with resulting 
hypothyroidism [114]. Supporting evidence for this theory include findings that thyroid 
cells express VEGF and VEGFR mRNA, and preclinical studies in mouse models have 
shown glandular capillary regression with TKI exposure [115]. In humans, case reports 
demonstrated reduced thyroid volume and reduced vascularity by Doppler ultrasound 
[116,117], with rapid increase in the size of the thyroid with cessation of sunitinib. This 
reduced thyroid volume secondary to reduced blood flow, may also explain the impaired 
radioactive iodine uptake in vivo, but not in vitro [118]. However, the role of VEGF in thyroid 
signaling is uncertain. Unlike treatment with antiangiogenic TKIs, bevacizumab is not 
associated with altered thyroid homeostasis [119]. In addition, in vitro experiments showed 
that VEGF reduces TSH induced iodine uptake by thyroid cells, and inhibition of VEGF 
restores iodine uptake [120]. Other factors, such as platelet derived growth factor α and c-
KIT, contribute to maintaining thyroid homeostasis, but so far no data on their role in this 
toxicity have been published. 
3.4.1. Imatinib  
Imatinib inhibits the kinase activity of the tyrosine kinases of breakpoint cluster region 
proto-oncogene ABL1 (BCR-ABL fusion protein), c-Kit and platelet derived growth factor 
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receptor (PDGFR) /β. It is currently approved for the treatment of chronic myeloid 
leukemia, gastrointestinal stromal tumors (GIST) and dermatofibrosarcoma protuberans. 
The influence of daily 400–800 mg imatinib on LT4 was reported in a cohort of 11 patients 
(10 with medullary thyroid carcinoma and 1 with GIST) [98]. Among the patients with 
medullary thyroid carcinoma, eight underwent thyroidectomy and received LT4 and three 
had thyroid carcinoma in situ. Thyroid function was evaluated before, during and 2 weeks 
after therapy with imatinib or LT4. Symptoms of hypothyroidism occurred in all patients 
who had undergone thyroidectomy, but not in those with intact thyroid. Patients who had 
undergone thyroidectomy had markedly elevated TSH levels, and required an increase of 
LT4 during imatinib dosing. The effect was reversible after discontinuation of treatment, 
suggesting that imatinib might be the causative agent. 
In another study on 68 patients with intact thyroid gland who received imatinib for chronic 
myeloid leukemia, no case of drug-induced alterations in thyroid laboratory parameters was 
observed. These data sustain the hypothesis that imatinib-induced thyroid dysfunction is 
limited to athyreotic patients and are not the consequence of a direct action of the drug on 
thyroid gland [121], but more probably of an interference of the drug in the nondeiodination 
clearance of LT4 through the induction of hepatic microsomal enzymes [98]. 
3.4.2. Sunitinib 
Sunitinib is an oral, multitarget inhibitor of VEGF receptor 1 (VEGFR1), VEGFR2, Fms-like 
tyrosine kinase 3 (Flt3), colony stimulating factor 1 receptor (CSF1R), RET, c-Kit, and 
PDGFR. This agent has been found to influence the thyroid function of patients with GIST 
or RCC.  
In total, 2 out of 56 patients with RCC and a history of well controlled hypothyroidism, and 
7 out of 21 patients with imatinib-resistant GIST, had a worsening hypothyroidism during 
sunitinib treatment [109,111,122], reported the case of a woman with GIST who was resistant 
to imatinib and received LT4 after thyroidectomy and 131I-ablation for follicular thyroid 
carcinoma. The patient’s dose of LT4 needed to be increased after sunitinib treatment. In this 
report, the marked increase in TSH levels has been attributed to a potential interference of 
sunitinib with thyroid hormone action at the pituitary level [122]. 
Desai et al. [123] prospectively evaluated the thyroid function tests (TFTs) in a phase I/II 
study of sunitinib therapy in 42 patients with imatinib-resistant GIST. Most patients 
received 50 mg sunitinib daily every 4–6 weeks, each consisting of 2–4 weeks of sunitinib 
followed by 2 weeks of wash-out. Initially, TFT were performed only if clinically indicated. 
Thereafter, serum TSH was evaluated before each sunitinib cycle. In total, 42 patients with 
normal baseline TFT who received at least 3 sunitinib treatment cycles for a median of 37 
weeks were evaluated. Abnormal serum TSH concentrations were documented in 26 
patients (62%). Sunitinib caused persistent primary hypothyroidism in 15 patients (36%), 
after an average of 50 weeks of therapy (range 12–94 weeks). Seven additional patients 
(17%) experienced transient, mild serum TSH elevation (5.0–7.0 mU/L). In 4 patients TSH 
was suppressed, but they discontinued treatment before the TFTs could be repeated. Out of 
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15 patients with hypothyroidism, 6 (40%) had at least one TSH value below 0.5 mU/L before 
developing the condition, which suggests a thyroiditis-induced thyrotoxicosis. The risk of 
hypothyroidism increased with the duration of sunitinib therapy. Subclinical or overt 
hypothyroidism was observed in 4 out of 22 patients [18%] who received sunitinib for 9 
months, and in 5 of 17 patients (29%) who received sunitinib for longer than 12 months. In 
patients treated for longer than 96 weeks, 90% developed increased levels of TSH. The mean 
time to onset of hypothyroidism was 50 weeks. Among the patients with TSH 
concentrations greater than 10 mU/L, none had spontaneous biochemical resolution. During 
the titration of LT4, serum TSH values remained elevated for a median of 17 weeks (range 
4–117 weeks). The TSH concentrations returned to normal in all patients who received 
conventional doses of LT4. Interestingly, in 2 patients with hypothyroidism and normal 
baseline TFTs, ultrasonography revealed atrophic thyroid tissue, which suggests destructive 
thyroiditis. This clinical trial was the first to report the prevalence of sunitinib related 
hypothyroidism [123]. 
Rini et al. [111] described thyroid abnormalities in a retrospective study of 66 patients with 
metastatic RCC treated with sunitinib. In all, 30 patients were pretreated with cytokine-
based therapy (6 of them were treated with bevacizumab), and 30 patients were treatment-
naive. All patients received the standard sunitinib dose of 50 mg daily for 4 weeks, followed 
by 2 weeks off therapy. TFT assessment, including free thyroxine index, was initiated in 29 
patients (and subsequently in another 37 patients) as a routine laboratory assessment at 
baseline and on day 28 of every even numbered cycle. Out of the 66 patients, 56 (85%) had 
one or more TFT abnormality. These abnormalities were consistent with hypothyroidism in 
all patients and primarily included the elevation of TSH, decreased levels of T3 and, less 
commonly, decreases in T4 and/or of the free thyroxine index. TFT abnormalities were 
detected early (the median time of detection was at cycle 2). Among patients with abnormal 
TFTs, signs and symptoms related to hypothyroidism were found in 47 patients (84%). 
These symptoms included fatigue, cold intolerance, anorexia, periorbital edema, fluid 
retention, and alterations in skin or hair. LT4 therapy was given at the discretion of the 
physician, on the basis of the degree of biochemical abnormality and/or clinical symptoms. 
A resolution of biochemical abnormalities occurred in all 17 patients treated with LT4, and 
an improvement of symptoms was recorded in 9 patients. Anti-TG antibodies were 
measured in 44 patients and were abnormal in 13 (30%). No association was observed 
between the presence of anti-TG antibodies and the incidence or severity of TFT 
abnormalities [111]. 
Feldman et al. [124] reported that hypothyroidism was found in 14 (18%) out of the 80 
patients enrolled in a prospective clinical trial that investigated the efficacy of sunitinib in 
metastatic RCC. Serum TSH levels were obtained only from symptomatic patients and 
ranged from 6.0 to 146.4 mU/L (normal range 0.35–5.5 mU/L). Hypothyroidism was detected 
after a median time of 10 months of therapy (range 1–26 months), being fatigue the 
predominant symptom. The Authors highlighted that the lower incidence of 
hypothyroidism reported might depend on the fact that TFT assessment was performed on 
symptomatic patients only [124]. 
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Wong et al. [109] explored the potential effects of sunitinib on thyroid function in a cohort of 
40 patients affected by different tumor histotypes, the majority of whom were affected by 
imatinib-resistant GIST. In this study a new onset or worsening condition of 
hypothyroidism occurred in 21 out of 40 patients (53%) patients who underwent TFTs. 
Patients developed elevated TSH levels after a median of 5 months of treatment (range, 1–36 
months). The median TSH level was 21.4 mU/L (range, 4.6–174 mU/L). The influence of 
sunitinib on peroxidase activity was assessed by testing its effects on guaiacol oxidation and 
protein iodination caused by lactoperoxidase. The potency of sunitinib antiperoxidase 
activity was about 25% of that noted with propylthiouracil. The Authors proposed that the 
antithyroid effect of sunitinib is mediated by the inhibition of peroxidase activity, which is 
involved in the synthesis of the thyroid hormone [109]. 
Wolter et al. [125] prospectively evaluated the incidence of hypothyroidism in patients with 
GIST or metastatic RCC treated with sunitinib at the standard dose [125]. TFTs included 
assessment of serum TSH, T3, free thyroxine index and thyroid antibodies (anti-TG, anti-
TPO antibodies, and TSH receptor antibodies) and was measured on days 1 and 28 of each 
treatment cycle. The analysis revealed that 16 patients (27%) developed sub- or clinical 
hypothyroidism requiring thyroid hormone replacement and 20 patients (34%) showed at 
least one thyroid test abnormality. The median time to develop thyroid dysfunction was 4 
weeks and patients who did not develop hypothyroidism within the first cycles did not 
develop hypothyroidism later during therapy. 
In another prospective phase I-II study, Mannavola et al. [110] evaluated TFT (serum TSH, 
free T3 and T4, thyroglobulin, anti-TG and anti-TPO antibodies) in 24 patients with GIST 
who were treated with sunitinib (4 weeks of 50 mg daily and 2 weeks of withdrawal). 
Urinary iodine was measured in 18 patients and urinary fluorine was assessed in 10 
patients. Thyroid ultrasonography and echocolor-Doppler were performed, both at 
enrollment and after a variable number of treatment cycles. To study thyroid function, 123I 
thyroidal uptake and scintigraphy were performed in 6 unselected patients at the end of the 
treatment and withdrawal periods. Hypothyroidism was documented in 46% of patients, 
and a transient elevation of TSH levels in 25% of cases. The overall prevalence of elevated 
TSH levels after sunitinib was 71%. At onset, hypothyroidism was subclinical in all but one 
patient with Hashimoto thyroiditis, the only one with detectable antithyroid autoantibodies. 
TSH levels were found to fluctuate according to whether treatment was given or 
withdrawn, and progressively increased during treatment. In most cases, progressive 
worsening of hypothyroidism was shown, but in a few cases a sudden development of 
severe hypothyroidism was observed. The normal echographic and echocolor-Doppler 
patterns, obtained both at baseline and during treatment, indicate that hypothyroidism is 
unlikely to be the consequence of a direct toxic effect on thyroid cells or secondary to an 
autoimmune process. Inhibition of iodine uptake seems to be a more likely explanation for 
hypothyroidism. Indeed, radioiodine uptake impairment has been demonstrated by a 
reduced uptake at the end of treatment periods, with a partial or total recovery during the 
withdrawal phase. Of particular interest was the observation of a blunted early 123I uptake 
curve, which suggests an alteration in the uptake phase rather than in the organification 
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process. The Authors noted that after sunitinib withdrawal, TSH levels returned to the 
normal range in a maximum of 60 days. 
Interestingly, the association between TKI-induced thyroid dysfunction and clinical 
efficacy has been demonstrated in two larger studies. Schmidinger et al. [126] in a 
prospective analysis of 87 patients with metastatic RCC who were to receive treatment 
with sunitinib or sorafenib, thyroid function was monitored every 4 weeks during the first 
2 months of treatment and every 2 to 4 weeks thereafter. Subclinical hypothyroidism was 
present in five patients at baseline and was diagnosed in 30 patients (36.1%) within the 
first 2 months of therapy. Patients with subclinical hypothyroidism had a statistically 
significant objective remission rate of 28.3% versus 3.3% in euthyroid patients (p<0.001) 
and median duration of survival (not reached versus 13.9 months in euthyroid patients; 
p=0.016). In addition, in a multivariate analysis, the development of subclinical 
hypothyroidism within 2 months of treatment was found to be an independent predictor 
of survival (p=0.014). In another study on patients with metastatic RCC who received 
sunitinib or sorafenib, Riesenbeck et al. [127] found that 21 (38.1%) out of the 66 evaluable 
patients developed hypothyroidism. Hypothyroidism was associated with a longer PFS 
(16.0 ± 0.8 months versus 6.0 ± 0.8 months, p=0.032). In agreement with the study by 
Schmidinger et al. [126], hypothyroidism was found to be an independent predictor of 
survival (p=0.01) in a multivariate analysis. 
3.4.3. Sorafenib 
Sorafenib is an oral multikinase inhibitor that inhibits the kinase activity of RAF/MEK/ERK, 
VEGFR2 and VEGFR3, Flt3, fibroblast growth factor receptor 1, RET, cMET, PDGFR β, Kit 
and other receptors involved in tumor progression and angiogenesis. It is approved for the 
treatment of advanced RCC and unresectable hepatocellular carcinoma. In addition, it is 
under clinical evaluation in a number of tumor types, including lung, pancreatic, prostate, 
melanoma and differentiated thyroid cancer. Tamaskar et al. [114] retrospectively 
investigated the incidence of TFT abnormalities in 39 patients with metastatic RCC treated 
with 400 mg sorafenib twice daily. Most patients had received at least one prior treatment. 
Out of the 39 patients, 16 (41%) had one or more serum TFT values outside the laboratory 
normal reference range during treatment with sorafenib. The median timing of the 
abnormal test was 1.8 months (range 0.6–7.3 months). Biochemical hypothyroidism occurred 
in 7 out of 39 patients (18%) during treatment, which was first observed 2–4 months after 
sorafenib initiation. Six of these patients had mild TSH level elevations (5.5–10.0 mU/L). 
Another patient showed a rapid onset of hypothyroidism with TSH level rising from 5.74 to 
160.64 mU/L, and T3 level decreasing from 72 to 49 ng/dl over 1.5 months. One patient had 
normal TSH concentration (2.42 mU/L) but low T3 and T4 at 4 months after starting 
sorafenib treatment, these abnormalities worsened over the next 4 months with further 
reductions of T3 and T4 levels, and abnormal TSH (9.930 mU/L). Both these patients 
received LT4. In two of the seven hypothyroid patients anti-TG antibody titers increased; 
two patients had persistent serum TSH elevation and in one case a normalization of the TSH 
values was observed. 
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Clement et al. [128] prospectively monitored thyroid function in 38 patients with metastatic 
RCC who were treated with sorafenib 400 mg twice daily. Thyroid function was assessed at 
baseline and on day 1 of each treatment cycle. Out of 23 patients with normal baseline 
thyroid function, seven patients (30%) developed at least one elevated serum TSH and 1 
patient (5%) developed low TSH levels. For these abnormalities no therapy was required. In 
addition, out of 15 patients with either thyroid dysfunction at baseline or previous treatment 
potentially interfering with thyroid function, two patients with baseline subclinical 
hypothyroidism (defined as an increase in serum TSH above normal and ≤ 10 mU/L, with 
normal T3 and T4 values) developed clinical hypothyroidism (TSH ≥ 10 mU/L or T3 and T4 
values below the normal range) requiring thyroid hormone replacement therapy. 
In another prospective observational study [129] on 69 Japanese patients affected by metastatic 
RCC refractory to cytokine therapy and subsequently treated with sorafenib for at least 12 
weeks, thyroid function was assessed before and every 4 weeks after the initiation of sorafenib 
treatment. Forty-six (67.7%) patients developed hypothyroidism. Interestingly, 11 (23.9%) of 
these patients first showed a suppressed TSH value accompanying the increase in free T3 
and/or free T4, before developing hypothyroidism. This pattern clearly suggests that sorafenib 
may have induced thyroiditis. LT4 was needed by 4 patients (5.8%) who presented severe 
clinical symptoms caused by hypothyroidism. Among several factors examined, only age was 
significantly associated with the risk of developing hypothyroidism.  
Sorafenib-associated thyroid dysfunction was not reported in two registration trials in 
patients affected by advanced hepatocellular carcinoma (HCC). More recently, in a series of 
38 consecutive patients with HCC treated with sorafenib, 5 (13%) of them developed 
subclinical hypothyroidism (TSH levels, 7,41 μIU/mL; range, 6,38-8,94 μIU/mL (unpublished 
data) [130]. Other case reports of patients affected by HCC showed progressive destructive 
thyroiditis after taking sorafenib. These data highlight the possibility that also 
hypothyroidism induced by sorafenib may be the result of an initial thyrotoxicosis [131]. 
Abdulrahman et al. [132] in a small prospective study on 21 patients with progressive 
nonmedullary thyroid carcinoma treated with sorafenib, measured serum total T4, free T4, 
total T3, free T3, reverse T3, and TSH concentrations at baseline and after 26 weeks of 
treatment with sorafenib. Results from this study suggested that sorafenib enhances T4 and 
T3 metabolism, which may be probably caused by an increased type 3 deiodination. 
3.4.4. Motesanib 
Motesanib diphosphate is a highly selective, oral inhibitor of VEGFR-1, -2, and -3; PDGFRs 
and c-KIT. The association between motesanib and thyroid function was recognized in a 
phase II study of 93 patients with progressive radioiodine-resistant differentiated thyroid 
cancer who daily received motesanib diphosphate [102]. All the patients had previously 
undergone thyroidectomies and were on thyroid hormone replacement therapy. Increased 
serum TSH concentrations, hypothyroidism or both were observed in 20 patients (22%). The 
Authors suggested that alterations in the absorption or metabolism of LT4 may explain 
changes in thyroid hormone levels while on motesanib. 
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In a phase II study [101] on 91 patients affected by locally advanced or metastatic medullary 
thyroid cancer (MTC), motesanib was taken orally at the standard dose for up to 48 weeks 
or until unacceptable toxicity or disease progression. Thirty-seven patients (41%) had 
elevated serum TSH levels compared with baseline and/or hypothyroidism.  
In another phase II study assessing the tolerability and activity of motesanib in 138 patients 
with imatinib-resistant GIST, only 3 patients (2%) developed hypothyroidism, but only in 
one case related to treatment [133]. 
3.4.5. Vandetanib 
Vandetanib is an oral inhibitor of VEGFR-2 and -3, RET kinases, and at higher 
concentrations, the epidermal growth factor receptor kinases. This drug has been approved 
in the United States for unresectable locally advanced or metastatic MTC and is under 
evaluation in phase III trials on patients affected by several cancer types [134]. 
In a phase II study of vandetanib, 19 patients with advanced hereditary MTC received 
vandetanib 100 mg daily [135]. All patients had undergone prior total thyroidectomy and 
were receiving LT4 therapy. In all 17 patients who had available baseline TFTs, an 
increase in serum TSH levels was observed. TSH elevation reached a maximum by day 84 
after the start of vandetanib treatment with a median 7.3-fold increases over baseline. No 
patients were reported to have symptomatic hypothyroidism, but LT4 was increased in 
two patients. 
Interestingly, in a study on 39 patients with progressive medullary or differentiated thyroid 
cancer included in two randomized placebo-controlled trials using vandetanib 300 mg/day 
[136] LT4 had to be increased by 50 μg/d to maintain serum TSH within the normal range, 
probably by increased type 3 deiodinase activity as described using sorafenib [132]. 
3.4.6. Axitinib 
Axitinib is an oral TKI that acts selectively inhibiting all VEGFR kinases [137]. The drug is 
approved by the FDA for the treatment of advanced RCC after the failure of one prior 
systemic therapy. In a Japanese study on 18 patients affected by various solid tumors 
receiving axitinib at different dosage, 16 (89%) patients experienced elevation in serum TSH 
above the upper limit of normal range [138]. 
In a phase II study on 60 patients with thyroid cancers resistant or not appropriate for 131I, 
who received axitinib (starting dose, 5 mg orally twice daily), no thyroid tests abnormalities 
were registered, except for the initial decreases in thyroglobulin seen in most patients, 
regardless of their clinical response to therapy. In another phase II study on 62 patients with 
metastatic RCC refractory to prior therapies, including sorafenib, G1-2 hypothyroidism was 
registered in 29% of patients [139]. In preclinical studies with axitinib inhibition of VEGFR-2 
and VEGFR-3 induced by axitinib lead to thyroid capillary regression [115,140]. Again, 
destructive thyroiditis mediated by the destruction of thyroid capillary appears a plausible 
mechanism of action explaining axitinib-associated hypothyroidism. 
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Clement et al. [128] prospectively monitored thyroid function in 38 patients with metastatic 
RCC who were treated with sorafenib 400 mg twice daily. Thyroid function was assessed at 
baseline and on day 1 of each treatment cycle. Out of 23 patients with normal baseline 
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addition, out of 15 patients with either thyroid dysfunction at baseline or previous treatment 
potentially interfering with thyroid function, two patients with baseline subclinical 
hypothyroidism (defined as an increase in serum TSH above normal and ≤ 10 mU/L, with 
normal T3 and T4 values) developed clinical hypothyroidism (TSH ≥ 10 mU/L or T3 and T4 
values below the normal range) requiring thyroid hormone replacement therapy. 
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RCC refractory to cytokine therapy and subsequently treated with sorafenib for at least 12 
weeks, thyroid function was assessed before and every 4 weeks after the initiation of sorafenib 
treatment. Forty-six (67.7%) patients developed hypothyroidism. Interestingly, 11 (23.9%) of 
these patients first showed a suppressed TSH value accompanying the increase in free T3 
and/or free T4, before developing hypothyroidism. This pattern clearly suggests that sorafenib 
may have induced thyroiditis. LT4 was needed by 4 patients (5.8%) who presented severe 
clinical symptoms caused by hypothyroidism. Among several factors examined, only age was 
significantly associated with the risk of developing hypothyroidism.  
Sorafenib-associated thyroid dysfunction was not reported in two registration trials in 
patients affected by advanced hepatocellular carcinoma (HCC). More recently, in a series of 
38 consecutive patients with HCC treated with sorafenib, 5 (13%) of them developed 
subclinical hypothyroidism (TSH levels, 7,41 μIU/mL; range, 6,38-8,94 μIU/mL (unpublished 
data) [130]. Other case reports of patients affected by HCC showed progressive destructive 
thyroiditis after taking sorafenib. These data highlight the possibility that also 
hypothyroidism induced by sorafenib may be the result of an initial thyrotoxicosis [131]. 
Abdulrahman et al. [132] in a small prospective study on 21 patients with progressive 
nonmedullary thyroid carcinoma treated with sorafenib, measured serum total T4, free T4, 
total T3, free T3, reverse T3, and TSH concentrations at baseline and after 26 weeks of 
treatment with sorafenib. Results from this study suggested that sorafenib enhances T4 and 
T3 metabolism, which may be probably caused by an increased type 3 deiodination. 
3.4.4. Motesanib 
Motesanib diphosphate is a highly selective, oral inhibitor of VEGFR-1, -2, and -3; PDGFRs 
and c-KIT. The association between motesanib and thyroid function was recognized in a 
phase II study of 93 patients with progressive radioiodine-resistant differentiated thyroid 
cancer who daily received motesanib diphosphate [102]. All the patients had previously 
undergone thyroidectomies and were on thyroid hormone replacement therapy. Increased 
serum TSH concentrations, hypothyroidism or both were observed in 20 patients (22%). The 
Authors suggested that alterations in the absorption or metabolism of LT4 may explain 
changes in thyroid hormone levels while on motesanib. 
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[136] LT4 had to be increased by 50 μg/d to maintain serum TSH within the normal range, 
probably by increased type 3 deiodinase activity as described using sorafenib [132]. 
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Axitinib is an oral TKI that acts selectively inhibiting all VEGFR kinases [137]. The drug is 
approved by the FDA for the treatment of advanced RCC after the failure of one prior 
systemic therapy. In a Japanese study on 18 patients affected by various solid tumors 
receiving axitinib at different dosage, 16 (89%) patients experienced elevation in serum TSH 
above the upper limit of normal range [138]. 
In a phase II study on 60 patients with thyroid cancers resistant or not appropriate for 131I, 
who received axitinib (starting dose, 5 mg orally twice daily), no thyroid tests abnormalities 
were registered, except for the initial decreases in thyroglobulin seen in most patients, 
regardless of their clinical response to therapy. In another phase II study on 62 patients with 
metastatic RCC refractory to prior therapies, including sorafenib, G1-2 hypothyroidism was 
registered in 29% of patients [139]. In preclinical studies with axitinib inhibition of VEGFR-2 
and VEGFR-3 induced by axitinib lead to thyroid capillary regression [115,140]. Again, 
destructive thyroiditis mediated by the destruction of thyroid capillary appears a plausible 
mechanism of action explaining axitinib-associated hypothyroidism. 
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3.4.7. Nilotinib 
Nilotinib is a second-generation TKI with greater potency and specificity for BCR-ABL 
inhibition compared with imatinib [141,142]. It is approved for the treatment of 
Philadelphia-positive chronic myeloid leukemia (Ph-positive CML). Kim et al. [143] 
retrospectively assessed the effect of nilotinib on TFT in 55 patients with Ph-positive CML. 
In 12 patients (22%), TFTs were consistent with hypothyroidism (6 subclinical, 6 clinical) 
and in 18 (33%) patients with hyperthyroidism (10 subclinical, 8 clinical) at some point 
during their therapy. Six (11%) of these patients were on thyroid medication prior to starting 
the nilotinib and in most patients an increase in LT4 dose was not required. In 4 patients 
evidence of thyroiditis was found (3 had positive anti-thyroid antibodies) with an episode of 
hyperthyroidism preceding the development of hypothyroidism. 
Recently, a case of overt hypothyroidism following initiation of treatment with nilotinib has 
been described in a 76-year-old euthyroid male with CML [144]. Serum TSH was 30.23 
μU/mL with low free T4 and free T3, and negative anti-thyroid antibodies. The ultrasound 
examination showed a normal size gland, markedly decreased inhomogeneous echo signals 
and slightly reduced vascularity, all compatible with thyroiditis. In this case symptoms 
dramatically regressed following the initiation of LT4 and nilotinib was not withdrawn. 
3.4.8. Dasatinib 
Dasatinib is another second-generation TKI with activity against BCR-ABL and Src family 
kinases that is approved for the treatment of imatinib-resistant Ph-positive CML and Ph-
positive acute lymphoblastic leukemia [145]. In a retrospective survey on patients with Ph-
positive CML who received dasatinib, 5 (50%) patients had TFT abnormalities consistent 
with hypothyroidism (4 subclinical, 1 clinical) and 2 patients (20%) had thyroid values 
consistent with subclinical hyperthyroidism. No patient required LT4, except one patient 
who developed hypothyroidism and was also taking amiodarone, a medication known to 
cause thyroid dysfunction. Two patients were on LT4 prior to starting dasatinib and 
modification of LT4 was not required [143]. 
3.4.9. Pazopanib 
Pazopanib is an oral angiogenesis inhibitor targeting VEGFR-1, PDGFR, and c-Kit. 
Pazopanib is under clinical development for the treatment of multiple tumor types and has 
been recently approved for the treatment of advanced RCC. Preliminary data on the 
incidence and severity of thyroid dysfunction in patients who received pazopanib as 
treatment for RCC in 3 prospective trials have been recently reported [146]. TFTs were 
systematically assessed in 578 patients with serum TSH values collected at baseline and 
every 12 weeks and serum free T3 and T4 at baseline and if TSH was abnormal during the 
treatment. Elevated TSH (>5 μUI/mL) before initiating pazopanib was found in 37 (6%) 
patients. TSH value >5 μUI/mL during the treatment was found in 167 (29%) patients. Overt 
hypothyroidism was diagnosed in 34 (6%) patients. Hyperthyroidism was seen in 8 (1%) 
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patients. Only 20 (3%) patients with a TSH elevation received LT4. Hypothyroidism was 
registered as a Grade 1/2 adverse event in 26 (4%) patients. Thyroid dysfunction was never 
reported as a severe adverse event in any patient. 
3.4.10. Cediranib 
Hypothyroidism was also reported with cediranib, another blocker of VEGFR 1-3 and c-Kit 
kinases in 45% of patients affected by advanced non-small-cell lung cancer enrolled in a 
randomized, double-blind trial of carboplatin and paclitaxel taking either oral cediranib or 
placebo daily [147]. Similarly, in a randomized phase II study on 46 patients affected by 
recurrent epithelial ovarian or fallopian tube cancer and treated with cediranib as single 
agent, Grade 2 hypothyroidism occurred in 56% of patients [148]. Details regarding the rate 
of patients requiring LT4 or effects of this treatment on hypothyroidism-related symptoms 
was not reported.  
3.5. Bexarotene 
Bexarotene is a selective agonist of the retinoid X receptor (RXR), a nuclear hormone 
receptor. It is approved for the treatment of cutaneous T cell lymphoma and has been found 
to induce secondary hypothyroidism [102]. Bexarotene appears to interfere with the normal 
feedback of thyroid hormone on the pituitary gland [102,149]. T3 binding to its receptor in 
the pituitary leads to heterodimerization of the receptor with RXR, which suppresses 
transcription of the β-subunit of TSH, which is required for thyroid stimulation. Bexarotene 
also has TSH-independent effects on thyroid hormone metabolism. Thyroidectomized 
thyroid cancer patients receiving thyroid hormone replacement who started bexarotene had 
a dramatic decrease in total T3 and T4, and free T4 levels with TSH levels that failed to rise 
appropriately [150].This may be probably due to an effect on peripheral thyroid hormone 
metabolism via non-deiodinase mechanisms. 
4. Why is it important to assess thyroid function in cancer patients? 
Abnormalities of thyroid function induced by anticancer drugs are variably common, 
accordingly to the agent used. Identifying thyroid dysfunction and disease in cancer 
patients may have important consequences for diagnostic, therapeutic and prognostic 
purpose.  
Diagnostic challenges are tendered by symptoms of thyroid dysfunction. For example, 
fatigue and constipation are present in the majority of patients with hypothyroidism, but 
they may be caused also by underlying malignancy, antineoplastic treatment(s) received, or 
medications used for control of other symptoms (i.e. nausea or pain) [1]. Similarly, many 
symptoms of thyrotoxicosis are similar to those attributable to other complications, such as 
sepsis. Inability to diagnose the presence of thyroid dysfunction or disease as treatment-
related toxic effects may lead to misguided treatment strategies, unjustified dose reduction 
or even to treatment withdrawal [1]. In addition, unrecognized hypothyroidism or 
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kinases in 45% of patients affected by advanced non-small-cell lung cancer enrolled in a 
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agent, Grade 2 hypothyroidism occurred in 56% of patients [148]. Details regarding the rate 
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purpose.  
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thyrotoxicosis may affect the metabolism of other medications [151]. Finally, it should be 
considered that thyroid dysfunction, although rarely, can lead to life-threatening 
consequences in cancer patients, as warned by case reports of patients who experienced 
myxedematous coma [152] or impaired cardiac function [153,154] as a complication of TKI-
induced hypothyroidism (i.e. sunitinib). 
Therefore, clinicians should maintain an adequate level of surveillance for thyroid 
abnormalities when patients receive certain anticancer treatments, such as TKI or certain 
immunomodulatory drugs, present with symptoms consistent with hypothyroidism (i.e. 
constipation, bradycardia, hypothermia, unexpected weight gain, dry skin or dry hair and 
brittle nails) or thyrotoxicosis (i.e. palpitations, weight loss, heat intolerance, frequent bowel 
movements, tremor, proximal muscle weakness, tachycardia, lid retraction or lid lag, 
insomnia, irritability, fever). Of note, hypophysitis has recently emerged as an unusual, 
peculiar side effect of ipilimumab/tremelimumab. Symptoms like headache, visual 
impairment, nausea, vomiting, loss of appetite, fatigue, weakness, asthenia, fever, lethargy, 
hypotension, hypoglycemia and hyponatremia in patients recently treated with ipilimumab 
should lead physicians to suspect hypophysitis. The early diagnosis of this side-effect allows 
to prevent primarily a life-threatening complication such as adrenal insufficiency, but also 
central hypothyroidism and other endocrine consequences of hypopituitarism [84]. 
Monitoring thyroid function even in asymptomatic patients has emerged as a prognostic 
tool as well. A lower cancer risk and a more indolent disease has been noted in patients with 
primary hypothyroidism and breast cancer [155]. The association between the appearance of 
treatment-induced hypothyroidism has been related to an increased likelihood of response 
to therapy and even of better outcomes. The development of hypothyroidism following 
radiotherapy for head and neck cancer was associated with better survival [156]. 
Propylthiouracil-induced hypothyroidism was associated with improved survival in 
patients with glioma [157]. Thyroid autoimmunity may predict an improved tumor 
response to interleukin 2 therapy for melanoma [62] and RCC [48,49,60]. When patients with 
RCC are treated with sorafenib or sunitinib, a higher rate of remission and better overall 
survival are seen in those who developed hypothyroidism compared to those who did not 
[126,158]. Studies of anti-CTLA4 monoclonal antibodies suggest that the presence of 
immune-related adverse events, including hypophysitis and thyroiditis, is associated with 
better clinical outcomes [159]. 
In patients who are going to start drugs potentially associated with thyroid side-effects, an 
accurate screening for thyroid function should be carried out at baseline and monitored 
throughout the period of treatment and follow-up. Despite specific guidelines generated by 
high level evidence are lacking, rational approaches have been proposed [1,160]. 
Successful treatment of thyroid dysfunction such as hypo- and hyperthyroidism, is likely to 
improve patient quality of life and may prevent erroneous withdrawal from effective 
anticancer therapies. Patients with TSH greater than 10 mIU/L or with low free T4 levels, 
should receive thyroid hormone replacement with LT4 at an average dose of 1.6 μg/kg per 
day. In the case of coronary artery disease, a lower initial dose (e.g. 50 μg/d) should be used 
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for the first few weeks [1]. Monitoring thyroid hormone replacement is usually carried out 
by serum TSH measurements, aimed at maintaining TSH within the normal range. On the 
contrary, in patients who develop central hypothyroidism (i.e. secondary to bexarotene and 
anti-CTLA4 monoclonal antibodies), TSH concentrations cannot be used, and free T4 levels 
should be monitored, with a goal of about 1–1.5 ng/dL [1]. 
The treatment of subclinical hypothyroidism (TSH 5–10 mIU/L with a normal free T4) is 
questionable in cancer patients. In general, treatment of this condition is discouraged in a 
healthy population because there is insufficient evidence of benefit [161,162]. However, it 
may be offered to patients with subclinical hypothyroidism and antiTPO/anti-TG 
antibodies, hypercolesterolemia, thyroid nodules, or symptoms (i.e. fatigue) that may 
greatly worsen quality of life of patients [5]. In one study [111], at least half of patients who 
started LT4 for sunitinib-associated hypothyroidism had improvement of their symptoms of 
fatigue [111]. Conversely, Garfield et al. [163] warned that some preclinical, epidemiological 
and clinical evidence suggests that LT4 is permissive for tumor growth. Possible actions of 
thyroid hormones on cancer cells include the amplification of EGFR, phosphorylation of 
insulin-like growth factor 1 receptor, stimulation of migration, a direct trophic effect on 
tumor cells, cell specific anti apoptotic activity and angiogenesis [164]. 
Practical suggestions for the treatment of individual cancer patients showing TKI-induced 
subclinical hypothyroidism are available [5]. However, the best approach seems to to start 
low-dose LT4 in individual patients as a therapeutic trial [1]. This prudent method may be 
extended to patients who develop this condition as a side effect of other anticancer agents. 
However, specific prospective studies evaluating the influence of thyroid replacement 
therapy in cancer patients, not only in term of quality of life, but also in term of survival, are 
urgently needed [165]. Thyrotoxicosis induced by anticancer drugs may result from an 
Hashi-toxocosis or Graves’ disease. Thyrotoxicosis from thyroiditis is generally self-limiting 
and specific treatment is not required. Corticosteroid and β-blockers, usually propranolol, 
can be efficacious in symptom control. However, patients with this side effect should be 
monitored for subsequent hypothyroidism. Patients presenting with Graves disease, are 
usually treated with antithyroid drugs (i.e. methimazole), followed by 131I ablation if 
indicated. However, due to its complexity, anticancer drug-induced thyrotoxicosis is 
advisable to be managed under close consultation with an endocrinologist [1].  
5. Conclusions 
Thyroid dysfunctions are emerging as a variably common endocrine toxicity of several 
highly selective anticancer drugs. Routine testing for thyroid abnormalities in patients 
receiving these agents are recommended at baseline, during the treatment and follow up. 
Furthermore, thyroid function tests should be included in routine toxicity assessment of 
TKIs and possibly in other classes of targeted drugs under clinical evaluation. 
Hypothyroidism per se is not an indication for dose reduction or discontinuation of these 
agents. The clinical relevance of overt and subclinical hypothyroidism, the value of thyroid 
hormone replacement in individuals with abnormal serum TSH levels following anticancer 
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fatigue [111]. Conversely, Garfield et al. [163] warned that some preclinical, epidemiological 
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insulin-like growth factor 1 receptor, stimulation of migration, a direct trophic effect on 
tumor cells, cell specific anti apoptotic activity and angiogenesis [164]. 
Practical suggestions for the treatment of individual cancer patients showing TKI-induced 
subclinical hypothyroidism are available [5]. However, the best approach seems to to start 
low-dose LT4 in individual patients as a therapeutic trial [1]. This prudent method may be 
extended to patients who develop this condition as a side effect of other anticancer agents. 
However, specific prospective studies evaluating the influence of thyroid replacement 
therapy in cancer patients, not only in term of quality of life, but also in term of survival, are 
urgently needed [165]. Thyrotoxicosis induced by anticancer drugs may result from an 
Hashi-toxocosis or Graves’ disease. Thyrotoxicosis from thyroiditis is generally self-limiting 
and specific treatment is not required. Corticosteroid and β-blockers, usually propranolol, 
can be efficacious in symptom control. However, patients with this side effect should be 
monitored for subsequent hypothyroidism. Patients presenting with Graves disease, are 
usually treated with antithyroid drugs (i.e. methimazole), followed by 131I ablation if 
indicated. However, due to its complexity, anticancer drug-induced thyrotoxicosis is 
advisable to be managed under close consultation with an endocrinologist [1].  
5. Conclusions 
Thyroid dysfunctions are emerging as a variably common endocrine toxicity of several 
highly selective anticancer drugs. Routine testing for thyroid abnormalities in patients 
receiving these agents are recommended at baseline, during the treatment and follow up. 
Furthermore, thyroid function tests should be included in routine toxicity assessment of 
TKIs and possibly in other classes of targeted drugs under clinical evaluation. 
Hypothyroidism per se is not an indication for dose reduction or discontinuation of these 
agents. The clinical relevance of overt and subclinical hypothyroidism, the value of thyroid 
hormone replacement in individuals with abnormal serum TSH levels following anticancer 
 
Thyroid Hormone 330 
systemic therapy, and the correct timing of thyroid replacement therapy need to be more 
accurately defined. Additional prospective clinical trials are necessary to investigate these 
important aspects. In parallel, these trials could offer the unique opportunity to clarify the 
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The thyroid is an endocrine gland formed by two lobes (Figure 1A L) located on each side of 
the trachea and the larynx; they are joined by an isthmus (ultimo-branchial origin) (Figure 
1A clear arrow) located between the trachea’s second and third cartilage rings (Figure 1A 
black arrow). 
1.1.1. Histology 
A fibrous connective tissue capsule covers each lobe from where the septa go inside, partially 
dividing the glandular parenchyma containing a very developed network of capillaries 
surrounding the follicles and irrigating the glandular parenchyma. The gland also contains 
adipocytes, nerve fibres, mastocytes and occasionally lymphocytes and macrophages [2]. 
The thyroid parenchyma mainly consists of follicles which are the thyroid’s functional unit 
(Figure 1B). It has an oval or spherical structure whose wall consists of a layer of cubic 
epithelial cells (thyrocytes) (Figure 1B black arrow) surrounding a viscous solution of proteins 
called colloid (Figure 1B Co) [2,3] containing 80% thyroglobulin (Tg) or thyroid hormone [4,5]. 
Follicle size varies according to an individual’s age, its localisation in the gland and animal 
species; for example, diameter varies from 50 to 150 μm in rats and mice where peripheral 
follicles are larger than the central ones (Figure 1A L), whilst diameter varies from 150 to 500 
μm in humans and pigs, the largest ones occurring towards the inside of the gland, even 
though their location could vary [6,2]. As well as follicle cells or thyrocytes, it has been found 
that 1% to 2% of neural crest cells in different mammals’ thyroids are parafollicular or clear 
cells, appearing clearer in different types of histological staining. These are located at the base 
of follicles but do not come into contact with the colloid and secrete calcitonin [7].  
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Figure 1. A. Histological cross-section of mouse trachea, showing cartilage (black arrow) and mouse 
thyroid lobes (L) and isthmus (clear arrow) adhering to connective tissue between cartilage and thyroid. 
The thyroid parenchyma consists of follicles which look like spherical or oval structures. B. The 
appearance of pig follicles in the lobe’s central region. Each follicle consists of simple cubic epithelium 
(black arrow) limits the follicle centre full of colloid (Co) which follicular cells or thyrocytes secrete. The 
capillaries surrounding the follicles can be seen (clear arrow). C. Rat thyrocyte ultra-structure or cytology. 
The rugose endoplasmic reticulum (RER) can be seen around the nucleus (N) and Golgi complex in 
supranuclear position; these organelles and lysosomes (L) occupy the cells’ base region. Different vesicles 
can be seen at apical level, from exocytosis (ex) being denser than electrons and endocytosis (en) and 
having the same density as electrons and colloid (Co), and the apical membrane forming microvellosities 
(M) in contact with colloid in the centre of the follicles. The binding complex can be observed in the 
lateral membrane at apical level: tight junctions (TJ) followed by belt desomosome (BD) and spot 
desmosome (SD). The thyrocytes’ basement membrane or basal lamina (white arrow) is in close contact 
with the endothelium’s (E) fenestrated capillaries’ basement membrane (black arrow); the endothelium 
cell nucleus (EN) can be seen (A and B H-E, MO. Scale bar A 1mm, B 40 μm. C TEM. 7300X).  
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1.1.2. Ultra-structure 
Endocrine gland cells are usually not polarised with their central nucleus and organelles; 
however, thyrocytes are exceptionally polarised endocrine cells and the nucleus and 
organelles are located in the cell’s basal region like exocrine epithelium cells. This is due to 
the larynx’s embryonic development by polarised cells involuting inside it. Such 
morphological and exocrine functional characteristics are conserved within follicles for 
thyroid hormone synthesis, storing and secretion (Figure 1C). The thyrocytes’ basal 
membrane is directly related to the follicles’ basement membrane or basal lamina (Figure 1C 
white arrow), in turn, being in direct contact with the fenestrated capillaries’ endothelial 
(Figure 1C E) basement membrane (Figure 1C black arrow). The thyrocytes’ apical membrane 
is in direct contact with colloid forming microvellosities (Figure 1C M) whose length and 
amount vary according to a gland’s functional state [8]. Exocytotic vesicles (Figure 1C ex) can 
be seen in the apical region, some of them being more electron dense than less electron dense 
endocytic vesicles (Figure 1C en) and some coated at the base of microvellosities [5]. 
The thyrocytes’ lateral membranes have binding complexes in the apical region formed by 
tight junction, belt desmosome and spot desmosome (Figure 1C TJ, BD, SD) isolating and 
separating colloid from the intercellular spaces and basolateral apical membranes [9]. 
The thyrocytes’ nucleus is surrounded by abundant RER in the cells’ basal region (Figure 1C 
RER) and the GC is in the supra-nuclear region in normal physiological conditions (Figure 
1C N). The lysosomes are located in the thyrocytes’ basal media region (Figure 1C L). The 
mitochondria are distributed throughout the whole cell. 
The thyrocytes form depends on their functional state; they are cubic in normal conditions 
(euthyroid morphology) and have the aforementioned ultra-structure (Figure 1C). Without 
thyrotrophic or thyrotropin-stimulating hormone (TSH), endocytic vesicles disappear at the 
beginning and exocytosis increases and microvellosities become reduced. The lysosomes 
increase in size and have very heterogeneous content following several days without TSH; the 
follicular cavity increases after a few days and cells become thin and atrophied because the RER 
and GC become reduced. Such cells disappear following 20 or 30 days’ suppression of TSH 
(hypothyroid morphology). A rapid increase in exocytic vesicles (micropendocytosis) occurs 
when the gland is stimulated by TSH and the apical membrane forms cytoplasmic expansions 
or pseudopods forming large macroendocytic vesicles called colloid droplets; such vesicles 
merge with lysosomes which migrate to the cells’ apical region [10]. When TSH stimulation is 
sustained for more than 5 days, microvellosities’ length and amount increase, follicular cavities 
become reduced and the thyrocytes become cylindrical and hypertrophied because the RER and 
GC increase, occupying almost the whole of a cell (hyperthyroid morphology) [2,8,10,11]. 
1.2. Function 
T3 (3,5,3’-triiodine-thyronine) and T4 thyroid hormone (3,5,3’,5’- tetraiodine-thyronine) 
synthesis reflects thyrocytes’ follicular morphology and ultra-structure which can be 
divided into 3 stages (Figure 2 circles): stage 1, Tg synthesis and colloid secretion at  
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Figure 2. A. A diagram of a thyroid follicle surrounded by capillaries (Cap); Co: colloid. B. A diagram 
of a thyrocyte showing the physiology of thyroid hormone synthesis. Iodide is captured in the basement 
membrane by the sodium/iodide symporter or Na+/I- symporter (NIS) and rapidly transported to 
colloid, mainly via pendrin (P); it is used there for thyroid hormone synthesis. Tg is synthsised in the 
RER and N-osidic glycosylation culminates in the GC; Tg is secreted to colloid by exocytic vesicles 
(green circle 1). Once in colloid, thyroperoxidase (blue) with thyroid oxidase 1 or 2 (red) fixes iodide 
to Tg (red circle 2) forming iodine-thyronine on Tg (Tg-I). When thyroid hormones are required, Tg-I is 
endocyted by microvesicles or macrovesicles (blue circle 3) when TSH stimulates the thyroid. Tg-I 
becomes degraded by lysosomal enzymes (L) releasing T3 and T4 into the blood stream. N: nucleus; 
RER: rugose endoplasmic reticle; GC: Golgi complex; I-: ion iodide; NIS: Na+/I- symporter; EeE: early 
endosome; Pre: prelysosome or late endosome; L: lysosome; BMs: basements membranes or basals 
laminas; T3 and T4: thyroid hormones. Diagram modified from Spinel (2003) [12]. 
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intracellular level; stage 2, iodide accumulation and its organification regarding Tg in 
colloid at thyrocyte extracellular level; and stage 3, endocytosis and intracellular hormone 
secretion [5,12]. 
The first stage occurs at intracellular level, Tg is synthesised and glycosylated (N-osidic 
glycosylation) in RER and then glycosylation in culminates in the GC. Tg is transported in 
exocytic vesicles which emerge from the GC (Figure 2 green circle 1) and is released to the 
colloid [5]. Iodide accumulation takes place in the basal membrane via the sodium/iodide 
symporter (NIS) or Na+/I- symporter (Figure 2 NIS) [13]. It then passes through colloid via 
pendrin (I-/Cl- apical exchanger) [14] (Figure 2 P), regulated by the apical region’s ClC-5 
channel [15]. 
The second stage happens at extracellular level. Thyroperoxidase (TPO) is found in the base 
of microvellosities anchored to the apical membrane which oxides iodide (Figure 2 blue) 
and thyroid oxidases 1 or 2 (Duox1 and 2) forming H2O2 (Figure 2 red). TPO fixes one or two 
iodines on specific Tg thyrosins in colloid (iodide organification), thereby forming mono- 
and di-iodinethyrosins (Figure 2 circle 2). TPO couples the iodinethyrosins, producing 
iodine-thyronine or T3 and T4 hormones on Tg19S or thyroid prohormone (Figure 2 Tg-I); in 
both processes TPO reduces H2O2 [16,17]. 
The third stage is intracellular. Tg19S is endocyted [10] (Figure 2 blue circle 3) and degraded 
in prelysosomes [18] and in lysosomes (Figure2 Pre, L), releasing the hormones which 
become diffused through the basal membrane to the blood stream [19] where they are 
transported by three families of blood proteins to an organism’s cells [20,21]. 
Due to the thyroid’s morphological characteristics and its function, “it is an exquisitely 
regulated gland”, [22]. Its function is essentially controlled by the hypothalamus-
hypophysis and also by the nervous system and other thyroid systems [22]. Thyroid gland 
function and growth is controlled by TSH secreted by adenohypophysis thyreotropic cells. 
TSH secretion is stimulated by thyrotropin releasing hormones (TRH) secreted by the 
hypothalamus. TSH and TRH concentration in circulation are regulated by T3 and T4 
concentration; thyroid and TSH concentrations are regulated by iodide concentration in the 
blood stream obtained during daily intake [2,3,22,23,24,25]. 
TSH mainly activates the AMPc route which stimulates transcription factors (CREB, TTF-1 
and -2, PAX8) and culminates by activating the transcription and expression of molecules 
implicated in T3 and T4 hormone synthesis (i.e. NIS in basal membrane, Tg in RER and its 
exocytosis, TPO and Douxs in the apical membrane and H2O2 formation). TSH’s effect can 
be shown by increased T3 and T4 in the blood stream [26,27]. 
Normal iodide in circulation ranges from 10E-9 to 10E-7 M. Concentrations of this ion 
greater than 10E-5 inhibit T3 and T4 organification and synthesis during the first 48 h (called 
the Wolff-Chaikoff effect) [1], regardless of TSH concentration. Iodide organification 
inhibition directly depends on iodide intrathyroid accumulation [28]. This thyroid auto-
regulatory effect happens when inorganic iodine concentration in blood exceeds a set 
threshold (overload) and the gland blocks iodine’s organic binding for 48 h [1]. The gland 
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colloid [5]. Iodide accumulation takes place in the basal membrane via the sodium/iodide 
symporter (NIS) or Na+/I- symporter (Figure 2 NIS) [13]. It then passes through colloid via 
pendrin (I-/Cl- apical exchanger) [14] (Figure 2 P), regulated by the apical region’s ClC-5 
channel [15]. 
The second stage happens at extracellular level. Thyroperoxidase (TPO) is found in the base 
of microvellosities anchored to the apical membrane which oxides iodide (Figure 2 blue) 
and thyroid oxidases 1 or 2 (Duox1 and 2) forming H2O2 (Figure 2 red). TPO fixes one or two 
iodines on specific Tg thyrosins in colloid (iodide organification), thereby forming mono- 
and di-iodinethyrosins (Figure 2 circle 2). TPO couples the iodinethyrosins, producing 
iodine-thyronine or T3 and T4 hormones on Tg19S or thyroid prohormone (Figure 2 Tg-I); in 
both processes TPO reduces H2O2 [16,17]. 
The third stage is intracellular. Tg19S is endocyted [10] (Figure 2 blue circle 3) and degraded 
in prelysosomes [18] and in lysosomes (Figure2 Pre, L), releasing the hormones which 
become diffused through the basal membrane to the blood stream [19] where they are 
transported by three families of blood proteins to an organism’s cells [20,21]. 
Due to the thyroid’s morphological characteristics and its function, “it is an exquisitely 
regulated gland”, [22]. Its function is essentially controlled by the hypothalamus-
hypophysis and also by the nervous system and other thyroid systems [22]. Thyroid gland 
function and growth is controlled by TSH secreted by adenohypophysis thyreotropic cells. 
TSH secretion is stimulated by thyrotropin releasing hormones (TRH) secreted by the 
hypothalamus. TSH and TRH concentration in circulation are regulated by T3 and T4 
concentration; thyroid and TSH concentrations are regulated by iodide concentration in the 
blood stream obtained during daily intake [2,3,22,23,24,25]. 
TSH mainly activates the AMPc route which stimulates transcription factors (CREB, TTF-1 
and -2, PAX8) and culminates by activating the transcription and expression of molecules 
implicated in T3 and T4 hormone synthesis (i.e. NIS in basal membrane, Tg in RER and its 
exocytosis, TPO and Douxs in the apical membrane and H2O2 formation). TSH’s effect can 
be shown by increased T3 and T4 in the blood stream [26,27]. 
Normal iodide in circulation ranges from 10E-9 to 10E-7 M. Concentrations of this ion 
greater than 10E-5 inhibit T3 and T4 organification and synthesis during the first 48 h (called 
the Wolff-Chaikoff effect) [1], regardless of TSH concentration. Iodide organification 
inhibition directly depends on iodide intrathyroid accumulation [28]. This thyroid auto-
regulatory effect happens when inorganic iodine concentration in blood exceeds a set 
threshold (overload) and the gland blocks iodine’s organic binding for 48 h [1]. The gland 
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adapts once such 48 h have elapsed and organified iodide escapes, producing new 
hormones [29]; NIS expression becomes reduced at this time, as does iodide capture [30]. It 
has been suggested that there is a reduction in the function of the molecules implicated in 
organification and hormone formation: TPO, Duox 1 and 2, pendrin and Tg [30,31]. 
Thyrocytes in culture in the presence of 10-E3 M iodide reduce NIS expression and inhibit 
TPO and Tg synthesis [32]. Such reduction of NIS does not happen in hypothyroid mice, nor 
is Duox 1 and 2, TPO, pendrin and Tg gene expression modified [33]. An excess of iodide 
leads to iodide organification inhibition depending on TPO and not on NIS. TSH effects 
become reduced in the presence of strong concentrations of iodide, resulting in them 
adopting antagonic roles [34]. 
2. Thyroid culture 
2.1. Introduction 
Thyroid tissue fragments were kept on glass in saline solution, or in vitro (as this involved a 
glass vessel). Established the neuron cell theory, it has since been established that the unit of 
life is a cell (i.e. cell theory 1910) and cell culture or in vitro study began [35]. Cell cultures 
were then developed, thereby leading to studying cell functions in controlled conditions and 
different descriptions of culture mediums, supports and conditions have been developed 
from 1910. Fibroblasts in culture leave a matrix on culture surface on which endothelium 
cells from blood capillaries can be cultured; this has been called an extracellular matrix 
(ECM) [36]. Extracellular supports close to the ECM surrounding cells in vivo (such as 
collagen, laminin, fibronectin or matrigel) are currently being used [37]. 
New culture techniques were developed in 1975 in view of the close structure-function 
relationship, recognising the importance of organs’ functional units, such as isolating and 
culturing isles of Langerhans from the pancreas [38] or “acini” regions from the lactant 
mammary gland or epithelial structures which needed to be conserved in polarised cell 
culture [39]. Thyroid follicle incubations and cultures could also be mentioned here. 
A brief description of the most pertinent techniques for culturing the thyroid, isolated 
thyrocytes and/or thyroid follicles is given below. 
2.2. Organotypical culture or organ culture 
Organ culture or organotypical culture consists of culturing an organ’s fragments or 
explants. Regarding the thyroid, this began with 2 to 3 h incubations (the term usually used 
to refer to cultures lasting less than 24h) of sheep thyroid fragments in the presence of 
radioactive iodide thereby demonstrating in vitro the ion’s incorpoproportion into 
diiodinethyronine (DIT) and T4 [40]. When the transmission electron microscope was 
developed in the 1970s, this led to an ultra-structural description of thyrocytes in vitro; the 
first descriptions of thyrocytes’ morphological changes in different culture conditions were 
made. It was shown that organ culture thyrocytes had reduced RER and GC in the absence 
of TSH [41,42]. Thyrocyte follicular architecture and ultra-structure were rapidly lost in 
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some of the models which were described. Approaching the 1990s attempts were made to 
use very small fragments (less than 1mm3) in organ cultures (called mini organ cultures) 
which lasted 2 to 3 days without necrosis, exhibited iodide, sulphate and phosphate 
transport, synthesised a 19S Tg (normally glycosylated and iodised) [43] and were 
maintained for up to 7 days without cell death when coated with collagen [44] 
2.3. Isolation and monolayer culture or cell culture 
Monolayer culture (better known as cell culture) mainly deals with a single cell type. This 
implies tissue dissociation by enzymatic digestion or mechanical action and the isolation of 
cellular types by different sepaproportion methods. Isolated cells are placed on different 
types of supports where they adhere and proliferate in a single layer until reaching 
confluence (called primary culture). Secondary culture consists of sowing cells removed 
from the primary culture in fresh recipients and so on. The term passage is used to indicate 
the number of successive secondary culture sowings, thus the 1st secondary culture is the 1st 
cell passage. Thyrocytes were first cultured in 1911 [45]. Using this dissociation technique 
and continuous shaking during culture has shown that sheep thyrocytes concentrate 
radioactive iodide and incorporate it in iodine-thyronine: MIT, DIT and T4 [46]. Isolated and 
small cells, aggregates of 10 to 15 thyrocytes, are obtained after dissociation with trypsin 
[47,48]. One of the greatest drawbacks is the loss of cultured thyrocytes’ cellular polarity 
when one wishes to study thyroid physiology since such polarity is fundamental in 
conserving thyrocyte membrane domains, and thus the expression of domain-specific 
molecules guaranteeing hormone synthesis [49]. 
Thyrocyte cultures were developed in dual chambers during the 1990s on cubic monolayers 
as in vivo with binding complexes in the lateral membranes’ apical region, separating in 
thyrocytes’ the apical membrane domains from the basolateral membrane domains, TSH 
favouring such cellular polarisation [50]. This model has demonstrated that ion flow is 
determined by thyrocytes’ polarity, thereby corroborating the fact that ion channels are 
different in both thyrocytes membrane domains when thyrocytes’ cubic form is conserved. 
A new channel has been described for the thyrocytes’ apical membrane [51]; this new 
channel is CLC5 which is located in the apical region in vivo and it has been proposed that 
thyrocytes have a position in the apical membrane for controlling pendrin, the I-/Cl- 
transporter [15]. 
The foregoing has shown the importance of conserving cell polarity and cubic form in 
thyrocyte culture for studying the gland’s physiology and biochemistry. 
Cell lines are continually growing and indefinitely proliferating cell cultures because they 
have lost control over their own cell division, contrary to primary and secondary cell 
cultures which die after a finite number of passes or subcultures, as is genetically 
determined in normal cells. Thethyrocyte cell line was described [52,53]; Fischer rat thyroid 
cell line or FRTL is most used around the world as it has a more similar ultra-structure to 
thyrocytes and synthesised Tg. These have been very useful in studying gene expression, 
cytoskeleton modification with different factors, iodide flow and that of other ions. 
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adapts once such 48 h have elapsed and organified iodide escapes, producing new 
hormones [29]; NIS expression becomes reduced at this time, as does iodide capture [30]. It 
has been suggested that there is a reduction in the function of the molecules implicated in 
organification and hormone formation: TPO, Duox 1 and 2, pendrin and Tg [30,31]. 
Thyrocytes in culture in the presence of 10-E3 M iodide reduce NIS expression and inhibit 
TPO and Tg synthesis [32]. Such reduction of NIS does not happen in hypothyroid mice, nor 
is Duox 1 and 2, TPO, pendrin and Tg gene expression modified [33]. An excess of iodide 
leads to iodide organification inhibition depending on TPO and not on NIS. TSH effects 
become reduced in the presence of strong concentrations of iodide, resulting in them 
adopting antagonic roles [34]. 
2. Thyroid culture 
2.1. Introduction 
Thyroid tissue fragments were kept on glass in saline solution, or in vitro (as this involved a 
glass vessel). Established the neuron cell theory, it has since been established that the unit of 
life is a cell (i.e. cell theory 1910) and cell culture or in vitro study began [35]. Cell cultures 
were then developed, thereby leading to studying cell functions in controlled conditions and 
different descriptions of culture mediums, supports and conditions have been developed 
from 1910. Fibroblasts in culture leave a matrix on culture surface on which endothelium 
cells from blood capillaries can be cultured; this has been called an extracellular matrix 
(ECM) [36]. Extracellular supports close to the ECM surrounding cells in vivo (such as 
collagen, laminin, fibronectin or matrigel) are currently being used [37]. 
New culture techniques were developed in 1975 in view of the close structure-function 
relationship, recognising the importance of organs’ functional units, such as isolating and 
culturing isles of Langerhans from the pancreas [38] or “acini” regions from the lactant 
mammary gland or epithelial structures which needed to be conserved in polarised cell 
culture [39]. Thyroid follicle incubations and cultures could also be mentioned here. 
A brief description of the most pertinent techniques for culturing the thyroid, isolated 
thyrocytes and/or thyroid follicles is given below. 
2.2. Organotypical culture or organ culture 
Organ culture or organotypical culture consists of culturing an organ’s fragments or 
explants. Regarding the thyroid, this began with 2 to 3 h incubations (the term usually used 
to refer to cultures lasting less than 24h) of sheep thyroid fragments in the presence of 
radioactive iodide thereby demonstrating in vitro the ion’s incorpoproportion into 
diiodinethyronine (DIT) and T4 [40]. When the transmission electron microscope was 
developed in the 1970s, this led to an ultra-structural description of thyrocytes in vitro; the 
first descriptions of thyrocytes’ morphological changes in different culture conditions were 
made. It was shown that organ culture thyrocytes had reduced RER and GC in the absence 
of TSH [41,42]. Thyrocyte follicular architecture and ultra-structure were rapidly lost in 
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some of the models which were described. Approaching the 1990s attempts were made to 
use very small fragments (less than 1mm3) in organ cultures (called mini organ cultures) 
which lasted 2 to 3 days without necrosis, exhibited iodide, sulphate and phosphate 
transport, synthesised a 19S Tg (normally glycosylated and iodised) [43] and were 
maintained for up to 7 days without cell death when coated with collagen [44] 
2.3. Isolation and monolayer culture or cell culture 
Monolayer culture (better known as cell culture) mainly deals with a single cell type. This 
implies tissue dissociation by enzymatic digestion or mechanical action and the isolation of 
cellular types by different sepaproportion methods. Isolated cells are placed on different 
types of supports where they adhere and proliferate in a single layer until reaching 
confluence (called primary culture). Secondary culture consists of sowing cells removed 
from the primary culture in fresh recipients and so on. The term passage is used to indicate 
the number of successive secondary culture sowings, thus the 1st secondary culture is the 1st 
cell passage. Thyrocytes were first cultured in 1911 [45]. Using this dissociation technique 
and continuous shaking during culture has shown that sheep thyrocytes concentrate 
radioactive iodide and incorporate it in iodine-thyronine: MIT, DIT and T4 [46]. Isolated and 
small cells, aggregates of 10 to 15 thyrocytes, are obtained after dissociation with trypsin 
[47,48]. One of the greatest drawbacks is the loss of cultured thyrocytes’ cellular polarity 
when one wishes to study thyroid physiology since such polarity is fundamental in 
conserving thyrocyte membrane domains, and thus the expression of domain-specific 
molecules guaranteeing hormone synthesis [49]. 
Thyrocyte cultures were developed in dual chambers during the 1990s on cubic monolayers 
as in vivo with binding complexes in the lateral membranes’ apical region, separating in 
thyrocytes’ the apical membrane domains from the basolateral membrane domains, TSH 
favouring such cellular polarisation [50]. This model has demonstrated that ion flow is 
determined by thyrocytes’ polarity, thereby corroborating the fact that ion channels are 
different in both thyrocytes membrane domains when thyrocytes’ cubic form is conserved. 
A new channel has been described for the thyrocytes’ apical membrane [51]; this new 
channel is CLC5 which is located in the apical region in vivo and it has been proposed that 
thyrocytes have a position in the apical membrane for controlling pendrin, the I-/Cl- 
transporter [15]. 
The foregoing has shown the importance of conserving cell polarity and cubic form in 
thyrocyte culture for studying the gland’s physiology and biochemistry. 
Cell lines are continually growing and indefinitely proliferating cell cultures because they 
have lost control over their own cell division, contrary to primary and secondary cell 
cultures which die after a finite number of passes or subcultures, as is genetically 
determined in normal cells. Thethyrocyte cell line was described [52,53]; Fischer rat thyroid 
cell line or FRTL is most used around the world as it has a more similar ultra-structure to 
thyrocytes and synthesised Tg. These have been very useful in studying gene expression, 
cytoskeleton modification with different factors, iodide flow and that of other ions. 
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Such studies have led to advances being made in knowledge regarding some precise 
processes but there are limitations for extrapolating this to the gland in vivo because they are 
cells which lost certain control over their tissue of origin. 
2.4. Pseudofollicles 
Some of the main problems involved in thyroid physiology in vitro studies are the loss of 
follicle architecture, thyrocyte polarity and T3 and T4 hormone synthesis [54]. As mentioned 
above, the follicle lumen disappears in the monolayer with its colloid and the thyrocyte 
membrane domain polarity necessary for carrying out hormone synthesis [55,56]. However, 
tridimensional structures can be induced by covering monolayers with ECM elements, they 
become re-organised into two- to four-cell structures around the intercellular cavity in the 
presence of TSH, called pseudofollicles by some authors and “follicles” by others 
[54,56,57,58,59,60,61,62]. These pseudofollicles are unstable, short-duration structures and 
do not reproduced in vitro the function of iodide incorporation in Tg or synthesis of T3 or T4, 
and shown that follicle structures’ thyrocyte polarity is necessary for studying thyroid 
physiology and the molecular processes implicated in such function [63]. 
3. Follicles 
A new culture technique was developed from 1965 to 1980 where the functional unit of 
different epithelial organs, isles of Langerhans in the pancreas [64,65] or the acinar region of 
the mammary gland [39] are isolated and cultivated, conserving in vivo morphology.  
It is clear that conserving multicellular structures in vitro forming exocrine glands’ 
functional units depends on preserving apical-basal polarity for imitating in vivo functions; 
this is why attempts at characterising the factors generating polarity and which molecules 
allow maintaining 3D structures in vitro in mammary gland acini [66], the endocrine 
pancreas [67] or kidneys [68] are continued. 
The 1980s saw the beginning of 24-h thyroid follicle cultures [23,69,70,71,72,73,74] on 
agarose, to avoid cell adhesion and monolayer formation [75]. Such incubations showed that 
iodide organification and H2O2 production took place in colloid [23,72] and that rat 
thyrocitos of open and closed follicles incubated for 12 h on agarose conserved their apical-
basal polarity and in vivo ultra-structure, in basal region nucleus surrounded by RER, 
supranuclear GC, in apical region vesicles’ and microvellosities. As well as responding to 
TSH-forming pseudopods [16,23,75], synthetic TSH peptides bound in the basolateral 
membrane [76]. Closed follicles were maintained for up to 3 days [69] and responded to 
thyrocytes’ TSH, increasing RER [23]. TSH has stimulated pig and human open follicle 
thyrocyte function in culture during the first two days [49,74]. Pig open follicles cultured for 
48 h with forskolin have been used for determining the function of H2O2 formation which is 
important in hormone synthesis [77]. The presence of TSH- or forskolin-induced cyclic 
adenosine monophosphate (AMPc) route stimulants has been seen to be indispensable in 
these cultures and has reiterated the importance of conserving follicle structure in culture 
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for promoting hormone formation, as happens with thyroid gland apical membrane in vivo. 
It is so important that specific genes have been described which govern follicle formation 
and maintain follicle architecture, the gene transcribing the thyroid-specific enhancer-
binding protein (T/ebp or Nkx2.1) regulating the transcription of genes implicated in 
hormone synthesis: NIS, TPO, TSH receptor and Tg and re-organised transfecteds thyrocites 
in follicles [78]. Human goitre follicle structure has been covered with collagen to preserve it 
longer and cavities in human [79,80] and mouse thyrocyte [78] thin cell bilayers have 
persisted 2 days more. Collagen’s importance in preserving epithelial cells’ apical-basal 
polarity has been described for obtaining MDKC (Madin-Darby canine kidney epithelial cell 
line) cell 3D cultures, but hepatic growth factor (HGF) was added to cultures [81]. 
The methodology developed by our group for reproducibly obtaining closed follicles, 
conserving their architecture and function in culture analogously to that of the gland in vivo 
is described below. 
4. Method used 
Most of the first work on rat follicle culture was open and became disorganised during the 
first days of culture [16,23,72]. We based our approach on these rat thyroid dissociation 
techniques. We describe the importance of isolating closed follicles, their culture and long-
term response to TSH and iodide (9 and 12 days) and to increasing doses of iodide. Details 
are given of the isolation methodology, the morphological study of these isolated follicles 
and in culture at morphological level by inverted (IM) optical (OM), electron (TEM) and 
(CM) confocal microscope and their functional study: iodide accumulation and 
organification, Tg, T3, T4 synthesis and NIS localisation. 
4.1. Isolation and closed follicle culture 
Wistar rat (200g) and ICR mouse (30g) thyroid was used; the animals were obtained from 
the Universidad Nacional de Colombia’s Bioterium. Pig Cialta and strain 769 thyroid was 
provided by two slaughterhouses in Bogotá. Some having sub-clinical hyperthyroidism due 
to - energetic injection, having T3 (1.34 ng/dL) and T4 (107.0 ng/dL) within the normal range 
and excessively low TSH (<0.005 mUI/mL), were called hypothyroidic, as morphologically 
and functionally described in mice [33], whilst the others were called euthyroidic. The 
animals were handled according to Colombian considerations for animals being used in 
research and care of animals for domestic consumption.  
The methodology mainly involved rat thyroid and was corroborated in mouse thyroid. 
Obtaining human thyroid fragments is difficult; pig was thus used due to its similarity with 
human metabolism [82,83,84,85,86], even though it is hoped to begin cultures with human 
thyroid in the near future. The differences between rodents and pig had to be considered. 
General metabolism regulated by the thyroid gland in rodents is 10 times greater than that 
in pigs and humans. Follicle diameter ranges from 50 to 150 μm in rodents, whilst this is 150 
to 500 μm in pigs and humans. Rodent lobes range from 3 to 5 mm3 at their widest whilst 
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Such studies have led to advances being made in knowledge regarding some precise 
processes but there are limitations for extrapolating this to the gland in vivo because they are 
cells which lost certain control over their tissue of origin. 
2.4. Pseudofollicles 
Some of the main problems involved in thyroid physiology in vitro studies are the loss of 
follicle architecture, thyrocyte polarity and T3 and T4 hormone synthesis [54]. As mentioned 
above, the follicle lumen disappears in the monolayer with its colloid and the thyrocyte 
membrane domain polarity necessary for carrying out hormone synthesis [55,56]. However, 
tridimensional structures can be induced by covering monolayers with ECM elements, they 
become re-organised into two- to four-cell structures around the intercellular cavity in the 
presence of TSH, called pseudofollicles by some authors and “follicles” by others 
[54,56,57,58,59,60,61,62]. These pseudofollicles are unstable, short-duration structures and 
do not reproduced in vitro the function of iodide incorporation in Tg or synthesis of T3 or T4, 
and shown that follicle structures’ thyrocyte polarity is necessary for studying thyroid 
physiology and the molecular processes implicated in such function [63]. 
3. Follicles 
A new culture technique was developed from 1965 to 1980 where the functional unit of 
different epithelial organs, isles of Langerhans in the pancreas [64,65] or the acinar region of 
the mammary gland [39] are isolated and cultivated, conserving in vivo morphology.  
It is clear that conserving multicellular structures in vitro forming exocrine glands’ 
functional units depends on preserving apical-basal polarity for imitating in vivo functions; 
this is why attempts at characterising the factors generating polarity and which molecules 
allow maintaining 3D structures in vitro in mammary gland acini [66], the endocrine 
pancreas [67] or kidneys [68] are continued. 
The 1980s saw the beginning of 24-h thyroid follicle cultures [23,69,70,71,72,73,74] on 
agarose, to avoid cell adhesion and monolayer formation [75]. Such incubations showed that 
iodide organification and H2O2 production took place in colloid [23,72] and that rat 
thyrocitos of open and closed follicles incubated for 12 h on agarose conserved their apical-
basal polarity and in vivo ultra-structure, in basal region nucleus surrounded by RER, 
supranuclear GC, in apical region vesicles’ and microvellosities. As well as responding to 
TSH-forming pseudopods [16,23,75], synthetic TSH peptides bound in the basolateral 
membrane [76]. Closed follicles were maintained for up to 3 days [69] and responded to 
thyrocytes’ TSH, increasing RER [23]. TSH has stimulated pig and human open follicle 
thyrocyte function in culture during the first two days [49,74]. Pig open follicles cultured for 
48 h with forskolin have been used for determining the function of H2O2 formation which is 
important in hormone synthesis [77]. The presence of TSH- or forskolin-induced cyclic 
adenosine monophosphate (AMPc) route stimulants has been seen to be indispensable in 
these cultures and has reiterated the importance of conserving follicle structure in culture 
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for promoting hormone formation, as happens with thyroid gland apical membrane in vivo. 
It is so important that specific genes have been described which govern follicle formation 
and maintain follicle architecture, the gene transcribing the thyroid-specific enhancer-
binding protein (T/ebp or Nkx2.1) regulating the transcription of genes implicated in 
hormone synthesis: NIS, TPO, TSH receptor and Tg and re-organised transfecteds thyrocites 
in follicles [78]. Human goitre follicle structure has been covered with collagen to preserve it 
longer and cavities in human [79,80] and mouse thyrocyte [78] thin cell bilayers have 
persisted 2 days more. Collagen’s importance in preserving epithelial cells’ apical-basal 
polarity has been described for obtaining MDKC (Madin-Darby canine kidney epithelial cell 
line) cell 3D cultures, but hepatic growth factor (HGF) was added to cultures [81]. 
The methodology developed by our group for reproducibly obtaining closed follicles, 
conserving their architecture and function in culture analogously to that of the gland in vivo 
is described below. 
4. Method used 
Most of the first work on rat follicle culture was open and became disorganised during the 
first days of culture [16,23,72]. We based our approach on these rat thyroid dissociation 
techniques. We describe the importance of isolating closed follicles, their culture and long-
term response to TSH and iodide (9 and 12 days) and to increasing doses of iodide. Details 
are given of the isolation methodology, the morphological study of these isolated follicles 
and in culture at morphological level by inverted (IM) optical (OM), electron (TEM) and 
(CM) confocal microscope and their functional study: iodide accumulation and 
organification, Tg, T3, T4 synthesis and NIS localisation. 
4.1. Isolation and closed follicle culture 
Wistar rat (200g) and ICR mouse (30g) thyroid was used; the animals were obtained from 
the Universidad Nacional de Colombia’s Bioterium. Pig Cialta and strain 769 thyroid was 
provided by two slaughterhouses in Bogotá. Some having sub-clinical hyperthyroidism due 
to - energetic injection, having T3 (1.34 ng/dL) and T4 (107.0 ng/dL) within the normal range 
and excessively low TSH (<0.005 mUI/mL), were called hypothyroidic, as morphologically 
and functionally described in mice [33], whilst the others were called euthyroidic. The 
animals were handled according to Colombian considerations for animals being used in 
research and care of animals for domestic consumption.  
The methodology mainly involved rat thyroid and was corroborated in mouse thyroid. 
Obtaining human thyroid fragments is difficult; pig was thus used due to its similarity with 
human metabolism [82,83,84,85,86], even though it is hoped to begin cultures with human 
thyroid in the near future. The differences between rodents and pig had to be considered. 
General metabolism regulated by the thyroid gland in rodents is 10 times greater than that 
in pigs and humans. Follicle diameter ranges from 50 to 150 μm in rodents, whilst this is 150 
to 500 μm in pigs and humans. Rodent lobes range from 3 to 5 mm3 at their widest whilst 
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this is 3 to 5 cm3 in pigs and humans, meaning that many rodents must be sacrificed for each 
experiment; 30% to 40% of a pig’s lobe is used. Rodents’ capsule is thin and the parenchyma 
does not have large amounts of connective tissue; this capsule is thick in pigs and connective 
tissue septa are very abundant and extensive. Shaving razors are used for stereoscopic 
micro-dissection. The capsule of rat and mice lobes is eliminated; each is cut in two along its 
major axis whilst pig lobes are opened in two with a scalpel and cut into 7 to 10 mm3 
fragments. Connective tissue is then eliminated as far as possible using stereoscopic 
microdissection with razors without affecting the parenchyma. Around 3 mm3 fragments 
are obtained (similar to rodent fragments) without connective tissue visible by stereoscope.  
The thyroid fragments are put together and washed 3 times with COON medium [55], 
enzymatically dissociated with collagenase II which digests collagen (250 U/mL rodents; 400 
U/mL pig) and 2 g/mL DNase 1 (nb, the original article [82] read “2 mg/ml DNase I” when 
it should have been 2 μg/ml). Dead cells form aggregates which are avoided with DNase 
which only dead cells’ DNA digest and become fragmented; live follicle cells or fragments 
become attached to these aggregates if DNase is not added [23]. 
Thyroid fragments become dissociated in enzyme solution in COON medium at 37ºC and 
being shaken at 140 oscillations per minute; without delay, they are mechanically 
dissociated in this solution, aspirating and expelling enzyme solution containing thyroid 
fragments with 20 mL pipettes (3 to 5mm distal diameter; extreme for liquid entry and exit 
from pipettes), 10 times. The technique with rodent fragments continues with 10mL pipettes 
(1.5 mm distal diameter), 10 times. Such pipette dissociation is done at 10 min intervals 
during enzyme dissociation (i.e. the supernatant containing isolated follicles is collected 
every 10 min after pipette dissociation and fresh enzyme solution added for the following 10 
min). This is done three times x 10 min with rodent thyroid and 6 x 10 min with pig thyroid; 
this is a modification of already described dissociation [16,23,72] and is most important for 
avoiding follicle opening. Most follicles are isolated during a second dissociation for rats 
and mice and in a third and fourth for pigs. 
The follicles isolated during each 10 min interval are washed 3 times with COON + 2% foetal 
calf serum (FCS) spun at 50g for rodent follicles and 30g for pig follicles. This must be done 
in a free rotor centrifuge using low centrifugal force, otherwise centrifugal pressure opens 
up many follicles. All the follicles are placed together and filtered through 100 m pore 
diameter mesh for rodents; those for pigs are left to decant at 1g for 10 min. Dissociation pre-
incubation or recuperation time is continued for 4 h for rats and mice and 12 h for pigs in 
COON medium + 0.5% FCS in a 95% air - 5% CO2 atmosphere and 100% humidity on 1% 
agarose type I (less grouping than with agarose type II) to avoid cells adhering to the 
support [44,75]. Culture medium (the same as pre-incubation) is changed for aspiration with 
follicles; it is spun at 50g for rodents and 30g for pigs. The supernatant is skimmed off and 
fresh medium added to begin culture in the same ambient conditions and on agarose type I; 
the same is done for changing medium when making the culture. 
Undissociated fragments (around 0.8 mm3) remaining after enzyme dissociation are washed 
3 times with COON + 2 % FCS and cultured in the same conditions as for follicles but with 
2% FCS. This has been called mini organ culture, according to Bauer and Herzog [43]. 
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Different supports have been tried for maintaining follicular architecture, such as glass, 
plastic, collagen or collagen coated (1mg/mL), and 1%, 5% and 10% FCS concentration. 
Closed follicles are conserved in culture; however, thyrocyte monolayers grow 
proportionally to serum concentration in the medium. Monolayer growth should be avoided 
because this increases iodide accumulation values and interferes with analysis of iodide 
organification function; fresh enzyme dissociation must be carried out to recover the follicles 
[82,86]. When follicular cell fragments are cultured in collagen they do not reform follicles as 
has been described for human [79,80] and mouse thyrocytes [78]; some MDKC epithelial 
cells are organised in follicle-like structures requiring HGF [81]. The foregoing meant that 
the use of glass, plastic and collagen for follicle culture was rejected and agarose type I used 
instead.  
Follicles’ functional and morphological state was controlled before beginning the cultures by 
5% Trypan blue exclusion exam [87], cell viability was determined by IM which also 
allowed visualising open or closed follicle architecture. Thyrocyte viability is usually around 
100% immediately after isolation and before beginning pre-incubation. Cells which do not 
exclude Trypan blue are usually endothelium cells bound to follicle periphery (Figure 3B 
solid black arrows) or follicular fragment aggregate thyrocytes (Figure 3B circle). 
Iodide accumulation and organification is determined (5 Ci/mL Na125I, 4 h) for ensuring a 
high percentage of closed follicles; the importance of this control before beginning culture is 
described and discussed 125I in 6.1. Importance of obtaining closed follicles.  
Follicles are culture for 0, 1, 3, 6, 9 and 12 days with TSH and without TSH (1 and 0.1 
mU/mL rat; 1 mU/mL pig) in the same conditions as for pre-incubation. Culture medium is 
changed during these days aspirating it with the follicles and spinning at 50g for rat and 30 g 
pig, discarding the supernatant which usually contains cell and follicle fragments. The 
follicles are examined by IM during each stage. 5 Ci/mL Na125I is added each culture day 4 
h before collecting the follicles for morphological and functional studies. 
The follicles are cultured for 1 day with and without TSH (0.1 mU/mL rats; 1 mU/mL pigs) 
for studying the effect of different iodide concentrations. The medium is changed and the 
follicles cultured for 0.5, 3, 8, 12, 24 and 48 h with 10E-10, 10E-7, 10E-5, 10E-3 M Na127I and 
Na125I 5 μCi/mL (kindly donated by Manuel E Patarroyo) with and without TSH. The 
follicles are collected after such treatment for morphological and functional analysis. 
4.2. Morphological studies 
Morphological study involves impregnating follicles in Epon resin; follicles are spun at 300g 
for dehydratation before being impregnated in the resin [23,82,83]. Semi-fine, 
autoradiographed slices are observed by OM and ultra-fine slices by TEM. 
Protein synthesis and NIS expression reduce excess iodide [30,31,32] and (bearing in mind 
that NIS has not been described in closed follicle cultures) the presence of NIS is determined 
in culture in the presence of different iodide and TSH concentrations, with anti-NIS/GS 
antibodies (1:500, kindly donated by Thierry Pourcher) and Alexa 488 anti-rabbit secondary 
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this is 3 to 5 cm3 in pigs and humans, meaning that many rodents must be sacrificed for each 
experiment; 30% to 40% of a pig’s lobe is used. Rodents’ capsule is thin and the parenchyma 
does not have large amounts of connective tissue; this capsule is thick in pigs and connective 
tissue septa are very abundant and extensive. Shaving razors are used for stereoscopic 
micro-dissection. The capsule of rat and mice lobes is eliminated; each is cut in two along its 
major axis whilst pig lobes are opened in two with a scalpel and cut into 7 to 10 mm3 
fragments. Connective tissue is then eliminated as far as possible using stereoscopic 
microdissection with razors without affecting the parenchyma. Around 3 mm3 fragments 
are obtained (similar to rodent fragments) without connective tissue visible by stereoscope.  
The thyroid fragments are put together and washed 3 times with COON medium [55], 
enzymatically dissociated with collagenase II which digests collagen (250 U/mL rodents; 400 
U/mL pig) and 2 g/mL DNase 1 (nb, the original article [82] read “2 mg/ml DNase I” when 
it should have been 2 μg/ml). Dead cells form aggregates which are avoided with DNase 
which only dead cells’ DNA digest and become fragmented; live follicle cells or fragments 
become attached to these aggregates if DNase is not added [23]. 
Thyroid fragments become dissociated in enzyme solution in COON medium at 37ºC and 
being shaken at 140 oscillations per minute; without delay, they are mechanically 
dissociated in this solution, aspirating and expelling enzyme solution containing thyroid 
fragments with 20 mL pipettes (3 to 5mm distal diameter; extreme for liquid entry and exit 
from pipettes), 10 times. The technique with rodent fragments continues with 10mL pipettes 
(1.5 mm distal diameter), 10 times. Such pipette dissociation is done at 10 min intervals 
during enzyme dissociation (i.e. the supernatant containing isolated follicles is collected 
every 10 min after pipette dissociation and fresh enzyme solution added for the following 10 
min). This is done three times x 10 min with rodent thyroid and 6 x 10 min with pig thyroid; 
this is a modification of already described dissociation [16,23,72] and is most important for 
avoiding follicle opening. Most follicles are isolated during a second dissociation for rats 
and mice and in a third and fourth for pigs. 
The follicles isolated during each 10 min interval are washed 3 times with COON + 2% foetal 
calf serum (FCS) spun at 50g for rodent follicles and 30g for pig follicles. This must be done 
in a free rotor centrifuge using low centrifugal force, otherwise centrifugal pressure opens 
up many follicles. All the follicles are placed together and filtered through 100 m pore 
diameter mesh for rodents; those for pigs are left to decant at 1g for 10 min. Dissociation pre-
incubation or recuperation time is continued for 4 h for rats and mice and 12 h for pigs in 
COON medium + 0.5% FCS in a 95% air - 5% CO2 atmosphere and 100% humidity on 1% 
agarose type I (less grouping than with agarose type II) to avoid cells adhering to the 
support [44,75]. Culture medium (the same as pre-incubation) is changed for aspiration with 
follicles; it is spun at 50g for rodents and 30g for pigs. The supernatant is skimmed off and 
fresh medium added to begin culture in the same ambient conditions and on agarose type I; 
the same is done for changing medium when making the culture. 
Undissociated fragments (around 0.8 mm3) remaining after enzyme dissociation are washed 
3 times with COON + 2 % FCS and cultured in the same conditions as for follicles but with 
2% FCS. This has been called mini organ culture, according to Bauer and Herzog [43]. 
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antibodies (1:1,000). The nuclei are visualised using DAPI/PBS (1:9,000). Follicles are 
compressed on commercial laminas as their diameter is greater than that of cells; a 1 mm 
high chamber was constructed to enable observing by CM without follicular compression. 
4.3. Functional studies 
Iodide organification (which is essential in thyroid hormone synthesis) becomes lost during 
the first days in the thyroid culture models described to date. Functional analysis of follicles 
in culture for determining whether follicular architecture is conserved has advantages over 
other cultures regarding hormone synthesis.  
Follicles’ accumulated and organified 125I-radiactivity is determined by  well counter. Rat 
follicles are washed 3 times for 5 min at 50g and at 30g for pig follicles with COON + Na127I 
(cold) 100 times the concentration of radioactive iodide used in culture and the radioactivity 
arising from accumulated (A) is determined. 10% trichloroacetic acid + Na127I 100 times the 
radioactive iodide concentration used in culture is then added and the radioactivity present 
in protein precipitate corresponding to protein binding iodide (PBI) or iodide organification 
(O) is determined. 
The precipitate is used for determining the amount of DNA by diphenylamine method [88], 
Tg19S by HPLC and iodine-thyronine (MIT, DIT, T3, rT3 and T4) in Tg by inverse-phase 
HPLC [89]. The results are expressed in % iodide dose in g DNA. Follicle structure does 
not allow the number of cells to be counted and statistical analysis requires having a 
parameter letting the results be homogenised; based on 1 pg DNA/mL equals 2E5 cells, the 
number of cells present in cultures can be determined and the results statistically correlated 
[82]. 
4.4. Statistical analysis 
Data given in the text are expressed as mean standard deviation for N values. Significant 
differences are established between some times for A and O variables by Student’s t-test. 
5. Results 
Closed follicular architecture is indispensable in agarose culture since open follicles become 
dissociated and cells die; it is thus essential to begin with maximum closed follicles possible 
to avoid this. The following item gives the criteria determined important for beginning 
culture. Then, the long-term culture results in which closed and isolated follicle morphology 
and function were compared. Last, the morphological and functional results in the presence 
of different doses of iodide and TSH. 
5.1. The importance of obtaining closed follicles for culturing them 
Many isolated cells and follicular fragments were obtained when thyrocytes became 
detached after 30 contiguous min, instead of 10 minute enzyme dissociation time (Figure 
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3A); these thyrocytes were eliminated 24 h later when culture medium was changed. If some 
fragments persisted after 1 or 2 days’ culture they became dissociated and thyrocytes died 
because they could not adhere to the agarose covered culture support [75] since normal cells 
require support for growing in culture. Trypan blue allowed an approximation of follicles’  
 
Figure 3. A. A follicle fragment from euthyroidic pig thyroid dissociated for 30 min without 
interruption pre-incubated for 12 h. Note the contour of thyrocytes which became detached from the 
follicular fragment and cell waste in culture support. B. Trypan blue for recently isolated rat thyroid 
follicles by strong dissociation (Strong dissociation, Table 1). Follicles which did not open (star) 
conserved colloid birefrigence and a clear and continuous boundary between colloid and cells, whilst 
those which became resealed (clear arrow) lost colloid birefrigence and the boundary between cavity 
and cells was not clear. Openings could be seen in those which did not reseal (triangles beam). Cells 
which did not exclude stain were mainly endothelium cells found in follicle periphery (solid arrows). 
Follicle fragments presented non-viable thyrocyte aggregates (circle). C. Pig euthyroid resealed follicles 
12 h pre-incubation. Note that the thyrocytes’ apical boundaries could be distinguished due to a lack of 
colloid. D. Trypan blue of closed follicle with colloid birefrigence of pig hypothyroids pre-incubated for 
12 h; colloid was birefrigent and the boundary between colloid and thyrocytes was clear and continuous 
(IM. Scale bar: A 20 μm, B 50 μm, C 15 μm, D 70 μm). 
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antibodies (1:1,000). The nuclei are visualised using DAPI/PBS (1:9,000). Follicles are 
compressed on commercial laminas as their diameter is greater than that of cells; a 1 mm 
high chamber was constructed to enable observing by CM without follicular compression. 
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in culture for determining whether follicular architecture is conserved has advantages over 
other cultures regarding hormone synthesis.  
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in protein precipitate corresponding to protein binding iodide (PBI) or iodide organification 
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The precipitate is used for determining the amount of DNA by diphenylamine method [88], 
Tg19S by HPLC and iodine-thyronine (MIT, DIT, T3, rT3 and T4) in Tg by inverse-phase 
HPLC [89]. The results are expressed in % iodide dose in g DNA. Follicle structure does 
not allow the number of cells to be counted and statistical analysis requires having a 
parameter letting the results be homogenised; based on 1 pg DNA/mL equals 2E5 cells, the 
number of cells present in cultures can be determined and the results statistically correlated 
[82]. 
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Data given in the text are expressed as mean standard deviation for N values. Significant 
differences are established between some times for A and O variables by Student’s t-test. 
5. Results 
Closed follicular architecture is indispensable in agarose culture since open follicles become 
dissociated and cells die; it is thus essential to begin with maximum closed follicles possible 
to avoid this. The following item gives the criteria determined important for beginning 
culture. Then, the long-term culture results in which closed and isolated follicle morphology 
and function were compared. Last, the morphological and functional results in the presence 
of different doses of iodide and TSH. 
5.1. The importance of obtaining closed follicles for culturing them 
Many isolated cells and follicular fragments were obtained when thyrocytes became 
detached after 30 contiguous min, instead of 10 minute enzyme dissociation time (Figure 
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3A); these thyrocytes were eliminated 24 h later when culture medium was changed. If some 
fragments persisted after 1 or 2 days’ culture they became dissociated and thyrocytes died 
because they could not adhere to the agarose covered culture support [75] since normal cells 
require support for growing in culture. Trypan blue allowed an approximation of follicles’  
 
Figure 3. A. A follicle fragment from euthyroidic pig thyroid dissociated for 30 min without 
interruption pre-incubated for 12 h. Note the contour of thyrocytes which became detached from the 
follicular fragment and cell waste in culture support. B. Trypan blue for recently isolated rat thyroid 
follicles by strong dissociation (Strong dissociation, Table 1). Follicles which did not open (star) 
conserved colloid birefrigence and a clear and continuous boundary between colloid and cells, whilst 
those which became resealed (clear arrow) lost colloid birefrigence and the boundary between cavity 
and cells was not clear. Openings could be seen in those which did not reseal (triangles beam). Cells 
which did not exclude stain were mainly endothelium cells found in follicle periphery (solid arrows). 
Follicle fragments presented non-viable thyrocyte aggregates (circle). C. Pig euthyroid resealed follicles 
12 h pre-incubation. Note that the thyrocytes’ apical boundaries could be distinguished due to a lack of 
colloid. D. Trypan blue of closed follicle with colloid birefrigence of pig hypothyroids pre-incubated for 
12 h; colloid was birefrigent and the boundary between colloid and thyrocytes was clear and continuous 
(IM. Scale bar: A 20 μm, B 50 μm, C 15 μm, D 70 μm). 
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closed or open state (Figure 3B); those conserving colloid showed up due to birefringence in 
IM and there was a clear boundary between colloid and cells (Figures 3B star and 3D) whilst 
those which became resealed lost their colloid birefringence and the boundary between 
cavity and cells was not clear (Figures 3B clear arrow and 3C). Openings in follicles which 
did not become resealed appeared (Figure 3B triangles beam) as did colloid loss. Cells which 
did not exclude the stain were mainly endothelium cells which were found on follicle 
periphery (Figure 3B black arrows). Follicle fragments could be seen because they lost 
follicular structure and organisation continued from thyrocytes’ epithelial layer (Figure 3B 
circle). 
Follicle morphology and function were analysed after 4 hours’ labelling with radioactive 
iodide, varying according to the dissociation procedure used with and without pre-
incubation. If pipette dissociation after each 10 min enzyme digestion was done in such a 
way that hydrodynamic forces were produced with turbulence, this was called strong 
dissociation, but when this was done slowly without turbulence in the liquid and avoiding 
air-bubble formation it was called mild dissociation. 
Iodide which did not bind to molecules was eliminated in fixation liquid until being 
impregnated in resin; labelling in autoradiographs (following pre-incubation, added for 2 h 
in the presence of Na125I 5 Ci/mL) was that which bound to proteins and was equivalent to 
organified iodide. The number of closed follicles could thus be counted and distinguished 
from open ones by autoradiographs. Open follicles were numerous in strong dissociation; 
they could be seen because no organified iodide was concentrated within follicle interior 
(Figure 4A star) even though histological cross-sections seemed to suggest that the cubic 
epithelial layer continued (Figure 4A circle). There were much fewer open follicles if 
dissociation was mild (Figure 4B). Follicles which resealed could be distinguished because, 
even though the labelling was homogeneous, it was less intense in colloid than in those 
which remained closed (Figure 4B arrow).  
Pre-incubation time was another key aspect for obtaining a maximum of closed follicles at 
the beginning of culture (4 h for rat follicles and 12 h for pig follicles when this was divided 
into 4 initial hours in which medium was changed by aspirating the medium with follicles 
and spinning at 30g x 5 min followed by pre-incubation for 8 h). The pre-incubation period 
was essential since this time allowed cells to recover from the aggression of the enzyme used 
for dissociation. 
Pre-incubation time following dissociation promoted an increase in closed follicles with two 
dissociations (strong or mild, 33% and 46%, respectively, Table 1). Open follicles which did 
become resealed or follicular fragments (Figure 4A) became disorganised and were 
discarded in the supernatant when changing the medium and spinning to wash them. 
Morphological modifications included modification of the amount of iodide accumulated 
and organified by follicles (Table 1); if dissociation was mild, iodide accumulation (A) and 
organification (O) values and O/A percentage increased following pre-incubation time, 
whereas if dissociation was strong then these values were lower. 
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Figure 4. Autoradiograph of dissociated follicles (following pre-incubation, they were added for 2 h in the 
presence of 5 Ci/mL Na125I). Iodide ions which did not bind to proteins were eliminated while washing the 
histotechnic preparation until being impregnated in resin. Closed follicles were labelled in the follicle centre 
even though they became resealed (arrow). A. Follicles isolated by strong dissociation (aliquot of follicles 
from Table 1, strong dissociation with pre-incubation). Follicles seeming to be closed by histological cross-
section but which did not accumulate organified iodide in colloid were open follicles (circle). B. Most 
follicles isolated by mild dissociation (aliquot of follicles from Table 1, mild dissociation with pre-incubation) 
were closed because of intense labelling within follicular cavities (OM. Toluidine bleu. Scale bar: 25 μm). 
Closed follicles counted on autoradiographies corresponded to O/A proportion percentage; 
thus mild dissociation gave 83% closed follicles and 85% O/A proportion whilst strong 
dissociation gave 45% closed and 58% O/A proportion (Table 1). 
Follicles isolated by mild dissociation, following 2 h with radioactive iodide, accumulated 
iodide 4.8 times and 7.8 times more with 0.1 and 1 mU/mL TSH, respectively, regarding 
without TSH. TSH did not modify morphology regarding follicular architecture or O/A 
proportion (Table 2). 
This follicle isolation method can be applied to other thyroid tissues from other species, such 
as rabbits or humans. The percentage of open follicles was greater in pig or human thyroid 
follicles and more tissue was obtained per experiment; 12 h was thus allowed for pre-
incubation (Figures 4C and 4D).  
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Figure 4. Autoradiograph of dissociated follicles (following pre-incubation, they were added for 2 h in the 
presence of 5 Ci/mL Na125I). Iodide ions which did not bind to proteins were eliminated while washing the 
histotechnic preparation until being impregnated in resin. Closed follicles were labelled in the follicle centre 
even though they became resealed (arrow). A. Follicles isolated by strong dissociation (aliquot of follicles 
from Table 1, strong dissociation with pre-incubation). Follicles seeming to be closed by histological cross-
section but which did not accumulate organified iodide in colloid were open follicles (circle). B. Most 
follicles isolated by mild dissociation (aliquot of follicles from Table 1, mild dissociation with pre-incubation) 
were closed because of intense labelling within follicular cavities (OM. Toluidine bleu. Scale bar: 25 μm). 
Closed follicles counted on autoradiographies corresponded to O/A proportion percentage; 
thus mild dissociation gave 83% closed follicles and 85% O/A proportion whilst strong 
dissociation gave 45% closed and 58% O/A proportion (Table 1). 
Follicles isolated by mild dissociation, following 2 h with radioactive iodide, accumulated 
iodide 4.8 times and 7.8 times more with 0.1 and 1 mU/mL TSH, respectively, regarding 
without TSH. TSH did not modify morphology regarding follicular architecture or O/A 
proportion (Table 2). 
This follicle isolation method can be applied to other thyroid tissues from other species, such 
as rabbits or humans. The percentage of open follicles was greater in pig or human thyroid 
follicles and more tissue was obtained per experiment; 12 h was thus allowed for pre-
incubation (Figures 4C and 4D).  
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Digestion conditions % follicles closes A O % O/A 
Without pre-incubation
Mild dissociation 57 ± 1,4 1.14 ± 0,01 0.89 ± 0,01 78 
Strong dissociation 45 ± 5,7 1.84 ± 0,37 1.08 ± 0,14 58 
With pre-incubation 4 hours
Mild dissociation 83 ± 1,4 1.93 ± 0,24 1.64 ± 0,17 85 
Strong dissociation 60 ± 7,1 1.32 ± 0,17 0.91 ± 0,01 68 
Table 1. Influence of dissociation conditions and pre-incubation time on the percentage of rat thyroid 
isolated and closed follicles and their function. It can be seen that the percentage of organified iodide on 
accumulated iodide (O/A) was equivalent to the percentage of closed follicles concentrating radioactive 
ion determined by follicle count using accumulated grains in follicular colloid in autoradiography of 
semi-fine cross-sections (Figure 4). Average values for two culture dishes ± SD. Following pre-
incubation, 125I- accumulation (A) and incorporation in proteins (O) were determined following 2 h in 
the presence of Na125I 5 Ci/mL and expressed in μg/dose/μg DNA. 
TSH A O % O/A 
None 0.73 ± 0,18 0.58 ± 0,11 79 
0,1mU/mL 3.48 ± 0,17 2.78 ± 0,04 80 
1mU/mL 5.71 ± 0,72 4.98 ± 0,67 87 
Table 2. Influence of TSH on iodide accumulation and organification in isolated rat follicles expressed 
in μg/dose/μg DNA. Follicles were cultured for 2 h in the presence of Na125I 5Ci/mL immediately 
following pre-incubation. TSH was stimulated by Na125I but O/A proportion was around 80% with or 
without TSH. The value without TSH represented the percentage of closed follicles obtained following 
correct mechanical dissociation and pre-incubation of follicles. Average values for culture dishes ± SD 
(these values were representative of 3 experiments). 
A good approximation of the percentage of closed follicles following pre-incubation must 
thus be born in mind (this corresponded to day 0 in our cultures). It can thus be generalised 
that O/A proportion values should be greater than 80% before beginning culture (day 0, Table 
2) and that there should be a potentially high number of closed follicles, even though follicle 
diameter may vary in each species or come from different thyroid functional states [85,86,90]. 
Open follicles’ ability to reveal themselves during the course of pre-incubation probably 
depended on the degree of initial opening. Even though groupings of rat thyroid cells 
became organised in the presence of TSH and on agarose, they became reorganised into 6- to 
10-cell follicles which could be cultured for 3 days [69,73]. In our results, rat or pig follicles 
which became resealed did not require TSH for conserving their follicular architecture. 
5.2. Long-term closed follicle culture 
5.2.1. Functional study 
On day zero (4 h pre-incubation in the presence of radioactive iodide) follicles accumulated 
3.5 ± 2.1% of the dose in the medium without TSH (9 experiments in rats). Organified iodide 
percentage varied according to closed follicle percentage at the start of each experiment. 
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O/Aprioportion was 57% in experiment 1 and 91% in experiment 2 (Table 3); more than two 
thirds of organified iodide bound to stable Tg19S (Table 4), the rest of the molecules having 
lower molecular weight. Capture increased in the presence of TSH regarding without TSH 
250 ± 210% (9 experiments in rats), but O/A percentage remained constant. The effect of TSH 
was evident on A and O, and higher than values without TSH (Tables 2, 3 and 4). Iodide 
accumulation on Tg19S slightly increased with TSH, but not significantly so (Table 4). 
Exp. 1 Exp. 2
TSH 0.0 0.1 1.0 0.0 0.1 1.0
Culture, day 
0 57 46 69 91 93 94 
1 69 75 71 78 94 93 
3 64 85 85 84 86 87 
6 0 58 83 60 51 84 
9 2 51 71 59 78 91 
12 0 54 82 50 73 90 
Table 3. Evolution of 125I- organification/accumulation in rat follicle culture. Comparing two 
experiments where rat closed follicle percentage varied during the course of two experiments (Exp. 1 
and Exp. 2). 80% of follicles were closed at the start of culture counted in autoradiographs of culture 
aliquots in experiment 2 (cf 65% in experiment 1). Na125I 5 Ci/mL was added 4 h before collecting 
follicles during each day of the experiment, expressed in %/dose/μg DNA. Each value was the average 
of two samples or culture dishes. Experiment 2 was representative of 7 independent experiments. TSH: 
mU/mL. 
Following one day’s culture without TSH, accumulation was low at the start of culture; it 
did not become modified, but if it was high it became reduced, whilst incorpoproportion of 
iodide in Tg became reduced (Table 4). T3 and T4 proportion in regarding Tg was not 
modified. Iodide accumulation increased in the presence of TSH, O/A percentage remained 
high and in starting values (Table 3). Iodide incorpoproportion in Tg19S was better (Table 4) 
and Tg19S content in follicles did not vary. 
Accumulation fell abruptly on the third day without TSH when starting with a low 
percentage of closed follicles, just like O/A percentage, whilst it became reduced with a high 
percentage of closed follicles, but O/A was maintained. O/A values were high in the 
presence of TSH and remained higher than 80% (Table 3). 
Accumulation and organification values and their O/A percentage differed on the sixth day 
regarding closed follicle percentage; A and O could not be determined in experiment 1 
which began with 57% (Table 3. Exp. 1) whilst experiment 2 began with 94% and became 
reduced to 60% (Table 3. Exp. 2). There was a reduction in all O/A percentages in rat or pig 
cultures by the sixth day which also differed with the percentage of closed follicles (Table 5), 
animal species and functional state at the start of culture. The percentage of iodide on Tg19S 
also became reduced (Table 4). 
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Digestion conditions % follicles closes A O % O/A 
Without pre-incubation
Mild dissociation 57 ± 1,4 1.14 ± 0,01 0.89 ± 0,01 78 
Strong dissociation 45 ± 5,7 1.84 ± 0,37 1.08 ± 0,14 58 
With pre-incubation 4 hours
Mild dissociation 83 ± 1,4 1.93 ± 0,24 1.64 ± 0,17 85 
Strong dissociation 60 ± 7,1 1.32 ± 0,17 0.91 ± 0,01 68 
Table 1. Influence of dissociation conditions and pre-incubation time on the percentage of rat thyroid 
isolated and closed follicles and their function. It can be seen that the percentage of organified iodide on 
accumulated iodide (O/A) was equivalent to the percentage of closed follicles concentrating radioactive 
ion determined by follicle count using accumulated grains in follicular colloid in autoradiography of 
semi-fine cross-sections (Figure 4). Average values for two culture dishes ± SD. Following pre-
incubation, 125I- accumulation (A) and incorporation in proteins (O) were determined following 2 h in 
the presence of Na125I 5 Ci/mL and expressed in μg/dose/μg DNA. 
TSH A O % O/A 
None 0.73 ± 0,18 0.58 ± 0,11 79 
0,1mU/mL 3.48 ± 0,17 2.78 ± 0,04 80 
1mU/mL 5.71 ± 0,72 4.98 ± 0,67 87 
Table 2. Influence of TSH on iodide accumulation and organification in isolated rat follicles expressed 
in μg/dose/μg DNA. Follicles were cultured for 2 h in the presence of Na125I 5Ci/mL immediately 
following pre-incubation. TSH was stimulated by Na125I but O/A proportion was around 80% with or 
without TSH. The value without TSH represented the percentage of closed follicles obtained following 
correct mechanical dissociation and pre-incubation of follicles. Average values for culture dishes ± SD 
(these values were representative of 3 experiments). 
A good approximation of the percentage of closed follicles following pre-incubation must 
thus be born in mind (this corresponded to day 0 in our cultures). It can thus be generalised 
that O/A proportion values should be greater than 80% before beginning culture (day 0, Table 
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which became resealed did not require TSH for conserving their follicular architecture. 
5.2. Long-term closed follicle culture 
5.2.1. Functional study 
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3.5 ± 2.1% of the dose in the medium without TSH (9 experiments in rats). Organified iodide 
percentage varied according to closed follicle percentage at the start of each experiment. 
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O/Aprioportion was 57% in experiment 1 and 91% in experiment 2 (Table 3); more than two 
thirds of organified iodide bound to stable Tg19S (Table 4), the rest of the molecules having 
lower molecular weight. Capture increased in the presence of TSH regarding without TSH 
250 ± 210% (9 experiments in rats), but O/A percentage remained constant. The effect of TSH 
was evident on A and O, and higher than values without TSH (Tables 2, 3 and 4). Iodide 
accumulation on Tg19S slightly increased with TSH, but not significantly so (Table 4). 
Exp. 1 Exp. 2
TSH 0.0 0.1 1.0 0.0 0.1 1.0
Culture, day 
0 57 46 69 91 93 94 
1 69 75 71 78 94 93 
3 64 85 85 84 86 87 
6 0 58 83 60 51 84 
9 2 51 71 59 78 91 
12 0 54 82 50 73 90 
Table 3. Evolution of 125I- organification/accumulation in rat follicle culture. Comparing two 
experiments where rat closed follicle percentage varied during the course of two experiments (Exp. 1 
and Exp. 2). 80% of follicles were closed at the start of culture counted in autoradiographs of culture 
aliquots in experiment 2 (cf 65% in experiment 1). Na125I 5 Ci/mL was added 4 h before collecting 
follicles during each day of the experiment, expressed in %/dose/μg DNA. Each value was the average 
of two samples or culture dishes. Experiment 2 was representative of 7 independent experiments. TSH: 
mU/mL. 
Following one day’s culture without TSH, accumulation was low at the start of culture; it 
did not become modified, but if it was high it became reduced, whilst incorpoproportion of 
iodide in Tg became reduced (Table 4). T3 and T4 proportion in regarding Tg was not 
modified. Iodide accumulation increased in the presence of TSH, O/A percentage remained 
high and in starting values (Table 3). Iodide incorpoproportion in Tg19S was better (Table 4) 
and Tg19S content in follicles did not vary. 
Accumulation fell abruptly on the third day without TSH when starting with a low 
percentage of closed follicles, just like O/A percentage, whilst it became reduced with a high 
percentage of closed follicles, but O/A was maintained. O/A values were high in the 
presence of TSH and remained higher than 80% (Table 3). 
Accumulation and organification values and their O/A percentage differed on the sixth day 
regarding closed follicle percentage; A and O could not be determined in experiment 1 
which began with 57% (Table 3. Exp. 1) whilst experiment 2 began with 94% and became 
reduced to 60% (Table 3. Exp. 2). There was a reduction in all O/A percentages in rat or pig 
cultures by the sixth day which also differed with the percentage of closed follicles (Table 5), 
animal species and functional state at the start of culture. The percentage of iodide on Tg19S 
also became reduced (Table 4). 
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A 125I- in Tg19S*
TSH 0.0 0.1 1.0 0.0 0.1 1.0 
Culture. Day 
Without NaI 
0 5.8 5.5 7.2 59 63 67 
1 1.4 2.7 3.1 43 66 65 
3 1.3 4.5 8.7 46 50 52 
6 0.7 1.2 4.0 25 13 42 
9 0.2 0.6 4.0 16 17 55 
12 0.2 0.7 8.0 15 25 52 
With NaI 
0 5.8 7.8 9.3 60 61 66 
1 1.1 1.8 3.1 31 58 64 
3 0.7 4.2 7.6 49 49 52 
6 0.1 1.4 3.4 10 22 39 
9 0.2 1.6 2.6 14 32 38 
12 0.1 1.9 2.9 11 33 58 
Table 4. Evolution of iodide accumulation (A) and its incorporation in stable Tg19S in rat follicle culture. 
Effect of adding a small dose of cold iodide (10E-10 M Na127I). A was expressed in %/dose/μg DNA. 
Radioactivity determined in stable Tg19S was expressed in % 125I- accumulation/dose/μg DNA. The results 
without NaI were those expressed in experiment 2, Table 3. Na125I 5 Ci/mL 4 h was added before collecting 
follicles during each day of the experiment. Each value was the average of two samples or culture dishes. 
O/A retained the same values on day 9 and 12 as those for day 6 in both experiments 
without TSH, whilst with TSH this increased in experiment 1 regressed to day 1 values and 
then maintained similar values to those of the two first days. The percentage of iodide on 
Tg19S with and without TSH was conserved (Table 4). 
The presence of a small dose of iodide (10E-10 M NaI) did not modify iodide accumulation 
values at the start of culture (Table 4), but responded better to TSH. Tg19S had more T3 and 
T4 and TSH increased the percentage of T3. O/A percentage increased with 0.1mU/mL TSH 
on days 6, 9 and 12 whilst it fell with 1 mU/mL (not significantly). Iodide had no effect on 
stable Tg19S content in follicles; more than two thirds of accumulated iodide was 
incorporated in Tg19S (Table 4) even in the absence of TSH where iodide accumulation was 
very low on day 12. 
Preserving the function of pig follicle thyrocytes during culture also depended on the 
percentage of closed follicles since the beginning. However, this differed from those for rats 
in the absence of TSH, because this began with 43% O/A equivalent to the percentage of 
closed follicles presenting iodide organification on days 6 and 9 (Table 5, euthyroidic follicles) 
contrary to rat follicles which was zero (Table 3. Exp. 1). As 7 times more material was 
obtained from pig thyroids than rat follicles, a greater number of recovered follicles were 
conserved in changes of medium by centrifuging, or different species having variations in 
response to the same medium conditions. 
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Euthyroid Hipothyroid
Culture, day TSH % O/A N % O/A N 
0 
0 43.4. ±.5.9 4 82.4. ±.7.2 4 
1mU/mL 61.5. ±.4.6 4 80.5. ±.3.7 4 
1 
0 56.94. ±.4.7 3 77.0. ±.3.8 4 
1mU/mL 71.4. ±.7.1 2 76.44. ±.3.9 4 
3 
0 37.4. ±.6.6 2 82.24. ±.4.1 3 
1mU/mL 43.2. ±.5.9 2 76.44. ±.5.3 2 
6 
0 9.16. ±.2.2 2 23.3. ±.9.4 2 
1mU/mL 15.0. ±.3.7 2 52.32. ±.4.2 2 
9 
0 52.66. ±.2.2 2 16.62. ±.1.5 3 
1mU/mL 64.8. ±.4.3 2 53.6. ±.5.0 3 
Table 5. Evolution of 125I- organification/accumulation (O/A proportion) percentage for pig follicles. 
Hypothyroid follicles had high O/A percentage at the start regarding euthyroids (representative results 
from 4 experiments). This experiment began with less than 50% O/A in euthyroids for comparing with 
Table 3, experiment 1; however, when 3 experiments began with euthyroid follicles having 80% or more 
O/A they behaved like those for rat follicles in experiment 2, Table 3. 5 Ci/mL Na125I were added 4 h 
before collecting follicles on each day of the experiment expressed in %/dose/μg DNA. Average values 
for the number (N) of culture dishes ± SD. 
The difference between euthyroidic rat or pig follicles regarding hypothyroid ones was that 
hypothyroids responded to TSH on the sixth and ninth culture days, perhaps due to 
adapting to normal culture conditions, like hypothyroid glands’ response in vivo when the 
effect induced by hypothyroidism stimulated with TSH was eliminated [24].  
We compared isolated follicles’ iodide accumulation and organification with their respective 
pig mini organ cultures lasting up to 9 days. Euthyroidic tissue became disorganised after 
the sixth day and functionality could not be determined after this day. Some follicles were 
conserved in the hypothyroids on the outside of the cultured fragment and presented this 
function on days 6 and 9 (Table 6). Mini organ culture functional values were higher than 
those of follicles isolated on the first day, but these were not significant; they were higher 
from the first day onwards in isolated follicles, maintaining higher values up to day 9 
(euthyroidic and hypothyroid) (Table 6). 
 
TSH A O % A/O N TSH A O % A/O N 
Euthyroid, follicles Euthyroid, mini organ culture 
0 0.049 0.025 51.6 ± 0.052 4 0 CND CND 3 
1mU/mL 0.074 0.048 65.3  ± 0.043 4 1mU/mL CND CND 3 
Hypothyroid, follicles Hypothyroid, mini organ culture 
0 0.122 0.0633 36.75 ± 0.67 4 0 0,115 0.025 22.7 ± 1.5 3 
1mU/mL 0.122 0.0655 53.6± 0.050 4 1mU/mL 0.723 0.278 38.5 ± 0.067 2 
Table 6. Determining iodide accumulation (A) and organification (O) for isolated follicles and mini 
organ cultures from the same pig thyroids after 9 days’ culture. 5 Ci/mL Na125I was added 4 h before 
collecting follicles and mini organ cultures on each day of the experiment expressed in %/dose/μg DNA. 
Average g of follicle DNA was 4.5 and 14.7 for mini organ cultures. Values represent the average 
number (N) of culture dishes ± SD. CND: could not be determined. 
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without NaI were those expressed in experiment 2, Table 3. Na125I 5 Ci/mL 4 h was added before collecting 
follicles during each day of the experiment. Each value was the average of two samples or culture dishes. 
O/A retained the same values on day 9 and 12 as those for day 6 in both experiments 
without TSH, whilst with TSH this increased in experiment 1 regressed to day 1 values and 
then maintained similar values to those of the two first days. The percentage of iodide on 
Tg19S with and without TSH was conserved (Table 4). 
The presence of a small dose of iodide (10E-10 M NaI) did not modify iodide accumulation 
values at the start of culture (Table 4), but responded better to TSH. Tg19S had more T3 and 
T4 and TSH increased the percentage of T3. O/A percentage increased with 0.1mU/mL TSH 
on days 6, 9 and 12 whilst it fell with 1 mU/mL (not significantly). Iodide had no effect on 
stable Tg19S content in follicles; more than two thirds of accumulated iodide was 
incorporated in Tg19S (Table 4) even in the absence of TSH where iodide accumulation was 
very low on day 12. 
Preserving the function of pig follicle thyrocytes during culture also depended on the 
percentage of closed follicles since the beginning. However, this differed from those for rats 
in the absence of TSH, because this began with 43% O/A equivalent to the percentage of 
closed follicles presenting iodide organification on days 6 and 9 (Table 5, euthyroidic follicles) 
contrary to rat follicles which was zero (Table 3. Exp. 1). As 7 times more material was 
obtained from pig thyroids than rat follicles, a greater number of recovered follicles were 
conserved in changes of medium by centrifuging, or different species having variations in 
response to the same medium conditions. 
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It has been described that pig thyroid mini organ cultures enables studying “thyroid tissue 
structural and functional integrity in vitro [54]”; however, we have considered that studying 
thyroids in vitro is better done with isolated follicles than using mini organ cultures. Since 
closed follicles maintain their architecture throughout culture time, thyrocytes are viable 
and their basement membrane is in direct contact with the medium and not with capillaries 
whose endothelial cells die rapidly in culture during the first 24 h (Figure CB). 
DNA content per culture dish did not show a significant change during 12 days’ rat follicle 
culture (1.55 ± 0.52 g/dish, N = 16) or 9 days’ pig follicle culture (5.35 ± 0.36 g/dish, N = 25). 
Even though closed and isolated follicles in culture had differences regarding stable Tg19S, 
the amount of T3 and T4 and iodide accumulation between different treatments with and 
without TSH and with or without 10E-10 M NaI, the follicles did have more iodide 
organification, iodised Tg19S and T3 and T4 at 12 days’ culture, even without TSH [83,86], 
than in all other culture models published to date except of the group [83,84,85,86]. Such 
variations were homologous to glands in vivo in the same study conditions. 
Our culture system has different characteristics distinguishing it from other models 
described up to now. Monolayers lose their function on the first day [48], become 
reorganised in pseudofollicles on the third day and only 2% to 4 % become incorporated or 
organified in iodine accumulated in poorly iodised Tg (Tg16S) [91], even though higher than 
90% O/A with TSH has been reported for a matrigel-covered monolayer culture forming a 
double cell layer having cavities [61]. Different models mentioning culturing “follicles” 
[92,93,94,95] have not shown these functions in their results; others culturing pig “follicles” 
for 2 days, based on Björkman and Ekholm [16] as we, require 5% FCS, 1 mU/mL TSH and 
non-physiological molecules such as forskolin or 8-(4-chlorophenylthio)-cAMP for 
maintaining thyrocyte functions [77]. Using closed follicles enables functional parameters to 
be conserved and measured: iodide accumulation, iodide organification and, particularly, 
Tg19S equivalent to that in vivo and T3 and T4 formation throughout culture with or without 
TSH. We have also shown that maintaining closed follicular architecture is an indispensable 
condition for conserving such thyroid functions in culture in vitro. If follicular architecture is 
to be conserved, it is not enough to maintain functions at the same values as those at the 
start of culture as TSH is required and culture becomes improved by adding iodide, as 
thyroid function in vivo is governed by TSH and iodide. 
5.2.2. Morphological study 
Pig hypothyroid follicles cultured 1 and 3 days without TSH have a very thin epithelial 
layer (Figure 5A) like original tissue’s follicle epithelium. The epithelium became cubic after 
day 6 and was preserved up to day 9 (Figure 5C). It was seen that follicles conserving colloid 
had a birefrigent aspect when observed by IM, thereby showing that this was conserved 
during culture. Epithelium thickness increased in the presence of TSH, becoming cubic on 
the first day of culture (Figure 5B) and being maintained so until day 9. 
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Figure 5. Morphological aspect of follicles in culture. A. Hypothyroid follicle 1 day’s culture without 
TSH; birefringent colloid and thin follicle epithelium can be seen. B. Hypothyroid follicle 1 day’s culture 
with 1mU/mL TSH; cubic epithelium and thyrocytes’ apical poles typical of a resealed follicle can be 
seen. C. Hypothyroid follicles in 9 days’ culture without TSH; the epithelium is cubic and colloid 
birefringence can be seen in all follicles. D. Euthyroid follicle 1 day culture without TSH. A resealed 
follicle (circle) having irregular contour between thyrocytes and cavity can be seen in the centre. Closed 
follicles preserve colloid birefringence and regular boundary between thyrocytes and colloid since the 
start of culture. E Pig euthyroid follicles in the presence of 1 mU/mL TSH; follicular cavities are difficult 
to distinguish. F. Autoradiography of rat follicles cultured 12 days in the presence of TSH (1 mU/mL) 
corresponding to experiment 2, Table 3. Follicle cavities are evident due to the organified iodide found 
only in very narrow follicular cavities (Scale bar: A and D 50 μm, B 25 μm, C 130 μm, E 100 μm, IM. F 
150 μm, OM. Toluidina bleu). 
Rat or pig euthyroid follicles without TSH kept the same follicular architecture throughout 
the whole culture time (Figure 5D). Colloidal cavities became reduced from the third day in 
the presence of TSH and were difficult to distinguish on day 9 and 12 by IM (Figure 5E); 
however, they could be seen by autoradiography where only iodide bound to molecules 
could be identified and they were only located in follicles’ very narrow colloidal cavities 
(Figure 5F). Colloidal cavities’ boundaries could also be seen by labelling thyrocytes’ apical 
membrane protein SLC5A8 (short-chain fatty acids transporter) [84].  
Rat thyrocyte and pig euthyroid follicle ultra-structure in one day culture without TSH 
(Figure 6A) and with TSH (Figure 6B) was comparable to that for cells in vivo (Figure 1C). 
They conserved their polarity and organelles, but exocytic vesicles were difficult to 
distinguish from those from endocytosis. RER was more abundant in the presence of TSH 
and microvellosities were more evident than without TSH. 
Thyrocytes had vacuolated and reduced RER and GC following 3 days’ culture without 
TSH; the GC could be seen in supra-nuclear position (Figure 6C G) as could numerous 
autophagic vacuoles (Figure 6C arrow) and secondary lysosomes. This became modified in  
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start of culture as TSH is required and culture becomes improved by adding iodide, as 
thyroid function in vivo is governed by TSH and iodide. 
5.2.2. Morphological study 
Pig hypothyroid follicles cultured 1 and 3 days without TSH have a very thin epithelial 
layer (Figure 5A) like original tissue’s follicle epithelium. The epithelium became cubic after 
day 6 and was preserved up to day 9 (Figure 5C). It was seen that follicles conserving colloid 
had a birefrigent aspect when observed by IM, thereby showing that this was conserved 
during culture. Epithelium thickness increased in the presence of TSH, becoming cubic on 
the first day of culture (Figure 5B) and being maintained so until day 9. 
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Figure 5. Morphological aspect of follicles in culture. A. Hypothyroid follicle 1 day’s culture without 
TSH; birefringent colloid and thin follicle epithelium can be seen. B. Hypothyroid follicle 1 day’s culture 
with 1mU/mL TSH; cubic epithelium and thyrocytes’ apical poles typical of a resealed follicle can be 
seen. C. Hypothyroid follicles in 9 days’ culture without TSH; the epithelium is cubic and colloid 
birefringence can be seen in all follicles. D. Euthyroid follicle 1 day culture without TSH. A resealed 
follicle (circle) having irregular contour between thyrocytes and cavity can be seen in the centre. Closed 
follicles preserve colloid birefringence and regular boundary between thyrocytes and colloid since the 
start of culture. E Pig euthyroid follicles in the presence of 1 mU/mL TSH; follicular cavities are difficult 
to distinguish. F. Autoradiography of rat follicles cultured 12 days in the presence of TSH (1 mU/mL) 
corresponding to experiment 2, Table 3. Follicle cavities are evident due to the organified iodide found 
only in very narrow follicular cavities (Scale bar: A and D 50 μm, B 25 μm, C 130 μm, E 100 μm, IM. F 
150 μm, OM. Toluidina bleu). 
Rat or pig euthyroid follicles without TSH kept the same follicular architecture throughout 
the whole culture time (Figure 5D). Colloidal cavities became reduced from the third day in 
the presence of TSH and were difficult to distinguish on day 9 and 12 by IM (Figure 5E); 
however, they could be seen by autoradiography where only iodide bound to molecules 
could be identified and they were only located in follicles’ very narrow colloidal cavities 
(Figure 5F). Colloidal cavities’ boundaries could also be seen by labelling thyrocytes’ apical 
membrane protein SLC5A8 (short-chain fatty acids transporter) [84].  
Rat thyrocyte and pig euthyroid follicle ultra-structure in one day culture without TSH 
(Figure 6A) and with TSH (Figure 6B) was comparable to that for cells in vivo (Figure 1C). 
They conserved their polarity and organelles, but exocytic vesicles were difficult to 
distinguish from those from endocytosis. RER was more abundant in the presence of TSH 
and microvellosities were more evident than without TSH. 
Thyrocytes had vacuolated and reduced RER and GC following 3 days’ culture without 
TSH; the GC could be seen in supra-nuclear position (Figure 6C G) as could numerous 
autophagic vacuoles (Figure 6C arrow) and secondary lysosomes. This became modified in  
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Figure 6. Ultra-structure of thyrocytes from follicles cultured without TSH A 1 day, C 3 days, D 12 days 
and with 1 mU/mL TSH B 1 day, D 3 days and F 12 days. Binding complexes were preserved in thyrocytes’ 
lateral membrane apical region during all the times with and without TSH. A. Thyrocytes conserved their 
polarisation; microvellosities in contact with electron-dense colloid. Binding complexes were located in 
lateral membrane’s apical region between cells. The rugose endoplasmic reticulum (RER) was found to be 
slightly vesiculated. B. Thyrocyte ultra-structure was comparable to without TSH, even though RER was 
more abundant. C. and D. Ultra-structure was conserved in thyrocytes; the supranuclear Golgi complex 
(G) and more abundant RER in thyrocytes in the presence of TSH can be seen. Autophagic vacuoles (C. 
arrow) and secondary lysosomes (D, arrows) with or without TSH can be seen. E. Thyrocyte polarity was 
conserved. Colloid was electron-dense and separated from follicle exterior. Thyrocytes had exiguous RER 
and G. F. Organelles were well conserved. RER was well developed and occupied thyrocytes’ apical region 
(TEM. A and C 7,300 X, B 7,500 X, D 7,438 X, E 9,810 X, F 8,260 X).  
 
Thyroid Culture from Monolayer to Closed Follicles 367 
the presence of TSH, presenting abundant RER and GC (Figure 6D G) and containing more 
autophagic vacuoles and secondary lysosomes in thyrocytes’ apical region (Figure 6D 
arrows) than without TSH. RER and GC became more reduced by the sixth day without 
TSH and thyrocytes became thin. Whilst autophagic vacuoles and secondary lysosomes 
became reduced with TSH, RER and GC also did so by day 3. 
Thyrocytes were thin by day 9 and 12 without TSH and had exiguous RER and GC and 
reduced microvellosities. The nuclei contained very little heterochromatin (Figure 6E). 
Follicular centres were very narrow in the presence of TSH, thyrocytes had abundant GC 
and RER reaching the cells’ apical regions (Figure 6F) and the other organelles had the same 
distribution as on the first days of culture. 
Adding 10E-10 M NaI did not modify thyrocytes’ follicular architecture or ultra-structure; 
however, RER and GC were preserved up to day 12 without TSH. 
Pig thyrocyte and hypothyroid follicle ultra-structure had exiguous RER and GC when 
culture began (Figure 7A), like original gland hypothyroids in vivo, and culture (even 
without TSH) developed these organelles from the third day of culture [86]. These 
hypothyroid follicles’ thyrocytes became cubic in the presence of TSH (Figure 5B) from the 
first day of culture and it was seen that the RER and GC developed and became more 
evident on the sixth and ninth day of culture (Figure 7B), similar to rat or pig euthyroid 
follicle response with TSH, but follicular cavity did not become reduced. 
Thyrocytes had normal mitochondria in rat follicle and pig euthyroidic and hypothyroid 
cultures for all culture times. 
 
Figure 7. Pig hypothyroid follicle culture. A. RER and GC were exiguous and cells were thin 1 day in 
the absence of TSH. B. 9 days in the presence of 1 mU/mL TSH. Cross-section of thyrocyte follicle basal 
pole. Abundant RER can be seen around the nucleus (TEM. A 7,800 X, B 9,000 X). 
Similar culture models to these have been described. Pig follicle culture has highlighted the 
importance of thyrocyte polarity, but OM morphological study was limited on day 1 [74,94]. 
Another, dealing with “normal” human follicle culture of thyroidectomy for goitre requiring 
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the presence of TSH, presenting abundant RER and GC (Figure 6D G) and containing more 
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TSH [93] had a TEM image showing thyrocytes having the ultra-structure for cells in the 
process of cell death with lysed mitochondria, without RER or GC. Using this human follicle 
culture model enabled analyzing the effect of TSH [95] or cytokines [95,96] without 
presenting culture morphology.  
Our results showed that if culture was begun with closed follicles then extracellular matrix 
support elements were not required [56,57,79,80] nor was TSH for maintaining follicular 
cavity, as has been described in most pseudofollicle or follicle cultures reconstructed from 
monolayers, or similar structures called “follicles” [57,50,60,61,62,79,96], thereby 
demonstrating that if closed follicles are used from the start of culture they conserve their 
morphology, having the correct polarity as that of their thyrocytes in culture and have a 
binding complex (tight junction, belt desmosome and spot desmosome) in lateral 
membranes’ apical part as well as in vivo [9]. Such closed follicles in culture responded to 
TSH, like other in vitro models [42] or like gland follicles in normal in vivo to TSH stimulus 
[3,25], epithelium thickness, RER and GC becoming increased, and follicular cavities 
becoming notably reduced [11,83,90]. Follicle response to the absence of TSH both in vivo 
[24] and in vitro [42] was also comparable as these organelles became reduced. This effect 
became reverted in vivo when TSH was added, reactivating thyroid functions [11,33,97]. 
Pig closed and isolated hypothyroid follicles behaved like the gland in vivo when the 
hypothyroid effect was deleted [24], RER and GC increased, follicular epithelium became 
thin to cubic and culture time became faster in the presence of TSH, but follicular cavity did 
not become reduced during the 9 days of culture. 
Our results thus showed that long-term thyroid follicle function and morphology can be 
maintained in vitro, being equivalent to the gland in vivo. 
The next section describes the effect of increasing doses of iodide on closed follicles in 
culture. 
5.3. Closed follicle cultures reproduce the Wolff-Chaikoff effect described in vivo 
5.3.1. Functional study 
Follicles were cultured for 1 day before starting to analyse the effect of different iodide 
concentrations. 
Follicles accumulated iodide linearly for 6 h in the presence of 10E-10 and 10E-7 M NaI; 
accumulation was at its maximum after the first 30 min with 10E-5 M and 10E-3 M NaI 
(Table 7); they became accumulated 100 times more than with 10E-10 M NaI in the presence 
of 10E-7 M NaI. Whilst high O/A percentages in follicles were maintained in the presence of 
10E-10 and 10E-7 M NaI, organification began after 2 h with 10E-5 M, accounting for only 
5% of accumulated iodide, these values being maintained for 6 h, whilst O/A proportion 
was zero for all times with 10E-3 M NaI (Table 7), even though accumulation could have 
been 100 times greater to that presented by follicles in the presence of 10E-7 M NaI [98]. 
 
Thyroid Culture from Monolayer to Closed Follicles 369 
% O/A
M, NaI 10E-10 10E-7 10E-5 10E-3 
Culture, hours 
0.5 82 64 0 0 
1 84 42 0 0 
2 88 90 5 0 
3 92 88 3 0 
4 95 87 6 0 
5 88 89 6 0 
6 84 93 4 0 
Table 7. Response of organification percentage regarding iodide accumulation (O/A proportion) by rat 
follicles cultured in the presence of increasing doses of iodide (NaI, M) and Na125I 5 Ci/mL. The 
follicles were cultured on agarose with 0.5% FCS for 1 day, medium was changed and culture began 
with NaI and TSH experimental points. Each value was the average of two samples or culture dishes 
expressed in %/dose/μg DNA. 
Iodide accumulation and organification in rat follicles could be assimilated to biochemical 
reactions after 30 min with and without TSH and thus define a constant (Km) and maximum 
speed (Vmax). Accumulation apparent Km without TSH was 5x10E-6 M and 10E-7 M de 
NaI with TSH; iodide organification apparent Km was 5x10E-7 M and was not modified by 
the presence of TSH (Figure 8). Iodide accumulation by isolated follicles corresponded well 
with saturable iodide transport characteristics [15,99] and stimulated TSH thereby reducing 
Km but not Vmax (Figure 8). It should be stated that organification had to be inhibited and  
 
Figure 8. Initial 125I-iodide accumulation (A) and organification (B) for follicles in culture measured 
following half an hour in the presence of increasing doses of 127-I Na and 5 Ci/mL 125-I Na expressed in -
log M with and without TSH. The follicles were cultured on agarose with 0.5% FCS for 1 day, the 
medium was changed and culture began with NaI and TSH experimental points. The results were the 
average of two samples and were expressed as percentage of maximum value. 
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the time between the end of the culture and the moment when accumulation was 
determined had to be reduced for measuring exact iodide transport parameters. The 
washing times meant that part of 125I- concentrated in follicles would be released before 
radioactivity was determined and this would induce under-stimulation of accumulation and 
perhaps overstimulation of O/A percentage. 
The presence of TSH for 30 min suppressed the inhibiting effect on iodide organification at 
10E-5 M, but did not suppress such iodide effect on organification in the presence of 10E-3 
M TSH (Table 8). 
 
M, NaI 10E-10 10E-7
Culture TSH A O % O/A A O % O/A 
0.5 - 2,58 1,29 50 ± 5* 360,9 156,34 43 ± 6* 
+ 8,06 4,52 56 ± 2* 676,69 406,02 60 ± 14* 
3 - 10,88 8,16 75 ± 10* 902,26 525,24 58 ± 7 
+ 14,84 11,81 79 ± 1* 1308,27 1079,24 82 ± 1 
8 - 35,97 29,84 83 ± 11 2255,64 1602,81 71 ± 4* 
+ 32,26 28,06 87 ± 23 1736,84 1371,98 79 ± 10* 
12 - ND 1849,62 1191,13 64 ± 9 
+ ND 1353,38 853,23 63 ± 13 
24 - ND 1714,29 1421,05 83 ± 10 
+ ND 1759,4 1254,17 71 ± 8 
48 - ND 1917,29 1361,98 71 ± 10* 
+ ND 3969,92 3194,23 80 ± 6* 
M, NaI 10E-5 10E-3
Culture TSH A O % O/A A O % O/A 
0.5 - 14749,09 0 0 * 233469,39 0 0 
+ 12480,01 2,63 21 ± 16* 244244,9 0 0 
3 - 15272,73 1553,64 10 ± 6 520816,33 0 0 
+ 17541,82 2987,27 17 ± 2 466938,78 0 0 
8 - 16495,45 2397,15 14 ± 5 574693,88 0 0 
+ 20770,91 4450,91 21 ± 2 790204,08 0 0 
12 - ND * 718367,35 0 0 
+ ND * 1957551,02 0 0 
24 - ND * 3071020,41 0 0 
+ ND * 682448,98 0 0 
48 - ND 664489,8 0 0 
+ ND 484897,96 0 0 
Table 8. The effect of I- dose on the accumulation (A) and organificación (O) of the rat follicles. Follicles 
cultured on agarose with 0.5% FCS for 1 day; the medium was changed and culture began with 
different experimental points. The follicles were keep in culture along the time (culture in hours) with 5 
µCi/mL Na125I, with (+) or without 0.1 mU/mL TSH (-) and doses of Na127I (NaI). Each value was the 
average of two samples expressed in μg/dose/μg DNA. This result was representative of 5 independent 
experiments. O/A: percentage of the proportion O/A ± SD. *p< 0.05. ND: not determinated. 
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Follicle culture in the presence of the same iodide dose with 0.1 mU/mL and without TSH 
led up to 8 h with 10E-10 M and 10E-5 M NaI and up to 48 h with 10E-7 M and 10E-3 M NaI. 
An iodide accumulation function directly proportional to NaI concentration was reproduced 
as in table 7. 
Accumulation in follicles became saturated after 8 h in the presence of 10E-7 M NaI with 
and without TSH, becoming slightly reduced at 12 and 24 h and increasing at 48 h; iodide 
accumulation with TSH was lower at 8, 12 and 24 h than without TSH (significant only at 12 
h, p< 0.05). Percentage of the proportion O/A was maintained high values with and without 
TSH, difference with and without TSH at 30 min and 48 h being significant (Table 8). 
Iodide accumulation satuproportion was reproduced in follicles in the presence of 10E-5 M 
NaI, whether with or without TSH. TSH significantly stimulated organification inhibited by 
10E-5 M NaI (p< 0.05) at 30 min, even though O/A percentage was slightly higher than at 
other times (but was not significant) (Table 8). 
Iodide accumulation in follicles in the presence of 10E-3 M NaI with and without TSH 
reached a plateau at 3 h (Table 8) and was greater in follicles without TSH than with TSH at 
12, 24 and 48 h; however, this difference was only significant at 12 and 48 h (p< 0.05). Iodide 
accumulation became reduced with and without TSH at 48 h to 3 h values, even though 
without TSH this was greater but not significantly so. Iodide organification was zero with 
such strong dose of iodide with and without TSH at all times examined (Table 8).  
Pig euthyroidic follicles had the same response as rat follicles when culturing for 48 h in the 
presence of increasing doses of iodide with or without TSH. Organification was zero at all 
times in the presence of 10-E3 M NaI with and without TSH (Table 9). 
 
M, NaI 10E-10 10E-7 10E-3 
Culture TSH % O/A N % O/A N % O/A N 
0.5 - 30.4 ± 0.56 2 30.4 ± 0.63 2 0 3 
+ 34.7  ± 9.21 2 72.7  ± 2.84 2 0 3 
3 - 67.0  ± 1.54 2 63.2  ± 9.14 2 0 3 
+ 79.5  ± 6.79 2 73.6 1 0 3 
12 - 71.8  ± 2.35 2 52.4 ± 2.63 1 0 3 
+ 78.9  ± 2.63 2 77.6  ± 3.15 2 0 3 
24 - 59.7  ± 2.09 2 87.6  ± 1.97 2 0 4 
+ 68.8  ± 7.13 2 85.7  ± 0.99 2 0 3 
Table 9. The effect of I- dose on the proportion accumulation/organificación pourcentage (% A/O) in 
euthyroidic pig follicles cultured. Follicles cultured on agarose with 0.5% FCS for 1 day; the medium 
was changed and culture began with different experimental points. The follicles were keep in culture 
along the time (culture in hours) with 5 µCi/mL Na125I, with (+) or without 1 mU/mL TSH (-) and doses 
of Na127I (NaI). Each value was the average of accumulated or organified (O/A) iodide expressed in 
%/dose/μg DNA per number (N) of culture dishes ± SD.  
Pig hypothyroid follicles had a different response to the presence of increasing doses of 
iodide than rat and pig euthyroidic follicles (Table 10). They accumulated 40 to 100 times 
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as in table 7. 
Accumulation in follicles became saturated after 8 h in the presence of 10E-7 M NaI with 
and without TSH, becoming slightly reduced at 12 and 24 h and increasing at 48 h; iodide 
accumulation with TSH was lower at 8, 12 and 24 h than without TSH (significant only at 12 
h, p< 0.05). Percentage of the proportion O/A was maintained high values with and without 
TSH, difference with and without TSH at 30 min and 48 h being significant (Table 8). 
Iodide accumulation satuproportion was reproduced in follicles in the presence of 10E-5 M 
NaI, whether with or without TSH. TSH significantly stimulated organification inhibited by 
10E-5 M NaI (p< 0.05) at 30 min, even though O/A percentage was slightly higher than at 
other times (but was not significant) (Table 8). 
Iodide accumulation in follicles in the presence of 10E-3 M NaI with and without TSH 
reached a plateau at 3 h (Table 8) and was greater in follicles without TSH than with TSH at 
12, 24 and 48 h; however, this difference was only significant at 12 and 48 h (p< 0.05). Iodide 
accumulation became reduced with and without TSH at 48 h to 3 h values, even though 
without TSH this was greater but not significantly so. Iodide organification was zero with 
such strong dose of iodide with and without TSH at all times examined (Table 8).  
Pig euthyroidic follicles had the same response as rat follicles when culturing for 48 h in the 
presence of increasing doses of iodide with or without TSH. Organification was zero at all 
times in the presence of 10-E3 M NaI with and without TSH (Table 9). 
 
M, NaI 10E-10 10E-7 10E-3 
Culture TSH % O/A N % O/A N % O/A N 
0.5 - 30.4 ± 0.56 2 30.4 ± 0.63 2 0 3 
+ 34.7  ± 9.21 2 72.7  ± 2.84 2 0 3 
3 - 67.0  ± 1.54 2 63.2  ± 9.14 2 0 3 
+ 79.5  ± 6.79 2 73.6 1 0 3 
12 - 71.8  ± 2.35 2 52.4 ± 2.63 1 0 3 
+ 78.9  ± 2.63 2 77.6  ± 3.15 2 0 3 
24 - 59.7  ± 2.09 2 87.6  ± 1.97 2 0 4 
+ 68.8  ± 7.13 2 85.7  ± 0.99 2 0 3 
Table 9. The effect of I- dose on the proportion accumulation/organificación pourcentage (% A/O) in 
euthyroidic pig follicles cultured. Follicles cultured on agarose with 0.5% FCS for 1 day; the medium 
was changed and culture began with different experimental points. The follicles were keep in culture 
along the time (culture in hours) with 5 µCi/mL Na125I, with (+) or without 1 mU/mL TSH (-) and doses 
of Na127I (NaI). Each value was the average of accumulated or organified (O/A) iodide expressed in 
%/dose/μg DNA per number (N) of culture dishes ± SD.  
Pig hypothyroid follicles had a different response to the presence of increasing doses of 
iodide than rat and pig euthyroidic follicles (Table 10). They accumulated 40 to 100 times 
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more in the three doses than euthyroidic follicles, presenting organification in the presence 
of 10E-3 M NaI with or without TSH. Iodide accumulation in these follicles in the presence 
of perchlorate (30 M) was only inhibited at 12 h in the presence of 10E-3 M NaI and at 3 h 
in the presence of 10E-7 M NaI (euthyroidic follicles in the presence of 30 M perchlorate 
inhibited iodide capture at all concentrations) and O/A percentages in follicles in the 
presence of 10E-7 M NaI were greater in the absence of TSH than in their presence (Table 
10), such value becoming reduced with culture time. 
 
NaI 10E-10 M 10E-7 M 10E-3 M 
Culture TSH % O/A N % O/A N % O/A N 
0.5 - 77.9 ± 0.61 4 74.9 ± 0.63 4 6.3 ± 0.63 3 
+ 57.3  ± 0.78 4 71.6  ± 2.84 4 15.1 ± 0.63 3 
3 - 75.8  ± 0.49 4 68.7  ± 9.14 4 5.4 ± 0.63 3 
+ 60.6  ± 0.68 4 57.2  ± 9.14 4 3.0 ± 0.63 3 
12 - ND 87.3 ± 2.63 4 10.4 ± 0.63 3 
+ ND 72.8  ± 3.15 4 3.8 ± 0.63 3 
24 - ND 44.3  ± 1.97 4 11.6 ± 0.63 4 
+ ND 28.7  ± 0.99 4 9.7 ± 0.63 3 
Table 10. The effect of I- dose on the proportion accumulation/organificación pourcentage (% A/O) in 
pig hypothyroid follicles cultured. Follicles cultured on agarose with 0.5% FCS for 1 day; the medium 
was changed and culture began with different experimental points. The follicles were keep in culture 
along the time (culture in hours) with 5 µCi/mL Na125I, with (+) or without 1 mU/mL TSH (-) and doses 
of Na127I (NaI). Each value was the average of iodide accumulated or organified (O/A) iodide expressed 
in %/dose/μg DNA per number (N) of culture dishes ± SD. ND: not determinated. 
Iodide accumulation values in the presence of 10E-3 M NaI in hypothyroid follicles were 2 
times greater in follicles in the presence of TSH than without TSH, had organification in 
similar proportions to euthyroidic follicles in the presence of 10E-5 M NaI. Percentage of the 
proporction O/A was higher at 30 min without TSH than with TSH; it was lower at the other 
times. Without TSH increased with culture time whilst values became reduced regarding 
time with TSH (Table 10). Organification in this case was not nil, but the organified iodine 
did not exceed 11% for accumulated iodide. 
Mouse follicles cultured 3 days in the presence of 10E-7 M NaI was more intense in the presence 
of reactive species at the boundary between apical membrane microvellosities and colloid 
and the oxide reduction system became completely closed down with an excess of iodide 
(10E-4 M NaI) [100]. This proved that an excess of iodide inhibited the enzymes responsible 
for organification in closed follicles as we have thought should be in the gland in vivo. 
Euthyroidic follicles accumulated iodide regarding medium constant proportion concentration. 
Accumulated iodide was organified in the presence of 10E-10 M and 10E-7 M NaI; 
organification was extremely reduced in the presence of 10E-5 M and zero with 10E-3 M NaI 
as described in vivo [1]. Accumulation was greater in follicles without TSH than with TSH in 
the presence of 10E-3 M NaI at 12, 24 and 48 h; this reduction was similar to that of the 
gland in vivo [101,102]. 
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Hypothyroid follicles in the presence of 10-3 M NaI accumulated more iodide without TSH 
than with TSH at the beginning (30 min), even though proportion of O/A percentage was 
greater at 30 min than at other times; this effect (different to euthyroidic ones) was similar to 
that described in vivo in hypothyroid glands [28]. They also responded by reproducing the 
effect observed in animals suffering experimental goitre as, when excess iodide was added 
to food, they did not respond to TSH [24]. 50% of human endemic goitre has responded to 
an iodine-rich diet and some of these to TSH [25] as hypothyroid follicles in the presence of 
TSH and 10E-3 M NaI have responded by becoming less organified than in the absence of 
TSH. It should be stated that there is no consensus regarding what should be the correct 
dose for defining low, medium or high iodide concentration in human alimentation [25]. 
Closed and isolated follicles thus responded to 10E-5 M and 10E-3 M NaI inhibiting iodide 
organification in a similar way to that described for the gland in vivo in 1948 [1] (i.e. 
reproducing the Wolff-Chaikoff effect).  
5.3.2. Morphological study 
Hypothyroid follicles conserved follicular architecture during 48 h of culture in the presence 
of different doses of iodide with and without TSH (Figures 9A, 9B and 9C). Rat follicles and 
pig euthyroidic follicles at all iodide doses in the presence or absence of TSH conserved 
follicular architecture for 48 h (Figure 9D). 
 
Figure 9. Appearance of pig follicles cultured on agarose with 0.5% FCS for 1 day; the medium was 
changed and culture lasted 48 h. A. Hypothyroid s follicles in the presence of 10E-10M NaI. B. 
Hypothyroid follicles in the presence of 10E-7M NaI. C. Hypothyroid follicles in the presence of 10E-3M 
NaI. D. Euthyroidic follicles in the presence of 10E-3M NaI. The follicular architecture of the gland in 
vivo was conserved in all cultures; hypothyroids (A, B and C) had thin epithelium and euthyroidic (D) 
ones cubic epithelium (IM. Scale bar: A, B, C 800 μm, D 200 μm). 
The Trypan blue exclusion exam of thyrocytes from follicles cultured with 10E-3 M NaI did 
not have an alteration to their membranes and excluded the stain, whether being pig 
euthyroidic follicles cultured 48 h (Figure 10A) or rat ones cultured for 6 days (Figure 10B). 
The cells of cell aggregates which did not have follicular structure became stained (Figure 
1C), the same as isolated cells (Figure 10B) or those found in follicles. 
The ultra-structure of thyrocytes in all treatments and times preserved cell polarisation and 
organelle distribution (Figure 11), like the gland in vivo (Figure 1C); endocytic vesicles can 
be seen in thyrocytes’ apical region (Figure 11) like follicles after 3 days of culture (Figures 
6C and 6D). 
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more in the three doses than euthyroidic follicles, presenting organification in the presence 
of 10E-3 M NaI with or without TSH. Iodide accumulation in these follicles in the presence 
of perchlorate (30 M) was only inhibited at 12 h in the presence of 10E-3 M NaI and at 3 h 
in the presence of 10E-7 M NaI (euthyroidic follicles in the presence of 30 M perchlorate 
inhibited iodide capture at all concentrations) and O/A percentages in follicles in the 
presence of 10E-7 M NaI were greater in the absence of TSH than in their presence (Table 
10), such value becoming reduced with culture time. 
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pig hypothyroid follicles cultured. Follicles cultured on agarose with 0.5% FCS for 1 day; the medium 
was changed and culture began with different experimental points. The follicles were keep in culture 
along the time (culture in hours) with 5 µCi/mL Na125I, with (+) or without 1 mU/mL TSH (-) and doses 
of Na127I (NaI). Each value was the average of iodide accumulated or organified (O/A) iodide expressed 
in %/dose/μg DNA per number (N) of culture dishes ± SD. ND: not determinated. 
Iodide accumulation values in the presence of 10E-3 M NaI in hypothyroid follicles were 2 
times greater in follicles in the presence of TSH than without TSH, had organification in 
similar proportions to euthyroidic follicles in the presence of 10E-5 M NaI. Percentage of the 
proporction O/A was higher at 30 min without TSH than with TSH; it was lower at the other 
times. Without TSH increased with culture time whilst values became reduced regarding 
time with TSH (Table 10). Organification in this case was not nil, but the organified iodine 
did not exceed 11% for accumulated iodide. 
Mouse follicles cultured 3 days in the presence of 10E-7 M NaI was more intense in the presence 
of reactive species at the boundary between apical membrane microvellosities and colloid 
and the oxide reduction system became completely closed down with an excess of iodide 
(10E-4 M NaI) [100]. This proved that an excess of iodide inhibited the enzymes responsible 
for organification in closed follicles as we have thought should be in the gland in vivo. 
Euthyroidic follicles accumulated iodide regarding medium constant proportion concentration. 
Accumulated iodide was organified in the presence of 10E-10 M and 10E-7 M NaI; 
organification was extremely reduced in the presence of 10E-5 M and zero with 10E-3 M NaI 
as described in vivo [1]. Accumulation was greater in follicles without TSH than with TSH in 
the presence of 10E-3 M NaI at 12, 24 and 48 h; this reduction was similar to that of the 
gland in vivo [101,102]. 
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Hypothyroid follicles in the presence of 10-3 M NaI accumulated more iodide without TSH 
than with TSH at the beginning (30 min), even though proportion of O/A percentage was 
greater at 30 min than at other times; this effect (different to euthyroidic ones) was similar to 
that described in vivo in hypothyroid glands [28]. They also responded by reproducing the 
effect observed in animals suffering experimental goitre as, when excess iodide was added 
to food, they did not respond to TSH [24]. 50% of human endemic goitre has responded to 
an iodine-rich diet and some of these to TSH [25] as hypothyroid follicles in the presence of 
TSH and 10E-3 M NaI have responded by becoming less organified than in the absence of 
TSH. It should be stated that there is no consensus regarding what should be the correct 
dose for defining low, medium or high iodide concentration in human alimentation [25]. 
Closed and isolated follicles thus responded to 10E-5 M and 10E-3 M NaI inhibiting iodide 
organification in a similar way to that described for the gland in vivo in 1948 [1] (i.e. 
reproducing the Wolff-Chaikoff effect).  
5.3.2. Morphological study 
Hypothyroid follicles conserved follicular architecture during 48 h of culture in the presence 
of different doses of iodide with and without TSH (Figures 9A, 9B and 9C). Rat follicles and 
pig euthyroidic follicles at all iodide doses in the presence or absence of TSH conserved 
follicular architecture for 48 h (Figure 9D). 
 
Figure 9. Appearance of pig follicles cultured on agarose with 0.5% FCS for 1 day; the medium was 
changed and culture lasted 48 h. A. Hypothyroid s follicles in the presence of 10E-10M NaI. B. 
Hypothyroid follicles in the presence of 10E-7M NaI. C. Hypothyroid follicles in the presence of 10E-3M 
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vivo was conserved in all cultures; hypothyroids (A, B and C) had thin epithelium and euthyroidic (D) 
ones cubic epithelium (IM. Scale bar: A, B, C 800 μm, D 200 μm). 
The Trypan blue exclusion exam of thyrocytes from follicles cultured with 10E-3 M NaI did 
not have an alteration to their membranes and excluded the stain, whether being pig 
euthyroidic follicles cultured 48 h (Figure 10A) or rat ones cultured for 6 days (Figure 10B). 
The cells of cell aggregates which did not have follicular structure became stained (Figure 
1C), the same as isolated cells (Figure 10B) or those found in follicles. 
The ultra-structure of thyrocytes in all treatments and times preserved cell polarisation and 
organelle distribution (Figure 11), like the gland in vivo (Figure 1C); endocytic vesicles can 
be seen in thyrocytes’ apical region (Figure 11) like follicles after 3 days of culture (Figures 
6C and 6D). 
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Figure 10. Trypan blue exclusion exam of culture aliquots for follicles cultured on agarose with 0.5% 
FCS 1 day; the medium was changed and culturing involved 10E-3 M NaI. A. 2 day rat follicle culture. 
B. 6 day pig euthyroid follicle culture. The thyrocytes from the follicles excluded the stain whilst 
isolated cells did not exclude it, whether separated from the follicle (A) or on the follicle (B) (IM, Scale 
bar A 60 μm, B 15 μm). 
 
Figure 11. The ultra-structure of rat follicle rat thyrocytes cultured on agarose with 0.5% FCS for 1 day; 
the medium was changed and 48-h culture involved different experimental points: A. 10E-7 M NaI. B. 
10E-3 M NaI + 0.1 mU/mL TSH. Thyrocytes kept their polarisation; microvellosities were in contact with 
electron-dense colloid. The binding complexes were located in the lateral membrane’s apical region 
between cells. The RER was slightly vesiculated. Thyrocytes did not have cytological differences 
regarding iodide dose; follicular centres only became narrowed in the presence of TSH (B) (TEM. A 
8,720 X, B 10,720 X) 
Follicles in the presence of TSH narrowed their follicle centres at all iodide doses used 
(Figures 12B and 12D), but did not undergo any ultra-structural modification in strong 
iodide concentrations: 10E-5M or 10E-3 M NaI. Organelle distribution was comparable to 
normal gland in vivo (Figure 1C) or follicles in long-term culture (Figures 6C and 6D). 
Lysosome fusion occurred in follicles in the presence of 10E-10 M NaI and 0.1 mU/mL TSH 
for 8 h (Figure 12B) while this did not happen in thyrocytes’ apical region (Figure 12B insert) 
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in the absence of TSH (Figures 12A and 12C). This was also observed en thyrocytes from 
follicles cultured for 8 h with 10E-3 M NaI and TSH, but colloid droplets were only located 
in the apical region in this dose (Figure 12D). Thyrocytes also had endocytic vesicles in this 
dose without TSH but also located in cells’ apical region (Figure 12C). Thyrocytes ultra-
structure in the presence of strong concentrations of iodide did not have morphological 
modifications, or distribution of organelles regarding normal or non-stimulated cells in vivo 
(Figure 1C) or in vitro (Figures 6C and 6D). 
 
Figure 12. The ultra-structure of rat follicle thyrocytes cultured on agarose with 0.5% FCS for 1 day; the 
medium was changed and 8 h of culture involved different experimental points: A. 10-E10 M NaI. B. 10-
E10 M NaI + 0.1 mU/mL TSH. C. 10-E3 M NaI. D. 10-E3 M NaI + 0.1 mU/mL TSH. A. The ultra-structure 
of thyrocytes in the absence of TSH was identical to that of thyrocytes from follicles cultured for 1 day. 
B. Lysosomes close to the nucleus and few colloid droplets located in the apical pole (insert) were 
observed in the presence of TSH. C. They were well conserved in the presence of TSH, even in this 
strong dose of NaI. Endocytic vesicles were present in such strong dose of iodide. D. Colloid droplets 
were also observed in the presence of TSH, having the same density as colloid and were located in the 
thyrocytes’ apical pole. Follicle centre was narrow and had abundant microvellosities (TEM. A 8,720 X, 
B 12,510 X, box 10,720 X, C 7,430 X, box 70,950 X, D 13,450 X). 
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The thyrocytes from follicles cultured from 30 min up to 6 days in the presence of 10E-3 M 
NaI did not have cytotoxic signs and all follicular cells were viable, like normal animals’ 
thyroid glands’ in vivo when fed with excess iodide for 3 weeks [103]. 
Open human follicle culture in the presence of 10E-3 M NaI with and without TSH for 24 h 
had ultra-structural alterations related to cytotoxicity [92] involving free radical attack and 
lipid peroxidation. Excess iodide in pig follicles led to thyrocyte apoptosis because iodine 
production in lactone became reduced, but did not present morphology. Our results showed 
that conserving closed follicles did not lead to signs of cell death with 10E-5 M or 10E-3 M 
NaI or disorganisation or alteration of thyrocyte ultra-structure. The difference with [92] and 
[94] was that they were open follicle cultures and thyrocytes died simply because they were 
cultured on a support which inhibited cellular adhesion, like our cell aggregates. 
Closed follicles were present (Figure 12), as described for the gland. There was apical 
membrane turnover between microvellosities which is important for maintaining Tg 
synthesis and its secretion to colloid [8]. Coated endocytic vesicles (Figure 12C insert) were 
also present in the base of microvellosities, like micro-endocytosis in vivo [5], and those 
stimulated by TSH formed pseudopods and colloid droplets (Figures 12B insert and 12C 
letter DC), called in vivo macro-endocytosis [10]. Thyrocyte fusion with prelysosomes or late 
endosomes from the lysosome route was also observed (Figure 12B arrows) for Tg 
degradation and thyroid hormones were formed in vivo [19] and in vitro [18]. 
Closed rat and pig euthyroidic follicles responded to increasing doses of iodide, as in vivo, 
thereby producing the Wolff-Chaikoff effect [1], and presented no modifications in 
thyrocytes’ follicular architecture or ultra-structure, being comparable to a gland in vivo.  
5.3.2.1. Na+/I- symporter determination  
Many thyrocyte culture studies have described reduced RNAm and NIS protein expression 
when maintained in the presence of strong iodide concentrations (10E-6 to 10E-4 M of 
iodide). We wanted to determine NIS in rat follicles cultured with strong iodide 
concentrations with and without TSH 0.1 mU/mL. 
Follicles cultured at 12 h in the presence of 10E-7 M NaI and without TSH had NIS in 
basolateral membranes (Figure 13A) and labelling was more intense in lateral membranes in 
the presence of TSH (Figure 13B). In the presence of 10E-3 M NaI NIS was mainly located in 
vesicles between nucleus and basolateral membranes (Figure 13C), and in the presence of 
TSH; as well as being presented in vesicles they were observed in basolateral membranes 
(Figure 13D). It could have been that inhibiting vesicular movement in the presence of 10E-3 
M NaI in the apical region (Figures 11C and 11D), as well as inhibiting the movement of the 
vesicles forming in the basement region with NIS symporter for avoiding excessive iodide 
entry to thyrocytes. 
The NIS symporter was located in the basolateral members in the presence of 10E-10 M NaI 
at 48 h (E and F), labelling being more intense in the presence of TSH. The NIS symporter 
was found in the cytoplasmatic vesicles with TSH (F). NIS symporter expression in the 
presence of 10E-3 M NaI for 48 h (G and H) was so low that confocal microscope parameters  
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Figure 13. Indirect immunofluorescence of NIS symporter (green) expression and localisation and DAPI-
labelled nuclei (blue) in follicles isolated from rats cultured for 1 day on agarose with 0.5% FCS for 1 day; 
the medium was changed and were cultured for 12 h (A, B, C and D) and for 48 h (E, F, G and H), with 
different experimental points: NaI with and without 0.1 mU/mL TSH. A. 10E-7 M NaI, B. 10E-7 M NaI + 
TSH. C. 10E-3 M NaI. D. 10E-3 M NaI + TSH. E. 10E-7 M NaI. F. 10E-7 M NaI + TSH. G. 10E-3 M NaI. H. 
10E-3 M NaI + TSH. NIS symporter was located in the basolateral membranes in the presence of 10E-10 M 
NaI at 12 h (A and B). TSH intensified labelling (B). NIS symporter was located in cytoplasmatic vesicles 
near thyrocytes’ basolateral membranes in the presence of 10E-3 M NaI at 12 h (C and D). There was 
more intense labelling in some thyrocytes’ basolateral membranes in the presence of TSH (D). [104] 
(laser intensity, detector gain, scanning time) had to be adjusted again to increase labelling 
intensity. NIS protein was mainly observed in cytoplasmatic vesicles in these follicles, being 
more intense than labelling without TSH (G). Basement membranes had exiguous NIS 
labelling (CM. Scale bar: 10 μm). 
The NIS symporter in follicles cultured for 48 h in the presence of 10E-7 M NaI were located 
in vesicles and basolateral membranes (Figure 13E); TSH intensified such labelling (Figure 
13F). NIS expression was very reduced regarding the other treatments in the presence of 
10E-3 M NaI with and without TSH and microscope parameters had to be readjusted for 
observing fluorescence. NIS was located in cytoplasmatic vesicles in this strong dose of NaI 
and without TSH (Figure 13G). TSH was located in vesicles in the base region but labelling 
was less intense (Figure 13H) than with TSH. 
NIS has normally been located in thyrocytes’ basolateral members in vivo [13], and a reduction 
in its normal expression has been associated with escape from the Wolff-Chaikoff effect [30] 
following 48 h in the presence of strong iodide concentrations [29]. Being found in vesicles has 
reduced NIS in its normal position for thyrocytes from follicles in the presence of a strong dose 
of NaI [104] and has thus suppressed I-transport for thyroid hormone production. 
These results were similar in the FRTL5 cell line where the same dose did not alter NIS 
RNAm percentage, but protein became reduced by 50% and 78 % at 24 and 48 h, 
respectively [32]. NIS RNAm became reduced in dogs with goitre at 48 h with a comparable 
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membrane turnover between microvellosities which is important for maintaining Tg 
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5.3.2.1. Na+/I- symporter determination  
Many thyrocyte culture studies have described reduced RNAm and NIS protein expression 
when maintained in the presence of strong iodide concentrations (10E-6 to 10E-4 M of 
iodide). We wanted to determine NIS in rat follicles cultured with strong iodide 
concentrations with and without TSH 0.1 mU/mL. 
Follicles cultured at 12 h in the presence of 10E-7 M NaI and without TSH had NIS in 
basolateral membranes (Figure 13A) and labelling was more intense in lateral membranes in 
the presence of TSH (Figure 13B). In the presence of 10E-3 M NaI NIS was mainly located in 
vesicles between nucleus and basolateral membranes (Figure 13C), and in the presence of 
TSH; as well as being presented in vesicles they were observed in basolateral membranes 
(Figure 13D). It could have been that inhibiting vesicular movement in the presence of 10E-3 
M NaI in the apical region (Figures 11C and 11D), as well as inhibiting the movement of the 
vesicles forming in the basement region with NIS symporter for avoiding excessive iodide 
entry to thyrocytes. 
The NIS symporter was located in the basolateral members in the presence of 10E-10 M NaI 
at 48 h (E and F), labelling being more intense in the presence of TSH. The NIS symporter 
was found in the cytoplasmatic vesicles with TSH (F). NIS symporter expression in the 
presence of 10E-3 M NaI for 48 h (G and H) was so low that confocal microscope parameters  
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Figure 13. Indirect immunofluorescence of NIS symporter (green) expression and localisation and DAPI-
labelled nuclei (blue) in follicles isolated from rats cultured for 1 day on agarose with 0.5% FCS for 1 day; 
the medium was changed and were cultured for 12 h (A, B, C and D) and for 48 h (E, F, G and H), with 
different experimental points: NaI with and without 0.1 mU/mL TSH. A. 10E-7 M NaI, B. 10E-7 M NaI + 
TSH. C. 10E-3 M NaI. D. 10E-3 M NaI + TSH. E. 10E-7 M NaI. F. 10E-7 M NaI + TSH. G. 10E-3 M NaI. H. 
10E-3 M NaI + TSH. NIS symporter was located in the basolateral membranes in the presence of 10E-10 M 
NaI at 12 h (A and B). TSH intensified labelling (B). NIS symporter was located in cytoplasmatic vesicles 
near thyrocytes’ basolateral membranes in the presence of 10E-3 M NaI at 12 h (C and D). There was 
more intense labelling in some thyrocytes’ basolateral membranes in the presence of TSH (D). [104] 
(laser intensity, detector gain, scanning time) had to be adjusted again to increase labelling 
intensity. NIS protein was mainly observed in cytoplasmatic vesicles in these follicles, being 
more intense than labelling without TSH (G). Basement membranes had exiguous NIS 
labelling (CM. Scale bar: 10 μm). 
The NIS symporter in follicles cultured for 48 h in the presence of 10E-7 M NaI were located 
in vesicles and basolateral membranes (Figure 13E); TSH intensified such labelling (Figure 
13F). NIS expression was very reduced regarding the other treatments in the presence of 
10E-3 M NaI with and without TSH and microscope parameters had to be readjusted for 
observing fluorescence. NIS was located in cytoplasmatic vesicles in this strong dose of NaI 
and without TSH (Figure 13G). TSH was located in vesicles in the base region but labelling 
was less intense (Figure 13H) than with TSH. 
NIS has normally been located in thyrocytes’ basolateral members in vivo [13], and a reduction 
in its normal expression has been associated with escape from the Wolff-Chaikoff effect [30] 
following 48 h in the presence of strong iodide concentrations [29]. Being found in vesicles has 
reduced NIS in its normal position for thyrocytes from follicles in the presence of a strong dose 
of NaI [104] and has thus suppressed I-transport for thyroid hormone production. 
These results were similar in the FRTL5 cell line where the same dose did not alter NIS 
RNAm percentage, but protein became reduced by 50% and 78 % at 24 and 48 h, 
respectively [32]. NIS RNAm became reduced in dogs with goitre at 48 h with a comparable 
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iodide dose [105]. This was perhaps presented by reduced AM2Pc levels at 48 h, as excess I- 
inhibited an increase in AMPc stimulated by TSH in hypophysectomised rats [106] and mice 
[34], which could have explained the low NIS level during Wolff-Chaikoff effect and in 
follicles at 48 h in the presence of excess iodide (Figure s13G and 13H). Excess I- inhibited IP3 
production and increased Ca2+ flow induced by TSH, which could have led to reduced 
peroxide production during Wolff-Chaikoff effect [107,108]. The organification observed in 
the presence of 10E-5 M (Table 8) did not completely inhibit TPO and had no effect on NIS 
in the presence of 10E-3 M NaI (Figures 13E and 13H), thereby demonstrating that 
organification depends on TPO and not on NIS as in cells transfected with the TPO gene 
[34]. TSH did not stimulate the organification of iodide captured in 10E-3 M but did so in 
10E-5 M NaI (Tables 8 and 10), as it has been described that the effect of TSH on thyroid 
physiology becomes reduced in the presence of excess I- , meaning that antagonic roles are 
assumed in vivo [102]. 
TSH modulated relative NIS expression and its subcellular localisation in the thyrocytes of 
isolated and closed follicles in vitro. These results were similar to those found in FRTL5cells, 
where it has been demonstrated that de novo synthesis [32], half-life time, NIS targeting 
and/or retention regarding cytoplasmatic membrane requires TSH to be located throughout 
cell membrane, due to loss of polarity [109]. 
Thyrocyte disposition in follicles has not been necessary for iodide accumulation, since it 
has been present in foetal thyroids before follicular lumen formation [110] and also in 
primary cultures from normal thyrocytes [111] or goitre patients [112] and in the FRTL cell 
line [113]; however, these cultures have required TSH, hormones and other molecules for 
maintaining them. Nevertheless, isolating the colloidal cavity from the exterior must be 
ensured for iodide accumulation and incorporation in Tg, T3 and T4 hormone synthesis, as 
demonstrated with rat or pig isolated and closed follicle cultures. 
Rat and pig follicles thus inhibited iodide organification in the presence of strong 
concentrations of iodide, i.e. performed the Wolff-Chaikoff effect. Neither thyrocytes’ 
follicular architecture nor ultra-structure was modified and no sign of cell death was 
presented. The TSH and iodide effects observed in vivo during the Wolff-Chaikoff effect 
were reproduced. 
6. Conclusion 
Loss of follicular structure during the first 24 h of culture has been the main drawback of in 
vitro thyroid studies and, therefore, hormone synthesis. It is not enough to conserve 
thyrocytes’ apical-basal polarity in culture in this specific tissue for maintaining colloid’s 
extracellular functions for the enzymes implicated in iodide fixation on Tg and hormone 
synthesis. 
We have shown that follicular architecture must be conserved in culture, especially the 
follicular cavity isolated from extracellular medium as this is indispensable for maintaining 
ultra-structure and the polarity of thyrocytes around the follicular cavity; such premise 
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conserving the idea of Tg19S synthesis usually being glycosylated and iodised, as also T3 
and T4 hormone synthesis. Follicular morphological conservation is necessary for 
reproducing the Wolff-Chaikoff effect in vitro, as has been described in vivo. NIS symporter 
localisation in thyrocytes depends on I and TSH concentration. 
This culture may be used for obtaining follicles from pathologies of human tissue whose 
epithelium may be thin plate-like cells for in vitro studies in controlled and homologous 
conditions regarding the pathology in vivo. It will also enable studying normal or 
pathological thyroid’s physiological, cellular and molecular mechanisms (for example CLC-
5 channel) in a homologous model of the gland in vivo. 
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